AUA 2018
MAY 18–21 san francisco
MEETING PROGRAM

American Urological Association
Education & Research, Inc.
Advancing Urology®
Upon progression on GnRH therapy* in mCRPC

Supported by 3 randomized, controlled trials

**AFFIRM TRIAL**
- **1199 patients** with metastatic CRPC who were previously on docetaxel therapy were randomized to XTANDI + GnRH therapy* (n = 800) or placebo + GnRH therapy* (n = 399).1

**PREVAIL TRIAL**
- **1717 patients** with metastatic CRPC who were asymptomatic or mildly symptomatic were randomized to XTANDI + GnRH therapy* (n = 872) or placebo + GnRH therapy* (n = 845).1,2

**TERRAIN TRIAL**
- **375 patients** with metastatic CRPC who were asymptomatic or mildly symptomatic were randomized to XTANDI + GnRH therapy* (n = 184) or bicalutamide + GnRH therapy* (n = 191).1,3

In the US alone, 106,000 patients have been prescribed XTANDI—and counting†


Visit XtandiHCP.com to learn more about XTANDI in metastatic CRPC patients

**Indication**
XTANDI (enzalutamide) capsules is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC).

**Select Safety Information**
XTANDI is not indicated for use in women. XTANDI can cause fetal harm and potential loss of pregnancy.

Seizure occurred in 0.5% of patients receiving XTANDI in clinical studies. In a study of patients with predisposing factors, seizures were reported in 2.2% of patients. See section 5.1 of the Prescribing Information for the list of predisposing factors. It is unknown whether anti-epileptic medications will prevent seizures with XTANDI. Permanently discontinue XTANDI in patients who develop a seizure during treatment.

There have been post approval reports of posterior reversible encephalopathy syndrome (PRES), a neurological disorder that can present with rapidly evolving symptoms and requires confirmation by brain imaging. Discontinue XTANDI in patients who develop PRES.

Please see reverse for Important Safety Information and adjacent pages for Brief Summary of Full Prescribing Information.

FDA approved for metastatic CRPC since 2012

GnRH therapy, gonadotropin-releasing hormone therapy; mCRPC, metastatic castration-resistant prostate cancer.
* Or after bilateral orchiectomy.1
Indication and Important Safety Information

Indication
XTANDI (enzalutamide) capsules is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC).

Important Safety Information

Contraindications
XTANDI is not indicated for women. XTANDI can cause fetal harm and potential loss of pregnancy.

Warnings and Precautions

Seizure occurred in 0.5% of patients receiving XTANDI in clinical studies. In a study of patients with predisposing factors, seizures were reported in 2.2% of patients. See section 5.1 of the Prescribing Information for the list of predisposing factors. It is unknown whether anti-epileptic medications will prevent seizures with XTANDI. Permanently discontinue XTANDI in patients who develop a seizure during treatment.

Posterior Reversible Encephalopathy Syndrome (PRES)
In post approval use, there have been reports of PRES in patients receiving XTANDI. PRES is a neurological disorder which can present with rapidly evolving symptoms including seizure, headache, lethargy, confusion, blindness, and other visual and neurological disturbances, with or without associated hypertension. A diagnosis of PRES requires confirmation by brain imaging, preferably MRI. Discontinue XTANDI in patients who develop PRES.

Adverse Reactions
The most common adverse reactions (≥ 10%) that occurred more commonly (≥ 2% over placebo) in the XTANDI patients from the two placebo-controlled clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo. In the bicalutamide-controlled study of chemotherapy-naive patients, the most common adverse reactions (≥ 10%) reported in XTANDI patients were asthenia/fatigue, back pain, musculoskeletal pain, hot flush, hypertension, nausea, constipation, upper respiratory tract infection, diarrhea, and weight loss.

In the placebo-controlled study of patients taking XTANDI who previously received docetaxel, Grade 3 and higher adverse reactions were reported among 47% of XTANDI patients and 53% of placebo patients. Discontinuations due to adverse events were reported for 16% of XTANDI patients and 18% of placebo patients. In the placebo-controlled study of chemotherapy-naive patients, Grade 3-4 adverse reactions were reported in 44% of XTANDI patients and 37% of placebo patients. Dis discontinuations due to adverse events were reported for 6% of both study groups. In the bicalutamide-controlled study of chemotherapy-naive patients, Grade 3-4 adverse reactions were reported in 38.8% of XTANDI patients and 37.6% of bicalutamide patients. Discontinuations due to adverse events were reported for 7.6% of XTANDI patients and 6.3% of bicalutamide patients.

Lab Abnormalities: In the two placebo-controlled trials, Grade 1-4 neutropenia occurred in 15% of XTANDI patients (1% Grade 3-4) and 6% of placebo patients (0.5% Grade 3-4). Grade 1-4 thrombocytopenia occurred in 6% of XTANDI patients (0.3% Grade 3-4) and 5% of placebo patients (0.5% Grade 3-4). Grade 1-4 elevations in ALT occurred in 10% of XTANDI patients (0.2% Grade 3-4) and 16% of placebo patients (0.2% Grade 3-4). Grade 1-4 elevations in bilirubin occurred in 3% of XTANDI patients (0.1% Grade 3-4) and 2% of placebo patients (no Grade 3-4).

Infections: In the study of patients taking XTANDI who previously received docetaxel, 1% of XTANDI patients compared to 0.3% of placebo patients died from infections or sepsis. In the study of chemotherapy-naive patients, 1 patient in each treatment group (0.1%) had an infection resulting in death.

Falls (including fall-related injuries) occurred in 9% of XTANDI patients and 4% of placebo patients in the two placebo-controlled trials. Falls were not associated with loss of consciousness or seizure. Fall-related injuries were more severe in XTANDI patients, and included non-pathologic fractures, joint injuries, and hematomas.

Hypertension occurred in 11% of XTANDI patients and 4% of placebo patients in the two placebo-controlled trials. No patients experienced hypertensive crisis. Medical history of hypertension was balanced between arms. Hypertension led to study discontinuation in < 1% of patients in each arm.

Drug Interactions

Effect of Other Drugs on XTANDI Avoid strong CYP2C8 inhibitors, as they can increase the plasma exposure to XTANDI. If co-administration is necessary, reduce the dose of XTANDI.

Avoid strong CYP3A4 inducers as they can decrease the plasma exposure to XTANDI. If co-administration is necessary, increase the dose of XTANDI.

Effect of XTANDI on Other Drugs Avoid CYP3A4, CYP2C9, and CYP2C19 substrates with a narrow therapeutic index, as XTANDI may decrease the plasma exposures of these drugs. If XTANDI is co-administered with warfarin (CYP2C9 substrate), conduct additional INR monitoring.

Please see adjacent pages for Brief Summary of Full Prescribing Information.

References:
Diarrhea, hot flush, upper respiratory tract infection, and disturbance in attention.

The most common adverse reactions (≥ 10%) that occurred more commonly (≥ 2% over placebo) in the XTANDI arm compared to placebo are presented in Table 1. Grade 3 and higher adverse reactions were reported among 47% of XTANDI-treated patients and 53% of placebo-treated patients. Discontinuations due to adverse events were reported for 16% of XTANDI-treated patients and 15% of placebo-treated patients. The most common adverse reaction leading to treatment discontinuation was seizure, which occurred in 0.9% of the XTANDI-treated patients compared to none (0%) of the placebo-treated patients. Table 1 shows adverse reactions reported in Study 1 that occurred at a ≥2% higher frequency in the XTANDI arm compared to the placebo arm.

### Study 2: XTANDI versus Placebo in Chemotherapy-Naïve Metastatic CRPC

Study 2 enrolled 1717 patients with metastatic CRPC who had not received prior cytotoxic chemotherapy, of whom 1715 received at least one dose of study drug. The median duration of treatment was 17.5 months with XTANDI and 4.6 months with placebo. Grade 3-4 adverse reactions were reported in 44% of XTANDI-treated patients and 37% of placebo-treated patients. Discontinuations due to adverse events were reported for 8% of XTANDI-treated patients and 6% of placebo-treated patients. The most common adverse reaction leading to treatment discontinuation was fatigue/asthenia, which occurred in 1% of patients on each treatment arm. Table 2 includes adverse reactions reported in Study 2 that occurred at a ≥2% higher frequency in the XTANDI arm compared to the placebo arm.

### Table 1. Adverse Reactions in Study 1

<table>
<thead>
<tr>
<th>Event</th>
<th>XTANDI N = 800</th>
<th>Placebo N = 399</th>
</tr>
</thead>
<tbody>
<tr>
<td>General Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthenia/Weaknessa</td>
<td>50.6 (9.0)</td>
<td>44.4 (9.3)</td>
</tr>
<tr>
<td>Periperal Edemac</td>
<td>15.4 (1.0)</td>
<td>13.3 (0.8)</td>
</tr>
<tr>
<td>Musculoskeletal And Connective Tissue Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Back Pain</td>
<td>28.4 (5.3)</td>
<td>24.3 (4.0)</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>20.5 (2.5)</td>
<td>17.3 (1.8)</td>
</tr>
<tr>
<td>Musculoskeletal Pain</td>
<td>15.0 (1.3)</td>
<td>11.5 (0.3)</td>
</tr>
<tr>
<td>Muscular Weakness</td>
<td>9.8 (1.5)</td>
<td>6.8 (1.8)</td>
</tr>
<tr>
<td>Musculoskeletal Stiffness</td>
<td>2.6 (0.3)</td>
<td>0.3 (0.0)</td>
</tr>
<tr>
<td>Gastrointestinal Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td>21.8 (11.1)</td>
<td>17.5 (0.3)</td>
</tr>
<tr>
<td>Vascular Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hot Flush</td>
<td>20.3 (0.0)</td>
<td>10.0 (3.0)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>6.4 (2.1)</td>
<td>2.8 (1.3)</td>
</tr>
<tr>
<td>Nervous System Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>12.1 (0.9)</td>
<td>5.5 (0.0)</td>
</tr>
<tr>
<td>Dizzinessa</td>
<td>9.5 (0.5)</td>
<td>7.5 (0.2)</td>
</tr>
<tr>
<td>Spinal Cord Compression and Cauda Equina Syndrome</td>
<td>7.4 (6.6)</td>
<td>4.5 (3.8)</td>
</tr>
<tr>
<td>Parathesia</td>
<td>6.6 (0.0)</td>
<td>4.5 (0.0)</td>
</tr>
<tr>
<td>Mental Impairment Disorders</td>
<td>4.3 (0.3)</td>
<td>1.8 (0.0)</td>
</tr>
<tr>
<td>Hypoesthesia</td>
<td>4.0 (0.3)</td>
<td>1.8 (0.0)</td>
</tr>
<tr>
<td>Infections And Infestations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upper Respiratory Tract Infectiona</td>
<td>10.9 (0.0)</td>
<td>6.5 (0.3)</td>
</tr>
<tr>
<td>Lower Respiratory Tract And Lung Infectiona</td>
<td>8.5 (2.4)</td>
<td>4.8 (1.3)</td>
</tr>
<tr>
<td>Psychiatric Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insomnia</td>
<td>8.6 (0.0)</td>
<td>6.0 (0.5)</td>
</tr>
<tr>
<td>Anxiety</td>
<td>6.5 (0.3)</td>
<td>4.0 (0.0)</td>
</tr>
<tr>
<td>Renal And Urinary Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hematuria</td>
<td>6.9 (1.8)</td>
<td>4.5 (1.0)</td>
</tr>
<tr>
<td>Polyuria</td>
<td>4.8 (0.0)</td>
<td>2.5 (0.0)</td>
</tr>
<tr>
<td>Injury, Poisoning And Procedural Complications</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fall</td>
<td>4.6 (0.3)</td>
<td>1.3 (0.0)</td>
</tr>
<tr>
<td>Non-pathologic Fractures</td>
<td>4.0 (1.4)</td>
<td>0.8 (0.3)</td>
</tr>
<tr>
<td>Skin And Subcutaneous Tissue Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pruritus</td>
<td>3.8 (0.0)</td>
<td>1.3 (0.0)</td>
</tr>
<tr>
<td>Dry Skin</td>
<td>3.5 (0.0)</td>
<td>1.3 (0.0)</td>
</tr>
<tr>
<td>Respiratory Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epistaxis</td>
<td>5.3 (0.1)</td>
<td>1.3 (0.3)</td>
</tr>
</tbody>
</table>

### Table 2. Adverse Reactions in Study 2

<table>
<thead>
<tr>
<th>Event</th>
<th>XTANDI N = 871</th>
<th>Placebo N = 844</th>
</tr>
</thead>
<tbody>
<tr>
<td>General Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthenic Conditionsa</td>
<td>46.9 (3.4)</td>
<td>33.0 (2.8)</td>
</tr>
<tr>
<td>Peripheral Edema</td>
<td>11.5 (2.0)</td>
<td>8.2 (0.4)</td>
</tr>
<tr>
<td>Musculoskeletal And Connective Tissue Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Back Pain</td>
<td>28.6 (2.5)</td>
<td>22.4 (3.0)</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>21.4 (1.6)</td>
<td>16.1 (1.1)</td>
</tr>
<tr>
<td>Gastrointestinal Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Constipation</td>
<td>21.3 (0.7)</td>
<td>17.3 (0.4)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>16.8 (0.3)</td>
<td>14.3 (0.4)</td>
</tr>
<tr>
<td>Vascular Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hot Flush</td>
<td>18.0 (0.1)</td>
<td>7.8 (0.0)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>14.2 (2.1)</td>
<td>4.1 (2.3)</td>
</tr>
<tr>
<td>Nervous System Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dizzinessb</td>
<td>11.3 (0.3)</td>
<td>7.1 (0.0)</td>
</tr>
<tr>
<td>Headache</td>
<td>11.0 (0.2)</td>
<td>7.0 (0.4)</td>
</tr>
<tr>
<td>Dyspesia</td>
<td>7.8 (0.1)</td>
<td>3.7 (0.0)</td>
</tr>
<tr>
<td>Mental Impairment Disorders</td>
<td>5.7 (0.0)</td>
<td>1.3 (0.0)</td>
</tr>
<tr>
<td>Reye's Syndrome</td>
<td>2.1 (0.1)</td>
<td>0.0 (0.0)</td>
</tr>
<tr>
<td>Respiratory Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyspneaa</td>
<td>11.0 (0.6)</td>
<td>8.5 (0.6)</td>
</tr>
<tr>
<td>Infections And Infestations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upper Respiratory Tract Infectionb</td>
<td>16.4 (0.0)</td>
<td>10.5 (0.0)</td>
</tr>
<tr>
<td>Lower Respiratory Tract And Lung Infectionb</td>
<td>7.9 (1.5)</td>
<td>4.7 (1.1)</td>
</tr>
<tr>
<td>Psychiatric Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insomnia</td>
<td>8.2 (0.1)</td>
<td>5.7 (0.0)</td>
</tr>
<tr>
<td>Renal And Urinary Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hematuria</td>
<td>8.8 (1.2)</td>
<td>5.8 (1.3)</td>
</tr>
<tr>
<td>Injury, Poisoning And Procedural Complications</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fall</td>
<td>12.7 (1.6)</td>
<td>5.3 (0.7)</td>
</tr>
<tr>
<td>Non-Pathological Fractures</td>
<td>8.8 (2.1)</td>
<td>3.0 (1.1)</td>
</tr>
<tr>
<td>Metabolism And Nutrition Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased Appetite</td>
<td>18.9 (0.3)</td>
<td>16.4 (0.7)</td>
</tr>
<tr>
<td>Investigations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight Decreased</td>
<td>12.4 (0.8)</td>
<td>8.5 (0.2)</td>
</tr>
<tr>
<td>Reproductive System And Breast Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gynecomastia</td>
<td>3.4 (1.3)</td>
<td>1.6 (0.5)</td>
</tr>
</tbody>
</table>

### Notes:
- a CTCAE v4.
- b Includes asthenia and fatigue.
- c Includes amnesia, memory impairment, cognitive disorder, and disturbance in attention.
- d Includes dyspepsia, esophageal dysphagia, and dysphagia at rest.
- e Includes nasopharyngitis, upper respiratory tract infection, sinusitis, rhinitis, pharyngitis, and laryngitis.
- f Includes pneumonia, lower respiratory tract infection, bronchitis, and lung infection.

Study 3: XTANDI versus Bicalutamide in Chemotherapy-Naïve Metastatic CRPC

Study 3 enrolled 375 patients with metastatic CRPC who had not received prior cytotoxic chemotherapy, of whom 372 received at least one dose of study drug. The median duration of treatment was 11.6 months with XTANDI.
Gastrointestinal Disorders: vomiting
Neurological Disorders: posterior reversible encephalopathy syndrome (PRES)
Skin and Subcutaneous Tissue Disorders: rash

**DRUG INTERACTIONS**

**Drugs that Inhibit CYP3A4**
Co-administration of a strong CYP3A4 inhibitor (gemfibrozil) increased the composite area under the plasma concentration-time curve (AUC) of enzalutamide plus N-desmethyl enzalutamide by 2.2-fold. Co-administration of XTANDI with strong CYP3A4 inhibitors should be avoided if possible. If co-administration of XTANDI with a strong CYP3A4 inhibitor cannot be avoided, reduce the dose of XTANDI.

**Drugs that Induce CYP3A4**
Co-administration of rifampin (strong CYP3A4 inducer and moderate CYP2C9 inducer) decreased the composite AUC of enzalutamide plus N-desmethyl enzalutamide by 37%. Co-administration of strong CYP3A4 inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifampin, rifabutin, rifapentine) with XTANDI should be avoided if possible. St John’s wort may decrease enzalutamide exposure and should be avoided. If co-administration of a strong CYP3A4 inducer with XTANDI cannot be avoided, increase the dose of XTANDI.

**Effect of XTANDI on Drug Metabolizing Enzymes**
Enzalutamide is a strong CYP3A4 inducer and a moderate CYP2C9 and CYP3A4 inducer in humans. At steady state, XTANDI reduced plasma exposure to midazolam (CYP3A4 substrate), warfarin (CYP2C9 substrate), and omeprazole (CYP2C19 substrate). Concomitant use of XTANDI with narrow therapeutic index drugs that are metabolized by CYP3A4 (e.g., alfentanil, cyclazocine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus and tacrolimus). CYP2C9 (e.g., phenytoin, warfarin) and CYP2C19 (e.g., S-mephénytoin) should be avoided, as enzalutamide may decrease their exposure. If co-administration with warfarin cannot be avoided, conduct additional INR monitoring.

**USE IN SPECIFIC POPULATIONS**

**Pregnancy**
Risk Summary
XTANDI is contraindicated for use in pregnant women because the drug can cause fetal harm and potential loss of pregnancy. XTANDI is not indicated for use in females.

In the two randomized placebo-controlled clinical trials, 75% were men and 25% were women. The mean age was 70 years.

Laboratory Abnormalities
In the two randomized placebo-controlled clinical trials, Grade 1-4 neutropenia occurred in 15% of patients treated with XTANDI (1% Grade 3-4) and in 6% of patients treated with placebo (0.3% Grade 3-4). The incidence of Grade 1-4 thrombocytopenia was 6% of patients treated with XTANDI (0.3% Grade 3-4) and 5% of patients treated with placebo (0.5% Grade 3-4). Grade 1-4 elevations in ALT occurred in 10% of patients treated with XTANDI (0.2% Grade 3-4) and 16% of patients treated with placebo (0.2% Grade 3-4). Grade 1-4 elevations in bilirubin occurred in 6% of patients treated with XTANDI (0.1% Grade 3-4) and 2% of patients treated with placebo (no Grade 3-4).

Infections
In Study 1, 4% of patients treated with XTANDI compared to 0.3% of patients treated with placebo died from infections or sepsis. In Study 2, 1 patient in each treatment group (0.1%) had an infection resulting in death.

Fails and Fail-related Injuries
In the two randomized placebo-controlled clinical trials, fails including fail-related injuries, occurred in 9% of patients treated with XTANDI compared to 4% of patients treated with placebo. Falls were not associated with loss of consciousness or seizure. Fail-related injuries were more severe in patients treated with XTANDI and included non-pathologic fractures, joint injuries and hematoma.

Hypertension
In the two randomized placebo-controlled trials, hypertension was reported in 11% of patients receiving XTANDI and 4% of patients receiving placebo. No patients experienced hypertensive crisis. Medical history of hypertension was balanced between arms. Hypertension led to study discontinuation in < 1% of patients in each arm.

Post-Marketing Experience
The following adverse drug reactions have been identified during post approval use of XTANDI. Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate the frequency or establish a causal relationship to drug exposure.

Body as a Whole: hypersensitivity (tongue edema, lip edema, and pharyngeal edema)

**Geriatric Use**

Of 1671 patients who received XTANDI in the two randomized placebo-controlled clinical trials, 75% were 65 and over, and while 31% were 75 and over. No overall differences in safety or effectiveness were observed between these patients and younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

**Patients with Renal Impairment**

A dedicated renal impairment trial for XTANDI has not been conducted. Based on the population pharmacokinetic analysis using data from clinical trials in patients with metastatic CRPC and healthy volunteers, no significant difference in enzalutamide clearance was observed in patients with pre-existing mild to moderate renal impairment (30 mL/min < creatinine clearance [CrCl] < 60 mL/min) compared to patients with baseline normal renal function (CrCl > 90 mL/min).

No initial dosage adjustment is necessary for patients with mild to moderate renal impairment. Severe renal impairment (CrCl < 30 mL/min) and end-stage renal disease have not been assessed.

**Patients with Hepatic Impairment**

Dedicated hepatic impairment trials compared the composite systemic exposure of enzalutamide plus N-desmethyl enzalutamide in volunteers with baseline mild, moderate, or severe hepatic impairment (Child-Pugh Class A, B, or C, respectively) versus healthy controls with normal hepatic function. The composite AUC of enzalutamide plus N-desmethyl enzalutamide was similar in volunteers with mild, moderate, or severe baseline hepatic impairment compared to volunteers with normal hepatic function. No initial dosage adjustment is necessary for patients with baseline mild, moderate, or severe hepatic impairment.

**OVERDOSE**

In the event of an overdose, stop treatment with XTANDI and initiate general supportive measures taking into consideration the half-life of 5.8 days. In a dose escalation study, no seizures were reported at ≥240 mg daily, whereas 3 seizures were reported, 1 each at 360 mg, 480 mg, and 600 mg daily. Patients may be at increased risk of seizure following an overdose.

**NONCLINICAL TOXICOLOGY**

**Carcinogenesis, Mutagenesis, Impairment of Fertility**

Long-term animal studies have not been conducted to evaluate the carcinogenic potential of enzalutamide. Enzalutamide did not induce mutations in the bacterial reverse mutation (Ames) assay and was not genotoxic in either the in vitro mouse lymphoma thymidine kinase (Tk) gene mutation assay or the in vivo mouse micronucleus assay.

Based on nonclinical findings in repeat-dose toxicity studies, which were consistent with the pharmacological action of enzalutamide, fertility may be impaired by treatment with XTANDI. In an 18-week study in rats, atrophy of the prostate and seminal vesicles was observed at 30 mg/kg/day (equal to the human exposure based on AUC in 4-, 13-, and 28-week studies in dogs, hypospermatogenesis and atrophy of the prostate and epididymides were observed at 4 mg/kg/day (0.5 times the human exposure based on AUC).

Manufactured for and Distributed by: Astellas Pharma US, Inc., Northbrook, IL 60062

Marketing by: Astellas Pharma US, Inc., Northbrook, IL 60062

Pfizer Inc., New York, NY 10017

Revised: July 2017
18K0089-XTA-WPI
Rx Only

© 2017 Astellas Pharma US, Inc.

XTANDI® is a registered trademark of Astellas Pharma Inc.
UROLOGISTS ARE CORDIALLY INVITED TO ATTEND THIS PRESENTATION SPONSORED BY

Astellas

Latest Perspectives in OAB Treatment

PRESENTED BY

SCOTT MACDIARMID, MD

FOR UROLOGISTS

SATURDAY, MAY 19, 2018
1:30PM – 2:30PM
THE MOSCONIE CENTER
SCIENCE & TECHNOLOGY HALL D
ICU THEATER, BOOTH #5366
800 HOWARD STREET
SAN FRANCISCO, CA 94103

REGISTRATION WILL BE CONDUCTED ON SITE ON A FIRST COME, FIRST SERVE BASIS

Astellas Pharma US, Inc. (“Astellas”) is subject to U.S. Federal and State transparency laws that require Astellas to track and report meals and other transfers of value provided to certain U.S. health care professionals (including physicians). To comply with these obligations, for attendees who receive any portion of the meal provided at this program, Astellas will report the attendee’s name and the value of the meal received. Astellas offers you the option to attend the event but not receive the meal. Please ask the Program Organizer for more information about this opt-out option.

Additional restrictions apply to the following individuals: For U.S. Healthcare Providers in Vermont or those affiliated with the U.S. Department of Veterans Affairs or Department of Defense: Several states and federal agencies in the United States restrict your interactions with Astellas, including the provision of in-kind benefits (such as meals) at company-sponsored events. If you are a healthcare professional in Vermont or are affiliated with the U.S. Department of Veterans Affairs, Department of Defense, or other federal executive branch entity, Astellas policy prohibits providing you a meal at this program. If you would like to attend, but not partake in the meal, please refer to the opt-out option below.

For U.S. Licensed Prescribers in Minnesota: Under Minnesota law, Astellas may provide meals and other transfers of value to Minnesota licensed prescribers if the annual (calendar year) aggregate total of all value transfers of any kind from Astellas to a Minnesota prescriber does not exceed $50.00 USD, subject to some exceptions. Astellas has policies and procedures that are intended to help ensure compliance with this annual aggregate limit. If you have questions about your annual aggregate value transfers from Astellas or the impact of accepting the meal provided at this event on your annual total, please consult the Program Organizer. In addition, if you would like to attend, but not partake in the meal, please refer to the opt-out option below.
APNs AND PAs ARE CORDIALLY INVITED TO ATTEND THIS PRESENTATION SPONSORED BY

Latest Perspectives in OAB Treatment

PRESENTED BY
MICHAEL KENNELLY, MD
FOR ADVANCED PRACTICE NURSES AND PHYSICIAN ASSISTANTS

SUNDAY, MAY 20, 2018
12:00PM – 1:00PM
THE MOSCONTE CENTER
ROOMS 215 & 216
800 HOWARD STREET
SAN FRANCISCO, CA 94103

REGISTRATION WILL BE CONDUCTED ON SITE ON A FIRST COME, FIRST SERVE BASIS

We look forward to seeing you!

For U.S. Healthcare Providers who maintain a New Jersey license to prescribe: New Jersey sets a limit of $15 for the value of a meal that can be provided to you at this program. In instances where the value exceeds $15, you are not permitted to receive a meal at the program. If you would like to attend, but not partake in the meal, please refer to the opt-out option below.

For Foreign Healthcare Providers: Some foreign countries restrict the provision of or require the reporting of in-kind benefits (such as meals) to health care professionals at company-sponsored events. Astellas has policies and procedures that are intended to help ensure compliance with these requirements and restrictions. To help ensure compliance with applicable requirements, Astellas policy prohibits providing a meal to you in conjunction with this event. If you would like to attend, but not partake in the meal, please refer to the opt-out option below.

Opt-Out Option: Astellas offers an opt-out option that allows you to still attend this event but not receive the meal. Please ask the Program Organizer for more information about the opt-out option. Astellas has adopted the PhRMA Code on Interactions with Healthcare Professionals, which is designed to foster ethical relationships with healthcare professionals. In accordance with the PhRMA Code, we will not pay for the expenses of a healthcare professional’s spouse or guest, and such individuals should not attend the program, unless they have a bona fide professional interest in the information being shared at the program. We appreciate your understanding and support of our commitment to these ethical standards.
Establishment of the AUA in 1902 represented a milestone in the advancement of urological science. Astellas is honored to be a President’s Circle Patron for the 14th consecutive year, sharing the AUA’s commitment to improving urological clinical care. By offering educational resources in 10 languages to healthcare professionals, relentlessly pursuing cutting-edge research, and forging new partnerships within the Urology community, Astellas shares the AUA’s monumental mission to support and improve the lives of patients with urologic conditions.

Changing tomorrow together.
# Table of Contents

<table>
<thead>
<tr>
<th>Category</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Board of Directors</td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>Committees</td>
<td></td>
<td>4</td>
</tr>
<tr>
<td>CME Information</td>
<td></td>
<td>7</td>
</tr>
<tr>
<td>Specialty Programs</td>
<td></td>
<td>9</td>
</tr>
<tr>
<td>Office of Education Courses</td>
<td></td>
<td>11</td>
</tr>
<tr>
<td><strong>Thursday</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Society of Academic Urologists</td>
<td></td>
<td>17</td>
</tr>
<tr>
<td>2018 Evidence-Based Clinical Management of Advanced and Castration-Resistant Prostate Cancer</td>
<td></td>
<td>18</td>
</tr>
<tr>
<td><strong>Friday</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plenary: Prime Time, Morning Session</td>
<td></td>
<td>19</td>
</tr>
<tr>
<td>Plenary: Prime Time, Afternoon Session</td>
<td></td>
<td>19</td>
</tr>
<tr>
<td>Engineering and Urology Section of the Endourological Society</td>
<td></td>
<td>20</td>
</tr>
<tr>
<td>Poster, Podium and Video Sessions (MP1-6, PD1-4, V1)</td>
<td></td>
<td>20</td>
</tr>
<tr>
<td>Urologic Oncology Research Symposium: Tumor Microenvironment and Immunology: Frontiers in Cancer Therapy</td>
<td></td>
<td>36</td>
</tr>
<tr>
<td>Society for Pediatric Urology</td>
<td></td>
<td>38</td>
</tr>
<tr>
<td>Indian American Urological Association</td>
<td></td>
<td>38</td>
</tr>
<tr>
<td>AUA/Confederación Americana de Urología</td>
<td></td>
<td>39</td>
</tr>
<tr>
<td>World Chinese Urological Society</td>
<td></td>
<td>39</td>
</tr>
<tr>
<td>Sexual Medicine Society of North America</td>
<td></td>
<td>42</td>
</tr>
<tr>
<td>Poster, Podium and Video Sessions (MP7-12, PD5-8, V2)</td>
<td></td>
<td>43</td>
</tr>
<tr>
<td>Society of Genitourinary Reconstructive Surgeons</td>
<td></td>
<td>59</td>
</tr>
<tr>
<td>Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction</td>
<td></td>
<td>60</td>
</tr>
<tr>
<td>Poster and Podium Sessions (MP13-18, PD9-12)</td>
<td></td>
<td>60</td>
</tr>
<tr>
<td>Poster, Podium and Video Sessions (MP19-24, PD13-16, V3)</td>
<td></td>
<td>76</td>
</tr>
<tr>
<td><strong>Saturday</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plenary: Prime Time, Morning Session</td>
<td></td>
<td>95</td>
</tr>
<tr>
<td>Plenary: Next Frontier, Afternoon Session</td>
<td></td>
<td>95</td>
</tr>
<tr>
<td>Plenary: Prime Time, Afternoon Session</td>
<td></td>
<td>96</td>
</tr>
<tr>
<td>Poster, Podium and Video Sessions (MP25-30, PD17-20, V4)</td>
<td></td>
<td>97</td>
</tr>
<tr>
<td>Society for Pediatric Urology</td>
<td></td>
<td>114</td>
</tr>
<tr>
<td>Society for Basic Urologic Research and Society of Urologic Oncology</td>
<td></td>
<td>114</td>
</tr>
<tr>
<td>American College of Osteopathic Surgeons</td>
<td></td>
<td>115</td>
</tr>
<tr>
<td>Urologic Care for the Advanced Practice Provider</td>
<td></td>
<td>115</td>
</tr>
<tr>
<td>Poster and Podium Sessions (MP31-36, PD21-24)</td>
<td></td>
<td>116</td>
</tr>
<tr>
<td>Society of Urologic Oncology</td>
<td></td>
<td>130</td>
</tr>
<tr>
<td>Research Forum I: Funding Opportunities and Grant Writing Guidance for Early-Career Investigators</td>
<td></td>
<td>131</td>
</tr>
<tr>
<td>Asociación Española de Urología</td>
<td></td>
<td>132</td>
</tr>
<tr>
<td>Poster, Podium and Video Sessions (MP37-42, PD25-29, V5)</td>
<td></td>
<td>132</td>
</tr>
<tr>
<td>Society for Basic Urologic Research</td>
<td></td>
<td>150</td>
</tr>
<tr>
<td>Hibernian Urological Society</td>
<td></td>
<td>150</td>
</tr>
<tr>
<td>Polish Urological Association and Hungarian Urological Association</td>
<td></td>
<td>150</td>
</tr>
<tr>
<td>Research Forum II: Early Career Investigators Showcase</td>
<td></td>
<td>151</td>
</tr>
<tr>
<td>Clinical Controversies in Men’s Health</td>
<td></td>
<td>152</td>
</tr>
<tr>
<td>Poster, Podium and Video Sessions (MP43-48, PD30-34, V6)</td>
<td></td>
<td>152</td>
</tr>
</tbody>
</table>
Sunday

Plenary: Next Frontier, Morning Session ................................................................. 171
Plenary: Prime Time, Morning Session ................................................................. 171
Plenary: Next Frontier, Afternoon Session ............................................................ 172
Plenary: Prime Time, Afternoon Session ............................................................... 173
Society of Women in Urology ............................................................................... 174
Poster, Podium and Video Sessions (MP49-54, PD35-38, V7) .............................. 174
Residents Forum .................................................................................................... 191
Challenges for Urologic Research: Moving Biomarkers into Practice ............... 192
Urologic Care for the Advanced Practice Provider – Sunday ............................. 192
Poster, Podium and Video Sessions (MP55-60, PD39-42, V8) .............................. 193
16th International Prostate Forum .......................................................................... 210
Society of Urologic Robotic Surgery ...................................................................... 210
Society for Infection and Inflammation in Urology ............................................. 211
Poster, Podium and Video Sessions (MP61-66, PD43-47, V9) .............................. 212
Basic Sciences Symposium: Session I: Understanding Disorders and Differences in Sexual Development ............................................................ 229
Geriatric Urological Society .................................................................................. 229
Korean World Urologic Congress .......................................................................... 230
R. Frank Jones Urological Society ......................................................................... 231
Society for the Study of Male Reproduction ....................................................... 231
Urological Society for American Veterans ............................................................ 232
British Association of Urological Surgeons – Urological Society of Australia and New Zealand .......................................................... 232
Japanese Urological Association ......................................................................... 233
Sociedad Argentina de Urologı´a ............................................................................ 233
Association Française d’Urologie .......................................................................... 234
Poster and Podium Sessions (MP67-72, PD48-52) .................................................. 234

Monday

Plenary: Next Frontier, Morning Session ................................................................. 251
Plenary: Prime Time, Morning Session ................................................................. 252
Plenary: Prime Time, Afternoon Sessions .............................................................. 252
Poster, Podium and Video Sessions (MP73-78, PD53-57, V10) ......................... 254
Basic Sciences Symposium: Session II: Understanding Male Infertility ............. 272
American Society for Men’s Health ...................................................................... 273
Urologic Society for Transplantation & Renal Surgery ......................................... 273
American Board of Urology Town Hall ................................................................. 274
Poster, Podium and Video Sessions (MP79-84, PD58-62, V11) ......................... 277
Young Urologists Forum ........................................................................................ 291
Poster, Podium and Video Sessions (MP85-89, PD63-66, V12) ......................... 291
AUA/Brazilian Portuguese Urology Program ...................................................... 305
Research on Calculus Kinetics Society ................................................................ 305
Pan African Urological Association/Caribbean Urological Surgeons Association .......................................................... 306
History of Urology Forum ..................................................................................... 307
Philippine Urological Association ....................................................................... 308
Società Italiana di Urologia .................................................................................. 308

Exhibitor Listing ..................................................................................................... 311
Author Index .......................................................................................................... 313
2017-2018 Board of Directors

Officers of the Board of Directors

President .............................................................................................................................................J. Brantley Thrasher
President-Elect .................................................................................................................................Robert C. Flanigan
Immediate Past President ..............................................................................................................Richard K. Babayan
Secretary ............................................................................................................................................Manoj Monga
Treasurer ...........................................................................................................................................David F. Green

Section Representatives to the Board of Directors
Mid-Atlantic.........................................................................................................................................Roger E. Schultz
New England.......................................................................................................................................E. Ann Gormley
New York........................................................................................................................................Frederick A. Gulmi
North Central.....................................................................................................................................Chandru P. Sundaram
Northeastern.......................................................................................................................................Barry A. Kogan
South Central .....................................................................................................................................Randall B. Meacham
Southeastern .......................................................................................................................................Thomas F. Stringer
Western.............................................................................................................................................Scott K. Swanson

AUA Headquarters
American Urological Association, Inc.
1000 Corporate Boulevard
Linthicum, Maryland 21090
Telephone: 410-689-3700
FAX: 410-689-3800
E-mail: aua@auanet.org
Website: www.auanet.org

Annual Business Meeting
Monday, May 21, 2018 @ 12:00 pm
Moscone Convention Center, Hall E
Room 22-23
2018 Committees

Program Planning Committee

- Rosalyn Adam
- Michael Albo
- Joseph Alukal
- John Barry
- Julia Barthold
- Kevin Billups
- David Bushinsky
- Douglas Canning
- Peter Carroll
- Toby Chai
- Michael Coburn
- Hillary Copp
- Ananias Diokno
- Tracy Downs
- Scott Eggener
- Sean Elliott
- Christopher Evans
- Robert Evans
- Matthew Gettman
- Khurshid Ghani
- Inderbir Gill
- Thomas Goebl
- Jacqueline Hamilton
- Ashok Hemal
- Tony Hemdon
- Jeffrey Holzbeierlein
- Adrian Joyce
- Byron Joyner
- Jihad Kaouk
- Anil Kapoor
- Louis Kavoussi
- Mohit Khera
- Ziya Kirkali
- Badrinath Konety
- Hari Koul
- Thomas Lendvay
- Kirk Lo
- Armando Lorenzo
- Brian Matlaga
- Stephen Nakada
- Caleb Nelson
- Victor Nitti
- Aria Olumi
- Lane Palmer
- Margaret Pearle
- David Penson
- Peter Pinto
- Michel Pontari
- Christopher Porter
- James Porter
- Glenn Preminger
- Ganesh Raj
- Pramod Reddy
- Robert Reiter
- Daniel Rosenstein
- Daniel Ruksals
- Andrew Rule
- Edmund Sabanegh
- Hossein Sadeghi-nejad
- Alp Sener
- Ajay Singla
- Elia Skinner
- Ariana Smith
- Evan Vapnek
- Run Wang
- John Wei
- J. Stuart Wolf
- Hadley Wood
- Dan Williams

Urologic Video Education Committee

Jennifer Anger
Ketan Badani
Clint Bahler
Norberto Bernardo
Benjamin Breyer
David Canes
Maude Carmel
Justin Chee
Seth Cohen
Akhill Das
Gregory Dean
Daniel Dugi
Patricio Gargollo
Kurshid Ghani
Reza Ghavamian
Jessie Gills
Serge Ginzburg
Mohan Gundeti
Justin Han
Brian Hu
Kiranpreet Khurana
Isaac Kim
John Knoedler
Bodo Knudsen
Costas Lallas
Susan MacDonald
Bahaa Malaeb
Brandon Manley
Akanksa Mehta
Bobby Najari
Michel Pontari
James Porter
Jay Raman
Adam Reese
Benjamin Ristau
Neal Rowe
Noah Schenkman
Michelle Semins
David Shin
Ajay Singla
C. J. Stimson
Jeffrey Tomaszewski
Ramakrishna Venkatesh
Paul Womble
Hadley Wyre
Jennifer Yang

Program Abstract Review Committee

Rosalyn M. Adam
Peter C. Albertsen
Zaki Almallah
Seth Alpert
Karl-Erik Andersson
Kenneth W. Angermeier
Jodi Antonelli
Monish Aron
William J. Aronson
Dean G. Assimos
Anthony Atala
Riccardo Autorino
Timothy D. Averch
Michael Bailey
Linda Baker
K. C. Balaji
D. Duane Baldwin
Chris Bangma
Daniel A. Barocas
Aaron P. Bayne
Arie S. Beldegrun
Carol J. Bennett
Nelson Bennett
Mitchell C. Benson
Ryan K. Berglund
Bob Berookhim
Jay T. Bishoff
Trinity Bivalacqua
Jerry G. Blaivas
Michael L. Blute
Stephen A. Boorjian
James F. Borin
Mike S. Borofsky
Robert Brannigan
William O. Brant
Peter N. Breetan
Benjamin Breyer
Alberto Briganti
Gerald Brock
Gregory A. Broderick
Statement of Need

Urologists need a thorough knowledge of the most recent developments and techniques as well as established guidelines in urology to ensure the highest standards of patient care and safety.

Learning Objectives

At the conclusion of the 2018 AUA Annual Meeting, participants should be able to:
● describe recent developments in the medical and surgical management of urology patients
● identify new technologies for the treatment of urological conditions
● integrate the latest guidelines on the management of urological diseases into their practice
● incorporate evidence-based research and literature into the shared decisions making process

Accreditation Statement

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American Urological Association designates this live activity for a maximum of 46.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credits™.

Evidence-Based Content

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous and free of commercial bias.

AUA Disclosure Policy

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments.

Resolution of Conflict of Interest

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest, and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
● Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director and/or Education Content Review Committee or its subgroup
● Limit content to evidence with no recommendations
● Introduction of a debate format with an unbiased moderator (point-counterpoint)
● Inclusion of moderated panel discussion
● Publication of a parallel or rebuttal article for an article that is felt to be biased
● Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
● Divestiture of the relationship by faculty

Off-label or Unapproved Use of Drugs or Devices

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

AUA ATTENDEE INFORMATION & POLICIES

Disclaimer

The opinions and recommendations expressed by faculty, authors, and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Consent to Use of Photographic Images

Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA’s use and distribution (both now and in the future) of the attendee’s image or voice in photographs and electronic reproductions of such events and activities.
Audio, Video and Photographic Equipment

The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

Reproduction Permission

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Special Assistance

The American Urological Association (AUA), an organization accredited for continuing medical education (CME), complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, a written request should be submitted at least one month in advance. For additional assistance with your request please call 1-800-908-9414.

Getting Your CME Credits or Certificate of Attendance

You can claim your CME/Certificate of Attendance several ways:

- Onsite: Hall A, CME Booth in Registration
  Saturday, 7:30 a.m. – 6 p.m.
  Sunday, 6:30 a.m. – 4 p.m.
  Monday, 6:30 a.m. – 6 p.m.

- Online

- Mobile App (iPhone, iPad, Android phones and tablets)

Note: All 2018 AUA Annual Meeting CME credits/participation must be claimed by December 31, 2018. Credits/participation for the 2018 AUA Annual Meeting cannot be claimed after this date. You must scan your badge upon entrance into courses and sessions (except for Plenary) offered for credit to have your credits automatically entered onto your transcript. All Plenary Session credits must be self-claimed with a valid badge login at the CME booth, online or via the Annual Meeting Mobile App. Credits will be awarded only to the person whose name is associated with the badge.

Questions? Email education@AUAnet.org.
<table>
<thead>
<tr>
<th>Specialty Program</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>American College of Osteopathic Surgeons</td>
<td>115</td>
</tr>
<tr>
<td>American Society for Men’s Health</td>
<td>273</td>
</tr>
<tr>
<td>Asociación Española de Urología</td>
<td>132</td>
</tr>
<tr>
<td>Association Française d’Urologie</td>
<td>234</td>
</tr>
<tr>
<td>AUA/Brazilian Portuguese Urology Program</td>
<td>305</td>
</tr>
<tr>
<td>AUA/Confederación Americana de Urología</td>
<td>39</td>
</tr>
<tr>
<td>British Association of Urological Surgeons – Urological Society of Australia and New Zealand</td>
<td>232</td>
</tr>
<tr>
<td>Engineering and Urology Section of the Endourological Society</td>
<td>20</td>
</tr>
<tr>
<td>Geriatric Urological Society</td>
<td>229</td>
</tr>
<tr>
<td>Hibernian Urological Society</td>
<td>150</td>
</tr>
<tr>
<td>Indian American Urological Association</td>
<td>38</td>
</tr>
<tr>
<td>Japanese Urological Association</td>
<td>233</td>
</tr>
<tr>
<td>Korean World Urologic Congress</td>
<td>230</td>
</tr>
<tr>
<td>Pan African Urological Association/Caribbean Urological Surgeons Association</td>
<td>306</td>
</tr>
<tr>
<td>Philippine Urological Association</td>
<td>308</td>
</tr>
<tr>
<td>Polish Urological Association and Hungarian Urological Association</td>
<td>150</td>
</tr>
<tr>
<td>R. Frank Jones Urological Society</td>
<td>231</td>
</tr>
<tr>
<td>Research on Calculus Kinetics Society</td>
<td>305</td>
</tr>
<tr>
<td>Sexual Medicine Society of North America</td>
<td>42</td>
</tr>
<tr>
<td>Sociedad Argentina de Urología</td>
<td>233</td>
</tr>
<tr>
<td>Società Italiana di Urologia</td>
<td>308</td>
</tr>
<tr>
<td>Society for Basic Urologic Research</td>
<td>150</td>
</tr>
<tr>
<td>Society for Basic Urologic Research and Society of Urologic Oncology</td>
<td>114</td>
</tr>
<tr>
<td>Society for Infection and Inflammation in Urology</td>
<td>211</td>
</tr>
<tr>
<td>Society for Pediatric Urology</td>
<td>38</td>
</tr>
<tr>
<td>Society for the Study of Male Reproduction</td>
<td>231</td>
</tr>
<tr>
<td>Society of Academic Urologists</td>
<td>17</td>
</tr>
<tr>
<td>Society of Genitourinary Reconstructive Surgeons</td>
<td>59</td>
</tr>
<tr>
<td>Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction</td>
<td>60</td>
</tr>
<tr>
<td>Society of Urologic Oncology</td>
<td>130</td>
</tr>
<tr>
<td>Society of Urologic Robotic Surgery</td>
<td>210</td>
</tr>
<tr>
<td>Society of Women in Urology</td>
<td>174</td>
</tr>
<tr>
<td>Urologic Society for Transplantation &amp; Renal Surgery</td>
<td>273</td>
</tr>
<tr>
<td>Urological Society for American Veterans</td>
<td>232</td>
</tr>
<tr>
<td>World Chinese Urological Society</td>
<td>39</td>
</tr>
</tbody>
</table>
### Thursday, May 17, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Course Code</th>
<th>Course Title</th>
<th>Course Director(s)</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 am - 5:00 pm</td>
<td>101HO</td>
<td>HANDS-ON UROLOGIC ULTRASOUND</td>
<td>Pat Fulgham, Course Director</td>
<td>MCC WEST, 3008 and 3010</td>
</tr>
<tr>
<td></td>
<td>102HO</td>
<td>GENITAL GENDER AFFIRMING SURGERY FOR THE TRANSGENDER PATIENT: A DIDACTIC AND HANDS-ON FRESH CADAVER-BASED COURSE</td>
<td>Maurice Garcia, Course Director, David Ralph, Stanton Honig, Dan Karasic, Lee Zhao, Polina Reyblat, Annemarie Donjacour, Nripendra Dhillon, Dana Rohde, Nlm Christopher, Philip Thomas, Nick Gorton and UCSF Anatomy Faculty</td>
<td></td>
</tr>
</tbody>
</table>

### Friday, May 18, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Course Code</th>
<th>Course Title</th>
<th>Course Director(s)</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 am - 9:30 am</td>
<td>009IC</td>
<td>NOCTURIA: ADVANCES IN DIAGNOSIS &amp; MANAGEMENT</td>
<td>Jeffrey Weiss, Course Director</td>
<td>MCC WEST, 2010</td>
</tr>
<tr>
<td></td>
<td>010IC</td>
<td>MULTI-DISCIPLINARY, INTERACTIVE TUMOR BOARD: MRI-TRUS FUSION-GUIDED PROSTATE BIOPSY</td>
<td>Inderbir Gill, Course Director, Andre Luis de Castro Abreu, Mahul Amin, Suzanne Palmer</td>
<td>MCC WEST, 2002</td>
</tr>
<tr>
<td>1:30 pm - 3:30 pm</td>
<td>011IC</td>
<td>MULTI-PARAMETRIC ULTRASOUND IN THE DIAGNOSIS OF PROSTATE CANCER</td>
<td>Pat Fulgham, Course Director, Tillmann Loch, Edouard Trabulsli</td>
<td>MCC WEST, 2009</td>
</tr>
<tr>
<td>4:00 pm - 6:00 pm</td>
<td>015IC</td>
<td>ADVANCED ROBOTIC UROLOGIC ONCOLOGY: EXTREME UNFORGETTABLE CASES &amp; THEIR MANAGEMENT</td>
<td>Vipul Patel, Course Director, David Albala, Sam Bhayani, Rafael Coelho, Alexandre Mottie, Bernardo Rocco</td>
<td>MCC WEST, 2010</td>
</tr>
</tbody>
</table>
OFFICE OF EDUCATION COURSES
ALL COURSES ARE APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 19, 2018 7:30 am - 6:00 pm

7:30 am - 9:30 am

021C SURGICAL & MEDICAL STONE GUIDELINES UPDATE: A CASE-BASED APPROACH
Ojas Shah, Course Director
Dean Assimos, John Lieske, Brian Matlaga
Room: MCC WEST, 2002

022C PERIOPERATIVE OPIOID-SPARING ANALGESIA STRATEGIES FOR ENHANCED RECOVERY AFTER UROLOGIC SURGERY
T. Anthony Anderson, Course Director
Francis McGovern
Room: MCC WEST, 2008

023C MANAGEMENT OF URETERAL STRicture DISEASE
Sammy Elsamra, Course Director
Thomas Jarrett, Louis Kavoussi, Richard Link
Room: MCC WEST, 2006

024C TÉCNICAS DE AVANZADA EN CIRUGÍA RECONSTRUCTIVA URETRAL: ANÁLISIS DE NUESTROS ERRORES (CURSO EN ESPAÑOL)
Ramón Virasoro, Course Director
Javier Angulo, Reynaldo Gomez
Room: MCC WEST, 2004

025C ROBOTIC SINGLE-PORT SURGERY: APPROPRIATE ADOPTION INTO YOUR PRACTICE
Jihad Kaouk, Course Director
Matthew Gettman, Jean Joseph
Room: MCC WEST, 2010

026C INFERTILITY UPDATE 2018: A COMPREHENSIVE APPROACH TO THE CLINICAL DIAGNOSIS & TREATMENT OF THE INFERTILE MALE
Larry Lipschultz, Course Director
Robert Brannigan, Michael Eisenberg
Room: MCC WEST, 2009

7:30 am – 10:30 am

103HO MR US FUSION GUIDED PROSTATE BIOPSY: INTEGRATING MP MRI AND BIOPSY INTO YOUR UROLOGIC PRACTICE FOR SCREENING, DIAGNOSIS AND TREATMENT PLANNING
Ardeshir Rastinehad, Co-Course Director
Peter Pinto, Co-Course Director
Arvin George, Soroush Rais-Bahrami, Samir Taneja, Leonard Marks, Ashutosh Tewari, James Wysock, Sara Lewis, Ismail Baris Turkbey, Robert Villani, Srini Vas Virganti, Osamu Ukimura, Jonathan Coleman, Winston Barzelli
Room: MCC WEST, 3008 and 3010

10:00 am - 12:00 pm

027C NEW TECHNOLOGY IN THE MANAGEMENT OF STONE DISEASE: WHAT’S NEW, WHAT WORKS, & WHAT TO BUY
Bodo Knudsen, Course Director
Ben Chew, Mitchell Humphreys
Room: MCC WEST, 2010

028C DISORDERS OF THE PENIS: PEYRONIE’S DISEASE, CONGENITAL CURVATURE & ADULT ACQUIRED BURIED PENIS
Laurence Levine, Course Director
David Ralph
Room: MCC WEST, 2008

029C TESTOSTERONE THERAPY: CHALLENGES & CONTROVERSIES FOR THE EXPERIENCED CLINICIAN (TRADUCIDO EN ESPAÑOL)
Abraham Morgentaler, Course Director
Abdulmaged Traish
Room: MCC WEST, 2002

030C WHAT A GENERAL UROLOGIST SHOULD KNOW ABOUT CARE FOR TRANSGENDER PATIENTS
Dmitriy Nikolavsky, Course Director
Curtis Crane, Lee Zhao
Room: MCC WEST, 2006

031C CONTEMPORARY PHARMACOTHERAPY FOR OAB
Eric Rovner, Course Director
Christopher Chapple, Alan Wein
Room: MCC WEST, 2004
032IC  VASECTOMY: A VERY PRACTICAL CASE-BASED COURSE ON PREOPERATIVE, INTRAOPERATIVE & POSTOPERATIVE MANAGEMENT  Ira Sharlip, Course Director  Stanton Honig, Joel Marmar, Jay Sandlow  Room: MCC WEST, 2009  1:00 pm - 3:00 pm

104HO  PROSTATE MR IMAGING: WHAT A UROLOGIST SHOULD KNOW  Ardeshir Rastinehad, Co-Course Director  Rajan Gupta, Co-Course Director  Ismail Baris Turkbey, Robert Villani, Eran Ben-Levi, Sara Lewis, Arvin George, Srinivas Vourganti  Room: MCC WEST, 3008  4:00 pm - 6:00 pm

033IC  PARADIGM CHANGES IN A 40-YEAR-OLD OPERATION: INFLATABLE PENILE IMPLANT (IPP)  Steve Wilson, Course Director  Tobias Kohler, Paul Perito  Room: MCC WEST, 2008  1:30 pm - 3:30 pm

035IC  VAGINAL SURGERY FOR THE UROLOGIST  Victor Nitti, Course Director  Benjamin Brucker  Room: MCC WEST, 2004

036IC  MANAGING MALE AND FEMALE IC/BPS: COMPREHENSIVE MULTIModal THERAPY FOR PATIENTS WITH UROLOGIC PELVIC PAIN  Robert Evans, Course Director  Jennifer Fariello, Robert Moldwin  Room: MCC WEST, 2009

Sunday, May 20, 2018  7:30 am - 6:00 pm

7:30 am - 11:00 am

041C  AUA GUIDELINES: EVALUATION & MANAGEMENT OF LOCALIZED RENAL MASS, CASE-BASED APPROACH  Steven Campbell, Course Director  Brian Lane, Philip Pierorazio, Robert Uzzo  Room: MCC WEST, 2008

042IC  TRANSURETHRAL RESECTION OF BLADDER CANCER: A DECEPTIVELY DIFFICULT COMMON OPERATION - HOW TO IMPROVE  Mark Soloway, Course Director  Arthur Sagalowsky, Alexandre Zlotta  Room: MCC WEST, 2006

8:00 am - 11:00 am

106HO  PRACTICAL PCNL: FROM ACCESS TO EXIT  Robert Sweet, Course Director  Ardeshir Rastinehad, Thomas Chi, Zeph Okeke, David Leavitt, Sammy Elsamra, Zhamshid Okhunov, Michael Borofsky, Helena Chang, Dalton Baldwin, Matthew Sorensen, Jaime Landman, Patrick Samson  Room: MCC WEST, 3008 and 3010

105HO  PROSTATE MR IMAGING: WHAT A UROLOGIST SHOULD KNOW  Ardeshir Rastinehad, Co-Course Director  Rajan Gupta, Co-Course Director  Ismail Baris Turkbey, Robert Villani, Eran Ben-Levi, Sara Lewis, Arvin George, Srinivas Vourganti  Room: MCC WEST, 3008

034IC  URINARY DIVERSION – CURRENT INDICATIONS, TECHNIQUES & COMPLICATIONS  Siamak Daneshmand, Course Director  Eila Skinner  Room: MCC WEST, 2008

037IC  URODYNAMIC EVALUATION & ADVANCES IN MANAGEMENT OF NEUROGENIC LOWER URINARY TRACT DYSFUNCTION IN ADULTS: A CASE-BASED APPROACH  Hari Tunuguntla, Course Director  Angelo Gouse, Stephen Kraus  Room: MCC WEST, 2004

038IC  UPPER TRACT UROTHELIAL CARCINOMA: ENDOUROLOGICAL MANAGEMENT & TOPICAL THERAPY  Mantu Gupta, Course Director  Jean de la Rosette, Joseph Liao, Olivier Traxer  Room: MCC WEST, 2006

039IC  UROLOGICAL TRAUMA & RECONSTRUCTION  Michael Coburn, Course Director  Noel Armenakas, Steven Hudak, Allen Morey  Room: MCC WEST, 2009

040IC  SURGICAL MANAGEMENT OF STONE DISEASE: OPPOSING VIEWS  Stephen Nakada, Course Director  Margaret Pearle  Room: MCC WEST, 2010

043IC  NOVEL AGENTS & CONCEPTS IN THE MANAGEMENT OF HORMONE-NAIVE & CASTRATE-RESISTANT PROSTATE CANCER (TRADUCIDO EN ESPAÑOL)  Judd Moul, Course Director  Lawrence Karsh, Christopher Sweeney  Room: MCC WEST, 2002

044IC  AUA GUIDELINES 2018: LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA  Steven Kaplan, Course Director  Harris Foster, Kevin McVary, J. Kellogg Parsons  Room: MCC WEST, 2004

045IC  MANAGEMENT OF COMPLICATED URINARY DYSFUNCTION AFTER PROSTATE CANCER TREATMENT  Jaspreet Sandhu, Course Director  Kurt McCammon, O. Lenaine Westney  Room: MCC WEST, 2009
10:00 am - 12:00 pm

046IC TRIMODALITY THERAPY FOR MANAGEMENT OF MUSCLE INVASIVE BLADDER CANCER
Adam Feldman, Course Director
Jason Elstathniou, Richard Lee, James Rooney
Room: MCC WEST, 2008

047IC THE PRACTICAL MANAGEMENT OF OVERACTIVE BLADDER: INTEGRATING THE SUFU OVERACTIVE BLADDER CLINICAL CARE PATHWAY INTO YOUR PRACTICE
Benjamin Brucker, Course Director
Stephen Kraus, Diane Newman
Room: MCC WEST, 2006

048IC PESADILLAS EN ENDUROLOGÍA: NIGHTMARES IN ENDOUROLOGY (CURSO EN ESPAÑOL)
Daniel Olvera-Posada, Course Director
Brian Eisner, Carlos Mendez-Probst
Room: MCC WEST, 2002

049IC COMPLEX PELVIC RECONSTRUCTION: USE OF FLAPS
Shlomo Raz, Course Director
Ja-Hong Kim
Room: MCC WEST, 2009

1:00 pm - 3:00 pm

050IC MAINTAINING & RESTORING WOMEN'S SEXUAL FUNCTION IN 2018
Irwin Goldstein, Course Director
Noel Kim, Rachel Rubin, Nicole Szell
Room: MCC WEST, 2010

051IC COMMON PROBLEMS IN PEDIATRIC UROLOGY: WHAT EVERY UROLOGIST SHOULD KNOW
Richard Rink, Course Director
Mark Cain
Room: MCC WEST, 2008

052IC NEW TECHNOLOGIES IN BPH SURGERY: ENDOSCOPIC ENUCLEATION
Peter Gilling, Course Director
Andreas Gross, Lori Lerner
Room: MCC WEST, 2006

053IC UPPER TRACT UROTHELIAL CARCINOMA TUMOR BOARD: A CASE-BASED APPROACH TO MANAGEMENT
Surena Matin, Course Director
Wes Kassouf, Shahrokh Shariat, Douglas Scherr
Room: MCC WEST, 2004

3:00 pm - 5:00 pm

107HO CONTEMPORARY URODYNAMICS
Craig Comiter, Course Director
Mikel Gray, Ekene Enemchukwu, Mike Albo, Christopher Elliott, Sandip Vasavada, David Ginsberg, Larissa Rodriguez, Anne Suskind, Polina Rebylat, Stephen Kraus, Una Lee
Room: MCC WEST, 3008 and 3010

4:00 pm - 6:00 pm

054IC UROLITHIASIS: METABOLIC EVALUATION & MEDICAL TREATMENT
Michael Lipkin, Course Director
Jodi Antonelli, Sara Best, Brian Eisner
Room: MCC WEST, 2002

055IC GENETIC TESTING IN PROSTATE CANCER: UNDERSTANDING CLINICAL IMPLICATIONS FOR EARLY DETECTION, LOCALIZED DISEASE & CRPC
Todd Morgan, Course Director
Heather Cheng, Leonard Gomella
Room: MCC WEST, 2009

1:30 pm - 3:30 pm

056IC CATASTROPHIES, COMPLICATIONS & CORRECTIONS IN PERCUTANEOUS RENAL SURGERY
Arthur Smith, Course Director
Ralph Clayman, Mahesh Desai, Evangelos Liatsikos
Room: MCC WEST, 2010

057IC 2018 CODING & REIMBURSEMENT UPDATE
Jonathan Rubenstein, Course Director
Stephanie Stinchcomb
Room: MCC WEST, 2008

058IC MANAGEMENT OF COMMON DILEMMAS IN PROSTATE CANCER DIAGNOSIS, STAGING & TREATMENT
Gerald Andriole, Course Director
Anthony D'Amico, Adam Kibel, A. Oliver Sartor
Room: MCC WEST, 2006

059IC INTEGRATING MOLECULAR IMAGING INTO UROLOGIC ONCOLOGY CLINICAL PRACTICE: CURRENT APPROACHES & FUTURE OPPORTUNITIES
Marc Bjurlin, Course Director
Michael Gorin, Thomas Hope, Homer Macapinlac
Room: MCC WEST, 2002

Monday, May 21, 2018 7:30 am - 6:00 pm

7:30 am - 9:30 am

050IC MAINTAINING & RESTORING WOMEN'S SEXUAL FUNCTION IN 2018
Irwin Goldstein, Course Director
Noel Kim, Rachel Rubin, Nicole Szell
Room: MCC WEST, 2010

051IC COMMON PROBLEMS IN PEDIATRIC UROLOGY: WHAT EVERY UROLOGIST SHOULD KNOW
Richard Rink, Course Director
Mark Cain
Room: MCC WEST, 2008

052IC NEW TECHNOLOGIES IN BPH SURGERY: ENDOSCOPIC ENUCLEATION
Peter Gilling, Course Director
Andreas Gross, Lori Lerner
Room: MCC WEST, 2006

053IC UPPER TRACT UROTHELIAL CARCINOMA TUMOR BOARD: A CASE-BASED APPROACH TO MANAGEMENT
Surena Matin, Course Director
Wes Kassouf, Shahrokh Shariat, Douglas Scherr
Room: MCC WEST, 2004

7:30 am - 9:30 am

060IC OPTIMIZING THE TEAM APPROACH TO KIDNEY STONE CLINIC: THE UROLOGIST & ADVANCED PRACTICE PROVIDER (APP)
Nicole Miller, Course Director
Amy Krambeck, Christy Krieg
Room: MCC WEST, 2010

061C EVALUATION & MANAGEMENT OF URINARY TRACT BLEEDING: FROM ASYMPTOMATIC MICROHEMaturIA TO INTRACTABLE HEMORRHAGIC CYSTITIS
Stephen Boorjian, Course Director
Daniel Barocas, Jay Raman
Room: MCC WEST, 2008

1:00 pm - 3:00 pm

054IC UROLITHIASIS: METABOLIC EVALUATION & MEDICAL TREATMENT
Michael Lipkin, Course Director
Jodi Antonelli, Sara Best, Brian Eisner
Room: MCC WEST, 2002

055IC GENETIC TESTING IN PROSTATE CANCER: UNDERSTANDING CLINICAL IMPLICATIONS FOR EARLY DETECTION, LOCALIZED DISEASE & CRPC
Todd Morgan, Course Director
Heather Cheng, Leonard Gomella
Room: MCC WEST, 2009

3:00 pm - 5:00 pm

107HO CONTEMPORARY URODYNAMICS
Craig Comiter, Course Director
Mikel Gray, Ekene Enemchukwu, Mike Albo, Christopher Elliott, Sandip Vasavada, David Ginsberg, Larissa Rodriguez, Anne Suskind, Polina Rebylat, Stephen Kraus, Una Lee
Room: MCC WEST, 3008 and 3010

4:00 pm - 6:00 pm

056IC CATASTROPHIES, COMPLICATIONS & CORRECTIONS IN PERCUTANEOUS RENAL SURGERY
Arthur Smith, Course Director
Ralph Clayman, Mahesh Desai, Evangelos Liatsikos
Room: MCC WEST, 2010

057IC 2018 CODING & REIMBURSEMENT UPDATE
Jonathan Rubenstein, Course Director
Stephanie Stinchcomb
Room: MCC WEST, 2008

058IC MANAGEMENT OF COMMON DILEMMAS IN PROSTATE CANCER DIAGNOSIS, STAGING & TREATMENT
Gerald Andriole, Course Director
Anthony D'Amico, Adam Kibel, A. Oliver Sartor
Room: MCC WEST, 2006

059IC INTEGRATING MOLECULAR IMAGING INTO UROLOGIC ONCOLOGY CLINICAL PRACTICE: CURRENT APPROACHES & FUTURE OPPORTUNITIES
Marc Bjurlin, Course Director
Michael Gorin, Thomas Hope, Homer Macapinlac
Room: MCC WEST, 2002
OFFICE OF EDUCATION COURSES

ALL COURSES ARE APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

062IC  AUA GUIDELINES ON NON-MUSCLE INVASIVE BLADDER CANCER
Sam Chang, Course Director
James McKiernan, Chad Ritch
Room: MCC WEST, 2004

063IC  PROSTATE CANCER UPDATE
William Catalona, Course Director
Douglas Dahl, Stanley Liauw, Stacy Loeb, Robert Nadler, Russell Szmulewitz
Room: MCC WEST, 2002

064IC  COMPLICATIONS OF INCONTINENCE & PROLAPSE SURGERY: EVALUATION, INTERVENTION & RESOLUTION—A REVIEW FROM BOTH SPECIALTIES
Roger Dmochowski, Course Director
Alexander Gomelsky, Mickey Karram, William Stuart Reynolds
Room: MCC WEST, 2009

10:00 am - 12:00 pm

065IC  PROSTATE CANCER FOCAL THERAPY: IS IT THE RIGHT TIME FOR YOUR PRACTICE?
John Davis, Course Director
Peter Pinto, Ardeshir Rastinehad, Ashutosh Tewari
Room: MCC WEST, 2010

066IC  PRIMARY & REOPERATIVE HYPOSPADIAS REPAIR: AN EVIDENCE-BASED APPROACH
Warren Snodgrass, Course Director
Nicol Bush
Room: MCC WEST, 2008

067IC  MANAGEMENT OF NON-MUSCLE INVASIVE BLADDER CANCER: PRACTICAL SOLUTIONS FOR COMMON PROBLEMS
Kamal Pohar, Course Director
Ashish Kamat, Cheryl Lee, J. Alfred Witjes
Room: MCC WEST, 2006

068IC  NUTRITION COUNSELING FOR THE PREVENTION OF UROLITHIASIS
Patrick Lowry, Course Director
Sutchin Patel, Kristina Penniston
Room: MCC WEST, 2002

069IC  FOUNDATIONS OF FEMALE UROLOGY
J. Christian Winters, Course Director
Stephen Kraus, Nirit Rosenblum
Room: MCC WEST, 2009

1:30 pm - 3:30 pm

070IC  TECHNICAL TIPS & TRICKS IN MALE INFERTILITY: A GUIDE FOR THE PRACTICING UROLOGIST
Peter Schlegel, Course Director
Sheldon Marks, Robert Oates
Room: MCC WEST, 2010

071IC  CONTROVERSIES IN PROSTATE BIOPSY
Allen Seftel, Course Director
Jeffrey Tomaszewski
Room: MCC WEST, 2009

072IC  GERIATRIC UROLOGY: BASIC PRINCIPLES FOR UROLOGIC PRACTICE
Tomas Griebling, Course Director
Jonathan Bergman, Camille Vaughan
Room: MCC WEST, 2006

073IC  AUA GUIDELINES 2018: THE EVALUATION & MANAGEMENT OF TESTOSTERONE DEFICIENCY: WHAT YOU NEED TO KNOW
John Mulhall, Course Director
Robert Brannigan, Landon Trost
Room: MCC WEST, 2004

074IC  AUA CRPC GUIDELINES
Michael Cookson, Course Director
David Jarrard, Adam Kibel
Room: MCC WEST, 2002

4:00 pm - 6:00 pm

075IC  COMPLICATIONS OF ROBOTIC UROLOGICAL SURGERY, PREVENTION, RECOGNITION & MANAGEMENT
Rene Sotelo, Course Director
Monish Aron, Reza Ghavamian, Joseph Smith
Room: MCC WEST, 2010

076IC  AUA GUIDELINES 2018: ERECTILE DYSFUNCTION
Arthur Burnett, Course Director
Ajay Nehra, Hossein Sadeghi-Nejad
Room: MCC WEST, 2008

077IC  LAPROSCOPIC DONOR NEPHRECTOMY
Mahesh Desai, Course Director
John Barry, Arvind Ganpule, Abraham Kurien
Room: MCC WEST, 2006

078IC  MANAGEMENT OF PROSTATE CANCER: A CASE-BASED APPROACH WITH EMPHASIS ON INTEGRATING NEW MOLECULAR DIAGNOSTICS INTO CLINICAL PRACTICE
Eric Klein, Course Director
Andrew Stephenson
Room: MCC WEST, 2004

079IC  SURGICAL & MEDICAL MANAGEMENT OF HIGH-RISK RENAL CELL CARCINOMA: NEW PARADIGMS FOR TREATMENT
Benjamin Lee, Course Director
A. Oliver Sartor, Chandru Sundaram
Room: MCC WEST, 2002

080IC  PRACTICAL & EVIDENCE-BASED MINIMALLY-INVASIVE AND ROBOTIC-ASSISTED SURGERY IN PEDIATRIC UROLOGY
Patricio Gargollo, Course Director
Michael Ost, Aseem Shukla
Room: MCC WEST, 2009
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>WELCOME AND INTRODUCTION</td>
<td>Program Chairs: E. Jason Abel, Lee Richstone</td>
</tr>
<tr>
<td>8:05</td>
<td>RRC UPDATE</td>
<td>Chad Ritenour</td>
</tr>
<tr>
<td>8:15</td>
<td>ABU UPDATE AND THE EVOLUTION OF RECERTIFICATION</td>
<td>Stephen Nakada</td>
</tr>
<tr>
<td>8:25</td>
<td>AUA OFFICE OF RESEARCH UPDATE</td>
<td>Aria Olumi</td>
</tr>
<tr>
<td>8:35</td>
<td>AAMC UPDATE</td>
<td>Mark Jordan</td>
</tr>
<tr>
<td>8:45</td>
<td>SAU UPDATE</td>
<td>Byron Joyner</td>
</tr>
<tr>
<td>8:55</td>
<td>DISCUSSION/Q &amp; A</td>
<td></td>
</tr>
<tr>
<td>9:05</td>
<td>RESIDENT RECRUITMENT: IS IT TIME FOR TECHNICAL SKILL ASSESSMENT OF MEDICAL STUDENTS?</td>
<td>Daniel Williams</td>
</tr>
<tr>
<td>9:20</td>
<td>SMARTPHONE APPLICATIONS (APPS) FOR RESIDENT ASSESSMENT AND FEEDBACK</td>
<td>Jessica Kreshover</td>
</tr>
<tr>
<td>9:35</td>
<td>LESSONS LEARNED FROM IMPLEMENTATION OF RESIDENT MILESTONES</td>
<td>Kirsten Greene</td>
</tr>
<tr>
<td>9:50</td>
<td>IS IT TIME FOR ATTENDING “MILESTONES”?</td>
<td>Christopher Amling</td>
</tr>
<tr>
<td>10:05</td>
<td>FACULTY CURRICULUM FOR PROFESSIONALISM ETHICS IN UROLOGY</td>
<td>Eric Singer</td>
</tr>
<tr>
<td>10:20</td>
<td>DISCUSSION/Q &amp; A</td>
<td></td>
</tr>
<tr>
<td>10:35</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td>10:55</td>
<td>SESSION I: TOPIC SIMULATION FOR NON-TECHNICAL SKILLS</td>
<td></td>
</tr>
<tr>
<td>11:55</td>
<td>LUNCH: ANNUAL BUSINESS MEETING</td>
<td></td>
</tr>
<tr>
<td>12:55</td>
<td>SESSION II: GRANT RECIPIENT REPORTS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SIMULATED PATIENT EXPERIENCE &amp; ASSESSMENT OF RESIDENTS (SPEAR)</td>
<td>Moben Mirza</td>
</tr>
<tr>
<td></td>
<td>DISCUSSION/Q &amp; A</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SESSION III: CHAIR CHALLENGES PANEL</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PREVENTING SEXUAL MISCONDUCT IN THE MEDICAL WORKPLACE</td>
<td>Cheryl Lee</td>
</tr>
<tr>
<td></td>
<td>POSITIVE STEPS TO REDUCE BURNOUT IN YOUR FACULTY</td>
<td>Christopher Weight</td>
</tr>
<tr>
<td></td>
<td>PHILANTHROPY: KEYS TO FUNDRAISING SUCCESS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SCRIBES AND EXTENDERS: WHAT DOES IT TAKE TO MAKE IT WORK FINANCIALLY?</td>
<td>Michael Williams</td>
</tr>
<tr>
<td></td>
<td>GETTING UROLOGISTS INVOLVED AS LEADERS IN MAJOR CLINICAL TRIALS</td>
<td>Brian Chapin</td>
</tr>
<tr>
<td></td>
<td>WHY UROLOGISTS INVOLVEMENT MATTERS IN HOSPITAL LEADERSHIP</td>
<td>J. Christian Winters</td>
</tr>
<tr>
<td></td>
<td>DISCUSSION/Q &amp; A</td>
<td></td>
</tr>
<tr>
<td></td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td></td>
<td>DEBATE: COMPENSATION MODELS ACADEMIC UROLOGY PROGRAMS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>MONEY CORRUPTS: SALARY-BASED COMPENSATION IS SUPERIOR</td>
<td>Claus Roehrborn</td>
</tr>
<tr>
<td></td>
<td>CAPITALISM IS KING: PRODUCTION BASED MODEL IS THE BEST</td>
<td>Gerald Andriole</td>
</tr>
<tr>
<td></td>
<td>CONCURRENT SURGERY: WHAT, WHEN, HOW, IF EVER, IS IT OKAY?</td>
<td>Viraj Master</td>
</tr>
<tr>
<td></td>
<td>GETTING SERIOUS ABOUT VALUE AND QUALITY METRICS IN UROLOGY</td>
<td>Jay Bishoff</td>
</tr>
<tr>
<td></td>
<td>DEVELOPING NEGOTIATION SKILLS FOR UROLOGY LEADERS</td>
<td>Karl Kreder</td>
</tr>
<tr>
<td></td>
<td>DISCUSSION/Q &amp; A</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ADJOURN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>APPROVED FOR AMA PRA CATEGORY 1 CREDIT™</td>
<td></td>
</tr>
</tbody>
</table>

*Presenting author
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00</td>
<td>WELCOME</td>
</tr>
</tbody>
</table>
|        | AUA Chair: Victor Nitti  
|        | Course Directors: Michael Cookson, David Jarrard                        |
| 10:10  | PRE-TEST                                                                |
|        | Michael Cookson, David Jarrard                                         |
| 10:25  | SESSION I                                                               |
|        | INITIAL MANAGEMENT AND IMAGING OF ADVANCED PROSTATE CANCER              |
|        | Todd Morgan                                                             |
|        | CHEMO-HORMONAL THERAPY FOR METASTATIC HORMONE SENSITIVE PROSTATE CANCER|
|        | Alicia Morgans                                                         |
|        | M0 CRPC: EMERGING TREATMENT OPTIONS                                     |
|        | Alicia Morgans                                                         |
|        | MDC AND REVIEW OF CRPC GUIDELINES                                      |
|        | Michael Cookson                                                        |
|        | CASE BASED ROUNDTABLE DISCUSSIONS: SESSION I                           |
|        | All Faculty                                                            |
| 10:50  | SESSION I POST-TEST                                                    |
|        | Michael Cookson, David Jarrard                                         |
| 12:20  | A NON-CME INDUSTRY SPONSORED LUNCH SYMPOSIUM                            |
|        | 4:45                                                                    |
| 1:35   | SESSION II                                                             |
|        | MANIPULATING THE ANDROGEN AXIS: ANDROGEN BIOSYNTHESIS INHIBITORS AND ANDROGEN RECEPTOR SIGNALING AGENTS |
|        | David Jarrard                                                          |
| 2:50   | RADIATION THERAPY AND BONE HEALTH                                      |
|        | Kelly Stratton                                                         |
| 3:10   | CASE BASED ROUNDTABLE DISCUSSIONS: SESSION II                          |
|        | All Faculty                                                            |
| 2:50   | BREAK                                                                 |
| 3:15   | SESSION III                                                            |
|        | ROLE OF CHEMOTHERAPY AND PERFORMANCE STATUS AND PAIN MANAGEMENT        |
|        | Robert Dreicer                                                        |
| 3:10   | TREATMENT SEQUENCING, IMMUNOTHERAPY AND FUTURE APPROACHES              |
|        | Kelly Stratton                                                        |
| 4:45   | CASE BASED ROUNDTABLE DISCUSSIONS: SESSION III                          |
|        | All Faculty                                                            |
| 5:00   | SESSION III POST-TEST                                                  |
|        | Michael Cookson, David Jarrard                                         |
| 5:00   | CLOSING REMARKS                                                        |
| 5:00   | ADJOURN                                                                |
|        | APPROVED FOR AMA PRA CATEGORY 1 CREDIT™                                |
MP = Moderated Poster Session, PD = Podium Session

**Friday, May 18, 2018**

**Plenary: Prime Time, Friday Morning Session**

**Esplanade BR @ MCC South**

**7:30**

**SURGICAL TECHNIQUES: TIPS & TRICKS: AN OPEN MIND**

Moderator: Edward Messing
Surgeons: Brett Carver, Joel Nelson, Urs Studer

**8:30**

**TUMOR BOARD: PROSTATE CANCER**

Moderator: Andrew Stephenson
Panelists: Matthew Gettman, Jorge Garcia, Donna Hansel, Daniel Spratt, Ashutosh Tewari

**9:00**

**SETBACKS AND OPERATIVE SOLUTIONS: ROBOTIC PROSTATECTOMY**

Moderator: Rene Sotelo
Panelists: Thomas Ahlering, Vipul Patel, Christopher Porter, Rosalia Viterbo

**9:30**

**TUMOR BOARD: KIDNEY CANCER**

Moderator: W. Marston Linehan
Panelists: Georges Pascal Haber, Louis Kavoussi, Sumanta Pal, Sandy Srinivas, Robert Uzzo

**10:00**

**SURGICAL TECHNIQUES: TIPS & TRICKS: ROBOTIC PARTIAL NEPHRECTOMY**

Moderator: Mihir Desai
Panelists: Gennady Bratslavsky, Duke Herrell, Ill, James Porter

**10:30**

**TUMOR BOARD: BLADDER CANCER**

Moderator: Eila Skinner
Panelists: Yair Lotan, Seth Lerner, Neha Vapiwala, Terence Friedlander

**11:00**

**CROSSFIRE: CONTROVERSIES IN UROLOGY: PROSTATE CANCER**

Moderator: Ian Thompson, Jr
Debaters - Pro: Francesco Montorsi, Jeanny Aragon - Ching
Debaters - Con: Robert Dreicer, Martin Gleave

**APPROVED FOR AMA PRA CATEGORY 1 CREDIT™**

**Friday, May 18, 2018**

**Plenary: Prime Time, Friday Afternoon Session**

**Esplanade BR @ MCC South**

**1:00**

**CROWDSOURCING: URETEROSCOPY**

Moderator: Khurshid Ghani
Panelists: Ojas Shah, Robert Sweet, Olivier Traxer

**1:30**

**COURT IS IN SESSION**

Judge: Diane Bieri
Attorneys: Ann Larson, Ben Rubinowitz

**1:35**

**COURT IS IN SESSION: BENIGN: OPIOID OVERDOSE IN PATIENT WITH CHRONIC FLANK PAIN**

Moderator: Deborah Lightner
Defendant: Arthur Smith
Expert Witness (Defense): Glenn Preminger
Expert Witness (Plaintiff): Gregory Auffenberg

**2:15**

**COURT IS IN SESSION: MALIGNANT: SEPSIS AND DEATH AFTER PROSTATE NEEDLE BIOPSY**

Moderator: Norm Smith
Defendant: Paul Crispen
Expert Witness (Defense): Jay Raman
Expert Witness (Plaintiff): Peter Black

**3:00**

**COMPLEX CASES: PROSTATE CANCER**

Moderator: John Davis
Panelists: Shilpa Gupta, Scott Eggener, Jeffrey Holzbeierlein

**3:30**

**SURVIVOR DEBATE: LOW-INTERMEDIATE RISK PROSTATE CANCER**

Moderator: Laurence Klotz
Debaters: Gerald Andriole, Peter Carroll, Jonathan Coleman, Leonard Marks, Jean de la Rosette, Herbert Lepor, Louis Pisters, Ronald Benoit, Richard Choo, Mack Roach, Raju Thomas, Misop Han, William Catalona

**APPROVED FOR AMA PRA CATEGORY 1 CREDIT™**

*Presenting author*
6:45  WELCOME
Program Chairs: Timothy Kowalewski, Robert Sweet

6:55  ENHANCED VISUALIZATION FOR ROBOTICALLY ASSISTED LAPAROSCOPIC PROSTATECTOMY
Speaker: Terry Peters
Provoker: Thomas Chi

7:20  UPDATE ON INTEGRATED ULTRASOUND TO IMAGE, FRAGMENT, AND REPOSITION STONES
Speaker: Michael Bailey
Provoker: Evangelos Liatsikos

7:45  HOLEP/TURP ROBOT
Speakers: Duke Herrell III, Robert Webster III,
Provoker: Nicole Miller

8:10  3D PRINTING INVIVO
Speaker: Anthony Atala
Provoker: Jens Rassweiler

8:35  TISSUE CHARACTERIZATION
Speaker: Timothy Kowalewski
Provoker: Louis Kavoussi

9:00  3D PRINTING FUNCTIONAL MATERIAL
Speaker: Michael McAlpine
Provoker: Robert Sweet

9:25  AWARDS PRESENTATION
Dan Stoianovici

9:35  KEYNOTE LECTURE: FUTURE ROBOTICS IN UROLOGY
9:55  REALTIME US INTEGRATION IN DA VINCI ROBOTS FOR UROLOGY
Speaker: Tim Salcudean
Provoker: Jeffrey Cadeddu

10:20  WILL SOFT ROBOTS CHANGE UROLOGY?
Speaker: Elliot Hawkes
Provoker: John Denstedt

10:45  CLOSING REMARKS

12:00  SESSION CLOSED/NETWORKING SESSION

1:00  SESSION 1: POSTER SESSION
Moderators: Jaime Landman, Dan Stoianovici

2:00  SESSION 2: POSTER SESSION
Moderators: Timothy Kowalewski, Domenico Veneziano

3:00  ADJOURN

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Friday, May 18, 2018

Moderated Poster Session 1

SURGICAL TECHNOLOGY & SIMULATION: TRAINING & SKILLS ASSESSMENT I
Room 3004 @ MCC West
Moderators: Thomas Lendvay, Michael Borofsky and Jean de la Rosette

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP01-01</td>
<td>IMPLEMENTATION AND USEFULNESS OF THE ACCREDITATION COUNCIL FOR GRADUATE MEDICAL EDUCATION MILESTONES SYSTEM FOR UROLOGY RESIDENT EVALUATION</td>
</tr>
<tr>
<td>MP01-02</td>
<td>SKILL ACQUISITION AND COGNITIVE LOAD, UTILIZING THREE DIFFERENT FORMS OF EXPERT-BASED FEEDBACK DURING SIMULATION-BASED ROBOTIC SKILLS TRAINING: A COMPARATIVE ANALYSIS</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP01-03</td>
<td>CAN EYE TRACKING HELP EXPLAIN AN EXPERT SURGEON’S BRAIN PERFORMANCE DURING ROBOT-ASSISTED SURGERY?</td>
</tr>
<tr>
<td>MP01-04</td>
<td>DOES SURGEON LEADERSHIP DURING ROBOT-ASSISTED SURGERY CORRELATE WITH TEAMWORK-RELATED OUTCOMES</td>
</tr>
</tbody>
</table>

Elisabeth M. Sebesta*, Kimberly L. Cooper, Gina Badalato, New York, NY
Somayeh Besharat Shafei*, Ahmed Aly Hussein, Youssef Ahmed, Khurshid Guru, Buffalo, NY
MP01-05 HOW ACCURATE IS THE CROWD: DETERMINING THE DISCRIMINATORY CAPABILITY OF EXPERT AND CROWDSOURCED GEARS EVALUATIONS FOR THE ROBOTIC ASSISTED RADICAL PROSTATECTOMY
Paul Oh*, Jian Chen, Los Angeles, CA, Anthony Jarc, Norcross, GA, Micha Titus, Andrew Hung, Los Angeles, CA

MP01-06 DEVELOPMENT OF A TECHNICAL CHECKLIST FOR THE ASSESSMENT OF SUTURING IN ROBOTIC SIMULATION
Ahmad Guni*, Nicholas Raison, Ben Challacome, Shamim Khan, Prokar Dasgupta, Kamran Ahmed, London, United Kingdom

MP01-07 USE OF COMPUTER VISION MOTION ANALYSIS TO AID IN SURGICAL SKILL ASSESSMENT OF SUTURING TASKS
Brady Miller*, David Azari, Robert Radwin, Brian Le, Madison, WI

MP01-08 CONCURRENT VALIDATION OF A ROBOTIC SIMULATOR CURRICULUM FOCUSED ON “CORE” EXERCISES: DOES IT HELP OVERCOME BASELINE SKILL LEVELS?
Young-Hwii Ko*, Jae Young Choi, Phil Hyun Song, Ki Hak Moon, Hee Chang Jung, Daegu, Korea, Republic of

MP01-09 VIDEO ANALYSIS OF SURGEONS PERFORMING ROBOT-ASSISTED RADICAL PROSTATECTOMY: IS THERE A RELATIONSHIP BETWEEN THE TIME TAKEN TO COMPLETE THE URETHROVESICAL ANASTOMOSIS WITH TECHNICAL SKILL?
William Johnston III*, Troy, MI, Parin Patel, Detroit, MI, Tae Kim, Ann Arbor, MI, Zack Prebay, Milwaukee, WI, Jaya Telang, Ji Qi, Susan Linsell, Ann Arbor, MI, Eduardo Kleer, Ypsilanti, MI, David Miller, Ann Arbor, MI, James Peabody, Detroit, MI, Khurshid Ghani, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI

MP01-10 CONTENT VALIDITY EVIDENCE FOR A NOVEL MIXED REALITY PERCUTANEOUS NEPHROLITHOTOMY SIMULATOR
Mitchell Goldenberg*, Toronto, Canada, Mohammed Shahait, Timothy Averch, Pittsburgh, PA, Jason Lee, Toronto, Canada

MP01-11 VIRTUAL REALITY-BASED VALIDATION OF THE ERUS CERTIFIED TRAINING PROGRAMS INTENSIVE SIMULATION MODULE: RESULTS FROM A HIGH-VOLUME ROBOTIC SURGERY TRAINING CENTRE
Alessandro Larcher*, Filippo Turri, Lorenzo Bianchi, Cristina Ferriero, Paolo Umari, Andres Clinckaert, Pieter Uvin, Vincenzo Ficarra, Alessandro Volpe, Giacomo Novara, Christian Gratze, Giorgio Gandaglia, Nicola Fossati, Alexandre Mottrie, Melle, Belgium

MP01-12 HOTDOGS AND REDVINES®: PILOT OF A COST-EFFECTIVE SIMULATION-BASED CURRICULUM FOR ACUTE ISCHEMIC PRIAPISM MANAGEMENT
Jessica Dai*, Justin Ahn, Shannon Cannon, Omer Raheem, Kevin Ostrowski, Thomas Walsh, Thomas Lendvay, Seattle, WA

MP01-13 VARIATIONS IN PROVIDER MANAGEMENT OF GROSS HEMATURIA DURING CONTINUOUS BLADDER IRRIGATION: AN INITIAL ASSESSMENT
Tony Chen*, Claudia Covelli, Akshay Randad, Eleftherios Kampianakis, Allegra Branch, Jialu Sun, John Gore, Robert Sweet, Seattle, WA

MP01-14 COMPARISON OF CLINICAL OUTCOMES AND AUTOMATED PERFORMANCE METRICS IN ROBOTIC-ASSISTED RADICAL PROSTATECTOMIES BETWEEN CASES WITH CARDINAL STEPS PERFORMED BY ATTENDINGS ONLY AND TEACHING CASES
Micha Titus*, Paul Oh, Jian Chen, Michael Lin-Brande, Austin Fullenkamp, Andrew Hung, Los Angeles, CA

MP01-15 FACE, CONTENT, AND CONSTRUCT VALIDATION OF ENDOSCOPIC NEEDLE INJECTION (ENI) SIMULATOR FOR TRANSETHRAL BULKING AGENT IN TREATMENT OF STRESS URINARY INCONTINENCE
Bilal Farhan*, Gamal Ghoniem, Rebecca Do, Orange, CA

MP01-16 VALIDATION OF 3D PRINTED VUA MODEL UTILIZING AUTOMATED AND MANUALLY OBSERVED METRICS, FEATURING TISSUE FEEDBACK MEASURES
Andrew Hung*, Jian Chen, Austin Fullenkamp, Paul Oh, Michael Lin-Brande, Los Angeles, CA, Yasser Nourredlin, Benha, Egypt, Troy Reihsen, Robert Sweet, Seattle, WA

*Presenting author
MP01-17 DEFINITION OF A STRUCTURED TRAINING CURRICULUM FOR ROBOT-ASSISTED PARTIAL NEPHRECTOMY: A DELPHI-CONSENSUS STUDY FROM THE ERUS EDUCATIONAL BOARD

Alessandro Larcher*, Melle, Belgium, Filippo Turri, Pisa, Italy, Justin Justinsson, Stockholm, Sweden, Ilhaar Derweesh, San Diego, CA, Alessandro Volpe, Novara, Italy, Jihad Kaouk, Cleveland, OH, Vincenzo Ficarra, Messina, Italy, Umberto Capitano, Milan, Italy, Francesco Porpiglia, Orvieto, Italy, Stefan Siemer, Homburg, Germany, Rha Koon, Seul, Korea, Republic of, Jens Uwe Stolzenburg, Leipzig, Germany, Rajesh Ahiawat, New Delhi, India, Declan Murphy, Melbourne, Australia, Geert De Naeyer, Aalst, Belgium, Christophe Vaessen, Paris, France, Ben Challacombe, London, United Kingdom, Giacomo Novara, Padova, Italy, James Porter, Seattle, WA, Daniel Moon, Richmond, Australia, Nicola Buffi, Rozzano, Italy, Andrea Minervini, Florence, Italy, Achilles Ploumidis, Athens, Greece, Francesco Montorsi, Milan, Italy, Peter Wiklund, Stockholm, Sweden, Henk Van Der Poel, Amsterdam, Netherlands, Alexandre Mattie, Melle, Belgium

MP01-18 QUANTIFYING THE ‘ASSISTANT EFFECT IN ROBOTIC-ASSISTED RADICAL PROSTATECTOMY: MEASURES OF TECHNICAL PERFORMANCE

Mitchell Goldenberg*, Hossein Sadat, Jason Lee, Antonio Finelli, Rajiv Singal, Teodor Grantcharov, Toronto, Canada

MP01-19 EXPLORING TECHNIQUE OF THE VESICOURETHRAL ANASTOMOSIS IN ROBOTIC-ASSISTED RADICAL PROSTATECTOMY WITH AUTOMATED AND MANUALLY OBSERVED METRICS

Jian Chen*, Paul Oh, Nathan Cheng, Ankeet Shah, Los Angeles, CA, Liheng Guo, Anthony Jarc, Norcross, GA, Andrew Hung, Los Angeles, CA

MP01-20 THE LEARNING CURVE FOR MULTIPARAMETRIC MRI/US FUSION GUIDED PROSTATE BIOPSY: A SINGLE CENTER EXPERIENCE

Cynthia Leung*, Jamil Syed, Shu Pan, Thomas Neville, Preston Sprengle, New Haven, CT

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
MP02-08 DISPARATE ACCESS TO ELECTRONIC HEALTH RECORDS AND QUALITY REPORTING AMONG US UROLOGISTS  
Hung-Jui Tan*, Durham, NC, Arlene Chung, David Gotz, Angela Smith, Eric Wallen, Raj Pruthi, Matt Nielsen, Chapel Hill, NC

MP02-09 INTRAVENOUS CEFAZOLIN IS AN APPROPRIATE AGENT FOR PERIOPERATIVE ENDOUROLOGIC ANTIBIOTIC PROPHYLAXIS  
Adam Ludvigson*, Jeffrey Sands, Christina Gentile, Jóhann Ingimarsson, Portland, ME

MP02-10 ARE UROLOGIC SURGEONS PERFORMING RADICAL PROSTATECTOMY IN THE CANADIAN UNIVERSAL HEALTH CARE SYSTEM PROVIDING HIGH QUALITY AND UNIFORM PROSTATE CANCER CONTROL?  
Trevor Haines*, Sunita Ghosh, Adrian Fairey, Niels Jacobsen, Benjamin Beech, Jan Rudzinski, Ryan Mclarty, Nick Dean, Steven Tong, Dylan Hoare, Edmonton, Canada

MP02-11 IDENTIFYING TRUE BARRIERS TO MEDICATION AVAILABILITY IN RURAL AND LOW-INCOME AREAS: AN OPPORTUNITY FOR PATIENT ADVOCACY  
Jorge Whitley, Amy Taylor, Paul Merguerian, Kathleen Kieran*, Seattle, WA

MP02-12 UROLOGIC PROCEDURES IN JEHOVAH’S WITNESS PATIENTS: SAFETY AND FEASIBILITY  
Thomas Clifford*, Los Angeles, CA, Antoin Douglawi, Noblesville, IN, Willem Xu, Soroush Bazargani, Hooman Djeladat, Siamak Daneshmand, Los Angeles, CA

MP02-13 MISSED REVENUE DUE TO INADEQUATE DOCUMENTATION IN UROLOGY PATIENTS: AN ACADEMIC CENTER EXPERIENCE  
Jagan Kansal MD, MBA*, Eric Fichtenbaum MD, Abhinav Sidana MD, Cincinnati, OH

MP02-14 PREDICTING FACTORS OF UNEXPECTED HOSPITAL RETURN FOLLOWING TRANSURETHRAL RESECTION OF BLADDER TUMOR  
Vera Marques*, Miguel Eliseu, Edgar Tavares-Da-Silva, Francisco Rolo, Arnaldo Figueiredo, Coimbra, Portugal

MP02-15 ASSESSMENT OF RADIATION SAFETY KNOWLEDGE AMONG HOUSE STAFF REVEALS APPROPRIATE PRECAUTIONS BUT DEFICIENT KNOWLEDGE  
Andrew Harris*, Marilyn Hopkins, John Loomis, Jason Bylund, Lexington, KY

MP02-16 WORKPLACE BULLYING OF UROLOGY RESIDENTS: IMPLICATIONS FOR THE PATIENT AND PROVIDER  
Mashrin Chowdhury*, Maha Husainat, Kristina Suson, Detroit, MI

MP02-17 THE JULY EFFECT IN UROLOGIC SURGERY: MYTH OR REALITY?  
Eric Kirshenbaum*, Maywood, IL, Robert Blackwell, Springfield, IL, Belinda Li, Emmanuel Eguia, Gopal Gupta, Kristin Baldea, Robert Flanigan, Paul Kuo, Alex Gorbonos, Maywood, IL

MP02-18 NON-NARCOTIC EMERGENCY MANAGEMENT OF RENAL COLIC IMPROVES LENGTH OF STAY AND DISCHARGE RATE  
Andrew Portis*, Neha Jain, Julia Portis, Suzanne Neises, St. Paul, MN

MP02-19 SPEAKING ROLES OF WOMEN UROLOGISTS AT ANNUAL AUA MEETINGS: A PROPOSED INDEX OF GENDER REPRESENTATION  
Colby Souders MD*, Los Angeles, CA, Deanna Wong BA, California, CA, Jennifer Anger MD MPH, Maurice Garcia MD, Los Angeles, CA

MP02-20 READMISSION RATES AMONG PATIENTS DISCHARGED ON THE WEEKEND: ARE WE FACILITATING GOOD TRANSITIONS OF CARE?  
Joseph Song*, Joel Vetter, Alethea Paradis, Gerald Andriole, Erica Traxel, Saint Louis, MO

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP03-01</td>
<td>ADRENALECTOMY: SHOULDN'T UROLOGISTS BE DOING MORE?</td>
</tr>
<tr>
<td></td>
<td>Jay Fuletra*, Amber Schilling, Hershey, PA, Christopher Hollenbeck, University Park, PA, Jay Raman, Hershey, PA</td>
</tr>
<tr>
<td>MP03-02</td>
<td>PRIMARY ADRENAL MALIGNANCY: INSIGHTS INTO THE EPIDEMIOLOGY OF A RARE HISTOLOGICAL SUBSET</td>
</tr>
<tr>
<td>MP03-03</td>
<td>β-CATENIN-DRIVEN ADRENOCORTICAL CARCINOMA IS ASSOCIATED WITH POOR PROGNOSIS AND DECREASED INHIBITORY IMMUNE CHECKPOINT</td>
</tr>
<tr>
<td></td>
<td>Chenchen Feng*, Shenghua Liu, Shanghai, China, People’s Republic of</td>
</tr>
<tr>
<td>MP03-04</td>
<td>BRAF V600E MUTATION PROMOTED EXCESS OF HORMONE AND TUMORIGENESIS IN ADRENAL CORTICAL ADENOMA WITH AUTONOMOUS CORTISOL SECRETION</td>
</tr>
<tr>
<td></td>
<td>Kazuyuki Numakura*, Taketoshi Nara, Sohei Kanda, Hiroshi Tsuruta, Mitsuru Saito, Shintaro Narita, Takamitsu Inoue, Shigeru Satoh, Tomonori Habuchi, Akita, Japan</td>
</tr>
<tr>
<td>MP03-05</td>
<td>IMAGING MASS SPECTROMETRY REVEALS CO-ACCUMULATION OF ALDOSTERONE AND 18-OXOCORTISOL WITH CYP11B2 IN PRE-ADENOMATOUS STATES OF PRIMARY ALDOSTERONISM</td>
</tr>
<tr>
<td></td>
<td>Yuki Sugiiura, Tokyo, Japan, Eimi Takeo, Shuichi Shimma, Osaka, Japan, Mai Yokota, Tatsuya Higashi, Tokyo, Japan, Tsugio Seki, Colton, CA, Mototsugu Oya, Takeo Kosaka, Tokyo, Japan, Tetsuo Nishikawa, Yokohama, Japan, Koshiro Nishimoto*, Hidaka, Japan, Makoto Suematsu, Tokyo, Japan</td>
</tr>
<tr>
<td>MP03-06</td>
<td>PATIENT SELECTION FOR CONFIRMATORY TESTS OF PRIMARY ALDOSTERONISM (PA) USING THE PA DISCRIMINATION SCORE</td>
</tr>
<tr>
<td></td>
<td>Hayato Yamamoto*, Shingo Hatakeyama, Atsushi Imai, Hirotake Kodama, Ayumu Kusaka, Noriko Tokui, Toru Yonemaya, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Koie, Shigeyuki Nakaji, Chikara Ohyama, Hirosaki, Japan</td>
</tr>
<tr>
<td>MP03-07</td>
<td>ADRENALECTOMY ATTENUATES THE RISK OF END STAGE RENAL DISEASE OF PRIMARY ALDOSTERONISM – A COMPETING RISK ANALYSIS</td>
</tr>
<tr>
<td></td>
<td>Chin-Fong AU*, Shiu-Dong Chung, Vin-Cent Wu, New Taipei City, Taiwan</td>
</tr>
<tr>
<td>MP03-08</td>
<td>POST ADRENALLECTOMY RENAL FUNCTION IN PATIENTS WITH PRIMARY ALDOSTERONISM</td>
</tr>
<tr>
<td></td>
<td>Tadashi Onohara*, Toshio Takagi, Kazuhiko Yoshida, Junpei Iizuka, Masayoshi OkumI, Hideki Ishida, Kazunari Tanabe, Tokyo, Japan</td>
</tr>
<tr>
<td>MP03-09</td>
<td>PROGNOSIS AND CONDITIONAL PROBABILITY SURVIVAL ANALYSIS OF ADRENAL CORTICAL CARCINOMA: A POPULATION LEVEL STUDY</td>
</tr>
<tr>
<td></td>
<td>Wenhun Xiao*, Yongjiang Huang, Fangning Wan, Yao Zhu, Dingwei Ye, Shanghai, China, People’s Republic of</td>
</tr>
<tr>
<td>MP03-10</td>
<td>OPEN ADRENALLECTOMY VERSUS LAPAROSCOPIC ADRENALLECTOMY FOR ADRENOCORTICAL CARCINOMA: A RETROSPECTIVE COMPARATIVE STUDY ON SHORT-TERM ONCOLOGICAL PROGNOSIS</td>
</tr>
<tr>
<td></td>
<td>Guo-yang Zheng*, Han-zhong Li, Xue-bin Zhang, Beijing, China, People’s Republic of</td>
</tr>
<tr>
<td>MP03-11</td>
<td>SURGICAL MARGINS, TUMOR SIZE PREDICTIVE OF OVERALL SURVIVAL IN ADRENOCORTICAL CARCINOMA</td>
</tr>
<tr>
<td></td>
<td>Tyler Thress*, Daniel Parker, Ian Maloney, Brionna Sandridge, Sanjay Patel, Oklahoma City, OK</td>
</tr>
<tr>
<td>MP03-12</td>
<td>SUITABLE PATIENTS FOR SINGLE-PORT LAPAROSCOPIC ADRENALLECTOMY: OPTIMAL CUT-OFF VALUE OF BODY MASS INDEX</td>
</tr>
<tr>
<td></td>
<td>Kazuhiro Matsumoto*, Keishiro Fukumoto, Akira Miyajima, Masanori Hasegawa, Toshikazu Takeda, Eiji Kikuchi, Hiroshi Asanuma, Mototsugu Oya, Tokyo, Japan</td>
</tr>
<tr>
<td>MP03-13</td>
<td>DELAYED RECOVERY OF KIDNEY FUNCTION IN PATIENTS WITH OBESITY AFTER LAPAROSCOPIC SURGERY FOR CUSHING’S SYNDROME</td>
</tr>
<tr>
<td></td>
<td>Kazuyuki Numakura*, Taketoshi Nara, Sohei Kanda, Hiroshi Tsuruta, Mitsuru Saito, Shintaro Narita, Takamitsu Inoue, Shigeru Satoh, Tomonori Habuchi, Akita, Japan</td>
</tr>
</tbody>
</table>
MP03-14 RETROPERITONEAL LAPAROSCOPIC COOL-TIP RADIOFREQUENCY ABLATION OF ADRENOCENTRAL ADENOMA WITH CUSHING SYNDROME
Linfang Yao*, Shiwei Zhang, Xiaohui Zhao, Rong Yang, Hongqian Guo, Nanjing, China, People’s Republic of

MP03-15 LAPAROSCOPIC ADRENALECTOMY FOR METASTATIC TUMORS IS FEASIBLE FOR SELECTED PATIENTS: RETROSPECTIVE MULTICENTER STUDY IN JAPANESE POPULATIONS
Takayuki Goto*, Takahiro Inoue, Takashi Kobayashi, Toshinari Yamasaki, Kyoto, Japan, Satoshi Ishihara, Shiga, Japan, Takehiko Segawa, Kyoto, Japan, Noriyuki Ito, Hyogo, Japan, Yasumasa Shichiri, Shiga, Japan, Kazuhiro Okumura, Nara, Japan, Hiroshi Okuno, Kyoto, Japan, Mutsushi Kawakita, Hyogo, Japan, Toshio Kanaoka, Wakayama, Japan, Naoki Terada, Shoichiro Mukai, Miyazaki, Japan, Motohiko Sugi, Hidefumi Kinoshita, Osaka, Japan, Toshiyuki Kamoto, Miyazaki, Japan, Tadashi Matsuda, Osaka, Japan, Osamu Ogawa, Kyoto, Japan

MP03-16 PREDICTIVE FACTORS FOR ADRENAL METASTASIS IN EXTRA-ADRENAL CANCER PATIENTS WITH AN ADRENAL MASS
Sang Won Kim*, Jun Koo Kang, You Jin Lee, Jae-Wook Chung, Yun-Sok Ha, Seock Hwan Choi, Jun Nyung Lee, Bum Soo Kim, Hyun Tae Kim, Tae-Hwan Kim, Eun Sang Yoo, Tae Gyun Kwon, Sung Kwang Chung, Daegu, Korea, Republic of

MP03-17 NON RENAL ORIGIN OF THE PRIMARY TUMOR AND LARGER TUMOR SIZE COMPROMISE THE ONCOLOGICAL OUTCOMES OF ADRENALECTOMY FOR ADRENAL METASTASIS

MP03-18 LONG TERM OUTCOMES FOR PATIENTS WITH VON HIPPEL LINDAU AND PHEOCHROMOCYTOMA: DEFINING THE BEST CANDIDATES FOR ACTIVE SURVEILLANCE
Thomas Sanford*, Rashid Siddiqui, Daniel Su, Julie An, Adam Metwalli, Bethesda, MD

MP03-19 BLOOD PRESSURE AND SUGAR TRENDS AND QUALITY OF LIFE IN PATIENTS UNDERGOING PHEOCHROMOCYTOMA SURGERY
Pradeep Prakash, Rashmi Ramachandran, Nihal Tandon, Rajeev Kumar*, New Delhi, India

MP03-20 PREDICTORS OF PHEOCHROMOCYTOMA SURGERY OUTCOMES USING A PREOPERATIVE SEVERITY CLASSIFICATION SCALE: AN INTERNATIONAL STUDY
Joel Hillelsohn*, Valhalla, NY, Soroush Rais-Bahrami, Vidhush Yarlagadda, Luciana Schwartz, Jennifer Gordetsky, Birmingham, AL, Victor Srougi, Sao Paulo, Brazil, John Phillips, Valhalla, NY

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

*Presenting author
<table>
<thead>
<tr>
<th>Abstract Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP04-02</td>
<td>Is Obesity Truly Associated with Larger Prostate Size? Insights from a LARGE PROSTATECTOMY Registry</td>
<td>Vidit Sharma*, Marcelino E. Rivera, Deepak K. Agarwal, Matteo Soligo, R. Jeffrey Kames, Rochester, MN</td>
</tr>
<tr>
<td>MP04-03</td>
<td>The Impacts of Metabolic Syndrome and Life Style on the Prevalence of Benign Prostatic Hyperplasia: Historical Cohort Study Using 130,454 Men with 5-Year Follow-Up</td>
<td>Sangjun Yoo*, Juhyun Park, Soonho Kang, Gwan Jang, Dongyoung Seon, Inyoung Sun, Seung-Ee Kim, Hyukdal Jung, Youngcheol Hwang, Sung Yong Cho, Min Chul Cho, Hyeon Jeong, Seoul, Korea, Republic of, Jin Kyu Oh, Inchon, Korea, Republic of, Hwancheol Son, Seoul, Korea, Republic of</td>
</tr>
<tr>
<td>MP04-04</td>
<td>Cost-utility Analysis of Upfront Pharmacotherapy Compared to an Upfront Surgical Intervention for Patients with Benign Prostate Hyperplasia</td>
<td>Dean Elterman*, Aysegul Ermanc, Lisa Masucci, Toronto, Canada, Shaun Shepherd, Hamilton, Canada, Murray Krahn, Toronto, Canada</td>
</tr>
<tr>
<td>MP04-05</td>
<td>Prevalence and Characteristics of Urinary Incontinence in a Treatment-seeking Male Prospective Cohort – Results from the LURN Study</td>
<td>Brian T. Helfand MD PhD*, Glenview, IL, Abigail R. Smith PhD, Ann Arbor, MI, H. Henry Lai MD, St. Louis, MO, Claire C. Yang MD, John L. Gore MD MS, Seattle, WA, Bradley A. Erickson MD MS FACS, Karl J. Kreder MD MBA, Iowa City, IA, Anne P. Cameron MD, Ann Arbor, MI, Kevin P. Weinfurt PhD, Durham, NC, James W. Griffith PhD, Chicago, IL, Aaron C. Lentz MD FACS, Durham, NC, Pooja Talaty MS MHA, Glenview, IL, Victor P. Andreev PhD DSc, Ann Arbor, MI, Ziya Kirkali MD and the LURN Study Group, Bethesda, MD</td>
</tr>
<tr>
<td>MP04-06</td>
<td>Polymorphisms of NOS3 G894T Are Associated with Responsiveness to Doxazosin in BPH/LUTS</td>
<td>Yung-Chin Lee*, Kaohsiung, Taiwan, Chia-Chu Liu, Pingtung, Taiwan, Shu-Pin Huang, Kaohsiung, Taiwan</td>
</tr>
<tr>
<td>MP04-07</td>
<td>The Association of Dietary Salt Intake and Nocturia: Data from the 2011-2014 National Health and Nutrition Examination Survey (NHANES)</td>
<td>Nima Baradaran*, Scott Bauer, Kirkpatrick Fergus, Anas Tresh, Thomas Gaither, Benjamin Breyer, San Francisco, CA</td>
</tr>
<tr>
<td>MP04-08</td>
<td>Characteristics of Men with Untreated Lower Urinary Tract Symptoms Participating in a Study Assessing Self-directed Use of OVER-THE-COUNTER TAMSULOSIN</td>
<td>Claus Roehrborn*, Dallas, TX, Franklin Lowe, Bronx, NY, Marc Gittelman, Aventura, FL, Jan Wruck, Anna Verbeek, Ridgfield, CT</td>
</tr>
</tbody>
</table>
MP04-09 ELEVATED POST-VOID RESIDUAL VOLUMES ARE ASSOCIATED WITH WORSE VOIDING SYMPTOMS AMONG WOMEN AND MEN – RESULTS FROM THE SYMPTOMS OF LOWER URINARY TRACT DYSFUNCTION RESEARCH NETWORK (LURN)

H. Henry Lai MD*, St. Louis, MO, Abigail R. Smith PhD, Ann Arbor, MI, Claire C. Yang MD, Seattle, WA, John O.L. DeLancey MD, Brenda W. Gillespie PhD, Ann Arbor, MI, John L. Gore MD MS, Seattle, WA, Pooja Talaty MS MHA, Glenview, IL, Victor P. Andreev PhD DSc, Anca Stefan PhD, Ann Arbor, MI, Karl J. Kreder MD MBA, Iowa City, IA, Margaret G. Mueller MD, Chicago, IL, Matthew O. Fraser PhD, Durham, NC, Bradley A. Erickson MD MS FACS, Iowa City, IA, Ziya Kirkali MD, Bethesda, MD, Andrew C. Peterson MD and the LURN Study Group, Durham, NC

MP04-10 USE OF 5A-REDUCTASE INHIBITORS FOR BENIGN PROSTATIC HYPERPLASIA AND RISK OF HIGH-GRADING PROSTATE CANCER: A FRENCH POPULATION-BASED STUDY

Lucie-Marie Scailteux*, Fre´de´ric Balusson, Rennes, France, Emmanuel Nowak, Brest, France, Sébastien Vincendeau, Nathalie Rioux-Leclercq, Emmanuel Oger, Rennes, France

MP04-11 CORRELATION OF MRI PROSTATE VOLUME WITH SERUM PROSTATE-SPECIFIC ANTIGEN IN MEN WITH NEGATIVE STANDARD AND MRI-FUSION BIOPSIES

Nabeel Shakir*, Niccolo Passoni, Daniel Wong, Dallas, TX, Samuel Gold, Graham Hale, Kareem Rayn, Joseph Baiocco, Jonathan Bloom, Vladimir Valero, Maria Merino, Baris Turkbey, Peter Choyke, Bradford Wood, Peter Pinto, Bethesda, MD, Daniel Costa, Claus Roehrborn, Dallas, TX

MP04-12 LOWER URINARY TRACT SYMPTOMS (LUTS) AND MORTALITY RISK AMONG OLDER U.S. MEN: THE OSTEOPOOROTIC FRACTIONS IN MEN (MROS) STUDY


MP04-13 METABOLIC SYNDROME AND SMOKING ARE ASSOCIATED WITH PERSISTENCE OF NOCTURIA AFTER TRANSURETHRAL RESECTION OF PROSTATE

Cosimo De Nunzio*, Riccardo Lombardo, Giorgia Tema, Antonio Naccia, Simone D’Annunzio, Luca Sarchi, Flavia Proietti, Aldo Brassetti, Andrea Tubaro, Rome, Italy

MP04-14 VALUE BASED CARE IN BENIGN PROSTATIC HYPERPLASIA: OFFICE-BASED PROCEDURES ARE MAJOR DRIVERS SECOND TO OPERATIVE INTERVENTIONS


MP04-15 NOCTURIA IS ASSOCIATED WITH INCREASED RISK OF DEATH: RESULTS FROM REDUCE

Stephen Freedland*, Los Angeles, CA, Lauren Howard, Durham, NC, Donald Bliwise, Atlanta, GA, Martin Hopp, Los Angeles, CA, Gerald Andriole, St. Louis, MO, Ramiro Castro-Santamaría, Bryn Mawr, PA, Daniel Moreira, Chicago, IL

MP04-16 URINARY INCONTINENCE IN OLDER MEN: PROSPECTIVE RELATIONSHIPS WITH BODY COMPOSITION AND MUSCLE STRENGTH IN A MULTICENTER STUDY

Scott R. Bauer*, Anne M. Suskind, Peggy M. Cawthon, Steven R. Cummings, Alison J. Huang, San Francisco, CA

MP04-17 BURDEN OF SYSTEMIC COMORBIDITIES USING THE ACTIONS PHENOTYPE PREDICTS DISCONTINUATION OF UROLOGIC MEDICATIONS FOLLOWING TRANSURETHRAL RESECTION OF THE PROSTATE

JJ Zhang*, Bradley Gill, Lamont Wilkins, Rathika Ramkumar, Daniel Shoskes, Cleveland, OH

MP04-18 POST-OPERATIVE URINARY RETENTION FOLLOWING WEIGHT BEARING JOINT REPLACEMENT SURGERY: INCIDENCE, RISK FACTORS AND OUTCOMES

Haidar Abdul-Muhsin*, Nicholas Jakob, Kian Ahmediah, Stephen Cha, Adam Schwartz, Anojan Navartnam, Aqsa Khan, Mitchell Humphreys, Phoenix, AZ

MP04-19 THYROID HORMONES AND BENIGN PROSTATIC HYPERPLASIA

Jun Ho Lee, Jeonghyouk Choi*, Dongki Lee, Seoul, Korea, Republic of

MP04-20 INCREASED RISK OF BPH, LOWER URINARY TRACT SYNDROMES, PROSTATITIS, AND KELOIDS IN MEN WITH PEYRONIE’S DISEASE: ANALYSIS OF UNITED STATES CLAIMS DATA

Alexander W. Pastuszak*, Katherine M. Rodriguez, Taylor P. Kohn, Larry I. Lipsultz, Houston, TX, Michael L. Eisenberg, Stanford, CA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP05-01</td>
<td>HEALTH-RELATED QUALITY OF LIFE CHANGES IN PROSTATE CANCER PATIENTS AFTER RADICAL PROSTATECTOMY: A LONGITUDINAL COHORT STUDY</td>
</tr>
<tr>
<td></td>
<td>Jinsung Park*, Daegu, Korea, Republic of, Sang Hyub Lee, Seoul, Korea, Republic of, Tae-Hwan Kim, Daejeon, Korea, Republic of, Seok Joong Yun, Cheongju, Korea, Republic of, Jong Kil Nam, Yangsan, Korea, Republic of, Seung Hyun Jeon, Seoul, Korea, Republic of, Seung Il Jung, Gwangju, Korea, Republic of, Jong-Hyeok Park, Goyang, Korea, Republic of, Dong Wook Shin, Seoul, Korea, Republic of</td>
</tr>
<tr>
<td>MP05-02</td>
<td>THE ADVERSE RISK FACTORS OF URINARY FUNCTION RECOVERY AFTER RADICAL PROSTATECTOMY</td>
</tr>
<tr>
<td></td>
<td>Wang Binshuai*, Ma Lulin, Beijing, China, People's Republic of</td>
</tr>
<tr>
<td>MP05-03</td>
<td>A COMBINATION OF PREOPERATIVE MEMBRANOUS URETHRAL LENGTH AND POSTOPERATIVE BLADDER NECK ANGLE IS A RELIABLE PREDICTIVE FACTOR FOR EARLY RECOVERY OF URINARY CONTINENCE AFTER LAPAROSCOPIC RADICAL PROSTATECTOMY</td>
</tr>
<tr>
<td></td>
<td>Takehisa Onishi, Takuji Shibahara, Syou Sekito*, Ise, Japan, Takeshi Sasaki, Tsu, Japan</td>
</tr>
<tr>
<td>MP05-04</td>
<td>ANATOMICAL BENCHMARKS IN PREOPERATIVE MAGNETIC RESONANCE IMAGING PREDICT EARLY CONTINENCE RECOVERY FOLLOWING ROBOTIC RADICAL PROSTATECTOMY</td>
</tr>
<tr>
<td></td>
<td>Lucas Regis, Merce Cuadras, Enric Miret, Ricardo Lopez, Aina Salazar, Sarai Roche, Ana Celma, David Lorente, Jose Placer*, Jacques Planas, Enrique Trillas, Juan Morote, Barcelona, Spain</td>
</tr>
<tr>
<td>MP05-05</td>
<td>ASSESSING THE EXTERNAL VALIDITY OF THE UPDATED PROSTATE CANCER(PCA) INTERVENTION Versus OBSERVATION TRIAL (PIVOT)</td>
</tr>
<tr>
<td></td>
<td>Firas Abdollah*, Deepansh Dalela, Akshay Sood, Jacob Keeley, Detroit, MI, Nicolas von Landenberg, Herne, Germany, Quoc-Dien Trinh, Boston, MA, Shaheen Alanees, James O. Peabody, Craig G. Rogers, Mani Menon, Detroit, MI</td>
</tr>
<tr>
<td>MP05-06</td>
<td>ESTABLISHMENT OF THE OPTIMAL FOLLOW-UP SCHEDULE AFTER RADICAL PROSTATECTOMY</td>
</tr>
<tr>
<td></td>
<td>Kazuhiro Matsumoto*, Seiya Hattori, Naoya Niwa, Takeo Kosaka, Ryuichi Mizuno, Toshikazu Takeda, Eiji Kikuchi, Hiroshi Asanuma, Motootsugu Oya, Tokyo, Japan</td>
</tr>
<tr>
<td>MP05-07</td>
<td>SHOULD GLEASON SCORE AT THE POSITIVE SURGICAL MARGIN APPEAR ON THE PATHOLOGY REPORT FOR ROBOT-ASSISTED RADICAL PROSTATECTOMY?</td>
</tr>
<tr>
<td></td>
<td>Kent Kanao*, Miho Sugie, Hiroyuki Muramatsu, Shingo Morinaga, Keishi Kajikawa, Ikko Kobayashi, Genya Nishikawa, Yoshinari Kato, Masahito Watanabe, Kogenta Nakamura, Makoto Sumitomo, Nagakute, Japan</td>
</tr>
<tr>
<td>MP05-08</td>
<td>ASSOCIATION OF MODIFIED SURGICAL TECHNIQUE FOR PATIENTS WITH SHORTER MEMBRANOUS URETHRAL LENGTH AND EARLY RECOVERY OF INCONTINENCE AFTER ROBOT-ASSISTED LAPAROSCOPIC PROSTATECTOMY</td>
</tr>
<tr>
<td></td>
<td>Daiki Ikarashi*, Ei Shiomi, Yoichiro Kato, Mitsugu Kanehira, Ryo Takata, So Ohmori, Wataru Obara, Morioka-shi, Japan</td>
</tr>
<tr>
<td>MP05-09</td>
<td>DURATION OF PSA SURVEILLANCE AFTER RADICAL PROSTATECTOMY: A RISK ADAPTED APPROACH</td>
</tr>
<tr>
<td></td>
<td>Mary E. Westerman*, Matthew T. Gettman, R. Jeffrey Karnes, Igor Frank, Rochester, MN</td>
</tr>
<tr>
<td>MP05-10</td>
<td>UPDATE ON THE LARGEST CANADIAN RARP EXPERIENCE: ONCOLOGICAL AND FUNCTIONAL OUTCOMES OF 1034 RARP CASES WITH 6-YEAR FOLLOW-UP</td>
</tr>
<tr>
<td></td>
<td>Côme Tholomier, Montreál, Canada, Félix Coutura, Marc Zanaty, Khaled Ajib, Assaad El-Hakim, Kevin C. Zorn*, Montreal, Canada</td>
</tr>
<tr>
<td>MP05-11</td>
<td>PATHOLOGICAL AND ONCOLOGICAL OUTCOMES IN PATIENTS WITH PSA (\geq 10) NG/ML LOW RISK PROSTATE CANCER</td>
</tr>
<tr>
<td></td>
<td>Cristina Negrean*, Montreal, Canada, Mila Mansour, Félix Coutura, Kevin C. Zorn, Montreal, Canada, Marc Zanaty, Pierre Karakiewicz, Côme Tholomier, Montreal, Canada, Naeem Bhogarai, Montreal, Canada, Azizi Mounsif, Tampa, FL</td>
</tr>
</tbody>
</table>
MP05-12 CLINICAL AND ONCOLOGICAL OUTCOMES OF ROBOT-ASSISTED RADICAL PROSTATECTOMY (RARP) WITH NERVE SPARING FOR HIGH-RISK PROSTATE CANCER PATIENTS
Kiyoshi Takahara*, Masaru Hikichi, Kosuke Fukaya, Manabu Ichino, Naohiko Fukami, Hitomi Sasaki, Mamoru Kusaka, Ryoichi Shiroti, Toyooka, Japan

MP05-13 ASSOCIATION BETWEEN MRI BASED URETHRAL PARAMETERS AND CONTINENCE FOLLOWING ROBOT ASSISTED RADICAL PROSTATECTOMY
Lawrence H. C. Kim*, Amit Patel, Netty Kinsella, Mansour Taghavi Azar Sharabiani, Derfel Ap Dalydd, Declan Cahill, London, United Kingdom

MP05-14 EXTERNAL VALIDATION AND EVALUATION OF THE NEW FIVE-TIERED PROSTATE CANCER GRADING SYSTEM FOR THE RADICAL PROSTATECTOMY POPULATION IN KOREA
Min Hyun Cho, Sangjun Yoo*, Juhyun Park, Soonho Kang, Gwan Jang, Dongyoung Seon, Inyoung Sun, Seung-Ee Kim, Hyukdal Jung, Youngschoel Hwang, Sung Yong Cho, Min Chul Cho, Hwancheol Son, Chang Wook Jeong, Ja Hyeon Ku, Cheol Kwak, Hyeon Hoe Kim, Hyeon Jeong, Seoul, Korea, Republic of

MP05-15 THE EORTC QLQ-C30 QUESTIONNAIRES PREDICTS EARLY AND LONG-TERM INCONTINENCE IN PATIENTS TREATED WITH ROBOTIC RADICAL PROSTATECTOMY: ANALYSIS OF A LARGE SINGLE CENTER COHORT
Cosimo De Nunzio*, Rome, Italy, Antonio Luigi Pastore, Latina, Italy, Riccardo Lombardo, Fabiana Cancrini, Rome, Italy, Antonio Carbone, Andrea Fuschi, Latina, Italy, Lorenzo Dutti, John H. Witt, Gronau, Germany, Andrea Tubaro, Rome, Italy

MP05-16 SALVAGE PROSTATECTOMY AFTER FOCAL THERAPY – SINGLE CENTRE EXPERIENCE
Jaime Herrera-Caceres*, Dixon T.S. Woon, Hanan Goldberg, Thenappan Chandrasekar, Zachary Klaassen, Neil Flesher, Toronto, Canada

MP05-17 IDENTIFICATION OF TREATABLE HIGH RISK PROSTATE CANCER ONLY BY RADICAL PROSTATECTOMY -WHO ARE GOOD CANDIDATES FOR RADICAL PROSTATE CANCER-
Kazuhiro Nagao*, Junichi Mori, Kosuke Shimizu, Yoshihisa Kawai, Ryo Inoue, Yoshiaki Yamamoto, Hiroaki Matsumoto, Hideyasu Matsuyama, Ube, Japan

MP05-18 EARLY VERSUS STANDARD CATHETER REMOVAL AFTER COMPLETE ANATOMICAL RECONSTRUCTION DURING ROBOT-ASSISTED RADICAL PROSTATECTOMY: RESULTS FROM A PROSPECTIVE SINGLE-INSTITUTIONAL RANDOMIZED TRIAL (RIPRECA)
Giuliana Lista*, Giovanni Lughezzani, Nicolò Buffi, Roberto Peschetza, Pasquale Cardone, Massimo Lazzeri, Paolo Casale, Luisa Pasini, Silvia Zangediocomo, Alessio Benetti, Alberto Saita, Rozzano (MI), Italy, Giorgio Guazzoni, Rozzano (MI), Italy

MP05-19 THE FACTORS ASSOCIATED WITH GLEASON UPGRADING AT RADICAL PROSTATECTOMY: A PERSPECTIVE FROM THE SINGLE INSTITUTIONAL ASSESSMENT OF BIOPSY AND FINAL PATHOLOGY
Selcuk Erdem*, Samed Verep, Tzevat Tefik, Yasemin Ozluk, Isin Kilicaslan, Murat Tunc, Oner Sanli, Ismet Nane, Faruk Ozcan, Istanbul, Turkey

MP05-20 IMPACT OF TUMOR LOCATION ON BIOCHEMICAL RECURRENCE AFTER LAPAROSCOPIC RADICAL PROSTATECTOMY
Kimiharu Takamatsu*, Kazuhiro Matsumoto, Toshikazu Takeda, Shinya Morita, Takeo Kosaka, Ryuichi Mizuno, Toshiaki Shingjima, Eiji Kikuchi, Hiroshi Asanuma, Mototsugu Oya, Tokyo, Japan

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

*Presenting author
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>ABSTRACT TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP06-01 UHRF1BP1: A TUMOR SUPPRESSOR GENE ASSOCIATED WITH BLADDER CANCER RISK IN HAN CHINESE</td>
<td>Junlong Wu*, Yao Zhu, DINGWEI Ye, Shanghai, China, People’s Republic of, Meilin Wang, Nanjing, China, People’s Republic of, Jianfeng Xu, Durham, NC</td>
</tr>
<tr>
<td>MP06-02 THE IMPACT OF SMOKING ON GENOMIC ALTERATIONS IN MUSCLE-INVASIVE BLADDER CANCER</td>
<td>Roland Seiler*, Bern, Switzerland, Rink Michael, Hamburg, Germany, Atilullah Aziz, Rostock, Germany, Kees Hendriksen, Amsterdam, Netherlands, Alex Wyatt, Peter C. Black, Vancouver, Canada, Friedrich-Carl von Rundstedt, Jena, Germany, Ewan A. Gibb, Vancouver, Canada, Shahrokh F. Shariat, Vienna, Austria, Cedric Poyet, Zurich, Switzerland, Florian Roghmann, Bochum, Germany, Xylinas Evanguelos, Paris, France</td>
</tr>
<tr>
<td>MP06-03 RACE BASED DISPARITIES IN GENE EXPRESSION AND MUTATIONS IN BLADDER CANCER</td>
<td>Kalen Rimar*, Joshua Meeks, Sarah Psutka, Edward Schaeffer, Chicago, IL</td>
</tr>
<tr>
<td>MP06-04 A NOVEL METHOD FOR IN VIVO ISOLATION OF UROTHELIAL CANCER CELLS IN URINE USING CELLCOLLECTOR - A FUNCTIONALIZED AND STRUCTURED MEDICAL WIRE UNDER CYSTOSCOPY</td>
<td>Liang Dong*, Wenhao Shen, Di Jin, Ming Cao, Lianhua Zhang, Haige Chen, Wei Xue, Yiran Huang, Shanghai, China, People’s Republic of</td>
</tr>
<tr>
<td>MP06-05 GEO-MAPPING AND SPATIAL ANALYSIS OF ENVIRONMENTAL EXPOSURES IN PATIENTS WITH BLADDER CANCER IN UPSTATE NEW YORK: AN EXPLORATORY STUDY</td>
<td>Hijab Khan*, Zhu Jin, Ahmed Aly Hussein, Youssef Ahmed, Samantha Bullkivish, Shelby Hall, Renuka Kannapann, Omer Rana, Peter Rogerson, Samina Raja, Khurshid Guru, Buffalo, NY</td>
</tr>
<tr>
<td>MP06-06 DOES URINARY CYTOLOGY HAVE A ROLE IN HEMATURIA INVESTIGATIONS? RESULTS OF A PROSPECTIVE OBSERVATIONAL STUDY (DETECT I)</td>
<td>Wei Shen Tan*, Andrew Feber, Liqin Dong, Rachael Sarpong, Simon Rodney, Pramit Khetrapal, Patricia de Winter, Rumana Jalil, Norman Williams, Chris Brew-Graves, John Kelly, London, United Kingdom, DETECT I trial group, England, United Kingdom</td>
</tr>
<tr>
<td>MP06-07 LONG-TERM OUTCOME OF HEMATURIA - PROSPECTIVE LARGE COHORT</td>
<td>S. Mishriki*, Aberdeen, United Kingdom</td>
</tr>
<tr>
<td>MP06-09 THE IMPACT OF AGENT ORANGE EXPOSURE ON BLADDER CANCER</td>
<td>Michael Risk, Vikram Narayan*, Cesar Ercole, Minneapolis, MN</td>
</tr>
<tr>
<td>MP06-10 PERIOPERATIVE BLOOD TRANSFUSION IS NOT AN INDEPENDENT PREDICTOR OF SURVIVAL AFTER RADICAL CYSTECTOMY</td>
<td>Yifan Meng*, Joel Vetter, Alexander Parker, Robert Grubb, Eric Kim, St. Louis, MO</td>
</tr>
<tr>
<td>MP06-11 PERIOPERATIVE HYPOTHERMIA IS A PROGNOSTIC FACTOR OF CYSTECTOMY ESPECIALLY FOR STAGE II MUSCLE-INVASIVE BLADDER CANCER</td>
<td>Kento Morozumi*, Yuki Takai, Yuki Katsumata, Akito Kuromoto, Sergi Hoshi, Kenji Numahata, Yamagata, Japan</td>
</tr>
<tr>
<td>MP06-12 CHEMORADIATION VERSUS RADICAL CYSTECTOMY FOR MUSCLE INVASIVE BLADDER CANCER: COMPARATIVE ANALYSIS OF NATIONAL CANCER DATABASE WITH PROPENSITY SCORE WEIGHTING</td>
<td>Dharam Kaushik*, Hanzhang Wang, Richapriya Jha, Qianqian Liu, Joel Michalek, Ahmed M. Mansour, San Antonio, TX</td>
</tr>
<tr>
<td>MP06-13 MALBAC-BASED WHOLE GENOME ABNORMALITY SCORE (WGAS): A NEW CONCEPT TECHNIQUE SHOWS ITS POTENTIAL IN NON-INVASIVE DIAGNOSIS OF BLADDER CANCER</td>
<td>Hao Liu*, Tianxin Lin, Nengtai Ouyang, Guangzhou, China, People’s Republic of, Sijia Lu, Shanghai, China, People’s Republic of, Jian Huang, Guangzhou, China, People’s Republic of</td>
</tr>
</tbody>
</table>
MP06-14 URINARY CELL-FREE MICRORNA RATIO WITH MIR-6124/MIR-4511 CAN DISCRIMINATE BLADDER CANCER FROM BENIGN HEMATURIA
Won Tae Kim*, Seok-Joong Yun, Xuan-Mei Piao, Ho Won Kang, Sung Pil Seo, Yong-June Kim, Sang Cheol Lee, Wun-Jae Kim, Cheongju, Korea, Republic of

MP06-15 REDEFINING THE BLADDER CANCER PHENOTYPE USING PATTERNS OF FAMILIAL RISK
Heidi Hanson*, Claire Leiser, Christopher Martin, Brock O’Neil, William Lowrance, Orly Alter, Sumati Gupta, Wendy Kohlmann, Samantha Greenberg, Ken Smith, Nicola Camp, Salt Lake City, UT

MP06-16 PREVALENCE AND CLONALITY OF SYNCHRONOUS PRIMARY CARCINOMAS IN THE BLADDER AND PROSTATE
Ruiyun Zhang*, Ying Jing, Wei Xue, Yiran Huang, Guanglei Zhuang, Haige Chen, Shanghai, China, People’s Republic of

MP06-17 COMPARISON OF OUTCOMES IN PATIENTS UNDERGOING CYSTECTOMY RECEIVING L-ARGININE IMMUNONUTRITION
Elizabeth Bearrick*, Niranjan Sathianathen, Priya Balaji, Ian Marigi, Badrinath Konety, Minneapolis, MN

MP06-18 PREDICTING PERIOPERATIVE COMPLICATIONS IN PATIENTS RECEIVING RADICAL CYSTECTOMY USING PRE-OPERATIVE CT-MEASURED ADIPOSE TISSUE INDICES

MP06-19 INCIDENCE AND ONCOLOGICAL OUTCOMES OF UROTHELIAL CARCINOMA IN KIDNEY TRANSPLANT RECIPIENTS
Jiwoong Yu*, Jong Hoon Lee, Young Hyo Choi, Jin Ho Choe, Hyun Hwan Sung, Kang Min Yong, Jeon Hwang Gyun, Jeong Byong Chang, Seo Seong Il, Jeon Seong Soo, Lee Hyun Moo, Seoul, Korea, Republic of

MP06-20 APPLICATION OF AUA RISK STRATIFICATION FOR NON-MUSCLE INVASIVE BLADDER CANCER: LONG-TERM RESULTS IN A CONTEMPORARY SINGLE INSTITUTION COHORT
Maria C. Velasquez*, Deukwoo Kwon, Nachiketh Soodana Prakash, Marcelo P. Barboza, Luis F. Savio, Omer Kineish, Mahmoud Alameddine, Sanoj Punnen, Mark Gonzalgo, Dipen J. Parekh, Chad R. Ritch, Chad R. Ritch, Miami, FL

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
7:50 PD01-06 IMPACT OF INSURANCE COVERAGE FOR IN-VITRO FERTILIZATION ON ACCESS TO ADVANCED FERTILITY CARE
James Dupree*, Zachary Levinson, Angela Kelley, Ann Arbor, MI, Jessica Dozier, Atlanta, GA, Marsha Manning, Michael Lanham, Vanessa Dalton, Helen Levy, Richard Hirth, Ann Arbor, MI

8:00 PD01-07 SYTO 17 FLUORESCENT ACTIVATED SPERM SORTING DEMONSTRATES EFFICACY IN SORTING VIABLE & MOTILE SPERM
Alexander Bolyakov*, Ryan Flannigan, Anna Mielnik, Russell Hayden, Peter N. Schlegel, Darius Paduch, New York, NY

8:10 PD01-08 IS THERE A ROLE FOR SALVAGE OR REDO MICRO-DISSECTION TESTICULAR SPERM EXTRACTION IN NON-OBSTRUCTIVE AZOOSPERMIA?
Samuel Morris*, Tet Yap, Khaled Alkematy, Chirag Bhanderi, Pippa Sangster, Majid Shabbir, Suks Minhas, London, United Kingdom

8:20 PD01-09 EFFECTS OF PREOPERATIVE MEDICAL TREATMENT ON SPERM RETRIEVAL RATES IN PRIMARY AND RECURRENT MICRO TESE
Murad Başar*, Yesim Kuntepe-Colakoglu, Hakan Yelke, Serkan Selimoglu, Mirac Turan, Semra Kahraman, Istanbul, Turkey

8:30 PD01-10 RESULTS OF A CONSERVATIVE APPROACH TO TESTICULAR TUMOURS DISCOVERED DURING INFERTILITY MANAGEMENT
Samuel Lagabrielle*, Bordeaux, France, Xavier Durand, Paris, France, Stephane Droupy, Nice, France, Vincent Izard, Paris, France, François Marcelli, Lille, France, Eric Huyghe, Toulouse, France, Jean- Marie Ferriere, Ludovic Ferretti, Bordeaux, France

8:40 PD01-11 INCREASES IN SERUM TESTOSTERONE 1 MONTH FOLLOWING THE START OF LOW DOSE CLOMIPHENE CITRATE PREDICTS THE MAGNITUDE OF INCREASES IN SPERM CONCENTRATION WITH 3 MONTHS OF THERAPY FOR MEN WITH INFERTILITY
Abdullah Al Fakhri*, Christopher Wu, Lior Kirmus, Ethan Grober, Kirk Lo, Keith Jarvi, Toronto, Canada

8:50 PD01-12 RESULTS OF CORRECTION OF SUBCLINICAL VARICOCELES ARE SIMILAR TO IMPROVEMENTS SEEN AFTER REPAIR OF PALPABLE VARICOCELES
Nannan Thirumavalavan*, Adithya Balasubramanian, Jason M. Scovell, Taylor P. Kohn, Byung C. Ji, Asad Hasan, Alexander W. Pastuszak, Larry I. Lipshultz, Houston, TX

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
7:50 PD02-06 RISK OF INFECTION COMPLICATIONS IN PATIENTS WITH TRAUMATIC URETHRAL INJURIES UNDERGOING INTERNAL FIXATION OF PELVIC FRACTURES AND SUPRAPUBIC TUBE PLACEMENT: A NATIONAL TRAUMA DATA BANK ANALYSIS
Niels Johnsen*, Bryan Voelzke, Seattle, WA

8:00 PD02-07 OUTCOMES FOLLOWING POSTERIOR URETHROPLASTY FOR PELVIC-FRACTURE URETHRAL INJURIES: A MULTI-INSTITUTIONAL ANALYSIS

8:10 PD02-08 THE IMPORTANCE OF THE TIMING OF EXCRETORY PHASE CT SCAN IN THE DIAGNOSIS OF URINARY EXTRAVASATION AFTER HIGH-GRADE RENAL TRAUMA
Sorena Keihani*, Darshan Patel, Bryn Putbrese, Douglas Rogers, Salt Lake City, UT, Xian Luo-Owen, Kaushik Mukherjee, Loma Linda, CA, Bradley Morris, Sarah Majercik, Murray, UT, Joshua Piotrowski, Christopher Dodgion, Milwaukee, WI, Brenton Sherwood, Bradley Erickson, Iowa City, IA, Ian Schwartz, Sean Elliott, Minneapolis, MN, Erik Desoucy, Scott Zakaluzny, Sacramento, CA, Nima Baradarani, Benjamin Breyer, San Francisco, CA, Brian Smith, Philadelphia, PA, Brandi Miller, Richard Santucci, Detroit, MI, Matthew Carrick, Plano, TX, Jurek Kocik, Tyler, TX, Timothy Hewitt, Frank Burks, Royal Oak, MI, Marta Heilbrun, Atlanta, GA, James Hotaling, Raminder Nirula, Jeremy Myers, Salt Lake City, UT

8:20 PD02-09 PRESERVED KIDNEY FUNCTION FOLLOWING CONSERVATIVE MANAGEMENT IN PATIENT WITH RENAL TRAUMA
Kanishka Kumar, Shrawan Singh*, Shivanshu Singh, Balwant Ram Mittal, Arup Kumar Mandal, Chandigarh, India

8:30 PD02-10 WHICH IS THE PLACE FOR IMMEDIATE RADIO-EMBOLIZATION IN THE MANAGEMENT OF HEMODYNAMICALLY INSTABLE PATIENTS WITH KIDNEY TRAUMA? RESULTS OF THE MULTICENTRIC NATIONAL FRENCH STUDY TRAUMAFU

8:40 PD02-11 EARLY DISCHARGE IN PATIENTS WITH LOW GRADE RENAL TRAUMA: ON THE WAY TO OUTPATIENT MANAGEMENT? RESULTS OF THE TRAUMAFU MULTICENTRE STUDY

8:50 PD02-12 A NOVEL ADULT ACQUIRED BURIED PENIS REPAIR CLASSIFICATION SYSTEM WITH AN ANALYSIS OF HIGH GRADE PERIOPERATIVE COMPLICATIONS AND URETHRAL STRICTURE DISEASE
Joseph Pariser*, Omar Soto-Aviles, Brandi Miller, Maha Husainat, Richard Santucci, Detroit, MI

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00</td>
<td>PD03-01</td>
<td>DISCOVERY OF SPONTANEOUS RANDALL’S PLAQUE STONE OVERGROWTH IN AN ANIMAL MODEL Michael Borofsky*, Minneapolis, MN, James C. Williams Jr., Indianapolis, IN, Jody Lulich, Minneapolis, MN</td>
</tr>
<tr>
<td>7:10</td>
<td>PD03-02</td>
<td>EVIDENCE FOR A DISTINCT GUT MICROBIOME AMONG GENETIC HYPERCALCIURIC STONE-FORMING RATS Joshua Stern*, Bronx, NY, Nancy Krieger, Rochester, NY, Daniel Schoenfeld, Sylvia Suadicani, Robert Burb, Bronx, NY, David Bushinsky, Rochester, NY</td>
</tr>
<tr>
<td>7:20</td>
<td>PD03-03</td>
<td>GENOTYPE CLASSIFICATION BASED ON THE MULTIPLE CYSTINE RELATED TRANSPORTERS IN JAPANESE CYSTINURIA PATIENTS Shinichi Sakamoto*, Akinori Takei, Chiba, Japan, Takaaki Tamura, Yokohama, Japan, Masaaki Fujimura, Chiba, Japan, Yasuhiro Shigeta, Funabashi, Japan, Yusuke Imamura, Chiba, Japan, Hitoshi Yano, Sakura, Japan, Yukio Naya, Anegasaki, Japan, Koji Kawamura, Akira Komiya, Chiba, Japan, Koichiro Akakura, Shinjuku, Japan, Tomohiko Ichikawa, Chiba, Japan</td>
</tr>
<tr>
<td>7:40</td>
<td>PD03-05</td>
<td>ANTIBIOTICS AND A HIGH FAT/HIGH SUGAR DIET REDUCE MICROBIAL OXALATE METABOLISM IN A MOUSE MODEL Aaron Miller*, Cleveland, OH, Teri Orr, Denise Dearing, Salt Lake City, UT, Manoj Monga, Cleveland, OH</td>
</tr>
<tr>
<td>7:50</td>
<td>PD03-06</td>
<td>PLAQUE, PITTING, CONTOUR LOSS - A PATHOGENETIC SEQUENCE IN RENAL PAPILLAE OF IDIOPATHIC CALCIUM STONE FORMERS Melanie Adamsky*, Andrew Cohen, Christopher Riedinger, Glenn Gerber, Elaine Worcester, Frederic Coe, Chicago, IL</td>
</tr>
<tr>
<td>8:00</td>
<td>PD03-07</td>
<td>RNA INTERFERENCE OF HEPATIC LACTATE DEHYDROGENASE REDUCES URINARY OXALATE IN A MOUSE MODEL OF PRIMARY HYPEROXALURIA TYPE 1 Kyle Wood*, John Knight, Dean Assimos, Ross Holmes, Birmingham, AL</td>
</tr>
<tr>
<td>8:10</td>
<td>PD03-08</td>
<td>VITAMIN D, BONE TURNOVER MARKERS AND BONE MINERAL DENSITY IN RECURRENT CALCIUM STONE FORMERS Urmila Dhakad*, Bhupendra Pai Singh, Kawaijit Singh Kaura, Satya Narayan Sankhwar, Siddharth Kumar Das, Lucknow, India</td>
</tr>
<tr>
<td>8:20</td>
<td>PD03-09</td>
<td>ESTABLISHMENT OF A NEW METHOD TO EVALUATE THE PHAGOCYTIC ABILITY OF CALCIUM OXALATE MONOHYDRATE CRYSTALS BY MACROPHAGES Atsushi Okada*, Hiroshi Takase, Teruaki Sugino, Rei Unno, Kazumi Taguchi, Shuzo Hamamoto, Ryosuke Ando, Keiichi Tozawa, Takahiro Yasui, Nagoya, Japan</td>
</tr>
<tr>
<td>8:30</td>
<td>PD03-10</td>
<td>COMPARATIVE URINARY METABOLICOMICS REVEAL DISTINCT PROFILE IN PATIENTS WITH URINARY STONE DISEASE Andrew Nguyen*, Anna Zampini, Emily Rose, Manoj Monga, Aaron Miller, Cleveland, OH</td>
</tr>
<tr>
<td>8:40</td>
<td>PD03-11</td>
<td>EXPANDED QUANTITATIVE CULTURE (EQC) DETECTS UNIQUE LIVE BACTERIA FROM KIDNEY STONES Petar Bajic*, Michelle Van Kuiken, Bethany Burge, Alan Wolfe, Maywood, IL, Andrew Schwaderer, Bodo Knudsen, Columbus, OH, Larissa Bresler, Ahmer Farooq, Thomas Turk, Kristin Baldea, Maywood, IL</td>
</tr>
<tr>
<td>8:50</td>
<td>PD03-12</td>
<td>SELECTIVE AUTOPHAGY VIA mTORC1 AND TFEB SIGNALS IN THE SUPPRESSION OF KIDNEY STONE FORMATION Rei Unno*, Nagoya, Japan, Tsuyoshi Kawabata, Osaka, Japan, Hiroshi Takase, Teruaki Sugino, Yutaru Tanaka, Kazumi Taguchi, Naoko Unno, Shuzo Hamamoto, Ryosuke Ando, Atsushi Okada, Kenjiro Kohri, Nagoya, Japan, Tamotsu Yoshimori, Osaka, Japan, Takahiro Yasui, Nagoya, Japan</td>
</tr>
</tbody>
</table>
### Podium Session 4

**URODYNAMICS/LOWER URINARY TRACT DYSFUNCTION/FEMALE PELVIC MEDICINE: NEUROGENIC VOIDING DYSFUNCTION I**  
Room 3018 @ MCC West  
**Moderators:** Christopher Elliott, Jennifer Rothschild and Elisabetta Costantini

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00</td>
<td>PD04-01</td>
<td>CHANGES IN BRAIN ACTIVITY FOLLOWING INTRADETRUSOR INJECTION OF ONABOTULINUMTOXINA IN PATIENTS WITH MULTIPLE SCLEROSIS: AN FMRI STUDY</td>
<td>8:10</td>
<td>PD04-08</td>
<td>PATIENT-REPORTED BLADDER FUNCTION AND SATISFACTION AMONG PARAPLEGIC PATIENTS WITH DIFFERENT BLADDER MANAGEMENT STRATEGIES</td>
</tr>
<tr>
<td></td>
<td>Rose Khavari*, Christof Kamonnik, Saba Elias, Timothy Boone, Houston, TX</td>
<td></td>
<td></td>
<td>Jeremy Myers*, Sara Lenherr, Salt Lake City, UT, John Stoffel, Ann Arbor, MI, Sean Elliott, Minneapolis, MN, Angela Presson, Chong Zhang, Salt Lake City, UT, Blayne Welk, London, Canada</td>
<td></td>
</tr>
<tr>
<td>7:10</td>
<td>PD04-02</td>
<td>SUPRASPINAL CONTROL VARIAITONS IN MULTIPLE SCLEROSIS PATIENTS WHO VOID SPONTANEOUSLY VERUS PATIENTS WITH VOIDING DYSFUNCTION</td>
<td>8:20</td>
<td>PD04-09</td>
<td>TELEMEDICINE FOR MANAGEMENT OF NEUROGENIC BLADDER AND URINARY TRACT INFECTION PREVENTION IN INDIVIDUALS WITH SPINAL CORD INJURY</td>
</tr>
<tr>
<td></td>
<td>Rose Khavari*, Christof Kamonnik, Timothy Boone, Houston, TX</td>
<td></td>
<td></td>
<td>Lynn Stothers*, Emily G. Deegan, Babak Shadgan, Andrew J. Macnab, Alex Kavanagh, Mark K. Nigro, Vancouver, Canada</td>
<td></td>
</tr>
<tr>
<td>7:20</td>
<td>PD04-03</td>
<td>PATIENTS WITH MULTIPLE SCLEROSIS LACK AWARENESS OF URINARY DYSFUNCTION</td>
<td>8:30</td>
<td>PD04-10</td>
<td>DEMOGRAPHIC AND URODYNAMIC RISK ANALYSIS OF RENAL DETERIORATION IN SPINAL CORD INJURED PATIENTS</td>
</tr>
<tr>
<td></td>
<td>Zhenyue Huang*, Olga Povcher, William Berg, Yu Wang, Justina Tam, Steven Weissbart, Jason Kim, Stony Brook, NY</td>
<td></td>
<td></td>
<td>Arthi Satyanarayan*, Nabeel Shakir, Jessica Eastman, Gary Lemack, Dallas, TX</td>
<td></td>
</tr>
<tr>
<td>7:30</td>
<td>PD04-04</td>
<td>ELEVATED POST-VOID RESIDUAL DOES NOT PREDICT WORSENING UROLOGIC SYMPTOMS IN PATIENTS WITH MULTIPLE SCLEROSIS</td>
<td>8:40</td>
<td>PD04-11</td>
<td>LONG TERM URODYNAMIC RESULTS FOLLOWING EXTERNAL SPHINCTEROTOMY IN SPINAL CORD INJURY PATIENTS</td>
</tr>
<tr>
<td></td>
<td>Elizabeth Dray*, John Stoffel, J. Quentin Clemens, Anne Pelletier Cameron, Priyanka Gupta, Paholo Barboglio-Romo, Diana Covalski, Yongmei Qin, Ann Arbor, MI</td>
<td></td>
<td></td>
<td>Andrew Margules*, Lawrence Lee, Whitney Smith, Mihir Shah, Alana Murphy, Akhil Das, Patrick Shenot, Philadelphia, PA</td>
<td></td>
</tr>
<tr>
<td>7:40</td>
<td>PD04-05</td>
<td>ASSESSMENT OF RENAL DETERIORATION AND ASSOCIATED RISK FACTORS IN PATIENTS WITH MULTIPLE SCLEROSIS AT MEDIAN FOLLOW-UP OF 81 MONTHS: IS EARLY TREATMENT OF DETRUSOR OVERACTIVITY WARRANTED?</td>
<td>8:50</td>
<td>PD04-12</td>
<td>ONABOTULINUMTOXINA FOR NEUROGENIC DETRUSOR OVERACTIVITY REDUCES FREQUENCY AND SEVERITY OF AUTONOMIC DYSREFLEXIA AND IMPROVES QUALITY OF LIFE FOR INDIVIDUALS WITH SPINAL CORD INJURY</td>
</tr>
<tr>
<td></td>
<td>Nabeel Shakir*, Arthi Satyanarayan, Jessica Eastman, Gary Lemack, Dallas, TX</td>
<td></td>
<td></td>
<td>Matthias Walter*, Stephanie L. Kran, Mark Nigro, Lynn Stothers, Daniel Rapoport, Alex Kavanagh, Andrei V. Krassioukov, Vancouver, Canada</td>
<td></td>
</tr>
<tr>
<td>7:50</td>
<td>PD04-06</td>
<td>LEVEL OF INJURY DOES NOT PREDICT URINARY QUALITY OF LIFE IN PATIENTS WITH SPINAL CORD INJURY ON CLEAN INTERMITTENT CATHETERIZATION</td>
<td></td>
<td></td>
<td>APPROVED FOR AMA PRA CATEGORY 1 CREDIT™</td>
</tr>
<tr>
<td></td>
<td>Iryna Crescenzze*, Dianna Covalski, Ann Arbor, MI, Sara M. Lenherr, Jeremy B. Myers, Angela P. Presson, Chong Zhang, Salt Lake City, UT, Sean Elliott, Minneapolis, MN, Blayne Welk, London, Canada, John T. Stoffel, Ann Arbor, MI</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00</td>
<td>PD04-07</td>
<td>URINARY TRACT INFECTION FREQUENCY AND SEVERITY IS ASSOCIATED WITH BLADDER MANAGEMENT METHOD IN SPINAL CORD INJURY</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sean Elliott*, Minneapolis, MN, Joshua Roth, Indianapolis, IN, John Stoffel, Ann Arbor, MI, Sara Lenherr, Angela Presson, Salt Lake City, UT, Blayne Welk, London, Canada, Jeremy Myers, Salt Lake City, UT</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Presenting author
Video Session 1

RECONSTRUCTION - LOWER URINARY TRACT

The videos in this session as well as the video libraries from the 2011-2016 Annual Meetings may be viewed in the Surgical Video Library and purchased in the AUA Store during the Annual Meeting. Both are located in Hall A. AUA members receive free online access to the Surgical Video Library throughout the year through AUA University. Visit www.AUAnet.org/University to access.

Room 3002 @ MCC West

Moderators: Daniel Dugi, Benjamin Breyer and Daniel Moon

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>V01-01</td>
<td>ROBOTIC URETERONEOCYSTOSTOMY WITH BILATERAL BOARI FLAP</td>
</tr>
<tr>
<td></td>
<td>Daniel Sagalovich*, Nitin Yerram, Juan Garisto, Julien Dagenais, Jaya Sai Chavali, Georges-Pascal Haber, Jihad Kaouk, Robert Stein, Cleveland, OH</td>
</tr>
<tr>
<td>V01-02</td>
<td>ROBOTIC BLADDER NECK RECONSTRUCTION FOR POST-PROSTATECTOMY BLADDER NECK CONTRACTURE</td>
</tr>
<tr>
<td></td>
<td>Woodson Smelser*, David Duchene, Kansas City, KS</td>
</tr>
<tr>
<td>V01-03</td>
<td>ROBOTIC ASSISTED POSTERIOR URETHROPLASTY: IMPROVING VISUALIZATION AND ERGONOMICS OF SUTURE PLACEMENT DURING ANASTOMOSIS</td>
</tr>
<tr>
<td></td>
<td>Stephen Underberg*, Sunil Patel, Jill Buckley, San Diego, CA</td>
</tr>
<tr>
<td>V01-04</td>
<td>USE OF BILATERAL PEDICLED SCROTAL FLAPS TO RESTORE PENILE SHAFT DEFECTS: TECHNIC AND RESULTS</td>
</tr>
<tr>
<td></td>
<td>Lionel MENDEL*, Nice, France, Nicolas MOREL JOURNAL, Killian ALLEPOT, Philippe PAPAREL, Alain RUFFION, Jean Etienne TERRIER, Pierre-Bénéte, France</td>
</tr>
<tr>
<td>V01-05</td>
<td>TURNBULL-CUTAIT COLOANAL PULL-THROUGH: A SALVAGE RECONSTRUCTIVE OPTION IN THE MANAGEMENT OF REFRACTORY RECTOURETHRAL FISTULAE</td>
</tr>
<tr>
<td></td>
<td>Christopher Haas*, Cooper Benson, Felipe Pedrosa, Steven Lee-Kong, Steven Brandes, NEW YORK, NY</td>
</tr>
<tr>
<td>V01-06</td>
<td>ROBOTIC Y-V PLASTY FOR RECALCITRANT BLADDER NECK CONTRACTURE</td>
</tr>
<tr>
<td></td>
<td>Michael Granieri, Aaron Weinberg, Jeffrey Sun, New York, NY, Michael Stifelman, Hackensack, NJ, Lee Zhao*, New York, NY</td>
</tr>
<tr>
<td>V01-07</td>
<td>PEDICLE PREPUTIAL TUBE FOR BULBAR URETHRAL NECROSIS IN FAILED URETHROPLASTY FOR PFUDD</td>
</tr>
<tr>
<td></td>
<td>Pankaj Joshi*, Sandesh Surana, Omkar Joglekar, Mohammad Akandari, Jyotsna Kulkarni, Sanjay Kulkarni, Pune, India</td>
</tr>
<tr>
<td>V01-08</td>
<td>A MULTI-CENTER ANALYSIS ON SURGICAL TECHNIQUE, OUTCOMES AND LEARNING CURVE OF MALE-TO-FEMALE PENOSCROTAL VAGINoplasty</td>
</tr>
<tr>
<td></td>
<td>Andrea Cocci*, Firenze, Italy, Gaia Polloni, Milan, Italy, Augusto Delle Rose, Simone Grisanti Carassai, Cito Gianmartin, Sergio Serni, Marco Carini, Florence, Italy, Valeria Matteucci, Girolamo Morelli, pisa, Italy</td>
</tr>
<tr>
<td>V01-09</td>
<td>GENDER-AFFIRMING VAGINoplasty</td>
</tr>
<tr>
<td></td>
<td>Kyle Gillis*, Jonathan Witten, Daniel Dugi, Portland, OR</td>
</tr>
<tr>
<td>V01-10</td>
<td>ROBOT REPAIR OF RECTOURETHRAL FISTULA AND VESICOURETHRAL ANASTOMOTIC DISRUPTION WITH GRACILIS FLAP INTERPOSITION</td>
</tr>
<tr>
<td></td>
<td>Michael Granieri, Rachel Bluebord-Langner, Jamie Levine, Lee Zhao*, New York, NY</td>
</tr>
<tr>
<td>V01-11</td>
<td>ROBOTIC POSTERIOR URETHROPLASTY FOR RADIATION INDUCED POSTERIOR URETHRAL STENOSIS</td>
</tr>
<tr>
<td></td>
<td>Michael Granieri, Aaron Weinberg, Lee Zhao*, New York, NY</td>
</tr>
<tr>
<td>V01-12</td>
<td>ROBOTIC REPAIR OF IATROGENIC PROSTATOSYPHSEAL FISTULA FOLLOWING PHOTOSELECTIVE VAPORIZATION OF THE PROSTATE</td>
</tr>
<tr>
<td></td>
<td>Andrew Sun*, Scott Lundy, Kenneth Angermeier, Amr Fergany, Cleveland, OH</td>
</tr>
</tbody>
</table>

Forums

UROLOGIC ONCOLOGY RESEARCH SYMPOSIUM: TUMOR MICROENVIRONMENT AND IMMUNOLOGY: FRONTIERS IN CANCER THERAPY

Room 208 @ MCC South

7:30 WELCOME AND SYMPOSIUM INTRODUCTION
William Dahut, Aria Olumi, Allan Pantuck

7:40 SESSION I: HISTORICAL OVERVIEW
Moderator: William Dahut
IMMUNOTHERAPY IN RENAL CELL CARCINOMA
Michael Atkins

IMMUNOTHERAPY FOR BLADDER AND PROSTATE CANCERS: STRATEGIES FOR HOT AND COLD
James Gulley

8:25 SESSION II: CHECKPOINT INHIBITORS
Moderator: Emmanuel Antonarakis

CHECKPOINT INHIBITORS (ALONE OR IN COMBINATION) FOR ADVANCED PROSTATE CANCER
Emmanuel Antonarakis

DEVELOPING IMMUNOTHERAPY AND OTHER TREATMENT STRATEGIES IN BIOCHEMICALLY RECURRENT PROSTATE CANCER
Ravi Madan

IMPROVING KIDNEY CANCER IMMUNOTHERAPY THROUGH NOVEL BIOMARKERS AND CLINICAL TRIAL DESIGN
David McDermott

TREATING UROTHELIAL CANCER IN THE NEW ERA
Alexandra Drakaki

9:50 BREAK

10:05 SESSION III: TUMOR VACCINES AND ANTIBODIES
Moderator: Douglas McNeil

USING DNA VACCINES WITH CHECKPOINT INHIBITION TO ACTIVATE THERAPEUTIC PROSTATE CANCER IMMUNITY
Douglas McNeil

STEM-LIKE CD8 T-CELLS IN UROLOGIC CANCERS
Haydn Kissick

MONOCLONALS, ANTIBODY-DRUG CONJUGATES, RADIOLABELLED ANTIBODIES - RENAL CELL CARCINOMA
Peter Mulders

DO NK CELLS AND NK LIGANDS HAVE A ROLE IN THE TREATMENT OF PC?
Jennifer Wu

11:30 CONFERENCE LUNCH BREAK

1:00 SESSION IV: ENGINEERED T CELLS, ADOPTIVE CELLULAR THERAPIES, AND CYTOKINES
Moderator: Susan Slovin

HARNESSING THE MIRNA-EPIGENETIC REGULATORY CIRCUITRY TO ENHANCE CD8+ T CELL ANTITUMOR IMMUNITY
Luca Gattinoni

TARGETING NEOANTIGENS AND THE PARADOX OF RENAL CANCER
James Yang

RADIOIMAGING OF PROSTATE ANTIGENS: CAN TARGETING IMPACT ON THE IMMUNE MILIEU?
Susan Slovin

T CELLS ENGINEERED TO TARGET MAGE A3/ A6+ GENITOURINARY AND OTHER MALIGNANCIES
Rajul Jain

BREAK

SESSION V: IMMUNE RESPONSE MONITORING
Moderator: Lawrence Fong

COMBINATION IMMUNOTHERAPY FOR PROSTATE CANCER: OX40 AGONISTS, CHECKPOINT BLOCKADE, AND BEYOND
William Redmond

PROSTATE CANCER IMMUNOTHERAPY: WHERE ARE WE AT?
Lawrence Fong

IMMUNOPET FOR PROBING IMMUNE CELLS AND RESPONSES TO IMMUNOTHERAPY
Anna Wu

THE FUNCTIONAL CONTRIBUTION OF TUMOR MICROENVIRONMENT IN CANCER PROGRESSION AND METASTASIS
Raghu Kanturi

FDA FRAMEWORK/ENDPOINTS MONITORING
B. Harpreet Singh

CLOSING DISCUSSION
William Dahut, Aria Olumi, Allan Pantuck

ADJOURN

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

*Presenting author
### SOCIETY FOR PEDIATRIC UROLOGY (SPU)

**Yerba Buena Salon 8-9 @ Marriott Marquis**

**Friday, May 18, 2018 7:30 am - 6:00 pm**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30</td>
<td><strong>WELCOME</strong></td>
<td>Caleb Nelson</td>
</tr>
<tr>
<td>7:35</td>
<td><strong>SCIENTIFIC SESSION I: HYPOSPADIAS AND PENILE SURGERY</strong></td>
<td></td>
</tr>
<tr>
<td>9:05</td>
<td><strong>BREAK</strong></td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td><strong>SCIENTIFIC SESSION II: CLINICAL PRIZE FINALISTS</strong></td>
<td></td>
</tr>
<tr>
<td>10:10</td>
<td><strong>SCIENTIFIC SESSION III: TESTIS AND SEXUAL DEVELOPMENT</strong></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td><strong>SCIENTIFIC SESSION IV: ADOLESCENT UROLOGY</strong></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td><strong>LUNCH</strong></td>
<td></td>
</tr>
<tr>
<td>1:00</td>
<td><strong>SOCIETY FOR FETAL UROLOGY SESSION I: UTD/FETAL 1</strong></td>
<td></td>
</tr>
<tr>
<td>1:50</td>
<td><strong>SOCIETY FOR FETAL UROLOGY PANEL: POSTERIOR URETHRAL VALVES</strong></td>
<td>Dana Giel, Elena Gates, Tony Herndon, Pramod Reddy, Vijaya Vemulakonda</td>
</tr>
<tr>
<td>2:50</td>
<td><strong>BREAK/SOCIETY FOR FETAL UROLOGY BUSINESS MEETING</strong></td>
<td></td>
</tr>
<tr>
<td>3:20</td>
<td><strong>SOCIETY FOR FETAL UROLOGY SESSION II: UTD/Fetal 2</strong></td>
<td></td>
</tr>
<tr>
<td>4:20</td>
<td><strong>SOCIETY FOR FETAL UROLOGY LECTURE</strong></td>
<td>Roberta Keller</td>
</tr>
<tr>
<td>5:00</td>
<td><strong>DSD TASK FORCE UPDATE</strong></td>
<td>Earl Cheng</td>
</tr>
<tr>
<td>5:30</td>
<td><strong>PEDIATRIC UROLOGIC ONCOLOGY WORK GROUP</strong></td>
<td>Nicholas Cost, Fernando Ferrer</td>
</tr>
<tr>
<td>6:00</td>
<td><strong>ADJOURN</strong></td>
<td></td>
</tr>
</tbody>
</table>

---

**APPROVED FOR AMA PRA CATEGORY 1 CREDIT™**

---

### INDIAN AMERICAN UROLOGICAL ASSOCIATION (IAUA)

**Room 216 @ MCC South**

**Friday, May 18, 2018 8:00 am - 2:00 pm**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00</td>
<td><strong>NON-CME INDUSTRY SPONSORED BREAKFAST SYMPOSIUM</strong></td>
<td></td>
</tr>
<tr>
<td>8:00</td>
<td><strong>INTRODUCTION</strong></td>
<td>Ajay Singla</td>
</tr>
<tr>
<td>8:05</td>
<td><strong>SESSION I: PROSTATE CANCER</strong></td>
<td>Ganesh Palapatitu</td>
</tr>
<tr>
<td></td>
<td><strong>CONTROVERSY IN PSA SCREENING: WHAT THE GUIDELINES SAY</strong></td>
<td>Ganesh Palapatitu</td>
</tr>
<tr>
<td>8:55</td>
<td><strong>SESSION II: SMALL RENAL MASSES</strong></td>
<td></td>
</tr>
<tr>
<td>9:45</td>
<td><strong>IAUA/SAKTI DAS AND KEDIA RESEARCH SCHOLAR PRESENTATIONS</strong></td>
<td>Rita Verma, Arjun Sivaraman</td>
</tr>
<tr>
<td>10:00</td>
<td><strong>BREAK</strong></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td><strong>DEBATE: REFRACTORY OVERACTIVE BLADDER</strong></td>
<td>Priya Padmanabhan</td>
</tr>
<tr>
<td>11:00</td>
<td><strong>DEBATE: RENAL STONE DISEASE FOR 1.5 CM LOWER POLE STONE</strong></td>
<td>Priyanka Gupta</td>
</tr>
<tr>
<td>11:30</td>
<td><strong>USI TALK: OVERVIEW OF FEMALE UROLOGY AND CURRENT STATUS IN INDIA</strong></td>
<td>Ajit Vaze</td>
</tr>
<tr>
<td>11:45</td>
<td><strong>PENILE REHABILITATION AFTER PROSTATE CANCER TREATMENT</strong></td>
<td>Ajay Nehra</td>
</tr>
<tr>
<td>12:00</td>
<td><strong>NON-CME INDUSTRY LUNCH SYMPOSIUM</strong></td>
<td></td>
</tr>
<tr>
<td>1:00</td>
<td><strong>IAUA MEMBER BUSINESS MEETING</strong></td>
<td></td>
</tr>
<tr>
<td>1:30</td>
<td><strong>POSTER PRESENTATIONS</strong></td>
<td></td>
</tr>
<tr>
<td>2:00</td>
<td><strong>ADJOURN</strong></td>
<td></td>
</tr>
</tbody>
</table>

**APPROVED FOR AMA PRA CATEGORY 1 CREDIT™**
### AUA/CONFEDERACION AMERICANA DE UROLOGIA (CAU)

**HALL E @ MCC North**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>MORNING SESSION</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderator: Shlomo Raz</td>
<td></td>
</tr>
<tr>
<td>8:00</td>
<td>ROBOTIC PROSTATECTOMY</td>
<td>Mani Menon</td>
</tr>
<tr>
<td>8:25</td>
<td>CARCINOMA OF KIDNEY</td>
<td>W. Marston Linehan</td>
</tr>
<tr>
<td>8:50</td>
<td>ADVANCES IN THE TREATMENT OF BPH</td>
<td>Peter Gilling</td>
</tr>
<tr>
<td>9:15</td>
<td>CARCINOMA OF THE BLADDER</td>
<td>Juan Palou</td>
</tr>
<tr>
<td>9:40</td>
<td>CARCINOMA OF THE PROSTATE</td>
<td>Ian Thompson</td>
</tr>
<tr>
<td>10:05</td>
<td>TREATMENT OF URETHRAL STRICTURES</td>
<td>Hunter Wessells</td>
</tr>
<tr>
<td>10:30</td>
<td>UPDATE IN TREATMENT OF URINARY STONES</td>
<td>Jorge Gutierrez-Aceves</td>
</tr>
<tr>
<td>10:55</td>
<td>UPDATE ON ED, PRIAPISM AND PEYRONIE'S DISEASE</td>
<td>Tom Lue</td>
</tr>
<tr>
<td>11:20</td>
<td>AU/AU REMARKS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AUA Secretary: Manoj Monga</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CAU General Secretary: Jorge Gutierrez-Aceves</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td>1:00</td>
<td>AFTERNOON SESSION: UPDATES IN UROLOGIC SURGERY</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderator: Jorge Gutierrez-Aceves</td>
<td></td>
</tr>
<tr>
<td>1:00</td>
<td>ENDOUROLOGY AND STONES: DISPOSABLE FLEXIBLE URETEROSCOPES: DO WE NEED TO PAY THE COST?</td>
<td>Mantu Gupta</td>
</tr>
<tr>
<td>3:00</td>
<td>UPDATE IN TREATMENT OF URINARY STONES</td>
<td></td>
</tr>
<tr>
<td>3:00</td>
<td>ONCOLOGY DIAGNOSIS AND THERAPY</td>
<td></td>
</tr>
<tr>
<td>4:00</td>
<td>TREATMENT OF URETHRAL STRICTURES</td>
<td></td>
</tr>
<tr>
<td>4:30</td>
<td>MICRON-URETEROSCOPY: TOTALLY MINIMALLY INVASIVE STONE TREATMENT</td>
<td>Juan Antonio Galan</td>
</tr>
</tbody>
</table>

### WORLD CHINESE UROLOGICAL SOCIETY (WCUS)

**Room 2014 @ MCC West**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>WELCOME</td>
<td>Tom Lue</td>
</tr>
<tr>
<td>8:05</td>
<td>SCIENTIFIC PROGRAM</td>
<td>Richard Lo</td>
</tr>
<tr>
<td>8:10</td>
<td>SESSION 1: LO PING-WAN MEMORIAL LECTURE</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderators: Dalin He, Richard Lo, Hui-Meng Tan</td>
<td></td>
</tr>
<tr>
<td>8:10</td>
<td>PROSTATE CANCER SCREENING AND DIAGNOSIS: CURRENT CONCEPT</td>
<td>John Davis</td>
</tr>
<tr>
<td>8:35</td>
<td>SESSION 2: PROSTHETIC SURGERY SESSION: FROM THE TRAINING IN US TO PRACTICE IN CHINA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderators: Qiang Dong, Zhong Wang, Tie Zhou</td>
<td></td>
</tr>
<tr>
<td>8:35</td>
<td>PERI-OPERATIVE ANTIBIOTICS FOR PENILE PROSTHESIS IMPLANTATION: THE DIFFERENCE AND CONSIDERATION BETWEEN CHINA AND USA</td>
<td>Yan Zhang</td>
</tr>
<tr>
<td>10:00</td>
<td>10-YEARS EXPERIENCE WITH PENILE PROSTHESIS IMPLANTATION: WHAT I HAVE LEARNT</td>
<td>Mingzhen Yuan</td>
</tr>
</tbody>
</table>
EARLY EXPERIENCE WITH PENILE PROSTHESIS RE-IMPLANTATION
Long Tian

EARLY EXPERIENCE WITH ARTIFICIAL URINARY SPHINCTER
Kexin Xu

EARLY EXPERIENCE WITH ARTIFICIAL URINARY SPHINCTER RE-IMPLANTATION
Yaoguang Zhang

Q & A WITH WCUS PANEL DISCUSSION

9:20 SESSION 3: BASIC SCIENCE: IMMUNOTHERAPY FOR CANCER
Moderators: Benyi Li, Haojie Huang, Zongbing You

CANCER IS TOO COMPLEX; COULD WE TAKE A SIMPLE LOOK?
Yuzhuo Wang

CELLULAR ANTIBODIES IN CANCER IMMUNOTHERAPY FOLLOWING A DISCOVERY OF A BELGIUM UROLOGIST
Xin Lu

IMMUNOTHERAPY FOR KIDNEY CANCERS
Junhang Luo

URINE STEM CELL AND ITS APPLICATION IN UROLOGY
Yuanyuan Zhang

DISCUSSION

10:15 WCUS AWARDS
Moderators: Tom Lue, Run Wang

10:30 BREAK

10:45 SESSION 4: UROLOGICAL ONCOLOGY-1
Moderators: Lap Hong Ian, Guan Wu, Nianzeng Xing

PROSTATE CANCER BRACHYTHERAPY: QUALITY, EFFICACY, AND SAFETY - THE MD ANDERSON CANCER CENTER EXPERIENCE
Chad Tang

UNIQUE CLINICAL, PATHOLOGICAL AND PROGNOSTIC ANALYSIS OF UPPER TRACT UROTHELIAL CARCINOMA (UTUC) OF CHINESE PATIENTS: A MULTI-INSTITUTIONAL STUDY
Liqun Zhou

INNOVATIVE SURGICAL TECHNIQUES IN LAPROSCOPIC RADICAL PROSTATECTOMY
Wei Chen

THEUTILITY OFRECTAL SWABS PRIOR TO TRANSRECTAL ULTRASOUND GUIDED BIOPSY OF THE PROSTATE
Wei Phin Tan

ROLE OF RADICAL PROSTATECTOMY IN HIGH-RISK AND LOCALLY ADVANCED PROSTATE CANCER: PARADIGM SHIFT IN THE PAST 10 YEARS
Wai Kit Ma

ULTRASOUND COMPUTED TOMOGRAPHY WITH ARTIFICIAL INTELLIGENCE FOR EARLY DETECTION OF PROSTATE CANCER
Liping Xie

DISCUSSION

SESSION 5: UROLOGICAL ONCOLOGY-2
Moderators: Alex Lin, Chi-Fai Ng, Eugen Wang

ADVANCES IN RENAL TUMOR IMAGING
Li-Ming Su

A NOVEL ANATOMIC LANDMARKS-BASED CLASSIFICATION SYSTEM FOR SURGICAL STRATEGIES OF RENAL TUMOR WITH VENOUS TUMOR THROMBUS
Xin Ma

DEVICE ASSISTED THERAPIES FOR NON-MUSCLE INVASIVE BLADDER CANCER
Wei Shen Tan

UPDATE IN PENILE CANCER MANAGEMENT AND ITS APPLICABILITY IN THE HONG KONG POPULATION
Wayne Lam

EVALUATION AND CONTEMPORARY MANAGEMENT OF MALE POST-PROSTATECTOMY STRESS URINARY INCONTINENCE
H. Henry Lai

PURE LAPAROSCOPIC SURGERY FOR RIGHT RCC WITH IVC THROMBUS (MAYO III)
Lulin Ma

STAGED PROCEDURES FOR MASSIVE TUMORS WITH INFERIOR VENA CAVA INVOLVED
Xiang Feng

DISCUSSION

SESSION 6: LIGHT LUNCH

SESSION 7: ENDOUROLOGY
Moderators: Edmund Chiong, Min-Che Tung, Jianlin Yuan

ROLE OF ROBOTIC SURGERY IN RENAL TRANSPLANT AND REVASCULARISATION SURGERY
Howard Lau

RECONSTRUCTIVE SURGERY OF THE URETER: THE IUPU TECHNIQUE
Xuesong Li
LONG-TERM OUTCOMES OF A NOVEL ENDOSCOPIC INTERVENTIONS FOR PERSISTENT OR REFRACTORY HEMOSPERMIA BY SEMINAL VESICULOSCOPY VIA NATURAL ORIFICAL EJACULATORY DUCT
Heng-Jun Xiao

IS SUPER MINI PCNL (SMP) A NEW WAY IN THE FUTURE?
Guohua Zeng

ICG-ASSISTED PARTIAL NEPHRECTOMY: BENEFITS AND TIPS
Joseph Wong

MINIMALLY INVASIVE SURGERY FOR THE REPAIR OF URETERAL STRICTURE
Shing-Hwa Lu

EARLY CONTINENCE AFTER ROBOTIC-ASSISTED LAPAROSCOPIC PROSTATECTOMY: PRACTICAL EXPERIENCE SHARING
Steven Huang

DISCUSSION

SESSION 8: PELVIC UROLOGY
Moderators: Kin Li, Kai Hong, Ming-Kwong Yiu

THE TRANVAGINAL MESH CRISIS IN AUSTRALIA: WHOSE FAULT IS IT AND WHAT DID WE LEARN?
Vincent Tse

ROLE OF PELVIC FLOOR U/S IN THE MANAGEMENT OF MALE INCONTINENCE
Lewis Chan

ARTIFICIAL URINARY SPHINCTER IN SOUTHEAST ASIA: MANAGING PRACTICAL CHALLENGES
Warren Lo

REGULATORY EFFECT ON THE IMBALANCE OF TH17/TREG IN CHRONIC NON-BACTERIAL PROSTATITIS
Chaozhao Liang

ENCAPSULATED 3D BIOPrinted STRUCTURE SEeded WITH UROTHELIAL CELLS FOR TISSUE ENGINEERED URETHRAL REPAIR
Yong Yang

10-YEARS EXPERIENCE OF KETAMINE CYSTITIS FROM HONG KONG
Chi-Fai Ng

ONABOTULINUMTOXIN-A TREATMENT FOR NLUTD IN SPINAL CORD INJURY
Yuan-Hong Jiang

DISCUSSION

SESSION 9: ANDROLOGY
Moderators: Philip Li, Zhong Li, Zhichao Zhang

PREMATURE EJACULATION IN CHINA 2017
Shujie Xia

PROTECTIVE EFFECTS OF COMPOUND AMINO ACIDS ON REPRODUCTIVE DAMAGE IN RATS WITH OLIGOASTHENOZOOOSPERMIA INDUCED BY TRIPTERYGII WILFORDII
Xuejun Shang

SAFETY AND EFFICACY STUDY ON A NOVEL DEVICE LIPUS(WBL-ED) ON ED
Zhongcheng Xin

THE BASIC RESEARCH STATUS OF ERECTILE DYSFUNCTION IN CHINA
Jihong Liu

NEW STRATEGYOF THE DIAGNOSOS AND THERAPY OF PE
Yutian Dai

THE APPLICATION POTENTIAL OF THE EXTRACELLULAR VESICLES (EVS) IN ERECTILE DYSFUNCTION
Haocheng Lin

LONG-TERM FOLLOW-UP OF SUPERSELECTIVE ARTERIAL EMBOLIZATION FOR PATIENTS WITH HIGH-FLOW PRIAPISM
Songxi Tang

HEALTH MANAGEMENT OF ED PATIENTS
Tao Jiang

ADJOURN

*Presenting author
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>PRESIDENTIAL WELCOME</td>
<td>Run Wang</td>
</tr>
<tr>
<td>8:05</td>
<td>CME ACTIVITY ANNOUNCEMENTS</td>
<td>Hossein Sadeghi-Nejad</td>
</tr>
<tr>
<td>8:10</td>
<td>SESSION 1: FEMALE SEXUAL DYSFUNCTION</td>
<td><strong>FSD FOR THE HEALTHCARE PROVIDER: HOW SHOULD I TREAT HYPOACTIVE SEXUAL DESIRE DISORDER IN WOMEN?</strong> Sharon Parish</td>
</tr>
<tr>
<td>8:10</td>
<td></td>
<td><strong>STRIDES AND SETBACKS IN FEMALE SEXUAL DYSFUNCTION: A 20-YEAR RETROSPECTIVE</strong> Annamaria Giraldi</td>
</tr>
<tr>
<td>8:50</td>
<td>Q &amp; A</td>
<td></td>
</tr>
<tr>
<td>8:40</td>
<td>SESSION 2: SEXUALLY TRANSMITTED INFECTIONS: HPV</td>
<td><strong>INTRODUCTION</strong> Ira Sharlip, Luiz Torres</td>
</tr>
<tr>
<td>8:40</td>
<td></td>
<td><strong>DIAGNOSIS OF HPV INFECTION OF THE MALE GENITALIA</strong> Michael Eisenberg</td>
</tr>
<tr>
<td>8:40</td>
<td></td>
<td><strong>TREATMENT OF HPV INFECTION OF THE MALE GENITALIA</strong> Alan Shindel</td>
</tr>
<tr>
<td>8:40</td>
<td></td>
<td><strong>WHAT SEXUAL MEDICINE EXPERTS NEED TO KNOW ABOUT HPV INFECTION</strong> Joel Palefsky</td>
</tr>
<tr>
<td>8:40</td>
<td></td>
<td><strong>Q &amp; A</strong></td>
</tr>
<tr>
<td>9:45</td>
<td>SESSION 3: STATE OF THE ART LECTURES</td>
<td><strong>URETHRAL COMPLICATIONS OF PENILE FRACTURE</strong> Allen Morey</td>
</tr>
<tr>
<td>9:45</td>
<td></td>
<td><strong>UNCOMMON BUT NOT UNIMPORTANT: DIAGNOSIS AND MANAGEMENT OF PENILE SUSPENSION LIGAMENT INJURY</strong> David Ralph</td>
</tr>
<tr>
<td>9:45</td>
<td></td>
<td><strong>COUNSELING PATIENTS PRIOR TO TESTOSTERONE REPLACEMENT THERAPY: ARE YOU IN COMPLIANCE?</strong> Mohit Khera</td>
</tr>
<tr>
<td>9:45</td>
<td></td>
<td><strong>Q &amp; A</strong></td>
</tr>
<tr>
<td>10:10</td>
<td>SESSION 4: SMSNA POSITION STATEMENTS AND NOVEL CONCEPTS</td>
<td><strong>THE OPIOID EPIDEMIC AND SEXUAL DYSFUNCTION</strong> Hossein Sadeghi-Nejad</td>
</tr>
<tr>
<td>10:10</td>
<td></td>
<td><strong>RESTORATIVE THERAPIES FOR ERECTILE DYSFUNCTION: BACKGROUND AND POSITION STATEMENT</strong> Gerald Brock</td>
</tr>
<tr>
<td>10:10</td>
<td></td>
<td><strong>Q &amp; A</strong></td>
</tr>
<tr>
<td>10:45</td>
<td>SESSION 5: MEDICAL AND HORMONAL THERAPIES</td>
<td><strong>DIET AND MEN'S SEXUAL HEALTH</strong> Faysal Yafi</td>
</tr>
<tr>
<td>10:45</td>
<td></td>
<td><strong>EXERCISE AND SEXUAL HEALTH: IS THERE REALLY A CORRELATION?</strong> Martin Miner</td>
</tr>
<tr>
<td>10:45</td>
<td></td>
<td><strong>SHOCKWAVE THERAPY FOR ERECTILE DYSFUNCTION: A SUMMARY OF RANDOMIZED TRIALS</strong> Ranjith Ramasamy</td>
</tr>
<tr>
<td>10:45</td>
<td></td>
<td><strong>Q &amp; A</strong></td>
</tr>
<tr>
<td>11:10</td>
<td>THE IRA SHARLIP LECTURE: FROM ORIENT TO OCCIDENT: COMPARISON AND CONTRAST OBSERVATIONS AND REFLECTIONS IN SEXUAL MEDICINE</td>
<td><strong>Non-CME Industry Sponsored Lunch Symposium</strong></td>
</tr>
<tr>
<td>11:30</td>
<td>NON-CME INDUSTRY SPONSORED LUNCH SYMPOSIUM</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td><strong>SESSION 5: MEDICAL AND HORMONAL THERAPIES</strong> Gregory Broderick, Andrew McCulloch</td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td><strong>BREAST CANCER</strong> Sharon Bober</td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td><strong>BLADDER CANCER</strong> Trinity Bivalacqua</td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td><strong>PROSTATE CANCER</strong> Daniela Wittmann</td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td><strong>Q &amp; A</strong></td>
</tr>
<tr>
<td>12:30</td>
<td>SESSION 7: PSYCHOLOGICAL FACTORS IN SEXUAL DYSFUNCTION: PROVIDING SEXUAL HEALTH CARE TO THE CANCER PATIENT</td>
<td><strong>BREAST CANCER</strong> Christian Nelson, Michael Perelman</td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td><strong>Bladder Cancer</strong> Trinity Bivalacqua</td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td><strong>Prostate Cancer</strong> Daniela Wittmann</td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td><strong>Q &amp; A</strong></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td><strong>SESSION 8: PEYRONIE’S DISEASE</strong> Moderators: Culley Carson III, Ronald Lewis</td>
</tr>
</tbody>
</table>
### Abstracts from Friday, May 18, 2018

#### Abstracts for Moderated Poster Session 7

**INFERTILITY: THERAPY II**

Room 3004 @ MCC West

**Moderators:** Mary Samplaski, Edmund Sabanegh and Andrea Salonia

<table>
<thead>
<tr>
<th>Abstract Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP07-01</td>
<td>REAL TIME TOUCH-PRINT SMEAR TECHNIQUE IN MICRO TESE FOR PATIENTS WITH NOA</td>
<td>William Huang*, I-Shen Huang, Hsin-Yang Li, Alex Lin, Taipei, Taiwan</td>
</tr>
<tr>
<td>MP07-02</td>
<td>BASELINE BODY MASS INDEX AND ESTRADIOL LEVELS PREDICT COMBINATION THERAPY WITH ANASTROZOLE IN HYPOGONADAL MEN TREATED WITH CLOMIPHENE CITRATE</td>
<td>Sorena Keihani*, Rachel Moses, Jeremy Myers, James Hotaling, Salt Lake City, UT</td>
</tr>
<tr>
<td>MP07-03</td>
<td>ANASTROZOLE IS AN EFFECTIVE TREATMENT FOR INFERTILE MEN WITH HYPERESTROGENEMIA</td>
<td>Andrew Radtke*, Milwaukee, WI, Dane Johnson, St. Louis, MO, Luriel Smith-Harrison, Jay Sandlow, Milwaukee, WI</td>
</tr>
<tr>
<td>MP07-04</td>
<td>PRE-TREATMENT FACTORS PREDICT HORMONAL RESPONSE TO CLOMIPHENE CITRATE THERAPY</td>
<td>Jacqueline Zillioux*, Charlottesville, VA, Nathan Starke, Houston, TX, TX, Karen Wheeler, Raymond Costabile, Charlottesville, VA, Parviz Kavoussi, Austin, TX, Ryan Smith, Charlottesville, VA</td>
</tr>
<tr>
<td>MP07-05</td>
<td>OUTCOMES OF ANASTROZOLE IN THE TREATMENT OF SUBFERTILE MALES WITH BODY MASS INDEX ≥ KG/M²</td>
<td>Tejash Shah*, Newark, NJ, Themba Nyrenda, Hackensack, NJ, Saikrishnaraya Doppalapudi, Newark, NJ, David Shin, Hackensack, NJ</td>
</tr>
<tr>
<td>MP07-06</td>
<td>PREDICTORS OF IMPROVEMENT IN SEMEN PARAMETERS IN MEN TREATED WITH CLOMIPHENE CITRATE</td>
<td>Devang Sharma*, Jingzhou Wang, Karen Wheeler, Nathan Starke, Charlottesville, VA, Parviz Kavoussi, Austin, TX, Raymond Costabile, Ryan Smith, Charlottesville, VA</td>
</tr>
<tr>
<td>MP07-07</td>
<td>SERUM TESTOSTERONE PROFILES IN MEN ON TESTOSTERONE THERAPY AFTER BILATERAL ORCHIECTOMY</td>
<td>Jose Torremade*, Coskun Kagacan, Yanira Ortega, John P. Mulhall, New York City, NY</td>
</tr>
<tr>
<td>MP07-08</td>
<td>TIME FOR IMPROVEMENT IN SEMEN PARAMETERS FOLLOWING VARICOCELECTOMY IN MEN WITH SEVERE OLGOSPERMIA</td>
<td>Thomas Masterson*, Aubrey Greer, Ranjith Ramasamy, Miami, FL</td>
</tr>
</tbody>
</table>

*Presenting author
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP07-09</td>
<td>DEFINING IMPROVEMENT AFTER VARICOCELE LIGATION</td>
</tr>
<tr>
<td></td>
<td>Dane Johnson*, St. Louis, MO, Melissa St. Ambin, Jay Sandlow, Milwaukee, WI</td>
</tr>
<tr>
<td>MP07-10</td>
<td>EFFECT OF MICROSURGICAL VARICOCELEXY ON SPERM DNA INTEGRITY AND ASSOCIATION WITH REPRODUCTIVE OUTCOMES AT IVF/ICSI</td>
</tr>
<tr>
<td></td>
<td>Hudson Pierce*, Phil Bach, Ryan Flannigan, Vanessa Dudley, Marc Goldstein, New York, NY</td>
</tr>
<tr>
<td>MP07-11</td>
<td>ANALYSIS OF THE CLINICAL AND COST-EFFECTIVENESS OF COMPOUNDED FSH FOR MALE INFERTILITY TREATMENT</td>
</tr>
<tr>
<td></td>
<td>Jabez C. Gondokusumo*, J. Abram McBride, Daniel J. Mazur, Larry I. Lipshultz, Houston, TX</td>
</tr>
<tr>
<td>MP07-12</td>
<td>A UK MULTICENTRE STUDY ANALYSING THE SURGICAL SPERM RETRIEVAL RATES IN MEN WITH NON-MOSAIC KLINEFELTER’S SYNDROME UNDERGOING MTESE</td>
</tr>
<tr>
<td></td>
<td>Philippa Sangster*, Mark Johnson, Amr Raheem, Yasmeen Zainal, Sameer Posealy, Marcus Heller, Bahar Mohammadi, London, United Kingdom, Thomas Johnson, Reading, United Kingdom, Khaled Hafez, Chirag Bhandar, Andrew Vicens, Tet Yap, Majid Shabbir, Suks Minhas, David Ralph, London, United Kingdom</td>
</tr>
<tr>
<td>MP07-13</td>
<td>MICRO SURGERY FOR OBSTRUCTIVE AZOOSPERMIA IN A DEVELOPING COUNTRY</td>
</tr>
<tr>
<td></td>
<td>Amir Zarrabi*, Cape Town, South Africa</td>
</tr>
<tr>
<td>MP07-14</td>
<td>VASECTOMY REVERSAL – EARLY LEARNING CURVE</td>
</tr>
<tr>
<td></td>
<td>Filipe Tenorio Lira Neto*, Recife, Brazil, Philip S. Li, New York, NY</td>
</tr>
<tr>
<td>MP07-15</td>
<td>EDUCATIONAL PROGRAM IN THE MANAGEMENT OF INFERTILITY IN MEN WITH SPINAL CORD INJURY: UPDATE</td>
</tr>
<tr>
<td></td>
<td>Emod Ibrahim*, Teodoro Aballa, Charles Lynne, Nancy Brackett, Miami, FL</td>
</tr>
<tr>
<td>MP07-16</td>
<td>CONCOMITANT TESTOSTERONE BASED ON HCG TREATMENT RESULTED IN EARLIER MASCLINIZATION AND NO INFERIOR SPERMATOGENESIS COMPARED TO HCG ALONE IN TREATMENT OF IHF PATIENTS</td>
</tr>
<tr>
<td></td>
<td>Yinwei Chen, Yonghua Niu, Hao Xu, Daoqi Wang, Hongyang Jiang, Gaurab Pokhrel, Tao Wang, Shaogang Wang, Jihong Liu*, Wuhan, China, People’s Republic of</td>
</tr>
<tr>
<td>MP07-17</td>
<td>FACTORS IMPACTING COUPLES’ DECISION MAKING BETWEEN VASECTOMY REVERSAL VERSUS SPERM RETRIEVAL/IVF/ICSI</td>
</tr>
<tr>
<td></td>
<td>Parviz Kavoussi*, Keikhosrow Kavoussi, Kate Odenwald, Shahrayar Kavoussi, Austin, TX</td>
</tr>
<tr>
<td>MP07-18</td>
<td>THE USAGE RATE OF SEMEN CRYOPRESERVATION BEFORE CANCER TREATMENT</td>
</tr>
<tr>
<td></td>
<td>Koji Chiba*, Mikito Tanaka, Takaki Ishida, Kenta Sumii, Teruo Fukuda, Keisuke Okada, Kei Matsushita, Masato Fujisawa, Kobe, Japan</td>
</tr>
<tr>
<td>MP07-19</td>
<td>CK18- AND AMH-POSITIVE SERTOLI CELLS FACILITATE THE ELUCIDATION OF SPERMATOGENESIS DYSFUNCTION</td>
</tr>
<tr>
<td></td>
<td>Yukihiro Umemoto*, Shoichi Sasaki, Shoichirow Ivatsuki, Tomoki Takeda, Satoshi Nozaki, Hiroki Kubota, Yasue Kubota, Takashi Hamakawa, Hiroyuki Kamiya, Takahiro Yasui, Nagoya, Japan</td>
</tr>
<tr>
<td>MP07-20</td>
<td>NUTRITIONAL SUPPLEMENTS IN IDIOPATHIC MALE INFERTILITY; A SYSTEMATIC REVIEW</td>
</tr>
<tr>
<td></td>
<td>Aashay Vaidya*, Kamran Ahmed, Oliver Brunkhorst, Tet Yap, Majid Shabbir, London, United Kingdom</td>
</tr>
</tbody>
</table>

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 19, 2018

Moderated Poster Session 8

9:30 am - 10:30 am

ABSTRACT NUMBER | TITLE |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>MP08-01</td>
<td>10-YEAR EXPERIENCE OF RITE THERMOCHEMOTHERAPY FOR HIGH RISK NON MUSCLE INVASIVE BLADDER CANCER THAT HAS FAILED BCG</td>
</tr>
<tr>
<td></td>
<td>Benjamin Ayres*, Chris Bannous, Domagej Tomic, Babbin John, London, United Kingdom, Matthew Perry, Guildford, United Kingdom, Mike Bailey, Rami Issa, London, United Kingdom</td>
</tr>
<tr>
<td>MP08-02</td>
<td>COMPARING LIDOCAINE VERSUS MEPIVACAINE IN OBTURATOR NERVE BLOCK FOR TRANSURETHRAL RESECTION OF THE BLADDER</td>
</tr>
<tr>
<td></td>
<td>Pascal Viktorin-Baier*, Isabelle Keller, Barbara Jung, Michael Ganter, Hubert John, Winterthur, Switzerland</td>
</tr>
</tbody>
</table>

ABSTRACT NUMBER | TITLE |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>MP08-03</td>
<td>10-YEAR EXPERIENCE OF RITE THERMOCHEMOTHERAPY FOR HIGH RISK NON MUSCLE INVASIVE BLADDER CANCER THAT HAS FAILED BCG</td>
</tr>
<tr>
<td></td>
<td>Benjamin Ayres*, Chris Bannous, Domagej Tomic, Babbin John, London, United Kingdom, Matthew Perry, Guildford, United Kingdom, Mike Bailey, Rami Issa, London, United Kingdom</td>
</tr>
</tbody>
</table>
MP08-03 ABSENCE OF INCHWORM SIGN ON DWI: A PREDICTIVE MARKER FOR PROGRESSION IN PT1 BLADDER CANCER
Shugo Yajima*, Soichiro Yoshida, Tokyo, Japan, Taro Takahara, kanagawa, Japan, Minato Yokoyama, Junichiro Ishioka, Yoh Matsuoka, Kazutaka Saito, Kazunori Kihara, Yasuhisa Fujii, Tokyo, Japan

MP08-04 PURIFIED PROTEIN DERIVATIVE SKIN TEST PRIOR TO BACILLUS CALMETTE-GUÉRIN THERAPY ENHANCES THE CLINICAL EFFICACY OF BCG THERAPY IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER
Naoya Niwa*, Eiji Kikuchi, Kazuhiro Matsumoto, Takeo Kosaka, Ryuichi Mizuno, Mototsugu Oya, Tokyo, Japan

MP08-05 MEDIUM SIZE BLADDER TUMORS’ EN-BLOCK BIPOLAR ABLATION PUT TO THE TEST – A LONG TERM, PROSPECTIVE, RANDOMIZED-CONTROLLED CLINICAL COMPARISON TO STANDARD RESECTION
Bogdan Geavlete*, Cosmin Ene, Catalin Bulai, Georgiana Balan, Petrisor Geavlete, Bucharest, Romania

MP08-06 EFFICIENCY OF BLADDER WASH CYTOMETRY DURING SURVEILLANCE OF NON-MUSCLE INVASIVE BLADDER CANCER: ANALYSIS IN A CONTEMPORARY PATIENT COHORT
Benedikt Kranzbühler*, Uwe Bieri, Cédric Poyet, Tullio Sulser, Tullio Sulser, Daniel Eberli, Thomas Hermanns, Zurich, Switzerland

MP08-07 THE IMPACT OF BLUE-LIGHT CYSTOSCOPY ON RESPONSE TO INDUCTION BCG IN PATIENTS WITH HIGH-GRADE NON-MUSCLE- INVASIVE BLADDER CANCER
Nina Mikkilineni*, Samuel Antoine, NY, NY, Ashley Alfond, Minneapolis, MN, Gen Li, Sven Wenske, G. Joel Decastro, James McKiernan, Christopher Anderson, NY, NY

MP08-08 DISCHARGE OF LOW RISK NON MUSCLE INVASIVE BLADDER CANCER AFTER ONE YEAR: RESULTS OF A BAUS/BAUN NATIONAL SURVEY OF THE ADOPTION OF THE NICE BLADDER CANCER GUIDELINES RECOMMENDATIONS IN THE UK
Hugh Mostafid*, Guildford, United Kingdom, Sachin Malde, Ali Mir-Kohler, London, United Kingdom, Pauline Bagnall, North Shields, United Kingdom, Julia Taylor, Manchester, United Kingdom, Jo Cresswell, Middlesbrough, United Kingdom, James Catto, Sheffield, United Kingdom

MP08-09 TRANSURETHRAL DENUDATION OF THE BLADDER MUCOSA BY A NEEDLE ELECTRODE: SHEDDING NEW LIGHT ON AN OLD TECHNIQUE
SHENGKUN SUN*, TAO SONG, XU ZHANG, Beijing, China, People’s Republic of

MP08-10 THE INTRODUCTION OF A SURGICAL CHECKLIST FOR THE TRANSURETHRAL RESECTION OF THE BLADDER IMPROVES RECURRENCE-FREE SURVIVAL IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS
Francesco Soria*, David D’Andrea, Vienna, Austria, Mirko Preto, Turin, Italy, Killian M. Gust, Vienna, Austria, Alberto Briganti, Milan, Italy, Shahrok F. Sharif, Vienna, Austria, Paolo Gontero, Turin, Italy

MP08-11 SWITCHING OF BACILLUS CALMETTE-GUÉRIN (BCG) STRAIN AT SECOND BCG THERAPY MAY REDUCE BCG-RELATED SIDE EFFECTS IN PATIENTS WITH BCG-RELAPSING TUMOR
Naoya Niwa*, Eiji Kikuchi, Kazuhiro Matsumoto, Takeo Kosaka, Ryuichi Mizuno, Mototsugu Oya, Tokyo, Japan

MP08-12 EVALUATION OF THE DWELL-TIME DIFFERENCE IN INTRAVESICAL BACILLUS CALMETTE-GUÉRIN THERAPY
Takashi Nagata*, Takehiko Okamura, Ryosuke Chaya, Daichi Kobayashi, Takahiro Kobayashi, Hitodoshi Akita, Anjo-city, Japan, Keitaro Iida, Toshiki Etani, Taku Naiki, Ryosuke Ando, Nariyasu Kawai, Takahiro Yasui, Nagoya, Japan

MP08-13 HOW IS OUTPATIENT BLUE LIGHT CYSTOSCOPY USED IN CLINICAL ROUTINE? FIRST RESULTS FROM THE NORDIC REGISTRY
Per Uno Malmstrom*, Uppsala, Sweden

MP08-14 EVALUATION OF THE UROVYSION™ TEST FOR PREDICTING RECURRENCE AND PROGRESSION IN PATIENTS RECEIVING BCG FOR HIGH GRADE NON-MUSCLE INVASIVE BLADDER CANCER

MP08-15 CORRELATION BETWEEN SURGEON’S EXPERIENCE AND PATHOLOGICAL AND ONCOLOGICAL OUTCOMES AFTER TRANSURETHRAL RESECTION OF THE BLADDER: RESULTS FROM A MULTICENTRIC RETROSPECTIVE STUDY
Richard Naspro*, Michele Manica, Bergamo, Italy, Rodolfo Hurle, Rozzano, Italy, Luca Cristinelli, Brescia, Italy, Giorgio Guazzoni, Massimo Lazzeri, Rozzano, Italy, Claudio Simeone, Brescia, Italy, La Croce Giovanni, Bergamo, Italy, Marco Lattarulo, Brescia, Italy, Andrea Gallina, Marco Moschini, Renzo Colombo, Milano, Italy, Luigi Da Pozzo, Bergamo, Italy, Richard Naspro, Treviolo, Italy

*Presenting author
## ABSTRACT NUMBER TITLE

**MP08-16** COMBINATION OF NUCLEAR ORIENTATION AND SHAPE FEATURES IN H&E STAINED IMAGES DISTINGUISH CONSENSUS LOW AND HIGH GRADE BLADDER CANCER  
Haojia Li*, Patrick Leo, Behtash Nezami, Mahmud Akgl, Robin Elliott, Holly Harper, Andrew Janowczyk, Gregory MacLennan, Anant Madabhushi, Cleveland, OH

**MP08-17** BLUE LIGHT CYSTOSCOPY IMPROVES DETECTION RATES FOR UROTHELIAL BLADDER CANCER COMPARED TO WHITE LIGHT CYSTOSCOPY: UPDATED RESULTS FROM A PROSPECTIVE MULTICENTER REGISTRY  

**MP09-01** EFFECT OF ASP6432, A TYPE 1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST, ON URETHRAL FUNCTION DURING THE VOIDING PHASE IN RATS  
Kazuyuki Sakamoto*, Tsukuba, Japan, Yukiko Noguchi, Tokyo, Japan, Katsunori Imazumi, Koji Ueshima, Akiyoshi Ohtake, Masahiro Takeda, Noriyuki Masuda, Tsukuba, Japan

**MP09-02** DIFFERENTIAL DISTRIBUTION OF HYPERPOLARIZATION-ACTIVATED CHANNELS IN PEPTIDERIC AND CHOLINERGIC FIBERS OF THE HUMAN BLADDER  
Pradeep Tyagi*, Mahendra Kashyap, Naoki Yoshimura, Pittsburgh, PA

**MP09-03** HYDROGEN SULFIDE CAN FUNCTION AS AN ENDOGENOUS RELAXATION FACTOR IN THE RAT BLADDER AND PROSTATE  
Takahiro Shimizu*, Suo Zou, Shogo Shimizu, Youichirou Igashii, Hideaki Ono, Kumiko Nakamura, Takaaki Aratake, Masaki Yamamoto, Tomoya Hamada, Yoshiki Nagao, Nankoku, Japan, Masashi Honda, Yonago, Japan, Motoaki Saito, Nankoku, Japan

**MP09-04** EFFECTS OF TRIPLE INHIBITION OF RECEPTORS OF VEGF, FGF, AND PDGF ON BLADDER DYSFUNCTION AND REMODELING IN MICE WITH SPINAL CORD INJURY  
Joonbeom Kwon*, Daegu, Korea, Republic of, Nobutaka Shimizu, Osaka-sayama, Japan, Eiichiro Takaoka, Takahisa Suzuki, Pittsburgh, PA, Yoonhyung Lee, Daegu, Korea, Republic of, Anthony Kanai, Naoki Yoshimura, Pittsburgh, PA

**MP09-05** SILK-ELASTINLIKE POLYMERS ENHANCE THE ANTI-INFLAMMATORY AND ANALGESIC PROPERTIES OF SEMISYNTHETIC GLYCOSAMINGLYCAN  
Mark Martin Jensen, Wanjian Jia, Austin Schults, Kyle Isaacs, Douglas Steinhauff, Bryant Green, Marcelo Correa, Jeremiah Alt, Joseph Cappello, Hamid Ghandehari, Salt Lake City, UT, Siam Oottamasathien*, Boston, MA

**MP09-06** AGE-IMPAIRED PURINE METABOLISM ALTERS BLADDER FUNCTION  
Amanda Wolf-Johnston*, Del Gillespie, Bronagh McDonnell, Edwina Jackson, Lori Birder, Pittsburgh, PA
MP09-07 DOES ELECTRICAL STIMULATION IN THE LOWER URINARY TRACT INDUCE DIURESIS?
Stéphanie van der Lely*, Martina D. Liechti, Werner L. Popp, Thomas M. Kessler, Ulrich Mehnert, Zurich, Switzerland

MP09-08 DECREASING ARTERIAL FLOW IN THE EX Vivo FUNCTIONAL PIG BLADDER MODEL DEMONSTRATES PRESERVATION OF TISSUE OXYGENATION AND NON-LINEAR DECREASE IN PERFUSION PRESSURE: POTENTIAL MECHANISMS FOR UNDERACTIVE BLADDER AND VASCULAR AUTOREGULATION
Uzoma Anele*, Andrew Tracey, Andrew Colhound, John Speich, Paul Ratz, Adam Klausner, Richmond, VA

MP09-09 BRAIN NITRIC OXIDE CAN INDUCE FREQUENT URINATION IN RATS
Takahiro Shimizu*, Hideaki Ono, Shogo Shimizu, Youichirou Higashi, Sou Zou, Masaki Yamamoto, Takaaki Aratake, Tomoya Hamada, Yosuke Nagao, Yusuke Ueba, Nankoku, Japan, Masashi Honda, Yonago, Japan, Motoaki Saito, Nankoku, Japan

MP09-10 EFFICACY OF DIFFERENT SPINAL NERVE ROOTS FOR NEUROMODULATION OF MCITURCEPTION REFELEX IN RATS
Jianshu Ni*, Xiaohu Wang, Nailong Cao, Baojun Gu, Shanghai, China, People’s Republic of

MP09-11 MARKED INCREASE IN MITOCHONDRIAL RESPIRATION, HYDROGEN PEROXIDE EMITTING POTENTIAL AND ATP PRODUCTION IN THE UROTHELIUM VERSUS DETRUSOR SMOOTH MUSCLE
Trevor Hunt, Michael Odom, Elena Pak, Michael Tarpey, Chien-Te Lin, Darrell Neufer, Espen Spangenburg, Johanna Hannan*, Greenville, NC

MP09-12 BETHANECHOL: IS IT STILL BEING PRESCRIBED FOR BLADDER DYSFUNCTION IN WOMEN?
Shivani Gaitonde*, Rena D. Malik, Gary E. Lemack, Philippe E. Zimmer, Dallas, TX

MP09-13 QUANTIFICATION OF CEREBRAL BLOOD FLOW DURING BLADDER FILLING IN HEALTHY SUBJECTS
Justina Tam*, Kenneth Wengler, Jason Kim, Wayne Waltzer, Xiang He, Steven Weissbart, Stony Brook, NY

MP09-14 ESTABLISHMENT OF IMMORTALIZED HUMAN BLADDER SMOOTH MUSCLE CELLS
Masaki Yoshida*, Naohiro Hashimoto, Hisae Nishii, Masanori Nomiya, Aichi, Japan

MP09-15 VALIDATION OF EX-VIVO MURINE BLADDER MODEL TO TEST RHOGDI-BASED BLADDER GENE THERAPIES FOR BENIGN AND MALIGNANT BLADDER PATHOLOGIES
Gregory Joice*, James Bell, Justin La Favor, Takahiro Yoshida, Gonzalo Torga, Kelly Harris, Xiaopu Liu, Baltimore, MD, Matthew Kiedrowski, Marc Penn, Rootstown, OH, Trinity Bivalacqua, Nikolai Sopko, Baltimore, MD

MP09-16 PHARMACOLOGICAL INHIBITION OF THE NLRP3 INFLAMMASOME PREVENTS BLADDER DECOMPENSATION IN A RAT MODEL OF CHRONIC BLADDER OUTLET OBSTRUCTION
Francis Hughes, Stephanie Sexton, Patrick Leidig, Huixia Jin, J. Purves*, Durham, NC

MP09-17 THE ASSOCIATION BETWEEN TETRAHYDROCANNABINOL AND LOWER URINARY TRACT SYMPTOMS UTILIZING THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY
Richard Fantus*, Christopher Riedinger, Chicago, IL, Cecilia Chang, Brian Helfand, Evanston, IL

MP09-18 METFORMIN ATTENUATED THE INFLAMMATION AFTER BLADDER ISCHEMIA/REPERFUSION AND SUPPRESSED APOPTOSIS OF URINARY BLADDER IN RATS
Jong Mok Park, Jae Geun Lee*, Ji Yong Lee, Seung Woo Yang, Ju Hyun Shin, Jae Sung Lim, Yong Gil Na, Ki Hak Song, Daejeon, Korea, Republic of

MP09-19 TERMINAL MARKERS OF UROTHELIAL DIFFERENTIATION: A COMPARISON OF NEWBORN AND DELAYED BLADDER EXSTROPHY CLOSURES TO CONTROLS
Matthew Kasaprens*, Zhiming Yang, Mahir Maruf, Karl Benz, Jonathan Epstein, Heather Di Carlo, John Gearhart, Baltimore, MD

MP09-20 UROSTATIC EVALUATION BEFORE ROBOT-ASSISTED RADICAL PROSTATECTOMY TO IDENTIFY FACTORS THAT AFFECT PRE-OPERATIVE URETHRAL FUNCTION IN MALES
Tsuyoshi Majima*, Yoshisasa Matsukawa, Shun Takai, Yasuhiro Funahashi, Tokunori Yamamoto, Momokazu Gotoh, Nagoya, Japan

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

*Presenting author
MP10-01 NICORANDIL INCREASES RENAL NITRIC OXIDE (NO), DECREASES TRANSFORMING GROWTH FACTOR (TGF)-β, AND AMELIORATES RENAL INJURY IN UNILATERAL URETERAL OBSTRUCTION (UUO) IN RATS
Ayako Masunaga*, Keiichi Ito, Takako Asano, Hitoshi Tsuda, Tomohiko Asano, Saitama, Japan

MP10-02 PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) EXPRESSION PROMOTES FIBROTIC RENAL TUBULAR DYSFUNCTION
Fei Lian*, Jiaqi Tang, Alex Arnouk, Rohan Samarakoon, Paul Higgins, Albany, NY

MP10-03 RENAL SALVAGE IN PATIENTS WITH URINARY TUBERCULOSIS IN THE ERA OF MODERN CHEMOTHERAPY AND SURGICAL ARMAMENTARIUM
Anuj Deep Dangi*, Amar Kumar, Rajiv Paul Mukha, Chandra Singh, Santosh Kumar, Antony Devasia, Nitin Kekre, Vellore, India

MP10-04 STEP WISE APPROACH TO URETERIC OBSTRUCTION CAUSED BY IDIOPATHIC RETROPERITONEAL FIBROSIS
Vimal Dassi, Anil Gulia, Ruchir Maheshwari, Samit Chaturvedi, Anant Kumar*, New Delhi, India

MP10-05 MALEK CLASS 2-3 AND INCREASED CREATININE LEVELS ON ADMISSION ARE PREDICTORS OF FURTHER COMPLICATIONS IN PATIENTS WITH XANTOGRANULOMATOUS PYEONEPHRITIS
Juan Ramon Torres-Anguiano*, Alvaro Ivan Carrasco-Gonzalez, Virgilio Augusto López-Sámano, Efrain Maldonado-Alcaraz, Guillermo Montoya-Martínez, León Octavio Torres-Mercado, Rodrigo Leon-Mar, Jorge Moreno-Palacios, Mexico City, Mexico

MP10-06 AMONG PATIENTS WITH ACUTE PYEONEPHRITIS COMPLICATED BY URETERAL STONE, THE RISK FACTORS CAUSING SEPSIS AND SEPTIC SHOCK ARE DIFFERENT
Jeonghyouk Choi*, Seoul, Korea, Republic of, Young Lee, Cheongyang-gun, Korea, Republic of, Taesoo Choi, Dong-Gi Lee, Koo Han Yoo, Seoul, Korea, Republic of

MP10-07 EVALUATION OF BACTERIAL BIOFILMS ON RENAL CALCULI
Negar Motayagheni, Sargurunnathan Subashchandrabose, Jorge Gutierrez-Aceves, Majid Mirzazadeh*, Winston Salem, NC

MP10-08 DECREASED ENDOTHELIAL PROLIFERATION CHARACTERIZES THE VASCULAR DEFECTS IN RADIATION CYSTITIS
Bernadette Zwaans*, Sarah Bartolone, Michael Chancellor, Laura Lamb, Royal Oak, MI

MP10-09 INCIDENCE AND MORBIDITY OF RADIATION-INDUCED HEMORRHAGIC CYSTITIS IN PROSTATE AND BLADDER CANCER
Sarah Martin*, Egial Samir, Detroit, MI, Mohammed Azaiza, Bradenton, FL, Evan Begun, Mazen Abdelhay, Detroit, MI

MP10-10 INFECTIOUS COMPLICATIONS FOLLOWING URETEROSCOPY IN PATIENTS TREATED WITH ALTERNATIVE ANTIMICROBIAL PROPHYLAXIS
Dimitri Papagiannopoulos*, Seth K. Bechis, Kathryn Tringale, Joel E. Abbott, Kaivon Sobhani, Daniel Han, Roger L. Sur, San Diego, CA

MP10-11 THE IMPACT OF CHANGE IN PROPHYLACTIC ANTIBIOTICS ON INFECTIOUS COMPLICATIONS AFTER RADICAL CYSTECTOMY WITH ORTHOTOPIC NEOBLADDER
Wan Song, Hyun Suk Yoon, Kwang Hyun Kim, Chung-Jong Kim, Hana Yoon, Woo Sik Chung, Bong Suk Sim*, Seoul, Korea, Republic of, In-Rae Cho, Goyang, Korea, Republic of, Hee Jung Choi, Dong Hyeon Lee, Seoul, Korea, Republic of

MP10-12 URINARY TRACT INFECTION FOLLOWING RADICAL CYSTECTOMY WITH AN ENHANCED RECOVERY PROTOCOL
Christine Van Horn*, Willem Xu, Jie Cai, Gus Miranda, Anne Schuckman, Siamak Daneshmand, Hooman Djaladat, Los Angeles, CA

MP10-13 RISK FACTORS ASSOCIATED WITH FEVER POST TUBELESS PERCUTANEOUS NEPHROLITHOTOMY
Pai-Yu Cheng*, Wei-Che Wu, Shiu-Dong Chung, New Taipei City, Taiwan

MP10-14 INCIDENCE, RISK FACTORS, AND OUTCOMES OF C. DIFFICILE INFECTION FOLLOWING RADICAL CYSTECTOMY: A NATIONAL SURGICAL QUALITY IMPROVEMENT PROGRAM (NSQIP) STUDY
Kevin Nguyen, Walter Hsiang, Jamil Syed, Adam Nolte, Amanda Lu, Alfredo Suarez-Sarmiento, Kamyar Ghabili, Brian Shuch, Michael Leapman*, New Haven, CT
MP10-15 THE IMPACT OF COMMON UROLOGIC COMPLICATIONS ON THE RISK OF A PROSTHETIC JOINT INFECTION
Nahid Punjani*, Brent Lanting, Andrew McClure, Jennifer Winick-Ng, Blayne Welk, London, Canada

MP10-16 THE IMPACT OF ACUTE KIDNEY INJURY ON PROGNOSIS IN PATIENTS WITH UROLOGICAL SEPSIS
Naoki Fujita*, Shingo Hatakeyama, Yuki Tobisawa, Tohru Yoneyama, Hayato Yamamoto, Atsushi Imai, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Koie, Chikara Ohyama, Hirosaki, Japan

MP10-17 COMPARATIVE ANALYSIS OF OUTCOMES BETWEEN UROSEPSIS AND INTRA-ABDOMINAL SEPSIS PATIENTS
Julie Stortz*, Gainsville, FL, Scott Brakenridge, Philip Efron, Lyle Moldawer, Frederick Moore, Gainesville, FL

MP10-18 SEPTIC SHOCK FOLLOWING SURGICAL DECOMPRESSION OF OBSTRUCTING URETERAL STONES: A PROSPECTIVE ANALYSIS
Paulo Moscardi, Victor Srougi, Giovanni Marchini*, Ricardo Haidar, Fabio Torricelli, Miguel Srougi, William Nahas, Eduardo Mazzucchi, Sao Paulo, Brazil

MP10-19 A PREDICTING MODEL BASED ON RISK FACTORS FOR UROSEPSIS AFTER ONE-PHASE PERCUTANEOUS NEPHROLITHOTOMY
Yuqing Liu*, Jian LU, Chunlei Xiao, Lulin Ma, Beijing, China, People’s Republic of China

MP10-20 RISK FACTORS FOR POSTOPERATIVE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME FOLLOWING MINIMALLY INVASIVE PERCUTANEOUS NEPHROLITHOTOMY
Yuqing Liu*, Jian LU, Chunlei Xiao, Lulin Ma, Beijing, China, People’s Republic of China

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
**MP11-05** ONCOLOGICAL OUTCOMES OF SALVAGE RADICAL PROSTATECTOMY IN A CONTEMPORARY, MULTICENTRE SERIES OF 395 CASES

Paolo Gontero*, Giancarlo Marra, Paolo Alessio, Marco Oderda, Anna Palazzetti, Francesca Pisano, Antonino Battaglia, Stefania Munegato, Giorgio Callenis, Bruno Frea, Turin, Italy, Fernando Munoz, Aosta, Italy, Claudia Filippini, Turin, Italy, Estefania Linares, Rafael Sanchez-Salas, Paris, France, Sanchia Goonewardene, Prokar Dasgupta, Declan Cahill, Ben Challacombe, Rick Popert, London, United Kingdom, David Gillatt, Raj Persad, Bristol, United Kingdom, Juan Palou, Barcelona, Spain, Steven Joniau, Leuven, Belgium, Salvatore Smelzo, Thierry Plechaud, Bordeaux, France, Alexandre De La Taille, Créteil, France, Morgan Roupret, Paris, France, Simone Albissini, Roland Van Velthoven, Bruxelles, Belgium, Alessandro Morlacco, Shanghai Vidit, Rochester, MN, Giorgio Gandaglia, Alexander Motttrie, Aalst, Belgium, Joseph Smith, Shreyas Joshi, Gabriel Fiscus, Nashville, TN, Andre Berger, Monish Aron, Los Angeles, CA, Henk Van Der Poel, Amsterdam, Netherlands, Derya Tiliki, Hamburg, Germany, Declan Murphy, Nathan Lawrentschuk, Melbourne, VIC, Australia, John Davis, Gordon Leung, Houston, TX, Robert Jeffrey Karnes, Rochester, MN

**MP11-06** IMPACT OF METABOLIC SYNDROME ON FUNCTIONAL OUTCOMES AND complications AFTER RADICAL PROSTATECTOMY

Alessandro Morlacco*, Fabrizio Dal Moro, Padova, Italy, Laureano J. Rangel, Carlson Rachel E. Rochester, MN, Filiberto Zattoni, Padova, Italy, Karnes R. Jeffrey, Rochester, MN

**MP11-07** THE ANTI-INFLAMMATORY EFFECT OF REGIONAL HYPOThERMIA DURING ROBOT-ASSISTED RADICAL PROSTATECTOMY FACILITATES EARLIER RECOVERY OF CONTINENCE AND IMPROVES POTENCY: A SECONDARY AD-HOC ANALYSIS

Young Hwi Ko, Daegu, Korea, Republic of, Linda Huynh, Douglas Skarecky, Thomas Ahlering*, Orange, CA

**MP11-08** A PREOPERATIVE NOMOGRAM TO PREDICT PROSTATE CANCER UPGRADING AFTER ROBOTIC RADICAL PROSTATECTOMY

Cosimo De Nunzio*, Rome, Italy, Antonio Luigi Pastore, Latina, Italy, Ricardo Lombardo, Rome, Italy, Antonio Carbone, Andrea Fuschì, Latina, Italy, Lorenzo Dutto, Gronau, Germany, Giuseppe Simone, Gabriele Tuderti, Rome, Italy, Joern Heinrich Witt, Gronau, Germany, Michele Gallucci, Andrea Tubaro, Rome, Italy

**MP11-09** METABOLIC SYNDROME INCREASES THE RISK OF UPGRADING EPSTEIN 2015 GLEASON SCORE IN PATIENTS WITH PROSTATE CANCER ON BIOPSY: A RADICAL PROSTATECTOMY MULTICENTER COHORT STUDY

Cosimo De Nunzio*, Giuseppe Simone, Costantino Leonardo, Rome, Italy, Riccardo Mastroianni, Collura Devis, Rome, Japan, Giovanni Muto, Turin, Italy, Michele Gallucci, Riccardo Lombardo, Carlo De Dominicis, Andrea Tubaro, Rome, Italy

**MP11-10** NEOADJUVANT ANDROGEN DEPRIVATION THERAPY PRIOR TO RADICAL PROSTATECTOMY: RECENT TRENDS IN UTILIZATION AND ASSOCIATION WITH POSTOPERATIVE SURGICAL MARGIN STATUS

Nicolas von Landenberg*, Herne, Germany, Alexander P. Cole, Tyler R. McClintock, Sean A. Fletcher, Boston, MA, Philipp Gild, Hamburg, Germany, Stuart R. Lipsitz, Maxine Sun, Boston, MA, Firas Abdollah, Detroit, MI, Florian Roghmann, Herne, Germany, Mani Menon, Detriot, MI, Joachim Noldus, Herne, Germany, Adam S. Kibel, Quoc-Dien Trinh, Boston, MA

**MP11-11** META-ANALYSIS OF THE PROGNOSTIC UTILITY OF THE CELL CYCLE PROGRESSION SCORE GENERATED FROM NEEDLE BIOPSY IN MEN TREATED WITH DEFINITIVE THERAPY


**MP11-12** ARE WE IMPROVING ERECTILE FUNCTION RECOVERY AFTER RADICAL PROSTATECTOMY?


**MP11-13** QUALITY OF LIFE AFTER SURGERY FOR LOCALIZED PROSTATE CANCER

Andrew Wang, M.D., Paul McClain, M.D.*, Jack Lambert, M.D., Norfolk, VA, Shaun Wason, M.D., Boston, MA, Michael Williams, M.D., John Malcolm, M.D., Kurt McCammon, M.D., F.A.C.S., Michael Fabrizio, M.D., F.A.C.S., Robert Given, M.D., F.A.C.S., Norfolk, VA
MP11-14 PROPENSITY MATCHED COMPARATIVE ANALYSIS OF CHARACTERISTICS OF POSITIVE SURGICAL MARGIN AND ONE YEAR MINIMAL ONCOLOGICAL OUTCOME FOLLOWING CONVENTIONAL ROBOT-ASSISTED RADICAL PROSTATECTOMY VS RETZIUS-SPARING ROBOT-ASSISTED RADICAL PROSTATECTOMY
Lawrence H. C. Kim*, Ali Raheem, Glen D. Santok, Kidon Chang, Trenton Lum, Byung Ha Chung, Young Deuk Choi, Koon Ho Rha, Seoul, Korea, Republic of

MP11-15 THE PRIME FRAMEWORK FOR INVESTIGATING EMOTIONS AND OTHER PATIENT FACTORS IN LOW-INTERMEDIATE RISK PROSTATE CANCER PATIENTS BASED ON ONLINE CANCER SUPPORT GROUP DISCUSSIONS
Weranja Ranasinghe*, Hawthorn East, Australia, Daswin de Silva, Tharindu Bandaragoda, Achini Adikari, Damien Bolton, Nathan Lawrence, Damminda Alahakoon, Victoria, Australia, Raj Persad, Bristol, United Kingdom

MP11-16 POSTOPERATIVE COMPLICATIONS OF CONTEMPORARY OPEN AND ROBOT-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY USING STANDARDIZED REPORTING SYSTEMS
Raisa Pompe*, Burkhard Beyer, Pierre Tennstedt, Felix Preisser, Thomas Steuber, Alexander Haese, Thorsten Schlomm, Georg Salomon, Markus Graefen, Hartwig Huland, Hamburg, Germany, Pierre Karakiewicz, Montreal, Canada, Derya Tilki, Hamburg, Germany

MP11-17 RADICAL PROSTATECTOMY AFTER PREVIOUS TUR-P: ONCOLOGICAL, SURGICAL AND FUNCTIONAL OUTCOMES
Raisa Pompe*, Sami-Ramzi Leyh-Banurah, Felix Preisser, Thorsten Schlomm, Georg Salomon, Hartwig Huland, Markus Graefen, Hamburg, Germany, Pierre Karakiewicz, Montreal, Canada, Derya Tilki, Hamburg, Germany

MP11-18 THE ROLE OF PRIMARY SURGERY AND EXTERNAL BEAM RADIATION THERAPY IN THE MANAGEMENT OF NON-METASTATIC DUCTAL PROSTATE CANCER: 20-YEAR OUTCOMES FROM A SINGLE INSTITUTION EXPERIENCE
Simone Francavilla*, Luca Triggiani, Carlotta Palumbo, Lidia Bardoscia, Riccardo Tellini, Angelo Peroni, Michela Buglione, Alessandro Antonelli, Stefano Maria Magrini, Claudio Simeone, Brescia, Italy

MP11-19 TARGETED LYMPH NODE DISSECTION AT RADIOTRACER-AVID SITES IN RECURRENT PROSTATE CANCER: AN EARLY ASSESSMENT OF EFFICACY
Luke Shumaker*, Clinton Bahler, Thomas Gardner, Michael Koch, James Fletcher, Indianapolis, IN

MP11-20 OTHER MALIGNANCIES PRIOR PROSTATE CANCER DIAGNOSIS – CLINICAL OUTCOME AFTER RADICAL PROSTATECTOMY
Pierre Tennstedt*, Peter Klippenstein, Thorsten Schlomm, Burkhard Beyer, Raisa S. Pompe, Uwe Michl, Georg Salomon, Alexander Haese, Budäus Lars, Hans Heinzer, Hendrik Isbarn, Thomas Steuber, Hartwig Huland, Derya Tilki, Markus Graefen, Hamburg, Germany

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
MP12-04  ONLY LESS THAN 10% OF PATIENTS SELECTED FOR RADICAL PROSTATECTOMY REACH THE COMPETING MORTALITY RATE OF THE PROSTATE CANCER INTERVENTION VERSUS OBSERVATION TRIAL (PIVOT)
Michael Froehner*, Rainer Koch, Matthias Hübner, Theresa Renner, Angelika Borkowetz, Stefan Zastrow, Manfred P. Wirth, Dresden, Germany

MP12-05  PROSTATE CANCER ANXIETY IN MEN UNDERGOING ACTIVE SURVEILLANCE. FINDINGS FROM A LARGE PROSPECTIVE COHORT STUDY
Karim Marzouk*, Melissa Assel, Behfar Ehdaiie, Andrew Vickers, New York, NY

MP12-06  LONG-TERM RISK OF METASTATIC PROSTATE CANCER IN MEN WITH GRADE GROUP 2 MANAGED WITH ACTIVE SURVEILLANCE
Sigrid Carlsson*, Nicole Benfante, Ricardo Alvim, Daniel D. Sjoberg, Behfar Ehdaiie, Peter Scardino, James Eastham, Karim Touijer, New York, NY

MP12-07  TARGETED BIOPSIES IN MEN ON ACTIVE SURVEILLANCE FOR LOW-RISK PROSTATE CANCER: WHEN IS UPGRADING REALLY INCREASED RISK?
Daniel Osses*, Jan Verbeek, Frank-Jan Drost, Monique Roobol, Ivo Schoots, Rotterdam, Netherlands

MP12-08  PATIENT NAVIGATION AND ITS ASSOCIATION WITH TREATMENT SELECTION FOR LOW-RISK PROSTATE CANCER
Emily C. Serrell*, Boston, MA, Moritz Hansen, Andrew Perry, Melanie Feinberg, Tracy Robbins, Scot Remick, Lisa Beaule, Tom Kinkead, Paul K.J. Han, Jesse D. Sammon, Portland, ME

MP12-09  APPARENT DIFFUSION COEFFICIENT PREDICTS RISK OF GRADE RECLASSIFICATION IN MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER
Mitchell Huang*, Patricia Landis, Jonathan Epstein, Katarzyna Macura, H. Ballentine Carter, Mufaddal Mamawala, Baltimore, MD

MP12-10  RATES AND VARIATION IN USE OF MRI, GENOMICS, AND PROSTATE BIOPSY AS CONFIRMATORY TESTS IN A LARGE ACTIVE SURVEILLANCE COHORT
Kevin Ginsburg*, Jesse Jacobs, Detroit, MI, Deborah Kaye, Ji Qi, Ann Arbor, MI, Michael Cher, Detroit, MI, For the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI

MP12-11  RATES AND RISK FACTORS OF LOST TO FOLLOW UP IN PROSTATE CANCER PATIENTS MANAGED WITH ACTIVE SURVEILLANCE
Kevin Ginsburg*, Detroit, MI, Gregory Auffenberg, Ji Qi, Ann Arbor, MI, Isaac Powell, Detroit, MI, James Montie, David Miller, Ann Arbor, MI, Michael Cher, Detroit, MI, For the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI

MP12-12  GENOMIC PROSTATE SCORE PREDICTS PROGRESSION IN MEN ON ACTIVE SURVEILLANCE
Zachary Kornberg*, Janet E. Cowan, Selma Masic, June M. Chan, Matthew R. Cooperberg, Peter R. Carroll, San Francisco, CA

MP12-13  THE IMPORTANCE OF NEGATIVE BASELINE MULTIPARAMETRIC MRI TO REDUCE THE RATE OF EARLY RECLASSIFICATION IN LOW-RISK PROSTATE CANCER PATIENTS MANAGED WITH ACTIVE SURVEILLANCE
Nazareno Suardi*, Elio Mazzone, Giorgio Gandaglia, Nicola Fossati, Andrea Gallina, Giovanni Alberto Pini, Franco Gaborardi, Emanuele Zaffuto, Marco Bandini, Paolo Dell'Oglio, Armando Stabile, Gianpiero Cardone, Milan, Italy, Vincenzo Mirone, Naples, Italy, Rodolfo Montironi, Ancona, Italy, Shahrokh F. Shariat, Vienna, Austria, Francesco Montorsi, Alberto Briganti, Milan, Italy

MP12-14  MODELS INTEGRATING MRI PREDICT PROSTATE CANCER UPGRADING ON CONFIRMATORY BIOPSY IN ACTIVE SURVEILLANCE PATIENTS
Nimrod S. Barashi*, Shay Golan, Chi Wang, Kimberly Hirschhorn, Jacqueline Petkewicz, Robert Silvers, Kiran Thakrar, Scott E. Eggener, Brian T. Helfand, Chicago, IL

MP12-15  NATIONAL TRENDS IN THE MANAGEMENT OF LOCALIZED PROSTATE CANCER FROM A POPULATION-BASED COHORT OF PRIVATELY INSURED PATIENTS
MP12-16 ACTIVE SURVEILLANCE BIOPSY CRITERIA DURING THE ERA OF PROSTATE MRI AND TARGETED FUSION BIOPSIES
Jonathan B. Bloom*, Joseph Baiocco, Sam Gold, Graham Hale, Kareem Rayn, Sherif Mehralivand, Vladimir Valera, Clayton Smith, Marcin Czarniecki, Maria Merino, Bradford J. Wood, Howard L. Parnes, Peter L. Choyke, Baris Turkbey, Peter A. Pinto, Bethesda, MD

MP12-17 COMPUTER EXTRACTED FEATURES OF NUCLEI SHAPE, ARCHITECTURE AND ORIENTATION FROM INITIAL H&E TISSUE BIOPSIES PREDICT DISEASE PROGRESSION FOR PROSTATE CANCER PATIENTS ON ACTIVE SURVEILLANCE
Sacheth Chandramouli*, Patrick Leo, Cleveland, OH, George Lee, Princeton, NJ, Robin Elliott, Cleveland, OH, Guangjing Zhu, Robert Veltri, Baltimore, MD, Anant Madabhushi, Cleveland, OH

MP12-18 ACTIVE SURVEILLANCE IN PROSTATE CANCER FOR PATIENTS WITH NON-SUSPICIOUS MRI AT ENTRY: CAN CONFIRMATORY BIOPSIES BE AVOIDED?
Jonathan OLIVIER*, Philippe Puech, Jean-Christophe Fantoni, Elodie Drumez, Xavier Leroy, Arnauld Villers, Lille, France

MP12-19 4KSCORE TEST AS A PREDICTOR OF RECLASSIFICATION IN PROSTATE CANCER ACTIVE SURVEILLANCE
José Rubio-Briones, Valencia, Spain, Ángel Borque-Fernando, Luis M. Esteban, Zaragoza, Spain, Ana Calatrava, Alvaro Gómez-Ferrer-Lozano*, Valencia, Spain, Enrique Gómez-Gómez, Córdoba, Spain, Jesús Gil-Fabra, Zaragoza, Spain, Nuria Rodríguez-Garcia, Palma de Mallorca, Spain, Pedro A. López-González, Murcia, Spain, Jorge García-Rodriguez, Oviedo, Spain, Miguel Rodrigo-Alaga, Castellón de la Plana, Spain, Bernardo Herrera-Imbroda, Málaga, Spain, Juan Soto-Villalba, Cádiz, Spain, Sara Martínez-Breijo, A Coruña, Spain, Virginia Hernández-Cañas, Madrid, Spain, Ana M. Soto-Poveda, Valencia, Spain, Carlos Sánchez-Rodriguez, Alcalá de Henares, Spain, Carlos Canillo-George, Murcia, Spain, Yumaira E. Hernández-Martínez, Manacor, Spain

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Friday, May 18, 2018
Podium Session 5
9:30 am - 11:30 am

URODYNAMICS/LOWER URINARY TRACT DYSFUNCTION/FEMALE PELVIC MEDICINE: FEMALE INCONTINENCE: THERAPY I
Room 2022 @ MCC West
Moderators: Anne Suskind, Steven Siegel and David Castro-Diaz

<table>
<thead>
<tr>
<th>ABSTRACT TIME NUMBER TITLE</th>
<th>ABSTRACT TIME NUMBER TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:40 PD05-02 TWENTY YEARS OUTCOME FOLLOW-UP OF FEMALE PATIENTS WITH STRESS URINARY INCONTINENCE RECEIVING AUTOLOGOUS FASCIA SLING Yun-Chu Chang*, Chih-Chieh Lin, Alex T.L. Lin, Taipei, Taiwan</td>
<td>10:00 PD05-04 MANAGEMENT OF UI RECURRENCE AFTER MUS EXPLANTATION FOR PELVIC OR PERINEAL PAIN Maximilien BARON*, Rouen, France, Marie-Aimée Perrouin-Verbe, Oussama Hedli, Loïc Le Normand, Amélie Levesque, Jerome Rigaud, Nantes, France</td>
</tr>
</tbody>
</table>

*Presenting author
10:10 PD05-05 TRANSOBTURATOR TAPE: OVER 10 YEARS FOLLOW-UP
Franca Natale*, Rome, Italy, Ester Illiano, Perugia, Italy, Chiara La Penna, Rome, Italy, Alessandro Zucchi, Francesca Parisi, Lorenzo Alunni, Elisabetta Costantini, Perugia, Italy

10:20 PD05-06 SAFETY OF AUTOLOGOUS FASCIAL PUBOVAGINAL SLINGS VERSUS SYNTHETIC MID-URETHRAL SLINGS
Melissa Daniel, Brooklyn, NY, Jerry Blaivas*, Linda Dayan, New York, NY

10:30 PD05-07 IMMUNOFLUORESCENCE LOCALIZATION OF BACTERIAL BIOFILMS ON EXPLANTED TRANSVAGINAL MESH SLINGS REMOVED FOR CHRONIC PAIN
Victoria Scott*, A. Lenore Ackerman, Guo Liu, Wenyuan Shi, Shlomo Raz, Los Angeles, CA

10:40 PD05-08 SURGICAL MANAGEMENT OF FEMALE STRESS URINARY INCONTINENCE: 22-YEAR POPULATION-LEVEL TRENDS
Joseph LaBossiere*, Christopher Wallis, Lesley Carr, Refik Sasaki, Robert Nam, Sender Herschorn, Toronto, Canada

10:50 PD05-09 ORAL ENOBOSARM SHOWS PROMISING ACTIVITY IN POST-MENOPAUSAL WOMEN WITH STRESS URINARY INCONTINENCE: RESULTS OF A PHASE 2 STUDY

11:00 PD05-10 RISK FACTORS FOR STRESS URINARY INCONTINENCE SURGERY FOLLOWING SLING REVISION: A MULTIVARIATE ANALYSIS OF PATIENTS UNDERGOING TOTAL AND SUBTOTAL EXCISION OF SYNTHETIC MESH SUBURETHRAL SLINGS FOR COMPLICATIONS
Janine Oliver*, Aurora, CO, Claire Burton, Lauren Wood, Los Angeles, CA, Zaid Chaudhry, West Covina, CA, Lorna Kwan, Z. Chad Baxter, Ja-Hong Kim, Christopher Tarnay, Shlomo Raz, Los Angeles, CA

11:10 PD05-11 IS PROPHYLACTIC STRESS INCONTINENCE SURGERY NECESSARY AT THE TIME OF PELVIC ORGAN PROLAPSE REPAIR? - RATES OF FUTURE SURGERY IN A LARGE POPULATION BASED COHORT IN CALIFORNIA
Raveen Syan, Palos Alta, CA, Kai Dallas*, Stanford, CA, Ericka Sohlberg, Palos Alta, CA, Christopher Elliot, Lisa Rogo-Gupta, Stanford, CA, Ekene Enemchukwu, Palos Alta, CA

11:20 PD05-12 OPIOID PRESCRIPTION PATTERNS AND USAGE AFTER UROGYNECOLOGIC SURGERY
Melissa Plummer, Shirly Solouki, Nitya Abraham*, Bronx, NY

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Friday, May 18, 2018
Podium Session 6
9:30 am - 11:30 am

PROSTATE CANCER: DETECTION & SCREENING I
Room 2011 @ MCC West
Moderators: William Catalona, Chris Bangma and Seiji Naito

ABSTRACT
TIME NUMBER TITLE
9:30 PD06-01 PCA3 IN PROSTATE CANCER RISK ASSESSMENT: HOW DOES IT HELP IN REAL LIFE? RESULT OF A 5-YEAR PROSPECTIVE STUDY
Lesourd Marine*, Beauval Jean Baptiste, Toulouse, France, Pradere Benjamin, Tours, France, Portalez Daniel, Gamé Xavier, Huygue Eric, Soulié Michel, Malavaud Bernard, Rischmann Pascal, Roumigué Mathieu, Toulouse, France

9:40 PD06-02 IMPORTANCE OF [-2] PROPSA MEASUREMENT IN A DIAGNOSIS OF PROSTATE CANCER: PROSTATE HEALTH INDEX TRIAL (PROPHET) - DIAGNOSTIC IMPACTS OF PROSTATE VOLUME-ADJUSTED INDICES ON GLEASON GRADE GROUP ≥2 OR ≥3 CANCER
Kazuto Ito*, Gunma, Japan, Akira Yokomizo, Shoji Tokunaga, Fukuoka, Japan, Gaku Arai, Koshigaya, Japan, Mikio Sugimoto, Fukuoka, Japan, Homare Shiomi, Tokyo, Japan, Hisashi Hasumi, Yokohama, Japan, Hideki Sakai, Nagasaki, Japan, Akiko Oura, Fukuoka, Japan, Kazuhiro Suzuki, Maebashi, Japan

 siding theibe}

54
9:50 PD06-03 INCREASE PSA EXPRESSION ON PROSTATE CANCER EXOSOMES IN IN VITRO CONDITION AND IN CANCER PATIENTS
Martina Maggi*, ALESSANDRO SCIARRA, ALESSANDRO GENTILUCCI, SUSANNA CATTARINO, STEFANO SALCICCIA, federico pierrella, Vittorio Marzio, vincenzo Gentile, Marta Logozzi, STEFANO Fais, ROME, Italy

10:00 PD06-04 RATE OF DISCORDANT PSA TESTING AMONG VARIED GUIDELINES, IDENTIFYING TARGETABLE INEFFICIENCIES IN OUR HEALTH SYSTEM
Christopher Martin*, Brock O’Neil, Ashley Kapron, Kennsaku Kawamoto, William Lowrance, Michael Flynn, Kathleen Cooney, Salt Lake City, UT

10:10 PD06-05 PSA KINETICS BEFORE 40 YEARS OF AGE
Cristiano Linck Pazeto*, Thiago Negris Lima, São Paulo, Brazil, Jose C. Truzzi, Nairo Sumita, São Paulo, Brazil, José de Sá, São Paulo, Brazil, Fernando R. Oliveira, Sidney Glin, São Paulo, Brazil

10:20 PD06-06 IMPORTANCE OF [-2] PROPSA MEASUREMENT IN A DIAGNOSIS OF PROSTATE CANCER: PROSTATE HEALTH INDEX TRIAL (PROPHET) - DIAGNOSTIC IMPACTS OF CLINICAL LABORATORY-BASED INDICES ON GLEASON GRADE GROUP ≥2 OR ≥3 CANCER
Kazuto Ito*, Maebashi, Japan, Akira Yokomizo, Shoji Tokunaga, Fukuoka, Japan, Gaku Arai, Koshigaya, Japan, Mikio Sugimoto, Takamatsu, Japan, Koichiro Akakura, Tokyo, Japan, Hisashi Hasumi, Yokohama, Japan, Hideki Sakai, Nagasaki, Japan, Akiko Ouraji, Fukuoka, Japan, Kazuhiro Suzuki, Maebashi, Japan

10:30 PD06-07 AGGRESSIVENESS OF PROSTATE CANCER: CORRELATION BETWEEN PROSPECTIVELY ASSIGNED APPARENT DIFFUSION COEFFICIENT VALUES AND ISUP GRADE GROUP
Daniel Costa*, Yin Xi, Muhammad Aziz, Franto Francis, Claus Roehrborn, Kenneth Goldberg, Niccolo Passoni, Nabeel Shakir, Alberto Diaz de Leon, Ivan Pedrosa, Dallas, TX

10:40 PD06-08 MACHINE LEARNING-BASED LESION DETECTION VIA QUANTITATIVE HIGH FREQUENCY ULTRASOUND FOR PROSTATE-CANCER IMAGING USING A NOVEL HIGH RESOLUTION MICRO-ULTRASOUND PLATFORM
Daniel Rohrbach*, New York, NY, Brian Wodlinger, Jerrold Wen, Markham, Canada, Jonathan Mamou, Ernest Feleppa, New York, NY

10:50 PD06-09 PROSTATE CANCER GENOMICS: COMPARING DECIPHER, PROLARIS, AND ONCOTYPEDX RESULTS
Syed Alam, Ilene Staff, Joseph Tortora, Tara McLaughlin, Joseph Wagner*, Hartford, CT

11:00 PD06-10 LIQUID BIOPSY BY PROSTATE-DERIVED TUMOR CELLS ENRICHED FROM SEMINAL FLUID (SF): THE SEMEN PROSTATE CANCER TUMOR ELEMENTS (SPECTRE) PROJECT
Massimo Lazzeri*, Federico Colombo, Chiara Chiereghin, NicolòMaria Buffi, Paolo Casale, Rodolfo Hurle, Alberto Saita, Giovanni Lughezzani, Rosanna Asselta, Piergiuseppe Colombo, Simona Monterisi, Milan, Italy, Giulia Soldà, Giulia Veronesi, Rozzano, Italy, Stefano Duga, Giorgio Guazzoni, Milan, Italy

11:10 PD06-11 68GA-PSMA PET/CT FOR PRIMARY DIAGNOSIS OF PROSTATE CANCER IN MEN WITH CONTRAINDICATIONS TO OR NEGATIVE MRI: A PROSPECTIVE OBSERVATIONAL STUDY
Massimo Lazzeri*, Egesta Lopci, Giovanni Lughezzani, NicolòMaria Buffi, Paolo Casale, Rodolfo Hurle, Alberto Saita, Roberto Peschechera, Alessio Benetti, Luisa Pasini, Silvia Zandegiacomo, Giuliana Lista, Pasquale Cardone, Arturo Chili, Giorgio Guazzoni, Milan, Italy

11:20 PD06-12 EFFECT OF A TUMOR STAGING TEMPLATE ON CONSISTENCY AND CLARITY OF PROSTATE CANCER STAGING
Ryan Nasseri*, Susan Levy, Hillary Prime, Uchey Dijey, David Prock, Edward Cohen, Paul Dafo, San Diego, CA, Jim Flicko, Cleveland, OH, Franklin Gaylis, San Diego, CA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
## Podium Session 7

**KIDNEY CANCER: LOCALIZED: SURGICAL THERAPY I**

*Room 3024 @ MCC West*

**Moderators:** Michael Blute, Walter Artibani and Stephen Savage

<table>
<thead>
<tr>
<th>Time</th>
<th>Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30</td>
<td>PD07-01</td>
<td>EFFECT OF WIT DURING ROBOTIC PARTIAL NEPHRECTOMY ON RENAL FUNCTION IN PATIENTS WITH AND WITHOUT CKD</td>
<td>Charbel Chalouhy*, Baltimore, MD, Tian Zhou, New York, NY, Jessica Ruck, Baltimore, MD, Pedro Maria, Abhishek Srivastava, Laura Douglas, New York, NY, Reza Ghavamian, Greenlawn, NY</td>
</tr>
<tr>
<td>9:40</td>
<td>PD07-02</td>
<td>3D-MODEL GUIDED ROBOT-ASSISTED PARTIAL NEPHRECTOMY: FEASIBILITY AND SHORT-TERM OUTCOMES ON AN INITIAL MONOCENTRE PROSPECTIVE 60-CASE SERIES</td>
<td>Clément Michiels*, Francois Cornelis, Astrid Boulenger de Hautecloque, Clément Allenet, Thibault Marquette, Souleymane Maiga, Chrystelle Latzague, Grégoire Capon, Grégoire Robert, Henri Bensadoun, Nicolas Grenier, Jean-Marie Ferrière, Jean-Christophe Bernhard, Bordeaux, France</td>
</tr>
<tr>
<td>9:50</td>
<td>PD07-03</td>
<td>STUDY OF RENAL AND KIDNEY TUMOR VASCULARIZATION USING DATA FROM PREOPERATIVE THREE-DIMENSIONAL ARTERIOGRAPHY BEFORE PARTIAL NEPHRECTOMY</td>
<td>Shahed Borojeni*, Antoinette Borojeni, Paul Panayotopoulos, Antoine Bouvier, Abdel Rahmene Azzouzi, Pierre Bigot, Angers, France</td>
</tr>
<tr>
<td>10:10</td>
<td>PD07-05</td>
<td>THE OUTCOME OF GASLESS LAPAROSCOPIC SINGLE-PORT CLAMPLESS SUTURELESS PARTIAL NEPHRECTOMY USING THREE-DIMENSIONAL HEAD-MOUNTED DISPLAY</td>
<td>Yosuke Yasuda*, Kazutaka Saito, Takahiko Soma, Toshihiko Kijima, Soichiro Yoshida, Minato Yokoyama, Junichiro Ishioka, Yoh Matsuoka, Kazunori Kihara, Yasuhisa Fuji, Tokyo, Japan</td>
</tr>
<tr>
<td>10:20</td>
<td>PD07-06</td>
<td>COMPARISON OF PARTIAL VS. RADICAL NEPHRECTOMY EFFECT ON OTHER CAUSE MORTALITY, CANCER SPECIFIC MORTALITY AND 30-DAY MORTALITY IN PATIENTS OLDER THAN 75 YEARS</td>
<td>Michele Marchioni*, Chieti, Italy, Felix Preisser, Hamburg, Germany, Marco Bandini, Milano, Italy, Sebastiano Nazzani, Milan, Italy, Zhe Tian, Montreal, Canada, Anil Kapoor, Hamilton, Canada, Firas Abdullah, Detroit, MI, Luca Cindolo, Giulia Primiceri, Chieti, Italy, Helen D. Bondarenko, Montreal, Canada, Derya Tilki, Hamburg, Germany, Alberto Briganti, Milano, Italy, Francesco Montorsi, Milan, Italy, Shahrokh F. Shariat, Vienna, Austria, Luigi Schips, Chieti, Italy, Pierre I. Karakiewicz, Montreal, Canada</td>
</tr>
<tr>
<td>10:30</td>
<td>PD07-07</td>
<td>CHRONIC KIDNEY DISEASE PRIMARILY RELATED TO RENAL CANCER SURGERY: IMPLICATIONS FOR SURVIVAL</td>
<td>Jitao Wu, Chalairat Suk-Ouichai*, Wen Dong, Elvis R. Caraballo, Cleveland, OH, Ithaar H. Derweesh, La Jolla, CA, Brian R. Lane, Grand Rapids, MI, Sevag Demirjian, Jianbo Li, Steven C. Campbell, Cleveland, OH</td>
</tr>
<tr>
<td>10:40</td>
<td>PD07-08</td>
<td>IMPACT OF POSITIVE SURGICAL MARGINS ON SURVIVAL AFTER PARTIAL NEPHRECTOMY IN LOCALIZED KIDNEY CANCER: ANALYSIS OF THE NATIONAL CANCER DATABASE</td>
<td>Stephen Ryan*, Reith Sarkar, Ahmet Bindayi, San Diego, CA, Zachary Hamilton, St. Louis, MO, James Murphy, Ithaar Derweesh, San Diego, CA</td>
</tr>
</tbody>
</table>
11:00 PD07-10 Utility of Lymph Node Dissection for Clinical Node Negative Upper Tract Urothelial Cell Carcinoma: A Multicenter Study

Zachary Hamilton*, St. Louis, MO, Miki Haifler, Philadelphia, PA, Laura-Maria Krabbe, Timothy Clinton, Dallas, TX, Daniel Han, Stephen Ryan, Madhumitha Reddy, Charles Field, Aaron Bloch, San Diego, CA, Robert Uzzo, Philadelphia, PA, Vitaly Margulis, Dallas, TX, Ithaar Derweesh, San Diego, CA

11:10 PD07-11 Tumor Contact Surface Area as a Predictor of Functional Outcomes After Partial Nephrectomy

Chalairat Suk-Ouichai*, Wen Dong, Jitao Wu, Hajime Tanaka, JJ H. Zhang, Elvis R. Caraballo, Erick Remer, Jianbo Li, Sushir Ishaqwal, Steven C. Campbell, Cleveland, OH

11:20 PD07-12 Tumor Coloring by Bleu Patente Sodique During Laparoscopic Partial Nephrectomy After Selective Embolization of Tumor Vessels in a Hybrid Operating Room: Feasibility and Safety

Maxime Benoit*, Paul Panayotopoulos, Edouard Fortier, Antoine Bouvier, Cosmina Nedelcu, Thibaut Culvy, Christophe Aube, Abdel Rahmène Azzouzi, Pierre Bigot, Angers, France

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Friday, May 18, 2018

Podium Session 8

STONE DISEASE: SHOCK WAVE LITHOTRIPSY

Room 3018 @ MCC West

Moderators: Michael Bailey, Kenneth Pace and Christian Chaussy

<table>
<thead>
<tr>
<th>ABSTRACT TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30</td>
<td>PD08-01</td>
<td>Trends in Utilization of Shockwave Lithotripsy and Ureteroscopy in a State Registry of Outpatient Procedures</td>
</tr>
<tr>
<td>9:40</td>
<td>PD08-02</td>
<td>Are Stone Surgeons Diversified in Shockwave Lithotripsy and Ureteroscopy Volumes?</td>
</tr>
<tr>
<td>9:50</td>
<td>PD08-03</td>
<td>3D Texture Analysis in Abdominal CT Aided by Machine Learning Classifiers Predicts Shock Wave Lithotripsy Success</td>
</tr>
<tr>
<td>10:00</td>
<td>PD08-04</td>
<td>Which Stones Will Fail Shockwave Lithotripsy Treatment? Analysis of Patient and Stone Factors in a Predictive Model</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:10</td>
<td>PD08-05</td>
<td>Cross Validation of an Updated Predictive Analytic Model Which Predicts Success and Complications of Shockwave Lithotripsy in the Treatment of Urinary Stones</td>
</tr>
<tr>
<td>10:20</td>
<td>PD08-06</td>
<td>Ureteral Stent Placement During Shockwave Lithotripsy: Characterizing Guideline Discordant Practice</td>
</tr>
<tr>
<td>10:30</td>
<td>PD08-07</td>
<td>Dry Head Lithotripter Coupling With Excess Gel or a Saline Bag Depgrades Stone Breakage Compared to Optimal Coupling</td>
</tr>
<tr>
<td>10:40</td>
<td>PD08-08</td>
<td>A Prospective Randomized Study to Investigate the Effect of Power Ramp on Treatment Outcome in Extracorporeal Shockwave Lithotripsy of Renal Calculi</td>
</tr>
</tbody>
</table>

*Presenting author
10:50 PD08-09 EFFECTIVENESS OF VARIABLE FREQUENCY IN STONE FRAGMENTATION DURING SHOCKWAVE LITHOTRIPSY: AN IN VITRO STUDY
Christopher Han*, Joel Vetter, Robert Endicott, Affan Zafar, Michael Chevinsky, Kefu Du, Eric Kim, Alana Desai, Robert Figenshau, Ramakrishna Venkatesh, Saint Louis, MO

11:00 PD08-10 PRACTICE PATTERNS AND UNPLANNED HEALTHCARE ENCOUNTERS FOR SHOCKWAVE LITHOTRIPSY IN A STATEWIDE SURGICAL COLLABORATIVE
David Leavitt*, John Hollingsworth, Tae Kim, Jaya Telang, Ann Arbor, MI, Brian Selfman, West Bloomfield, MI, Anna Johnson, Susan Linsell, Ji Qi, Khurshid Ghani, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI

11:10 PD08-11 COMPARATIVE ANALYSIS OF LOST PRODUCTIVITY AND COSTS, BETWEEN EXTRACORPOREAL LITHOTRIPSY TREATMENT AND ENDOSCOPIC TREATMENT FOR RENO-URETERAL LITHIASIS LESS THAN 2 CM
Javier Perez-Ardavin*, Valenci, Spain, Laura Lorenzo, Alberto Budia, Vicent Caballer Tarazona, Pilar Bahilo, Jose Daniel Lopez-Acón, Domingo Guzman Ordaz, Marta Trassier, Jose Vicente Sanchez-Gonzalez, David Vivas Consuelo, Francisco Boronat, Valencia, Spain

11:20 PD08-12 AUTOMATIC MEASUREMENT OF MEAN STONE DENSITY BY THREE-DIMENSIONAL STONE IMAGES FOR PREDICTING SHOCK WAVE LITHOTRIPSY SUCCESS
Shimpei Yamashita*, Yasuo Kohjimoto, Yuya Iwahashi, Takashi Iguchi, Akinori Iba, Isao Hara, Wakayama, Japan

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
V02-09 LAPAROSCOPIC PYELO-URETEROSTOMY OF GRAFT KIDNEY TO NATIVE URETER FOR A POST TRANPLANT RECURRENT URETERAL STRICTURE
Jitendra Jagtap*, Lokesh Sinha, Vinayak Kore, Vikash Kumar, Sachin Veer, Pradeep Rao, Mumbai, India

V02-10 ROBOT ASSISTED KIDNEY TRANSPLANTATION WITH VAGINAL INSERTION OF RENAL ALLOGRAFT
R. Vishnu*, Thiruvananthapuram, India, Ramaprasad Manasser Koduveli, Kochi, India, India, Kishore Thekkie Adiyat, Kochi, India

V02-11 LIVING DONORS WITH MULTIPLE RENAL ARTERIES ARE NOT A CONTRAINDICATION FOR ROBOTIC KIDNEY TRANSPLANTATION: TECHNIQUES FOR SUCCESS AND THEIR OUTCOMES
Feroz Zafar, Ashwin Mallya*, Indranee Banerjee, Tarun Jindal, Sachin Nataraj Arakere, Rajesh Ahlawat, New Delhi, India

V02-12 NEW TECHNOLOGIES FOR OLD PROCEDURES WHEN FIREFLY TECHNOLOGY IMPROVES ROBOTIC BLADDER DIVERTICULECTOMY
Francesca Vedovo*, Trieste, Italy, Bernardino de Concilio, Guglielmo Zeccolini, Antonio Celia, Bassano del Grappa, Italy

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
12:30 WELCOME AND INTRODUCTION: OFFICE FEMALE UROLOGY - A DAY IN THE LIFE
Program Chair: Suzette Sutherland

12:35 OAB – THERAPEUTIC ALGORITHM FOR THIRD-LINE THERAPIES: WHEN I USE WHAT AND WHY?
Susan Kalota

12:55 WHAT’S KEEPING YOU UP AT NIGHT?: NOCTURIA AS THE PRIMARY COMPLAINT
Lindsey Kerr

1:15 UNDERACTIVE BLADDER: EVALUATION AND MANAGEMENT
Hadley Wood

1:35 RECURRENT UTI PREVENTION: FACT VS FICTION
Melissa Kaufman

1:55 VAGINAL LASERS: THE SCIENCE BEHIND THE LASERS
Michael Kennelly

2:15 BREAK

2:30 SETTING YOURSELF UP FOR SUCCESS: HOW TO INCORPORATE OFFICE-BASED PROCEDURES INTO YOUR ALREADY BUSY PRACTICE
Moderator: Suzette Sutherland

INTRODUCTION
Program Chair: Suzette Sutherland

ONABOTULINUMTOXIN A
Christopher Chernansky

PNE
Jannah Thompson

URETHRAL BULKING AGENTS
Benjamin Brucker

VAGINAL LASERS
Michael Kennelly

ONE STOP SERVICES: INCORPORATING MEANINGFUL ANCILLARY TREATMENT SERVICES INTO YOUR PRACTICE
Steven Siegel

Judith Rosenbaum

TWITTER 101 TEACHING SESSION
Judith Rosenbaum

ADJOURN

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Friday, May 18, 2018

Moderated Poster Session 13

STONE DISEASE: EPIDEMIOLOGY & EVALUATION I
Room 3004 @ MCC West
Moderators: Charles Scales, Thomas Turk and Andreas Skolarikos

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP13-01</td>
<td>KIDNEY STONE HOTSPOTS IN SOUTH CAROLINA USING CLUSTER DETECTION</td>
</tr>
<tr>
<td></td>
<td>Michelle Ross, Lihai Song, Philadelphia, PA, David Ladner, Clemson, SC, Gregory Tasian*, Philadelphia, PA</td>
</tr>
<tr>
<td>MP13-02</td>
<td>TAPPING INTO GEOGRAPHIC VARIATION IN URINARY STONE DISEASE: WHAT’S IN THE WATER?</td>
</tr>
<tr>
<td></td>
<td>William Brubaker*, Kai Dallas, Stanford, CA, Christopher Elliott, San Jose, CA, Alan Pao, Stanford, CA, John Leppert, Palo Alto, CA, Simon Conif, Stanford, CA</td>
</tr>
<tr>
<td>MP13-03</td>
<td>SCREENING FOR PRIMARY HYPERPARATHYROIDISM IN A TERTIARY STONE CLINIC, A USEFUL ENDEAVOR</td>
</tr>
<tr>
<td></td>
<td>Carter Boyd*, Kyle Wood, John Knight, Ross Holmes, Herbert Chen, Dean Assimos, Birmingham, AL</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP13-04</td>
<td>SPORADIC PRIMARY HYPERPARATHYROIDISM AND STONE DISEASE: A COMPREHENSIVE METABOLIC EVALUATION BEFORE AND AFTER PARATHYROIDECTOMY</td>
</tr>
<tr>
<td></td>
<td>Giovanni Marchini*, Kauy Faria, Fabio Torricelli, Sao Paulo, Brazil, Manoj Monga, Cleveland, OH, Fabio Vicentini, Alexandre Danilovic, Miguel Srougi, William Nahas, Eduardo Mazzucchelli, Sao Paulo, Brazil</td>
</tr>
<tr>
<td>MP13-05</td>
<td>URINARY STONES AND INTERVENTION QUALITY OF LIFE (USIQOL) – DEVELOPMENT AND VALIDATION OF A COMPREHENSIVE PATIENT REPORTED OUTCOME MEASURE</td>
</tr>
<tr>
<td></td>
<td>Hrishikesh Joshi*, Cardiff, United Kingdom, Aditya Raja, Leeds, United Kingdom, Haitham Abdelmoteleb, Cardiff, United Kingdom, David Bratt, Shekhar Biyani, Leeds, United Kingdom, Fiona Wood, Cardiff, United Kingdom</td>
</tr>
</tbody>
</table>
MP13-06 CORRELATION OF AGE AND GENDER WITH PATIENTS’ KIDNEY STONE RELATED QUALITY OF LIFE
Karen Stern*, Cleveland, OH, Jodi Antonelli, Dallas, TX, Davis Viprakasit, Chapel Hill, NC, Timothy Averch, Pittsburgh, PA, Thomas Chi, San Francisco, CA, Ben Chen, Vancouver, Canada, Vincent Bird, Gainesville, FL, Vernon Pais, Hanover, NH, Necole Streeper, Hershey, PA, Roger Sur, San Diego, CA, Stephen Nakada, Kristina Penniston, Madison, WI, Sri Sivalingam, Cleveland, OH

MP13-07 INCOME IS STRONGLY ASSOCIATED WITH KIDNEY STONE DISEASE-SPECIFIC QUALITY OF LIFE
Tessamin R. Ahmad, BS*, David T. Tzou, MD, Shalonda Reiford-Titus, BA, Clinton Wu, BSc, Jeremy Goodman, BA, San Francisco, CA, Jodi A. Antonelli, MD, Dallas, TX, Davis P. Viprakasit, MD, FACS, Chapel Hill, NC, Timothy D. Averch, MD, Pittsburgh, PA, Sri Sivalingam, MD, FRCSC, Cleveland, OH, Ben H. Chew, MD, Vancouver, Canada, Vincent G. Bird, MD, Gainesville, FL, Vernon M. Paize Jr., MD, Hanover, NH, Necole M. Streeper, MD, State College, PA, Roger L. Sur, MD, La Jolla, CA, Stephen Y. Nakada, MD, FACS, FRCSC, Kristina L. Penniston, PhD, RD, Madison, WI, Thomas Chi, MD, San Francisco, CA

MP13-08 GENOTYPING IN CYSTINURIA – DO FIRST DEGREE RELATIVES SHARE A SIMILAR PHENOTYPE?
Francesca Kum, Kathie Wong, Rachel Mein, Matthew Bultitude*, Kay Thomas, London, United Kingdom

MP13-09 THE IMPACT OF FAMILY HISTORY ON UROLITHIASIS SEVERITY OF DISEASE: FINDINGS FROM RESKU
Kazumi Taguchi*, Nagoya, Japan, David Tzou, San Francisco, CA, Manint Usawachintachit, Bangkok, Thailand, Benjamin Sherer, Marshall Stoller, Thomas Chi, San Francisco, CA

MP13-10 TRENDS IN AMBULATORY CARE OF OLDER ADULTS WITH URINARY STONE DISEASE
Leonid Aksenov*, Ashley C. Wietsma, Brenton Winship, Daniel Wollin, Michael Lipkin, Glenn Preminger, Jonathan Routh, Charles Scales, Durham, NC

MP13-11 RACE- AND SEX-RELATED DIFFERENCES IN NEPHROLITHIASIS RISK AMONG BLACKS AND WHITES IN THE SOUTHERN COMMUNITY COHORT STUDY
Ryan Hsi*, Edmond Kabagambe, Xiang Shu, Nashville, TN, Qijin Han, Rockville, MD, Nicole Miller, Loren Lipworth, Nashville, TN

MP13-12 KIDNEY STONE COMPOSITION VARIES ACCORDING TO RACIAL AND ETHNIC BACKGROUND; MULTI-INSTITUTIONAL ANALYSIS OF STONE FORMERS IN THE NORTHEASTERN UNITED STATES

MP13-13 STONE COMPOSITION IN PEDIATRIC PATIENTS PRESENTING TO A MULTI-DISCIPLINARY STONE CLINIC
Alison C. Keenan, MD*, Thomas G. Leffler, MPH, Kristina L. Penniston, PhD, RD, Madison, WI

MP13-14 TRENDS IN URINARY CALCULI COMPOSITION FROM 2005-2015: A SINGLE-TERTIARY CENTER STUDY
Vidit Talati, Ricardo De Oliveira Soares*, Robert Nadler, Kent Perry, Chicago, IL

MP13-15 THE CORRELATION BETWEEN RENAL STONE COMPOSITION AND THE RISK OF STONE RECURRENTNESS
Oleg Levi*, Alexander Tsivian, Holon, Israel, Jack Daniil, Petach Tikva, Israel, Amihay Nevo, David Lifshitz, Petah Tikva, Israel

MP13-16 ASSOCIATION BETWEEN VISCERAL FAT VOLUME RATIO BASED ON COMPUTED TOMOGRAPHY IMAGES AND SEVERITY OF URINARY STONE DISEASE
Shimpei Yamashita*, Yasuo Kohjimoto, Yuuya Iwashashi, Takashi Iuchi, Akinori Iba, Isao Hara, Wakayama, Japan

MP13-17 ASSOCIATION OF OBESITY WITH INCREASED ENDONICOUS OXALATE SYNTHESIS
Kyle Wood*, John Knight, Dean Assimos, Barbara Gower, Ashwani Singal, Carter Boyd, Ross Holmes, Birmingham, AL

MP13-18 LOW SERUM URIC ACID PREDICTS LONG-TERM CHRONIC KIDNEY DISEASE RISK FOLLOWING INITIAL UROLITHIASIS EVENT
Andrew Ostrowski*, Emily Gansert, Colleen Thomas, Joseph Cerniglia, William Haley, David Thiel, Jacksonville, FL

MP13-19 TESTOSTERONE REPLACEMENT THERAPY IS ASSOCIATED WITH INCREASED INCIDENCE OF UROLITHIASIS
Tyler R. McClintock*, Alexander P. Cole, Niccoliette Kyunghee Kwon, Sean A. Fletcher, Sebastian Berg, Junaid Nabi, Boston, MA, Mani Menon, Detroit, MI, Adam S. Kibel, Quoc-Olen Trinh, Boston, MA

MP13-20 THE RELATIONSHIP BETWEEN PAPILLARY GRADING AND METABOLIC RISK FACTORS FOR STONE FORMATION

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
MP14-01 USE OF FLUORODEOXYGLUCOSE (FDG) PET/CT FOR STAGING PELVIC LYMPH NODES IN 100 PATIENTS WITH PENILE CARCINOMA
Sarah Ottenhof*, Amsterdam, Netherlands, Rosa Djejadiningrat, den Haag, Netherlands, Niels Graafland, Michelle Versleijen, Erik Vegt, Simon Horenblads, Amsterdam, Netherlands

MP14-02 ROLE OF [18F] FLUORODEOXYGLUCOSE-PET IN DIFFERENTIATING PAPILLARY RENAL CELL CARCINOMA FROM CLEAR CELL RENAL CELL CARCINOMA AND ONCOCYTOMA
Moozhan Nikpanah*, Mark A. Ahlman, A. Cahid Civelek, S. Mojdeh Mirmomen, Xiaobai Li, Anna K. Paschall, Ramaprasad Srinivasan, Faraz Farhadi, W. Marston Linehan, Ashkan A. Malayeri, Bethesda, MD

MP14-03 DEVELOPMENT OF INTERDISCIPLINARY IMAGING RECOMMENDATIONS FOR PATIENTS WITH ACUTE RENAL COLIC
Kevan Sternberg*, Burlington, VT, Christopher Moore, New Haven, CT, Amy Krambeck, Indianapolis, IN, Melissa Shaw, New Haven, CT, Christopher Carpenter, St. Louis, MO, Kevin Klauser, Knoxville, TN, Marta Heilbrun, Courtney Moreno, Atlanta, GA, Erick Remer, Cleveland, OH, Carolyn Borkowski, New Haven, CT, Charles Scales, Durham, NC

MP14-04 CT SOFTWARE-BASED CALCULATION OF STONE VOLUME IS ACCURATE AND REPRODUCIBLE COMPARED TO THE ELLIPSOID FORMULA IN AN IN-VITRO MODEL
Rajat Jain*, Mohamed Omar, Hemant Chaparala, Adam Kahn, Leonard Kahn, Sri Sivalingam, Cleveland, OH

MP14-05 DUPLEX SCAN AND HISTOLOGIC ASSESSMENT OF ACUTE RENAL INJURY IN A KIDNEY-KIDNEY CROSSTALK SWINE EXPERIMENTAL MODEL
Anna Sinicos, Angela Mazzeo, Igor Sinicos, Felipe Coelho Neto, Nelson Wolosker, Katia Leite, Vitoria Penido, Oskar Kaufmann*, Sao Paulo, Brazil

MP14-06 A LOW DOSE COMPUTED TOMOGRAPHY PROTOCOL FOR STONE DISEASE CAN BE ACHIEVED IN TWO EASY STEPS: RESULTS OF AN INTERNAL AUDIT
Thomas Tallity*, Matthias Beyenss, Chloe Standaert, Carl Van Haute, Geert Villeirs, Pieter De Visschere, Ghent, Belgium

MP14-07 A NOVEL METHOD TO MEASURE BLADDER WALL MICROMOTION WITH M-MODE ULTRASOUND VALIDATED IN AN ANESTHETIZED PIG MODEL
Anna Nagle*, Zachary Cullingsworth, Uzoma Anele, Charles Blocher, Adam Klausner, John Speich, Richmond, VA

MP14-08 COMPARISON OF CONVENTIONAL 3D ULTRASOUND, BLADDERSCAN, AND UROFLOW MEASUREMENTS OF BLADDER VOID VOLUME IN HEALTHY VOLUNTEERS
Naomi Vinod*, Anna Nagle, Hameeda Naimi, Derek Sheen, Hiren Kolli, Uzoma Anele, Adam Klausner, John Speich, Richmond, VA

MP14-09 TESTICULAR ULTRASOUND UNDERESTIMATES THE SIZE OF SMALL TESTICULAR MASSES: A RADIOLOGIC-PATHOLOGIC CORRELATION STUDY
Zeyad Schwen*, Hiten Patel, Mohit Gupta, James Liu, Mohamad Alif, Phillip Pierorazio, Baltimore, MD

MP14-10 PROSTATE CANCER HETEROGENEITY: TEXTURE ANALYSIS OF MULTIPLE MRI SEQUENCES FOR DETECTION AND SELECTION OF BIOPSY TARGETS
Clement Orczyk*, London, United Kingdom, Arnauld Villers, Lille, France, Henry Rusinek, New York City, NY, Vincent Le Pennec, Celine Bazile, Caen, France, Artem Mikheev, New York City, NY, Myriam Bemaudin, Audrey Pohlen, Samuel Valable, Caen, France

MP14-11 PREDICTIVE VALUE OF PIRADS V2 FOR ANY AND CLINICALLY SIGNIFICANT PROSTATE CANCER ON PROSTATE BIOPSY IN A HIGH RISK ETHNIC COHORT
Wilson Lin*, Ethan Fram, Victoria Chernyak, Kara Watts, Bronx, NY

MP14-12 COMPARISON OF TRANSPERINEAL SYSTEMATIC BIOPSY VERSUS TRANSPERINEAL TARGETED BIOPSY WITH MR/US FUSION GUIDANCE AND ELECTROMAGNETIC (EM) TRACKING FOR SUSPICIOUS LESIONS ON PROSTATE MRI: A PHASE III STUDY
Jared S. Winoker*, Harry Anastos, Pratik A. Shukla, John P. Stfkianos, Cynthia J. Knaurer, Sara C. Lewis, Bachir A. Taouli, Ardeshr R. Rastinehad, New York, NY
MP14-13 HIGH-RESOLUTION 3D MAGNETIC RESONANCE SPECTROSCOPIC IMAGING WITHOUT ENDORECTAL SURFACE COIL CLEARLY ILLUSTRATES PROSTATE CANCER USING NOVEL IMAGING SEQUENCE
Masahiro Sumura*, Taku Yamasaki, Taichi Nagarni, Yusuke Nakanishi, Keita Inoue, Naoko Anichi, Hirofumi Kishi, Hiroaki Yasumoto, Hiroaki Shiina, Shimane, Japan

MP14-14 PROPENSITY SCORE MATCHED STUDY TO EXAMINE THE EFFECT OF RACE ON THE NUMBER OF LESIONS SUSPICIOUS FOR PROSTATE CANCER DETECTED THROUGH MAGNETIC RESONANCE IMAGING OF THE PROSTATE
Mustafa Deebajah*, Richard Thompson, Grace Yaguchi, Milan Pantelic, James Peabody, Mani Menon, Ali Dabaja, Shaheen Alanees, Detroit, MI

MP14-15 RESTRICTION SPECTRUM IMAGING IN PROSTATE CANCER DIAGNOSIS
Fuad Elkhoury*, Richard Raman, Grace Yaguchi, Lorna Kwan, Steven Raman, David Lu, Sipah Shakeri, Pooria Khoshnoodi, Los Angeles, CA, Nathan White, David Karow, La Jolla, CA, Leonard Marks, Los Angeles, CA

MP14-16 THE CHARACTERISTICS OF PROSTATE CANCER ON FINAL PATHOLOGY IN MEN UNDERGO RADICAL PROSTATECTOMY WITH A NEGATIVE MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING
Richard Thompson*, Mustafa Deebajah, Grace Yaguchi, Eric Walton, Mahdi Bazzi, James Peabody, Mani Menon, Shaheen Alanees, Ali Dabaja, Detroit, MI

MP14-17 ROLE OF MAGNETIC RESONANCE IMAGING IN PREDICTING ADVERSE PATHOLOGY POST-RADICAL PROSTATECTOMY
Alp Tuna Beksac*, Ugo Falagario, Shivaram Cumaramsamy, Akriti Gupta, Paige Xu, Sonya Prasad, Alberto Martini, Hani Thulasidass, Isuru Jayaratna, Ardeshe Rastinehad, Ash Tewari, New York, NY

MP14-18 FOLLOW UP FOR PATIENTS ON ACTIVE SURVEILLANCE FOLLOWING A CONFIRMATORY PROSTATE MRI-FUSION BIOPSY
Jonathan B. Bloom*, Joseph Baiocco, Sam Gold, Graham Hale, Kareem Rayn, Sherif Mehralivand, Bethesda, MD, Vladimir Valera, Bethesda, MD, Clayton Smith, Marcin Czarnecki, Maria Merino, Bradford J. Wood, Howard L. Barnes, Peter L. Choyke, Baris Turkley, Peter A. Pinto, Bethesda, MD

MP14-19 CORRELATION OF MULTIPARAMETRIC MRI FINDINGS AND FINAL PROSTATECTOMY PATHOLOGY ACROSS THE PENNSYLVANIA UROLOGIC REGIONAL COLLABORATIVE (PURC)

MP14-20 CREATING AND EVALUATING AN ULTRASOUND TRAINING CURRICULUM FOR UROLOGY RESIDENTS
Joseph Wan*, Geoffrey Box, Columbus, OH

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Friday, May 18, 2018 1:00 pm - 3:00 pm
Moderated Poster Session 15
INFECTIONS/INFLAMMATION/CYSTIC DISEASE OF THE GENITOURINARY TRACT: PROSTATE & GENITALIA I
Room 3009 @ MCC West
Moderators: J. Curtis Nickel, Robert Moldwin and Giuseppe Morgia

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP15-01</td>
<td>A COMMENSAL BACTERIAL STRAIN PREVENTS AND EFFECTIVELY AMELIORATES CHRONIC PELVIC PAIN</td>
</tr>
<tr>
<td>MP15-02</td>
<td>SEMEN REACTIVE OXYGEN SPECIES LEVELS IN PATIENTS WITH CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME CATEGORY IIIA: RELATIONSHIP WITH THE NATIONAL INSTITUTES OF HEALTH-CHRONIC PROSTATITIS SYMPTOM INDEX</td>
</tr>
</tbody>
</table>

*Presenting author
MP15-05 TREATMENT OUTCOMES OF UREAPLASMA AND MYCOPLASMA SPECIES ISOLATED FROM PATIENTS WITH PAIN AND LOWER URINARY TRACT SYMPTOMS
Iryna Crescenze*, Parth Shah, Gayle Adams, Anne Pelletier Cameron, John Stoffel, Paholo Barboglio Romo, Priyanka Gupta, Quentin Clemens, Ann Arbor, MI

MP15-06 DESPERATE NEED FOR OPTIMIZED MANAGEMENT IN FOURNIER’S GANGRENE
Laila Schneidewind*, Greifswald, Germany, Jennifer Kranz, Eschweiler, Germany, Daniel Schlager, Freiburg/Brisg., Germany, Petra Anheuser, Hamburg, Germany, Sandra Mühlstaedt, Halle/Saale, Germany, Benedict Brücher, Muenster, Germany, Tanja Frank, Rosenheim, Germany, Dimitri Barski, Neuss, Germany, Roman Mayr, Regensburg, Germany, Andreas Lunacek, Vienna, Austria, Alexandre Egon Pelzer, Wels, Austria

MP15-07 EMPIRIC ANTIBIOTIC THERAPY FOR ACUTE EDIDIDYMO-ORCHITIS IN YOUNG MEN – DOES ‘ONE SIZE’ FIT ALL?
Arnon Lavi*, Sharon Tzemah, Genady Zelichenko, Anan Hussein, Ibrahim Bishara, Michael Gross, Michael Cohen, Afula, Israel

MP15-08 A PROSPECTIVE ANALYSIS CONCERNING THE LIMITED CLINICAL CONSEQUENCES OF POSITIVE MICROBIAL CULTURES AFTER TURP
Evert Baten*, Hasselt, Belgium, Frank Van der Aa, Christophe Orye, Leuven, Belgium, Reinoud Cartuyvels, Koenraad van Renterghem, Hasselt, Belgium

MP15-09 ALTERATIONS IN THE URETHRAL MICROBIOME IN PATIENTS WITH GENITOURINARY LICHEN SCLEROSIS
Thomas Gaither*, San Francisco, CA, Erick Castellanos, South San Francisco, CA, Kirkpatrick Fergus, Nima Baradaran, Alan Shindel, Benjamin Breyer, San Francisco, CA

MP15-10 NEOVAGINAL MICROFLORA AFTER SURGICAL GENDER REASSIGNMENT IN HIV, HBV AND HCV SERONEGATIVE TRANSSEXUAL WOMEN
Michele Rizzo*, Giuseppina Campisciano, Francesca Migliozzi, Manola Comar, Stefano Bucci, Giovanni Liguori, Trieste, Italy

MP15-11 A PROSPECTIVE STUDY TO EXAMINE THE ASSOCIATION OF THE URINARY AND FECAL MICROBIOME WITH PROSTATE CANCER AND BENIGN PROSTATIC HYPERPLASIA USING 16SRNA ANALYSIS
Shaheen Alane*, Detroit, MI, Ahmed El-Zawahry, Mallory Carr, Carbondale, IL, Mustafa Deebajah, Ali Dabaja, Detroit, MI, Danuta Dynda, Springfield, IL, Kevin Mcvary, Andrea Braundmeier-Fleming, Carbondale, IL

MP15-12 INTESTINAL MICROBIOME SHOWS ALTERED DIVERSITY AND ENTEROBACTERIACEAE OVERGROWTH IN CARRIERS OF FLUOROQUINOLONE RESISTANT E. COLI
Michael Liss*, Dimpy Shah, Elizabeth Rourke, Joseph Basler, San Antonio, TX, James White, Baltimore, MD

MP15-13 EXAMINING CHANGES IN THE URINARY MICROBIOME INDUCED BY TRANSRECTAL ULTRASOUND GUIDED BIOPSY OF THE PROSTATE USING 16SRNA ANALYSIS
Shaheen Alane*, Detroit, MI, Ahmed El-Zawahry, Mallory Carr, Carbondale, IL, Mustafa Deebajah, Ali Dabaja, Detroit, MI, Danuta Dynda, Springfield, IL, Kevin Mcvary, Andrea Braundmeier-Fleming, Carbondale, IL

MP15-14 THE VALUE OF NEXT GENERATION DNA SEQUENCING TESTING IN RECTAL SWABS BEFORE TRANSRECTAL PROSTATE BIOPSY FOR INDIVIDUAL AND TARGETED PROPHYLAXIS OF URINARY TRACT INFECTION
Vladimir Mouraviev*, Davenport, FL, Michael W. McDonald, Celebration, FL, Colby Skinner, Orlando, FL, Srinivas Vourganti, Chicago, IL, David M. Albala, Syracuse, NY, Kurt Naber, Munich, Germany, Florian M.E. Wagenlehner, Giessen, Germany, Truls E. Bjerkund Johansen, Oslo, Norway

MP15-15 TARGETED ANTIMICROBIAL PROPHYLAXIS DOES NOT ALWAYS PREVENT SEPSIS AFTER TRANSRECTAL PROSTATE BIOPSY
Pengbo Jiang, Orange, CA, Michael Liss, San Antonio, TX, Richard Szabo*, Irvine, CA

MP15-16 PREVALENCE OF FLUOROQUINOLONE RESISTANT RECTAL FLORA IN PATIENTS UNDERGOING TRANSRECTAL ULTRASOUND GUIDED PROSTATE NEEDLE BIOPSY: A PROSPECTIVE MULTICENTER STUDY
Yang Hyun Cho, Soo Min Son*, Seong Hyeon Yu, Se Heon Jeong, Tae Ju Park, Myung Soo Kim, Ho Seok Chung, Kyung Jin Oh, Eu Chang Hwang, Sun-Ouck Kim, Seung Il Jung, Taek Won Kang, KwangSung Park, Dong Deuk Kwon, Gwangju, Korea, Republic of

MP15-17 TRIAL COMPARING A COMBINED REGIMEN OF AMIKACIN AND CIPROFLOXACIN TO CIPROFLOXACIN ALONE AS TRANSRECTAL PROSTATE BIOPSY PROPHYLAXIS IN THE ERA OF HIGH FLUOROQUINOLONE-RESISTANT RECTAL FLORA
Yang Hyun Cho, Joo Yong Oh*, Ho Seok Chung, Myung Soo Kim, Kyung Jin Oh, Sun-Ouck Kim, Eu Chang Hwang, Seung Il Jung, Taek Won Kang, KwangSung Park, Dong Deuk Kwon, Gwangju, Korea, Republic of
MP15-18 HOSPITAL-SPECIFIC ANTIBIOTICGRAMS AND ANTIBIOTIC PROPHYLAXIS FOR PROSTATE BIOPSIES: A REEXAMINATION OF AUA RECOMMENDATIONS
Mark Mann*, Brian Calio, Adam Reese, Raju Chelluri, Erich Hufnagel, James Ryan Mark, Costas Lallas, Edouard Trabulsi, Leonard Gomella, Philadelphia, PA

MP15-19 THE CLINICAL IMPORTANCE OF ANTIBIOTIC REGIMEN IN PROSTATE BIOPSY: A SINGLE CENTER ANALYSIS OF MORE THAN 10,000 CASES
Lee Minseung*, Lee Sangchul, Seo Youngeun, Oh Jongjin, Hwang Sungil, Lee Hak jong, Hong sungkyu, Byun seoksoo, Lee sangeun, Seongnam, Korea, Republic of

MP15-20 ANTIBIOTIC SELECTION FOR PROSTATE BIOPSY PROPHYLAXIS USING RECTAL SWAB CULTURES REFLECTS LOCAL ANTIBIOTICGRAM
Elizabeth Ann Rourke*, Steven Madsen, Andrea Yunes, Joseph W. Basler, Michael A Liss, San Antonio, TX

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
Friday, May 18, 2018 1:00 pm - 3:00 pm
Moderated Poster Session 16
PROSTATE CANCER: LOCALIZED: SURGICAL THERAPY III
Room 3020 @ MCC West
Moderators: Jean Joseph, Ganesh Palapattu and Leticia Ruiz

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP16-01</td>
<td>ROLE OF METABOLIC SYNDROME ON PERIOPERATIVE AND ONCOLOGICAL OUTCOMES AT RADICAL PROSTATECTOMY IN A LOW-RISK PROSTATE CANCER COHORT POTENTIALLY ELIGIBLE FOR ACTIVE SURVEILLANCE Michele Colicchia*, Rochester, MN, Alessandro Morlacco, Padua, Italy, Laureano J. Rangel, Rachel E. Carlson, Rochester, MN, Fabrizio Dal Moro, Padua, Italy, R. Jeffrey Karnes, Rochester, MN</td>
</tr>
<tr>
<td>MP16-02</td>
<td>ONCOLOGICAL OUTCOMES OF ROBOT-ASSISTED RADICAL PROSTATECTOMY IN ISUP GRADE 5 PROSTATE CANCER Alexander Govorov*, Konstantin Kolontarev, Pavel Rasner, Vladimir Dyakov, Dmitry Pushkar, Moscow, Russian Federation</td>
</tr>
<tr>
<td>MP16-03</td>
<td>ONCOLOGICAL AND FUNCTIONAL OUTCOME OF RADICAL SALVAGE PROSTATECTOMY IN A LARGE CONTEMPORARY SERIES Axel Heidenreich*, Köln, Germany, Matteo Soligo, Rochester, MN, Tobias Kohl, Markus Grabbert, David Pfister, Köln, Germany, Alessandro Morlacco, Jeffrey R. Karnes, Rochester, MN</td>
</tr>
<tr>
<td>MP16-04</td>
<td>THE ROLE OF G8 SCREENING TOOL IN THE ASSESSMENT OF SURGICAL OUTCOME OF ELDERLY PATIENTS (≥ 75 Y.O.) WITH HIGH-RISK PROSTATE CANCER: A PILOT STUDY Kazuhito Matsushita*, Tokyo, Japan, Jaspreet Sandhu, New York, NY, Shigeo Horie, Fumiyasu Endo, Masaki Shimbo, Kazutaka Narimoto, Kazunori Hattori, Tokyo, Japan</td>
</tr>
<tr>
<td>MP16-05</td>
<td>PERIOPERATIVE PARAMETERS AND PROGNOSIS ANALYSIS OF PATIENTS AGED 80 YEARS OLD OR OLDER TREATED WITH RADICAL PROSTATECTOMY FOR PROSTATE CANCER Fan Zhang*, Yi Huang, Lulin Ma, Beijing, China, People’s Republic of</td>
</tr>
<tr>
<td>MP16-06</td>
<td>QUANTIFICATION OF SECONDARY GLEASON PATTERN 4 IN PATIENTS WITH GLEASON SCORE 3+4=7/GRADE GROUP 2 ON BIOPSY AND RISK OF ADVERSE PATHOLOGY AT RADICAL PROSTATECTOMY Lucas W. Dean*, Behfar Ehdaiie, Melissa Assel, Victor E. Reuter, Samson W. Fine, New York, NY</td>
</tr>
<tr>
<td>MP16-08</td>
<td>REVO-I® SURGICAL ROBOTIC SYSTEM: RESULTS OF KOREAN FDA (KFDA) APPROVED CLINICAL TRIAL Ki Don Chang*, Seoul, Korea, Republic of, Ali abdel Raheem, Tanta, Egypt, Tariq Abdulaziz Alomair, Hyun Kyu Ahn, Koon Ho Rha, Seoul, Korea, Republic of</td>
</tr>
</tbody>
</table>

*Presenting author
MP16-09 LONG-TERM OUTCOMES OF THE EXTRAPERITONEAL ROBOT-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY
Dong Hoon Koh*, Won Sik Jang, Min Seok Kim, Hyun Kyu Ahn, Kyung Taek Oh, Seoul, Korea, Republic of, Young Sig Kim, Gimhaye, Korea, Republic of, In Rae Cho, Goyang, Korea, Republic of, Joong Shik Lee, Seoul, Korea, Republic of, Won Tae Kim, Cheongju, Korea, Republic of, Won Sik Ham, Young Deuk Choi, Seoul, Korea, Republic of

MP16-10 ANESTHESIOLOGIC IMPLICATIONS OF LOW GAS EXTRAPERITONEAL INSUFFLATION COMPARED TO STANDARD ONE DURING RARP
Morena Turco*, Francesca Quadri, Andrea Boni, Giovanni Cochetti, Giovanni Gaudio, Ettore Mearini, Perugia - Terni, Italy

MP16-11 RETZIUS-SPARING ROBOT-ASSISTED RADICAL PROSTATECTOMY IS ONCOLOGICALLY SAFE MODE OF SURGICAL TREATMENT OF PROSTATE CANCER: ANALYSIS OF 359 CASES
Ali Raheem*, Tanta, Egypt, Ki Don Chang, Seoul, Korea, Republic of, Mohammed Alenzi, Aljouf, Saudi Arabia, Ahmed Elghiaty, Tariq Alomir, Jong Won Kim, Won Sik Ham, Woong Kyo Han, Young Deuk Choi, Koon Ho Rha, Seoul, Korea, Republic of

MP16-12 LATERAL BLADDER NECK DISSECTION OPTIMALLY PRESERVING INTRINSIC BLADDER NECK SPHINCTER WITH POSTERIOR BLADDER WALL RECONSTRUCTION LEAD TO EARLY URINARY CONTINENCE AFTER ROBOTIC-ASSISTED RADICAL PROSTATECTOMY
GyungTak Sung*, Soodong Kim, Busan, Korea, Republic of

MP16-13 PREDICTION OF VOIDING STATUS AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY WITH INTRAVESICAL PROSTATIC PROTRUSION
Takashi Hamakawa*, Yasuke Kubota, Yuya Ota, Taku Naiki, Shuzo Hamamoto, Ryosuke Ando, Atsushi Okada, Noriyasu Kawai, Keiichi Tazawa, Takehiro Yasui, Nagoya, Japan

MP16-14 THE UNPREDICTABILITY OF SOCIAL CONTINENCE AFTER RADICAL PROSTATECTOMY
Karandeep Singh*, Khurshid R. Ghani, Saifdad Seyedsalehi, Ann Arbor, MI, M. Hugh Solomon, Ypsilanti, MI, Gregory Auffenberg, New York, NY, Benjamin Stockton, St. Joseph, MI, David C. Miller, Brian Denton, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI

MP16-15 T-STAGE MIGRATION WITH ROUTINE MRI STAGING MAY IMPACT ON RISK ASSESSMENT WITH CURRENT RISK CALCULATORS

MP16-16 DEVELOPING A NEW PI-RADS V2-BASED PREOPERATIVE NOMOGRAM FOR PREDICTING THE PROBABILITY OF BIOCHEMICAL RECURRENCE AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY
Naoto Kaburaki*, Yosuke Hirasawa, Taiyo Harada, Yu Tajima, Daizuke Yunaiyama, Takeshi Hashimoto, Naoya Satake, Tatsuo Gondo, Yoshihiro Nakagami, Makoto Otori, Kazunori Namiki, Yoshiho Ohno, Tokyo, Japan

MP16-17 TEN YEAR UPGRADING RATE AFTER PROSTATECTOMY IN THE MRI AND FUSION BIOPSY ERA
Samuel Gold*, Graham Hale, Jonathan Bloom, Kareem Rayn, Joseph Baiocco, Sherif Mehralivand, Vladimir Valera Romero, Clayton Smith, Marcin Czarneckie, Maria Merino, Brad Wood, Peter Choyke, Baris Turkbey, Peter Pinto, Bethesda, MD

MP16-18 VALIDATION OF STAMPEDE CRITERIA FOR NON-METASTATIC PROSTATE CANCER - AN EMPIACT STUDY
Steven Joniau*, Brecht Chys, Leuven, Belgium, Alberto Briganti, Milan, Italy, Piotr Chlosta, Krakow, Poland, Gert De Meerleer, Wouter Everaerts, Leuven, Belgium, Paolo Gontero, Turin, Italy, Markus Graefen, Hamburg, Germany, Christian Gratzieke, Munich, Germany, R. Jeffrey Kames, Rochester, MN, Gianluisio Marchioro, Novara, Italy, Rafael Sanchez-Salas, Paris, France, Martin Spahn, Bern, Switzerland, Bertrand Tombal, Brussels, Belgium, Henk Van der Poel, Amsterdam, Netherlands, Hein Van Poppel, Leuven, Belgium

MP16-19 RISK FACTORS FOR PROLONGED SEVERE URINARY INCONTINENCE AFTER ROBOTIC-ASSISTED RADICAL PROSTATECTOMY
Ryo Tanji*, Nobuhiro Haga, Akifumi Onagi, Runko Takinami, Seiji Hoshi, Junya Hata, Yuichi Sato, Hidenori Akahata, Masao Kataoka, Soichiro Ogawa, Kei Shibashi, Ken Akawa, Yoshiyuki Kojima, Fukushima, Japan

MP16-20 OUTCOMES OF RADICAL PROSTATECTOMY FOR LOCALIZED PROSTATE CANCER IN AFRICAN AMERICAN PATIENTS: SYSTEMATIC REVIEW AND META-ANALYSIS OF CONTEMPORARY LITERATURE
Wilson Lin*, Kara Watts, Ahmed Aboumohamed, Bronx, NY

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
**Abstracts**

**MP17-01**  
**Heterogeneity in detection rates of higher grade prostate cancer by multiparametric MRI in an active surveillance cohort**  
Mufaddal Mamawala*, Patricia Landis, Katarzyna Macura, Jonathan Epstein, H. Ballentine Carter, Baltimore, MD

**MP17-02**  
**The impact of confirmatory testing on the adoption of active surveillance for men with favorable-risk prostate cancer**  
Deborah Kaye*, Ji Qi, Todd Morgan, Susan Linsell, Ann Arbor, MI, Brian Lane, Grand Rapids, MI, James Montie, David Miller, Ann Arbor, MI, Michael Cher, Detroit, MI, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI

**MP17-03**  
**Recurrence rates following testosterone therapy in a large clinical cohort of men with prostate cancer**  
Abraham Morgentaler*, Dean Magauran, Dylan Neel, Yonah Krakowsky, William Conners, Chestnut Hill, MA

**MP17-04**  
**Managing low risk prostate cancer: a cost analysis**  
Franklin Gaylis*, Kevin McGill, Susan Levy, Catherine Ball, Hillary Prime, Paul Dato, Edward Cohen, San Diego, CA

**MP17-05**  
**Correlation between single-reader MRI-based prostate volume measurements and serum prostate-specific antigen in men with low-risk prostate cancer on active surveillance**  
Zachary S. Feuer*, Vinay Prabhu, Elton Lukani, Richard Huang, Andrew Rosenkrantz, Xiaosong Meng, James S. Wysock, William C. Huang, Samir Taneja, Herbert Lepor, New York, NY

**MP17-06**  
**Utility of Oncotype DX in men with intermediate-risk prostate cancer**  
Miguel Cantu, Ron Golan*, Hiral McCarthy, Theresa Scognamiglio, Timothy McClure, Christopher Barbieri, Brian Robinson, Francesca Khani, New York, NY

**MP17-07**  
**Increasing rate of non-interventional treatment management in localized prostate cancer candidates for active surveillance**  
Marco Bandini, Nazareno Suardi, Marco Moschini, Milan, Italy, Ariane Smith*, Helen Bondarenko, Sebastiano Nazani, Michele Marchion, Montreal, Canada, Felix Preisser, Hamburg, Germany, Zhe Tian, Montreal, Canada, Firas Abdollah, Detroit, MI, Markus Graeven, Hamburg, Germany, Francesco Montorsi, Milan, Italy, Shahrrook Shariat, Vienna, Austria, Fred Saad, Montreal, Canada, Alberto Brigantti, Milan, Italy, Pierre Karakiewicz, Montreal, Canada

**MP17-08**  
**Surgical outcomes of men with localized Gleason 3+4 prostate cancer on active surveillance in an Australian population**  
Arveen Kalapara*, Adam Landau, Michael Fahey, Joseph Ischia, Mark Frydenberg, Melbourne, Australia

**MP17-09**  
**Testosterone supplementation therapy does not increase the risk of prostate cancer progression but might alter patient choice for definitive treatment during active surveillance**  
Unwanaobong Nseyo*, Stephen Unterberg, Mike Hsieh, San Diego, CA

**MP17-10**  
**Neo active surveillance for patients with negative upfront prostate MRI**  
Jeremy Grummet*, Rowan Miller, Mark Frydenberg, Ross Snow, Uri Hanegbi, Adam Landau, Daniel Moon, Sarah Mann, Kirolbel Begashaw, Richard O’Sullivan, Andrew Ryan, Melbourne, Australia

**MP17-11**  
**Active surveillance follow-up strategies: a cost-effectiveness analysis**  
Niranjan Sathianathan*, Badrinath Konety, Fernando Alarid-Escudero, Minneapolis, MN, Nathan Lawrentschuk, Heidelberg, Australia, Karen Kurtz, Minneapolis, MN

**MP17-12**  
**Utility of serial MRI/ultrasound fusion targeted biopsy in men with low risk prostate cancer managed with active surveillance**  
Walter Hsiang*, Kamyar Ghabili, Amanda Lu, Jamil Syed, Kevin Nguyen, Alfredo Suarez-Sarmiento, Michael Leapman, Preston Sprinkle, New Haven, CT

*Presenting author
MP17-13 ACTIVE SURVEILLANCE IN YOUNG PROSTATE CANCER PATIENTS: FROM THE PRIAS-JAPAN STUDY
Takuma Kato*, Mikio Sugimoto, Yoshiyuki Kakehi, kita-gun Mikicho, Japan

MP17-14 THE PROGNOSTIC IMPACT OF A NEGATIVE CONFIRMATORY BIOPSY IN MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER
Keyan Salari*, Dimitar Zlatev, David Kuppermann, Mark Preston, Douglas Dahl, Jason Efstathiou, Michael Blute, Anthony Zietman, Adam Feldman, Boston, MA

MP17-15 PREDICTORS OF TRANSITION TO WATCHFUL WAITING FROM ACTIVE SURVEILLANCE AMONG MEN WITH LOW-RISK PROSTATE CANCER (FIVO COHORT)
Maria Carmen Mir*, Miguel Ramirez-Backhaus, Jose Luis Dominguez-Escrig, Juan Casanova, Immaculada Iborra, Argimiro Collado, Alvaro Gomez-Ferrer, Juan Manuel Mascaros, Jose Rubio-Briones, Valencia, Spain

MP17-16 A NOVEL RISK SCORE IMPROVES THE PREDICTION OF TRUE LOW-RISK PROSTATE CANCER
Omar Al Kadhi*, London, United Kingdom, Lorenzo Dutto, Jorn Witt, Mustapha Addali, Gronau, Germany, Amir Ahmad, Greg Shaw, London, United Kingdom

MP17-17 LONGITUDINAL ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE AND DECISIONAL REGRET IN MEN WITH LOCALIZED PROSTATE CANCER
Sudhir Ishwarwal*, Anna Zampini, Shree Agrawal, Sij Hemal, Tianming Gao, Eric Klein, Andrew Stephenson, Cleveland, OH

MP17-18 INCREASED EXPRESSION OF PLK3 PREDICTS DISEASE-FREE SURVIVAL IN PATIENTS WITH PROSTATE CANCER
Chunhao Lin, Yiming Lai, Shengmeng Peng, Xiaoming Ma, Wanhua Wu, Jian Huang, Zhenghui Guo, Hai Huang*, Guangzhou, China, People’s Republic of

MP17-19 HOW LOW CAN YOU GO: HOW DO VERY-LOW RISK AND LOW RISK PROSTATE CANCER PATIENTS FARE ON ACTIVE SURVEILLANCE?

MP17-20 IMPROVING RISK-STRATIFICATION OF LOCALIZED PROSTATE CANCER IN A PROSPECTIVE ACTIVE SURVEILLANCE COHORT
Justin Gregg*, Chad Reichard, Xuemei Wang, Brian Chapin, Louis Pisters, Curtis Pettaway, John Ward, Mary Achim, Seungtaek Choi, Deborah Kuban, John Davis, Jeri Kim, Houston, TX

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
MP18-02 EFFICACY OF PREOPERATIVE CHEMOTHERAPY ON OUTCOMES OF HIGH-RISK UPPER TRACT UROTHELIAL CARCINOMA (UTUC)
Beat Foerster*, Vienna, Austria, Surena F. Matin, Houston, TX, Mohit Gupta, Baltimore, MD, Donald Schweitzer, Amsterdam, Netherlands, Timothy Clinton, Dallas, TX, Shoji Kimura, Tokyo, Japan, Marco Bandini, Milan, Italy, Ja H. Ku, Seoul, Korea, Republic of, Tim Mulwijk, Leuven, Belgium, Leonardo L. Monteiro, Montreal, Canada, Mohammad Abufaraj, Vienna, Austria, Firas Petros, Houston, TX, Trinity J. Bivalacqua, Baltimore, MD, Kees Hendriksen, Amsterdam, Netherlands, Laura-Maria Krabbe, Dallas, TX, Shin Egawa, Tokyo, Japan, Alberto Briganti, Milan, Italy, Steven Joniau, Leuven, Belgium, Wassim Kassouf, Montreal, Canada, Phillip M. Pierorazio, Baltimore, MD, Bas W.G. van Rhijn, Amsterdam, Netherlands, Vitaly Margulis, Dallas, TX, Andrea Necchi, Milan, Italy, Shahrokh F. Shariat, Vienna, Austria

MP18-03 RESULTS OF POUT - A PHASE III RANDOMISED TRIAL OF PERI-OPERATIVE CHEMOTHERAPY VERSUS SURVEILLANCE IN UPPER TRACT UROTHELIAL CANCER (UTUC)
Alison Birtle, Preston, United Kingdom, James Catto*, Sheffield, United Kingdom, Mark Johnson, Newcastle upon Tyne, United Kingdom, Roger Kockelbergh, Leicester, United Kingdom, Francis Keeley, Bristol, United Kingdom, Richard Bryan, Birmingham, United Kingdom, John Chester, Cardiff, United Kingdom, Robert Jones, Glasgow, United Kingdom, Michaela Hill, London, United Kingdom, Jenny Donovan, Bristol, United Kingdom, Ann French, Southend, United Kingdom, Chris Harris, Thomas Powles, Rachel Todd, Lucy Tregellas, London, United Kingdom, Caroline Wilson, Bristol, United Kingdom, Andrew Winterbottom, Chinnor, United Kingdom, Rebecca Lewis, Emma Hall, London, United Kingdom

MP18-04 MULTIMODAL TREATMENT WITH CHEMOTHERAPY AND RADICAL NEPHROURETERECTOMY MAY IMPROVE OVERALL SURVIVAL IN PATIENTS WITH CLINICALLY POSITIVE LYMPH NODE DISEASE
Harry Anastos*, David Paullucci, Alp Tuna Beksc, New York, NY, Greg Gin, Long Beach, CA, Matt Galsky, Ketan Badani, John Stakianos, New York, NY

MP18-05 CAN IMAGING RESPONSE FOLLOWING NEOADJUVANT CHEMOTHERAPY IN UPPER TRACT UROTHELIAL CANCER BE A SURROGATE FOR PATHOLOGIC RESPONSE?
NIRMAL THAMPI JOHN*, AMY TIN, DANIEL SJOBORG, NICOLE BENEFAnte, A RI HAKIMI, PAUL RUSSO, JONATHAN COLEMAN, NEW YORK, NY

MP18-06 VALUE OF CIRCULATING MICRORNAS AS PROGNOSTIC BIOMARKERS IN UPPER TRACT UROTHELIAL CARCINOMA
Ruth Montalbo*, Laura Izquierdo, Mercedes Ingelmo-Torres, Juan Jose Lozano, Noelia Ventura, Antonio Alcaraz, Lourdes Menguai, Barcelona, Spain

MP18-07 USING MICRORNA TO PREDICT BLADDER RECURRENT AFTER NEPHROURETERECTOMY FOR UPPER TRACT UROTHELIAL CARCINOMA
Alison Levy*, Travis Sullivan, Brendan Browne, Kristian Stensland, Eric Burks, Chintan Patel, Burlington, MA, Joshua Warrick, Jay Raman, Hershey, PA, David Canes, Kimberly Rieger-Christ, Burlington, MA

MP18-08 GENOMIC ANALYSIS OF SAME-PATIENT METACHRONOUS UPPER-TRACT AND BLADDER UROTHELIAL CARCINOMA
Firas Petros*, Yuqi Qi, Houston, TX, Woonyoung Choi, Baltimore, MD, Roger Li, Xiaoping Su, Charles Guo, Colin Dinney, Houston, TX, David McConkey, Baltimore, MD, Surena Matin, Houston, TX

MP18-09 GENOMIC PREDICTORS OF RESPONSE TO NEOADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN UPPER TRACT UROTHELIAL CARCINOMA (UTUC)
NIRMAL THAMPI JOHN*, AMY TIN, GOPAKUMAR IYER, RENZO DINATALE, NICOLE BENEFAnte, DANIEL SJOBORG, A RI HAKIMI, PAUL RUSSO, JONATHAN COLEMAN, NEW YORK, NY

MP18-10 STAT3 EXPRESSION IS A PROGNOSTIC MARKER IN UPPER URINARY TRACT UROTHELIAL CARCINOMA
Kazutoshi Fujita*, Kyosuke Matsuizaki, Satoshi Nojima, Kentaro Jingushi, Taigo Kato, Atsushi Kawashima, Takeshi Ujike, Akira Nagahara, Motohide Uemura, Sita, Japan, Seiji Yamaguchi, Hiroaki Fushimi, Osaka, Japan, Eiji Mori, Sita, Japan, Hiroshi Miyamoto, Rochester, NY, Ryochi Imamura, Norio Nonomura, Sita, Japan

MP18-11 RISK-STRATIFIED SURVEILLANCE PROTOCOL IMPROVES COST-EFFECTIVENESS AFTER RADICAL NEPHROURETERECTOMY IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA
Momota Masaki*, Hatakeyama Shingo, Tobisawa Yuki, Yonemaya Tohru, Yamamoto Hayato, Yoneyama Takahiro, Hashimoto Yasuhiro, Koie Takuya, Hiroaki, Japan, Iwabuchi Ikuya, Ogasaawara Masaru, Kawaguchi Toshiaki, Aomori, Japan, Ohyama Chiikara, Hiroaki, Japan
### Podium Session 9

**INFERTILITY: EPIDEMIOLOGY & EVALUATION I**

*Room 2022 @ MCC West*

**Moderators:** Robert Brannigan, Raymond Costabile and Ates Kadioglu

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td>PD09-01</td>
<td>ADVANCED PATERNAL AGE AFFECTS EMBRYO ANEUPLOIDY IN EGG DONOR CYCLES</td>
</tr>
<tr>
<td>1:10</td>
<td>PD09-02</td>
<td>EVALUATION OF A PRECONCEPTION MALE FERTILITY RISK ASSESSMENT SCORING ALGORITHM WITH MEN ACTIVELY TRYING TO CONCEIVE</td>
</tr>
<tr>
<td>1:20</td>
<td>PD09-03</td>
<td>COST-EFFECTIVENESS OF SPERM FLUORESCENCE IN SITU HYBRIDIZATION TESTING FOR INFERTILE MEN WITH SUSPECTED SPERM ANEUPLOIDY</td>
</tr>
<tr>
<td>1:30</td>
<td>PD09-04</td>
<td>LATER HEALTH OUTCOMES OF OFFSPRING FROM CLINICALLY INFERTILE MEN AND WOMEN: COMPARISON OF RISK OF INTELLECTUAL DISABILITY, PSYCHOSIS, AUTISM, AND CANCER</td>
</tr>
<tr>
<td>1:40</td>
<td>PD09-05</td>
<td>THE PREVALENCE OF Y-CHROMOSOME MICRODELETIONS IN OLIOSPERMIC MEN STRATIFIED BY SPERM CONCENTRATION: A SYSTEMATIC REVIEW AND META-ANALYSIS</td>
</tr>
<tr>
<td>1:50</td>
<td>PD09-06</td>
<td>FERTILITY IN ADOLESCENTS WITH KLINEFELTER SYNDROME – A SURVEY OF CURRENT CLINICAL PRACTICE</td>
</tr>
<tr>
<td>2:00</td>
<td>PD09-07</td>
<td>MEASURING REPRODUCTIVE CONCERNS AMONG YOUNG MALE CANCER SURVIVORS: PRELIMINARY ANALYSIS OF REPRODUCTIVE CONCERNS AFTER CANCER SCALE</td>
</tr>
<tr>
<td>2:10</td>
<td>PD09-08</td>
<td>NO DIFFERENCE IN SEMEN PARAMETERS FOR INFERTILE MEN WHO HAD EARLY OR LATE ORCHIOPEXIES FOR UNDESCENDED TESTIS</td>
</tr>
<tr>
<td>2:20</td>
<td>PD09-09</td>
<td>ASSOCIATION BETWEEN USE OF MARIJUANA AND INFERTILITY IN MEN AND WOMEN: FINDINGS FROM THE NATIONAL SURVEY OF FAMILY GROWTH</td>
</tr>
<tr>
<td>2:30</td>
<td>PD09-10</td>
<td>IMPAIRED SLEEP IS ASSOCIATED WITH LOW TESTOSTERONE IN US ADULT MALES: RESULTS FROM THE NATIONAL HEALTH AND NUTRITION SURVEY</td>
</tr>
<tr>
<td>2:40</td>
<td>PD09-11</td>
<td>EVALUATION OF TESTICULAR SPERM EXTRACTION AND TESTIS HISTOLOGY IN GENDER AFFIRMING SURGERY PATIENTS</td>
</tr>
</tbody>
</table>

---

*Presenting author*
Friday, May 18, 2018 1:00 pm - 3:00 pm

Podium Session 10
PROSTATE CANCER: ADVANCED (INCLUDING DRUG THERAPY) I
Room 2011 @ MCC West
Moderators: Judd Moul, Stephen Freedland, and Neal Shore

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td>PD10-01</td>
<td>DOES CURCUMIN PLAY A ROLE IN PROSTATE CANCER SUPPRESSION?: A RANDOMIZED, DOUBLE-BLIND</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Young Hyo Choi*, Deok Hyun Han, Hyun Hwan Sung, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Han Yong Choi, Seoul, Korea, Republic of</td>
</tr>
<tr>
<td>1:10</td>
<td>PD10-02</td>
<td>ADJUVANT RADIATION WITH ANDROGEN DEPRIVATION THERAPY FOR MEN WITH LYMPH NODE METASTASES FOLLOWING RADICAL PROSTATECTOMY: IDENTIFYING MEN WHO BENEFIT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mohit Gupta*, Hiten Patel, Zeyad Schwen, Phuoc Tran, Alan Partin, Baltimore, MD</td>
</tr>
<tr>
<td>1:20</td>
<td>PD10-03</td>
<td>ASSESSING THE UNDER-ESTIMATION OF NODAL TUMOUR BURDEN BY 68GA-PSMA AND 11C-CHOLINE PET/CT SCAN IN PATIENTS TREATED WITH SALVAGE LYMPH NODE DISSECTION FOR NODAL RECURRENCE OF PROSTATE CANCER: A LARGE MULTI-INSTITUTIONAL ANALYSIS</td>
</tr>
<tr>
<td>1:30</td>
<td>PD10-04</td>
<td>A POPULATION-BASED STUDY OF THE ASSOCIATION OF PROSTATE-SPECIFIC ANTIGEN DOUBLING TIME (PSADT) WITH METASTASIS-FREE SURVIVAL (MFS) AND OVERALL SURVIVAL (OS) IN NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) PATIENTS (PTS)</td>
</tr>
<tr>
<td>1:40</td>
<td>PD10-05</td>
<td>PHASE 3 STUDY OF INTERMITTENT MONOTHERAPY VERSUS CONTINUOUS COMBINED ANDROGEN DEPRIVATION</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fernando Calais da Silva Junior*, Fernando Calais da Silva Senior, Lisboa, Portugal, Frederico Goncalves, Bratislava, Slovakia (Slovak Republic), Jan Kliment, Martin, Slovakia (Slovak Republic), Américo Santos, Braga, Portugal, Spiros Pastidis, Athens, Greece, Antonio Queimadelos, Santiago Compostela, Spain, Chris Robertson, Glasgow, United Kingdom</td>
</tr>
<tr>
<td>1:50</td>
<td>PD10-06</td>
<td>THE IMPACT OF PRIOR LOCAL THERAPY ON OVERALL SURVIVAL IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: RESULTS FROM SEARCH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Devin Patel*, Los Angeles, CA, Shalini Jha, Lauren Howard, Durham, NC, Christopher Amling, Portland, OR, William Aronson, Los Angeles, CA, Matthew Cooperberg, San Francisco, CA, Christopher Kane, San Diego, CA, Martha Terris, Augusta, GA, Brian Chapin, Houston, TX, Stephen Freedland, Los Angeles, CA</td>
</tr>
<tr>
<td>2:00</td>
<td>PD10-07</td>
<td>PREDICTORS OF RADIOGRAPHIC PROGRESSION IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS TREATED WITH ABIRATERONE: RETROSPECTIVE ANALYSIS OF COU-AA-302</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lisa Martin, Shabbir AliBhai, Maria Komisarenko, Narhari Timishina, Antonio Finelli*, Toronto, Canada</td>
</tr>
<tr>
<td>2:10</td>
<td>PD10-08</td>
<td>ABIRATERONE ACETATE (AA) + PREDNISOLONE (P) FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) WITH EARLY PROGRESSION OR NO-RESPONSE TO ANDROGEN DEPRIVATION THERAPY (ADT); FINAL ANALYSIS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hiroomi Nakatsu*, Chiba, Japan, Akimitsu Maniwa, Shizuoka, Japan, Naoto Kaniya, Chiba, Japan, Mizue Ogi, Hisanori Kobayashi, Masahiko Nakayama, Tokyo, Japan</td>
</tr>
</tbody>
</table>
2:20 PD10-09 THE PROSPERO TRIAL: CHEMOTHERAPY-RELATED ENDPOINTS IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER TREATED WITH ENZALUTAMIDE

Neal Shore*, Myrtle Beach, SC, Fred Saad, Montreal, Canada, Maha Hussain, Chicago, IL, Karim Fizazi, Villejuif, France, Per Rathenborg, Hertlev, Denmark, Eren Demirhan, Katharina Modelska, San Francisco, CA, De Phung, Andrew Krivoshik, Northbrook, IL, Cora N. Sternberg, Rome, Italy

2:30 PD10-10 A PROSPECTIVE, RANDOMIZED CONTROLLED TRIAL EVALUATING OVERALL SURVIVAL IN PATIENTS WITH PRIMARY BONE METASTATIC PROSTATE CANCER (MPCA) RECEIVING EITHER ANDROGEN DEPRIVATION THERAPY (ADT) OR ADT COMBINED WITH CONCURRENT RADIATION THERAPY TO THE PROSTATE, F

Liselotte Boeve*, Maarten Hulshof, André Vis, Koos Zwinderman, Jos Twisk, Amsterdam, Netherlands, Karl Delaere, Heerlen, Netherlands, Jeroen van Moorselaar, Amsterdam, Netherlands, Paul Verhagen, Rotterdam, Netherlands, George van Andel, Amsterdam, Netherlands

2:40 PD10-11 PROSTATE-SPECIFIC ANTIGEN (PSA) OUTCOMES IN PATIENTS (PTS) WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) TREATED WITH APALUTAMIDE (APA): RESULTS FROM PHASE 3 SPARTAN STUDY

Eric J. Small*, San Francisco, CA, Ji Youl Lee, Seoul, Korea, Republic of, Angela Lopez-Gillitz, Los Angeles, CA, Fred Saad, Montreal, Canada, Brendan Rooney, High Wycombe, United Kingdom, Boris A. Hadaschik, Essen, Germany, Hiroji Uemura, Yokohama, Japan, Youyi Shu, Margaret Yu, Los Angeles, CA, Matthew R. Smith, Boston, MA

2:50 PD10-12 NO SIGNIFICANT IMPACT OF RESPONSE TO PRIOR ANDROGEN RECEPTOR-AXIS-TARGETED AGENTS ON THE EFFICACY OF SUBSEQUENT DOCETAXEL IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Takayuki Sugiyama*, Yuto Matsushita, Keita Tamura, Hideaki Miyake, Hamamatsu, Japan

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
1:50 PD11-06 COMPREHENSIVE CHARACTERIZATION OF RETURNS TO THE OPERATING ROOM FOLLOWING RADICAL CYSTECTOMY
Timothy Lyon*, Stephen Boorjian, Paras Shah, Robert Tarrell, Prabin Thapa, John Cheville, Igor Frank, R. Jeffrey Barnes, R. Houston Thompson, Matthew Tollefson, Rochester, MN

2:00 PD11-07 RADICAL CYSTECTOMY PROVIDES IMPROVED SURVIVAL OUTCOMES AND DECREASED COSTS COMPARED WITH TRIMODAL THERAPY FOR PATIENTS DIAGNOSED WITH LOCALIZED MUSCLE-INVASIVE BLADDER CANCER
Stephen Williams*, Christopher Kosarek, Yong Shan, Usama Jazzar, Hemalkumar Mehta, Jacques Bailargeon, Galveston, TX, Jinhai Huo, Gainesville, FL, Anthony Senagore, Eduardo Orhuela, Douglas Tyler, Todd Swanson, Galveston, TX, Ashish Kamat, Houston, TX

2:10 PD11-08 OOPHORECTOMY AT TIME OF RADICAL CYSTECTOMY: RE-EVALUATING THE DEFINITION OF RADICAL CYSTECTOMY IN WOMEN
Marc A. Abboud*, Oklahoma City, OK, Allan K. Topham, Philadelphia, PA, Daniel C. Parker, Heather R. Burks, Michael S. Cookson, Sanjay G. Patel, Oklahoma City, OK

2:20 PD11-09 RACIAL DISPARITIES IN QUALITY OF CARE AND OVERALL SURVIVAL AMONG MUSCLE-INVASIVE BLADDER CANCER PATIENTS TREATED WITH RADICAL CYSTECTOMY: A NATIONAL CANCER DATABASE ANALYSIS
Philipp Gild*, Hamburg, Germany, Stephanie A. Wankowicz, Boston, MA, Akshay Sood, Detroit, MI, Nicolas von Landenberg, Herne, Germany, David F. Friedlander, Boston, MA, Shaheen Alanee, Detroit, MI, Felix K.H. Chun, Frankfurt, Germany, Margit Fisch, Hamburg, Germany, Mani Menon, Detroit, MI, Quoc-Dien Trinh, Joaquim Bellmunt, Boston, MA, Firas Abdollah, Detroit, MI

2:30 PD11-10 NEOADJUVANT DOSE-DEEP MVAC INCREASES DOWN-STAGING AND IMPROVES SURVIVAL COMPARED TO OTHER CHEMOTHERAPY REGIMENS
Dominic Tang*, Charles Peyton, Richard Reich, Juan Chipollini, Mounsif Azizi, Julio Pow-Sang, Brandon Manley, Philippe Spiess, Michael Poch, Wade Sexton, Mayer Fishman, Jingsong Zhang, Scott Gilbert, Tampa, FL

2:40 PD11-11 INTERIM RESULTS FROM PURE-01: A PHASE 2, OPEN-LABEL STUDY OF NEOADJUVANT PEMBROLIZUMAB (PEMBRO) BEFORE RADICAL CYSTECTOMY FOR MUSCLE-INVASIVE UROTHELIAL BLADDER CARCINOMA (MIUC)
Andrea Necchi*, Milan, Italy, Alberto Briganti, Milano, Italy, Daniele Raggi, Patrizia Giannatempo, Milan, Italy, Marco Bianchi, Milano, Italy, Luigi Mariani, Antonella Messina, Andrea Anichini, Milan, Italy, Massimo Freschi, Milano, Italy, Maurizio Colecchia, Roberto Salvioni, Milan, Italy, Renzo Colombo, Andrea Gallina, Francesco Montorsi, Milano, Italy

2:50 PD11-12 GENOMIC CHARACTERIZATION OF PAIRED CYSTECTOMY AND LYMPH NODE METASTASES IN BLADDER UROTHELIAL CARCINOMA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
### Podium Session 12

**KIDNEY CANCER: LOCALIZED: SURGICAL THERAPY II**  
Room 3018 @ MCC West  
**Moderators:** Paul Russo, Casey Ng and Robert Stein

<table>
<thead>
<tr>
<th>Time</th>
<th>Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td>PD12-01</td>
<td>DOES CO-MEDICATION WITH NON-ANTICANCER DRUGS AFFECT OUTCOMES IN PATIENTS WITH SURGICALLY TREATED CLEAR CELL RENAL CELL CARCINOMA ? - EVALUATION OF SURVIVAL, CELL-CYCLE ACTIVITY, AND PROLIFERATION</td>
<td>Steffen Rausch, Eva Neumann*, Peter Klaiber, Kathleen Freitag, Tuebingen, Germany, Matthias Schwab, Elke Schaeffeler, Stuttgart, Germany, Jörg Hennenlotter, Falko Fend, Stephan Kruck, Marcus Scharpf, Amulf Stenzl, Jens Bedke, Tuebingen, Germany</td>
</tr>
<tr>
<td>1:10</td>
<td>PD12-02</td>
<td>PERIOPERATIVE OUTCOMES OF ASPIRIN USE IN PARTIAL NEPHRECTOMY</td>
<td>Matthew Ingham*, Ross Krasnow, Matthew Mossanen, Ye Wang, Adam Althaus, Steven Chang, Boston, MA</td>
</tr>
<tr>
<td>1:20</td>
<td>PD12-03</td>
<td>ASSOCIATION OF PARTIAL AND RADICAL NEPHRECTOMY ON SURVIVAL IN YOUNG PATIENTS WITH NON-CLEAR CELL RENAL CELL CARCINOMA</td>
<td>Kristian Stensland*, Jared Schober, David Canes, Burlington, MA, Navneet Ramesh, Brendan Waldoch, Boston, MA, Alireza Moinzadeh, Harras Zaid, Burlington, MA</td>
</tr>
<tr>
<td>1:30</td>
<td>PD12-04</td>
<td>RISK-BASED SURVEILLANCE AFTER SURGICAL TREATMENT OF RENAL CELL CARCINOMA</td>
<td>Paolo Capogrosso*, Alessandro Larcher, Milan, Italy, Daniel D. Sjöberg, Emily A. Vertosick, New York, NY, Francesco Cianflone, Fabio Muttin, Paolo Dell’oglio, Andrea Salonia, Milan, Italy, Andrew J. Vickers, New York, NY, Francesco Montorsi, Roberto Bertini, Umberto Capitanio, Milan, Italy</td>
</tr>
<tr>
<td>1:40</td>
<td>PD12-05</td>
<td>EVALUATING INDIVIDUAL RECURRENCE RISK FOLLOWING SURGERY FOR HIGH RISK NON-METASTATIC RENAL CELL CARCINOMA</td>
<td>E. Jason Abel*, Madison, WI, Jay D. Raman, Hershey, PA, Philippe E. Spiess, Charles C. Peyton, Tampa, FL, Daniel D. Shapiro, Madison, WI, Wilson Chan, Hershey, PA, Glenn O. Allen, Madison, WI, Dattatraya Patil, Viraj Master, Atlanta, GA</td>
</tr>
<tr>
<td>1:50</td>
<td>PD12-06</td>
<td>ONCOLOGIC OUTCOMES PERINEPHRIC VERSUS SINUS FAT INVASION IN PATHOLOGIC T3A RENAL CELL CARCINOMA</td>
<td>Jeman Ryu, Se Young Choi, Jaehoon Lee, Wonchul Lee, Han Kyu Chae, Wonseok Choi, Bumjin Lim*, Jae Hyeon Han, Teak Jun Shin, Yoon Soo Kyung, Seoul, Korea, Republic of, Sungchan Park, Kyung Hyun Moon, Ulsan, Korea, Republic of, Dalsan You, In Gab Jeong, Jun Hyuk Hong, Hanjong Ahn, Choung-Soo Kim, Seoul, Korea, Republic of</td>
</tr>
<tr>
<td>2:00</td>
<td>PD12-07</td>
<td>PREDICTORS OF PATHOLOGICALLY NODE POSITIVE DISEASE IN PATIENTS UNDERGOING RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) FOR RENAL CELL CARCINOMA (RCC): RESULTS FROM THE CANADIAN KIDNEY CANCER COLLABORATION</td>
<td>Andrea Kokorovic*, Halifax, Canada, Rodney Breau, Ottawa, Canada, Antonio Finelli, Toronto, Canada, Simon Tanguay, Montreal, Canada, Anil Kapoor, Hamilton, Canada, Jun Kawakami, Calgary, Canada, Adrian Fairey, Edmonton, Canada, Alan So, Vancouver, Canada, Darrel Drachenberg, Winnipeg, Canada, Luke T. Lavallée, Ottawa, Canada, Jean-Baptiste Lattouf, Montreal, Canada, Frederic Pouliot, Quebec City, Canada, Ranjeeta Mallick, Ottawa, Canada, Ricardo A. Rendon, Halifax, Canada</td>
</tr>
<tr>
<td>2:10</td>
<td>PD12-08</td>
<td>THE ASSOCIATION OF LYMPH NODE DISSECTION WITH SURVIVAL IN HIGH-RISK NON-METASTATIC RENAL CELL CARCINOMA: AN ANALYSIS OF THE NATIONAL CANCER DATABASE</td>
<td>Janine Bacic, Tao Liu, Providence, RI, R. Houston Thompson, Stephen Boorjian, Bradley Leibovich, Rochester, MN, Dragan Golijanin, Boris Gershman*, Providence, RI</td>
</tr>
<tr>
<td>2:20</td>
<td>PD12-09</td>
<td>SURGICALLY-INDUCED HYPERTENSION AND CARDIOVASCULAR MORBIDITY FOLLOWING TREATMENT FOR LOCALIZED KIDNEY CANCER: THE IMPACT OF NEPHRON LOSS</td>
<td>Umberto Capitanio*, Alessandro Larcher, Francesco Trevisani, Francesco Cianflone, Milan, Italy, Andrea Mari, Riccardo Campi, Firenze, Italy, Riccardo Tellini, Alessandro Veglia, Brescia, Italy, Alexandre Mottrie, Melle, Belgium, Hendrik Van Poppel, Leuven, Italy, Marco Carini, Firenze, Italy, Claudio Simeone, Brescia, Italy, Andrea Salonia, Milan, Italy, Andrea Minervini, Firenze, Italy, Alessandro Antonelli, Brescia, Italy, Francesco Montorsi, Roberto Bertini, Milan, Italy</td>
</tr>
</tbody>
</table>

*Presenting author
**2:30 PD12-10 SURGICAL NOMOGRAM FOR PREDICTING THE LIKELIHOOD OF POSTOPERATIVE SURGICAL COMPLICATIONS IN PATIENTS TREATED WITH PARTIAL NEPHRECTOMY: A PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY (THE RECORD 2 PROJECT)**  
Andrea Mari, Riccardo Campi, Firenze, Italy, Marco Borghesi, Bologna, Italy, Andrea Cocci*, Firenze, Italy, Riccardo Schiavina, Eugenio Brunocilla, Bologna, Italy, Paolo Gontero, Maurizio Barale, Torino, Italy, Francesco Porpiglia, Riccardo Bertolo, Orbassano, Torino, Italy, Alessandro Antonelli, Claudio Simeone, Berscia, Brazil, Francesco Montorsi, Umberto Capitanio, Milano, Italy, Nicola Longo, Vincenzo Mirone, Napoli, Italy, Marco Roscigno, Bergamo, Italy, Vincenzo Li Marzi, Firenze, Italy, Emanuele Montanari, Milano, Italy, Carlo Trombetta, Trieste, Italy, Salvatore Siracusano, Walter Artibani, Verona, Italy, Sergio Serni, Firenze, Italy, Alessandro Volpe, Novara, Italy, Vincenzo Ficarra, Messina, Italy, Luigi Schips, Chieti, Italy, Giuseppe Vespasiani, Roma, Italy, Antonio Celli, Bassano, Italy, Giuseppe Morgia, Catania, Italy, Marco Carini, Andrea Minervini, Firenze, Italy

**2:40 PD12-11 THE EFFECT OF DAY OF DISCHARGE ON HOSPITAL READMISSION AFTER PARTIAL NEPHRECTOMY**  
Kristian Stensland*, Burlington, MA, Joan Delto, Boston, MA, Jared Schober, Burlington, MA, Navneet Ramesh, Brendan Waldoch, Peter Chang, Andrew Wagner, Boston, MA

**2:50 PD12-12 EARLY DISCHARGE FOLLOWING RADICAL NEPHRECTOMY DOES NOT INCREASE READMISSION RISK**  
Ian Berger*, Leilei Xia, Chris Wirtalla, Rachel Kelz, Thomas Guzzo, Philadelphia, PA

---

**Friday, May 18, 2018**

**3:30 pm - 5:30 pm**

**Moderated Poster Session 19**

**INFERTILITY: EPIDEMIOLOGY & EVALUATION II**

Room 3004 @ MCC West

Moderators: Mark Sigman, Larry Lipshultz and Keith Jarvi

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MP19-01</strong></td>
<td>ATTRIBUTABLE CASES OF CANCER AND NEUROCOGNITIVE DISORDERS IN CHILDREN IN THE UNITED STATES BASED ON PARENTAL AGE</td>
</tr>
<tr>
<td>Yash S. Khandwala*, San Diego, CA, Ying Lu, Michael L. Eisenberg, Palo Alto, CA</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MP19-02</strong></td>
<td>BIPOLAR DISORDER SEEN AT HIGHER RATE IN THE OFFSPRING OF MEN EXPOSED TO CHEMOTHERAPY</td>
</tr>
<tr>
<td>Biren Patel*, Huong Meeks, Yuan Wan, Erica B. Johnstone, Martha Glenn, Darshan P. Patel, Ken Smith, James M. Hotaling, Salt Lake City, UT</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MP19-03</strong></td>
<td>DISCREPANCIES AMONG GENOMIC &amp; HISTOLOGIC PHENOTYPING OF NON-OBSTRICTIVE AZOOSPERMIA</td>
</tr>
<tr>
<td>Ryan Flannigan*, Francesca Khan, Brian Robinson, Russell Hayden, Anna Mielnik, Alexander Bolyakov, Peter N. Schlegel, Darius Paduch, New York, NY</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MP19-04</strong></td>
<td>LOWER REFERENCE LIMITS FOR NUMBER OF SPERM OBTAINED VIA TESTICULAR SPERM EXTRACTION USING FERTILE CONTROLS</td>
</tr>
<tr>
<td>J. Abram McBride*, Taylor P. Kohn, Houston, TX, Daniel T. Lybbert, Reno, NV, Nannan Thirumavalavan, Stephen M. Pickett, Daniel J. Mazur, Alexander W. Pastuszak, Larry I. Lipshultz, Houston, TX</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MP19-05</strong></td>
<td>CRYPTOSPERMIA IS ASSOCIATED WITH SIGNIFICANTLY HIGHER SPERM RETRIEVAL RATES WHEN COMPARED TO PATIENTS WITH AZOOSPERMIA</td>
</tr>
<tr>
<td>James Wren*, Matthew Hudnall, Minh Pham, CHICAGO, IL, Annie Darves-Bomzon, Nashville, TN, Nelson Bennett, Robert Brannigan, CHICAGO, IL</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MP19-06</strong></td>
<td>NOVEL MEASURES OF SPERM DNA DAMAGE INCREASE ITS USEFULNESS TO DIAGNOSE MALE INFERTILITY AND PREDICT LIVE BIRTHS FOLLOWING BOTH IVF AND ICSI</td>
</tr>
<tr>
<td>Tet Yap*, Nicopoullos James, Ramsay Jonathan, Minhas Suks, London, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>
Y-CHROMOSOME ABNORMALITIES IN MEN WITH SUB-FERTILITY: AN ANALYSIS OF THE FREQUENCY OF ABNORMALITIES AND DETERMINATION OF A THRESHOLD SPERM CONCENTRATION FOR GENETIC ANALYSIS

Mark Johnson*, Amr Raheem, Francesco De Luca, Thomas Johnson, Yasmeen Zainal, Sameer Poselav, Marcus Hallerstrom, Mohammadi Bahr, Amr Moubasher, Phillippa Sangster, Asif Muneer, David Ralph, London, United Kingdom

AGE AND PARTIAL AZFc DELETION DO NOT PREDICT SPERM RETRIEVAL IN NON-MOSAIC KLINEFELTER PATIENTS

I-shen Huang*, William J. Huang, Taipei, Taiwan, James Wren, Nelson E. Bennett, Robert E. Brannigan, Chicago, IL

RESULTS OF A NORTH AMERICAN SURVEY ON THE CHARACTERISTICS OF MEN PRESENTING FOR INFERTILITY INVESTIGATIONS: THE ANDROLOGY RESEARCH CONSORTIUM


RACIAL STRATIFICATION IN INFERTILE MEN SEEKING REPRODUCTIVE CARE: THE CHICAGO EXPERIENCE

Ramy Abou Ghayda*, Tolulope Bakare, Samuel Ohlander, Rodrigo Pagani, Craig Niederberger, Chicago, IL

THE EFFECT OF ETHNICITY AND RACE ON SEMEN ANALYSIS AND HORMONES IN THE INFERTILE PATIENT

Nahid Punjani*, London, Canada, Madhur Nayan, Ethan Grober, Kirk Lo, Susan Lau, Keith Jarvi, Toronto, Canada

PREDIABETES IN PRIMARY INFERTILE MEN – RESULTS FROM A CROSS-SECTIONAL STUDY


UNCERTAIN IMPACT OF ANTI-TNF AGENTS ON MALE FERTILITY: ARE MEN BEING COUNSELED?

Lauren F. Cooley*, Isaac Lam, James Wren, Nelson Bennett, Robert Brannigan, Chicago, IL

FERTILITY-RELATED QUALITY OF LIFE, GONADAL FUNCTION, AND ERECTILE DYSFUNCTION IN MALE PARTNERS OF COUPLES WITH UNEXPLAINED INFERTILITY

Robert Coward*, Chapel Hill, NC, Christy Stetter, Allen Kunselman, Hershey, PA, JC Trussell, Syracuse, NY, Mark Lindgren, Oklahoma City, OK, Michael Diamond, Augusta, GA, Karl Hansen, Oklahoma City, OK, Stephen Krawetz, Detroit, MI, Richard Legro, Hershey, PA, Pasquale Patrizio, New Haven, CT, James Smith, San Francisco, CA, Anne Steiner, Chapel Hill, NC, Robert Wild, Oklahoma City, OK, Esther Eisenberg, Bethesda, MD, Heping Zhang, New Haven, CT, Nanette Santoro, Aurora, CO

PATIENT KNOWLEDGE AND INTEREST IN CRYOPRESERVATION OF SPERM IN PATIENTS PRESENTING FOR MALE TO FEMALE GENDER AFFIRMING SURGERY

Ruth Blum*, Farmington, CT, Rafaela Penarreta, James Rosoff, Stanton Honig, New Haven, CT

COMPARISON OF THE CLINICAL CHARACTERISTICS OF PATIENTS WITH VARICOCELES ACCORDING TO THE PRESENCE OR ABSENCE OF SCROTAL PAIN

Hyun Jun Park*, Jong Kil Nam, Tae Nam Kim, Sung Woo Park, Nam Cheol Park, Busan, Korea, Republic of

HYPOGONADISM IN MEN WITH PITUITARY TUMOR AFTER TRANS-SPHENOIDAL SURGERY AND SERIAL CHANGE AFTER ADJUVANT STEREOTACTIC RADIOSURGERY

Yun-Chu Chang*, William J. Huang, Alex T.L. Lin, Taipei, Taiwan

THE USE OF FORMALIN AS A FIXATIVE FOR TESTICULAR BIOPSIES

James Ellenburg*, Joseph Driewiega, Anna Posey, Matthew Goldberg, Jennifer Gordetsky, Peter Kolettis, Birmingham, AL

ANDROLOGY/MALE INFERTILITY SUBSPECIALTY EXPOSURE DURING U.S BASED UROLOGY RESIDENCY TRAINING

Ramy Abou Ghayda*, Tolulope Bakare, Samuel Ohlander, Rodrigo Pagani, Craig Niederberger, Chicago, IL

IMPACT OF THE 2012 AMERICAN UROLOGICAL ASSOCIATION VASECTOMY GUIDELINES ON NATIONAL TRENDS IN POST- VASECTOMY OUTCOMES IN THE UNITED STATES

Tony Chen*, Sarah Holt, John Gore, Kevin Ostrowski, Seattle, WA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| MP20-01         | PERFORMANCE CHARACTERISTICS OF TRANSRECTAL SHEAR WAVE ELASTOGRAPHY (SWE) IMAGING IN THE EVALUATION OF CLINICALLY LOCALISED PROSTATE CANCER: A PROSPECTIVE STUDY  
Cheng Wei, Dilip Upreti, Stephen Lang, Magdelena Szewczyk-Bieda, Ghulam Nabi*, Dundee, United Kingdom |
| MP20-02         | QUANTITATIVE TRANSRECTAL SHEAR WAVE ELASTOSONOGRAPHY UNDERGOING SALVAGE EXTRAPERITONEAL LAPAROSCOPIC RADICAL PROSTATECTOMY FOLLOWING FAILED RADIOThERAPY  
Cheng Wei, Stephen Lang, Magdelena Szewczyk-Bieda, Ghulam Nabi*, Dundee, United Kingdom |
| MP20-03         | POWER DOPPLER SONOGRAPHY (PDS) AND MODIFIED TRUS SYSTEMATIC BIOPSIES – CAN THIS COMBINATION ADEQUATELY REPLACE MULTIPARAMETRIC PROSTATE MAGNETIC RESONANCE IMAGING (MP-MRI) IN CANDIDATES FOR RE-BIOPSIES WHO CANNOT UNDERGO MP-MRI  
Sergey Kravchick*, Syracuse, NY, Shmuel Cytron, Yavne, Israel, Eugenia Cherniavsky, Ashkelon, Israel |
| MP20-04         | AUTOMATED DIAGNOSIS OF PROSTATE CANCER LOCATION AND FORM BY ARTIFICIAL INTELLIGENCE IN MULTIPARAMETRIC MRI  
Yuichiro Oishi*, Takeya Kitta, Nobuo Shinohara, Sapporo Hokkaido, Japan, Hirokazu Nosato, Hidenori Sakanashi, Masahiro Murakawa, Tsukuba Ibaraki, Japan |
| MP20-05         | CLINICAL SIGNIFICANCE OF GRADE 5 LESIONS ON MRI  
Demetrios Simopoulos*, Jacob Vandel, Ely Felker, Lorna Kwan, Anthony Sisk Jr, Leonard Marks, Los Angeles, CA |
| MP20-06         | FALSE POSITIVE LESIONS ON MRI FUSION PROSTATE NEEDLE BIOPSY AND INFLAMMATION  
Elizabeth Ann Rourke*, Osmah Al-Bayati, Dharam Kaushik, Michael A Liss, San Antonio, TX |
| MP20-07         | PReOperative MRI and CLINICAL PARAMETERS FOR ACCURATE PREDICTION OF CONTINENCE RECOVERY FOLLOWING RADICAL PROSTATECTOMY – MEMBRANOUS URETHRAL LENGTH ON MRI OUTPERFORMS PREDICTIVE MODELS  
Joanne Nyarangi-Dix, Jan Wörner, Annette Kopp-Schneider, Viktoria Schütz, David Bonekamp, Manuel Wiesenfarth, Albrecht Stenzinger, Winfried Roth, Heidelberg, Germany, Boris Hadaschik, Essen, Germany, Heinz-Peter Schlemmer, Gencay Haltbloglu, Dogu Teber, Markus Hohenfellner, Jan Philipp Radtke*, Heidelberg, Germany |
| MP20-08         | MR IMAGING OF PROSTATE CANCER SHOWS REDUCED ENHANCEMENT KINETIC CURVES IN MEN ON 5-ALPHA REDUCTASE INHIBITORS WITH IMPLICATIONS FOR CANCER DETECTION  
Shivashankar Damodaran*, Lori Mankowski Gettle, Kelcz Frederick, Glenn O. Allen, Kyle Richards, E.Jason Abel, Tracy Downs, David Jarrard, Madison, WI |
| MP20-09         | MRI-BASED RISK ASSESSMENT FOR POSTOPERATIVE BIOCHEMICAL RECURRENCE USING THE PROSTATE IMAGING REPORTING AND DATA SYSTEM (PI-RADS) SCORES AND CAPSULAR CONTACT LENGTH  
Yoh Matsuoka*, Junichiro Ishioka, Hiroshi Tanaka, Tomo Kimura, Yuma Waseda, Sho Uehara, Yosuke Yasuda, Toshiki Kijima, Soichiro Yoshida, Minato Yokoyama, Kazutaka Saito, Kazunori Kihara, Yasuhsia Fuji, Tokyo, Japan |
| MP20-10         | DEEP LEARNING WITH A CONVOLUTIONAL NEURAL NETWORK ALGORITHM FOR FULLY AUTOMATED DETECTION OF PROSTATE CANCER USING PRE-BIOPSY MRI  
Junichiro Ishioka*, Yoh Matsuoka, Sho Uehara, Yosuke Yasuda, Toshiki Kijima, Soichiro Yoshida, Minato Yokoyama, Kazutaka Saito, Tomo Kimura, Kosei Kudo, Itsuo Kumazawa, Yasuhsia Fujii, Tokyo, Japan |
| MP20-11         | THE DIAGNOSTIC EFFICACY OF BIPARAMETRIC NON-CONTRAST MRI IN PATIENTS WITH TOTAL PROSTATE-SPECIFIC ANTIGEN LEVEL OF 4-10 NG/ML: A MULTI-CENTER STUDY  
Chengyue Jin*, Xiao Jin, Linyun Zhai, Beijing, China, People’s Republic of, Can Cui, New Haven, CT, Wei Yu, Tao Xu, Beijing, China, People’s Republic of |
MP20-12 STANDARDIZED TEMPLATE FOR PROSTATE MRI REPORTING IMPROVES UROLOGIST UNDERSTANDING OF RESULTS AND CONFIDENCE IN COUNSELING PATIENTS ON PROSTATE CANCER MANAGEMENT
Elisabeth M. Sebesta*, Michael Lipsky, Gen Li, Hiram Shaish, Sven Wenske, New York, NY

MP20-13 FACTORS AFFECTING POSITIVITY OF GA-68-PSMA PET/CT IN RECURRENCE OF LOCALIZED PROSTATE CANCER FOLLOWING DEFINITIVE THERAPY
Ahmet Aydin*, Bahadir Haberal, Meylis Artykov, Berk Hazir, Bulent Akdogan, Cemk Bilin, Sertac Yazici, Haluk Ozen, Ankara, Turkey

MP20-14 POSITIVE PROSTATE 68GAPPSMA-PET/CT CORRELATES WITH DETECTION OF CD45-/PSMA+/NON-SPERM EPITHELIAL CELLS OBTAINED BY LIQUID BIOPSY OF SEMINAL FLUID IN PATIENTS WITH PROSTATE CANCER (PCA)
Massimo Lazzeri*, Egesta Lopci, Giovanni Lughezzani, Paolo Casale, Rodolfo Hurle, Alberto Saia, Roberto Peschechera, Alessio Benetti, Luisa Pasini, Silvia Zandegiacomo, Giuliana Lista, Pasquale Cardone, Arturo Chilti, Giorgio Guazzoni, Federico Colombo, Chiara Chiereghin, Rosanna Assetta, Piergiuseppe Colombo, Simon Monterisi, Milan, Italy, Giulia Soldà, Giulia Veronesi, Rozzano, Italy, Stefano Duga, Milan, Italy

MP20-15 COMPARISON BETWEEN 68Ga-LABELLED PSMA AND 18F-FDG PET/CT IN THE DIAGNOSTIC VALUE OF CLEAR CELL RENAL CELL CARCINOMA
Chengwei Zhang*, Xiaozhi Zhao, Shiming Zang, Feng Wang, Hongqian Guo, Nanjing, China, People’s Republic of China

MP20-16 68Ga-PSMA-11 PET/CT VS 18F-FLUCICLOVINE PET/CT: A CASE SERIES IN PROSTATE CANCER PATIENTS WITH BIOCHEMICAL RECURRENCE
Fuad Elkhoury*, Jeremie Calais, Johannes Czernin, Wolfgang Fendler, Ken Herrmann, Matthias Elber, Francesco Ceci, Robert Reiter, Leonard Marks, Los Angeles, CA

MP20-17 CENTRAL ABDOMINAL UPTAKE ON INDIUM-111 CAPROMAB PENDETIDE IMAGING: A POWERFUL PROGNOSTIC INDICATOR FOR PROSTATE CANCER IN HIGH-RISK PATIENTS AND IN THE SETTING OF BIOCHEMICAL RECURRENCE
Goran Rac, Shepherd Caitlin*, Sarah Starosta, Barry Keane, Sam Keane, William Riefer, Thomas Keane, Charleston, SC

MP20-18 SEMI-AUTOMATIC SEGMENTATION ANALYSIS OF DIFFUSION-WEIGHTED MRI AS AN IMAGING BIOMARKER FOR HISTOLOGICAL GRADE OF BLADDER CANCER
Kasumi Kaneko*, Soichiro Yoshida, Taro Takahara, Shugo Yajima, Tsuyoshi Sakamoto, Tokyo, Japan, Thomas Kwee, Groningen, Netherlands, Yuk Arita, Minato Yokoyama, Junichiro Ishioka, Yoh Matsuoka, Kazutaka Saito, Kazunori Kihara, Yasuhisa Fuji, Tokyo, Japan

MP20-19 A PROSPECTIVE DIAGNOSTIC ACCURACY STUDY OF PROSTATE IMAGING REPORTING AND DATA SYSTEM VERSION 2 ON 3 TESLA MULTIPARAMETRIC MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING IN DETECTING PROSTATE CANCER WITH WHOLE-MOUNT PATHOLOGY
Gianluca Giannarini*, Rossano Girometti, Stefano Sioletic, Udine, Italy, Marta Rossanese, Catania, Italy, Vito Palumbo, Messina, Italy, Mattia Calandriello, Alessandro Crestani, Chiara Zuiiani, Udine, Italy, Vincenzo Ficarra, Messina, Italy

MP20-20 BETTER PREDICTION OF TUMOR AGGRESSIVENESS IN MRI/ULTRASOUND-FUSION-BIOPSY COMPARED TO SYSTEMATIC PROSTATE BIOPSY
Angelika Borkowetz*, Ivan Platzek, Marieta Toma, Theresa Renner, Michael Froehner, Stefan Zastrow, Manfred Wirth, Dresden, Germany

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

*Presenting author
MP21-01 MOLECULAR TUMOR PROFILING TO IDENTIFY MECHANISMS LINKING STATINS WITH LOWER RISK OF LETHAL PROSTATE CANCER

MP21-02 PROSTATE CANCER INCIDENCE AND MORTALITY AMONG MEN USING STATINS AND NON-STATIN LIPID-LOWERING MEDICATIONS

MP21-03 SERUM LIPID PROFILE AT TIME OF ANDROGEN DEPRIVATION THERAPY AND RISK OF CASTRATION-RESISTANT PROSTATE CANCER: RESULTS FROM THE SEARCH DATABASE
Shweta Dambal, Los Angeles, CA, Lauren Howard, Durham, NC, Emma Allott, Chapel Hill, NC, William Aronson, Los Angeles, CA, Christopher Kane, San Diego, CA, Christopher Amling, Portland, OR, Matthew Cooperberg, San Francisco, CA, Martha Terris, Augusta, GA, Stephen Freedland*, Los Angeles, CA

MP21-04 NON-ALCOHOLIC FATTY LIVER DISEASE IN MEN UNDERGOING ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER
Philipp Gild*, Hamburg, Germany, Alexander P. Cole, Boston, MA, Nicolas von Landenberg, Herne, Germany, Anna Krasnova, Maxine Sun, Lorelei A. Mucci, Stuart R. Lipsitz, Boston, MA, Felix K.H. Chun, Frankfurt, Germany, Paul L. Nguyen, Shehzad Basaria, Adam S. Kibel, Quoc-Dien Trinh, Boston, MA

MP21-05 IS THERE SUCH THING AS FAT AND FIT WHEN IT COMES TO PROSTATE CANCER RISK? INTERPLAY BETWEEN BMI, EXERCISE, AND PROSTATE CANCER RISK
Jamie Michael*, Taofik Oyekunde, Lauren Howard, Amanda DeHoedt, Charlotte Bailey, Durham, NC, Stephen Freedland, Los Angeles, CA

MP21-06 ASSOCIATION BETWEEN ENVIRONMENTAL QUALITY AND PROSTATE CANCER STAGE AT DIAGNOSIS
David T. Greenwald*, Jyotsna S. Jagai, Chicago, IL, Achal P. Patel, Chapel Hill, NC, Daniel M. Moreira, Michael R. Abern, Chicago, IL

MP21-07 PREDICT: PROSTATE – A NOVEL PROGNOSTIC MODEL THAT ESTIMATES INDIVIDUAL SURVIVAL IN NEWLY DIAGNOSED PRIMARY NON-METASTATIC PROSTATE CANCER
David Thurtle*, Cambridge, United Kingdom, David Greenberg, Fulbourn, United Kingdom, Hong Huang, Lui Shong Lee, Singapore, Singapore, Paul Pharao, Vincent Gnanapragasam, Cambridge, United Kingdom

MP21-08 OTHER CAUSE MORTALITY IS HIGHER IN HIGH RISK VERSUS LOW AND INTERMEDIATE RISK PROSTATE CANCERS
Michael Feuerstein*, New York, NY, Rehana Rasul, Paola DiMarzio, Anne Golden, Great Neck, NY

MP21-09 WHO DIES FROM PROSTATE CANCER? A COMPREHENSIVE ANALYSIS OF A LARGE SERIES OF PATIENTS TREATED WITH RADICAL PROSTATECTOMY WITH LONG-TERM FOLLOW-UP
Nazaren Suardi*, Nicola Fossati, Giorgio Gandaglia, Paolo Dell’Oglio, Armando Stabile, Emanuele Zaffuto, Carlo Andrea Bravi, Elio Mazzone, Fabio Muttin, Manuela Tutola, Federico Dehò, Milan, Italy, Rocco Damiano, Catanzano, Italy, Firas Abdollah, Detroit, MI, Pierre I. Karakiewicz, Montreal, Canada, Francesco Montorsi, Alberto Briganti, Milan, Italy

MP21-10 THE VARIABLE IMPACT OF RACE AND MORE IMPORTANT FACTORS ON PROSTATE CANCER MORTALITY
Heidi Hanson, Christopher Martin*, Brock O’Neil, Salt Lake City, UT, Erik Mayer, Los Angeles, CA, Claire Leiser, William Lowrance, Salt Lake City, UT

MP21-11 IS LOW SOCIOECONOMIC STATUS ASSOCIATED WITH WORSE TUMOR BIOLOGY FOR MEN WITH PROSTATE CANCER?
Adam Weiner*, Chicago, IL, Mohammed Alshalafa, Elai Davicioni, Nicholas Erho, Nick Fishbane, Vancouver, Canada, Edward Schaeffer, Chicago, IL

MP21-12 ONCOLOGICAL OUTCOMES NODE POSITIVE PROSTATE CANCER AFTER RADICAL PROSTATECTOMY
Souhil LEBDAI*, Angers, France, Amy Tin, Ricardo Alvim, Daniel Sjoberg, Karim Touijer, New York, NY
MP21-13 ASSESSING THE 20-YEAR OUTCOMES OF LYMPH NODE POSITIVE PROSTATE CANCER PATIENTS: A PLEA FOR LIFELONG FOLLOW-UP

MP21-14 STAGE-MIGRATION AND SURVIVAL OF LYMPH NODE POSITIVE PROSTATE CANCER PATIENTS: A COMPREHENSIVE TREND ANALYSES OF SURGICALLY TREATED MEN OVER THE LAST TWO DECADES

MP21-15 WHEN CAN BIOCHEMICAL RECURRENCE BE CONSIDERED A SURROGATE FOR HARDER CLINICAL ENDPOINTS IN HIGH RISK PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY? RESULTS FROM A LARGE, MULTI-INSTITUTIONAL, LONG-TERM ANALYSES
Emanuele Zaffuto*, Marco Bianchi, Giorgio Gandaglia, Nicola Fossati, Paolo Dell'Oglio, Milan, Italy, Lorenzo Tosco, Leuven, Belgium, Paolo Gontero, Torino, Italy, R. Jeffrey Kerns, Rochester, MN, Piotr Chloda, Krakow, Poland, Felix KH Chun, Hamburg, Germany, Christian Gratze, Munich, Germany, Markus Graefen, Derya Tilki, Hamburg, Germany, Burkhard Kneitz, Wurzburg, Germany, Gianislvio Marchioro, Novara, Italy, Rafael Sanchez-Salas, Paris, France, Bertrand Tombal, Brussel, Belgium, Henk Van Der Poel, Amsterdam, Netherlands, Jocheen Waltz, Marseille, France, Pierre I. Karakiewicz, Montreal, Canada, Hein Van Poppel, Leuven, Belgium, Martin Spahn, Bern, Switzerland, Francesco Montorsi, Alberto Briganti, Milan, Italy

MP21-16 ASSOCIATIONS OF GENETIC POLYMORPHISMS IN SLCO TRANSPORTERS WITH CLINICAL AGGRESSIVENESS OF PROSTATE CANCER IN THE NORTH CAROLINA-LOUISIANA PROSTATE CANCER PROJECT
Li Tang*, Qianqian Zhu, Buffalo, NY, Jeannette Benson, Chapel Hill, NC, Jack Taylor, Research Triangle, NC, Gary Smith, Elena Pop, Gissou Azabdaftari, James Mohler, Yue Wu, Buffalo, NY

MP21-17 BLACK RACE PREDICTS SIGNIFICANT PROSTATE CANCER INDEPENDENT OF CLINICAL SETTING, AND CLINICAL AND SOCIOECONOMIC RISK FACTORS: EVIDENCE FOR A BIOLOGICAL BASIS OF DISPARITIES
Oluwarotimi Nettey*, Austin Walker, Mary Kate Keeter, Aishwarya Nugooru, Chicago, IL, Iman Martin, Bethesda, MD, Maria Ruden, Pooja Gogana, Michael Dixon, Chicago, IL, Tijani Osumi, Miramur, FL, Courtney Hollowell, Roohollah Sharifi, Michael Abear, Peter Gann, Marin Sekosan, Ximing Yang, William Catalonia, Joshua Meeks, Andre Kajdacsy-Balla, Virgilia Macias, Chicago, IL, Rick Kittles, Duarte, CA, Adam Murphy, Chicago, IL

MP21-18 PROSTATE CANCER PRESENTATION, TREATMENT SELECTION, AND OUTCOMES AMONG MEN WITH HIV/AIDS: A CLINICAL STAGE AND AGE-MATCHED ANALYSIS
Maria Ruden*, Christopher Olivares, Matthew Fakhoury, Patricia Vidal, Courtney Hollowell, Sarah Pesuta, Chicago, IL

MP21-19 THE PREVALENCE AND BIOPSYCHOSOCIAL PREDICTORS OF SUICIDALITY IN MEN WITH PROSTATE CANCER
Jason Izard*, D. Robert Siemens, Phyllicia Verreault, Angela Black, Dean Tripp, Kingston, Canada

MP21-20 ANTIDEPRESSANT USE BY MEN UNDERGOING TREATMENT FOR LOCALIZED PROSTATE CANCER: A POPULATION BASED COHORT STUDY
Rano Matta*, Christopher J.D. Wallis, Amanda Hird, Erin Dvorani, Zachary Klaassen, Girish Kulkarni, Ronald T. Kodama, Sender Herschorn, Robert K. Nam, Toronto, Canada

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

*Presenting author
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>ABSTRACT TITLE</th>
</tr>
</thead>
</table>
| MP22-01         | TREND OF USE OF ADJUVANT AND SALVAGE RADIATION THERAPY AFTER RADICAL PROSTATECTOMY AND IMPACT ON LONG-TERM OUTCOMES: RESULTS FROM THREE HIGH VOLUME CENTERS OVER THE LAST TWO DECADES  

Marco Bandini*, Paolo Dell'Oglio, Nicola Fossati, Giorgio Gandaglia, Carlo Andrea Bravi, Emanuele Zaffuto, Armando Stabile, Elio Mazzone, Milan, Italy, Felix Preissler, Hamburg, Germany, Pierre I. Karakiewicz, Montreal, Canada, Matteo Soligo, Jeffrey R. Karnes, Rochester, MN, Markus Graefen, Derya Tilki, Hamburg, Germany, Francesco Montorsi, Alberto Briganti, Milan, Italy |
| MP22-02         | COMPARISON OF PATIENT-REPORTED OUTCOMES AFTER EXTERNAL BEAM RADIATION THERAPY AND COMBINED EXTERNAL BEAM WITH LOW-DOSE RATE BRACHYTHERAPY BOOST IN MEN WITH LOCALIZED PROSTATE CANCER  

Daniel Lee*, Zhiguo Zhao, Li-Ching Huang, Tatsuki Koyoma, Matthew Resnick, David Penson, Daniel Barocas, Nashville, TN, Karen Hoffman, Houston, TX |
| MP22-03         | UTILIZATION OF SALVAGE RADIATION THERAPY FOR BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY  

Scott Haukens*, Daniel E. Spratt, Ji Qi, Susan M. Linsell, Ann Arbor, MI, Michael L. Cher, Detroit, MI, Kurshid R. Ghani, David C. Miller, James E. Montie, Todd M. Morgan, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI |
| MP22-04         | HOW FREQUENTLY ARE PELVIC LYMPH NODES IRRADIATED IN MEN RECEIVING PRIMARY EXTERNAL BEAM RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER?  

Adam Weiner*, Chicago, IL, Jim Hu, New York, NY, Edward Schaeffer, Chicago, IL |
| MP22-05         | TESTING THE IMPACT OF ADJUVANT RADIOTHERAPY (ART) AFTER RADICAL PROSTATECTOMY (RP) ON OVERALL MORTALITY (OM) IN PROSTATE CANCER PATIENTS WITH PATHOLOGICALLY NODE POSITIVE DISEASE: A NATIONWIDE ANALYSIS  

Firas Abdollah*, Akshay Sood, Deepanshu Dalela, Jacob Keeley, Detroit, MI, Quoc-Dien Trinh, Boston, MA, Shaheen Alanees, Craig G. Rogers, James O. Peabody, Mani Menon, Detroit, MI |
| MP22-06         | SALVAGE RADIATION THERAPY FOR RECURRENT PROSTATE CANCER: CAN THE PROGNOSTIC GRADE GROUP SYSTEM INFORM TREATMENT TIMING?  

| MP22-07         | WHAT IS APPROPRIATE DEFINITION OF IPSS RESOLUTION WHICH CORRELATES CLOSELY WITH QOL RECOVERY AFTER PROSTATE BRACHYTHERAPY?  

Hidehisa Morii*, Tomoharu Fukumori, Kei Daizumoto, Keisuke Ozaki, Yoshito Kusuha, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Hiro-omi Kanayama, Tokushima, Japan |
| MP22-08         | IMPACT OF GREENLIGHT LASER VAPORIZATION ON PATIENTS WITH PROSTATE CANCER TREATED WITH IMAGE GUIDED RADIOTHERAPY  

| MP22-09         | ASSOCIATION BETWEEN ANDROGEN-DEPRIVATION THERAPY AND NON-PROSTATE CANCER MORTALITY AMONG MEN WITH NON-METASTATIC PROSTATE CANCER  

Christopher Wallis*, Toronto, Canada, Raj Satkunasivam, Houston, TX, Sender Herschorn, Calvin Law, Arun Seth, Ronald Kodama, Girish Kulkarni, Robert Nam, Toronto, Canada |
| MP22-10         | ONCOLOGIC OUTCOMES IN MEN WITH HIGH RISK PROSTATE CANCER ELIGIBLE FOR BOTH RADICAL PROSTATECTOMY AND RADIOTHERAPY: THE MD ANDERSON MULTIDISCIPLINARY CLINIC EXPERIENCE  

Chad A. Reichard*, Karen Hoffman, Pamela K. Allen, Houston, TX, Stephen B. Williams, Galveston, TX, Mary F. Achim, Deborah A. Kuban, Brian F. Chapin, Houston, TX |
MP22-11 NADIR TESTOSTERONE 20 NG/DL PREDICT TESTOSTERONE RECOVERY TO SUPRACASTRATE LEVEL IN PROSTATE CANCER PATIENTS WHO RECEIVED EXTERNAL BEAM RADIOTHERAPY
Akinori Takei*, Asahi, Japan, Shinichi Sakamoto, Takaaki Tamura, Chiba, Japan, Ken Wakai, Sakura, Japan, Yusuke Imamura, Chiba, Japan, Hitoshi Yano, Sakura, Japan, Koji Kawamura, Takashi Imamoto, Akira Komiya, Chiba, Japan, Koichiro Akakura, Shinjuku, Japan, Tomohiko Ichikawa, Chiba, Japan

MP22-12 INFLUENCE OF HORMONE THERAPY AND TESTOSTERONE LEVEL ON ALL CAUSE SURVIVAL AFTER BRACHYTHERAPY FOR LOCALIZED PROSTATE CANCER
Nelson Stone*, Richard Stock, New York, NY

MP22-13 FUNCTIONAL AND PSYCHOLOGICAL COMPARATIVE AND PROSPECTIVE ANALYSIS OF PATIENTS WITH PROSTATE CANCER SUBMITTED TO RADICAL PROSTATECTOMY, EXTERNAL RADIOTHERAPY OR ACTIVE SURVEILLANCE
Martina Maggi*, ALESSANDRO SCIARRA, ALESSANDRO GENTILUCCI, STEFANO SALCICCIA, vincezno Gentile, Daniela Musio, Vincenzo Tombolini, Alessio Guandalini, ROME, Italy

MP22-14 DOES SPACING ORGANS AT RISK (SPACEOAR™) PLACEMENT ADEQUATELY PROVIDE UNIFORM PROSTATE-RECTUM SEPARATION?
Anojan Navaratnam*, Jameson Cumskey, Robert Ferrigni, Mitchell Humphreys, Phoenix, AZ

MP22-15 LONG-TERM ONCOLOGICAL AND FUNCTIONAL OUTCOMES SUPPORT USE OF LOW DOSE RATE BRACHYTHERAPY IN YOUNG MEN (<60 YEARS) WITH LOCALIZED PROSTATE CANCER
Jared S. Winoker*, Richard G. Stock, Nelson N. Stone, New York, NY

MP22-16 TRIFECTA OUTCOMES FOR MEN WITH LOCALIZED PROSTATE CANCER AFTER TREATMENT WITH LOW-DOSE-RATE BRACHYTHERAPY
Marissa Kent*, Jared Winoker, Richard Stock, Nelson Stone, New York, NY

MP22-17 17-YEAR CAUSE-SPECIFIC SURVIVAL FOLLOWING PERMANENT PROSTATE BRACHYTHERAPY
Nelson Stone*, Richard Stock, New York, NY

MP22-18 RISK OF SECONDARY BLADDER CANCER AFTER HIGH DOSE RATE BRACHYTHERAPY FOR PROSTATE CANCER
Yoshiyuki Miyaji*, Tota Nakatsuk, Hiroyasu Takasaki, Seiitsu Kin, Shin Ohiha, Masahiro Fujita, Shinjiro Shimizu, Shohei Tsukimori, Mikako Kaifu, Ryoei Hara, Tomohiro Fuji, Atsushi Nagai, Kurashiki, Japan

MP22-19 PREDICTION AND STRATIFICATION OF THE BIOCHEMICAL RECURRENCE IN PATIENTS WITH HIGH-RISK PROSTATE CANCER AFTER LOW DOSE RATE PERMANENT SEED IMPLANTATION
Yu Ozawa*, Masanori Hasegawa, Noriaki Santo, Yasuto Yagi, Toru Nishiyama, Ryo Yabusaki, Keisuke Aoki, Ken Nakamura, Choichiro Ozu, Kazuhiro Toya, Masanori Yorozu, Shiro Salto, Toyko, Japan

MP22-20 THE IMPACT OF ADJUVANT RADIATION THERAPY AFTER RADICAL PROSTATECTOMY ON LONG-TERM OUTCOMES

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
MP23-04 DISRUPTION OF AFFERENT INNERVATION OF THE CANINE BLADDER INCREASES SUSCEPTIBILITY TO URINARY TRACT INFECTIONS THROUGH MODULATION OF UROTHELIAL NADPH OXIDASE (NOX)-ASSOCIATED OXIDATIVE STRESS
Nagat Frara*, Danielle M. Salvadeo, Ekta Tiwari, Michael Mazzei, Alan S. Braverman, Mary F. Barbe, Philadelphia, PA, Changhao Wu, Guildford, United Kingdom, Michael R. Ruggieri, Sr., Philadelphia, PA

MP23-05 DEVELOPMENT OF NOVEL KNOCK-IN MICE PROVIDES DIRECT EVIDENCE THAT UROPLAKIN IA IS THE UROTHELIAL RECEPTOR FOR TYPE 1-PILIATED UROPATHOGENIC E. COLI (UPEC)
Yan Liu*, Ellen Shapiro, Herbert Lepor, Tung-Tien Sun, Xue-Ru Wu, New York, NY

MP23-06 AN UTILIZATION OF NEXT GENERATION SEQUENCING OF URINE SAMPLES FOR MONITORING OF URINARY TRACT INFECTION IN PATIENTS WITH NEUROGENIC BLADDER
Vladimir Mouraviev*, Davenport, FL, Michael W. McDonald, Celebration, FL

MP23-07 CLINICAL PRACTICE GUIDELINE: UNCOMPLICATED BACTERIAL COMMUNITY ACQUIRED URINARY TRACT INFECTION IN ADULTS—EPIDEMIOLOGY, DIAGNOSIS, TREATMENT, AND PREVENTION
Jennifer Kranz*, Eschweiler, Germany, Stefanie Schmidt, Berlin, Germany, Cordula Lebert, Nürnberg, Germany, Laila Schneidewind, Greifswald, Germany, Guido Schmiemann, Bremen, Germany, Florian Wagenlehner, Giessen, Germany

MP23-08 LACK OF UNIFORMITY AMONG UNITED STATES GUIDELINES FOR DIAGNOSIS & MANAGEMENT OF ACUTE, UNCOMPLICATED CYSTITIS
Lauren N. Wood, Andrew R. Medendorp*, Melissa Markowitz, Shiloma Raz, David A. Haake, Ja-Hong Kim, Los Angeles, CA

MP23-09 COMPARISON OF POSTOPERATIVE CATHETER-ASSOCIATED URINARY TRACT INFECTION (CAUTI) RATES IN THE UROLOGIC PATIENT WITH A SUPRAPUBIC CATHETER VERSUS TRANSURETHRAL CATHETER
Jason Warncke*, Brittan Sulphin, John Hohenmeyer, E. David Crawford, Brian Flynn, Denver, CO

MP23-10 INCREASING INTERNATIONAL PROSTATE SYMPTOM SCORE PREDICTS PRESENCE OF BACTERIA WITHIN THE BLADDER IN THE ABSENCE OF URINARY TRACT INFECTION
Petar Bajic*, Michelle Van Kuiken, Bethany Burge, Eric Kirshenbaum, Alan Wolfe, Cara Joyce, Kristin Baldea, Larissa Bresler, Ahmer Farooq, Maywood, IL

MP23-11 REGULATION OF CONJUGATIVE TRANSFER OF $\beta$-LACTAM RESISTANCE FROM UROPATHOGENIC STRAINS OF ESCHERICHIA COLI
Tatyana A Sysoeva*, Youlim Kim, Lingchong You, Durham, NC

MP23-12 A CONTEMPORARY VIEW OF ANTIBIOTIC RESISTANCE IN UROLOGY IN THE UNITED KINGDOM
Emma Coleman, Hugo Donaldson, Ranan DasGupta*, London, United Kingdom

MP23-13 ANTIMICROBIAL RESISTANCE AND EXTENDED SPECTRUM BETA-LACTAMASE AGENTS IN URINARY TRACT INFECTIONS: A SERIOUS PROBLEM IN THE NORTH OF MEXICO
José Iván Robles-Torres*, Lauro Gómez-Guerra, Elvira Garza-González, Soraya Mendoza-Olazarán, Samantha Flores-Treviño, Rolando Delgado-Balderas, Adrián Gutiérrez-González, Monterrey, Mexico

MP23-14 RISK AND PROTECTIVE FACTORS FOR RECURRENT URINARY TRACT INFECTION FOLLOWING PERCUTANEOUS NEPHROLITHOTOMY
Chin-Fong AU*, Chung-You Tsai, Shiu-Dong Chung, New Taipei City, Taiwan

MP23-15 TRENDS OF QUINOLONE-RESISTANT AND/OR ESBL PRODUCING ESCHERICHIA COLI ISOLATED FROM COMMUNITY-ACQUIRED URINARY TRACT INFECTIONS
Yoshitsugu Nasu*, Daisuke Tanaka, Noriko Kosaka, Morito Sugimoto, Atsushi Takamoto, Okayama, Japan

MP23-16 ULTIMATE FATE OF RECURRENT CYSTITIS CAUSED BY ESBL-PRODUCING E.COLI; A PROSPECTIVE LONGITUDINAL STUDY
Sun Tae Ahn*, Hyeong Guk Jeong, Tae Yong Park, Jong Wook Kim, Hong Seok Park, Du Geon Moon, Jeong Gu Lee, Mi Mi Oh, Seoul, Korea, Republic of

MP23-17 CYTOCHROME BD-I IS A POTENTIAL TARGET FOR ERADICATING UROPATHOGENIC E. COLI BIOFILMS
Allison Eberly*, Connor Beebout, John Brannon, Shuvro De, Madison Fitzgerald, Corrine Baroni, Douglass Clayton, Maria Hadjifrangiskou, Nashville, TN

MP23-18 CLINICAL STUDY UPDATE ON A NOVEL RIBOSOMAL RNA-BASED RAPID DIAGNOSTIC METHOD TO DETECT, IDENTIFY AND ASSESS ANTIBIOTIC SUSCEPTIBILITY OF UROPATHOGENS
Victoria Scott*, Lauren Wood, Melissa Markowitz, Seth A. Cohen, Andrew R. Medendorp, Colin Halford, Gabriel Monti, Bernard Churchill, David A. Haake, Ja-Hong Kim, Los Angeles, CA
MP23-19 THE ANALYSIS OF BACTERIAL SPECTRUM AND ANTIBIOTIC RESISTANCE OF UROPATHOGENS ISOLATED FROM URINARY STONE PATIENTS
Wenqi Wu*, Dong Chen, Yuyan Zhang, Jian Huang, Xiongfa Liang, Tao Zeng, Chuangxin Lan, Xiaolu Duan, Guohua Zeng, Guangzhou, China, People’s Republic of, Hans-goran Tiselius, Stockholm, Sweden

MP23-20 PROBIOTICS IN RECURRENT UTIS: COLLECTIVE INFORMATION ON COMMERCIALLY AVAILABLE PRODUCTS
Lyfong Lor*, Daniel Igel, Majid Mirzazadeh, Winston-Salem, NC

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Friday, May 18, 2018
3:30 pm - 5:30 pm
Moderated Poster Session 24
STONE DISEASE: BASIC RESEARCH & PATHOPHYSIOLOGY II
Room 2005 @ MCC West
Moderators: Dean Assimos, Aaron Miller and Tanecia Mitchell

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP24-01</td>
<td>COMPARISON OF SCORES FROM THE VALIDATED PPLA RENAL PAPILLARY GRADING SYSTEM TO STONE ANALYSIS PROVIDES INSIGHTS TO STONE PATHOGENESIS</td>
</tr>
<tr>
<td>MP24-02</td>
<td>CALCIUM OXALATE MONOHYDRATE STONE MATRIX PROTEIN COMPARISON BETWEEN SPECIES. ARE CATS THE BEST ANIMAL MODEL FOR CALCIUM OXALATE STONES?</td>
</tr>
<tr>
<td>MP24-03</td>
<td>FECAL TRANSPLANT MODULATES URINARY STONE RISK FACTORS IN AN ANIMAL MODEL</td>
</tr>
<tr>
<td>MP24-04</td>
<td>URINARY OXALATE EXCRETION IN OBESE MOUSE MODEL</td>
</tr>
<tr>
<td>MP24-05</td>
<td>THE URINE AND STONE MICROBIOME IN KIDNEY STONE PATIENTS</td>
</tr>
<tr>
<td>MP24-06</td>
<td>CYCLOPHILIN D PARTICIPATION IN THE PROMOTION OF KIDNEY STONE FORMATION VIA OXIDATIVE STRESS</td>
</tr>
<tr>
<td>MP24-07</td>
<td>PRO-INFLAMMATORY AND IMMUNE-ACTIVE RESPONSES PREDOMINANTLY LEADING TO RANDALL’S PLAQUE FORMATION ON CALCIUM PHOSPHATE STONE</td>
</tr>
<tr>
<td>MP24-08</td>
<td>IDENTIFICATION OF A NOVEL GENOMIC MUTATIONS THROUGH A NEXT-GENERATION SEQUENCE AMONG JAPANESE CYSTINURIA PATIENTS</td>
</tr>
<tr>
<td>MP24-09</td>
<td>THE UPPER AND LOWER TRACT URINARY MICROBIOMES OF STONE FORMERS ARE SIMILAR: A PILOT STUDY</td>
</tr>
<tr>
<td>MP24-10</td>
<td>WAVELENGTH AND PULSE SHAPE EFFECTS ON STONE FRAGMENTATION OF LASER LITHOTRIPTERS</td>
</tr>
<tr>
<td>MP24-11</td>
<td>LONG-TERM TREATMENT OF VITAMIN D INSUFFICIENCY OR DEFICIENCY IN POSTMENOPAUSAL WOMEN WITH HYPERCALCIURIA DOES NOT INCREASE URINARY CALCIUM EXCRETION</td>
</tr>
</tbody>
</table>

*Presenting author
MP24-12 TRANSDIFFERENTIATION FROM WHITE ADIPOCYTES TO BEIGE CELLS PREVENTS KIDNEY STONE FORMATION
Teruaki Sugino*, Kazumi Taguchi, Rei Unno, Shuzo Hamamoto, Ryosuke Ando, Atsushi Okada, Nagoya, Japan, Tohru Mogami, Komono, Japan, Keiichi Tozawa, Kenjiro Kohri, Takahiro Yasui, Nagoya, Japan

MP24-13 A NEW MOBILE APPLICATION FOR KIDNEY STONE PATIENTS
Benedikt Becker*, Hamburg, Germany, Nariman Gadzhiev, St. Petersburg, Russian Federation, Christopher Netsch, Hamburg, Germany, Marcin Popiolek, Örebro, Sweden, Alexey V. Pisarev, V. Obidnyak, S. Petrov, St. Petersburg, Russian Federation, Andreas J. Gross, Hamburg, Germany

MP24-14 SLC26A6 UNDERLIES VITAMIN D3 MEDIATED INTESTINAL OXALATE SECRETION AND KIDNEY CAOX CRYSTAL FORMATION VIA VDR-MIR-125B-SLC26A6 BASED MECHANISMS
Kun Tang, Haoran Liu*, Tao Ye, Xifeng Sun, Hua Xu, Zhangqun Ye, Wuhan, China, People’s Republic of

MP24-15 SURFACE-TREATED PELLETHANE: COMPARATIVE QUANTIFICATION OF ENCRUSTATION IN ARTIFICIAL URINE SOLUTION
Kevin Guan, Roshan Patel*, Orange, CA, Buddy Ratner, Seattle, WA, Zhamshid Okhunov, Kamaljot Kaler, Jaime Landman, Ralph Clayman, Orange, CA

MP24-16 THE ANALYSIS OF UROLITHIASIS INCIDENCE IN THE CONTRALATERAL KIDNEY OF UNINEPHRECTOMY PATIENTS
Xie Tianpeng, Ganzhou, China, People’s Republic of, Xu Qingsuan, Huang Xiaobo, Beijing, China, People’s Republic of, Zou xiaofeng*, Zhang Guoxi, Ganzhou, China, People’s Republic of, Xiong Liulin, Beijing, China, People’s Republic of

MP24-17 SALIVARY AND KIDNEY STONES: INSIGHTS INTO PATHOLOGIC BIOMINERALIZATION
Scott Wiener*, Nicholas Jaber, Sofia Inbarren, Misun Kang, Jolie Chang, Marshall Stoller, Sunita Ho, San Francisco, CA

MP24-18 ARCHITECTURE GUIDED FLUID PROPULSION IN A SIMULATED NEPHRON
Scott Wiener*, Misun Kang, Marshall Stoller, Sunita Ho, San Francisco, CA

MP24-19 ENTERAL NUTRITION FORMULAS WITH HIGHER OXALATE CONTENT MAY CONTRIBUTE TO HIGHER OXALATE ABSORPTION AND URINARY EXCRETION IN PATIENTS REQUIRING NUTRITION SUPPORT
Kristina L. Penniston*, Eve A. Palmer, Riley C. Medenwald, Sarah N. Johnson, Leema M. John, David J. Beahensky, Ibrahim A. Saeed, Madison, WI

MP24-20 COMPONENTS OF URINARY STONES ACTIVATE THE NLRP3 INFLAMMASOME IN BLADDER UROTHELIUM
Patrick Leidig*, Francis Hughes, J. Todd Purves, Durham, NC

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Friday, May 18, 2018
Podium Session 13
3:30 pm - 5:30 pm
GENERAL & EPIDEMIOLOGICAL TRENDS & SOCIOECONOMICS: ADVANCED PRACTICE PROVIDERS
Room 2022 @ MCC West
Moderators: Claus Roehrborn, Deepak Kapoor and Heather Schultz

<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>USE OF ADVANCED PRACTICE PROVIDERS TO IMPROVE PATIENT ACCESS IN UROLOGY</td>
<td>3:30</td>
<td>PD13-01</td>
<td>Melody Chen*, Jonathan Kiechle, Cleveland, OH, Zachary Maher, Christopher Gonzalez, Cleveland, OH</td>
</tr>
<tr>
<td>PATIENT SATISFACTION AND PREFERRED CHOICE OF PROVIDER: ADVANCED PRACTICE PROVIDERS VERSUS UROLOGISTS</td>
<td>3:40</td>
<td>PD13-02</td>
<td>Jennifer Lindelow, Hope Birdsong, Cassandra Hepp, James Baumgardner, Maggie Dear, Arielle McKee, Brooks Goodgame, Cheryl Castleberry, Donald Finnerty, Christopher Filson, Muta M. Issa*, Decatur, GA</td>
</tr>
<tr>
<td>ADVANCED PRACTICE PROVIDERS IN UROLOGIC CARE IN THE UNITED STATES</td>
<td>3:50</td>
<td>PD13-03</td>
<td>Raymond Fang*, Lithicum, MD, Patrick McKenna, Madison, WI, J. Stuart Wolff, Jr., Austin, TX, William Meeks, Lithicum, MD, Brad Erickson, Salt Lake City, IA, Christopher Gonzalez, Cleveland, OH, Steve Schlossberg, Walnut Creek, CA, J. Quentin Clemens, Ann Arbor, MI</td>
</tr>
<tr>
<td>DEFINING PRODUCTIVITY BENCHMARKS AND FINANCIAL MARGINS FOR ADVANCED PRACTICE PROVIDERS IN UROLOGY</td>
<td>4:00</td>
<td>PD13-04</td>
<td>Melody Chen*, Jonathan Kiechle, Cleveland, OH, Zachary Maher, Christopher Gonzalez, Cleveland, OH</td>
</tr>
</tbody>
</table>
4:10 PD13-05 UROLOGIC CARE FOR THE ADULT SPINA BIFIDA POPULATION
Philip Cheng*, Boston, MA, Courtney Rowe, Seattle, WA, Steven Chang, Jairam Eswara, Boston, MA

4:20 PD13-06 PATIENT SATISFACTION WITH TELECYSTOSCOPY: USE OF REMOTE VIDEO TECHNOLOGY FOR BEDSIDE FLEXIBLE CYSTOSCOPY
Alexander D. Tapper*, Harjivan S. Kohli, Adam J. Folbe, Jay B. Hollander, Frank N. Burks, Royal Oak, MI

4:30 PD13-07 THE MAJORITY OF OVERACTIVE BLADDER PATIENTS DO NOT REQUIRE SPECIALIST CARE
Stephen Strahan*, Camille Charbonneau, Richard Baverstock, Trafford Crump, Kevin Carlson, Calgary, Canada

4:40 PD13-08 THE FREQUENCY OF AND ATTITUDES TOWARD CONDOM USE AMONG ADULTS IN KOREA: A NATIONAL POPULATION-BASED STUDY
Sun Tae Ahn*, Hyeong Guk Jeong, Tae Yong Park, Jong Wook Kim, Je Jong Kim, Du Geon Moon, Seoul, Korea, Republic of

4:50 PD13-09 ACUTE KIDNEY INJURY AFTER UROLOGIC SURGERIES
Shahab Bozorgmehr*, Gainesville, FL, Scott Gilbert, Tampa, FL, Robert L. Cook, Rebecca Beyth, Tezcan Ozrazgat- Baslant, Azra Bihorac, Muna Canales, Gainesville, FL

5:00 PD13-10 IMPACT OF METFORMIN ON SERUM PROSTATE-SPECIFIC ANTIGEN LEVELS: DATA FROM THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY 2007-2008
Jee Soo Park*, Yoon Soo Ha, Kwang Suk Lee, Hyun Kyu Ahn, Jee Soo Ha, Won Sik Ham, Byung Ha Chung, Kyo Chul Koo, Seoul, Korea, Republic of

5:10 PD13-11 THE ASSOCIATION BETWEEN RACE AND FRAILTY IN OLDER ADULTS PRESENTING TO A BENIGN UROLOGIC PRACTICE
Samuel Washington, III*, Kathryn Quanstrom, Mark Bridge, Emily Fintayson, Louise Walter, Sima Porten, Anne Suskind, San Francisco, CA

5:20 PD13-12 FELLOWSHIP TRAINING IN UROLOGY: AN ANALYSIS OF ROBOTIC-ASSISTED PARTIAL NEPHRECTOMY (RAPN)
Olamide Omidele*, Natan Davoudzadeh, New York, NY, Michael Palese, New York, NY

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Friday, May 18, 2018
Podium Session 14
3:30 pm - 5:30 pm

PROSTATE CANCER: ADVANCED (INCLUDING DRUG THERAPY) II
Room 2011 @ MCC West
Moderators: Daniel Petrylak, David Crawford and Giorgio Gandaglia

<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| PD14-01   | 3:30 | CLINICAL EXPERIENCE WITH LUTETIUM 177-LABELED PSMA-I&T FOR RADIOLIGAND THERAPY IN 100 CONSECUTIVE PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Matthias Heck*, Sebastian Schwaiger, Karina Knorr, Margitta Retz, Tobias Maurer, Friederike Janssen, Calogero D'Alessandria, Munich, Germany, Hans-Jürgen Wester, Gauting, Germany, Jürgen Gschwend, Markus Schwaiger, Robert Tauber, Matthias Eiber, Munich, Germany |

<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| PD14-03   | 3:50 | PREDICTION OF TREATMENT RESISTANCE UNDER ABIRATERONE AND ENZALUTMIDE VIA DETECTION OF AR-V7 IN PERIPHERAL WHOLE BLOOD OF CASTRATION-RESISTANT PROSTATE CANCER PATIENTS
Anna-Katharina Seitz, Silvia Thoene, Andreas Bietenbeck, Roman Nawroth, Robert Tauber, Mark Thalgott, Sebastian Schmid, Ramona Secci, Margitta Retz, Jürgen Gschwend, Jürgen Ruland, Christof Winter, Matthias Heck*, Munich, Germany |

<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| PD14-04   | 4:00 | CHEMILUMINESCENT IMMUNOAASSAYS SHOULD NOT BE USED TO MEASURE SERUM TESTOSTERONE IN PROSTATE CANCER PATIENTS UNDERGOING ANDROGEN DEPRIVATION THERAPY
Mercè Cuadras, Enric Miret, Ricardo López, Imma Comas, Roser Ferrer, Jacques Planas, Ana Celma, Xavier Maldonado, Joan Carles, Lucas Regis, Juan Morote*, Barcelona, Spain |

*Presenting author
4:10 PD14-05 NEOADJUVANT ENZALUTAMIDE AND ANDROGEN DEPRIVATION IN HIGH-RISK PROSTATE CANCER: INITIAL IMAGING AND SURGICAL FINDINGS FROM A PHASE II CLINICAL TRIAL

Samuel Gold*, Sahwn Marhamati, Bethesda, MD, Stephanie Harmon, Frederick, MD, Jonathan Bloom, Fatima Karzai, Graham Hale, Kareem Rayn, Vik Sabarwal, Sherif Mehravand, Marcin Czarniecki, Clayton Smith, David VanderWeele, William Dahut, Baris Turkbey, Peter Pinto, Bethesda, MD

4:20 PD14-06 SIPULEUCELT (SIP-T) WITH ENZALUTAMIDE (ENZ) (STRIDE): CLINICAL OUTCOMES IN PATIENTS (PTS) WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) BY BASELINE (BL) PROSTATE-SPECIFIC ANTIGEN (PSA) QUARTILES


4:30 PD14-07 REAL-TIME IMAGING DEMONSTRATING T-CELL MEDIATED DESTRUCTION OF PROSTATIC ACID PHOSPHATASE (PAP)-EXPRESSING CELLS IN PATIENTS (PTS) TREATED WITH SIPULEUCELT (SIP-T)


4:40 PD14-08 ROLE OF INTEGRATIVE EQTL-BASED ANALYSES REVEALED THE RISK LOCI IN PATIENTS WITH PROSTATE CANCER UNDERGOING ANDROGEN DEPRIVATION THERAPY

Qiang Liu*, Jian Kang, Jun Qi, Shanghai, China, People’s Republic of

4:50 PD14-09 CIRCULATING TUMOR DNA PRIOR TO THERAPY INITIATION IN DE NOVO METASTATIC PROSTATE CANCER

Werner J. Struss*, Gillian Vandekerkhove, Matti Annala, Kevin Beja, Kim N. Chi, Martin E. Gleave, Alexander W. Wyatt, Vancouver, Canada

5:00 PD14-10 VALIDITY OF THE NATIONAL DEATH INDEX TO ACCURATELY CODE THE DATE OF DEATH AND DEATHS FROM PROSTATE CANCER, IN MEN HAVING UNDERGONE PROSTATECTOMY

Drew Moghanaki*, Richmond, VA, Lauren Howard, Amanda De Hoedt, Durham, NC, William Aronson, Los Angeles, CA, Christopher Kane, San Diego, CA, Christopher Amling, Portland, OR, Matthew Cooperberg, San Francisco, CA, Martha Terris, Augusta, GA, Stephen Freedland, Los Angeles, CA

5:10 PD14-11 HEALTH-RELATED QUALITY OF LIFE (HRQL) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) TREATED WITH CABAZITAXEL (CBZ) IN A PROSPECTIVE OBSERVATIONAL STUDY (CAPRISTANA)

Angelika Pichler, Leoben, Austria, Gisoo Barnes, Cambridge, MA, Jana Katolicka, Brno, Czech Republic, Hana Korunkova, Plzen, Czech Republic, Antoaneta Tomova, Plovdiv, Bulgaria, Marwan Ghosn, Fadi El Karak, Beirut, Lebanon, Irina Koroleva, Samara, Russian Federation, Joseph Makdessi, Beirut, Lebanon, Ayse Ozatilgan, Cambridge, MA, Simon Hitler, Chilly-Mazarin, France, Joan Carles*, Barcelona, Spain

5:20 PD14-12 SECONDARY OUTCOMES OF A PROSPECTIVE RANDOMIZED TRIAL OF DIETARY CARBOHYDRATE RESTRICTION FOR MEN INITIATING ANDROGEN DEPRIVATION THERAPY: CARBOHYDRATE AND PROSTATE STUDY I (CAPS1)

Stephen Freedland*, William Aronson, Los Angeles, CA, Lauren Howard, Jordan Smith, Durham, NC, Matthew Smith, Boston, MA, Jennifer Stout, Jennifer Allen, Daniel George, Andrew Armstrong, Brant Inman, Pao-Hwa Lin, Durham, NC

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| 3:30  | PD15-01| CHARACTERIZATION OF THE GENOMIC LANDSCAPE OF A PROSPECTIVE MUSCLE-INVASIVE BLADDER CANCER COHORT WITH A FOCUS ON SECONDARY VARIANT HISTOLOGY  
Vikram Narayan*, Minneapolis, MN, Ewan Gibb, Nicholas Erho, Andrea Cronican, Tyler Kolisnik, Elai Davicioni, San Diego, CA, Badrinath Konety, Minneapolis, MN |
| 3:40  | PD15-02| IMPACT OF LYMPHOVASCULAR INVASION AT TRANSURETHRAL RESECTION OF BLADDER TUMOR (TURBT) AND THE RISK OF LN METASTASIS AT SURGERY  
Ryan Werntz*, Zach Smith, Vignesh Packiam, Chris Riedinger, Norm Smith, Gary Steinberg, Chicago, IL |
| 3:50  | PD15-03| AN INTERVENTION TO IMPROVE BLADDER CANCER KNOWLEDGE AND TREATMENT DECISION MAKING IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER: A PILOT STUDY  
Nihal Mohamed*, Tung Ming Leung, Reza Mehrzarin, John Slakianos, Cynthia Knauer, New York, NY |
| 4:00  | PD15-04| ACCURACY OF ACS NSQIP® UNIVERSAL SURGICAL RISK CALCULATOR IN PREDICTING COMPLICATIONS FOLLOWING ROBOT-ASSISTED RADICAL CYSTECTOMY AT A NATIONAL COMPREHENSIVE CANCER CENTER  
Tomoki Terakawa*, Ahmed Aly Husseain, Youssef Ahmed, Paul May, Austin Miller, Zhe Jing, Luciano A. Nunez Bragayrac, Jared Cohen, Hijab Khan, Adam Cole, Omer Rana, Michelle Whittum, Renuka Kannapan, Christian Prechtl, Terrell Johnson, Qiang Li, Khurshid Guru, Buffalo, NY |
| 4:10  | PD15-05| EXTERNAL VALIDATION OF A DECISION-SUPPORT TOOL FOR BORDERLINE OPERABLE MUSCLE-INVASIVE BLADDER CANCER (MIBC) PATIENTS CHOOSING BETWEEN RADICAL CYSTECTOMY AND CHEMO-RADIOThERAPY  
Brian Baumann*, St. Louis, MO, Wei-Ting Hwang, Sharadha Srinivasan, Ronac Mamtani, David Vaughan, Leilei Xia, S. Bruce Malkowicz, Thomas Guzzo, John Christodoulouas, Philadelphia, PA |
| 4:20  | PD15-06| TIMING OF ADJUVANT CHEMOTHERAPY AND SURVIVAL FOLLOWING RADICAL CYSTECTOMY  
Joshua Jue*, Zachary Kroege, Tulay Koru-Sengul, Feng Miao, Kevin Moore, Mahmoud Alameddine, Chad Ritch, Mark Gonzalgo, Miami, FL |

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30</td>
<td>PD16-01</td>
<td>DO ISCHEMIA SPARING TECHNIQUES BENEFIT RENAL FUNCTION IN PATIENTS WITH STAGE III-V CHRONIC KIDNEY DISEASE UNDERGOING PARTIAL NEPHRECTOMY?</td>
</tr>
<tr>
<td>3:40</td>
<td>PD16-02</td>
<td>REEVALUATING WARM ISCHEMIA TIME AS A PREDICTOR OF RENAL FUNCTION OUTCOMES IN PATIENTS UNDERGOING ROBOTIC PARTIAL NEPHRECTOMY</td>
</tr>
<tr>
<td>3:50</td>
<td>PD16-03</td>
<td>OPEN, LAPAROSCOPIC AND ROBOTIC PARTIAL AND RADICAL NEPHRECTOMY: PRACTICE PATTERNS AND THE NEW STANDARD OF CARE</td>
</tr>
<tr>
<td>4:00</td>
<td>PD16-04</td>
<td>ANALYZING NATIONAL INCIDENCES AND PREDICTORS FOR OPEN CONVERSION DURING MINIMALLY INVASIVE PARTIAL NEPHRECTOMY</td>
</tr>
<tr>
<td>4:10</td>
<td>PD16-05</td>
<td>VARIABILITY IN PARTIAL NEPHRECTOMY OUTCOMES: DOES YOUR SURGEON MATTER?</td>
</tr>
<tr>
<td>4:20</td>
<td>PD16-06</td>
<td>A NEW PROPOSAL TO IMPROVE THE SURVEILLANCE OF RENAL CELL CARCINOMA PATIENTS AFTER SURGERY</td>
</tr>
<tr>
<td>4:30</td>
<td>PD16-07</td>
<td>IMPACT OF SURGICAL MARGIN STATUS AFTER PARTIAL NEPHRECTOMY FOR RENAL CELL CARCINOMA</td>
</tr>
<tr>
<td>4:40</td>
<td>PD16-08</td>
<td>INTERNATIONAL AND MULTI-INSTITUTIONAL ASSESSMENT OF FACTORS ASSOCIATED WITH PERFORMANCE AND QUALITY OF LYMPH NODE DISSECTION DURING RADICAL NEPHRECTOMY</td>
</tr>
<tr>
<td>4:50</td>
<td>PD16-09</td>
<td>PARTIAL NEPHRECTOMY CONVERTING TO RADICAL NEPHRECTOMY: IMPACT OF PATIENT AND SURGICAL FACTORS</td>
</tr>
<tr>
<td>5:00</td>
<td>PD16-10</td>
<td>HISTOLOGIC VARIANTS OF LOCALIZED RENAL CELL CARCINOMA AND VARIATION BY RACE: RESULTS FROM THE NATIONAL CANCER DATA BASE</td>
</tr>
<tr>
<td>5:10</td>
<td>PD16-11</td>
<td>LONG-TERM ONCOLOGIC OUTCOMES OF POSITIVE SURGICAL MARGINS FOLLOWING ROBOTIC PARTIAL NEPHRECTOMY</td>
</tr>
<tr>
<td>5:20</td>
<td>PD16-12</td>
<td>PROGNOSTIC EVALUATION OF PERINEPHRIC FAT, RENAL SINUS FAT, AND RENAL VEIN INVASION FOR PATIENTS WITH PATHOLOGIC STAGE T3A RENAL CELL CARCINOMA</td>
</tr>
</tbody>
</table>

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>V03-01</td>
<td>UNDERSTANDING NON-CONTACT LASER LITHOTRIPSY FOR DUSTING – THE POPCORN EFFECT: A VIDEO ANALYSIS</td>
</tr>
<tr>
<td></td>
<td>Ali Aldoukhi*, William Roberts, Timothy Hall, Khrushid Ghani, Ann Arbor, MI</td>
</tr>
<tr>
<td>V03-02</td>
<td>FIRST CLINICAL STUDY ON SUPERPULSE THULIUM FIBER LASER FOR LITHOTRIPSY</td>
</tr>
<tr>
<td>V03-03</td>
<td>TARGETING MICROBUBBLE ENHANCEMENT OF HOLMIUM LASER STONE ABLATION</td>
</tr>
<tr>
<td>V03-04</td>
<td>BENCH AND CLINICAL TESTING OF TWO SINGLE USE AND ONE REUSABLE DIGITALURETERORENOSCOPE</td>
</tr>
<tr>
<td></td>
<td>Kynora Scotland*, Karla Rebullar, Ben Chew, Vancouver, Canada</td>
</tr>
<tr>
<td>V03-05</td>
<td>TREATMENT OF LARGE KIDNEY STONES BY USING ROBOTIC ASSISTED FLEXIBLE URETEROSCOPY</td>
</tr>
<tr>
<td></td>
<td>Remzi Saglam, ANKARA, Turkey, Anup Patel*, London, United Kingdom, Jens Rassweiler, Heilbronn, Germany, Jan Klein, Ulm, Germany, Yasser Farahat, Abdulgadir Al Zarooni, Umm Al Qwein, United Arab Emirates, Selahattin Bedir, Ankara, Turkey, Ahmet Müşlimanuoğlu, Istanbul, Turkey, Zafer Tokatl, ANKARA, Turkey, Kemal Sarica, Istanbul, Turkey</td>
</tr>
<tr>
<td>V03-06</td>
<td>CROSS-TABLE BULLSEYE FOR PERCUTANEOUS NEPHROLITHOTOMY</td>
</tr>
<tr>
<td></td>
<td>Rus Korets, Timothy Batter*, Brian Eisner, Boston, MA</td>
</tr>
<tr>
<td>V03-07</td>
<td>THE COMPLETE GUIDE TO A SIMPLIFIED PERCUTANEOUS CALYX PUNCTURE WITHOUT ROTATING THE C-ARM</td>
</tr>
<tr>
<td></td>
<td>Mohammed Lezrek*, Meknes, Morocco, Hicham Tazi, Fes, Morocco, Mohammad Aboufaraj, Vienna, Austria, adil slimani, mohammed alami, ammani abdelghani, Meknes, Morocco</td>
</tr>
<tr>
<td>V03-08</td>
<td>THE NEW DEVICE FOR LITHOEXTRACTION DURING CONVENTIONAL PCNL. NO BASKETS, NO GRASPERS</td>
</tr>
<tr>
<td></td>
<td>Stanislav Ali*, Nikolay Grigoriev, Housein Ali, Evgenii Bezrukov, Roman Sukhanov, Alim Dymov, Petr Glybochko, Moscow, Russian Federation</td>
</tr>
<tr>
<td>V03-09</td>
<td>PERCUTANEOUS ENDOSCOPIC PUNCTURE OF THE PROXIMAL URETER FOR RECANALIZATION OF THE URETEROPELVIC JUNCTION</td>
</tr>
<tr>
<td></td>
<td>Mohammed Lezrek*, Meknes, Morocco, Hicham Tazi, Fes, Morocco, Mohammad Aboufaraj, Vienna, Austria, adil slimani, mohammed alami, ammanni abdelghani, Meknes, Morocco</td>
</tr>
<tr>
<td>V03-10</td>
<td>COMPLICATED REMOVAL OF AN ENCRUSTED ALLIUM™ URETERAL STENT</td>
</tr>
<tr>
<td></td>
<td>Ettiene Xavier Keller*, Vincent De Coninck, Maria Rodriguez-Monsalve, Steeve Doizi, Olivier Traxer, Paris, France</td>
</tr>
<tr>
<td>V03-11</td>
<td>PURE ENDOSCOPIC CLOSURE OF BLADDER WALL AFTER TRANSURETHRAL DISINSERTION OF DISTAL URETER DURING LAPAROSCOPIC NEPHROURETERECTOMY: PROOF OF CONCEPT IN HUMANS</td>
</tr>
<tr>
<td></td>
<td>Joao Pimentel Torres*, Emanuel Carvalho Dias, Sara Anacleto, Nuno Morais, Agostinho Cordeiro, Paulo Mota, Carlos Oliveira, Estevao Lima, Braga, Portugal</td>
</tr>
<tr>
<td>V03-12</td>
<td>CONCURRENT ROBOTIC PARTIAL NEPHRECTOMY AND PYELOLITHOTOMY: TIPS AND TRICKS</td>
</tr>
<tr>
<td></td>
<td>Juan Garisto, Julien Dagenais, Hans Arora*, Jihad Kaouk, Cleveland, OH</td>
</tr>
</tbody>
</table>

*Presenting author
Plenary: Prime Time, Saturday Morning Session

Esplanade BR @ MCC South

Saturday, May 19, 2018
7:30 am - 11:30 am

7:30 JOURNAL OF UROLOGY 2017: YEAR IN REVIEW
Presenter: Joseph Smith

7:35 JOURNAL OF UROLOGY: TOP PAPERS: FEMALE UROLOGY AND STONES
Presenter: Craig Comiter

7:45 JOURNAL OF UROLOGY: TOP PAPERS: BPH AND ERECTILE DYSFUNCTION
Presenter: Kevin McVary

7:55 JOURNAL OF UROLOGY: TOP PAPERS: PROSTATE AND TESTIS CANCER
Presenter: Laurence Klotz

8:05 JOURNAL OF UROLOGY: TOP PAPERS: BLADDER AND RENAL CANCER
Presenter: Badrینath Konety

8:15 JOURNAL OF UROLOGY LECTURE: LONG TERM FOLLOWING OF THE PROSTATE CANCER PREVENTION TRIAL: IMPACT OF FINASTERIDE ON PROSTATE CANCER MORTALITY
Presenter: Ian Thompson, Jr

8:35 MEET THE PRESS: EDITOR'S PICKS
Panelists: James Catto, Prokar Dasgupta, Joseph Smith, Eric Klein

9:05 PRESIDENTIAL ADDRESS: ARTIFICIAL INTELLIGENCE, ROBOTICS AND THE FUTURE OF UROLOGY
AUA President: J. Brantley Thrasher

9:25 RAMON GUITERAS LECTURE: TRANSLATING A TRILLION POINTS OF DATA INTO THERAPIES, DIAGNOSTICS, AND NEW INSIGHTS INTO DISEASE
Presenter: Atul Butte

9:45 JOHN K. LATTIMER LECTURE: BIOMINERALIZATION IN UROLOGY
Presenter: Marshall Stoller

10:05 PRESENTATION OF HONORARY MEMBERS AND SECRETARY COMMENDATIONS FOR GLOBAL LEADERSHIP

10:15 SOCIETE INTERNATIONALE D’UROLOGIE (SIU) LECTURE: TIPS AND TRICKS: VESICOVAGINAL FISTULA
Presenter: Serigne Gueye

10:35 CONFEDERACION AMERICANA DE UROLOGIA (CAU) LECTURE: GENITOURINARY TUBERCULOSIS: AN UNINVITED GUEST
Presenter: Mariano Sotomayor

10:45 EUROPEAN UROLOGICAL ASSOCIATION (EAU) LECTURE: TIPS AND TRICKS: CHALLENGING THE GUIDELINES ON NERVE SPARING SURGERY
Presenter: Hendrik Van Poppel

11:00 UROLOGICAL ASSOCIATION OF ASIA (UAA) LECTURE: TIPS AND TRICKS: ROBOTIC OFF CLAMP PARTIAL NEPHRECTOMY
Presenter: Koon Rha

Presenter: Frederic Moll

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Plenary: Next Frontier, Saturday Afternoon Session

HALL E @ MCC North

Saturday, May 19, 2018
1:00 pm - 5:00 pm

1:00 RISING STARS SPOTLIGHT: INTRODUCTION
Presenter: Aria Olumi

1:05 RISING STARS SPOTLIGHT: THE “METABOLIC” OVERACTIVE BLADDER SYNDROME
Presenter: Lysanne Campeau

1:15 UROLOGY CARE FOUNDATION PRESENTATION: OUR FOUNDATION. TOGETHER WE CARE
Presenter: Harris Nagler

1:30 AUA QI SUMMIT: CHALLENGES AND OPPORTUNITIES FOR STEWARDSHIP OF UROLOGICAL IMAGING
Presenter: Matthew Nielsen

*Presenting author
1:45  AUA DATA GRANTS: THE EVIDENCE SPEAKS FOR ITSELF  
Presenter: Benjamin Breyer

2:00  LBA-01: CHARACTERISTICS OF PARTICIPANTS IN THE AUA QUALITY (AQUA) REGISTRY AND EARLY IMPACT OF PARTICIPATION ON QUALITY OF CARE  
Presenter: Jeremy Shelton

2:10  LBA-02: THE USE OF TELEMEDICINE FOR THE POSTOPERATIVE UROLOGIC CARE OF CHILDREN: RESULTS OF A PILOT PROGRAM  
Presenter: Julia Finkelstein

2:20  LBA-03: THE CHANGING FACE OF UROLOGIC ONCOLOGIC SURGERY FROM 2000-2018 (63 141 PATIENTS) - IMPACT OF ROBOTICS  
Presenter: Inderbir Gill

2:30  LBA-04: IMPLEMENTATION OF A NOVEL POINT OF CARE PCR TEST TO GUIDE ANTIBIOTIC PROPHYLAXIS PRIOR TO TRANSRECTAL PROSTATE BIOPSY  
Presenter: Michael Liss

2:40  LBA-05: INITIAL RESULTS OF A PROSPECTIVE COHORT STUDY EVALUATING RELIABILITY OF ENDOSCOPIC EVALUATION IN PREDICTING PTO DISEASE AT THE TIME OF RADICAL CYSTECTOMY: WHERE AND HOW DOES CYSTOSCOPY FALL SHORT?  
Presenter: Daniel Parker

2:50  LBA-06: FINAL RESULTS OF A PHASE 1 CLINICAL TRIAL EVALUATING THE USE OF A TISSUE ENGINEERED NEO-URINARY CONDUIT USING ADIPOSE DERIVED SMOOTH MUSCLE CELLS FOR URINARY RECONSTRUCTION  
Presenter: Trinity Bivalacqua

3:00  THE GREAT DEBATE: AUA CHIEF RESIDENTS  
Moderators: Lee Richstone, Jessica Kreshover

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 19, 2018  
Plenary: Prime Time, Saturday Afternoon Session  
1:00 pm - 5:00 pm  
Esplanade BR @ MCC South

1:00  PANEL DISCUSSION: CONTROLLING THE COSTS OF FLEXIBLE URETEROSCOPY  
Moderator: Vernon Pais  
Panelists: Ben Chew, Michael Lipkin, Brian Matlaga, Eduardo Mazzucchi

1:30  SURGICAL TECHNIQUES: TIPS & TRICKS: PERCUTANEOUS NEPHROLITHOTOMY (PCNL)  
Moderator: Stephen Nakada  
Surgeons: Dalton Baldwin, Thomas Chi, Sri Sivalingam, Roger Sur

2:30  SECOND OPINION CASES (ASK THE GUIDELINES!): BENIGN PROSTATIC HYPERPLASIA (BPH)  
Moderator: Kevin McVary  
Panelists: Harris Foster, Steven Kaplan, Charles Welliver

3:00  SURGICAL TECHNIQUES: TIPS & TRICKS: BENIGN PROSTATIC HYPERPLASIA (BPH)  
Moderator: Steven Kaplan  
Surgeons: Thorsten Bach, Gregg Eure, Ricardo Gonzalez, Kevin McVary, Jonathan Warner

4:15  SURVIVOR DEBATE: ENDourology  
Moderator: John Denstedt  
Debaters: Kenneth Pace, Bodo Knudsen, Brian Eisner, Ravindra Sabnis, Michael Borofsky, Thomas Knoll

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
**Moderated Poster Session 25**

**TRAUMA/RECONSTRUCTION/DIVERSION: EXTERNAL GENITALIA RECONSTRUCTION AND UROTRAUMA (INCLUDING TRANSGENDER SURGERY) II**

*Room 3004 @ MCC West*

**Moderators:** Richard Santucci, Lee Zhao and Arnulf Stenzl

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP25-01</td>
<td>CT VOLUMETRIC MEASUREMENTS ESTIMATE FUTURE SPLIT RENAL FUNCTION IN RENAL TRAUMA PATIENTS WITH SEGMENTAL VASCULAR INJURIES</td>
<td>MP25-06 PRESENTING SYMPTOMS TO A RECONSTRUCTIVE UROLOGIST AFTER FEMALE TO MALE GENITAL RECONSTRUCTIVE SURGERY</td>
<td></td>
</tr>
<tr>
<td>MP25-02 PENILE DISASSEMBLY IN EXSTROPHY: TIME TO REEVALUATE?</td>
<td>MP25-07 SURGICAL MANAGEMENT OF ADULT ACQUIRED BURIED PENIS: IMPACT ON URINARY AND SEXUAL QUALITY OF LIFE OUTCOMES</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Matthew Kasprenski*, Mahir Maruf, John Jayman, Karl Benz, Jason Michaud, Emily Dunn, John Gearhart, Baltimore, MD</td>
<td>Katherine Theisen*, Thomas Fuller, Paul Rusilko, Pittsburgh, PA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MP25-03 PELVIC FRACTURE URETHRAL INJURY – THE NATURE OF THE CAUSATIVE INJURY CORRELATES STRONGLY WITH SURGICAL TREATMENT AND OUTCOME</td>
<td>MP25-08 EFFECTS OF HORMONE THERAPY ON SPERMATOGENESIS IN MALE-TO-FEMALE TRANSGENDER PATIENTS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MP25-04 IATROGENIC UROLOGIC INJURIES DURING HYSTERECTOMY: INFREQUENT YET SIGNIFICANT ECONOMIC IMPACT</td>
<td>MP25-09 GENITAL BURNS IN THE UNITED STATES: DISPROPORTIONATE PREVALENCE IN THE PEDIATRIC POPULATION</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cooper Benson*, Gen Li, Stephanie Thompson, Denise Asafu-Adjei, Steven Brandes, New York, NY</td>
<td>Anas Tresh*, Nima Baradaran, Thomas Gaither, Kirkpatrick Fergus, Aron Liaw, Ashwin Balakrishnan, Lindsay Hampson, Benjamin Breyer, San Francisco, CA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MP25-05 IS SYSTEMATIC EARLY DRAINAGE RELEVANT TO TREAT URINARY TRACT RUPTURE IN NON-PENETRATING RENAL TRAUMA? RESULTS FROM A MULTICENTER STUDY</td>
<td>MP25-10 AN EXAMINATION OF THE MANAGEMENT OF RENAL TRAUMA WITH CONCURRENT SPLENIC INJURY</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Presenting author</strong></td>
<td>MP25-11 REDO PENILE HYPOSPADIAS REPAIR WITH TUBULARIZED INCISED PLATE URETHEMPLASTY USING BUCCAL MUCOSA GRAFT AND DOUBLE DARTOS FLAP</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kamyr Tavakkoli Tabassi, Alireza Ghorbani*, Simin Hajian, Mashhad, Islamic Republic of Iran</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MP25-12 CLINICAL PREDICTORS OF IMMEDIATE INTERVENTION FOLLOWING EMERGENCY ROOM (ER) PRESENTATION WITH ISOLATED RENAL TRAUMA</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### MP25-13 Outpatient Surgical Management of Acquired Buried Penis Performed in a Single Center: Short and Intermediate Follow-Up
Marilyn Hopkins*, Scott Erpelding, James Liau, Shubham Gupta, Lexington, KY

### MP25-14 Surgical Realignment of Penile Suspensory Ligament in Penoscrotal Hypospadias Has Better Cosmetic and Functional Outcomes
Ashish Pardeshi*, Pune, India, Vijay Raghoji, NaviNath Fulari, Solapur, India, Pratikshit Mahajan, Rajesh Rajendran, Pune, India

### MP25-15 Concomitant Bladder and Rectal Injuries: Results from the American Association for the Surgery of Trauma (AAST) Multi-Center Rectal Injury Study Group
E. Charles Osterberg*, Jacob Velth, Carlos V.R. Brown, Austin, TX, John P. Sharpe, Memphis, TN, Tashinga Musonza, John Holcomb, Houston, TX, Eric Biu, San Francisco, CA, Brandon Bruns, Baltimore, MD, Andrew Hopper, Nashville, TN, Michael S. Truitt, Dallas, TX, Clay C. Burrew, Denver, CO, Morgan Schellenberg, Los Angeles, CA, Jack Sava, Rockville, MD, Jonathan Van Horn, Portland, OR

### MP25-16 Catheter-Associated Meatal Damage in Hospitalized Males
Chen Shenhar*, Marina Mansvetov, Gailt Louie, Camille Finz, Sophie Zeltzer, Jack Baniel, Shay Golan, Shachar Aharony, Petah Tikva, Israel

### MP25-17 Does Routine Repeat Imaging Change Management in High-Grade Renal Trauma? Results from a Level 1 Trauma Center
David Bayne*, Nima Baradaran, San Francisco, CA, Gregory Murphy, St. Louis, MO, Anas Tresh, San Francisco, CA, Charles Osterberg, Austin, TX, Lindsay Hampson, Jack McAninch, Benjamin Breyer, San Francisco, CA

### MP25-18 Imaging Findings Associated with Renal Bleeding Interventions after High-Grade Renal Trauma: Results from the American Association for Surgery of Trauma (AAST) Genito-Urinary Trauma Study
Sorena Keihani*, Rachel Moses, Yihe Xu, Bryn Rubbrese, Douglas Rogers, Salt Lake City, UT, Xian Luo-Owen, Kaushik Mukherjee, Loma Linda, CA, Bradley Morris, Sarah Majerick, Murray, UT, Joshua Pietrowski, Christopher Dodgion, Milwaukee, WI, Brenton Sherwood, Bradley Erickson, Iowa City, IA, Ian Schwartz, Sean Elliott, Minneapolis, MN, Erik DeSoucy, Scott Zakaluzny, Sacramento, CA, Nima Baradaran, Benjamin Breyer, San Francisco, CA, Brian Smith, Philadelphia, PA, Brandon Miller, Richard Santucci, Detroit, MI, Matthew Carrick, Plano, TX, Jurek Kocik, Tyler, TX, Timothy Hewitt, Frank Burks, Royal Oak, MI, Marta Heilbrun, Atlanta, GA, James Hotaling, Angela Presson, Raminder Nirula, Jeremy Myers, Salt Lake City, UT

### MP25-19 Neophallus Penile Prosthesis Placement—Anatomical Challenges, Considerations for Device Selection, Potential Pitfalls, and Proposed Surgical Technique
Maurice Garcia*, Los Angeles, CA

### MP25-20 Survey of Urologic and Orthopedic Surgeon Views Regarding the Management of Patients with Pelvic Fracture Urethral Injuries
Niels Johnsen*, Reza Firoozabadi, Bryan Voelzke, Seattle, WA

---

**APPROVED FOR AMA PRA CATEGORY 1 CREDIT™**

---

### SATURDAY, MAY 19, 2018

**Moderated Poster Session 26**

**SURGICAL TECHNOLOGY & SIMULATION: INSTRUMENTATION & TECHNOLOGY I**

Room 3006 @ MCC West

Moderators: Lee Richstone, Peter Schulam and Jens Rassweiler

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP26-01</td>
<td>Preoperative Neutrophil/Lymphocyte Ratio as a Prognosticator in Upper Tract Urothelial Carcinoma Patients Treated Conservatively</td>
</tr>
<tr>
<td>Lorenzo Defidio*, Mauro De Dominicis, Luca Di Gianfrancesco, Alessandro Calarco, Michele Antonucci, Rome, Italy, Anup Patel, London, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP26-02</td>
<td>Preoperative Neutrophil/Lymphocyte Ratio as a Prognosticator in Upper Tract Urothelial Carcinoma Patients Treated Conservatively: A Retrospective Evaluation</td>
</tr>
<tr>
<td>Lorenzo Defidio*, Mauro De Dominicis, Luca Di Gianfrancesco, Alessandro Calarco, Michele Antonucci, Rome, Italy, Anup Patel, London, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>
MP26-03 IN VIVO MICROSCOPIC IMAGING OF BLADDER LESIONS
Christopher R. Kannady*, Richard A. Schwarz, Jennifer Carns, Katelin D. Cherry, Imran Vohra, Yubo Tang, Timothy Quang, Jonathan Clavell Hernandez, Rebecca Richards-Kortum, Nadeem Dhanani, Houston, TX

MP26-04 WEARABLE FITNESS TRACKERS FOR MEASUREMENT OF BEHAVIORAL PATTERNS AMONG PATIENTS UNDERGOING RADICAL CYSTECTOMY: A PILOT STUDY ASSESSING FEASIBILITY AND UTILITY
Madeleine L. Burg*, Shane M. Pearce, Daniel E. Zainfeld, Saum Ghodoussipour, Ankeet Shah, Anne K. Schuckman, Hooman Djaladat, Siamak Daneshmand, Los Angeles, CA

MP26-05 COMPARISON OF ISCHEMIC INTERMITTENT AND CONTINUOUS INFLOW OCCLUSION DURING LAPAROSCOPIC PARTIAL NEPHRECTOMY IN THE PORCINE MODEL
Cheng Peng*, Lei Wang, Qingbo Huang, Xin Ma, Beijing, China, People’s Republic of China

MP26-06 INITIAL EXPERIENCE WITH RENAL VIRTUAL REALITY MODELS AS EDUCATIONAL AND PREOPERATIVE PLANNING TOOLS FOR PARTIAL NEPHRECTOMY
Egor Parkhomenko*, Shoaib Safiullah, Michael Owyong, Sartaaj Walia, Mitchell O’Leary, Ryan James, Roshan Patel, Kamaljot Kaler, Edward Uchio, Ralph Clayman, Jaime Landman, Orange, CA

MP26-07 IN-OFFICE FREEHAND TRANSPERINEAL TEMPLATE MAPPING BIOPSY PERFORMED UNDER LOCAL ANESTHESIA USING A NOVEL NEEDLE GUIDE: FEASIBLE, SAFE, AND EFFECTIVE FOR CANCER DETECTION
Matthew Lee*, Ann Arbor, MI, Shaan Setia, Chicago, IL, Adam Cole, Michael Fenstermaker, Chandly Ellimoottil, Lindsey Herrel, John Wei, Ann Arbor, MI, Srinivas Vourganti, Chicago, IL, Arvin George, Ann Arbor, MI

MP26-08 COMPARISON OF ELASTIC AND RIGID REGISTRATION DURING MAGNETIC RESONANCE IMAGING/ULTRASOUND FUSION-GUIDED PROSTATE BIOPSY
Graham R. Hale*, Marcin Czarniecki, Alexis Cheng, Jonathan B. Bloom, Reza Seifabadi, Samuel A. Gold, Kareem N. Rayn, Vik Sabanwal, Gustavo Pena-La Grave, Vladimir Valera, Sherif Mehralivand, Baris Turkbey, Brad Wood, Peter A. Pinto, Bethesda, MD

MP26-09 NOVEL TRACKED FOLEY CATHETER FOR MOTION COMPENSATION DURING IMAGE GUIDED PROSTATE PROCEDURES

MP26-10 MAGNETIC RESONANCE IMAGING GUIDED FOCAL LASER THERAPY OF PROSTATE CANCER: FOLLOW UP RESULTS FROM A SINGLE CENTER PHASE I TRIAL
Sherif Mehralivand*, Bethesda, MD, Arvin George, Ann Arbor, MI, Anthony Hoang, Houston, TX, Soroush Rais-Bahrami, Birmingham, AL, Ardeshrastinastehad, New York, NY, Vladimir Valera Romero, Jonathan Bloom, Samuel Gold, Graham Hale, Kareem Rayn, Marcin Czarniecki, Clayton Smith, Stephanie Harmon, Maria Menino, Peter Choyke, Baris Turkbey, Bradford Wood, Peter Pinto, Bethesda, MD

MP26-11 MR/US FUSION GUIDED ULTRA-FOCAL GOLD NANOPARTICLE DIRECTED LASER ABLATION OF PROSTATE TUMORS: SAFETY RESULTS IN THE FIRST 11 PATIENTS
Harry Anastas*, Jared S. Winoker, Pratik A. Shukla, Shivaram Cumarasamy, John P. Sfakianos, New York, NY, Michael R. Carrick, Houston, TX, Bodhi K. Rastinshad, Cynthia J. Knaue, Sara C. Lewis, Bachir A. Taouli, New York, NY, Jon A. Schwartz, Houston, TX, Ardeshrastinastehad, New York, NY

*Presenting author
MP26-12 TRIFECTA OUTCOMES OF PARTIAL NEPHRECTOMY IN PATIENTS OVER 75 YEARS OLD: A MULTI-INSTITUTIONAL STUDY: ANALYSIS OF THE RENAL SURGERY IN ELDERLY (RESURGE) GROUP

MP26-13 THULIUM LASER CONSERVATIVE TREATMENT OF UPPER TRACT URINARY CANCER: 10 YEARS-EXPERIENCE OF A REFERRAL CENTER
Lorenzo Defidio*, Mauro De Dominici, Luca Di Gianfrancesco, Rome, Italy, Anup Patel, London, United Kingdom

MP26-14 ROBOT ASSISTED RETROPERITONEAL LYMPH NODE DISSECTION OF POST CHEMOTHERAPY RESIDUAL MASS – A SINGLE CENTER EXPERIENCE OF 18 PATIENTS
AMITABH SINGH*, Jiten Jaipuria, Saroj Bairdia, Raghubir Bhardwaj, JALAJ JAIN, Sudhir Rawal, North Delhi, India

MP26-15 EFFECTIVENESS OF HYALURONIC ACID/CARBOXYMETHYLCELLULOSE IN PREVENTING ADHESIVE BOWEL OBSTRUCTION AFTER LAPAROSCOPIC RADICAL CYSTECTOMY
Kyu Shik Kim*, Jae Hoon Chung, Seoul, Korea, Republic of, Joon Hwa Noh, Jun Seok Kim, Gwangju, Korea, Republic of, Tae Nam Kim, Moon Kee Chung, Jorg Kil Nam, Jeong Zoo Lee, Busan, Korea, Republic of, Seung Wook Lee, Jae Heon Kim, Seoul, Korea, Republic of

MP26-16 COMPARISON OF VALVE-LESS AND STANDARD INSUFFLATION ON PNEUMOPERITONEUM-RELATED COMPLICATIONS IN ROBOTIC PARTIAL NEPHRECTOMY: A PROSPECTIVE RANDOMIZED TRIAL
Tom Feng*, Gerald Heulitt, Adel Islam, James Porter, Seattle, WA

MP26-17 OUTCOMES OF ROBOTIC PROSTATECTOMY PERFORMED AT ULTRALOW PNEUMOPERITONEUM PRESSURE OF 6 MMHG
Matthew Ferroni*, Janice Rosenthal, Ronney Abaza, Dublin, OH

MP26-18 PRELIMINARY EXPERIENCE WITH HYPER-ACCURACY IMAGE-GUIDED ROBOTIC PARTIAL NEPHRECTOMY WITH NON-GLOBAL ISCHEMIA TECHNIQUE
Francesco Porpiglia, Riccardo Bertolo*, Daniele Ampanaro, Enrico Checcucci, Cristian Fiori, Orabasso, Italy

MP26-19 AUTOMATED AND DYNAMIC CLASSIFICATION OF BLADDER CANCER USING DEEP LEARNING ON REAL-TIME CONFOCAL LASER ENDOMICROSCOPY IMAGES
Timothy Chang*, Darvin Yi, Daniel Rubin, Joseph Liao, Stanford, CA

MP26-20 VIRTUAL-REALITY PROJECTED RENAL MODELS WITH UROLITHIASIS AS AN EDUCATIONAL AND PREOPERATIVE PLANNING TOOL FOR NEPHROLITHOTOMY: A PILOT STUDY
Egor Parkhomenko*, Shoab Safiullah, Sartaaj Walia, Michael Owyong, Cyrus Lin, Mitchell O'Leary, Ryan James, Roshan Patel, Kamaljot Kaler, Jaime Landman, Ralph Clayman, Orange, CA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>ABSTRACT TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP27-01</td>
<td>URODYNAMIC STUDIES QUALITY CONTROL AND INITIAL PRESSURES</td>
</tr>
<tr>
<td></td>
<td>Peter Rosier*, Utrecht, Netherlands</td>
</tr>
<tr>
<td>MP27-02</td>
<td>DO AMBULATORY UDS CHANGE THE PRIMARY CLINICAL DIAGNOSIS AND/OR TREATMENT PATHWAY IN PATIENTS WHERE CONVENTIONAL UDS WERE NON-DIAGNOSTIC</td>
</tr>
<tr>
<td></td>
<td>Richard Axell, Vahit Guzelburc, Megan Duffy, Jai Seth, Mahureen Pakzad, Rizwan Hamid, Jeremy Ockrim, Tamsin Greenwell*, London, United Kingdom</td>
</tr>
<tr>
<td>MP27-03</td>
<td>PRE-OPERATIVE URODYNAMIC EVALUATION IN FEMALE MEDICARE PATIENTS UNDERGOING A STRESS URINARY INCONTINENCE PROCEDURE: RATES BEFORE AND AFTER THE VALUE TRIAL</td>
</tr>
<tr>
<td></td>
<td>Annah Vollstedt*, Lebanon, NH, Rachel Moses, Salt Lake City, UT, E. Ann Gormley, Lebanon, NH</td>
</tr>
<tr>
<td>MP27-04</td>
<td>THE UTILITY OF URODYNAMIC EVALUATION IN CLINICAL PRACTICE</td>
</tr>
<tr>
<td></td>
<td>Rena D. Malik*, Deborah S. Hess, Maude E. Carmel, Gary E. Lemack, Philippe E. Zimmern, Dallas, TX</td>
</tr>
<tr>
<td>MP27-05</td>
<td>EDUCATION PRIOR TO URODYNAMICS INCREASES PATIENT SATISFACTION</td>
</tr>
<tr>
<td></td>
<td>Russell Terry, Mohit Gupta, Aaron Brafman, Anja Zann, Julia Han, Andrew Rabley*, Louis Moy, Gainesville, FL</td>
</tr>
<tr>
<td>MP27-06</td>
<td>RISK FACTORS ASSOCIATED WITH FECAL INCONTINENCE IN PATIENTS WITH OVERACTIVE BLADDER</td>
</tr>
<tr>
<td></td>
<td>Caitlin Lim*, Joshua Cohn, Philadelphia, PA, Casey Kowalik, Melissa Kaufman, Roger Dmochowski, W. Stuart Reynolds, Nashville, TN</td>
</tr>
<tr>
<td>MP27-07</td>
<td>ANTIMICROBIAL PROPHYLAXIS BEFORE URODYNAMIC STUDY: SINGLE INSTITUTION EXPERIENCE IN A FACE OF AUA/SUFU BEST POLICY STATEMENT ON URODYNAMIC ANTIMICROBIAL PROPHYLAXIS</td>
</tr>
<tr>
<td></td>
<td>Michael Vainrib*, Kfar Saba, Israel</td>
</tr>
<tr>
<td>MP27-08</td>
<td>IMPACT OF LIFETIME OBESITY ON URINARY INCONTINENCE IN THE WOMEN'S HEALTH INITIATIVE</td>
</tr>
<tr>
<td></td>
<td>Judy Choi*, Orange, CA, Jenny Chang, Argyrios Ziegas, Hoda Anton-Culver, Irvine, CA</td>
</tr>
<tr>
<td>MP27-09</td>
<td>RELATIONSHIPS BETWEEN METABOLIC FACTORS, URINARY INCONTINENCE AND OVERACTIVE BLADDER SYMPTOMS AMONG MEN AND WOMEN IN THE LURN OBSERVATIONAL COHORT STUDY</td>
</tr>
<tr>
<td></td>
<td>H. Henry Lai MD*, St. Louis, MO, Margaret E. Helmuth MA, Abigail R. Smith PhD, Brenda W. Gillespie PhD, Ann Arbor, MI, Ziya Krikali MD, and the LURN Study Group, Bethesda, MD</td>
</tr>
<tr>
<td>MP27-10</td>
<td>HOW DOES DIABETES AFFECT VOIDING DYSFUNCTION? A MATCHED PAIRS STUDY</td>
</tr>
<tr>
<td></td>
<td>Dina Manasherova*, Gen Li, Carrie M. Aisen, Doreen E. Chung, New York, NY</td>
</tr>
<tr>
<td>MP27-11</td>
<td>OVERACTIVE BLADDER, URINARY INCONTINENCE AND DEPRESSION</td>
</tr>
<tr>
<td></td>
<td>Antonella Giannantoni, Marilena Gubbiotti, Ettore Mearini, Pierfrancesco Maria Baldiucci, Jacopo Adolfo Rossi de Vermandois*, Perugia, Italy</td>
</tr>
<tr>
<td>MP27-12</td>
<td>EARLY AND CONSISTENT IMPROVEMENTS IN QUALITY OF LIFE AND URINARY SYMPTOMS WITH ONABOTULINUMTOXINA IN OVERACTIVE BLADDER PATIENTS WITH URINARY INCONTINENCE IN A RANDOMIZED, PLACEBO-CONTROLLED TRIAL</td>
</tr>
<tr>
<td></td>
<td>Kurt McCammon*, Norfolk, VA, Angelo Gousse, Miramar, FL, Jennifer Gruenerfelder, Laguna Hills, CA, Douglass Hale, Indianapolis, IN, Amelia Orejudos, Tamer Abouhashweb, Irvine, CA, Alfred Kohan, Bethpage, NY</td>
</tr>
<tr>
<td>MP27-13</td>
<td>DETRUSOR OVERACTIVITY IN PATIENTS WITH ADJUNCTIVE BOTULINUM TOXIN A INJECTION AFTER NEUROMODULATION</td>
</tr>
<tr>
<td></td>
<td>Jason Giller*, Royal Oak, MI, Brian Yuhan, Rochester, MI, Kim Killinger, Jamie Bartley, Laura Nguyen, Esther Han, Larry Sirls, Judy Boura, Kenneth Peters, Royal Oak, MI</td>
</tr>
<tr>
<td>MP27-14</td>
<td>CLINICAL EVALUATION AND TREATMENT OF NOCTURIA IS MODEST AT BEST</td>
</tr>
<tr>
<td></td>
<td>Siri Drangsholt*, Jeremy Slawin, Benjamin Brucker, New York, NY</td>
</tr>
<tr>
<td>MP27-15</td>
<td>URINARY INCONTINENCE IN NULLIPAROUS WOMEN: RESULTS FROM A NATIONWIDE SAMPLE</td>
</tr>
<tr>
<td></td>
<td>Michael Daugherty*, Timothy Byler, Natasha Ginzburg, Syracuse, NY</td>
</tr>
</tbody>
</table>
**MP27-16** THE IMPACT OF OVER-WEIGHT IN THE EFFICIENCY AND COMPLICATIONS OF MIDURETHRAL SLING IN PATIENTS WITH STRESS URINARY INCONTINENCE: A SYSTEM REVIEW AND META-ANALYSIS  
Yi Sun*, Hong Shen, Chengdu, China, People’s Republic of

**MP27-17** COULD DETRUSOR OVERACTIVITY PREDICT THE USE OF ANTIMUSCARINICS AFTER MID-URETHRAL SLING IN WOMEN WITH MIXED URINARY INCONTINENCE?  
Yun-Chu Chang*, Yu-Hua Fan, Alex T.L. Lin, Taipei, Taiwan

**MP27-18** DAILY AMOUNT OF URINARY INCONTINENCE AT THE TIME OF CATHETER REMOVAL CAN STRONGLY PREDICT POSTOPERATIVE URETHRAL FUNCTION AND URINARY INCONTINENCE RECOVERY FOLLOWING ROBOT-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY  
Yoshisita Matsukawa*, Tsuyoshi Majima, Masashi Kato, Kousuke Tochigi, Yoshie Kanada, Yasushi Yoshino, Momokazu Gotoh, Nagoya, Japan

**MP27-19** A NEW CLINICAL PROTOCOL FOR DEMONSTRATION OF CORTICAL BRAIN ACTIVITY MAPPING DURING VOLUNTARY UROFLOW AND PELVIC FLOOR MUSCLE ACTIVITY USING FUNCTIONAL NEAR INFRA-RED SPECTROSCOPY (FNIRS)  
Lynn Stothers*, Andrew Macnab, Vancouver, Canada

**MP27-20** TRADITIONAL ULTRASOUND UNDERREPRESENTS EXTENT OF UPPER TRACT DILATION AS COMPARED TO INTEGRATED URODYNAMICS ULTRASOUND  
Devon Snow-Lisy, Seattle, WA, Jennifer Nicholas, St. Louis, MO, Renea Sturm, Christopher Halline, Dawn Diaz- Saldano, Ilina Rosoklijia, Chicago, IL, Edward Diaz, Palo Alto, CA, Karen Rychlik, Earl Cheng, Elizabeth Yerkes*, Chicago, IL

---

**Saturday, May 19, 2018**

**Moderated Poster Session 28**  
**Room 3020 @ MCC West**  
**Moderators: Robert Flanigan, Moben Mirza and Pilar Laguna Pes**

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MP28-01</strong></td>
<td>GERMLINE MUTATIONS OF RENAL TUMOR PREDISPOSITION GENES IN EARLY-ONSET PATIENTS</td>
</tr>
<tr>
<td><strong>MP28-02</strong></td>
<td>COMPARATIVE ANALYSIS OF OUTCOMES OF PAPILLARY TYPE 1 AND TYPE 2 AND CLEAR CELL RENAL CELL CARCINOMA: A MULTI-INSTITUTIONAL STUDY</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MP28-03</strong></td>
<td>CONTRAST MEDIA ENHANCEMENT REDUCTION PREDICTS TUMOR RESPONSE TO PRESURGICAL MOLECULAR-TARGETING THERAPY IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA</td>
</tr>
<tr>
<td><strong>MP28-04</strong></td>
<td>DO HIGH-VOLUME RENAL TUMOR BIOPSY CENTERS HAVE LOWER RATES OF BENIGN HISTOLOGY FOLLOWING NEPHRECTOMY FOR SMALL RENAL MASSES?</td>
</tr>
</tbody>
</table>
MP28-05 COMPLICATIONS FOLLOWING 1053 PERCUTANEOUS CORE RENAL MASS BIOPSIES: RISK FACTORS AND SAFETY ASSESSMENT

MP28-06 METASTATIC RISK STRATIFICATION OF CLEAR CELL RENAL CELL CARCINOMA PATIENTS BASED ON A GENOMIC SCORE
Julia Grimm, Martin Janssen, Stefan Wagenpfeil, Homburg, Germany, Arndt Hartmann, Christine Stöhr, Bastian Keck, Andreas Kahlermeyer, Erlangen, Germany, Michael Stöckle, Kerstin Junker*, Homburg, Germany

MP28-07 RENAL FUNCTION VARIABILITY: A SIMPLE METHOD TO IDENTIFY SUBCLINICAL KIDNEY DISEASE BEFORE NEPHRECTOMY
Andrew Sun*, I-Chun Thomas, Calyani Ganesan, Joanna Sylman, Alan Pao, Todd Wagner, James Brooks, Glenn Chertow, John Leppert, Stanford, CA

MP28-08 CLINICOPATHOLOGIC AND GENOMIC EVALUATION OF TRANSLOCATION RENAL CELL CARCINOMA

MP28-09 CYTOREDUCITIVE NEPHRECTOMY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA AND TUMOR THROMBUS – TRENDS AND EFFECT ON OVERALL SURVIVAL
Andrew Lenis*, Claire Burton, Izak Faiena, Amirali Salmasi, Aydin Poohi, David Johnson, Alexandra Drakaki, Los Angeles, CA, Kiran Gollapudi, Jeremy Blumberg, Torrance, CA, Allan Pantuck, Karim Chami, Los Angeles, CA

MP28-10 AUTOMATED DIGITAL ANALYSIS OF RENAL CORE BIOPSY SPECIMENS USING A DEEP-LEARNING ARTIFICIAL INTELLIGENCE NETWORK
Michael Fenstermaker*, Scott Tomlins, Todd Morgan, Ann Arbor, MI

MP28-11 A 4-MIRNA SCORE PREDICTS THE INDIVIDUAL METASTATIC RISK OF RENAL CELL CARCINOMA PATIENTS
Joana Heinzelmann, Madeleine Arndt, Ramona Players, Tobias Fehlmann, Sebastian Hölters, Martin Janssen, Alexey Pryanulkin, Rainer Bohle, Homburg, Germany, Mieczyslaw Gajda, Jena, Germany, Elke Schaeffer, Stuttgart, Germany, Michael Stöckle, Kerstin Junker*, Homburg, Germany

MP28-12 SUPPRESSION OF ONCOGENIC MICRORNA-1274A INDUCES CELL APOPTOSIS THROUGH BMPR1B ACCELERATION IN RENAL CELL CARCINOMA
Hideki Enokida*, Hirofumi Yoshino, Satoshi Sugita, Takashi Sakaguchi, Youichi Osako, Shuichi Tatarano, Takashi Yamane, Masayuki Nakagawa, Kagoshima, Japan

MP28-13 DIAGNOSTIC YIELD AND ACCURACY OF OPTICAL COHERENCE TOMOGRAPHY (OCT) AND RENAL MASS BIOPSY FOR RENAL MASS DIFFERENTIATION
Mara Buijs*, Peter G. Wagstaff, Patricia J. Zondervan, C. Dilara Savci-Heijink, Otto M. van Delden, Ton G. van Leeuwen, Amsterdam, Netherlands, Netherlands, R. Jeroen van Moorselaar, Amsterdam, Netherlands, Jean JMCH de la Rosette, M. Pilar Laguna Pes, Daniel M. de Bruin, Amsterdam, Netherlands, Netherlands

MP28-14 REPRESENTATION OF KIDNEY CANCER IN THE CANCER GENOME ATLAS KIDNEY CANCER COHORT
Elizabeth Hagan, Stephen Proctor*, Spencer Krane, New Orleans, LA

MP28-15 PREOPERATIVE KIDNEY FUNCTION TRENDS: IMPROVING ESTIMATES OF BASELINE KIDNEY FUNCTION PRIOR TO KIDNEY CANCER SURGERY
Andrew Sun*, I-Chun Thomas, Calyani Ganesan, Joanna Sylman, Alan Pao, Todd Wagner, James Brooks, Glenn Chertow, John Leppert, Stanford, CA

MP28-16 EVALUATION OF TISSUE BIOMARKERS FOR RENAL CELL CANCER
Gande Li*, E. Abel, Madison, WI

MP28-17 NON-TYPE 1 PAPILLARY RENAL CELL CARCINOMA IS ASSOCIATED WITH A WORST ONCOLOGICAL OUTCOME IN PATIENTS TREATED SURGICALLY

MP28-18 INHERITED PATHOGENIC VARIANTS IDENTIFIED IN PATIENTS WITH RENAL CANCER
Maegan Roberts, Megan Marshall, Natalie Carter, Kevin Arvai, Lance Grau*, Shirley Yao, Ying Wang, Rachel Klein, Kathleen Hruska, Gaithersburg, MD

*Presenting author
<table>
<thead>
<tr>
<th>Abstract Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP28-19</td>
<td>Dermatologic Findings and Family History are the Only Predictors of a Positive Genetic Test Result in Patients with a Suspected Hereditary Kidney Cancer Syndrome: Experience from a Provincial Genetics Unit</td>
<td>Andrea Kokorovic*, Aidan Thomas, Meghan Ferguson, Ricardo A Rendon, Halifax, Canada</td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>Saturday, May 19, 2018</th>
<th>7:00 am - 9:00 am</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Moderated Poster Session 29</strong></td>
<td><strong>Prostate Cancer: Basic Research &amp; Pathophysiology I</strong></td>
</tr>
<tr>
<td>Room 3005 @ MCC West</td>
<td>Moderators: Natasha Kyprianou, Christian Stief</td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>Abstract Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP29-01</td>
<td>DNA Replication Stress by the Loss of Male Specific Histone Demethylase ‘KDM5D’ in Aggressive Prostate Cancer</td>
<td>Kazumasa Komura*, Takatsuki city, Japan, Christopher Sweeney, Boston, MA, Teruo Inamoto, Naokazu Iwaki, Haruhito Azuma, Takatsuki city, Japan, Philip Kantoff, New York, NY</td>
</tr>
<tr>
<td>MP29-02</td>
<td>Elucidating Cross-Resistance Between Taxanes and Next-Generation Anti-Androgens in Castration Resistant Prostate Cancer</td>
<td>Alan Lombard*, Chengfei Liu, Vito Cucchiara, Liangren Liu, Wei Lou, Christopher Evans, Allen Gao, Sacramento, CA</td>
</tr>
<tr>
<td>MP29-03</td>
<td>MTOR Expression in Prostate Cancer and Implications as Prognostic Role with Meta-Analysis of the Literature</td>
<td>Giorgio Ivan Russo*, Catania, Italy, Jörg Hennelottner, Ursula Kühn, Ulrich Vogel, Manfred Thomas Wurm, Valentina Gerber, Tim Neumann, Tübingen, Germany, Giuseppe Morgia, Catania, Italy, Arnulf Stenzl, Tilman Todenhöfer, Tübingen, Germany</td>
</tr>
<tr>
<td>MP29-04</td>
<td>Combination Therapy with EPI-002 and Ionizing Radiation for Castration-Resistant Prostate Cancer</td>
<td>Yusuke Ito*, C. Adriana Banuelos, Marianne D. Sadar, Vancouver, Canada</td>
</tr>
</tbody>
</table>
MP29-10 TRIM36, A NOVEL ANDROGEN-RESPONSIVE GENE, ENHANCES ANTI-ANDROGEN EFFICACY AGAINST PROSTATE CANCER BY INHIBITING MAPK/ERK SIGNALING PATHWAYS
Jie Li*, Chao Liang, Shangqian Wang, Biaojian Liu, Gong Cheng, Chao Qin, Pengfei Shao, Zengjun Wang, Nanjing, China, People’s Republic of

MP29-11 TARGETING DHEA-S TRANSPORT AND STEROID SULFATASE FOR MORE EFFICIENT ANDROGEN DEPRIVATION THERAPY
Yue Wu*, Michael Greene, Gary Smith, Buffalo, NY

MP29-12 ASSOCIATION OF NEUROPILIN 2 AND EGFR CO-EXPRESSION WITH CANCER-SPECIFIC SURVIVAL IN PROSTATE CANCER AND THE INFLUENCE OF NEUROPILIN 2-DEPLETION COMBINED WITH EGFR-INHIBITION ON CELL FUNCTIONING IN CISPLATIN-SENSITIVE AND –RESISTANT DU145 PROSTATE CANCER C
Angelika Borkowetz*, Susanne FuesSEL, Kati Erdmann, Alexander Schulz, Marieta Toma, Gustavo BarettOn, Michael Froehner, Michael MUDers, Manfred Wirth, Dresden, Germany

MP29-13 TUMOR ENDOTHELIAL CELLS AS A TARGETABLE GATEWAY THAT MODULATES ACCESS OF DRUGS TO CANCER CELLS
Yue Wu*, Michael Greene, Jianmin Wang, Gary Smith, Buffalo, NY

MP29-14 MACROPHAGE INHIBITORY CYTOKINE-1 STIMULATES STROMAL CYTOKINE PRODUCTION IN HIGH-FAT DIET-INDUCED PROSTATE CANCER PROGRESSION
Mingguo Huang*, Shintaro NARita, Takamitsu Inoue, Tomonori Habuchi, Akita, Japan

MP29-15 MAKE IT FROM SCRATCH OR HAVE IT DELIVERED? SATISFYING THE FATTY ACID DEMAND OF PROSTATE CANCER
Sandra Gaston*, Boston, MA, Soroush RAis-Bahrami, Jeffrey Nix, Peter Kolettis, James Bryant, Birmingham, AL, James Kearns, Boston, MA, Oelschlager Denise, Dennis Otali, William Grizzle, Birmingham, AL

MP29-16 ROLE OF A NOVEL TUMOR SUPPRESSOR MICRO-RNA IN PROSTATE CANCER
Nadeem Bhat, Varahram Shahryari, Sharanjot Saini, Soichiro Yamamura, Yuichiro Tanaka, Rajvir Dahiya, Shahana Majid*, San Francisco, CA

MP29-17 ASSOCIATION BETWEEN RS6152 POLYMORPHISM IN THE ANDROGEN RECEPTOR GENE AND DISEASE AGGRESSIVENESS IN A PROSPECTIVE COHORT OF PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY
Vito Cucchiara*, Vincenzo Mirone, Naples, Italy, Dejan Lazarevic, Davide Cittaro, Giovanni Tonon, Matteo Zoccolillo, Marco Emilio Bianchi, Milan, Italy, Rodolfo Montironi, Ancona, Italy, Giorgio Gandaglia, Nicola Fossati, Milan, Italy, Shahrokh F. Shariat, Vienna, Austria, Francesco Montorsi, Alberto Briganti, Milan, Italy

MP29-18 THE EPH FAMILY OF RECEPTOR TYROSINE KINASES AS TUMOR SUPPRESSORS IN AFRICAN-AMERICANS WITH PROSTATE CANCER
Albert H. Kim*, Jane Nguyen, Mark Schlucht, Bingcheng Wang, Carvell Nguyen, Cleveland, OH

MP29-19 SIPULEUCEL-T IMMUNOTHERAPY FOR CASTRATE-RESISTANT PROSTATE CANCER MODULATES SOLUBLE B7-H3: A NOVEL MECHANISM OF ACTION
Andrew Chang*, Smita Nair, Daniel George, Brant INman, Durham, NC

MP29-20 INTRAPROSTATIC SYMPATHETIC NERVE COUNT PREDICTS PROSTATE CANCER RECURRENCE
Fairleigh Reeves, Melbourne, Australia, Shane Battye, Mount Waverley, Australia, Hedley Roth, Frankston, Australia, Justin Peters, Christopher Hovens, Anthony Costello, Niall Corcoran*, Melbourne, Australia

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP30-01</td>
<td>TWO YEAR ONCOLOGICAL OUTCOMES FOLLOWING FOCAL LASER ABLATION</td>
</tr>
<tr>
<td>MP30-02</td>
<td>TRANSRECTALLY DELIVERED, OUTPATIENT MRI-GUIDED LASER FOCAL THERAPY OF PROSTATE CANCER: SEVEN YEAR INTERIM RESULTS OF NCT #02243033</td>
</tr>
<tr>
<td>MP30-05</td>
<td>PROSTATE RADIOFREQUENCY ABLATION FOCAL TREATMENT (PRORAF): RESULTS OF A PROSPECTIVE DEVELOPMENT STUDY FOR LOCALISED PROSTATE CANCER</td>
</tr>
<tr>
<td>MP30-06</td>
<td>INTERIM FOLLOW UP OF A PHASE II TRIAL OF MRI-ULTRASOUND FUSION BIOPSY GUIDED PROSTATE CANCER (PCA) FOCAL THERAPY BY BIPOLAR RADIOFREQUENCY ABLATION</td>
</tr>
<tr>
<td>MP30-07</td>
<td>TRANSPERINEAL MRI-US FUSION TO AID CONFORMAL FOCAL ABLATION FOR INTERMEDIATE RISK ANTERIOR TUMORS</td>
</tr>
<tr>
<td>MP30-08</td>
<td>PERINEURAL INVASION PREDICTS FAILURE OF MR/US FUSION BIOPSY-BASED SELECTION CRITERIA FOR HEMIALABLATIVE FOCAL THERAPY IN PATIENTS WITH INTERMEDIATE-RISK PROSTATE CANCER</td>
</tr>
<tr>
<td>MP30-09</td>
<td>MODERATE MINIMUM TUMOR TEMPERATURE IN CRYOTHERAPY IS ASSOCIATED WITH SUPERIOR QUALITY OF LIFE AND NO DIFFERENCE IN DISEASE CONTROL IN PROSTATE CANCER PATIENTS</td>
</tr>
<tr>
<td>MP30-10</td>
<td>HIFU DOSE ESCALATION LEADS TO FEWER RECURRANCES IN FOLLOWING FOCAL HIFU IN PROSTATE CANCER</td>
</tr>
</tbody>
</table>
MP30-11 PREDICTORS OF POOR FUNCTIONAL OUTCOMES AFTER FOCAL HIGH INTENSITY FOCUSED ULTRASOUND (HIFU)
Taimur T. Shah*, London, United Kingdom, Max Peters, Utrecht, Netherlands, Stephanie Guillaume, London, United Kingdom, Manit Arya, Harlow, United Kingdom, Naveed Afzal, Dorset, United Kingdom, Fergus Hogsking-Jervis, London, United Kingdom, Tim Dudderidge, Southampton, United Kingdom, Richard Hindley, Basingstoke, United Kingdom, Henry Lewi, Chelmsford, United Kingdom, Neil McCartan, Caroline M. Moore, London, United Kingdom, Raj Nigam, Surrey, United Kingdom, Chris Ogden, London, United Kingdom, Raj Persad, Bristol, United Kingdom, Karishma Shah, London, United Kingdom, Jaspar Virdi, Harlow, United Kingdom, Mathias Winkler, Mark Emberton, Hashim U. Ahmed, Suks Minhas, London, United Kingdom

MP30-12 FOCAL CRYOABLATION IS ASSOCIATED WITH SUPERIOR QUALITY OF LIFE AND NO DIFFERENCE IN DISEASE CONTROL RELATIVE TO TOTAL CRYOABLATION IN PROSTATE CANCER PATIENTS

MP30-13 EFFECT OF THE TYPE OF CRYO PROBE ON ONCOLOGICAL & FUNCTIONAL OUTCOMES FOR PRIMARY WHOLE GLAND PROSTATE CRYOABLATION

MP30-14 URINARY INCONTINENCE AFTER PRIMARY WHOLE GLAND PROSTATE CRYOABLATION: DOES FUNCTION IMPROVE AT 1-YEAR FOLLOWING TREATMENT?
Ahmed Elshafei*, Cleveland, OH, Yaw Nyame, Cleveland heights, OH, Thomas Polascik, Durham, NC, Arora Hans, Cleveland heights, OH, Ashley Ross, Baltimore, MD, Mohamed Eltemamy, Cleveland heights, OH, Asmaa Hatem, Cleveland, OH, Robert Given, Eastern Virginia, VA, Jim C. Hu, New York, NY, Michael Cher, Detroit, MI, J. Stephen Jones, Cleveland, OH

MP30-15 PROGNOSTIC INDICATORS FOR FAVORABLE NADIR PSA (<0.4NG/ML) FOLLOWING PRIMARY WHOLE GLAND PROSTATE CRYOABLATION

MP30-16 LOCAL IMMUNE MODULATION BY DECREASING CD4+ / CD8+ T CELLS RATIO AFTER PROSTATE CANCER HEMI-CRYOABLATION
Michael A. Cercequeira, Karen L. Ferrari, Amilcar C. de Mattos, Leonardo Reis*, Campinas, Brazil

MP30-17 OFFICE-BASED MRI/US FUSION TARGET PROSTATE CANCER CRYOABLATION UNDER LOCAL ANESTHESIA: 348 PATIENTS
Fernando J. Bianco*, Jose Antonio Grandez, Sergio Lozano-Kaplun, Ariel Kaufman, Marlin Nicholson, Gloria Egui-Benatouil, Miami, FL

MP30-18 HEMI-GLAND CRYOABLATION OF PROSTATE CANCER: USE OF MRI-GUIDED BIOPSY FOR EVALUATION AND FOLLOW-UP
Demetrios Simopoulos*, Merdie Delfin, Lorna Kwan, Alan Piester, Ely Felker, Anthony Sisk Jr, Leonard Marks, Los Angeles, CA

MP30-19 PROPENSITY SCORE COMPARATIVE MATCHING OF ONCOLOGICAL AND FUNCTIONAL OUTCOMES OF PRIMARY FOCAL VS WHOLE GLAND CRYOTHERAPY FOR PROGNOSTIC GRADE GROUPS (PGG) 4 AND 5 PROSTATE CANCER
Ahmed Elshafei*, Cleveland, OH, Thomas Polascik, Durham, NC, Ashley Ross, Baltimore, MD, Robert Given, Eastern Virginia, VA, Asmaa Hatem, Cleveland, OH, Michael Cher, Detroit, MI, Jim C. Hu, New York, NY, J. Stephen Jones, Cleveland, OH

MP30-20 PROPENSITY SCORE MATCHING (PSM) COMPARISON OF SALVAGE FOCAL TO SALVAGE TOTAL CRYOABLATION OF THE PROSTATE
Ahmed Elshafei*, Cleveland, OH, Asmaa Hatem, Cleveland, OH, J. Kellogg Parsons, San Diego, CA, Thomas Polascik, Kae Jack Tay, Durham, NC, Robert Given, Eastern Virginia, VA, Ashley Ross, Baltimore, MD, Michael Cher, Detroit, MI, Vladimir Mouraviev, Celebration, FL, J. Stephen Jones, Cleveland, OH

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

*Presenting author
Podium Session 17

STONE DISEASE: MEDICAL & DIETARY THERAPY I
Room 2022 @ MCC West
Moderators: John Asplin, Davis Viprakasit and Fabio Torricelli

ABSTRACT

PD17-01 INCREASING FLUID INTAKE TO REDUCE STONE RECURRENCE RISK: IS MORE TECHNOLOGY BETTER?
Kristina L. Penniston*, Zhihui Ju, Mariana M. Coughlin, Stephen Y. Nakada, R. Allan Jhagroo, Madison, WI

7:10 PD17-02 GREEN TEA INTAKE AND RISK OF INCIDENT KIDNEY STONES: A REPORT FROM THE SHANGHAI MEN’S AND WOMEN’S HEALTH STUDIES
Xiang Shu, Hui Cai, Nashville, TN, Yong-Bing Xiang, Honglian Li, Shanghai, China, People’s Republic of, Loren Lipworth, Nicole Miller, Wei Zheng, Xiao-Ou Shu, Ryan Hsi*, Nashville, TN

7:20 PD17-03 CAN COCONUT WATER CONSUMPTION POTENTIALLY PREVENT KIDNEY STONES?
Roshan Patel*, Orange, CA, John Asplin, Ignacio Granja, Chicago, IL, Pengbo Jiang, Kathryn Osann, Jaime Landman, Ralph Clayman, Orange, CA

7:30 PD17-04 MAGNESIUM SUPPLEMENTATION IMPROVES URINARY CITRATE EXCRETION IN THE METABOLIC STONE CLINIC SETTING
Natasza Posielski*, Roy A. Jhagroo, Stephen Y. Nakada, Kristina L. Penniston, Madison, WI

7:40 PD17-05 WITHDRAWL OF TAMSULOSIN FROM URETERAL STONE MANAGEMENT DOES NOT INCREASE STONE SURGERY
Andrew Portis*, Jennifer Portis, St. Paul, MN, Michael Borofsky, Minneapolis, MN, Suzanne Neises, St. Paul, MN

8:00 PD17-07 CT-BASED EVALUATION OF THE IMPACT OF THIazides AND POTASSIUM CITRATE ON BONE MINERAL DENSITY IN STONE FORMERS
Luay Alshara*, Carlos Batagello, Tianming Gao, Erick M. Remer, Cleveland, OH, Nishant D. Patel, Santa Monica, CA, Sherif Armanyous, Manoj Monga, Cleveland, OH
<table>
<thead>
<tr>
<th>ABSTRACT (TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
<th>ABSTRACT (TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 PD18-01</td>
<td>MANAGEMENT OF URETHRAL INJURY AT</td>
<td>EFFECT OF TISSUE SEALING SHEETS ON</td>
<td>8:00 PD18-07</td>
<td>EFFECT OF TISSUE SEALING SHEETS ON</td>
<td></td>
</tr>
<tr>
<td></td>
<td>THE TIME OF PENILE PROSTHESIS</td>
<td>ERECTILE FUNCTION FOLLOWING</td>
<td></td>
<td>ERECTILE FUNCTION FOLLOWING</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IMPLANTATION: A PARADIGM SHIFT</td>
<td>ROBOTIC-ASSISTED LAPAROSCOPIC</td>
<td></td>
<td>ROBOTIC-ASSISTED LAPAROSCOPIC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bhavik Shah*, Aram Loeb, Jon</td>
<td>PROSTATECTOMY: INTERIM RESULTS OF</td>
<td></td>
<td>PROSTATECTOMY: INTERIM RESULTS OF</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Beilan, Adam Baumgarten,</td>
<td>A RANDOMIZED CONTROLLED TRIAL</td>
<td></td>
<td>A RANDOMIZED CONTROLLED TRIAL</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Julio Slongo, Justin Parker,</td>
<td>Shinichi Yamashita*, Koji</td>
<td></td>
<td>Shinichi Yamashita*, Koji</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rafael Carrion, Tampa, FL</td>
<td>Mitsuizuka, Akihiro</td>
<td></td>
<td>Mitsuizuka, Akihiro</td>
<td></td>
</tr>
<tr>
<td>7:10 PD18-02</td>
<td>EMERGING COMPLICATIONS AFTER</td>
<td>Ito, Hisanobu Adachi, Yasuhiro</td>
<td></td>
<td>Ito, Hisanobu Adachi, Yasuhiro</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ECTOPIC PLACEMENT OF RESERVOIRS</td>
<td>Kaiho, Naoki Kawamoto, Hideo</td>
<td></td>
<td>Kaiho, Naoki Kawamoto, Hideo</td>
<td></td>
</tr>
<tr>
<td></td>
<td>DURING INFLATABLE PENILE</td>
<td>Salt, Haruo Nakagawa, Hideaki</td>
<td></td>
<td>Salt, Haruo Nakagawa, Hideaki</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PROSTHESIS SURGERY: A MULTI-</td>
<td>Izumi, Yoshihide Kawasak, Takuro</td>
<td></td>
<td>Izumi, Yoshihide Kawasak, Takuro</td>
<td></td>
</tr>
<tr>
<td></td>
<td>INSTITUTIONAL EXPERIENCE</td>
<td>Goto, Shinji Fujii, Yoichi</td>
<td></td>
<td>Goto, Shinji Fujii, Yoichi</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jonathan Clavell Hernandez*,</td>
<td>Arai, Sendai, Japan</td>
<td></td>
<td>Arai, Sendai, Japan</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Houston, TX, Joshua Ring,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Springfield, IL, Landon</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Trost, Tobias Kohler,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rochester, MN, Run Wang,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Houston, TX</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:20 PD18-03</td>
<td>DOOMED TO IMPOTENCE: ANALYSIS</td>
<td>THE PERFORMANCE CHARACTERISTICS</td>
<td>8:20 PD18-09</td>
<td>THE PERFORMANCE CHARACTERISTICS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>OF ERECTILE DYSFUNCTION (ED) AND</td>
<td>OF A SHAPE MEMORY PENILE</td>
<td></td>
<td>OF A SHAPE MEMORY PENILE</td>
<td></td>
</tr>
<tr>
<td></td>
<td>INFLATABLE PENILE PROSTHESIS (IPP)</td>
<td>PROSTHESIS IN HUMAN CADAVERS</td>
<td></td>
<td>PROSTHESIS IN HUMAN CADAVERS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>INSURANCE COVERAGE FROM</td>
<td>Brian Le*, Madison, WI, Kevin</td>
<td></td>
<td>Brian Le*, Madison, WI, Kevin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>VERIFICATION BENEFITS DATABASES</td>
<td>McVary, Alberto Colombo,</td>
<td></td>
<td>McVary, Alberto Colombo,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Daniel J. Mazur*, Jabe C.</td>
<td>Springfield, IL, IL</td>
<td></td>
<td>Springfield, IL, IL</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gondokusumo, J. Abram</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>McBride, Alexander W.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pastuszak, Larry I. Lipshultz,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Houston, TX</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:30 PD18-04</td>
<td>EFFECT OF RADIOTHERAPY ON</td>
<td>PENILE PROSTHESIS PLACEMENT IN THE</td>
<td>8:30 PD18-10</td>
<td>PENILE PROSTHESIS PLACEMENT IN THE</td>
<td></td>
</tr>
<tr>
<td></td>
<td>INFLATABLE PENILE PROSTHETIC</td>
<td>SETTING OF PROLONGED REFRACTORY</td>
<td></td>
<td>SETTING OF PROLONGED REFRACTORY</td>
<td></td>
</tr>
<tr>
<td></td>
<td>COMPLICATION AND REOPERATION</td>
<td>ISCHEMIC PRIAPISM: A SINGLE</td>
<td></td>
<td>ISCHEMIC PRIAPISM: A SINGLE</td>
<td></td>
</tr>
<tr>
<td></td>
<td>RATES</td>
<td>INSTITUTION EXPERIENCE</td>
<td></td>
<td>INSTITUTION EXPERIENCE</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ron Golan*, Tianyi Sun, Adrien</td>
<td>Adam Baumgarten*, Bhavik</td>
<td></td>
<td>Adam Baumgarten*, Bhavik</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bernstein, Jim Hu, Art Sedrakyan,</td>
<td>Shah, Michael</td>
<td></td>
<td>Shah, Michael</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Loeb, Justin</td>
<td></td>
<td>Loeb, Justin</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Parker, Rafael</td>
<td></td>
<td>Parker, Rafael</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Carrion, Tampa, FL</td>
<td></td>
<td>Carrion, Tampa, FL</td>
<td></td>
</tr>
<tr>
<td>7:40 PD18-05</td>
<td>EMERGING DATA REGARDING FUNGAL</td>
<td>PENILE IMPLANT DOES NOT REDUCE</td>
<td>8:40 PD18-11</td>
<td>PENILE IMPLANT DOES NOT REDUCE</td>
<td></td>
</tr>
<tr>
<td></td>
<td>INFECTIONS OF INFLATABLE PENILE</td>
<td>PENILE LENGTH</td>
<td></td>
<td>PENILE LENGTH</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PROSTHESSES</td>
<td>Mohamad Habous*, Jedd, Saudi</td>
<td></td>
<td>Mohamad Habous*, Jedd, Saudi</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Martin Gross*, Keene, NH, Gerard</td>
<td>Arabia, Osama</td>
<td></td>
<td>Arabia, Osama</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Henry, Shreveport, LA, Stanton</td>
<td>Abdelwahab, Benha, Egypt, David</td>
<td></td>
<td>Abdelwahab, Benha, Egypt, David</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Honig, New Haven, CT, Peter</td>
<td>Ralph, London, United Kingdom,</td>
<td></td>
<td>Ralph, London, United Kingdom,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Stahl, New York City, NY,</td>
<td>Simone Giona, London, United</td>
<td></td>
<td>Simone Giona, London, United</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Arthur Burnett, Baltimore, MD,</td>
<td>Kingdom, Osama Labar, Tabouk,</td>
<td></td>
<td>Kingdom, Osama Labar, Tabouk,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pedro Maria, New York</td>
<td>Saudi Arabia, Saleh</td>
<td></td>
<td>Saudi Arabia, Saleh</td>
<td></td>
</tr>
<tr>
<td></td>
<td>City, NY, Nelson Bennett,</td>
<td>Binsalesh, Riyadh, Saudi Arabia,</td>
<td></td>
<td>Binsalesh, Riyadh, Saudi Arabia,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chicago, IL, Rafael</td>
<td>Gordon Muir, London, United</td>
<td></td>
<td>Gordon Muir, London, United</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Carrion, Tampa,</td>
<td>Kingdom, John Mulhall, New</td>
<td></td>
<td>Kingdom, John Mulhall, New</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FL, Tobias Kohler,</td>
<td>York, NY</td>
<td></td>
<td>York, NY</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rochester, MN, Ricardo</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Munarriz, Boston, MA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:50 PD18-06</td>
<td>SEXUAL SATISFACTION OF MEN WITH</td>
<td>IMPLANT SELECTION PATTERNS AND</td>
<td>8:50 PD18-12</td>
<td>IMPLANT SELECTION PATTERNS AND</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ERECTILE DYSFUNCTION TREATED</td>
<td>REOPERATION RATES IN</td>
<td></td>
<td>REOPERATION RATES IN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>WITH PENILE PROSTHESIS VERSUS</td>
<td>IMMUNOCOMPROMISED PATIENTS THAT</td>
<td></td>
<td>IMMUNOCOMPROMISED PATIENTS THAT</td>
<td></td>
</tr>
<tr>
<td></td>
<td>MEDICAL TREATMENT MODALITIES: ARE WE</td>
<td>UNDERWENT PENILE PROSTHESIS</td>
<td></td>
<td>UNDERWENT PENILE PROSTHESIS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>WAITING TOO LONG TO IMPLANT?</td>
<td>SURGERY</td>
<td></td>
<td>SURGERY</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Meenakshi Davuluri*, New York,</td>
<td>Denise Asafu-Adjei*, George</td>
<td></td>
<td>Denise Asafu-Adjei*, George</td>
<td></td>
</tr>
<tr>
<td></td>
<td>NY, Abhishek Srivastava, Pedro</td>
<td>Moran, Michael Lipsky, Gen Li,</td>
<td></td>
<td>Moran, Michael Lipsky, Gen Li,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Maria, Bronx, NY</td>
<td>Doron Stember, Peter J. Stahl,</td>
<td></td>
<td>Doron Stember, Peter J. Stahl,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>New York, NY</td>
<td></td>
<td>New York, NY</td>
<td></td>
</tr>
</tbody>
</table>

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
### ABSTRACT

<table>
<thead>
<tr>
<th>Time</th>
<th>Number</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00</td>
<td>PD19-01</td>
<td>EVALUATION OF THE VAGINAL MYCOBIOME IN ASYMPTOMATIC PRE-MENOPAUSAL WOMEN</td>
</tr>
<tr>
<td>7:10</td>
<td>PD19-02</td>
<td>CHARACTERIZATION OF BACTERIAL IDENTIFIED ON EXPLANTED MESH SLINGS USING NEXT-GENERATION SEQUENCING TECHNIQUES</td>
</tr>
<tr>
<td>7:20</td>
<td>PD19-03</td>
<td>BLADDER MICROBIOTA DIFFER IN MEN AND WOMEN WITH AND WITHOUT LOWER URINARY TRACT SYMPTOMS</td>
</tr>
<tr>
<td>7:30</td>
<td>PD19-04</td>
<td>BLADDER SENSORY MECHANISM EARLY IMPAIRMENT INDUCES DETERUSOR UNDERACTIVITY (DU) FOLLOWING BLADDER OUTLET OBSTRUCTION (BOO)</td>
</tr>
<tr>
<td>7:40</td>
<td>PD19-05</td>
<td>THERAPEUTIC EFFECTS OF PDE9 INHIBITOR IN STORAGE AND VOIDING DYSFUNCTION IN MICE WITH SPINAL CORD INJURY (SCI)</td>
</tr>
<tr>
<td>7:50</td>
<td>PD19-06</td>
<td>NO-RELEASING NANOPARTICLES DECREASE DETRUSOR OVERACTIVITY IN DNOS+/− KNOCKOUT AND TRANSGENIC SICKLE CELL MICE</td>
</tr>
<tr>
<td>8:00</td>
<td>PD19-07</td>
<td>CRH NEURONS OF BARRINGTON’S NUCLEUS ARE NECESSARY BUT NOT SUFFICIENT FOR CO-ORDINATED VOIDING IN MICE</td>
</tr>
<tr>
<td>8:10</td>
<td>PD19-08</td>
<td>BLADDER UROTHELIUM TRIGGERS AN IMMEDIATE DEFENSIVE RESPONSE AGAINST BACTERIAL LIPOPOLYSACCHARIDE VIA ATP SIGNALING</td>
</tr>
<tr>
<td>8:20</td>
<td>PD19-09</td>
<td>SENSORY RECEPTORS AND RELATED PROTEIN INVESTIGATION IN THE PATHOPHYSIOLOGY OF KETAMINE CYSTITIS</td>
</tr>
<tr>
<td>8:30</td>
<td>PD19-10</td>
<td>P38 MITOGEN-ACTIVATED PROTEIN KINASE INHIBITOR REDUCES HYPEREXCITABILITY OF CAPSAICIN SENSITIVE BLADDER AFFERENT NEURONS IN MICE WITH SPINAL CORD INJURY</td>
</tr>
<tr>
<td>8:40</td>
<td>PD19-11</td>
<td>ISOLATED TRIGONE ONABOTULINUMTOXINA INJECTION DOES NOT ADVERSELY CHANGE AMBULATORY VOIDING FUNCTION IN A RAT MODEL OF OVERACTIVE BLADDER</td>
</tr>
<tr>
<td>8:50</td>
<td>PD19-12</td>
<td>TEMPORAL EFFECTS OF CHRONIC BLADDER OVER-DISTENSION ON HIF-1A AND VEGF EXPRESSION IN MOUSE UROTHELIUM</td>
</tr>
</tbody>
</table>

*Presenting author*
<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAN ACTIVE SURVEILLANCE REALLY REDUCE THE HARMs OF PSA TESTING, LIKE THE U.S. PREVENTATIVE SERVICES TASK FORCE CURRENTLY SUGGESTS? THE PRIAS-STUDY IMPLICATES CAUTION</td>
<td>7:10</td>
<td>PD20-02</td>
<td>Frank-Jan Drost*, Rotterdam, Netherlands, Antti Rannikko, Helsinki, Finland, Riccardo Valdagni, Milan, Italy, Tom Pickles, Vancouver, Canada, Yoshiyuki Kakehi, Kagawa, Japan, Monique Roodbol, for the PRIAS-study group, Rotterdam, Netherlands</td>
</tr>
<tr>
<td>RATES OF UpGRADING AND PROGRESSION TO TREATMENT IN PATIENTS ON ACTIVE SURVEILLANCE DEPEND ON CHOICE OF CONFIRMATORY TEST AT THE TIME OF DIAGNOSIS</td>
<td>7:20</td>
<td>PD20-03</td>
<td>Kevin Ginsburg*, Jesse Jacobs, Detroit, MI, Deborah Kaye, Ji Qi, Ann Arbor, MI, Michael Cher, Detroit, MI, For the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI</td>
</tr>
<tr>
<td>THE IMPACT OF MULTIPARAMETRIC MRI ON PREDICTING PROGRESSION IN MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER</td>
<td>7:50</td>
<td>PD20-06</td>
<td>Zachary Kornberg*, Antonio Carlos Westphalen, Janet E. Cowan, June M. Chan, Matthew R. Cooperberg, Katsuto Shinohara, Peter R. Carroll, San Francisco, CA</td>
</tr>
<tr>
<td>LONG-TERM OUTCOMES OF ACTIVE SURVEILLANCE FOR PROSTATE CANCER – THE MEMORIAL SLOAN KETTERING CANCER CENTER EXPERIENCE</td>
<td>8:00</td>
<td>PD20-07</td>
<td>Sigrid Carlsson, Nicole Benfante*, Ricardo Alvim, Daniel D. Sjoberg, Behfar Ehdane, Peter Scardino, James Eastham, Karim Touijer, New York, NY</td>
</tr>
<tr>
<td>THE EFFECT OF SELECTION AND REFERRAL BIASES FOR THE TREATMENT OF LOCALIZED PROSTATE CANCER WITH SURGERY OR RADIATION</td>
<td>8:10</td>
<td>PD20-08</td>
<td>Christopher Wallis, Gerard Morton, Sender Herschom, Ronald Kodama, Girish Kulkarni, Sree Apuu, Toronto, Canada, Bobby Shayegean, Hamilton, Canada, Roger Buckley, Arthur Grabowski, Steven Narod, Robert Nam*, Toronto, Canada</td>
</tr>
</tbody>
</table>
8:30 PD20-10 UPGRADING AT PROSTATECTOMY FOLLOWING INITIATION OF ACTIVE SURVEILLANCE IN MEN WITH LOCALIZED PROSTATE CANCER
Justin Gregg*, Chad Reichard, Mary Achim, Xuemei Wang, Brian Chapin, Curtis Pettaway, Louis Pisters, John F. Ward, Seungtaek Choi, Deborah Kuban, John Davis, Jeri Kim, Houston, TX

8:40 PD20-11 17-GENE GENOMIC PROSTATE SCORE CAN ACCURATELY DETERMINE THE NEED FOR CONFIRMATORY BIOPSY IN PATIENTS ELECTING ACTIVE SURVEILLANCE
Daniel Hettel, Anna Faris, Shree Agrawal*, Bryan Naelitz, Khaled Fareed, James Ulchaker, Andrew Stephenson, Michael Gong, Eric Klein, Cleveland, OH

8:50 PD20-12 ACTIVE SURVEILLANCE OF PROSTATE CANCER IN AFRICAN-AMERICANS DURING THE MRI ERA
Jonathan B. Bloom*, Sam Gold, Graham Hale, Kareem Rayn, Joseph Baoico, Sherif Mehralivand, Vladimir Valera, Clayton Smith, Marcin Czarniecki, Sam Gold, Bradford J. Wood, Howard L. Pames, Peter L. Choyke, Baris Turkbey, Peter A. Pinto, Bethesda, MD

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 19, 2018 7:00 am - 9:00 am
Video Session 4

RECONSTRUCTION - UPPER URINARY TRACT
The videos in this session as well as the video libraries from the 2011-2016 Annual Meetings may be viewed in the Surgical Video Library and purchased in the AUA Store during the Annual Meeting. Both are located in Hall A. AUA members receive free online access to the Surgical Video Library throughout the year through AUA University. Visit www.AUAnet.org/University to access.

Room 3002 @ MCC West
Moderators: Bahaa Malaeb, Reza Ghavamian and Justin Chee

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>V04-01</td>
<td>ROBOTIC ASSISTED LEFT RENAL VEIN TRANSPOSITION</td>
</tr>
<tr>
<td>V04-02</td>
<td>ROBOT-ASSISTED LAPAROSCOPIC EXTRAVASCULAR STENT FOR NUTCRACKER SYNDROME</td>
</tr>
<tr>
<td>V04-03</td>
<td>TRANSNEPHROTOMIC ICG GUIDED ROBOTIC URETERAL REIMPLANTATION FOR URETEROILEAL STRICTURES AFTER ROBOTIC CYSTECTOMY AND NEobladder: STEP BY STEP TECHNIQUE</td>
</tr>
<tr>
<td>V04-04</td>
<td>THE USE OF COLOR SEGMENTED FLUORESCENCE TO ASSESS URETERAL PERFUSION AT THE TIME OF URINARY DIVERSION</td>
</tr>
<tr>
<td>V04-05</td>
<td>REPAIR OF AN IATROGENIC RIGHT URETERAL AVULSION WITH ROBOTIC APPENDICECAL INTERPOSITION AND LOWER POLE APPENDICOCALICOSTOMY</td>
</tr>
<tr>
<td>V04-06</td>
<td>LAPAROSCOPIC LEFT URETERAL SUBSTITUTION USING CECAL APPENDIX RECTOSIGMOIDECTOMY: A CASE REPORT AND VIDEO DEMONSTRATION</td>
</tr>
<tr>
<td>V04-07</td>
<td>COMPLEX ROBOTIC-ASSISTED LAPAROSCOPIC URETERAL RECONSTRUCTION: TIPS AND TRICKS</td>
</tr>
<tr>
<td>V04-08</td>
<td>SEGMENTAL URETERECTOMY WITH BUCCAL MUCOSA GRAFT RECONSTRUCTION IN A PATIENT WITH LYNCH SYNDROME AND UROTHELIAL CARCINOMA</td>
</tr>
<tr>
<td>V04-09</td>
<td>ROBOTIC-ASSISTED URETEROENTERIC ANASTOMOTIC STRICURE REPAIR USING A SIDE-TO-SIDE ANASTOMOSIS AND FIREFLY® TECHNOLOGY</td>
</tr>
<tr>
<td>V04-10</td>
<td>LAPAROSCOPIC IN SITU DISMEMBERED PYELOPLASTY TO FACILITATE LAPAROSCOPIC URETEROPELVIC JUNCTION OBSTRUCTION REPAIR</td>
</tr>
</tbody>
</table>

*Presenting author
V04-11 ROBOTIC ASSISTED LAPAROSCOPIC UPPER POLE MOIETY URETERECTOMY
Zachary Panfili*, Marcus Austenfeld, David Duchene, Kansas City, KS

V04-12 ROBOT-ASSISTED PARTIAL NEPHRECTOMY AND BILATERAL PYELOLYTHOTOMY OF ECTOPIC PELVIC KIDNEYS
Carlotta Palumbo*, Maria Furlan, Stefania Zamboni, Alessandro Veccia, Angelo Peroni, Alessandro Antonelli, Claudio Simeone, Brescia, Italy

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 19, 2018
7:30 am - 5:30 pm

SOCIETY FOR PEDIATRIC UROLOGY (SPU)
Yerba Buena Salon 8-9 @ Marriott Marquis

7:30 WELCOME
Caleb Nelson

7:35 SCIENTIFIC SESSION V: BASIC SCIENCE PRIZE FINALISTS

8:05 MEREDITH CAMPBELL LECTURE: PEDIATRIC UROLOGY GROWS UP
Philip Ransley

8:50 SCIENTIFIC SESSION VI: ENDOUROLOGY AND STONE DISEASE

9:26 BREAK

9:55 PANEL DISCUSSION: THE SCOPE OF UNWARRANTED VARIATION IN PEDIATRIC UROLOGICAL CARE, AND WHAT TO DO ABOUT IT
Moderator: Caleb Nelson
Panelists: Carlos Estrada, Jonathan Routh, Julian Wan

10:40 SCIENTIFIC SESSION VII: HEALTH SERVICES AND POPULATION RESEARCH

11:50 PRESENTATION OF SPU RESEARCH GRANTS AND INTRODUCTION OF FELLOWS

12:00 SPU PRESIDENTIAL ADDRESS AND SPU BUSINESS MEETING

12:30 LUNCH

1:30 COMBINED SPU/CONGENITALISM WORKING GROUP PROGRAM

2:30 SCIENTIFIC SESSION VIII: GENITOURINARY IMAGING AND DIAGNOSTICS

3:00 BREAK

3:30 SCIENTIFIC SESSION IX: MAJOR RECONSTRUCTION AND URODYNAMICS

5:00 SCIENTIFIC SESSION X: TUMORS, TRAUMA & TRANSPLANTATION

5:30 ADJOURN

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 19, 2018
8:00 am - 11:45 am

SOCIETY FOR BASIC UROLOGIC RESEARCH AND SOCIETY OF UROLOGIC ONCOLOGY (SBUR/SUO):
Grand B @ Hilton SF Union Square

8:00 WELCOME AND INTRODUCTION
Christopher Evans, Allen Gao

8:05 OVERVIEW OF IMMUNOTHERAPY IN GU
James Gulley

8:35 TARGETING MYELOID DERIVED SUPPRESSOR CELLS IN UROLOGICAL CANCERS
Timothy Ratliff

8:55 ENGAGING THE IMMUNE SYSTEM TO COMBAT PROSTATE CANCER
Lauren Harshman

9:15 PANEL DISCUSSION AND QUESTIONS

9:30 IMMUNOTHERAPY IN UROTHELIAL CANCER
Moderators: Siamak Daneshmand, Timothy Ratliff

10:50 DONALD S. COFFEY LECTURE INTRODUCTION
Matthew Campbell

11:35 Q & A

11:45 ADJOURN

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
Saturday, May 19, 2018 8:00 am - 5:00 pm

AMERICAN COLLEGE OF OSTEOPATHIC SURGEONS (ACOS)
Room 214 @ MCC South

Program Chair: Nathan Hale
Co-Chairs: Julie Brownell, Kirin Syed

8:00 USE AND ABUSE OF OPIOIDS IN UROLOGIC SURGERY
Ben Davies

8:45 IMPLICATIONS OF TECHNOLOGY ADOPTION IN PROSTATE CANCER
Bruce Jacobs

9:30 VAPOING AND BLADDER CANCER: IS THERE A RISK?
Tatum Tarin

10:15 BREAK

10:30 IMMUNOTHERAPY IN BLADDER CANCER
Megan Merrill

11:15 MALE SLING VS AUS FOR POST-PROSTATECTOMY INCONTINENCE
Angelo Gousse

12:00 INTERVENTIONAL UROLOGY
Ardeshir Rastinehad

12:45 NON-CME INDUSTRY SPONSORED LUNCH

1:45 NEUROGENIC BLADDER
Nazia Bandukwala

2:00 FEMALE SEXUAL DYSFUNCTION
Rachel Rubin, Nicole Szell

2:45 ROLE OF ROBOTICS IN THE TREATMENT OF BLADDER CANCER
Khurshid Guru

3:30 GO-GO GONADS
Margaret Vereb

4:15 RETHINKING UROLOGY: A PARADIGM SHIFT

5:00 ADJOURN

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

---

Saturday, May 19, 2018 8:30 am - 5:00 pm

Forums

UROLOGIC CARE FOR THE ADVANCED PRACTICE PROVIDER - SATURDAY
Room 2018 @ MCC West

8:30 WELCOME/INTRODUCTION
Course Directors: Kenneth Mitchell, Heather Schultz

8:40 ARS PRE-TEST SESSIONS I, II & III

8:50 SESSION I: ONCOLOGY
PROSTATE CANCER UPDATE: CLINICAL GUIDELINES & MANAGEMENT
Daniel Park

9:30 BLADDER CANCER: NEW DIAGNOSTIC TOOLS, INTRAVESICAL THERAPIES, AND MANAGEMENT OF INTRAVESICAL DRUG TOXICITIES
Michael O’Donnell

10:10 PROSTATE CANCER MANAGEMENT: VARIABILITIES IN CARE BETWEEN A RURAL PRIVATE PRACTICE AND AN URBAN ACADEMIC CENTER
Thomas McBride, Anne Calvaresi

10:50 SESSION I: PANEL DISCUSSION Q&A AND ARS POST-TEST

11:10 BREAK

11:20 SESSION II: VOIDING DYSFUNCTION OVERACTIVE BLADDER – MAKING AND SETTING EXPECTATIONS FOR TREATMENT SELECTION
Sandip Vasavada

8:00 USE AND ABUSE OF OPIOIDS IN UROLOGIC SURGERY
Ben Davies

8:45 IMPLICATIONS OF TECHNOLOGY ADOPTION IN PROSTATE CANCER
Bruce Jacobs

9:30 VAPOING AND BLADDER CANCER: IS THERE A RISK?
Tatum Tarin

10:15 BREAK

10:30 IMMUNOTHERAPY IN BLADDER CANCER
Megan Merrill

11:15 MALE SLING VS AUS FOR POST-PROSTATECTOMY INCONTINENCE
Angelo Gousse

12:00 INTERVENTIONAL UROLOGY
Ardeshir Rastinehad

12:45 NON-CME INDUSTRY SPONSORED LUNCH

1:45 NEUROGENIC BLADDER
Nazia Bandukwala

2:00 FEMALE SEXUAL DYSFUNCTION
Rachel Rubin, Nicole Szell

2:45 ROLE OF ROBOTICS IN THE TREATMENT OF BLADDER CANCER
Khurshid Guru

3:30 GO-GO GONADS
Margaret Vereb

4:15 RETHINKING UROLOGY: A PARADIGM SHIFT

5:00 ADJOURN

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

---

*Presenting author
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| MP31-01 | THIS TOO SHALL PASS: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFECT OF TAMSULOSIN ON RATES OF DISTAL URETERAL STONE PASSAGE  
Kristian Stensland*, Burlington, MA, Larry Malinconico, Lawrence Zhang, Boston, MA, David Canes, Burlington, MA |
| MP31-02 | MEDICAL EXPULSIVE THERAPY IN PREGNANCY; A RETROSPECTIVE STUDY  
Benoit Theriault*, Fannie Morin, Jonathan Cloutier, Quebec, Canada |
| MP31-03 | COMBINATION OF PREDNISOLONE WITH SILODOSIN IS EFFICIENT AND SAFE TREATMENT FOR PASSAGE OF LOWER URETERIC STONES THAN SILODOSIN ALONE  
Ahmed Abd El Latif*, Osama Sayed, Ahmed ElBatanouny, Aymen Salah, Amr Massoud, Beni Suef, Egypt |
| MP31-04 | TAMSULOSIN, OXYBUTYNIN, OR THEIR COMBINATION IN THE TREATMENT OF URETERAL STENT-RELATED SYMPTOMS  
Efrain Maldonado-Alcaraz, Jorge Moreno-Palacios, Virgilio Augusto Lopez-Samano, Leon Octavio Torres-Mercado, Jason Damian Landa-Salas, Carlos Garcia-Cruz*, Mexico City, Mexico |
| MP31-05 | POTASSIUM CITRATE FOR URIC ACID STONE RISK: DOES DIABETES MATTER?  
Kimberly A Maciolek*, Kristina L. Penniston, Sara L. Best, Madison, WI |
| MP31-06 | OPTIMIZATION OF URIC ACID DISSOLUTION THERAPY BY HAND HELD DIGITAL PH METER  
Mohamed Omar*, Shibin el Kom, Egypt |
| MP31-07 | IS THERE A RELATIONSHIP BETWEEN METFORMIN USE AND KIDNEY STONE FORMATION IN DIabetics?  
Stephanie Purnell*, Blair Gallante, Kyle Blum, Julie Thai, Egor Parkhomenko, William Atallah, Mantu Gupta, New York, NY |
| MP31-08 | AN INTERVENTION TO INCREASE 24-HOUR URINE COLLECTION COMPLIANCE  
Carter Boyd*, Kyle Wood, Omotola Ashorobi, John Knight, Ross Holmes, Dean Assimos, Birmingham, AL |
| MP31-09 | A PREDICTIVE MODEL TO HELP IDENTIFY FACTORS ASSOCIATED WITH SUBMITTING 24-HOUR URINE COLLECTIONS  
Eric Ghiraldi*, Ryan Griggs, Carmen Tong, Leonard Brailtman, Justin Friedlander, Philadelphia, PA |

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| MP31-10 | THIAZIDES MORE EFFECTIVE IN PREVENTING STONE EVENTS IN PATIENTS WITH SEVERE HYPERCALCIURIA (>500 MG/D) THAN MILD HYPERCALCIURIA (250-300 MG/D): PRELIMINARY RESULTS  
Shuang Li*, R. Allan Jhagroo, Stephen Y. Nakada, Kristina L. Penniston, Madison, WI |
| MP31-11 | ROLE OF ALLOPURINOL AND FEBUXOSTAT IN CHRONIC KIDNEY DISEASE: META-ANALYSIS FROM A UROLOGIST’S PERSPECTIVE  
Peter Cai, Christopher Gaffney*, Clara Oromendia, Paul Christos, Joseph Del Pizzo, Timothy McClure, Richard Lee, New York, NY |
| MP31-12 | DEVELOPMENT OF A PREDICTIVE MODEL TO ESTIMATE SUCCESS RATES OF CONSERVATIVE DIETARY MANAGEMENT ON 24-HOUR URINARY PH IN STONE FORMERS  
Daniel Wollin*, Leah Davis, Brenton Winship, Evan Carlos, Westin Tom, Durham, NC, John Asplin, Chicago, IL, Charles Scales, Michael Ferrandino, Michael Lipkin, Glenn Preminger, Durham, NC |
| MP31-13 | IMPROVING FLUID INTAKE BEHAVIOR AMONG PATIENTS’ WITH KIDNEY STONES: A FOCUS GROUP TO UNDERSTAND PATIENTS’ EXPERIENCES AND ACCEPTABILITY OF SENSORS  
Necole Streeper*, Hershey, PA, Alexandra Dubnansky, Ashley Sanders, University Park, PA, Kathleen Lehman, Hershey, PA, David Conroy, University Park, PA |
| MP31-14 | DOES DIETARY ASSESSMENT AID IN DECISION-MAKING FOR MEDICAL MANAGEMENT OF HYPERCALCIURIA?  
John Roger Bell*, Lexington, KY, Mark E. Ehlers, Chapel Hill, NC, Amy Schweitzer, Stephen Y. Nakada, Kristina L. Penniston, Madison, WI |
| MP31-15 | SERUM VITAMIN D STATUS, VITAMIN D3 SUPPLEMENTATION AND URINE CALCIUM LEVELS AMONG 140 CALCIUM KIDNEY STONE PATIENTS  
Barry S. Farber, M.D.*, Robert E. Kennedy, Jr., Ph. D., Springfield, MO |
| MP31-16 | THE IMPACT OF REDUCING DIETARY SODIUM IN HYPERCALCIURIC STONE FORMERS  
Abdulaziz Alathel*, Jennifer Bjahelvic, Linda Nott, Hassan Razvi, London, Canada |
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITILE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP32-01</td>
<td>PROSPECTIVE OBSERVATIONAL LONGITUDINAL STUDY EVALUATING ERECTILE DYSFUNCTION IN 50 TYPE 2 DIABETIC PATIENTS WITH BMI BELOW 35 KG/M2 SUBMITTED TO ILEAL INTERPOSITION ASSOCIATED TO SLEEVE GASTRECTOMY Ricardo Ferro*, Brasilia, Brazil, Aureo de Paula, Sérgio Vencio, Rafael Caiado-Vencio, Goiânia, Brazil, Marco Antonio Rodrigues, Marco Túlio Diniz, Belo Horizonte, Brazil</td>
</tr>
<tr>
<td>MP32-02</td>
<td>PROSTHESIS-SPECIFIC SURVEY: CHARACTERIZING SEXUAL QUALITY OF LIFE WITH A 3-PIECE PENILE PROSTHESIS Evan Carlos*, Leah Gerber, Chloe Peters, Durham, NC, Aaron Lentz, Raleigh, NC</td>
</tr>
<tr>
<td>MP32-03</td>
<td>ERECTILE FUNCTION RESTORATION POST-RADICAL PROSTATECTOMY: UTILISATION OF A NEW NOVEL END-TO-SIDE NERVE GRAFTING PROCEDURE Christopher Coombs*, Jeanette Reece, David Dangerfield, Melbourne, Australia</td>
</tr>
<tr>
<td>MP32-06</td>
<td>DELAY IN PENILE PROSTHESIS AND ARTIFICIAL URINARY SPHINCTER SURGERY FOLLOWING RADICAL PROSTATECTOMY: LESSONS FROM A STATEWIDE DATABASE Denise Asafu-Adjei*, Cooper Benson, Stephanie Thompson, Doreen E. Chung, Gen Li, Matthew Runman, James Kashanian, Dhoron Stember, Peter J. Stahl, New York, NY</td>
</tr>
<tr>
<td>MP32-07</td>
<td>CONCOMITANT SCROTOPLASTY DURING PENILE PROSTHESIS SURGERY: IS IT WORTH THE RISK? Matthew Brennan*, Ryan Barlotta, Jacob Lucas, Jay Simhan, Philadelphia, PA</td>
</tr>
<tr>
<td>MP32-08</td>
<td>HIGH INGUINAL MICROSURGICAL DENERVATION OF THE SPERMATIC CORD FOR CHRONIC ORCHIALGIA: A NOVEL APPROACH FOR ADULT AND PEDIATRIC PATIENTS Koji Shiraiishi*, Masanori Tabara, Shintaro Oka, Hideyasu Matsuyama, Ube, Japan</td>
</tr>
<tr>
<td>MP32-09</td>
<td>IMPACT OF POST-HOSPITAL SYNDROME ON OUTCOMES FOLLOWING PENILE PROSTHESIS Eric Kirshenbaum, Marc Nelson*, Marah Hehemann, Anai Kothari, Gopal Gupta, Ahmer Farooq, Larissa Bresler, Grace Delos Santos, Maywood, IL</td>
</tr>
<tr>
<td>MP32-10</td>
<td>GLANS PENIS SENSITIVITY TO VIBRATION AFTER INFLATABLE PENILE PROSTHESIS IMPLANTATION USING A PENOSCROTAL AND INFRAPUBIC APPROACH Nika Akhdevldani*, Dmitry Enikeev, Denis Butmaru, Igor Matukhov, Moscow, Russian Federation</td>
</tr>
</tbody>
</table>
MP32-11 PROSTHETIC SPARING SURGERY: RISK FACTORS FOR INFECTION AND KEYS TO SUCCESS
Bhavik Shah*, Michael Binner, Jon Beilan, Adam Baumgarten, Justin Parker, Rafael Carrion, Tampa, FL

MP32-12 PENILE REVASCULARIZATION SURGERY IN PATIENTS WITH DIABETIC ERECTILE DYSFUNCTION: LONG TERM RESULTS
Onder Kayigil*, Emrah Okulu, Fatih Akdemir, Ankara, Turkey

MP32-13 NOVEL MULTIMODAL ANALGESIA (MMA) PROTOCOL SIGNIFICANTLY DECREASES POSTOPERATIVE OPIOID REQUIREMENTS IN INFLATABLE PENILE PROSTHESIS (IPP) PATIENTS
Jacob Lucas*, Carmen Tong, Ankur Shah, Christopher Foote, Matthew Brennan, Jay Simhan, Philadelphia, PA

MP32-14 NEW FINDINGS REGARDING THE TIMELINE OF MICROORGANISMS, INFECTION SEVERITY AND SURGICAL INTERVENTION IN INFLATABLE PENILE PROSTHESIS INFECTIONS
Martin Gross*, Keene, NH, Jason Greenfield, Arlington, TX, Laurence Levine, Chicago, IL, Joseph Alukal, New York City, NY, William Conners, Boston, MA, Sidney Glina, Sao Paulo, Brazil, Cigdem Tannikut, Boston, MA, Stanton Honig, New Haven, CT, Edgardo Becher, Buenos Aires, Argentina, Nelson Bennett, Chicago, IL, Run Wang, Houston, TX, Paul Pento, Miami, FL, Peter Stahl, New York City, NY, Mariano Rosselló Gayá, Mariano Rosselló Barbará, Palma de Mallorca, Spain, Edward Gheiler, Miami, FL, David Ralph, London, United Kingdom, Doron Stemmer, New York City, NY, Rafael Carrion, Tampa, FL, Tobias Kohler, Rochester, MN, Pedro Maria, New York City, NY, William Brant, Salt Lake City, UT, Bruce Garber, Philadelphia, PA, Arthur Burnett, Baltimore, MD, J. Francois Eid, New York City, NY, Gerard Henry, Shreveport, LA, Ricardo Munariz, Boston, MA

MP32-15 UTILIZING GRIP STRENGTH PRIOR TO THREE-PIECE IPP PLACEMENTS AS A PREDICTOR FOR POST-OPERATIVE PATIENT SATISFACTION. PRELIMINARY, PRE-OPERATIVE DATA
Raunak Patel*, Hayden Jahn, Daniel Canter, Eric Laborde, New Orleans, LA

MP32-16 POSTOPERATIVE COMPLICATIONS AND THE NEED FOR REVISION OR EXPLANTATION OF INFLATABLE PENILE PROSTHESIS – DO REAR-TIP EXTENDERS PLAY A ROLE?
Andrew Gabrielson*, Lailt Alzweri, Kenneth Delay, New Orleans, LA, Faysal Yafi, Orange, CA, Wayne Hellstrom, New Orleans, LA

MP32-17 PELVIC PAIN FROM INFLATABLE PENILE PROSTHESIS IMPLANTATION PERSISTS AFTER REVISION OR EXPLANTATION
Jeffrey D. Campbell*, Emad Rajih, Arthur L. Burnett, Baltimore, MD

MP32-18 CLINICAL OUTCOME/PATIENT AND PARTNER SATISFACTION AFTER PENILE IMPLANT SURGERY
Helene De Bruyn, Stevoort, Belgium, Cedric Jorissen*, Heusden-Zolder, Belgium, Evert Baten, Leuven, Belgium, Koenraad van Renterghem, Zonhoven, Belgium

MP32-19 AUGMENTATION PHALLOPLASTY SURGERY FOR PENILE DYSMORPHOPHOBIA: A NEW TECHNIQUE USING HUMAN DERMAL ACCELLULAR MATRIX
Chengyue Jin*, Xiaowei Zhang, Beijing, China, People’s Republic of, Can Cui, New Haven, CT, Wenbo Yang, Beijing, China, People’s Republic of, Min Zhang, Chengdu, China, People’s Republic of, Wenjun Bai, Tao Xu, Beijing, China, People’s Republic of

MP32-20 EXPERIENCE OF TRANSURETHRAL SEMINAL VESICULOSCOPY THROUGH EJACULATORY DUCT NATURAL OPENINGS
Yu Tian*, Kai Hong, Hui Jiang, Lulin Ma, Beijing, China, People’s Republic of

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP33-01</td>
<td>COST IMPACT OF ELECTIVE CESAREAN DELIVERY ON FUTURE PELVIC FLOOR DISORDERS</td>
</tr>
<tr>
<td></td>
<td>Devin Patel*, Justin Houman, James Weinberger, Lauren Wood, Jennifer Anger, Karyn Eilber, Los Angeles, CA</td>
</tr>
<tr>
<td>MP33-02</td>
<td>ARE CARE SEEKING PATTERNS DIFFERENT IN WOMEN REQUIRING A REPEAT PELVIC ORGAN PROLAPSE SURGERY DUE TO NATIVE TISSUE REPAIR FAILURE VERSUS A MESH COMPLICATION?</td>
</tr>
<tr>
<td></td>
<td>Kai Dallas*, San Jose, CA, Lisa Rogo-Gupta, Christopher Elliot, Stanford, CA</td>
</tr>
<tr>
<td>MP33-03</td>
<td>THE EVALUATION OF PELVIC FLOOR MUSCLE CONTRACTION USING TRANSPERINEAL ULTRASOUND IN PATIENTS WITH PELVIC ORGAN PROLAPSE</td>
</tr>
<tr>
<td></td>
<td>Takeya Kitta*, Mifuka Ouchi, Yukiko Kanno, Madoka Higuchi, Mio Togo, Mayuko Tsukiyama, Kimihiko Moriya, Sapporo, Japan, Kumiko Kato, Nagoya, Japan, Nobuo Shinohara, Sapporo, Japan</td>
</tr>
<tr>
<td>MP33-04</td>
<td>RISK OF PROLAPSE RECURRANCE AFTER NATIVE TISSUE ANTERIOR VAGINAL WALL SUSPENSION FOLLOWING ANTERIOR COLPORRHAPHY WITH LONG-TERM FOLLOWUP</td>
</tr>
<tr>
<td></td>
<td>Deborah Hess*, Rena Malik, Alana Christie, Feras Alhalabi, Maude Carmel, Philippe Zimmer, Dallas, TX</td>
</tr>
<tr>
<td>MP33-05</td>
<td>ROLE OF Hysterectomy AT THE TIME OF NATIVE PELVIC ORGAN PROLAPSE (POP) REPAIR</td>
</tr>
<tr>
<td></td>
<td>Bilal Chughtai, Dominique Thomas*, Jialin Mao, Tirsit Asfaw, New York, NY, Jennifer Anger, Beverly Hills, CA, Art Sedrakyan, New York, NY</td>
</tr>
<tr>
<td>MP33-06</td>
<td>CONCOMITANT HYSTERECTOMY LOWERS THE RATE OF RECURRENT PROLAPSE SURGERY FOR ALL COMPARTMENTS IN A COHORT OF OVER 100,000 WOMEN</td>
</tr>
<tr>
<td></td>
<td>Ekode Enemmchukwu, Palo Alto, CA, Kai Dallas*, Stanford, CA, Raven Eric Suhilberg, Palo Alto, CA, Christopher Elliot, Lisa Rogo-Gupta, Stanford, CA</td>
</tr>
<tr>
<td>MP33-07</td>
<td>QUALITY OF LIFE OUTCOMES AFTER ROBOTIC SACROCOLOPEXY FOR THE MANAGEMENT OF PELVIC ORGAN PROLAPSE</td>
</tr>
<tr>
<td></td>
<td>Annah Vollstedt*, Lebanon, NH, Paholo Barboglio, Ann Arbor, MI, William Meeks, Linthicum, MD, Veronica Triaca, Concord, NH</td>
</tr>
</tbody>
</table>

*Presenting author
**MP33-16** DEXTROSE INSTILLATION AS AN ALTERNATIVE AGENT TO OBSERVE URETERAL EFFLUX DURING PELVIC RECONSTRUCTIVE SURGERY
Julie Cheng*, G. Austin Krishingner, Kristin Chung, Hillary Wagner, Junchan Yune, Andrea Staack, Loma Linda, CA

**MP33-17** MESHING AROUND: LONG-TERM OUTCOMES FOLLOWING VAGINAL RECONSTRUCTIVE SURGERY WITH SYNTHETIC MESH AUGMENTATION
Sarah McChran*, Hayley Barnes, Elizabeth Meller, Caroline Kieserman-Shmokler, Dobie Giles, Christine Heisler, Heidi Brown, Madison, WI

**MP33-18** IS MESH EVER APPROPRIATE FOR USE IN VAGINAL PELVIC ORGAN PROLAPSE REPAIR? A POPULATION-BASED ANALYSIS OF 110,329 WOMEN
Kai Dallas*, Lisa Rogo-Gupta, Stanford, CA, Katherine Choi, Orlando, FL, Christopher Elliot, Stanford, CA

**MP33-19** SYMPTOM RESOLUTION AND RECURRENT PROLAPSE RATES FOLLOWING VAGINAL MESH REMOVAL
Andrew Bergersen*, Elinora Price, Tucson, AZ, Michael Callegari, Oklahoma City, OK, Evan Austin, Oduoyosi Oduyemi, Joel Funk, Christian Twiss, Tucson, AZ

**MP33-20** SYNTHEtic MID-URETHRAL SLING COMPLICATIONS: EVOLUTION OF PRESENTING SYMPTOMS OVER TIME
Connie Wang*, Alana Christie, Philippe Zimmerm, Dallas, TX

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
MP34-06 SOCIOECONOMIC DISPARITIES IN RADICAL PROSTATECTOMY PROCEDURE UTILIZATION
Olamide Omidole*, Mark Finkelstein, New York, NY, Michael Palese, New York, NY

MP34-07 DISPARITIES IN THE DIAGNOSIS AND MANAGEMENT OF METASTATIC PROSTATE CANCER IN YOUNG MEN
Amanda Lu*, Kamyar Ghabili Amirkhiz, Kevin Nguyen, Walter Hsiang, Michael Leapman, New Haven, CT

MP34-08 AGGRESSIVE PROSTATE CANCER IN VETERANS WITH A PRIOR PSA OF ≤1.0 NG/ML
Stephen Ryan*, Alex Bryant, Sunil Patel, San Diego, CA, Zachary Hamilton, St. Louis, MO, Brent Rose, Christopher Kane, James Murphy, A. Karim Kader, San Diego, CA

MP34-09 PREVALENCE AND PROGNOSTIC IMPACT OF PROSTATE CANCER HISTOLOGICAL VARIANTS AT RADICAL PROSTATECTOMY: A LONG-TERM, SINGLE CENTER ANALYSIS
Carlo Andrea Bravi*, Giorgio Gandaglia, Nicola Fossati, Roberta Lucianò, Emanuele Zaffuto, Vincenzo Scattoni, Andrea Gallina, Roberto Bertini, Massimo Freschi, Milan, Italy, Shahrkhok F. Shariat, Vienna, Austria, Vincenzo Mirone, Naples, Italy, Pierre I. Karakiewicz, Montreal, Canada, Rodolfo Montironi, Ancona, Italy, Claudio Doglioni, Francesco Montorsi, Alberto Briganti, Milan, Italy

MP34-10 CHARACTERISING PROSTATE DUCTAL ADENOCARCINOMA: MORPHOMETRY AND CLINICAL OUTCOMES
Timothy Harkin*, Melbourne, Australia, Ashish Chandra, Oussama Elhage, London, United Kingdom, Mark Frydenberg, Melbourne, Australia, Prokar Dasgupta, London, United Kingdom

MP34-11 OBESITY, RISK OF BIOCHEMICAL RECURRENCE, AND PSA DT AFTER RADICAL PROSTATECTOMY: RESULTS FROM THE SEARCH DATABASE
Brandee Branche, Lauren Howard*, Durham, NC, Robert Hamilton, Toronto, Canada, William Aronson, Los Angeles, CA, Martha Terris, Augusta, GA, Matthew Cooperberg, San Francisco, CA, Christopher Amling, Portland, OR, Christopher Kane, San Diego, CA, Stephen Freedland, Los Angeles, CA

MP34-12 SUPERUSERS OF POST-PROSTATECTOMY CARE: IDENTIFYING DRIVERS OF EXTREME HEALTHCARE COSTS
Chirag Doshi*, Eric Kirshenbaum, Alex Gorbonos, Marcus Quek, Gopal Gupta, Anai Kothari, Grace Delos Santos, Maywood, IL

MP34-13 PREDICTING PATIENTS WITH HIGH PENETRANCE GENES IN MEN REFERRED TO A PRECISION MEDICINE UROLOGY CLINIC
Richard Fantus*, Chicago, IL, Jianfeng Xu, Chi-Hsiung Wang, Brian Helfand, Evanston, IL

MP34-14 WHICH PATIENTS WITH CLINICALLY NODE POSITIVE PROSTATE CANCER BENEFIT FROM RADICAL PROSTATECTOMY? THE IMPACT OF THE SIZE AND SITE OF NODEAL INVOLVEMENT

MP34-15 PROSTATE CANCER QUALITY OF CARE DISPARITIES AND THEIR IMPACT ON PATIENT OUTCOMES
Keith Lawson*, Katherine Daignault, Olli Saarel, Toronto, Canada, Robert Abouassaly, Cleveland, OH, Antonio Finelli, Toronto, Canada

MP34-16 FACILITY LEVEL VARIATION IN RATES OF DEFINITIVE THERAPY FOR LOW RISK PROSTATE CANCER AMONG MEN WITH LIMITED LIFE EXPECTANCY: AN OPPORTUNITY FOR VALUE-BASED CARE REDESIGN
David F. Friedlander*, Boston, MA, Nicolas von Landenberg, Herne, Germany, Sebastian Berg, Boston, MA, Bjorn Loppenberg, Joachim Noldus, Florian Raghmann, Herne, Germany, Quoc-Dien Trinh, Boston, MA

MP34-17 AN INDIVIDUAL PATIENT DATA META-REGRESSION FOR CONTINENCE RECOVERY AT SIX MONTHS FOLLOWING PROSTATECTOMY
Sean F. Mungovan*, Westmead, Australia, Petra L. Graham, Sydney, Australia, Jaspreet S. Sandhu, Oguz Akin, Peter T. Scardino, New York, NY, Fergus V. Coakley, Portland, OR, Kazuhiro Matsushita, Tokyo, Japan, Hong K. Ha, Busan, Korea, Republic of, Antonio Tienza, Pamplona, Spain, Seung-Kwon Choi, Seoul, Korea, Republic of, Nikolaos Gritas, Amsterdam, Netherlands, Seong C. Kim, Busan, Korea, Republic of, Seong J. Jeong, Seoul, Korea, Republic of, Manish I. Patel, Sydney, Australia

MP34-18 PERFORMANCE OF MULTIGENE PANEL TESTING IN HEREDITARY PROSTATE CANCER
Mary Pritzlaff, Kyle Allen, Holly LaDuca, Aliso Viejo, CA, Richard Fantus, Brian Helfand*, Evanston, IL

*Presenting author
**MP34-19** POPULATION-BASED OUTCOMES OF MEN WITH A SINGLE NEGATIVE PROSTATE BIOPSY: IMPORTANCE OF CONTINUED FOLLOW UP AMONG OLDER PATIENTS  
Rashid Sayyid*, Augusta, GA, Shabbir Alihrai, Rinku Sutradhar, Maria Eberg, Kinwah Fung, Zachary Klaassen, Hanan Goldberg, Nathan Perlis, David Urbach, Neil Fleshner, Toronto, Canada

**MP34-20** MOBILE PHONE APPS FOR THE PREDICTION OF PROSTATE CANCER: A MULTICENTER EXTERNAL VALIDATION AND COMPARISON  
Riccardo Lombardo*, Cosimo De Nunzio, Giorgia Tera, Fabiana Cancrini, Rome, Italy, Rodrigo Chacon, Eduard Garcia-Cruz, Jordi Huguet, Maria J. Ribal, Antonio Alcaraz, Barcellona, Spain, Andrea Tubaro, Rome, Italy

---

**Moderated Poster Session 35**  
PROSTATE CANCER: MARKERS I  
Room 3005 @ MCC West  
Moderators: Douglas Scherr, Andrew Stephenson and Mark Frydenberg

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| MP35-01         | PROSTATE TUMOR TEXTURAL HETEROGENEITY OF 11C-ACETATE POSITRON EMISSION TOMOGRAPHY AND T2-WEIGHTED MAGNETIC RESONANCE IMAGING CORRELATE WITH BIOCHEMICAL RECURRENCE: PRELIMINARY FINDINGS  
Lin Li*, Cleveland, OH, Ivan Jambor, Pekka Taimen, Harri Merisaar, Heikki Minn, Peter Bostrom, Hannu Aronen, Turku, Finland, Ahmad Alghohary, Anant Madabhushi, Cleveland, OH |
| MP35-02         | COMPUTER-EXTRACTED FEATURES OF NUCLEAR AND GLANDULAR MORPHOLOGY FROM DIGITAL H&E TISSUE IMAGES PREDICT PROSTATE CANCER BIOCHEMICAL RECURRENCE AND METASTASIS FOLLOWING RADICAL PROSTATECTOMY  
Patrick Leo*, Anna Gawlik, Cleveland, OH, Guangjing Zhu, Baltimore, MD, Michael Feldman, Philadelphia, PA, Sanjay Gupta, Cleveland, OH, Robert Veltri, Baltimore, MD, Anant Madabhushi, Cleveland, OH |
| MP35-03         | METABOLOMIC EVALUATION OF MRI/US FUSION BIOPSIES DIFFERENTIATES MALIGNANT FROM BENIGN  
Adam Feldman*, Lindsey Vandergrift, Taylor Fuss, Emily Decelle, Shulin Wu, Chris Dietz, Felix Ehret, Sarah Dinges, Yannick Berker, Chin-Lee Wu, Leo Cheng, Boston, MA |
| MP35-04         | IS PSA DENSITY USEFUL IN PREDICTING LOW RISK PROSTATE CANCER IN AFRICAN AMERICAN MEN?  
Kara Babaian*, Maira Qayyum, Clifton Frilot, Shreveport, LA |
| MP35-05         | INTEGRATING THE PRESENCE OF INTRADUCTAL CARCINOMA OF THE PROSTATE INTO THE GRADE GROUP SYSTEM IMPROVES PREDICTION OF BIOCHEMICAL FAILURE IN RADICAL PROSTATECTOMY PATIENTS  
Masashi Kato*, Nagoya, Japan, Toyonori Tsuzuki, Nagakute, Japan, Ryo Ishida, Tohru Kimura, Nagoya, Japan, Osamu Kamihira, Komaki, Japan, Tomoyoshi Ohashi, Tsuyoshi Majima, Yasuhiro Funahashi, Naoto Sassa, Yoshihisa Matsukawa, Yasushi Yoshino, Ryohi Hattori, Momokazu Gotoh, Nagoya, Japan |
| MP35-06         | MULTI-CENTER PROSPECTIVE STUDY OF PROSTATE HEALTH INDEX (PHI) TESTING AS A STRATEGY FOR PROSTATE CANCER SCREENING: COLLABORATION BETWEEN UROLOGY, PRIMARY CARE, AND COMMUNITY OUTREACH  
Elizabeth Wendel*, Dattatraya Patil, Atlanta, GA, Brandon Weaver, Robin Leach, Ian Thompson, San Antonio, TX, Lori Sokoll, Daniel Chan, Baltimore, MD, Jack Groskoph, San Diego, CA, James Carter, Boston, MA, Mersiha Torlak, Martin Sanda, Atlanta, GA |
| MP35-07         | THE 17-GENE RT-PCR PROSTATE ASSAY: CLINICAL EXPERIENCE IN 29,000 PATIENTS WITH CLINICALLY LOW-RISK PROSTATE CANCER  
Aaron Katz*, Garden City, NY, Cindy Loman, Ruixiao Lu, Phillip Febo, Bela Denes, Redwood City, CA |
| MP35-08         | INCORPORATING PROSTATE HEALTH INDEX DENSITY, MRI, AND PRIOR NEGATIVE BIOPSY STATUS TO IMPROVE THE DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER  
Sasha Druskin*, Jeffrey Tosoian, Allen Young, Sarah Collica, Arnav Srivastava, Kamyar Ghabili, Katarzyna Macura, Ballentine Carter, Alan Partin, Lori Sokoll, Ashley Ross, Christian Pavlovich, Baltimore, MD |
MP35-09 COMBINATION OF NF-KB/P65 NUCLEAR LOCALIZATION AND GLAND MORPHOLOGIC FEATURES IS PREDICTIVE OF BIOCHEMICAL RECURRENCE
Patrick Leo, Eswar Shankar, Robin Elliott, Andrew Janowczyk, Nafiseh Janaki, Gregory MacLennan, Anant Madabhushi, Sanjay Gupta*, Cleveland, OH

MP35-10 DETECTION OF PROSTATE CANCER-ASSOCIATED TRANSCRIPTS IN URINARY EXTRACELLULAR VESICLES
Kathryn Pellegrini*, Dattatraya Patil, Kristen Douglas, Ella Anastasiades, Kristin Larsen, Frances Kim, Almira Catic, Mersha Torlak, Eugene Huang, Carlos Moreno, Martin Sanda, Atlanta, GA

MP35-11 METABOLIC BIOMARKERS ARE PREDICTIVE OF RESPONSE TO RADIATION THERAPY IN PROSTATE CANCER PATIENTS

MP35-12 GENETIC RISK SCORES ARE ASSOCIATED WITH EARLY AGE OF PROSTATE CANCER DIAGNOSIS: RESULTS FROM THE REDICE TRIAL
Rong Na*, Yishuo Wu, S. Lilly Zheng, Brian Helfand, Chi-Hsiung Wang, Charles B. Brendler, Evanston, IL, Gerald L. Andriole, St. Louis, MO, Jianfeng Xu, Evanston, IL

MP35-13 WHITE BLOOD CELLS FROM PROSTATE CANCER PATIENTS CARRY DISTINCT CHROMOSOME CONFORMATIONS
Dmitri Pchejetski, Norwich, United Kingdom, Taimur T. Shah*, London, United Kingdom, Heba Alshaker, Amman, Jordan, Aroul Ramadass, Ewan Hunter, Alexandre Akoulitch, Oxford, United Kingdom, Mathias Winkler, London, United Kingdom

MP35-14 A 17-GENE ASSAY DRIVES HIGH ACTIVE SURVEILLANCE PERSISTENCE IN CLINICALLY LOW-RISK PROSTATE CANCER: 1 YEAR RESULTS FROM A 1,200 PATIENT PROSPECTIVE OBSERVATIONAL TRIAL
Neal Shore*, Myrtle Beach, SC, Gregg Eure, Virginia Beach, VA, Daniel Saltzstein, San Antonio, TX, John Bennett, Ruixiao Lu, Phillip Febbo, Bela Denes, Redwood City, CA

MP35-15 DEVELOPMENT AND VALIDATION OF A NOVEL PROGNOSTIC MODEL FOR PREDICTING OVERALL SURVIVAL IN TREATMENT NAÏVE CASTRATION-SENSITIVE METASTATIC PROSTATE CANCER
Shusuke Akamatsu*, Masashi Kubota, Ryuji Uozumi, Kyoto, Japan, Shintaro Narita, Akita, Japan, Masahiro Takahashi, Koji Mitsuzuka, Sendai, Japan, Shingo Hatakeyama, Hiroaki, Japan, Toshihiko Sakurai, Yamagata, Japan, Sadafumi Kawamura, Natori, Japan, Shigeto Ishidoya, Sendai, Japan, Senri Hoshi, Yamagata, Japan, Masanori Ishida, Oshu, Japan, Kei Mizuno, Kyoto, Japan, Keiji Ogura, Otsu, Japan, Takayuki Goto, Naoki Terada, Takashi Kobayashi, Toshinari Hamasaki, Takahiro Inoue, Kyoto, Japan, Northiko Tsuchiya, Yamagata, Japan, Chikara Ohyama, Hiroaki, Japan, Yoichi Arai, Sendai, Japan, Tomonori Habuchi, Akita, Japan, Satoshi Morita, Osamu Ogawa, Kyoto, Japan

MP35-16 IS KI67 PROGNOSTIC FOR AGGRESSIVE PROSTATE CANCER? A MULTICENTER REAL-WORLD STUDY
Joseph J. Fantony, Lauren E. Howard, Durham, NC, Ilona Csizmadi*, Los Angeles, CA, Andrew J. Armstrong, Amy L. Lark, Durham, NC, Colette Galet, Iowa City, IA, William J. Aronson, Stephen J. Freedland, Los Angeles, CA

MP35-17 COMPARISON OF CELL CYCLE PROGRESSION (CCP) SCORE TO TWO IHC MARKERS (PTEN AND KI-67) FOR PREDICTING OUTCOME IN PROSTATE CANCER AFTER RADICAL PROSTATECTOMY
Priscilla Leon*, Reims, France, Geraldine Cancel-Tassin, Sarah Drouin, Marie Audouin, Justine Varinot, Eva Compérat, xavier cathelineau, François Rozet, christophe vaessen, Steve Stone, paris, France, William melbourn, Julia Reid, Zaina Sangale, Patrick Kormann, salt lake city, NY, Morgan Rouprêt, paris, France, Gaëlle Fromont Hankard, tours, France, Olivier Cussenot, paris, France

MP35-18 NEUTROPHIL TO LYMPHOCYTE RATIO IS ASSOCIATED WITH LYMPH NODE INVASION AND HIGHER NODAL BURDEN IN CONTEMPORARY HIGH RISK PATIENTS TREATED WITH RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE DISSECTION
Carlo Andrea Bravi*, Marco Bianchi, Nicola Fossati, Giorgio Gandaglia, Emanuele Zaffuto, Simone Scuderi, Daniele Robesti, Francesco Barletta, Luigi Nocera, Umberto Capitanio, Andrea Gallina, Nazareno Suardi, Milan, Italy, Shahrokh F. Shariat, Vienna, Austria, Pierre L. Karakiewicz, Montreal, Canada, Francesco Montorsi, Alberto Briganti, Milan, Italy

*Presenting author
MP36-01 OUTCOMES OF LYMPHADENECTOMY FOR NON-METASTATIC RENAL CELL CARCINOMA: A PROPENSITY SCORE-WEIGHTED ANALYSIS

MP36-02 DIAGNOSTIC VALUE OF 68GA-LABELLED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) PET/CT IMAGING FOR RENAL CELL CARCINOMA
Chengwei Zhang*, Xiaozhi Zhao, Zang Shiming, Feng Wang, Hongqian Guo, Nanjing, China, People's Republic of

MP36-03 THE ROLE OF PROGNOSTIC NUTRITIONAL INDEX TO PREDICT ONCOLOGICAL OUTCOMES IN PATIENTS WITH CLINICAL STAGE THREE OR LOWER KIDNEY CANCER
Axel Alberto Cayetano Alcaraz*, Christian Anibal Quiñones-Capistrán, Juan Sebastián Rodríguez-Álvarez, Francisco Rodríguez-Covarrubias, Mexico City, Mexico

MP36-04 PRETREATMENT DIAGNOSIS OF THE SMALL RENAL MASS: STATUS OF RENAL BIOPSY IN THE U.S.A
Roshan Patel*, Shoaib Saifullah, Zhamshid Okhunov, Kamaljot Kaler, Kathryn Osann, Jaime Landman, Ralph Clayman, Orange, CA

MP36-05 CHANGES IN PATTERN OF RECURRENCE OVER TIME AFTER RADICAL NEPHRECTOMY IN PATIENTS WITH LOCALIZED CLEAR CELL RENAL CELL CARCINOMA
Kenji Tanabe*, Kazutaka Saito, Tokyo, Japan, Kazuaki Nakagomi, Hamamatsu, Japan, Chizuru Arisawa, Tokyo, Japan, Tetsuro Tsukamoto, Kodaira, Japan, Tetsuo Okuno, Toride, Japan, Katsushi Nagahama, Ichikawa, Japan, Akira Noro, Saitama, Japan, Shinji Morimoto, Tsuchiura, Japan, Satoshi Kitahara, Tama, Japan, Kazunori Kihara, Yasuhisa Fujii, Tokyo, Japan

MP36-06 USING AORTA-LESION-ATTENUATION-DIFFERENCE (ALAD) ON PREOPERATIVE CONTRAST-ENHANCED CT SCAN TO DIFFERENTIATE BETWEEN MALIGNANT AND BENIGN RENAL TUMORS
Joseph Grajo, Russell Terry*, Justin Ruoss, Blake Noennig, Jonathan Pavliniec, Shahab Bozorgmehr, Paul Crispen, Li-Ming Su, Gainesville, FL

MP36-07 ROUTINE RENAL MASS BIOPSY IN DIAGNOSIS OF RENAL CANCER
Chandran Tanabalan, Joana Neves*, Miles Walkden, Lee Grant, Navin Ramachandran, Faiz Mumtaz, Prasad Patki, Maxine Tran, Michael Aitchison, Ravi Barod, London, United Kingdom

MP36-08 A CONVOLUTIONAL NEURAL NETWORKS ALGORITHM FOR DIFFERENTIAL DIAGNOSIS OF FAT-POOR ANGIOMYOLIPOMA AND RENAL CELL CARCINOMA IN ENHANCED CT AND T2-WEIGHTED MAGNETIC RESONANCE IMAGING
Takahiko Soma*, Junichiro Ishioka, Hajime Tanaka, Sho Uehara, Yousuuke Yasuda, Toshiki Kijima, Soichiro Yoshida, Minato Yokoyama, Yoh Matsuoka, Kazutaka Saito, Kazunori Kihara, Yasuhisa Fujii, Tokyo, Japan

MP36-09 VALIDATION OF THE PREOPERATIVE NOMOGRAM PREDICTING 12-YEAR PROBABILITY OF METASTATIC RENAL CANCER
Mazyar Ghanaat, Cihan Duzgol, Debra A. Goldman, Kyle A. Blum, New York, NY, Mahyar Kashan, Brooklyn, NY, Maria F. Becerra, Alejandro Sanchez*, Renzo DiNatale, Daniel Nassau, Jozefina Casuscelli, Nicole Benfante, Jonathan Coleman, Michael W. Kattan, Paul Russo, Oguz Akin, Irina Ostrovnaya, A. Ari Hakimi, New York, NY
MP36-10 CHEST FOLLOW-UP SCHEDULE OF SURGICALLY RESECTED RENAL CELL CARCINOMA SHOULD BE DIFFERENTIATED ACCORDING TO HISTOLOGICAL SUBTYPE
Michele Rizzo*, Trieste, Italy, Paolo Umari, Alessandro Volpe, Novara, Italy, Umberto Capitanio, Milan, Italy, Alessandro Antonelli, Maria Furlan, Carlotta Palumbo, Claudio Simeone, Brescia, Italy, Francesco Montorsi, Alessandro Larcher, Roberto Bertini, Milan, Italy, Lorenzo Canceddini, Trieste, Italy, Francesco Porpiglia, Riccardo Bertolo, Orbassano, Italy, Enrica Verzotti, Nicola Pavan, Trieste, Italy, Riccardo Campi, Andrea Cocci, Andrea Mari, Andrea Minervini, Florence, Italy, Francesco Alessandro Mistretta, Andrea Conti, Ottavio de Cobelli, Milan, Italy, Giovanni Liguori, Carlo Trombetta, Trieste, Italy

MP36-11 CLINICOPATHOLOGIC AND GENOMIC FACTORS ASSOCIATED WITH RECURRENCE IN PATIENTS WITH STAGE III-IV CHROMOPHOBE RENAL CELL CARCINOMA
Alp Tuna Beksac*, David Paulucci, John Sfakianos, Ketan Badani, New York, NY

MP36-12 CAN A 3D TUMOR VOLUME CONTOUR ON MULTIPHASIC CT PREDICT THE TUMOR MICROENVIRONMENT OF CLEAR CELL RENAL CARCINOMA?
Heidi Coy*, Jonathan Young, Michael Douek, Anthony Sisk, Clara Magyar, Matthew Brown, James Sayer, Steven Raman, Los Angeles, CA

MP36-13 U-SMART: (UCSD SMALL MASS ALT RENAL SCORE TUMOR DIAMETER) A NOVEL SCORING SYSTEM OF PREOPERATIVE PREDICTORS TO STRATIFY ONCOLOGIC RISK OF SMALL RENAL MASS

MP36-14 RISK FACTORS FOR SURVIVAL IN PATIENTS WITH VON HIPPEL-LINDAU DISEASE
Jiang-Yi Wang*, Sheng-Jie Liu, Bao-An Hong, Jing-Cheng Zhou, Kai-Fang Ma, Kan Gong, Beijing, China, People's Republic of China

MP36-15 SELF-REPORTED QUALITY OF LIFE FOR PREDICTING MORTALITY IN RENAL CELL CARCINOMA
Ridwan Alam*, Hiten D. Patel, Michael A. Gorin, Michael H. Johnson, Mohamad E. Allaf, Phillip M. Pierorazio, Baltimore, MD

MP36-16 THE ROLE OF HISTOLOGIC SUBTYPES IN FOLLOW-UP SCHEME OF POSTSURGICAL KIDNEY CANCER PATIENTS
Alessandro Nini*, Francesco Cianflone, Roberta Lucianto, Alessandro Larcher, Cristina Carenzi, Walter Cazzaniga, Rayan Matloob, Francesco Montorsi, Claudio Doglioni, Luigi Gianolli, Patrizio Rigatti, Francesco De Cobelli, Alessandro Del Maschio, Giorgio Gandaglia, Alberto Brigni, Andrea Salonia, Maria Picchio, Massimo Freschi, Roberto Nicoletti, Umberto Capitanio, Roberto Bertini, Milan, Italy

MP36-17 USEFULNESS OF MORPHOLOGICAL CLASSIFICATION OF CLINICAL T1 RENAL CELL CANCER ON PREDICTING UPSTAGING TO PATHOLOGICAL T3 OR HIGHER
Jun Teishima*, Tetsutaro Hayashi, Hiroyuki Kitano, Kousuke Sadahide, Shunside Shinmei, Shogo Inoue, Yukiko Honda, Kazuhiro Sentani, Kazuo Awai, Wataru Yasui, Akio Matsubara, Hiroshima, Japan

MP36-18 PREDICTORS OF READMISSIONS WITHIN 90 DAYS FOLLOWING RADICAL NEPHRECTOMY: A POPULATION-BASED ANALYSIS FROM 1995 TO 2015
Anthony Yang*, Mark Finkelstein, Khawaja Bilal, Natan Davoudzadeh, Michael Paleese, New York, NY

MP36-19 FACTORS DRIVING WORSE SURVIVAL BETWEEN BLACK AND WHITE PATIENTS WITH RENAL CELL CARCINOMA

MP36-20 INCREASED FIBRINOGEN AND D-DIMER LEVELS ARE ASSOCIATED WITH ADVERSE TUMOR CHARACTERISTICS AND DECREASED SURVIVAL IN RENAL CELL CARCINOMA: THE 2ND REPORT WITH EXTENDED PATIENT NUMBER AND FOLLOW-UP
Selcuk Erdem*, Samed Verep, Yasar Pazir, Tzeval Tefik, Murat Tunc, Faruk Ozcan, Oner Sanli, Ismet Nane, Istanbul, Turkey

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

*Presenting author
## Podium Session 21

**TRAUMA/RECONSTRUCTION/DIVERSION: URETHRAL RECONSTRUCTION (INCLUDING STRicture, DIVertICULUM) I**

Room 2022 @ MCC West  
Moderators: Jerilyn Latini, Keith Rourke and Miro Djordjevic

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
<th>ABSTRACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30</td>
<td>PD21-01</td>
<td>SURGICAL APPROACHES AND LONG-TERM OUTCOMES IN ADULTS WITH COMPLEX RE-OPTERATIVE HYPOSPADIAS REPAIR</td>
<td>Christopher Morrison*, Davide Cina, Chicago, IL, Christopher Gonzalez, Cleveland, OH, Matthias Hofer, Chicago, IL</td>
</tr>
<tr>
<td>9:40</td>
<td>PD21-02</td>
<td>INITIAL MULTI-INSTITUTIONAL EXPERIENCE OF INCISIONLESS BUCCAL MUCOSA GRAFT INLAY FOR DISTAL URETHRAL STRICTURES</td>
<td>Michael Daneshvar*, Stephen Blakely, Syracuse, NY, Javier Angulo, Madrid, Spain, Jay Simhan, Jacob Lucas, Philadelphia, PA, Craig Hunter, Reno, NV, Justin Chee, Melbourne, Australia, Damian Porphyrio, Erick Ramirez Perez, Mexico City, Mexico, Dmitriy Nikolavsky, Syracuse, NY</td>
</tr>
<tr>
<td>9:50</td>
<td>PD21-03</td>
<td>LICHEN SCLEROSUS OF THE URETHRA, PENILE SKIN AND VULVA: 3 DISTINCT DISEASE PROCESSES</td>
<td>Alison Levy*, Kristian Stensland, Brendan Browne, Jennifer Bennett, Ariel Fredrick, Travis Sullivan, Burlington, MA, Jason Badrinarain, Jorge Yao, Ramsey, NJ, Kimberly Rieger-Christ, Alex Vanni, Burlington, MA</td>
</tr>
<tr>
<td>10:00</td>
<td>PD21-04</td>
<td>PATHOPHYSIOLOGY OF LICHEN SCLEROSUS URETHRAL STRICTURES: THE ROLE OF INFLAMMATION, VIRAL INFECTION, AND ANDROGEN RECEPTORS</td>
<td>Alison Levy*, Brendan Browne, Kristian Stensland, Jennifer Bennett, Ariel Fredrick, Travis Sullivan, Burlington, MA, Jason Badrinarain, Jorge Yao, Ramsey, NJ, Kimberly Rieger-Christ, Alex Vanni, Burlington, MA</td>
</tr>
<tr>
<td>10:10</td>
<td>PD21-05</td>
<td>ANDROGEN RECEPTOR EXPRESSION IN LICHEN SCLEROSUS URETHRAL STRicture DISEASE</td>
<td>Michael Hughes*, Tiffany Caza, Stephen Blakely, Dmitriy Nikolavsky, Syracuse, NY</td>
</tr>
<tr>
<td>10:20</td>
<td>PD21-06</td>
<td>FLUID DYNAMICS AND MORPHOLOGY IN THE OBSTRUCTED URETHRA</td>
<td>Sunchin Kim*, Cameron Hinkel, Tucson, AZ, Donald Coffey, Baltimore, MD, Yitshak Zohar, Benjamin Lee, Matthew Gretzer, Tucson, AZ</td>
</tr>
<tr>
<td>10:30</td>
<td>PD21-07</td>
<td>SUSTAINED-RELEASE OF STROMAL CELL-DERIVED FACTOR-1 ALPHA FROM SILK FIBROIN NANOFIBERS FOR PROMOTING URETHRAL RECONSTRUCTION IN RABBITS</td>
<td>Lujie Song*, Shanghai, China, People’s Republic of</td>
</tr>
<tr>
<td>10:40</td>
<td>PD21-08</td>
<td>ROLE OF GIV/GIRDIN AND INTEGRIN SIGNALING PATHWAYS IN URETHRAL STRicture FIBROGENESIS</td>
<td>M. Raj Rajasekaran*, San Diego, CA, Seung-Ryeol Lee, Seongnam, Korea, Republic of, Ki-Ho Kim, Gyeongju, Korea, Republic of, Ho-Song Yu, Gwangju, Korea, Republic of, Sarah To, Valmik Bhargava, Jill Buckley, SAN DIEGO, CA</td>
</tr>
<tr>
<td>10:50</td>
<td>PD21-09</td>
<td>MYOFIBROBLAST-DOMINANT PROLIFERATION BUT NOT FIBROBLAST PROLIFERATION ASSOCIATES WITH MORE SEVERE FIBROSIS IN BULBAR URETHRAL STRicture</td>
<td>Yusuke Hirano*, Tokyo, Japan, Akio Horiguchi, Yusuke Shinchi, Keichi Ito, Tomohiko Asano, Salitama, Japan, Kosuke Miyai, Tokyo, Japan</td>
</tr>
<tr>
<td>11:00</td>
<td>PD21-10</td>
<td>AN EXPERIMENTAL STUDY OF TOPICAL INSULIN-LIKE GROWTH FACTOR-1 DELIVERY TO IMPROVE URETHRAL WOUND HEALING IN A RABBIT MODEL</td>
<td>Masayuki Shinchi*, Toshihiro Kushibiki, Yoshine Mayumi, Keichi Ito, Tomohiko Asano, Miya Ishihara, Akio Horiguchi, Salitama, Japan</td>
</tr>
<tr>
<td>11:10</td>
<td>PD21-11</td>
<td>PLACENTAL MEMBRANE GRAFTS FOR THE TREATMENT OF URETHRAL STRICTURES IN A RABBIT MODEL</td>
<td>Chad Pusateri, Alexander Doudt*, Steven Gauerke, San Diego, CA, Britni Ork, Xiaofei Qin, Joseph Khoury, Virginia Beach, VA, Kurt McCammon, Jack Zuckerman, San Diego, CA</td>
</tr>
<tr>
<td>11:20</td>
<td>PD21-12</td>
<td>A NOVEL ENDOLUMINAL ULTRASOUND (US) IMAGING TECHNIQUE TO DETERMINE URETHRAL LUMINAL CROSS-SECToNAL AREA</td>
<td>Raag Bhargava*, SAN DIEGO, CA, Ho-Song Yu, Gwangju, Korea, Republic of, AbinavTeja Chilukuri, SAN DIEGO, CA, Jaesoo Kim, Daegu, Korea, Republic of, Jill Buckley, M. Raj Rajasekaran, Valmik Bhargava, SAN DIEGO, CA</td>
</tr>
</tbody>
</table>

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30</td>
<td>PD22-01</td>
<td>IN VITRO EVALUATION OF SINGLE-USE DIGITAL FLEXIBLE URETEROSCOPES: A PRACTICAL COMPARISON FOR A PATIENT-CENTERED APPROACH</td>
</tr>
<tr>
<td>9:40</td>
<td>PD22-02</td>
<td>COMPARISON OF FLEXIBLE URETERORENOSCOPE QUALITY OF VISION: AN IN VITRO STUDY</td>
</tr>
<tr>
<td>9:50</td>
<td>PD22-03</td>
<td>IN VIVO ASSESSMENT OF A BIODEGRADABLE URETERAL STENT BASED ON NATURAL ORIGIN POLYMERS</td>
</tr>
<tr>
<td>10:00</td>
<td>PD22-04</td>
<td>EFFECT OF LASER FIBER DIAMETER AND PEAK POWER ON THE RESULTING TISSUE DAMAGE ZONES IN A PIG KIDNEY MODEL</td>
</tr>
<tr>
<td>10:00</td>
<td>PD22-05</td>
<td>ENDOSCOPIC STONE MEASUREMENT DURING URETEROSCOPY</td>
</tr>
<tr>
<td>10:30</td>
<td>PD22-07</td>
<td>‘TORQUE’ ABILITIES OF REUSABLE AND SINGLE-USE FLEXIBLE URETERORENOSCOPES: A NOVEL IN-VITRO EVALUATION OF TWELVE SCOPES</td>
</tr>
<tr>
<td>10:40</td>
<td>PD22-08</td>
<td>DEVELOPMENT OF AN INNOVATIVE INTRARENAL PRESSURE REGULATION SYSTEM (IPRS) FOR MINI-PERC - A PRELIMINARY STUDY</td>
</tr>
<tr>
<td>10:50</td>
<td>PD22-09</td>
<td>DEFLECTION CAPABILITIES OF DIGITAL SINGLE-USE VS REUSABLE FLEXIBLE URETERORENOSCOPES: AN IN-VITRO EVALUATION ON K-BOX SIMULATOR</td>
</tr>
<tr>
<td>11:00</td>
<td>PD22-10</td>
<td>DURABILITY OF FLEXIBLE URETEROSCOPES: A PROSPECTIVE STUDY ON LONGEVITY AND AFFECTING FACTORS</td>
</tr>
</tbody>
</table>

*Presenting author
11:20 PD22-12 VALIDATION STUDY OF NEW ADVANCED BENCH MODEL FOR FLEXIBLE URETEROSCOPIC TRAINING: THE SMART SIMULATOR
Takaaki Inoue*, Osaka, Japan, Shinsuke Okada, Chiba, Japan, Shouzo Hamamoto, Nagoya, Japan, Tadashi Matsuda, Osaka, Japan

Saturday, May 19, 2018
Podium Session 23
PROSTATE CANCER: DETECTION & SCREENING II
Room 3024 @ MCC West
Moderators: Daniel Barocas, Marc Smaldone and Christopher Barbieri

<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD23-01</td>
<td>9:30</td>
<td>9:30</td>
<td>TARGETED VS STANDARD PROSTATE BIOPSY: A PROSPECTIVE TRIAL IN BIOPSY-NAIVE MEN Fuad Elkhoury*, Shyam Natarajan, Lorna Kwan, Ely Felker, Merdie Delfin, Anthony Sisk, Leonard Marks, Los Angeles, CA</td>
</tr>
<tr>
<td>PD23-02</td>
<td>9:40</td>
<td>9:40</td>
<td>THE FUTURE TRIAL; A MULTICENTER RCT ON THREE TECHNIQUES OF MRI TARGETED PROSTATE BIOPSY Olivier Wegelin*, Nieuwegein, Netherlands, Leonie Exterkate, Rik Somford, Jelle Barentsz, Marloes van der Leest, Nijmegen, Netherlands, Alain Kummer, Nieuwegein, Netherlands, Willem Vreuls, Nijmegen, Netherlands, Peter de Bruin, Nieuwegein, Netherlands, Ruud Bosch, Utrecht, Netherlands, Harm van Melick, Nieuwegein, Netherlands</td>
</tr>
<tr>
<td>PD23-03</td>
<td>9:50</td>
<td>9:50</td>
<td>THE FUTURE TRIAL; A RCT ON MRI TARGETED PROSTATE BIOPSY. COMPARISON OF TARGETED AND SYSTEMATIC BIOPSY OUTCOMES Leonie Exterkate*, Nijmegen, Netherlands, Olivier Wegelin, Harm van Melick, Nieuwegein, Netherlands, Jelle Barentsz, Marloes van der Leest, Nijmegen, Netherlands, Alain Kummer, Nieuwegein, Netherlands, Willem Vreuls, Nijmegen, Netherlands, Peter de Bruin, Nieuwegein, Netherlands, Ruud Bosch, Utrecht, Netherlands, Rik Somford, Nijmegen, Netherlands</td>
</tr>
<tr>
<td>PD23-04</td>
<td>10:00</td>
<td>10:00</td>
<td>ADDED VALUE OF SYSTEMATIC BIOPSY IN MEN WITH ABNORMAL MULTIPARAMETRIC MRI UNDERGOING MRI-TRUS FUSION PROSTATE BIOPSY Yuval Freifeld*, Yin Xi, Claus Roehrborn, Franto Francis, Niccolo Passoni, Yair Lotan, Kenneth Goldberg, Brad Hornberger, Vitaly Margulis, Ivan Pedrosa, Ganesh Raj, Jeffrey Cadeddu, Daniel Costa, Dallas, TX</td>
</tr>
<tr>
<td>PD23-06</td>
<td>10:20</td>
<td>10:20</td>
<td>DETECTION RATE OF PROSTATE CANCER AT TARGET BIOPSY AFTER 3 DIFFERENT TECHNICAL APPROACHES Giorgio Ivan Russo*, Catania, Italy, Sascha Kaufman, Tübingen, Germany, Giuseppe Morgia, Catania, Italy, Nikolau Konstantin, Arnulf Stenzl, Stephan Kruck, Jens Bedke, Tübingen, Germany</td>
</tr>
<tr>
<td>PD23-07</td>
<td>10:30</td>
<td>10:30</td>
<td>INCREASED DETECTION OF HIGHER GRADE PROSTATE CANCER WITH MRI-FUSION PROSTATE BIOPSY AT HIGHER PSA Nabeel Shakir, Niccolo Passoni*, Daniel Wong, Dallas, TX, Samuel Gold, Graham Hale, Kareem Raym, Joseph Baiocco, Jonathan Bloom, Vladimir Valero, Maria Merino, Baris Turkbey, Peter Choyke, Bradford Wood, Peter Pinto, Bethesda, MD, Daniel Costa, Claus Roehrborn, Dallas, TX</td>
</tr>
<tr>
<td>PD23-09</td>
<td>10:50</td>
<td>10:50</td>
<td>MULTIVARIABLE RISK-STRATIFICATION IN A PRIMARY HEALTHCARE SETTING: REFERRAL RATE AND BIOPSY RESULTS FROM A UROLOGY OUTPATIENT CENTER Daniël Osses*, Arnout Alberts, Gonny Bausch, Monique Roobol, Rotterdam, Netherlands</td>
</tr>
</tbody>
</table>
**11:00 PD23-10 WHAT IS THE PREDICTIVE VALUE OF A NEGATIVE MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING IN EXCLUDING PROSTATE CANCER AT BIOPSY?**

Ricardo Lopez del Campo, Merce Cuadras Sole, Enric Miret Domenech, David Lorente Garcia, Jose Placer Santos*, Jacques Pianas Morin, Enrique Trilla Herrera, Juan Morote Robles, Barcelona, Spain

**11:10 PD23-11 COMPLICATIONS RATE AFTER ANTIBIOTIC PROPHYLAXIS WITH FOSFOMYCIN VS. STANDARD OF CARE IN PATIENTS UNDERGOING PROSTATE BIOPSY: A RANDOMIZED, SINGLE-BLINDED, CLINICAL STUDY**

Sebastiano Cimino, Catania, Italy, Paolo Verze, Napoli, Italy, Giorgio Ivan Russo*, Catania, Italy, Luca Ventorino, Napoli, Italy, Paolo Alessio, Catania, Italy, Ciro Imbimbo, Vincenzo Mirono, Napoli, Italy, Giuseppe Morgia, Catania, Italy

**11:20 PD23-12 UTILIZATION OF FACEBOOK, TWITTER, YOUTUBE AND INSTAGRAM IN THE PROSTATE CANCER COMMUNITY**

Julian Struck, Luebeck, Germany, Fabian Siegel, Mannheim, Germany, Mario Kramer, Luebeck, Germany, Igor Tsaur, Mainz, Germany, Axel Heidenreich, Cologne, Germany, Axel Hafekamp, Mainz, Germany, Hendrik Borgmann, Mainz, Germany, Johannes Salem*, Cologne, Germany

**9:30 PD24-01 DOES TUMOR SIZE AT THE TIME OF CYTOREDUCTIVE NEPHRECTOMY INFLUENCE SURVIVAL?**

Renzo DiNatale*, New York, NY, Maria Becerra, Miami, FL, Alejandro Sanchez, Kyle Blum, Nirmal John, Mazyar Ghaanat, New York, NY, Wanling Xie, Boston, MA, Daniel Heng, Calgary, Canada, Toni Choueiri, Boston, MA, Paul Russo, Ari Hakimi, New York, NY

**9:40 PD24-02 SURVIVAL AFTER CYTOREDUCTIVE NEPHRECTOMY IN METASTATIC NON-CLEAR CELL RENAL CELL CARCINOMA PATIENTS: A POPULATION-BASED STUDY**

Michele Marchioni*, Chieti, Italy, Marco Bandini, Milano, Italy, Felix Preisser, Hamburg, Germany, Zhe Tian, Montreal, Canada, Anil Kapoor, Hamilton, Canada, Luca Cindolo, Giulia Primiceri, Francesco Berardinelli, Chieti, Italy, Alberto Briganti, Milano, Italy, Shahrrokh F. Shariat, Vienna, Austria, Luigi Schips, Chieti, Italy, Pierre I. Karakiewicz, Montreal, Canada

**9:50 PD24-03 SURVIVAL FOLLOWING UPFRONT CYTOREDUCTIVE NEPHRECTOMY VERSUS TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA**

Bimal Bhindi*, Elizabeth Habermann, Ross Mason, Brian Costello, Lance Pagliaro, R. Houston Thompson, Bradley Leibovich, Stephen Boorjian, Rochester, MN

**10:00 PD24-04 INCIDENCE AND OUTCOMES OF DELAYED TARGETED THERAPY FOLLOWING CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA: A NATIONWIDE CANCER REGISTRY STUDY**

Solomon Woldu*, Dallas, TX, Justin Matulay, New York, NY, Timothy Clinton, Nirmish Singla, Yuval Freifeld, Oner Sanli, Laura-Maria Krabbe, Ryan Hutchinson, Yair Lotan, Hans Hammars, Raquibul Hannam, James Brugarolas, Aditya Bagrodia, Vitaly Margulis, Dallas, TX

**10:10 PD24-05 EFFECT OF AFRICAN-AMERICAN RACE ON CANCER SPECIFIC MORTALITY DIFFERS ACCORDING TO CLEAR-CELL VS. NON- CLEAR CELL HISTOLOGIC SUBTYPE IN METASTATIC RENAL CELL CARCINOMA**

Michele Marchioni*, Chieti, Italy, Sabrina Hammouch, Montreal, Canada, Marco Bandini, Milano, Italy, Felix Preisser, Hamburg, Germany, Sebastiano Nazzani, Milan, Italy, Zhe Tian, Helen D. Bondarenko, Montreal, Canada, Anil Kapoor, Hamilton, Canada, Luca Cindolo, Chieti, Italy, Alberto Briganti, Milano, Italy, Shahrrokh F. Shariat, Vienna, Austria, Luigi Schips, Chieti, Italy, Pierre I. Karakiewicz, Montreal, Canada
PD24-06 AN EVALUATION OF RACE, ETHNICITY, AGE, AND GENDER-BASED REPRESENTATION IN PHASE I-II RENAL CELL CARCINOMA CLINICAL TRIALS IN THE UNITED STATES
Alain Kaldany*, Kyle Blum, David Paulucci, Isuru Jayaratna, John Sfakianos, Ketan Badani, New York, NY

PD24-07 THE NATURAL HISTORY OF RENAL CELL CARCINOMA WITH ISOLATED LYMPH NODE METASTASES IN THE TARGETED THERAPY ERA
Jorge Pereira*, Dragao Golijanin, Ali Amin, Anthony Mega, Providence, RI, Stephen A. Boorjian, R. Houston Thompson, Bradley C. Leibovich, Rochester, MN, Boris Gershman, Providence, RI

PD24-08 RENAL CELL CARCINOMA AND BRAIN METASTASIS: A SEER ANALYSIS
Michael Daugherty*, Emily Daugherty, Joseph Jacob, Oleg Shapiro, Gennady Bratslavsky, Syracuse, NY

PD24-09 PROGNOSTIC VALUE OF THE GLASGOW PROGNOSTIC SCORE FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH CYTOREDUCTIVE NEPHRECTOMY
Hironori Fukuda*, Toshio Takagi, Tsunenori Kondo, Kazuhiro Yoshida, Satoru Shimizu, Yoji Nagashima, Kazunari Tanabe, Tokyo, Japan

PD24-10 RENAL COLLECTING DUCT CARCINOMA: CLINICAL PRESENTATION AND PATTERNS OF CARE
Zain Hyder*, Michael Callegari, Daniel Parker, Michael Cookson, Brian Cross, Sanjay Patel, Oklahoma City, OK

PD24-11 PREDICTORS OF RECURRENCE AND SURVIVAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA UNDERGOING COMPLETE SURGICAL RESECTION
Daniel D. Shapiro*, Madison, WI, Viraj Master, Atlanta, GA, Jay D. Raman, Hershey, PA, Nirmish Singla, Vitaly Margulis, Connie Wang, Patrick Roberts, Dallas, TX, Wilson Chan, Hershey, PA, Dattatraya Patil, Atlanta, GA, Glenn O. Allen, E. Jason Abel, Madison, WI

PD24-12 COMPARISON BETWEEN LIVER DEROTATION WITH PRINGLE MANOEUVRE AND CARDIOPULMONARY BYPASS WITH DEEP- HYPOTHERMIC CARDIAC ARREST FOR KIDNEY CANCER WITH MAYO III TUMOR THROMBUS: INTRA-, PERI- AND POSTOPERATIVE OUTCOMES
Alessandro Nini*, Fabio Muttin, Francesco Cianfoni, Cristina Carenzi, Roberta Lucianó, Marco Catena, Elisabetta Lapenna, Alessandro Larcher, Filippo Pederzoli, Rayan Matloob, Giovanni La Croce, Renzo Colombo, Michele Paganielli, Francesco Montorsi, Claudio Doglioni, Alberto Zangrillo, Ottavio Aliferi, Patrizio Rigatti, Umberto Capitanio, Massimo Freschi, Guglielmo Cornino, Alessandro Castiglioni, Luca Aldrighetti, Roberto Bertini, Milan, Italy

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
SUO-CTC PROSTATE COMMITTEE: SUO TRIALS UPDATE AND OTHER IMPORTANT TRIALS
Daniel Lin

THREE ARTICLES LAST YEAR THAT CHANGED OR INFLUENCED MY PRACTICE
Samir Taneja

2:20 INVITED GUEST LECTURE: SELECTION OF APPROPRIATE GENITOURINARY CANCERS FOR IMMUNOTHERAPY
Jeffrey Ross

2:40 BREAK

2:55 SESSION II: BLADDER CANCER
Moderator: Siamak Daneshmand

ADHERENCE TO BLADDER CANCER GUIDELINES AND ISSUES WITH IMPLEMENTATION
Ralph deVere White

HIGH RISK BCG RECURRENT/REFRACTORY DISEASE: SECONDARY INTRAVESICAL THERAPY
Sima Porten

HIGH RISK BCG RECURRENT/REFRACTORY DISEASE: IMMEDIATE CYSTECTOMY
Joseph Jacob

TREATMENT FOR MIBC FOR CIS-PLATINUM INELIGIBLE PATIENTS: IMMEDIATE CYSTECTOMY
Jonathan Wright

TREATMENT FOR MIBC FOR CIS-PLATINUM INELIGIBLE PATIENTS: OTHER SYSTEMIC OPTIONS AND TRIALS
Evan Yu

DEBATE: MOLECULAR SUBTYPING, IMMUNOHISTOCHEMISTRY INFLUENCES MY TREATMENT SELECTION
Debater - Pro: Peter Black
Debater - Con: David McConkey

PANEL DISCUSSION/Q&A

SUO-CTC BLADDER COMMITTEE: SUO TRIALS UPDATE AND OTHER IMPORTANT TRIALS
Ashish Kamat

THREE ARTICLES LAST YEAR THAT CHANGED OR INFLUENCED MY PRACTICE
Badrinath Konety

SESSION III: KIDNEY CANCER
Moderator: Viraj Master

DEBATE: ACTIVE SURVEILLANCE FOR LARGE RENAL MASSES IS APPROPRIATE
Debater - Pro: Marc Smaldone
Debater - Con: R. Houston Thompson

DEBATE: TUMOR ENucleation FOR SPORAdIC T1 RCC IS ONCOLOGICALLY SOUND
Debater - Pro: Ronald Boris
Debater - Con: E. Jason Abel

DEBATE: ADJUVANT THERAPY FOR HIGH RISK RCC SHOULD BE USED
Debater - Pro: Daniel George
Debater - Con: Hans Hammers

DEBATE: TEN YEARS OF BIG DATA CHANGED THE WAY WE MANAGE RCC
Debater - Pro: Brian Shuch
Debater - Con: Jose Karam

PANEL DISCUSSION/Q&A

SUO-CTC RENAL CELL CARCINOMA COMMITTEE: SUO TRIALS UPDATE AND OTHER IMPORTANT TRIALS
Eric Singer

THREE ARTICLES LAST YEAR THAT CHANGED OR INFLUENCED MY PRACTICE
Ithaar Derweesh

ADJOURN

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 19, 2018 1:00 pm - 3:00 pm

Forums

RESEARCH FORUM I: FUNDING OPPORTUNITIES AND GRANT WRITING GUIDANCE FOR EARLY-CAREER INVESTIGATORS
Room 208 @ MCC South

1:00 INTRODUCTION
Carolyn Best

2:20 AMERICAN CANCER SOCIETY FUNDING OPPORTUNITIES
Ellie Daniels

1:05 KEYNOTE: GRANTWRITING 101
Erika Wolff

2:35 AUA AND UROLOGY CARE FOUNDATION FUNDING OPPORTUNITIES AND EXTERNAL FUNDING SOURCES
Krystal Brinson

1:40 NIDDK TRAINING AND RESEARCH MECHANISMS
Tracy Rankin

2:50 Q&A

1:55 UROLOGY RESEARCH FUNDING AT THE DOD CDMRP
Carolyn Best

3:00 ADJOURN

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

*Presenting author
1:00 WELCOME MESSAGE
Society President: Manuel Esteban
Director: José Luis Alvarez-Ossorio
AUA Incoming President-Elect: John Lynch

1:10 INNOVATIVE BPH THERAPIES SUCH AS AQUABLATION
Moderator/Society Chair: Antonio Gomez
Speaker: Steven Kaplan

1:30 MANAGING MIXED URINARY INCONTINENCE
Moderator/Society Chair: José Ramón Cortíñas
Speaker: John Stoffel

1:50 ROLE OF NEO ADJUVANT PRE-SURGICAL TARGETED THERAPY IN RCC
Moderator/Society Chair: José Manuel Cozar
Speaker: José Karam

2:20 NON-METASTATIC CRPC: IS IT A REAL ENTITY? AND WHAT DOES SPARTAN TELL US ABOUT THERAPEUTIC APPROACHES?
Moderator/Society Chair: Jacoquin Carballido
Speaker: Eric Small

2:40 SURGERY VS RADIATION FOR HIGH-RISK LOCALIZED PROSTATE CANCER: WHAT IS THE EVIDENCE?
Moderator/Society Chair: Venancio Chantada
Speaker: Laurence Klotz

3:00 ADJOURN

Saturday, May 19, 2018
Moderated Poster Session 37
SEXUAL FUNCTION/DYSFUNCTION: PENIS/TESTIS/URETHRA: BENIGN DISEASE & MALIGNANT DISEASE I
Room 3004 @ MCC West
Moderators: Phillip Pierorazio, Philippe Spiess and Curtis Pettaway

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP37-01</td>
<td>UTILIZATION AND IMPACT OF POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION IN ADVANCED NON-SEMINOMATOUS GERM CELL TUMOR</td>
<td>MP37-04</td>
<td>METASTASIS IN SEMINOMATOUS GERM CELL TUMOURS IS CHARACTERIZED BY A SPECIFIC MIRNA PATTERN</td>
</tr>
<tr>
<td></td>
<td>Solomon Woldu, Joseph Moore, Yuval Freifeld, Timothy Clinton, Nirmish Singla, Laura-Maria Krabbe, Ryan Hutchinson, Yair Lotan, Yull Arniaga, Vitaly Margulis, Aditya Bagrodia, Dallas, TX</td>
<td></td>
<td>Simone Ernst*, Joana Heinzelmann, Sebastian Hölters, Georg Weber, Rainer M. Bohle, Michael Stöckle, Kerstin Junker, Julia Heinzelbecker, Homburg, Germany</td>
</tr>
<tr>
<td></td>
<td>Kelly Ward*, Birmingham, United Kingdom, Khaled Almekaty, London, United Kingdom, Brian Kelly, Birmingham, United Kingdom, Chirag Bhandari, London, United Kingdom, Kamlesh Patel, Prashard Patel, Birmingham, United Kingdom, Majid Shabbir, Suks Minhas, London, United Kingdom, Richard Viney, Birmingham, United Kingdom</td>
<td></td>
<td>Daniel Edwards*, Jason Levy, Brian McGreen, Noah May, Laurence Belkoff, Philadelphia, PA</td>
</tr>
<tr>
<td>MP37-03</td>
<td>QUALITY OF LIFE AND LONG-TERM TOXICITIES IN TESTICULAR CANCER</td>
<td>MP37-06</td>
<td>IS SURVEILLANCE WITHOUT IMMEDIATE TREATMENT AN OPTION FOR NEWLY DIAGNOSED TESTICULAR GERM-CELL CANCER PATIENTS WITH BORDERLINE SIZE RETROPERITONEAL LYMPH NODES ON COMPUTED TOMOGRAPHY SCAN?</td>
</tr>
<tr>
<td></td>
<td>Simone Ernst*, Karla Kaßmann, Homburg, Germany, Jan Lehmann, Kiel, Germany, Maximilian Cohausz, Münster, Germany, Carsten-Henning Ohlmann, Michael Stöckle, Julia Heinzelbecker, Homburg, Germany</td>
<td></td>
<td>Nadav Milk*, Ilan Leibovitch, Daniel Keizman, Hadas Dresler, Itay Sternberg, Kfar Saba, Israel</td>
</tr>
<tr>
<td>MP37-07</td>
<td>THE PRIMETEST TRIAL – INTERIM RESULTS OF A PHASE II TRIAL FOR PRIMARY RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) IN STAGE II A/B SEMINOMA PATIENTS WITHOUT ADJUVANT TREATMENT</td>
<td></td>
<td>Achim Lusch*, Robert grosse Siemer, Peter Albers, Dusseldorf, Germany</td>
</tr>
</tbody>
</table>
MP37-08 SERUM MIRNA PREDICTS VIABLE DISEASE POST-CHEMOTHERAPY IN TESTICULAR NON-SEMINOMA GERM CELL TUMOR PATIENTS
Ricardo Leão*, Toronto, Canada, Ton van Aghoven, Rotterdam, Netherlands, Kamel Fadaak, Toronto, Canada, Pedro Castelo-Branco, Faro, Portugal, Michael Jewett, Joan Sweet, Ardalain E. Ahmad, Lynn Anson-Cartwright, Peter Chung, Aaron Hansen, Padraig Warde, Martin O’Malley, Philippe L. Bedard, Toronto, Canada, Leendert H.J. Looijenga, Rotterdam, Netherlands, Robert J. Hamilton, Toronto, Canada

MP37-09 LATE RELAPSE OF TESTICULAR CANCER – UPDATE OF THE MSKCC EXPERIENCE
Roy Mano*, Renzo Dinatale, New York, NY, Maria Becerra, Miami, FL, Brett Carver, New York, NY, David Sharp, Columbus, OH, Darren Feldman, Samuel Funt, Dean Bajorin, Robert Motzer, George Bosl, Joel Sheinfeld, New York, NY

MP37-10 REFRACTORY TESTICULAR PURE SEMINOMA (PS) AND NON-SEMINOMATOUS(NS) GERM CELL TUMORS (GCT): A COMPREHENSIVE GENOMIC PROFILING (CGP) STUDY

MP37-11 CAN SQUAMOUS CELL CARCINOMA OF THE ANTERIOR MALE URETHRA BE MANAGED BY FOLLOWING A PENILE CANCER BEST PRACTICE PATHWAY?
Aditya Manjunath, Hussain AlNajjar, Catherine Corbishley, Benjamin Ayres*, Nick Watkin, London, United Kingdom

MP37-12 THE ROLE OF INGUINAL LYMPH NODE DISSECTION IN MEN WITH URETHRAL SQUAMOUS CELL CARCINOMA
Ryan Werntz*, Zach Smith, Vignesh Packiam, Chris Riedinger, Jake Fantus, Norm Smith, Gary Steinberg, Chicago, IL

MP37-13 ROBOTIC ASSISTED INGUINAL LYMPH NODE DISSECTION (RAIL) FOR CLINICAL NODE NEGATIVE PENILE SQUAMOUS CARCINOMA: RECENT RESULTS FROM THE MD ANDERSON CANCER CENTER (MDACC) EXPERIENCE AND COMPARISON TO A CONTEMPORARY OPEN COHORT
Barrett McCormick*, Matthew Meissner, John Papadopoulos, Surena Matin, Curtis Pettaway, Houston, TX

MP37-14 SURGICAL MANAGEMENT OF THE CLINICALLY NEGATIVE CONTRALATERAL GROIN WHEN THE IPSILATERAL GROIN IS CLINICALLY AND PATHOLOGICALLY POSITIVE IN SQUAMOUS CELL CARCINOMA OF THE PENIS
Michael Ager*, Aditya Manjunath, Sylvia Yan, Wayne Lam, Brendan Tinwell, Cathy Corbishley, Benjamin Ayres, Nick Watkin, London, United Kingdom

MP37-15 PI3K-AKT-MTOR PATHWAY IN PENILE SQUAMOUS CELL CARCINOMA: CLINICAL SIGNIFICANCE OF PTEN, AKT AND S6 EXPRESSION
Mounsif Azizi*, Dominic H. Tang, Daniel Verduzco, Juan Chipollini, Charles C. Peyton, Jun-Min Zhou, Braydon Schable, Jasreman Dhillon, Philippe E. Spiess, Tampa, FL

MP37-16 RISK FACTORS FOR MALIGNANCY IN PATIENTS WITH LEYDIG CELL TUMORS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF 1,375 PATIENTS
Christian Fankhauser*, Josias Grogg, Peter Bode, Tullio Sulser, Joerg Beyer, Thomas Hermanns, Zurich, Switzerland

MP37-17 COMPLICATIONS OF POSTCHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION FOR ADVANCED TESTICULAR CANCER

MP37-18 SURVIVAL FOLLOWING SALVAGE SURGERY AFTER FAILED RADIOTHERAPY FOR PENILE CANCER. LONG TERM FOLLOW- UP
Mahmoud Khalili*, Mohamed Kamel, Fel Wan, Ehab Eltahawy, Rodney Davis, Little Rock, AR, Philippe spiessi, Tampa, FL, Nabil Bissada, Houston, TX

MP37-19 THE IMPACT OF BLEOMYCIN ON PULMONARY AND OPERATIVE MORBIDITY AFTER POST- CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION IN GOOD RISK GERM CELL TUMORS
Adam Calaway*, Clint Cary, Timothy Masterson, Richard Bihlhe, Richard Foster, Indianapolis, IN

MP37-20 SURGICAL MANAGEMENT OF THE GROWING TERATOMA SYNDROME: A MULTICENTER STUDY
Pia Paffenholz*, David Pfister, Axel Heidenreich, Cologne, Germany

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP38-01</td>
<td>DEVELOPMENT OF ATHEROSCLEROSIS-INDUCED CHRONIC PELVIC ISCHEMIA RAT MODEL FOR REPRODUCING THE DETRUSOR UNDERACTIVITY</td>
</tr>
<tr>
<td></td>
<td>Myong Kim, Hwan Yeul Yu*, Daehun Choi, Jyung Hyun Shin, Aram Kim, Chae-Min Ryu, Ju-Young Han, Dong-Myung Shin, Myung-Soo Choo, Seoul, Korea, Republic of</td>
</tr>
<tr>
<td>MP38-02</td>
<td>AGE-ASSOCIATED CHANGES OF NITRIC OXIDE-MEDIATED URETHRAL SMOOTH MUSCLE RELAXATION AND EXTERNAL URETHRAL SPHINCTER FUNCTION IN RATS</td>
</tr>
<tr>
<td></td>
<td>Takuma Oshiro*, Naha Okinawa, Japan, Minoru Miyazato, Ryu Kimura, Asuka Ashikari, Seiichi Saito, Nishihara Okinawa, Japan</td>
</tr>
<tr>
<td>MP38-03</td>
<td>THE OXIDATIVE STRESS AND EPITHELIAL MESENCHYMAL TRANSITION CHANGE INDUCED BY LONG TERM USE OF ANTimusCARINIC OR ADRENERGIC AGONIST ON ISCHEMIA RELATED BLADDER OVERACTIVITY</td>
</tr>
<tr>
<td></td>
<td>Dong-Ru Ho*, Chih-Shou Chen, Wei-Yu Lin, Yun-Ching Huang, Jian-Hui Lin, Kuo-Tsai Huang, Pu-Z City, Taiwan</td>
</tr>
<tr>
<td>MP38-04</td>
<td>ELECTROCORTICOGRAPHY AS A MEANS TO STUDY BRAIN CONTROL OF URINATION</td>
</tr>
<tr>
<td></td>
<td>Tracie Tran, Po Wang, Irvine, CA, Brian Lee, Los Angeles, CA, Zoran Nenadic, Irvine, CA, Charles Liu, Los Angeles, CA, An Do, Irvine, CA, Evgeniy Kreydin*, Los Angeles, CA</td>
</tr>
<tr>
<td>MP38-05</td>
<td>NLRP3 INFLAMMASOME MEDIATED INFLAMMATION AND DENERVATION ARE CRITICAL PROCESSES IN THE DEVELOPMENT OF DIABETIC BLADDER DYSFUNCTION</td>
</tr>
<tr>
<td></td>
<td>Francis Hughes, Brian Inouye, Eloise Stanton, Chloe Yun, Huixia Jin, J. Purves*, Durham, NC</td>
</tr>
<tr>
<td>MP38-06</td>
<td>RAPAMYCIN REGULATION OF CORE CLOCK GENES IS ASSOCIATED WITH ALTERED DE-OBSTRUCTION SIGNATURES COORDINATE WITH PHYSIOLOGY</td>
</tr>
<tr>
<td></td>
<td>Annette Schroder, Mainz, Germany, Karen Aitken*, Jia-Xin Jiang, Aliza Siebenaller, Thenuka Thanabalasingham, Martin Sidler, Darius Bagli, Toronto, Canada</td>
</tr>
<tr>
<td></td>
<td>THE EFFECT OF BETA-3 ADRENERGIC RECEPTOR AGONIST ON MICROMOTIONS OF MAJOR PELVIC GANGLION DISCONNECTED RAT BLADDER</td>
</tr>
<tr>
<td></td>
<td>Hee Seo Son*, Soo Young Moon, Hyun Kyu Ahn, Kyung Taek Oh, Jee Soo Park, Jee Soo Ha, Jang Hwan Kim, Seoul, Korea, Republic of</td>
</tr>
<tr>
<td>MP38-08</td>
<td>NUTRIENT INTAKE AND URINARY INCONTINENCE IN KOREAN WOMEN: A PROPENSITY SCORE-MATCHED ANALYSIS FROM THE KOREAN NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY DATA</td>
</tr>
<tr>
<td></td>
<td>Jun Ho Lee*, Seoul, Korea, Republic of</td>
</tr>
<tr>
<td>MP38-10</td>
<td>LONG-TERM ADMINISTRATION OF PRAZOSIN IMPROVES BLADDER STORAGE FUNCTION INDUCED BY AUTONOMIC NERVOUS SYSTEM OVERACTIVITY THROUGH REDUCTION OF AFFERENT ACTIVITY IN SPONTANEOUSLY HYPERTENSIVE RATS</td>
</tr>
<tr>
<td></td>
<td>Nobuhiro Haga*, Hidenori Akaishita, Ken Alkawa, Kei Ishibashi, Yoshiyuki Kojima, Fukushima, Japan</td>
</tr>
<tr>
<td>MP38-11</td>
<td>ROLE OF MICRONRNAS, INHIBITED BY TNF-A, IN SMOOTH MUSCLE REMODELING DURING OUTLET OBSTRUCTION-INDUCED LOWER URINARY TRACT DYSFUNCTION</td>
</tr>
<tr>
<td></td>
<td>Ali Hashemi Gheinani*, Ivonne Koeck, Fiona C. Burkhard, Katia Monastyrskaya, Bern, Switzerland</td>
</tr>
<tr>
<td>MP38-12</td>
<td>URETHRAL DYSFUNCTION AND THERAPEUTIC EFFECTS OF A PDE 5 INHIBITOR (TADALAFIL) IN A RAT MODEL OF NEUROGENIC UNDERACTIVE BLADDER INDUCED BY PELVIC NERVE CRUSH</td>
</tr>
<tr>
<td></td>
<td>Ei-Ichiro Takaoka*, Shun Takai, Takahisa Suzuki, Nobutaka Shimizu, Joongbeom Kwon, Hiroki Okada, Christopher J. Chermansky, Pittsburgh, PA, Jun Miyazaki, Chiba, Japan, Naoki Yoshimura, Pittsburgh, PA</td>
</tr>
</tbody>
</table>
MP38-13 URINARY INCONTINENCE AND LOW BONE MINERAL DENSITY AMONG OLDER UNITED STATES ADULTS
Nikki Steinsiek*, Brittany L. Morgan, Lynn M. Marshall, Kamran P. Sajadi, Portland, OR

MP38-14 CONSTIPATION INDUCES OVERACTIVE BLADDER THROUGH ALTERATIONS OF NICOTINIC AND PURINERGIC PATHWAYS IN MOUSE BLadders
Nao Iguchi*, Ricardo Pineda, Aurora, CO, Alonso Carrasco Jr., Kansas City, MO, M. irfan Dönmez, Anna Malykhina, Duncan Wilcox, Aurora, CO

MP38-15 DIFFERENTIAL PROTEIN EXPRESSION IN PATIENTS WITH UCPPS: A MAPP STUDY
Jennifer Anger*, Weston Spivia, Irene van den Broek, Los Angeles, CA, Daniel Crear, Gloucester Point, VA, A. Lenore Ackerman, Karyn Eilber, Michael Freeman, Jayoung Kim, Qin Fu, Jennifer Van Eyk, Los Angeles, CA, Multi-Disciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Network, Philadelphia, PA

MP38-16 PELVIC ARTERIAL OCCLUSIVE DISEASE CAUSES UROPLAKIN II DEFICIENCY IN THE BLADDER OF RAT
Hidetoshi Akaigawa*, Akifumi Onagi, Ryo Tanji, Runiko Takanami, Kanako Matsuoka, Hoshi Seiji, Tomoyuki Koguchi, Junya Hata, Yuichi Sato, Masao Kataoka, Soichiro Ogawa, Nobuhiro Haga, Kei Ishibashi, Ken Akawa, Yoshiyuki Kojima, Fukushima, Japan

MP38-17 METABOLOMICS APPROACH FOR ASSOCIATION WITH OVERACTIVE BLADDER IN MALES: AN IDENTIFICATION OF POTENTIAL TARGETS FOR NEW TREATMENTS
Hiroshi Shimura*, Tokyo, Japan, Takahiko Mitsui, Satoru Kira, Tatsuya Ihara, Hiroshi Nakagomi, Norifumi Sawada, Masayuki Takeda, Yamanashi, Japan

MP38-18 METABOLOMICS APPROACH FOR ASSOCIATION WITH OVERACTIVE BLADDER IN MALES: AN IDENTIFICATION OF POTENTIAL TARGETS FOR NEW TREATMENTS
Yuan-Hong Jiang*, Hann-Chong Kuo, Hualien, Taiwan

MP38-19 PROTEOMIC INVESTIGATION OF THE URINARY BIOMARKERS FOR INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME PATIENTS – MAPPING CHARACTERISTICS AND THE PREDICTION OF TREATMENT OUTCOME
José L. Palacios*, Tlaxcala, Mexico, Carlos Pérez, Chihuahua, Mexico, Margot S. Damaser, Cleveland, OH, Margarita Juárez, Yolanda Cruz Gomez, Tlaxcala, Mexico

MP38-20 TRANSCUTANEOUS ELECTRICAL STIMULATION OF DORSAL NERVE OF CLITORIS FACILITATES URINARY CONTINENCE RECOVERY AFTER VAGINAL DISTENSION IN RATS
José L. Palacios*, Tlaxcala, Mexico, Carlos Pérez, Chihuahua, Mexico, Margot S. Damaser, Cleveland, OH, Margarita Juárez, Yolanda Cruz Gomez, Tlaxcala, Mexico

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
MP39-03 OPTOGENETIC MODULATION OF MICTURITION CENTERS BY BASAL FOREBRAIN-MEDIATED NEURAL CIRCULATORY ACTIVITY IN IC/BPS MICE
Su Jin Kim*, Wonju, Korea, Republic of, Sae Woong Kim, Seoul, Korea, Republic of, Khae Hawn Kim, Incheon, Korea, Republic of

MP39-04 GENE EXPRESSION PROFILES IN URINARY BLADDER MUSCOSA ARE HIGHLY CORRELATED WITH ANESTHETIZED BLADDER CAPACITY IN IC/BPS PATIENTS
Stephen Walker*, Gopal Badlani, Catherine Matthews, Joao Zambon, Robert Evans, Winston Salem, NC

MP39-05 THE UROTHELIAL FIBROGENESIS CYTOKINES AND RECEPTORS IN PATIENTS OF INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME WITH DIFFERENT CLINICAL PHENOTYPES AND SYMPTOM SEVERITY
Jia-Fong Jhang*, Han-Chen Ho, Yuan-Hong Jiang, Yung-Hsiang Hsu, Hann-Chorng Kuo, Hualien, Taiwan

MP39-06 PELVIC PAIN MODULATION AND TARGETING THROUGH ARACHIDONIC ACID METABOLISM
Wenbin Yang*, Ryan Yaggie, Charles Rudick, Anthony Schaeffer, David Klumpp, Chicago, IL

MP39-07 THE ROLE OF EPSTEIN-BARR VIRUS INFECTION IN BLADDER OF INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME
Jia-Fong Jhang*, Han-Chen Ho, Yuan-Hong Jiang, Yung-Hsiang Hsu, Hann-Chorng Kuo, Hualien, Taiwan

MP39-08 PAINFUL URGENCY AND/OR PAINFUL FILLING PREDICTIVE OF SOMATIC SYMPTOMS AND CHRONIC PAIN IN WOMEN WITH OVERACTIVE BLADDER

MP39-09 EFFECT OF INTRAVESICAL HYALURONIC ACID INSTILLATION ON KETAMINE-INDUCED CYSTITIS
Chi-Hang Yee*, Cindy Yuek-Lam Hong, Franco Pui-Tak Lai, Yuk-Him Tam, Chi-Fai Ng, Hong Kong, Hong Kong

MP39-10 NOVEL CONTRAST MIXTURE ACHIEVES CONTRAST RESOLUTION OF HUMAN BLADDER WALL SUITABLE FOR T1 MAPPING: APPLICATIONS IN INTERSTITIAL CYSTITIS (IC) AND BEYOND
Pradeep Tyagi*, Joe Janicki, Chan-Hong Moon, Jonathan Kaufman, Christopher Chermansky, Pittsburgh, PA

MP39-11 TOWARD PERSONALIZED MEDICINE FOR AN INTERSTITIAL CYSTITIS INDIVIDUALIZED DIAGNOSIS USING A NEW BLADDER INFLAMMATION SCORE
Laura Lamb*, Royal Oak, MI, Joseph Janicki, Pittsburgh, PA, Sarah Bartolone, Bernadette Zwaans, Kenneth Peters, Michael Chancellor, Royal Oak, MI

MP39-12 CHANGES IN WHOLE BODY PAIN INTENSITY AND WIDESPREADNESS DURING UROLOGIC CHRONIC PELVIC PAIN SYNDROME SYMPTOM (UCPPS) FLARES – FINDINGS FROM ONE SITE OF THE MAPP STUDY
Tianlin Xu, H. Henry Lai, Ratna Pakpahan, Gerald Andriole, St. Louis, MO, Catherine Bradley, Iowa City, IA, Graham Colditz, Siobhan Sutcliffe*, St. Louis, MO

MP39-13 AN OPEN-LABEL, TWO-PART, SEQUENTIAL DOSE STUDY ASSESSING THE ABSOLUTE BIOAVAILABILITY, MASS BALANCE, AND RECOVERY FOR [14C]-ROSIPTOR (AQX-1125) IN HEALTHY SUBJECTS
Patrick Tam*, Dorothea Scholl, Judy Toews, Curtis Harwig, Lloyd F. Mackenzie, Vancouver, Canada

MP39-14 THERAPEUTIC EFFECT OF PLATELET-RICH-PLASMA INTRAVESICAL REPEAT INJECTIONS FOR INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME REFRACTORY TO CONVENTIONAL TREATMENT
Shu-Yu Wu*, Hueih-Ling Ong, Yu-Khun Lee, Jia-Fong Jhang, Hann-Chorng Kuo, Hualien, Taiwan

MP39-15 IPSE, A UROGENITAL PARASITE DERIVED PROTEIN, DRIVES UROTHELIAL PROLIFERATION AND ALLEVIATES CHEMOTHERAPY INDUCED HEMORRHAGIC CYSTITIS
Evaristus Mbanofo*, Loc Le, Nirad Banskota, Rockville, MD, Luke Pennington, Stanford, CA, Abdulaziz Alouffi, Riyadh, Saudi Arabia, Debalina Ray, Milpitas, CA, David Heery, Nottingham, United Kingdom, Theodore Jardetzky, Stanford, CA, Franco Falcone, Nottingham, United Kingdom, Michael Hsieh, Rockville, MD

MP39-16 IMPACT OF PATIENT AGE ON CLINICAL SYMPTOMS OF UROLOGIC CHRONIC PELVIC PAIN SYNDROME (UCPPS)
James Htein Thu*, Niraj Badhiwala, Frederick Moh, Joel Vetter, H. Henry Lai, St. Louis, MO

MP39-17 THE MISDIAGNOSIS OF INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME
Stephanie L. Skove, Lauren E. Howard, Justin Senechal, Amanda De Hoedt, Durham, NC, Catherine Bresee, Jayoung Kim, Stephen Freedland, Jennifer Anger*, Los Angeles, CA
MP39-18 GENITAL PAIN IN UROLOGIC CHRONIC PELVIC PAIN SYNDROMES (UCPPS) – A MAPP RESEARCH NETWORK STUDY
H Henry Lai*, St. Louis, MO, Robert Gallop, Philadelphia, PA, Siobhan Sutcliffe, St. Louis, MO, J Quentin Clemens, Ann Arbor, MI, John Krieger, Seattle, WA, Larissa Rodriguez, Los Angeles, CA, Claire Yang, Seattle, WA, Catherine Bradley, Iowa City, IA, Jennifer Anger, Los Angeles, CA, Theresa Spitznagle, St. Louis, MO, Frank Tu, Chicago, IL, John Farrar, J. Richard Landis, Philadelphia, PA

MP39-19 THE ROLE OF URINARY CATIONS IN THE ETOLOGY OF INTERSTITIAL CYSTITIS: A MULTISITE STUDY

MP39-20 THE LONGITUDINAL ROLE OF CATASTROPHIZING AND EMOTION REGULATION IN THE RELATIONSHIP BETWEEN DEPRESSION AND PAIN IN WOMEN WITH INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME
Dean Tripp*, Alison Crawford, J. Curtis Nickel, Kingston, Canada, Robert Moldwin, New York, NY, Lesley Carr, Toronto, Canada, Robert Mayer, Grant Pass, OR, Laura Katz, Kingston, Canada

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 19, 2018
1:00 pm - 3:00 pm

Moderated Poster Session 40
PROSTATE CANCER: DETECTION & SCREENING III
Room 3020 @ MCC West
Moderators: Fred Saad, Andrew Vickers and Rafael Sanchas Salas

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP40-01</td>
<td>EVALUATION OF PRE-BIOPSY RECTAL SWABS, AUGMENTED ANTIBIOTICS, AND FORMALIN NEEDLE DISINFECTION ON RATES OF TRANRECTAL PROSTATE BIOPSY COMPLICATIONS</td>
</tr>
<tr>
<td>MP40-02</td>
<td>TARGETED PROSTATE BIOPSY: CANCER EXTENDS BEYOND THE ROI</td>
</tr>
<tr>
<td>MP40-03</td>
<td>CHANGES IN PROSTATE SPECIFIC ANTIGEN SCREENING AND PROSTATE CANCER DIAGNOSIS AFTER GUIDELINE CHANGES</td>
</tr>
<tr>
<td>MP40-04</td>
<td>THE IMPACT OF FALSE NEGATIVE PROSTATE SPECIFIC ANTIGEN- AND BIOPSY RESULTS IN PROSTATE CANCER SCREENING</td>
</tr>
<tr>
<td>MP40-05</td>
<td>EFFECTS OF INTRODUCING PRE-BIOPSY MP-MRI INTO CONTEMPORARY UK PROSTATE CANCER DETECTION</td>
</tr>
<tr>
<td>MP40-06</td>
<td>CONFIRMATION OF IMPROVED DIAGNOSTIC PERFORMANCE OF SYSTEMATIC FREEHAND TRANSRECTAL BIOPSY: COMPARISON OF OBSERVED OUTCOMES TO PCPTRC 2.0 NOMOGRAM PREDICTIONS</td>
</tr>
<tr>
<td>MP40-07</td>
<td>3T MULTIPARAMETRIC MRI BASED DETECTION OF PROSTATE CANCER: FEATURES OF DETECTED AND MISSED TUMORS BASE ON PI-RADS V2 IN 429 PATIENTS- USING WHOLE MOUNT HISTOPATHOLOGY REFERENCE</td>
</tr>
<tr>
<td>MP40-08</td>
<td>PROSPECTIVE COMPARISON OF RANDOM TRUS BIOPSY VERSUS PROSTATE HISTOSCANNING–GUIDED AND RANDOM BIOPSY VERSUS MRI–GUIDED AND RANDOM BIOPSY: WHICH TECHNIQUE IS OPTIMAL FOR PROSTATE CANCER DETECTION AND ITS GRADE GROUP DETECTION?</td>
</tr>
</tbody>
</table>
MP40-09 MOVING TOWARDS ZERO SEPSIS; OUR REGISTRARS CAN DO IT! AN ANALYSIS OF 214 CASES OF TRANSPERINEAL PROSTATE BIOPSY OVER THREE YEARS
Hansi Pathirana, Jonathan Kam*, Yusgi Yuminaga, Kieran Beatle, Sunny Naivenkata, Mohan Anayavagam, Bertram Canagasingh, Richard Ferguson, Raymond Ko, Celi Varol, Matthew Winter, Mohamed Khadra, Kingswood, Australia

MP40-10 EXTENDED VALIDATION RESULTS FROM A PROSPECTIVE ADAPTIVE UTILITY TRIAL CONFIRM PERFORMANCE OF A NOVEL URINE EXOSOME GENE EXPRESSION ASSAY TO PREDICT HIGH-GRADE PROSTATE CANCER AT INITIAL BIOPSY

MP40-11 USE OF PSA AND 4-KALLIKREIN PANEL TO IDENTIFY LETHAL PROSTATE CANCERS AND REDUCE UNNECESSARY SCREENING AND BIOPSY

MP40-12 IS SERUM TESTOSTERONE LEVEL IS NOT RELATED TO ADENOCARCINOMA DIAGNOSIS OF THE PROSTATE EVEN AMONG DEFINITELY HYPOGONADAL PATIENTS?
Jung Jun Kim*, Sung Kyu Hong, Seok-Soo Byun, Seong Nam, Korea, Republic of

MP40-13 OPTIMIZED CLINICAL ALGORITHM TO COMBINE TESTING OF SERUM PHI AND URINARY PCAS TO IMPROVE PROSTATE CANCER DETECTION BY REDUCING UNNECESSARY BIOPSY
Martin Sanda*, Eugene Huang, Dattatraya Patil, Atlanta, GA, Lori Sokoll, Daniel Chan, Baltimore, MD, Doug Scherr, New York, NY, Javed Siddiqui, John Wei, Ann Arbor, MI

MP40-14 IS LOCAL ANAESTHETIC TRANSPERINEAL PROSTATE BIOPSY FEASIBLE AND ACCEPTABLE? A COMPARISON OF PATIENT EXPERIENCE UNDER LOCAL ANESTHETIC (LA) OR SEDATION
Laura Sarmiento, Jose Marenco*, Collins Tom, Clement Orczyk, Caroline Moore, Mark Emberton, London, United Kingdom

MP40-15 DOES MRI PERFORM DIFFERENTLY IN MEN UNDERGOING TARGETED BIOPSY FOR EVALUATION OF PROSTATE CANCER VERSUS THOSE ON ACTIVE SURVEILLANCE?
Marcelo P. Barboza, Isildinha M. Reis, Feng Miao, Nachiketh Soodana Prakash, Maria C. Velasquez*, Rosa Castillo, Chad R. Ritch, Mark L. Gonzalez, Bruce Kava, Ramgopal Satyanarayana, Dine J. Parekh, Sanoj Punnen, Miami, FL

MP40-16 MRI-TRUS FUSION PROSTATE BIOPSY: LEARNING CURVE EXPERIENCE WITH A MULTIDISCIPLINARY TEAM APPROACH
Cihan Demirel*, Muamer Altok, Hyunseon Kang, Haesun Choi, Joseph Andres, Eugenio Familiar, John Davis, John Ward, Houston, TX

MP40-17 WHAT IS THE IMPACT OF NUMBER OF LESIONS IDENTIFIED ON MULTI-PARAMETRIC MAGNETIC RESONANCE IMAGING?

MP40-18 TITLE: PIRADS 3 RADIOLOGIC “GREY ZONE” - WHAT PROPORTION OF MEN WHO HAVE PIRADS 3 LESIONS REPORTED ON MP-MRI HAVE PROSTATE CANCER?
Daniel Costello*, Melbourne, Australia, Paul Cathcart, London, United Kingdom, Cameron Parkin, Mark Frydenberg, Daniel Moon, Justin Peters, Melbourne, Australia, Oussama El Hage, Ben Challacombe, London, United Kingdom, Anthony Costello, Melbourne, Australia

MP40-19 INITIAL EXPERIENCE OF NOVEL HYBRID PSMA PET / MRI IMAGING FOR LYMPH NODE STAGING IN PROSTATE CANCER
Georges Mehawed*, Wilson Choi, Andre Joshi, Handoo Rhee, Kenneth Miles, Sonja Gustafson, Ian Vela, Brisbane, Australia

MP40-20 NOVEL CIRCULATING TUMOR CELLS BLOOD ASSAY FOR THE CLARIFICATION OF 4-10 NG/ML PSA RESULTS ASSESSED IN A PROSPECTIVE CLINICAL STUDY
See-Tong Pang*, Ying-Hsu Chang, Po-Hung Lin, LinKou, Taiwan, Ying-Chih Chang, Taipei, Taiwan, Drew Watson, Los Altos, CA, Oscar Segurado, San Jose, CA, Si-Hong Lu, Jen-chia Wu, Hung-Jen Shao, Jr-Ming Lai, Shih-En Chang, Ben Hsieh, Mana Jarvey, Sunnyvale, CA, Mahul Amin, Memphis, TN, Rui Mei, Sunnyvale, CA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP41-01</td>
<td>IMPACT OF VARIANT HISTOLOGIC DIFFERENTIATION IN BLADDER CANCER PATIENTS ON RECURRENCE PATTERN AFTER RADICAL CYSTECTOMY: IMPLICATIONS FOR FOLLOW UP SCHEMES</td>
</tr>
<tr>
<td></td>
<td>Marco Moschini*, Switzerland, Switzerland, Giusy Burgio, Milan, Italy, Rocco Damiano, Catanzaro, Italy, Nazareno Suardi, Nicola Fossati, Giorgio Gandaglia, Federico Deho*, Marco Bianchi, Milan, Italy, Agostino Mattei, Luzern, Switzerland, Andrea Salonia, Alberto Briganti, Francesco Montorsi, Renzo Colombo, Andrea Gallina, Milan, Italy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP41-02</td>
<td>OUTCOMES OF NESTED VARIANT OF UROTHELIAL CARCINOMA FOLLOWING RADICAL CYSTECTOMY</td>
</tr>
<tr>
<td></td>
<td>Joel Hillelsohn*, Valhalla, NY, Amy Tin, Dev Malley, Guido Dalbagni, New York, NY</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP41-03</td>
<td>EXPRESSION OF SOMATOSTATIN RECEPTORS IN PATIENTS WITH ADVANCED BLADDER CANCER IS AN INDICATOR FOR FAVORABLE OUTCOME</td>
</tr>
<tr>
<td></td>
<td>Moritz Maas*, Jörg Hennenlotter, Lisa Rudolph, Simon Walz, Marcus Scharpf, Ursula Kühls, Tim Neumann, Arnulf Stenzl, Tilman Todenhöfer, Tübingen, Germany</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP41-04</td>
<td>URINARY CORRELATES OF PATHOLOGIC COMPLETE RESPONSE IN BLADDER CANCER PATIENTS RECEIVING NEOADJUVANT CHEMOTHERAPY</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP41-05</td>
<td>IMPACT OF CLINICAL STAGING ON SURVIVAL FOR PATIENTS DOWNSTAGED FOLLOWING NEOADJUVANT CHEMOTHERAPY AND RADICAL CYSTECTOMY</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP41-06</td>
<td>IMPLICATIONS OF NEOADJUVANT CHEMOTHERAPY ON COST AND OUTCOMES IN MUSCLE INVASIVE BLADDER CANCER</td>
</tr>
<tr>
<td></td>
<td>Timothy Clinton*, Solomon Woldu, Oner Sanli, Richard Wang, Louis Gianni, Ganesh Raj, Arthur Sagalowsky, Vitaly Margulis, Yair Lotan, Dallas, TX</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP41-07</td>
<td>COULD ADJUVANT CHEMOTHERAPY HAVE ADDITIONAL THERAPEUTIC BENEFIT IN BLADDER CANCER PATIENTS TREATED WITH RADICAL CYSTECTOMY AND NEOADJUVANT CHEMOTHERAPY?</td>
</tr>
<tr>
<td></td>
<td>Minami Omura*, Eiji Kikuchi, Koichiro Oghara, Kyohsei Hakozaki, Keishiro Fukumoto, Tokyo, Japan, Gou Kaneko, Yasumasa Miyazaki, Kanagawa, Japan, Nobuyuki Tanaka, Suguru Shirotake, Kunimitsu Kanai, Saitama, Japan, Kazuhiro Matsumoto, Mototsugu Oya, Tokyo, Japan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP41-08</td>
<td>TIME FROM DIAGNOSIS TO CHEMOTHERAPY AS A PREDICTOR OF OVERALL SURVIVAL IN BLADDER CANCER PATIENTS WITH CLINICALLY POSITIVE LYMPH NODES</td>
</tr>
<tr>
<td></td>
<td>Nicholas Chakiryan*, Ann Martinez, Jen-Jane Liu, Christopher Amling, Ryan Kopp, Portland, OR</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP41-09</td>
<td>SUPERIOR EFFICACY OF NEOADJUVANT CHEMOTHERAPY AND RADICAL CYSTECTOMY IN CT3-4AN0M0 COMPARED TO CT2N0M0 BLADDER CANCER</td>
</tr>
<tr>
<td></td>
<td>Tom Hermans, Charlotte Voskuilen*, Marc Deelen, Laura Mertens, Simon Horenblas, Amsterdam, Netherlands, Richard Meijer, Utrecht, Netherlands, Joost Boormans, Rotterdam, Netherlands, Katja Aben, Utrecht, Netherlands, Michel van der Heijden, Floris Pos, Amsterdam, Netherlands, Ronald de Wit, Rotterdam, Netherlands, Laurens Beerepoot, Tilburg, Netherlands, Rob Verhoeven, Utrecht, Netherlands, Bas van Rhijn, Amsterdam, Netherlands</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP41-10</td>
<td>NEOADJUVANT CHEMOTHERAPY RESULTS IN SKELETAL MUSCLE INDEX DECLINE IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER</td>
</tr>
<tr>
<td></td>
<td>Nikki Steinseik*, Ashland, OR, Ann Martinez Acevedo, Alexander Guimaraes, Virginie Achim, Paul Jones, Jasper Bash, Makena Whitaker, Christopher L. Amling, Jeremy Celnar, Jen-Jane Liu, Portland, OR</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP41-11</td>
<td>IMPACT OF HIGH VOLUME SURGICAL CARE ON MEDIAN OVERALL SURVIVAL FOR LOCALIZED BLADDER CANCER</td>
</tr>
<tr>
<td></td>
<td>Alexander P. Cole*, Boston, MA, Nicolas von Landenberg, Herne, Germany, Thomas Seisen, Paris, France, Philipp Gild, Hamburg, Germany, Stuart R. Lipshitz, Boston, MA, Akshay Sood, Firas Abdollah, Mani Menon, Detroit, MI, Adam S. Kibel, Quoc-Dien Trinh, Boston, MA</td>
</tr>
</tbody>
</table>
MP41-12 RADICAL CYSTECTOMY IN PATHOLOGICAL T4A AND T4B PATIENTS: IS THERE ANY SPACE FOR SUBSTRATIFICATION? Marco Moschini*, Switzerland, Switzerland, Giusy Burgio, Milan, Italy, Shahroksh Shariat, Vienna, Austria, Nazareno Suardi, Giorgio Gandaglia, Nicola Fossati, Milan, Italy, Agostino Mattei, Luzern, Switzerland, Andrea Salonia, Alberto Briganti, Francesco Montorsi, Andrea Gallina, Renzo Colombo, Milan, Italy

MP41-13 THE ASSOCIATION OF CHRONIC KIDNEY DISEASE WITH TUMOR RECURRENCE AND MORTALITY FOLLOWING RADICAL CYSTECTOMY FOR UROTHELIAL CARCINOMA Ross J. Mason*, Bimal Bhindi, Igor Frank, Prabin Thapa, Matthew K. Tollefson, R. Houston Thompson, R. Jeffrey Karnes, Stephen A. Boorjian, Rochester, MN

MP41-14 UROTHELIAL CARCINOMA IN BLADDER DIVERTICULA: A MULTICENTER ANALYSIS OF CHARACTERISTICS AND TREATMENT OUTCOME Charlotte Voskuilen*, Amsterdam, Netherlands, Roland Seiler, Bern, Switzerland, Michael Rink, Hamburg, Germany, Cédric Poyet, Zurich, Switzerland, Aidan Noon, Sheffield, United Kingdom, Florian Roghmann, Herne, Germany, Andrea Necchi, Milan, Italy, Atiqullah Aziz, Rostock, Germany, Alexandre Lavollé, Paris, France, Matthew Young, Sheffield, United Kingdom, Phillip Marks, Hamburg, Germany, Karim Saba, Zurich, Switzerland, Bas van Rhijn, Elisabeth Fransen van de Putte, Amsterdam, Netherlands, Jason Ablat, Peter Black, Vancouver, Canada, Roman Sosnowski, Jakub Dobruch, Warsaw, Poland, James Catto, Sheffield, United Kingdom, Evangelos Xylina, Paris, France, Kees Hendricksen, Amsterdam, Netherlands


MP41-16 ONCOLOGICAL AND FUNCTIONAL OUTCOMES OF PROSTATE SPARING CYSTECTOMY COMPARED WITH STANDARD RADICAL CYSTECTOMY Ahmed Abdelaziz, Giza, Egypt, Hossam Shaker, Mohamed Kamal*, Seif Elnasr, Fayoum, Egypt, Mohamed Nazim, Cairo, Egypt, Mohamed Mahmoud, Fayoum, Egypt

MP41-17 SHOULD ORTHOTOPIC BLADDER SUBSTITUTION BE OMITTED IF PRECYSTECTOMY BIOPSIES OF THE PROSTATIC URETHRA (MALE) OR BLADDER NECK (FEMALE) ARE POSITIVE? Bernhard Kiss*, Ioannis Giannakis, Furrer Marc, Patrick Wuehricht, Fiona Burkhard, Gerorge Thalmann, Beat Roth, Bern, Switzerland

MP41-18 THE INFLUENCE OF ENHANCED RECOVERY PROGRAMME ON PATIENT REPORTED CONVALESCENCE AND HEALTH-RELATED QUALITY OF LIFE AFTER ROBOTIC ASSISTED RADICAL CYSTECTOMY Dimitrios Moschonas, Pavlos Pavlakis, Murthy Kusuma, Stylianos Chintzoglou, Chris Jones, Alison Roodhouse, Simon Woodhams, Michael Swinn, Hugh Mostafid, Matthew Perry, Krishnaji Patil, Dimitrios Moschonas*, Guildford, United Kingdom

MP41-19 THE EFFECT OF SMOKING ON RADICAL CYSTECTOMY SURGICAL OUTCOMES: A PROPENSITY-MATCHED ANALYSIS Niranjan Sathianathan*, Badrinath Konety, Minneapolis, MN

MP41-20 THE ASSOCIATION OF PREOPERATIVE ASPIRIN USE WITH SURVIVAL FOLLOWING RADICAL CYSTECTOMY Timothy Lyon*, Igor Frank, Paras Shah, Robert Tarrell, Prabin Thapa, John Cheville, R. Jeffrey Karnes, R. Houston Thompson, Matthew Tollefson, Stephen Boorjian, Rochester, MN

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP42-01</td>
<td>SURGICAL MANAGEMENT OF RENAL CELL CARCINOMA WITH LEVELS III AND IV TUMOR THROMBUS USING THE TECHNIQUE</td>
</tr>
<tr>
<td></td>
<td>Charles Chawhan*, Adrian Turcanu, Feras Alharbi, Kerem Guleryuz, Grégoire Leon, Anne-Lise Fiant, Lionel Vaudreuil, Xavier Tillou, Caen, France, Arnaud Doerfler, Brussels, Belgium</td>
</tr>
<tr>
<td>MP42-02</td>
<td>TUMOR ENUCLEATION: FUNCTIONAL COMPARISON WITH STANDARD PARTIAL NEPHRECTOMY</td>
</tr>
<tr>
<td></td>
<td>Wen Dong, Cleveland, OH, Gopal N. Gupta, Robert H. Blackwell, Maywood, IL, Jitao Wu, Chalairat Suk-Ouichai*, Cleveland, OH, Arpeet Shah, Sarah E. Capodice, Marcus L. Quek, Maywood, IL, Elvis Caraballo, Diego Aguilar, Erick Remer, Jianbo Li, Joseph Zabell, Sudhir Isharwal, Steven C. Campbell, Cleveland, OH</td>
</tr>
<tr>
<td>MP42-03</td>
<td>COMPARISON OF KIDNEY FUNCTION IN THE EARLY POSTOPERATIVE PERIOD BETWEEN A TRANSPERITONEAL VERSUS RETROPÉRITONEAL ROBOT-ASSISTED LAPAROSCOPIC PARTIAL NEPHRECTOMY FOR POSTERIOR RENAL TUMORS: A PROPENSITY SCORE-MATCHED STUDY</td>
</tr>
<tr>
<td></td>
<td>Toshio Takagi*, Tsunenori Kondo, Kazuhiro Yoshida, Junpei lizuka, Hirohito Kobayashi, Masayoshi Okumi, Hideki Ishida, Kazunari Tanabe, Tokyo, Japan</td>
</tr>
<tr>
<td>MP42-04</td>
<td>MODIFIED ROBOT-ASSISTED SIMPLE ENUCLEATION WITH SINGLE LAYER RENORRHAPHY TECHNIQUE VERSUS STANDARD ROBOT-ASSISTED PARTIAL NEPHRECTOMY FOR TREATING LOCALIZED RENAL CELL CARCINOMA</td>
</tr>
<tr>
<td></td>
<td>Xiaozhi Zhao*, Qun Lu, Rong Yang, Guangxiang Liu, Feng Qu, Xiaogong Li, Weidong Gan, Hongqian Guo, Nanjing, China, People’s Republic of</td>
</tr>
<tr>
<td>MP42-05</td>
<td>ACUTE KIDNEY INJURY AND INTERMEDIATE-TERM RENAL FUNCTION AFTER CLAMPLESS PARTIAL NEPHRECTOMY</td>
</tr>
<tr>
<td></td>
<td>Minato Yokoyama*, Naoko Kawamura, Sho Uhara, Yosuke Yasuda, Toshiki Kijima, Soichiro Yoshida, Junichiro Ishioka, Yoh Matsuoka, Kazutaka Saito, Kazunori Kihara, Yasuhisa Fujii, Tokyo, Japan</td>
</tr>
<tr>
<td>MP42-06</td>
<td>PERCENT PARENCHYMAL MASS PRESERVED WITH PARTIAL NEPHRECTOMY: COMPARATIVE ANALYSIS OF POTENTIAL PREDICTORS</td>
</tr>
<tr>
<td></td>
<td>Hajime Tanaka*, Chalairat Suk-Ouichai, Diego Aguilar, Elvis Caraballo, Erick Remer, Jianbo Li, Sudhir Isharwal, Steven C. Campbell, Cleveland, OH</td>
</tr>
<tr>
<td>MP42-07</td>
<td>POSTOPERATIVE OUTCOMES OF ELDERLY PATIENTS UNDERGOING PARTIAL NEPHRECTOMY: A MULTICENTRIC-STUDY OF THE FRENCH RESEARCH NETWORK ON KIDNEY CANCER UROCCR</td>
</tr>
<tr>
<td>MP42-08</td>
<td>RENAL CANCER SURGERY FOR PATIENTS WITHOUT PREEXISTING CHRONIC KIDNEY DISEASE: IS THERE A SURVIVAL BENEFIT FOR ELECTIVE PARTIAL NEPHRECTOMY?</td>
</tr>
<tr>
<td></td>
<td>Chalairat Suk-Ouichai*, Hajime Tanaka, Jitao Wu, Elvis R. Caraballo, Sevag Demirjian, Jianbo Li, Sudhir Isharwal, Steven C. Campbell, Cleveland, OH</td>
</tr>
<tr>
<td>MP42-09</td>
<td>A COMPARISON BETWEEN ROBOTIC AND OPEN PARTIAL NEPHRECTOMY FOR MULTIFOCAL TUMORS</td>
</tr>
<tr>
<td></td>
<td>Nitin Yerram*, Julien Dagenais, Darren Bryk, Matthew Maurice, Jihad Kaouk, Cleveland, OH</td>
</tr>
</tbody>
</table>

*Presenting author
MP42-10 ROBOT-ASSISTED PARTIAL NEPHRECTOMY FOR CT2 RENAL TUMORS: PERIOPERATIVE, FUNCTIONAL AND ONCOLOGICAL OUTCOMES FROM A MULTICENTER ANALYSIS (THE ROSULA PROJECT)
Riccardo Bertolo*, Orbassano, Italy, Ilhaar Derweesh, La Jolla, CA, Giuseppe Simone, Michele Gallucci, Rome, Italy, Stephen Ryan, Ahmet Binday, La Jolla, CA, Andrea Minervini, Marco Carini, Andrea Mari, Florence, Italy, Daniel Eun, Aryeh Keel, Philadelphia, PA, Sisto Perdona, Giuseppe Quarto, Naples, Italy, James Porter, Michael Liao, Seattle, WA, Matteo Ferro, Milan, Italy, Alexandre Mottrie, Geert De Naeyer, Brussels, Belgium, Koon Rha, Kidon Chang, Seoul, Korea, Republic of, Robert Uzzo, Alexander Kutikov, David Chen, Marc Smaldone, Philadelphia, PA, Francesco Berardinelli, Luigi Schips, Chieti, Italy, Wesley White, Knoxville, TN, Bo Yang, Chao Zang, Shanghai, China, People’s Republic of, Ottavio De Cobelli, Milan, Italy, Ken Jacobsohn, Peter Langenstroer, Peter Dietrich, Milwaukee, WI, Prokar Dasgupta, Ben Challacombe, Nicolò De Luyk, London, United Kingdom, Clayton Lau, Patrick Kilday, Duarte, CA, Jay Sulek, Chandra Sundaram, Indianapolis, IN, Francesco Montorsi, Alessandro Larcher, Umberto Capitanio, Milan, Italy, Inderbir Gill, Monish Aron, Akbar Ashrafi, Los Angeles, CA, Uzoma Aniele, Lance Hampton, Richmond, VA, Gabriele Tuderti, Manuela Costantini, Rome, Italy, Riccardo Autorino, Richmond, VA, Francesco Porpiglia, Orbassano, Italy

MP42-11 EXCESSIVE RISKS FOR DEVELOPING RENAL FAILURE AFTER CYTOREDUCTIVE NEPHRECTOMY IN THE METASTATIC SETTING

MP42-12 TESTING THE EXTERNAL VALIDITY OF EORTC 30904 COMPARING OVERALL SURVIVAL AFTER RADICAL NEPHRECTOMY VS NEPHRON SPARING SURGERY IN CONTEMPORARY NORTH AMERICAN PATIENTS WITH RENAL CELL CANCER
Firas Abdollah*, Sohrab Arora, Detroit, MI, Nicolas von Landenberg, Herne, Germany, Philipp Gild, hamburg, Germany, Akshay Sood, Deepansah Dalela, Detroit, MI, Quoc-Dien Trinh, Boston, MA, Mani Menon, Craig Rogers, Detroit, MI

MP42-13 RETROPERITONEAL VERSUS TRANSPERITONEAL ROBOT-ASSISTED PARTIAL NEPHRECTOMY: COMPARISON IN A MULTI-INSTITUTIONAL SETTING
Sohrab Arora*, Detroit, MI, Gerald Heuitt, Seattle, WA, Daniel Moon, Melbourne, Australia, Umberto Capitanio, Milan, Italy, Kris Maes, Lisbon, Portugal, Alexander Mottrie, Melle, Belgium, Mahendra Bhandari, Craig Rogers, Detroit, MI, James Porter, Seattle, WA

MP42-14 ONCOLOGICAL OUTCOMES BETWEEN CYSTIC AND SOLID RENAL TUMORS AFTER PARTIAL NEPHRECTOMY: A MULTICENTRIC STUDY

MP42-15 DEVELOPMENT OF A PATIENT DECISION AID FOR COMPLEX, LOCALIZED RENAL MASSES
Kristen Mc Alpine*, Rodney H. Breau, Dawn Stacey, Christopher Knee, Luke T. Lavallée, Ottawa, Canada

MP42-16 IMPACT OF PRE-EXISTING DIABETES MELLITUS ON SURVIVAL IN STAGE I RENAL CELL CARCINOMA

MP42-17 COMPARISON OF PERI-OPERATIVE AND FUNCTIONAL OUTCOMES BETWEEN ROBOT-ASSISTED AND LAPAROSCOPIC PARTIAL NEPHRECTOMY FOR RENAL TUMORS WITH A MAP SCORE ≥3
Yu Gao*, Xu Zhang, Xin Ma, Hongzhao Li, Baojun Wang, Yang Fan, Beijing, China, People’s Republic of

MP42-18 PURE LAPAROSCOPIC VERSUS ROBOT-ASSISTED PARTIAL NEPHRECTOMY FOR CT1B RENAL TUMORS: A SINGLE TERTIARY CENTER EXPERIENCE
Riccardo Bertolo*, Cristian Fiori, Daniele Amparone, Ivano Morra, Michele Di Dio, Roberto Mario Scarpa, Francesco Porpiglia, Orbassano, Italy
MP42-19 IMPACT OF COMORBIDITIES ON FUNCTIONAL RECOVERY FROM PARTIAL NEPHRECTOMY
Sudhir Isharwal*, Wenda Ye, Cleveland, OH, Alice Wang, Nashville, TN, Joseph Abraham, Joseph Zabell, Wen Dong, Jitao Wu, Chalairat Suk-Ouiichai, Elvis Caraballo, Tianming Gao, Steven Campbell, Cleveland, OH

MP42-20 SAFETY AND FEASIBILITY OF NEXT-DAY DISCHARGE FOR MINIMALLY-INVASIVE PARTIAL NEPHRECTOMY - A NATIONAL SURGICAL QUALITY IMPROVEMENT PROGRAM STUDY
Leilei Xia*, Raju Chelluri, Ian Berger, Philadelphia, PA, Benjamin Taylor, New York, NY, Jose Pulido, Thomas Guzzo, Philadelphia, PA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 19, 2018
1:00 pm - 3:00 pm
Podium Session 25
TRANSPLANTATION & VASCULAR SURGERY: RENAL TRANSPLANTATION & VASCULAR SURGERY I
Room 2024 @ MCC West
Moderators: Peter Bretan, Mark Jordan and Bashir Sankari

<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>ABSTRACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>TIME</td>
<td>NUMBER</td>
</tr>
<tr>
<td>1:00</td>
<td>PD25-01</td>
</tr>
<tr>
<td>1:10</td>
<td>PD25-02</td>
</tr>
<tr>
<td>1:20</td>
<td>PD25-03</td>
</tr>
<tr>
<td>1:30</td>
<td>PD25-04</td>
</tr>
<tr>
<td>1:40</td>
<td>PD25-05</td>
</tr>
</tbody>
</table>

*Presenting author
DOES STENTED REIMPLANTATION IN RENAL TRANSPLANTATION INCREASE THE RISK OF URINARY INFECTION?
Cristovao Barbosa Neto, Eder Ilario, Marcos Mello*, Hideki Kanashiro, Rafael Localli, Hugo Barone, Renato Falcí Junior, William Nahas, Afonso Piovesan, Sao Paulo, Brazil

MONOZYGOTIC TWIN UTERUS TRANSPLANTATION
Miroslav Djordjevic*, Belgrade, Serbia, Milan Milenkovic, Stockholm, Sweden, Pernilla Dahm-Kähler, Nicolas Kvamström, Gothenburg, Sweden, Stefan Tullius, Boston, MA, Marta Bizic, Gradimir Korac, Belgrade, Serbia, Mats Brännström, Gothenburg, Sweden

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 19, 2018 1:00 pm - 3:00 pm
Podium Session 26
URODYNAMICS/LOWER URINARY TRACT DYSFUNCTION/FEMALE PELVIC MEDICINE: MALE INCONTINENCE: THERAPY I
Room 2022 @ MCC West
Moderators: Daniel Elliott, Karyn Eilber and Tamsin Greenwell

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| 1:00 | PD26-01 | EFFECT OF ORAL DDAVP ON NIGHT-TIME INCONTINENCE FOLLOWING OPEN RADICAL CYSTECTOMY AND ORTHOTOPIC URINARY DIVERSION
Soroush Bazargani*, Zhooibin Bateni, Thomas Clifford, Kevin Wayne, Jie Cai, Gus Miranda, Hooman Djaladat, Anne Schuckman, Siamak Daneshmand, Los Angeles, CA |
| 1:10 | PD26-02 | USE OF REGENERATIVE PHARMACOLOGY FOR POST RADICAL PROSTATECTOMY URINARY INCONTINENCE AND ERECTILE DYSFUNCTION IN A NON-HUMAN PRIMATE MODEL: A PILOT STUDY
Joao Zambon*, Winston-Salem, NC, Marish Patel, Ashok Hemal, Gopal Badlani, Renata Magalhaes, Winston Salem, NC, Karl Andersson, Aarhus, Denmark, Shannon Lankford, Koudy Williams, Winston Salem, NC |
| 1:20 | PD26-03 | EFFICACY OF HYALURONIC ACID-CARBOXYCELULOSE MEMBRANE APPLICATION ON EARLY RETURN OF CONTINENCE AFTER NERVE-SPARING ROBOT-ASSISTED RADICAL PROSTATECTOMY
Nobuyuki Hinata*, Junya Furukawa, Ken-ichi Harada, Yozo Nakano, Masato Fujisawa, Kobe, Japan |
| 1:30 | PD26-04 | IS THE ICIQ-SF QUESTIONNAIRE RELIABLE IN PREDICTING QOL OUTCOMES? RESULTS OF A PROSPECTIVE SINGLE-CENTER STUDY
Manuela Tutolo*, Marco Bianchi, Giulia Castagna, Alberto Briganti, Andrea Salonia, Milan, Italy, Steven Joniau, Ben Van Cleynenbreugel, Youri Bekhuis, Leuven, Belgium, Francesco Montorsi, Milan, Italy, Wouter Everaerts, Frank Van der Aa, Leuven, Belgium |
| 1:40 | PD26-05 | PROLONGED DURATION OF INCONTINENCE FOR MEN PRIOR TO INITIAL ANTI-INCONTINENCE SURGERY: AN OPPORTUNITY FOR IMPROVEMENT
Joceline Fuchs*, Nabeel Shakir, Maxim McKibben, Jeremy Scott, Allen Morey, Dallas, TX |
| 1:50 | PD26-06 | BACTERIAL CULTURES AT THE TIME OF ARTIFICIAL URINARY SPHINCTER REVISION SURGERY IN CLINICALLY UNINFECTED DEVICES: A PROSPECTIVE CONTEMPORARY SERIES
Matthew Ziegelmann*, Brian Linder, Ross Avant, Daniel Elliott, Rochester, MN |
| 2:00 | PD26-07 | EXPOSING THE MYTH OF URETHRAL ATROPHY AS ETIOLOGY OF RECURRENT INCONTINENCE AFTER ARTIFICIAL URINARY SPHINCTER: THE ROLE OF CAPSULOTOMY WITH INTRAOPERATIVE PRESSURE PROFILING OF THE PRESSURE REGULATING BALLOON
Amy Pearlman*, Winston Salem, NC, Alison Rasper, Lexington, KY, Ryan Terlecki, Winston Salem, NC |
| 2:10 | PD26-08 | THERMOEXPANDABLE METALLIC URETHRAL STENT FOR MANAGING ELDERLY PEOPLE WITH INDWELLING URINARY CATHETER: A COMPELLING OPTION TO AVOID LONG-TERM CATHETERIZATION
Cyrielle Rambaud*, Sébastien Gonfrier, Cyprien Arlaud, Laetitia Imbert de la Phalecque, Jérémy Fallot, Romain Haider, Brannwel Tibi, Olivier Güérin, Matthieu Durand, Nice, France |
| 2:20 | PD26-09 | TO INCREASE THE SUCCESS OF REMOVING THE URINARY CATHETER IN ELDERLY PATIENTS WITH RECURRENT URINARY RETENTION
Cyrielle Rambaud*, Sébastien Gonfrier, Laetitia Imbert de la Phalecque, Jérémy Fallot, Romain Haider, Brannwel Tibi, Olivier Güérin, Matthieu Durand, Nice, France |
2:30 PD26-10 **URINARY FUNCTION IN 776 HYPOGONADAL MEN WITH MILD OR MODERATE IPPS WITH AND WITHOUT TESTOSTERONE THERAPY FOR UP TO 10 YEARS**  
Karim Sultan Haider*, Ahmad Haider, Bremerhaven, Germany, Gheorghe Doros, Abdulmaged Traish, Boston, MA

2:40 PD26-11 **IS URODYNAMIC INVESTIGATION PROPERLY PRESCRIBED IN DAILY CLINICAL PRACTICE? REPORT OF DATA COLLECTED FROM AN URODYNAMIC CENTRE**  
Giovanni Palleschi*, Antonio Carbone, Yazan Al Salhi, Andrea Fuschi, Gennaro Velotti, Lorenzo Capone, Antonio Luigi Pastore, Latina, Italy

2:50 PD26-12 **PROSPECTIVE ANALYSIS OF URETHRAL STRICTURE OCCURRENCE AFTER CUFF EROSION WITH AMS ARTIFICIAL SPHINCTER DEVICES**  
Tim Ludwig, Katharina Kuhlencord, Valentin Maurer*, Phillip Marks, Clemens Rosenbaum, Oliver Engel, Silke Riechersdt, Margit Fisch, Roland Dahlem, Hamburg, Germany

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

---

Saturday, May 19, 2018

**Podium Session 27**

**SEXUAL FUNCTION/DYSFUNCTION: EVALUATION I**  
Room 2011 @ MCC West  
Moderators: Hossein Sadeghi-Nejad, Edward Kim and Alexander Pastuszak

<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td>PD27-01</td>
<td>PENILE DOPPLER ULTRASOUND AS A DIAGNOSTIC TOOL FOR PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY FOR VASCULOGENIC ERECTILE DYSFUNCTION</td>
<td>Sheng-Yung Tung, Yi-Kai Chang*, Shih-Ping Liu, Ju-Ton Hsieh, Hong-Chiang Chang, Taipei, Taiwan</td>
</tr>
<tr>
<td>1:10</td>
<td>PD27-02</td>
<td>PENILE DOPPLER ULTRASOUND AT A TERTIARY REFERRAL CENTER FOR ERECTILE DYSFUNCTION: WHAT WE LEARNED OVER A 12 YEAR PERIOD</td>
<td>Eric Schommer*, John Moore, Zachary McNulty, Rishubh Shah, Colleen Thomas, Gregory Broderick, Jacksonville, FL</td>
</tr>
<tr>
<td>1:20</td>
<td>PD27-03</td>
<td>TIGHTER BLOOD PRESSURE CONTROL IS ASSOCIATED WITH LOWER INCIDENCE OF ERECTILE DYSFUNCTION IN HYPERTENSIVE MEN</td>
<td>Wayland Hsiao*, Oakland, CA, Ruth Ann Bertsch, Sacramento, CA, David Aaronson, Oakland, CA</td>
</tr>
<tr>
<td>1:30</td>
<td>PD27-04</td>
<td>ERECTILE DYSFUNCTION MANAGEMENT AFTER FAILED PHOSPHODIESTERASES-INHIBITOR TRIAL: A COST-EFFECTIVENESS ANALYSIS</td>
<td>Rachel A. Moses, MD, MPH*, James R. Craig, MD, Sorena Keihani, MD, Jeremy B. Myers, MD, Sara M. Lenherr, MD, MS, William O. Brant, MD, James M. Hotaling, MD, MS, Salt Lake City, UT</td>
</tr>
<tr>
<td>1:40</td>
<td>PD27-05</td>
<td>ERECTILE FUNCTION AND LOWER URINARY TRACT SYMPTOMS FOLLOWING MRI FUSION-GUIDED PROSTATE BIOPSY</td>
<td>Ashley Shumate*, Neil Sood, Colleen Thomas, Gregory Broderick, Jacksonville, FL</td>
</tr>
<tr>
<td>1:50</td>
<td>PD27-06</td>
<td>SHIFT WORK SLEEP DISORDER AND NIGHT SHIFT WORK SIGNIFICANTLY IMPAIR ERECTILE FUNCTION</td>
<td>Katherine M. Rodriguez*, Taylor P. Kohn, Jaden R. Kohn, E. Will Kirby, Stephen M. Pickett, Alexander W. Pastuszak, Larry I. Lipshultz, Houston, TX</td>
</tr>
<tr>
<td>2:00</td>
<td>PD27-07</td>
<td>INCIDENCE AND CHARACTERISTICS OF MEN AT HIGH RISK FOR SLEEP APNEA IN A HIGH VOLUME ANDROLOGY CLINIC</td>
<td>J. Abram McBride*, Taylor P. Kohn, Katherine M. Rodriguez, Nannan Thirumavalavan, Daniel J. Mazur, Alexander W. Pastuszak, Larry I. Lipshultz, Houston, TX</td>
</tr>
<tr>
<td>2:10</td>
<td>PD27-08</td>
<td>POOR SLEEP QUALITY IS ASSOCIATED WITH CLINICALLY SIGNIFICANT ERECTILE DYSFUNCTION</td>
<td>Taylor P. Kohn*, Katherine M. Rodriguez, John T. Sigalos, Asad Hasan, Alexander W. Pastuszak, Larry I. Lipshultz, Houston, TX</td>
</tr>
<tr>
<td>2:20</td>
<td>PD27-09</td>
<td>IMPROVEMENT OF SEXUAL FUNCTIONS, METABOLIC SYNDROME COMPONENTS AND REDUCED INFLAMMATION UNDER LONG-TERM TREATMENT IN HYPOGONADAL MEN FOR UP TO 14 YEARS: REAL-LIFE DATA FROM A REGISTRY STUDY</td>
<td>Aksam Yassin*, Mahmoud Salman, Norderstedt, Germany</td>
</tr>
</tbody>
</table>

*Presenting author
### DEVELOPMENT OF NOMOGRAMS TO PREDICT ERECTILE FUNCTION AFTER RADIATION THERAPY

Helen L. Bernie*, Bruno Nascimento, Eduardo Miranda, Elizabeth Schofield, New York, NY, Alex Zajichek, Michael Kattan, Cleveland, OH, John P. Mulhall, New York, NY

### DEVELOPMENT OF NOMOGRAMS TO PREDICT TESTOSTERONE RECOVERY AFTER CESSATION OF ANDROGEN DEPRIVATION THERAPY IN MEN WITH PROSTATE CANCER

Helen L. Bernie*, Bruno Nascimento, Eduardo Miranda, Elizabeth Schofield, Lawrence Jenkins, New York, NY, Alex Zajichek, Michael Kattan, Cleveland, OH, John P. Mulhall, New York, NY

### GENERAL & EPIDEMIOLOGICAL TRENDS & SOCIOECONOMICS: QUALITY IMPROVEMENT & PATIENT SAFETY II

**Moderators:** Matthew Gettman, Fernando Kim and Michael Leonard

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
<th>ABSTRACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td>PD28-01</td>
<td>DOES BIASED CARE LEAD TO AN INCREASE IN PATIENT MORBIDITY AND OVERALL USE OF HEALTHCARE SYSTEM RESOURCES: A SINGLE ACADEMIC CENTER EXPERIENCE</td>
<td>Eric Fichtenbaum, MD*, Jagan Kansal, MD MBA, Eamonn Bahnsen, MD, James Donovan, MD, Cincinnati, OH</td>
</tr>
<tr>
<td>1:10</td>
<td>PD28-02</td>
<td>IMPLEMENTING A PATIENT SAFETY CULTURE SURVEY TO IDENTIFY AND TARGET PROCESS IMPROVEMENTS IN ACADEMIC AMBULATORY UROLOGY PRACTICES: A MULTI-INSTITUTIONAL COLLABORATIVE</td>
<td>Alexander Skokan*, Philadelphia, PA, Andrew Harris, Lexington, KY, Kamran Sajadi, Christopher Tessier, Portland, OR, Ruchika Talwar, Ian Berger, Thomas Guzzo, Justin Ziamba, Philadelphia, PA</td>
</tr>
<tr>
<td>1:20</td>
<td>PD28-03</td>
<td>EARLY IMPACT OF A PREOPERATIVE SAFETY CHECKLIST ATTESTATION ON FIRST CASE ON-TIME START RATE AND OPERATING ROOM UTILIZATION</td>
<td>Neil J. Kocher*, Amber L. Schilling, Jay D. Raman, Hershey, PA</td>
</tr>
<tr>
<td>1:30</td>
<td>PD28-04</td>
<td>THE EFFECT OF HOSPITAL AND PROVIDER VOLUME ON SHORT-TERM OUTCOMES FOR NEPHRECTOMIES</td>
<td>Mark Finkelstein*, Michael Palese, New York City, NY</td>
</tr>
<tr>
<td>1:40</td>
<td>PD28-05</td>
<td>REDUCING PREVENTABLE EMERGENCY DEPARTMENT VISITS IN POST-UROLOGIC SURGERY PATIENTS IN A SAFETY NET HOSPITAL</td>
<td>Jamal Nabhani, Jeremy Montez*, Saum Ghoudoussipour, Hari Sawkar, Leo Doumanian, Jeffrey Loh-Doyle, Los Angeles, CA</td>
</tr>
<tr>
<td>1:50</td>
<td>PD28-06</td>
<td>EFFECTS OF HOSPITAL COMPETITION ON RACIAL ETHNIC DISPARITY IN PROSTATE CANCER CARE</td>
<td>Sumedha Chhatre*, S. Bruce Malkowicz, J. Sanford Schwartz, Ravishankar Jayadevappa, Philadelphia, PA</td>
</tr>
<tr>
<td>2:00</td>
<td>PD28-07</td>
<td>EVIDENCE-BASED OPIOID PRESCRIBING GUIDELINES FOR THE POSTOPERATIVE UROLOGIC SURGERY PATIENT AT DISCHARGE</td>
<td>Matthew Ziegelmann*, Halena Gazelka, Jason Joseph, Derek Lomas, Amy Glasgow, Rochester, MN, Mark Tyson, Scottsdale, AZ, Matthew Gettman, Elizabeth Habermann, Rochester, MN</td>
</tr>
<tr>
<td>2:10</td>
<td>PD28-08</td>
<td>COMPLIANCE AND INFECTION RATE FOLLOWING CYSTOSCOPY ANTIMICROBIAL PROPHYLAXIS PROTOCOL IMPLEMENTATION</td>
<td>Emily Clennon*, Ann Acevedo, Kamran Sajadi, Portland, OR</td>
</tr>
<tr>
<td>2:20</td>
<td>PD28-09</td>
<td>IMPLEMENTATION OF A PERIOPERATIVE VENOUS THROMBOEMBOLISM PROPHYLAXIS PROGRAM FOR PATIENTS UNDERGOING RADICAL CYSTECTOMY ON AN ENHANCED RECOVERY AFTER SURGERY PROTOCOL</td>
<td>H. Abraham Chiang*, Philip J. Cheng, Jacqueline M. Speed, Jill Steinberg, Peter A. Najjar, Graeme S. Steele, Quoc-Dien Trinh, Jairam R. Eswara, Steven L. Chang, Adam S. Kibel, Matthias F. Stopfkuchen-Evans, Matthew Mossanen, Mark A. Preson, Boston, MA</td>
</tr>
<tr>
<td>2:30</td>
<td>PD28-10</td>
<td>RACIAL AND ETHNIC DISPARITIES IN MAJOR UROLOGIC ONCOLOGIC PROCEDURES</td>
<td>Melody Chen*, Anand Patel, Cleveland, OH, Carvell Nguyen, Cleveland, OH</td>
</tr>
</tbody>
</table>
2:40  PD28-11 POST-DISCHARGE OPIOID ANALGESIA AFTER RADICAL PROSTATECTOMY: PROVIDER AND PATIENT DISCONNECT
Hiten Patel*, Wesley Ludwig, Zeyad Schwen, Gregory Joice, Mohamad Allaf, Misop Han, Amin Herati, Baltimore, MD

2:50  PD28-12 ASSESSING THE EDUCATIONAL VALUE OF INTENSIVE UROLOGY DIDACTICS FOR NON-URUROLOGY RESIDENTS
Filipe La Fuente Carvalho*, Charlotte Goldman, Jordan Alger, Lambros Stamatakis, Daniel Marchalk, Washington, DC

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 19, 2018 1:00 pm - 3:00 pm
Podium Session 29
PROSTATE CANCER: LOCALIZED: SURGICAL THERAPY IV
Room 3018 @ MCC West
Moderators: Michael Gong, Adam Feldman and Shahrokh Shariat

<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
<th>ABSTRACT</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| PD29-01  | 1:00 |       | THE VALUE OF 99MTC-PSMA SPECT/CT GUIDED SURGERY TO IDENTIFY AND LOCALIZE LYMPH NODE METASTASIS FOR PROSTATE CANCER PATIENTS
Hengchuan Su*, ShangHai, China, People’s Republic of |
| PD29-02  | 1:10 |       | IMPACTS OF AGE AND COMORBIDITY ON SURVIVAL VARIES BY RISK GROUP IN PATIENTS WITH PROSTATE CANCER TREATED BY RADICAL PROSTATECTOMY: A COMPETING RISK ANALYSIS FROM K-CAP REGISTRY
Kyo Chul Koo, Kwang Suk Lee*, In Young Choi, Ji Youl Lee, Jun Hyuk Hong, Choung-Soo Kim, Hyun Moo Lee, Sung Kyu Hong, Seok-Soo Byun, Seung Hwan Lee, Koon Ho Rha, Byung Ha Chung, Seoul, Korea, Republic of |
| PD29-03  | 1:20 |       | COMPARISON OF URINARY CONTINENCE BETWEEN RETZIUS-SPARING ROBOT-ASSISTED RADICAL PROSTATECTOMY AND CONVENTIONAL ROBOT-ASSISTED RADICAL PROSTATECTOMY: PRELIMINARY DATA FROM A PROSPECTIVE RANDOMIZED CONTROLLED STUDY
Xuefeng Qiu*, Linfeng Xu, Haoxin Ma, Xiaogong Li, Hongqian Guo, Nanjing, China, People’s Republic of |
| PD29-04  | 1:30 |       | COMPLICATIONS AND FUNCTIONAL OUTCOMES OF SALVAGE RADICAL PROSTATECTOMY: A COMPARISON BETWEEN OPEN AND ROBOT-ASSISTED APPROACHES IN A MULTICENTRE SERIES
Paolo Gontero*, Giancarlo Marra, Paolo Alessio, Marco Oderda, Anna Palazzetti, Francesca Pisano, Antonino Battaglia, Stefania Munegato, Bruno Frea, Turin, Italy, Fernando Munoz, Aosta, Italy, Claudia Filippini, Turin, Italy, Estefania Linares, Rafael Sanchez-Salas, Paris, France, Sanchia Goonewardene, Prokar Dasgupta, Declan Cahill, Ben Challacombe, Rick Popert, London, United Kingdom, David Gillatt, Raj Persad, Bristol, United Kingdom, Juan Palou, Barcelona, Spain, Steven Joniau, Leuven, Belgium, Salvatore Smeit, Thierry Piechaud, Bordeaux, France, Alexandre De La Taille, Creteil, France, Morgan Roupret, Paris, France, Simone Albiens, Roland Van Velthoven, Bruxelles, Belgium, Alessandro Morlacco, Sharma Vidit, Rochester, MN, Giorgio Gandaglia, Alexander Mottrie, Aalst, Belgium, Joseph Smith, Shreyas Joshi, Gabriel Fiscus, Nashville, TN, Andre Berger, Monish Aron, Los Angeles, CA, Henk Van Der Poel, Amsterdam, Netherlands, Derya Tilki, Hamburg, Germany, Declan Murphy, Nathan Lawrentschuk, Melbourne, VIC, Australia, John Davis, Gordon Leung, Houston, TX, Robert Jeffrey Karnes, Rochester, MN |
| PD29-05  | 1:40 |       | HOW DO URINARY INCONTINENCE AND PSA RECURRENCE AFFECT HEALTH RELATED QOL AFTER RADICAL PROSTATECTOMY?
Haruka Miya*, Shun Ueno, Yuya Iwashashi, Takashi Iuchi, Takahito Wakamiya, Shimpei Yamashita, Satoshi Nishizawa, Akinori Iba, Yasuo Kohjimoto, Isao Hara, Wakayama, Japan |

*Presenting author
1:50 PD29-06 IMPACT OF THE ROCCO STITCH ON RETURN TO CONTINENCE AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY: RESULTS OF A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL
Jennifer Hoogenes, Derek Bos*, Lisa Patterson, Yuding Wang, Christopher Wu, Forough Farrokhyar, Bobby Shayegan, Hamilton, Canada

2:00 PD29-07 PROGRESS, A WEB-BASED RESOURCE FOR PROSTATE CANCER PATIENTS: EVIDENCE OF ONE-MONTH QUALITY OF LIFE IMPROVEMENTS

2:10 PD29-08 IMPACT OF BLOOD LOSS DURING RADICAL PROSTATECTOMY ON FUNCTIONAL OUTCOMES
Felix Preisser*, Raisa Pompe, Hamburg, Germany, Pierre Karakiewicz, Montreal, Canada, Marco Bandini, Milan, Italy, Raisa Pompe, Hamburg, Germany, Francesco Montorsi, Milan, Italy, Markus Graefen, Hartwig Huland, Hamburg, Germany

2:20 PD29-09 APPLICABILITY OF BRIGANTI NOMOGRAM: AN ABSOLUTE REQUIREMENT BEFORE LYMPH NODE DISSECTION IN INTERMEDIATE- RISK PROSTATE CANCER? ASSESSMENT OF THE EXTERNAL APPLICABILITY
Benjamin Pradere*, Tours, France, Mathieu Roumigué, Mathieu Thoulouzan, Jerome Gas, Pierre-Marie Patard, Xavier Gamé, Nicolas Doumerc, Pascal Rischmann, Michel Soulé, Jean Baptiste Beauval, Toulouse, France

2:30 PD29-10 VALIDATED ASSESSMENT OF URINARY, SEXUAL AND GASTROINTESTINAL QUALITY OF LIFE AFTER ROBOTIC ASSISTED LAPAROSCOPIC PROSTATECTOMY: BEYOND CONTINENCE AND ERECTIONS
Simone Albisinni*, Fouad Aoun, Quentin Marcelis, Mehdi Idrissi, Thierry Quackels, Ksenija Limani, Eric Hawaux, Alexandre Peltier, Roland van Velthoven, Thierry Roumeguère, Bruxelles, Belgium

2:40 PD29-11 IMPACT OF BILATERAL NEUROVASCULAR BUNDLE PRESERVATION ON ONCOLOGICAL OUTCOMES IN NON-ORGAN CONFINED PROSTATE CANCER
Felix Preisser*, Hamburg, Germany, Gorgio Gandaglia, Milan, Italy, Pierre Karakiewicz, Montreal, Canada, Marco Bandini, Milan, Italy, Raisa Pompe, Hamburg, Germany, Francesco Montorsi, Milan, Italy, Markus Graefen, Hartwig Huland, Hamburg, Germany, Alberto Briganti, Milan, Italy, Derya Tilki, Hamburg, Germany

2:50 PD29-12 PAIN CONTROL AFTER LAPAROSCOPIC RADICAL PROSTATECTOMY (LRP): COMPARISON BETWEEN TRANSVERSUS ABDOMINS PLANE BLOCK (TAP BLOCK) & WOUND INFILTRATION
Tarek Taha*, Holon, Israel
Saturday, May 19, 2018 1:00 pm - 3:00 pm

Video Session 5

BLADDER ONCOLOGY & DIVERSION

The videos in this session as well as the video libraries from the 2011-2016 Annual Meetings may be viewed in the Surgical Video Library and purchased in the AUA Store during the Annual Meeting. Both are located in Hall A. AUA members receive free online access to the Surgical Video Library throughout the year through AUA University. Visit www.AUAnet.org/University to access.

Room 3002 @ MCC West
Moderators: Hadley Wyre, Ketan Badani and Gilad Amiel

**ABSTRACT NUMBER** | **TITLE** | **ABSTRACT NUMBER** | **TITLE**
--- | --- | --- | ---
V05-01 | TECHNICAL ASPECTS OF TRANSURETHRAL THULIUM LASER EN Bloc Resection of Bladder Cancer | V05-09 | THE TECHNIQUE AND CLINICAL APPLY OF PELVIC RE-PERITONEALIZATION IN THE ERAS PROGRAM FOR PATIENTS RECEIVED LAPAROSCOPIC RADICAL CYSTECTOMY
Leonid Rapoport, Andrey Vinarov, Dmitry Enikeev, Nikolay Sorokin, Alim Dymov*, Roman Sukhanov, Dmitry Kislyakov, Alexandra Proskura, Akhmed Daniev, Gregory Gololobov, Vladimir Lekarev, Moscow, Russian Federation
| Qiang Lu*, Pengchao Li, Qiang Cao, Jian Qian, Xiao Yang, Rui Zhou, Wenbo Yuan, Xiaoheng Deng, Jun Tao, Nanjing, China, People’s Republic of China
V05-02 | EN-BLOC EXCISION OF UROTHELIAL BLADDER CANCERS BY HOLMIUM LASER: A FEASIBILITY STUDY | V05-10 | TOTALLY INTRACORPOREAL LAPAROSCOPIC RADICAL CYSTECTOMY WITH MODIFIED ILEAL PADUA NEOBLADDER RECONSTRUCTION IN MALE. SURGICAL APPROACH EVOLUTION AND OUTCOMES
Pankaj Maheshwari*, Mumbai, India
| Giovanni Palleschi*, Antonio Luigi Pastore, Andrea Fuschi, Yazen Al Salhi, Antonio Carbone, Latina, Italy
V05-03 | ROBOT-ASSISTED LAPAROSCOPIC REVISION OF ILEAL CONDUIT: DESCRIPTION OF SURGICAL TECHNIQUE | V05-11 | ROBOT ASSISTED TOTALLY INTRACORPOREAL VESCICA ILEALE PADOVANA (RA-VIP): A NEW TECHNIQUE FOR ROBOTIC BLADDER REPLACEMENT
Saman Talab*, Newark, NJ, Gregory Lvallo, Mutahar Ahmed, Hackensack, NJ
| Mehrez Alemozaffar*, Atlanta, GA
V05-04 | ROBOTIC REPAIR OF LEFT URETERO-NEOBLadder Anastomotic Stricture Following Prior Robotic Radical Cystectomy and Intracorporeal Neobladder Diversion | V05-12 | FLORENCE ROBOTIC INTRACORPOREAL NEOBLADDER (FLORIN). A NEW CONFIGURATION USING STRATEGY DEVELOPED FOLLOWING THE IDEAL GUIDELINES
Mehrez Alemozaffar*, Atlanta, GA
| Andrea Minervini, Davide Vanacore, Simone Sforza, Francesco Sessa, Riccardo Campi, Andrea Mari, Martina Milanesi, Fabrizio Di Maio, Giovanni Tasso, Andrea Cocc*, Agostino Tuccio, Gianni Vittori, Giampaolo Siena, Marco Carini, Florence, Italy
V05-05 | ROBOTICAnterior Exenteration in Females– TIPS AND TRICKS | | 
Mehrez Alemozaffar*, Atlanta, GA
| 
V05-06 | ROBOTIC ASSISTED RADICAL CYSTOURETRECTOMY | | 
Elaine Lee, Maurice Coret, Benjamin Thomas*, Cambridge, United Kingdom
| 
V05-07 | ROBOT ASSISTED EXTENDED PELVIC LYMPH NODE DISSECTION FOR BLADDER CANCER: TECHNIQUE, EXTENT AND FEASIBILITY IN MINIMAL INVASIVE ERA | | 
Puneet Ahluwalia*, Ludhiana, India, Surya Ojha, Gurgaon, India, Ashwin Tamhankar, New Delhi, India, Gagan Gautam, Gurgaon, India
| 
V05-08 | PERITONEUM, NERVE AND PROSTATE APEX SPARING EXTRAPERITONEAL RADICAL CYSTOPROSTATECTOMY (RC) AND EXTRAPERITONEAL ORTHOTOPIC NEOBLADDER FORMATION | | 
Guram Karazanashvili*, Tbilisi, Georgia
| 
V05-09 | THE TECHNIQUE AND CLINICAL APPLY OF PELVIC RE-PERITONEALIZATION IN THE ERAS PROGRAM FOR PATIENTS RECEIVED LAPAROSCOPIC RADICAL CYSTECTOMY
Qiang Lu*, Pengchao Li, Qiang Cao, Jian Qian, Xiao Yang, Rui Zhou, Wenbo Yuan, Xiaoheng Deng, Jun Tao, Nanjing, China, People’s Republic of China
| 
V05-10 | TOTALLY INTRACORPOREAL LAPAROSCOPIC RADICAL CYSTECTOMY WITH MODIFIED ILEAL PADUA NEOBLADDER RECONSTRUCTION IN MALE. SURGICAL APPROACH EVOLUTION AND OUTCOMES
Giovanni Palleschi*, Antonio Luigi Pastore, Andrea Fuschi, Yazen Al Salhi, Antonio Carbone, Latina, Italy
| 
V05-11 | ROBOT ASSISTED TOTALLY INTRACORPOREAL VESCICA ILEALE PADOVANA (RA-VIP): A NEW TECHNIQUE FOR ROBOTIC BLADDER REPLACEMENT
Giovanni Cacciamani*, Vincenzo De MArco, Marco Sebben, Riccardo Rizetto, Maria Angela Cerruto, Antonio Benito Porcaro, Walter Arbani, Verona, Italy
| 
V05-12 | FLORENCE ROBOTIC INTRACORPOREAL NEOBLADDER (FLORIN). A NEW CONFIGURATION USING STRATEGY DEVELOPED FOLLOWING THE IDEAL GUIDELINES
Andrea Minervini, Davide Vanacore, Simone Sforza, Francesco Sessa, Riccardo Campi, Andrea Mari, Martina Milanesi, Fabrizio Di Maio, Giovanni Tasso, Andrea Cocc*, Agostino Tuccio, Gianni Vittori, Giampaolo Siena, Marco Carini, Florence, Italy

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

*Presenting author
Saturday, May 19, 2018

SOCIETY FOR BASIC UROLOGIC RESEARCH (SBUR)

Union Square 22 @ Hilton SF Union Sq

1:00 SESSION I: NOVEL MODELS
Moderators: Benyi Li, William Ricke

BLADDER REGENERATION
George Christ

MODELING BLADDER CANCER IN THE POST-GENOME ERA
Xue-Ru Wu

MAGNETIC RESONANCE IMAGING OF PROSTATIC DISEASE
Diego Hernando

HUMAN PRIMARY PROSTATE ORGANOIDS AND TUMOROIDS MAINTAIN THEIR TISSUE PHENOTYPE WHEN CO-CULTURED WITH PROSTATE STROMA
Larisa Nonn

PROSTATE CANCER ORGAN-SPECIFIC METASTASIS: THE MEDIATION THROUGH PROTEIN-PROTEIN INTERACTIONS
Shian-Ying Sung

2:40 SESSION II: EMERGING THERAPIES
Moderators: JT Hsieh, Christina Jamieson

ORPHAN NUCLEAR RECEPTORS AS TARGETS IN THERAPY-RESISTANT PROSTATE CANCER
Hongwu Chen

DEVELOPING AND TRANSLATING THERAPIES FOR BONE METASTATIC PROSTATE CANCER USING NEW PRECLINICAL MODELS
Christina Jamieson

NOVEL TARGETED-THERAPY FOR NEUROENDOCRINE PROSTATE CANCER
Mohammad Saleem Bhat

THERAPEUTIC IMPLICATIONS OF PROSTATE CANCER BIOMARKERS
Jun Luo

4:00 ADJOURN

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 19, 2018

HIBERNIAN UROLOGICAL SOCIETY (HUS)

Yerba Buena Salon 6 @ Marriott Marquis

2:00 INTRODUCTION
Society President: Eamonn Rogers
AUA President-Elect: Robert Flanigan

2:05 PROSTATE CANCER SCREENING
William Catalona

2:25 AUA TESTOSTERONE GUIDELINES UPDATE
Landon Trost

2:45 DOES ONE SLING FIT ALL?: SIZING UP SUI SURGERY IN 2018
Eric Rovner

3:05 THE STRUGGLES TO IMPROVE OUTCOMES FOR PATIENTS WITH BLADDER CANCER
Ralph deVere White

3:25 ROUNDTABLE DISCUSSION: TREATMENT OF MEN WITH LOWER URINARY TRACT SYMPTOMS
Chairman: James Forde
Panelists: Paul Anderson, Christopher Chapple, Steven Kaplan, Claus Roehrborn

4:00 ADJOURN

Saturday, May 19, 2018

POLISH UROLOGICAL ASSOCIATION (PTU) AND HUNGARIAN UROLOGICAL ASSOCIATION (HUA)

Yerba Buena Salon 10 @ Marriott Marquis

3:00 WELCOME AND INTRODUCTIONS
PTU Society President: Piotr Chlosta
HUA Society President: Peter Tenke

3:10 PTU SESSION
MAGNETIC RESONANCE IMAGING IN PROSTATE CANCER: 2018 UPDATE
Anna Czhech

MALE INCONTINENCE: ARE THERE ANY ALTERNATIVES FOR AMS800?
Michał Skrzypczyk

3:50 AUA SESSION

LAPAROSCOPIC VS. ROBOTIC ANALYSIS RADICAL CYSTECTOMY: COMPLICATIONS AND COST-EFFECTIVE ANALYSIS
Adam Ostrowski

RADICAL PROSTATECTOMY IN HIGH-RISK PROSTATE CANCER: IS IT WORTH IT?
Filip Kowalski

4:00 ADJOURN
TARGETING NEUROENDOCRINE PROSTATE CANCER WITH NEUROPEPTIDE ANALOGS
Ferenc Rick

4:05 HUA SESSION
OUR EXPERIENCES WITH INTRAOPERATIVE FROZEN SECTION DURING RADICAL PROSTATECTOMY
Peter Tenke

NEW TRENDS IN URETHRAL SURGERY
Peter Nyirady

Saturday, May 19, 2018 3:00 pm - 5:00 pm

Forums
RESEARCH FORUM II: EARLY-CAREER INVESTIGATORS SHOWCASE
Room 208 @ MCC SOUTH

3:00 POSTER VIEWING
3:25 INTRODUCTION AND WELCOME
Carolyn Best
3:30 UTILIZING AN ONCOLOGY MODEL TO ADVANCE URETHRAL RECONSTRUCTION
Bradley Erickson
3:39 CANCER CELLS MITIGATE STRESS THROUGH A TARGETABLE PROTEOSTASIS ADAPTIVE RESPONSE
Hao Nguyen
3:48 THE URINARY MICROBIOTA AND HOST INFLAMMATION IN LOWER URINARY TRACT SYMPTOMS
A. Lenore Ackerman
3:57 99MTC-SESTAMIBI SPECT/CT FOR THE NONINVASIVE DIAGNOSIS OF BENIGN RENAL ONcocytomas AND HYBRID ONcocytic/CHROMOPHOBE TUMORS: COMBINED DATA FROM PROSPECTIVE STUDIES AND REAL-WORLD CLINICAL EXPERIENCE
Michael Gorin
4:06 A NOVEL URINARY KIDNEY INJURY TEST DIFFERENTIATES NEPHROLITHIASIS FROM IMMUNE-MEDIATED RENAL DISEASE
Thomas Chi
4:15 THE EFFECT OF EXTERNAL BEAM RADIATION ON AMBULATORY VOIDING AND ANESTHETIZED CYSTOMETRY DURING THE ACUTE AND CHRONIC PHASES OF RADIATION CYSTITIS
Amy Dobberfuhl

4:24 PD1/PDL1 PATHWAY INHIBITION WITH VASCULAR TARGETED PHOTODYNAMIC THERAPY (VTP) PREVENTS SECONDARY LUNG TUMORS IN RENAL TUMOR MODEL
Katie Murray

4:33 ASSESSMENT OF BLUE LIGHT FLEXIBLE CYSTOSCOPY WITH CYSVIEW ON PATIENT REPORTED OUTCOMES: A PROSPECTIVE, MULTICENTER, WITHIN-PATIENT CONTROLLED STUDY IN DETECTION OF BLADDER CANCER DURING SURVEILLANCE
Angela Smith

4:42 UNDERSTANDING SURVEILLANCE FOR NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)
Florian Schroeck

4:51 OFFICE OF RESEARCH PROGRAMS FOR EARLY-CAREER INVESTIGATORS AND PRESENTATION OF AWARDS
Carolyn Best

5:00 ADJOURN
APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

*Presenting author
Forums

CLINICAL CONTROVERSIES IN MEN'S HEALTH
Room 2014 @ MCC West

Moderators: Larry Lipshultz, Abraham Morgentaler

3:00

JUST FIX IT! MEDICAL VS SURGICAL THERAPY FOR PEYRONIE'S DISEASE
Martin Geibard, Laurence Levine

Q & A

3:35

DEBATE: TESTOSTERONE THERAPY CAUSES CARDIOVASCULAR DISEASE
Debater - Pro: Landon Trost
Debater - Con: Jacques Baillargeon

Q & A

4:05

NOTHING BEATS A TURP

STEAM TREATMENT
Tobias Köhler

TURE COMPRESSION
Steven Kaplan

TURP
Claus Roehrborn

Q & A

5:00

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 19, 2018

Moderated Poster Session 43

SEXUAL FUNCTION/DYSFUNCTION: BASIC RESEARCH & PATHOPHYSIOLOGY I
Room 3004 @ MCC West

Moderators: Mohit Khera, Carol Podlasek and Trinity Bivalacqua

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP43-01</td>
<td>EFFECTS OF COMBINATION THERAPY WITH SILDENAFIL AND LOW-ENERGY SHOCKWAVE THERAPY IN A PELVIC NEUROVASCULAR TRAUMA MODEL</td>
</tr>
<tr>
<td>Alexandria Hertz*, Evalyn George, Amanda Reed-Maldonado, Timothy Brand, Shashikumar Salgar, Tacoma, WA</td>
<td></td>
</tr>
<tr>
<td>MP43-02</td>
<td>SERUM CADMIUM LEVELS PREDICT ERECTILE DYSFUNCTION IN MEN</td>
</tr>
<tr>
<td>Joseph Gabrielsen*, Larry Lipshultz, Dolores Lamb, Houston, TX</td>
<td></td>
</tr>
<tr>
<td>MP43-03</td>
<td>3T FUNCTIONAL MRI DETECTS DIFFERENCES IN NEURAL ACTIVATION AMONG MEN WITH DELAYED EJACULATION &amp; ORGASM</td>
</tr>
<tr>
<td>Ryan Flannigan*, Linda Heier, Henning Voss, Levi Chazen, Darius Paduch, New York, NY</td>
<td></td>
</tr>
<tr>
<td>MP43-04</td>
<td>CAVERNOUS NERVE INJURY INDUCES APOPTOSIS IN ALL NERVES OF THE PELVIC PLEXUS</td>
</tr>
<tr>
<td>Marah Hehemann*, Chicao, IL, Shawn Choe, Elizabeth Kalmanek, Chicago, IL, Kevin McVary, Springfield, Il, Carol Podlasek, Chicago, IL</td>
<td></td>
</tr>
<tr>
<td>MP43-05</td>
<td>S-NITROSGLUTATHIONE REDUCTASE (GSNOR) DEFICIENCY IS A NOVEL MODEL OF SECONDARY HYPOGONADISM</td>
</tr>
<tr>
<td>Thomas Masterson*, Himanshu Arrora, Shathiyah Kulandavelu, Joshua Hare, Ranjith Ramasamy, Miami, FL</td>
<td></td>
</tr>
<tr>
<td>MP43-06</td>
<td>INHIBITION OF PRONGF PATHWAY RESTORES ERECTILE FUNCTION THROUGH DUAL ANGIogenic AND NEUROTrophic EFFECTS IN THE DIABETIC MOUSE</td>
</tr>
<tr>
<td>MP43-07</td>
<td>INTRACAVERNOSAL ADENO-ASSOCIATED VIRUS MEDIATED S100A1 GENE TRANSFER ENHANCES ERECTILE FUNCTION IN DIABETIC RATS</td>
</tr>
<tr>
<td>Zhe Yu*, Yan Zhang, Jun Yang, Zhe Tang, Tao Wang, Jihong Liu, Shaogang Wang, Wuhan, China, People's Republic of</td>
<td></td>
</tr>
<tr>
<td>MP43-08</td>
<td>INHIBITION OF PENILE SMOOTH MUSCLE CONTRACTION BY BLOCKADE OF STIM/ORAI CALCIUM ENTRY SYSTEM AS A POTENTIAL STRATEGY FOR ERECTILE DYSFUNCTION</td>
</tr>
<tr>
<td>Javier Romero-Otero*, javier Angulo, Jose Medina-Polo, Borja García-Gómez, Mariam El Assar, Madrid, Spain, José María La Fuente, Porto, Portugal, Argentina Fernández, Alberto Sánchez-Ferrer, Alejandro Sevilla-Ortiz, Leocadio Rodríguez-Mañas, Madrid, Spain</td>
<td></td>
</tr>
</tbody>
</table>
MP43-09 EFFECTS OF PLATELET RICH PLASMA ON IMPROVING ERECTILE DYSFUNCTION IN STREPTOZOTOCIN-INDUCED DIABETIC RATS
ChunHou Liao*, YiNo Wu, HanSun Chiang, New Taipei City, Taiwan

MP43-10 THE ENDOCANNABINOID SYSTEM IN MALE REPRODUCTIVE FUNCTION: EXPRESSION AND LOCALIZATION OF FATTY ACID AMIDE HYDROLASE (FAAH) IN THE SEMINAL VESICLES AND VAS DEFERENS
Stefan Ueckert*, Hannover, Germany, Giorgia Colciago, Fabio Benigni, Milano, Italy, Andreas Bannowsky, Rendsburg, Germany, Markus Kuczyk, Hannover, Germany, Petter Hedlund, Lund, Sweden

MP43-11 JAK2 KNOCKOUT IMPROVES ERECTILE FUNCTION IN DIABETIC MICE THROUGH ATTENUATION OF FIBROSIS AND APOPTOSIS
Hao Li, Yinwei Chen, Gaurab Pokhrel*, Jun Yang, Tao Wang, Shaogang Wang, Jihong Liu, Wuhan, China, People’s Republic of

MP43-12 THE BENEFICIAL EFFECTS OF COMBINED TREATMENT OF SODIUM HYDROGEN SULFIDE AND TADALAFIL ON ERECTILE FUNCTION IN A RAT MODEL OF PARTIAL BLADDER OUTLET OBSTRUCTION

MP43-13 ENDOPEPTIDASE INHIBITION - A POTENTIAL NEW OPTION TO TARGET ERECTILE DYSFUNCTION? AN IN VITRO STUDY
Pejman Shahin, Stefan Uckert*, Hannover, Germany, Harrina Rahardjo, Jakarta, Indonesia, Andreas Bannowsky, Rendsburg, Germany, Markus Kuczyk, Hannover, Germany

MP43-14 SONIC HEDGEHOG REGULATION OF SPROUTING IN PENILE PROJECTING NEURONS
Ryan Dobbs, Shawn Choe, Elizabeth Kalmanek, Chicago, IL, Daniel Harrington, Houston, TX, Samuel Stupp, Chicago, IL, Kevin McVary, Springfield, IL, Carol Podlasek*, Chicago, IL

MP43-15 EFFECTS OF TESTOSTERONE AND PHOSPHODIESTERASE TYPE 5 INHIBITORS ON ERECTILE TISSUE AFTER PELVIC IRRADIATION
Dongsup Lee*, Suwon, Korea, Republic of, Dong-Wan Sohn, Seoul, Korea, Republic of

MP43-16 TRANSPELVIC MAGNETIC STIMULATION (TPMS) AS A NOVEL THERAPY TO ENHANCE PENILE MICRO AND MACRO CIRCULATION
Ki-Ho Kim*, Gyeongju, Korea, Republic of, Seung-Ryeol Lee, Seongnam, Korea, Republic of, Ho-Song Yu, Gwangju, Korea, Republic of, Tung-Chin (Mike) Hsieh, Valmik Bhargava, M. Raj Rajasekaran, SAN DIEGO, CA

MP43-18 HUMAN TISSUE KALLIKREIN 1 RESCUES ERECTILE FUNCTION IN RATS WITH HYPERHOMOCYSTEINAEMIA BY PROTECTING ENDOTHELIAL FUNCTION AND INHIBITING FIBROSIS
Kai Cui*, Zhe Tang, Yang Luan, Tao Wang, Shaogang Wang, Zhong Chen, Jihong Liu, Wuhan, China, People’s Republic of

MP43-19 A CONTEMPORARY ASSESSMENT OF NORMAL ERECTION PHYSIOLOGY
Katherine Cockerill*, Jacksonville, FL, Ram Pathak, Winston-Salem, NC, Ciarra Boyne, Gregory Broderick, Jacksonville, FL

MP43-20 JTE-013 SUPPLEMENTATION IMPROVES ERECTILE DYSFUNCTION IN RATS WITH STREPTOZOTOCIN-INDUCED TYPE 1 DIABETES THROUGH INHIBITION OF RHO-KINASE PATHWAY AND CORPORAL FIBROSIS
Kang Liu, Kai Cui, Rui Li, Huang Lin, Haihang Feng, Jihong Liu*, Bo Wen, Ke Rao, Wuhan, China, People’s Republic of

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>ARTICLE</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MP44-01</strong></td>
<td>A NATIONAL STUDY OF RISK-ALIGNED SURVEILLANCE PRACTICE FOR NON-MUSCLE INVASIVE BLADDER CANCER</td>
<td>Florian Schroek*, Lebanon, NH, Kristine Lynch, Ji Won Chang, Salt Lake City, UT, Douglas Robertson, John Seigne, Philip Goodney, Brenda Sirovich, Lebanon, NH</td>
</tr>
<tr>
<td><strong>MP44-02</strong></td>
<td>CHANGING TRENDS IN THE USE OF CHEMOTHERAPY FOR MUSCLE-INVASIVE BLADDER CANCER IN THE UNITED STATES</td>
<td>Mina Fam*, Jonathan Yabes, Pittsburgh, PA, Nathan Hale, Charleston, WV, Robert Turner, Michelle Yu, Liam Macleod, Lee Hugar, Jeffrey Gingrich, Pittsburgh, PA, Tudor Borza, Ted Skolarus, Ann Arbor, MI, Benjamin Davies, Bruce Jacobs, Pittsburgh, PA</td>
</tr>
<tr>
<td><strong>MP44-03</strong></td>
<td>DETERMINING CLINICALLY MEANINGFUL CHANGES IN BLADDER CANCER INDEX SCORES BY DISTRIBUTION AND ANCHOR BASED MINIMALLY IMPORTANT DIFFERENCE ESTIMATION</td>
<td>Charles Peyton*, Tampa, FL, Carl Henriksen, Gainsville, FL, Scott Gilbert, Tampa, FL</td>
</tr>
<tr>
<td><strong>MP44-04</strong></td>
<td>PREDICTING THE 10-YEAR RISK OF DEATH FROM OTHER CAUSES IN MEN WITH LOCALIZED PROSTATE CANCER USING PATIENT-REPORTED FACTORS: DEVELOPMENT OF A TOOL</td>
<td>Daniel Frendl, MD, PhD*, Boston, MA, Gordon FitzGerald, PhD, Mara Epstein, ScD, Jeroan Allison, MD, MS, Mitchell Sokoloff, MD, FACS, John Ware, Jr, PhD, Worcester, MA</td>
</tr>
<tr>
<td><strong>MP44-06</strong></td>
<td>THE DEVELOPMENT AND COMPARATIVE EFFECTIVENESS OF A PATIENT CENTERED PROSTATE BIOPSY REPORT IN CLINICAL PRACTICE</td>
<td>Jasmir Nayak*, Winnipeg, Canada, Nicholas Scalzo, Alice Chu, Geolani Dy, Seattle, WA, Liam Macleod, Pittsburgh, PA, Matthew Mossanen, Boston, MA, William Ellis, Daniel Lin, Lawrence True, John Gore, Seattle, WA</td>
</tr>
<tr>
<td><strong>MP44-07</strong></td>
<td>CROWD-SOURCING PARENTAL PREFERENCE ASSESSMENTS FOR VESICOURETERAL REFLUX</td>
<td>Zachary Dionise*, Durham, NC, Michael Garcia-Roig, Andrew Kirsch, Atlanta, GA, Jonathan Routh, Durham, NC</td>
</tr>
<tr>
<td><strong>MP44-08</strong></td>
<td>PATTERNS OF PRESCRIBING AND MONITORING TESTOSTERONE REPLACEMENT THERAPY AMONG 40,081 USERS IN BRITISH COLUMBIA BETWEEN 1997-2013</td>
<td>Jennifer Locke*, Ryan Flannigan, Mahyar Etminan, Hamid Tavokoli, Vancouver, Canada, Sean Skeldon, Toronto, Canada, Ted Hoyda, Larry Goldenberg, Vancouver, Canada</td>
</tr>
<tr>
<td><strong>MP44-09</strong></td>
<td>MARKETING AND TESTOSTERONE TREATMENT IN THE UNITED STATES</td>
<td>Jathin Bandari*, Omar Ayyash, Pittsburgh, PA, Sherry Emery, Chicago, IL, Charles Wessel, Benjamin Davies, Pittsburgh, PA</td>
</tr>
<tr>
<td><strong>MP44-10</strong></td>
<td>THE IMPACT OF THE FDA TESTOSTERONE SUPPLEMENTATION THERAPY SAFETY ADVISORY ON PRESCRIBING PATTERNS</td>
<td>Valary Raup*, Tyler McClintock, Ramy Abou Ghayda, Alexandra Berger, Boston, MA, Allen Seftel, Camden, NJ, Martin Kathrins, Boston, MA</td>
</tr>
<tr>
<td><strong>MP44-11</strong></td>
<td>CREATION AND VALIDATION OF A CLAIMS-BASED ALGORITHM FOR IDENTIFYING IN-VITRO FERTILIZATION SERVICES</td>
<td>James Dupree*, Zachary Levinson, Angela Kelley, Ann Arbor, MI, Jessica Dozier, Atlanta, GA, Marsha Manning, Michael Lanham, Vanessa Dalton, Helen Levy, Richard Hirth, Ann Arbor, MI</td>
</tr>
<tr>
<td><strong>MP44-12</strong></td>
<td>RURAL DIFFERENCES IN STAGE AT DIAGNOSIS FOR UROLOGICAL MALIGNANCIES</td>
<td>Adam Gadzinski*, San Francisco, CA, S. Jane Henley, Atlanta, GA, Anobel Odisio, Sima Porten, Peter Carroll, Matthew Cooperberg, San Francisco, CA</td>
</tr>
</tbody>
</table>
MP44-13 VARIABLE USE OF POSTOPERATIVE IMAGING FOLLOWING URETEROSCOPIC STONE TREATMENT ACROSS DIVERSE UROLOGY PRACTICES IN MICHIGAN
Casey Dauw*, Khurshid Ghani, Ji Qi, Tae Kim, Ann Arbor, MI, Brian Selfman, Detroit, MI, Mohammed Jafri, Royal Oak, MI, John Hollingsworth, Ann Arbor, MI

MP44-14 SOCIOECONOMIC DISPARITIES EXIST IN THE ACUTE MANAGEMENT OF STONE DISEASE
Eric Kirshenbaum*, Chirag Doshi, Maywood, IL, Robert Blackwell, Springfield, IL, Petar Bajic, Gopal Gupta, Alex Gorbonos, Thomas Turk, Robert Flanigan, Paul Kuo, Kristin Baldea, Maywood, IL

MP44-15 REGIONAL VARIATION IN TRANSURETHRAL RESECTION OF PROSTATE DECLINE IN THE MODERN SURGICAL ERA
Elisabeth M. Sebesta*, Matthew P. Rutman, Elias Hyams, New York, NY

MP44-16 VARIATION IN NATIONAL OPIOID PRESCRIBING PATTERNS FOLLOWING SURGERY FOR KIDNEY STONES
Michael Leapman*, New Haven, CT, Eric DeRycke, West Haven, CT, Melissa Skanderson, William Becker, New Haven, CT, Danil Makarov, New York, NY, Cary Gross, Mary Driscoll, New York, NY

MP44-17 CLINICAL IMPLICATION OF A SIMPLE QUANTITATIVE FRAILTY ASSESSMENT TOOL FOR PROGNOSIS IN PATIENTS WITH UROLOGICAL CANCERS
Soma Osamu*, Shingo Hatakeyama, Teppei Matsumoto, Ayumu Kusaka, Shogo Hosogoe, Itsuto Hamano, Yuki Tobisawa, Tohru Yoneyama, Hayato Yamamoto, Atsushi Imai, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Koie, Shigeyuki Nakaji, Chikara Ohyama, Hiroaki Aomori, Japan

MP44-18 EXAMINING TRENDS IN UNDERREPRESENTED MINORITIES IN UROLOGY RESIDENCY
Govind Shantharam*, Timothy Tran, Heather McGee, Simone Thavaseelan, Providence, RI

MP44-19 THE CURRENT LANDSCAPE OF TRANSGENDER PATIENT CARE IN UROLOGY: AN EVALUATION OF ATTITUDES, KNOWLEDGE, AND PRACTICE PATTERNS AMONG UROLOGISTS
Jared S. Winoker*, Marissa A. Kent, Aaron B. Grotas, New York, NY

MP44-20 DO ONLINE RATINGS OF UROLOGISTS PREDICT OUTCOMES FOLLOWING RADICAL AND PARTIAL NEPHRECTOMY?
Anthony Yang*, Mark Finkelstein, Khawaja Bilal, Natan Davoudzadeh, Michael Palese, New York, NY

APPROVED FORAMA PRA CATEGORY 1 CREDIT™
MP45-06 BLADDER UROTHELIAL AND AFFERENT DYSFUNCTIONS UNDERLYING BLADDER OVERACTIVITY IN RATS WITH CHEMICALLY INDUCED PROSTATIC INFLAMMATION
Shinsuke Mizoguchi*, Amanda S. Wolf-Johnson, Takahisa Suzuki, Eiichiro Takaoka, Donald B. DeFranco, Zhou Wang, Lori A. Birder, Naoki Yoshimura, Pittsburgh, PA

MP45-07 ROLES OF PROSTATE ENLARGEMENT, INFLAMMATION AND FIBROSIS IN BLADDER OUTLET OBSTRUCTION
Matthew D. Grimes*, Andrew Schneider, Sijian Wang, Wade Bushman, Madison, WI

MP45-08 INFLUENCE OF A Tryptophan-RICH DIET ON PROSTATIC GROWTH AND ANDROGEN RECEPTOR EXPRESSION
Paulo Mota, Agostinho Cordeiro*, Nuno Morais, João Torres, Alexandria Rocha, Rute Moura, Alice Miranda, Jorge Correia-Pinto, Estélvio Lima, Emanuel Carvalho-Dias, Braga, Portugal

MP45-09 EFFECTS OF CASTRATION AND TESTOSTERONE REPLACEMENT OVER SEROTONIN (PROSTATIC AND PLASMATIC): A MICE IN VIVO STUDY
Paulo Mota, Nuno Morais, Agostinho Cordeiro*, João Torres, João Martins, Rute Moura, Alice Miranda, Jorge Correia-Pinto, Estélvio Lima, Emanuel Carvalho-Dias, Braga, Portugal

MP45-10 BLEBBISTATIN MODULATES PROSTATIC CELL GROWTH AND CONTRACTILITY THROUGH MYOSIN II SIGNALING
Ping Chen, Deqiang Xu, He Xiao, Xinghuan Wang, Wuhan, China, People's Republic of, Michael E. DiSanto, Camden, NJ, Xinhua Zhang*, Wuhan, China, People's Republic of

MP45-11 NEW STRATEGIES FOR INHIBITION OF NON-ADRENERGIC PROSTATE SMOOTH MUSCLE CONTRACTION BY PHARMACOLOGICAL INTERVENTION
Qingfeng Yu*, Christian Gratzke, Paul Kuppermann, Annika Herlemann, Yiming Wang, Frank Strittmatter, Raphaela Waidelich, Christian Steif, Martin Hennenberg, Munich, Germany

MP45-12 INHIBITION OF PROSTATE SMOOTH MUSCLE CONTRACTION BY INHIBITORS OF POLO-LIKE KINASES (PLK): AN ALPHA1-ADRENERGIC SPECIFIC ROLE FOR PLK1 IN SMOOTH MUSCLE CONTRACTION?
Martin Hennenberg*, Paul Kuppermann, Qingfeng Yu, Beata Rutz, Yiming Wang, Annika Herlemann, Raphaela Waidelich, Frank Strittmatter, Christian Steif, Christian Gratzke, Munich, Germany

MP45-13 POST-OBSTRUCTIVE BLADDER SMOOTH MUSCLE REMODELING IS DEPENDENT ON BLADDER STEM CELLS
Belinda Li*, Megan Y. Devine, Nicholas M. Tassone, Robert W. Dettman, Edward M. Gong, Chicago, IL

MP45-14 LONG-TERM LEPTIN ADMINISTRATION REDUCES PROSTATIC EPITHELIAL HYPERPLASIA IN THE OB/OB MOUSE MODEL
Takeshi Sasaki*, Mie, Japan, Omar Franco, Yana Filipovich, Evanston, IL, LaTayja Aaron, Nashville, TN, Philip Fitchev, Evanston, IL, Douglas Strand, Dallas, TX, Susan Crawford, Simon Hayward, Evanston, IL

MP45-15 TRANSFORMING GROWTH FACTOR BETA 1 INCREASES BENIGN PROSTATIC LUMINAL EPITHELIAL CELL LAYER PERMEABILITY
Feng Li*, Xi'an, China, People's Republic of, Ke Wang, Laura E. Pascal, YiBin Zhou, Morgan Dressel, Donna Stolz, Rajiv Dhir, Joel B. Nelson, Pittsburgh, PA, Peng Guo, DaLin He, Xi'an, China, People's Republic of, Zhou Wang, Pittsburgh, PA

MP45-16 EVIDENCE FOR A ROLE OF THE GHRELIN SYSTEM IN THE HYPERPLASTIC PROSTATE: CONNECTING THE METABOLIC SYNDROME AND LOWER URINARY TRACT SYMPTOMS SUGGESTIVE OF BPH?
Xiaolong Wang*, Christian Gratzke, Yiming Wang, Christian Sterr, Qingfeng Yu, Frank Strittmatter, Christian Steif, Martin Hennenberg, Munich, Germany

MP45-17 GALECTIN-3 PLAYS CRITICAL ROLES FOR THE GROWTH OF BENIGN PROSTATIC HYPERPLASIA
Kei Daizumoto*, Yayoi Fukuhara, Keisuke Ozaki, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama, Tokushima City, Japan

MP45-18 INHIBITION OF HUMAN PROSTATE STROMAL CELL GROWTH BY THALIDOMIDE: A NOVEL REMEDY IN LUTS?
Alexander Tamalunas*, Anna Ciotkowska, Raphaela Waidelich, Christian G. Stief, Christian Gratzke, Martin Hennenberg, Munich, Germany

MP45-19 THE EFFECTS OF LOCAL ATHEROSCLEROSIS OF THE PROSTATIC ARTERY IN PATIENTS WITH PROSTATIC ENLARGEMENT
Nobuhiro Haga*, Hidenori Akaihata, Ken Akaiwa, Kei Ishibashi, Yoshiyuki Kojima, Fukushima, Japan

MP45-20 THE EFFECT ON BLOOD FLOW RATE OF PROSTATE IN DAILY ADMINISTRATION OF MIRODENAFIL 50MG FOR BENIGN PROSTATIC HYPERPLASIA PATIENTS: RANDOMIZED CONTROLLED STUDY
Kyu Shik Kim*, Jae Hoon Chung, Seoul, Korea, Republic of, Jun Hwa Noh, Jun Seok Kim, Gwangju, Korea, Republic of, Seung Wook Lee, Dong-Gi Lee, Seoul, Korea, Republic of

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
ABSTRACT NUMBER | TITLE
--- | ---
MP46-01 | DEVELOPMENT OF PROSTATE CANCER SCREENING NOMOGRAMS FOR PREDICTING 15-YEAR RISK OF PROSTATE CANCER DIAGNOSIS AND PROSTATE CANCER MORTALITY, WITH OTHER-CAUSE MORTALITY AS COMPETING EVENT
Sigrid Carlsson, New York, NY, Michael Brooks*, Alexander Zajichek, Kevin Chagin, Cleveland, OH, Jonas Hugosson, Göteborg, Sweden, Michael Kattan, Andrew Stephenson, Cleveland, OH

MP46-02 | PROSTATE CANCER SCREENING NOMOGRAM PREDICTING 15-YEAR RISK OF CLINICALLY SIGNIFICANT PROSTATE CANCER, DEVELOPED USING COMPETING RISK ANALYSIS
Michael Brooks*, Cleveland, OH, Sigrid Carlsson, New York, NY, Alexander Zajichek, Kevin Chagin, Cleveland, OH, Jonas Hugosson, Göteborg, Sweden, Michael Kattan, Andrew Stephenson, Cleveland, OH

MP46-03 | THE UTILITY OF REPEAT BIOPSY IN DETECTING CLINICALLY SIGNIFICANT PROSTATE CANCER AFTER PRIOR NEGATIVE MRI FUSION GUIDED BIOPSY
Joseph A. Baiocco*, Bethesda, MD, Abhinav Sidana, Cincinnati, OH, Jonathan Bloom, Meet Kadakia, Graham Hale, Samuel Gold, Kareem Rayn, Vladimir Valera, Arvin George, Maria Merino, Peter Choyke, Baris Turkbey, Bradford Wood, Peter Pinto, Bethesda, MD

MP46-04 | LARGE SINGLE PRACTICE LONG TERM EXPERIENCE WITH AUGMENTED ANTIMICROBIAL PROPHYLAXIS FOR TRANSCRANAL PROSTATE BIOPSY
Deepak Kapoor*, Kathleen Latino, Elliott Lieberman, Carl Olsson, Melville, NY

MP46-05 | DEVELOPMENT OF A CLINICAL IMPLEMENTATION PLAN (CAREPATH) FOR A NOVEL URINE EXOSOME GENE EXPRESSION ASSAY AS PART OF A TWO-COHORT, ADAPTIVE DECISION IMPACT UTILITY TRIAL

ABSTRACT NUMBER | TITLE
--- | ---
MP46-06 | NOMOGRAM TO PREDICT ABSENCE OF CLINICALLY SIGNIFICANT PROSTATE CANCER ON PATIENTS WITH NEGATIVE MULTIPARAMETRIC MRI UNDERGOING PROSTATE BIOPSY

MP46-07 | PROSTATE CANCER DETECTION IN BIOPSY-NAÏVE MEN: A PROSPECTIVE, COMPARATIVE, ONGOING CLINICAL TRIAL OF MULTIPARAMETRIC MRI- AND CONTRAST ENHANCED ULTRASOUND-TARGETED BIOPSY VERSUS SYSTEMATIC BIOPSY
Christophe Manniara*, Olivia Lodeizen, Arnaud Postema, Amsterdam, Netherlands, Ruud Van Sloun, Rogier Wildeboer, Massimo Mischi, Eindhoven, Netherlands, Dilara Savci-Heijink, Marc Engelsbrecht, Theo De Reijke, Hessel Wijkstra, Amsterdam, Netherlands

MP46-08 | WHAT IS THE PERFORMANCE OF MPMRI IN MEN WHO HAVE NEVER HAD A PRIOR BIOPSY OF THE PROSTATE: A META-ANALYSIS OF PROSPECTIVE STUDIES
Mahmoud Alameddine*, Leonardo Tamariz, Ana Palacio, Zsuzsanna Nemeth, Joshua S. Jue, Luis Felipe Sávio, Nachiketh Soodana Prakash, Maria C. Velasquez Escobar, Chad Ritch, Mark Gonzalez, Marcelo Panizzutti, Sanoj Punnun, Miami, FL

MP46-09 | IMAGE-BASED DIAGNOSIS OF PROSTATE CANCER (DIMCAPRO STUDY): RANDOMIZED PROSPECTIVE STUDY IN BIOPSY-NAÏVE POPULATION COMPARING DIAGNOSIS STANDARD PATHWAY VS AN IMAGE-GUIDED APPROACH USING MPMRI AND TARGET BIOPSY
Ana Plata Bello*, Laura González Pérez, Lucio Díaz Flores, Sergio Pitti Reyes, Ibrahim Hermández, Jose María Pérez González, Julio Plata Bello, Marisol Pastor Santoveña, Tomas Concepcion Masip, La Laguna, Spain

MP46-10 | INITIAL SCREENING USING PCA3 WITH PSA/D PROSTATE CANCER DETECTION
EVALUATION OF TWO URINARY RNA BIOMARKER TESTS WITH AN EPGENETIC DNA ASSAY FOR THE IDENTIFICATION OF MEN WITH HIGH-GRADE PROSTATE CANCER
Geert Trooskens, Irvine, CA, Anglita Yantisetiasti, Rianne Hendriks, Inge Van Oort, Peter Mulders, Christina Hulsbergen-van de Kaa, Nijmegen, Netherlands, Wim Van Criekeging, Gent, Belgium, Jack Schalken*, Nijmegen, Netherlands

THE LEARNING CURVE OF THE MR/US FUSION PROSTATE BIOPSY: A PATHOLOGY-GUIDED ANALYSIS

CLINICAL IMPACT OF INCLUDING THE 4KSCORE IN THE CRIBRIFORM-UPDATED ERSPC ROTTERDAM PROSTATE CANCER RISK CALCULATOR PREDICTING CLINICALLY SIGNIFICANT PROSTATE CANCER
Jan Verbeek*, Theodorus van der Kwast, Charlotte Kweldam, Intan Kümmerlin, Geert van Leenders, Monique Roobol, Rotterdam, Netherlands

LOOKING BEYOND CANCER DETECTION: IS TEMPLATE BIOPSY BETTER THAN TRUS BIOPSY IN PLANNING NERVE SPARING ROBOTIC RADICAL PROSTATECTOMY IN THE MULTIPARAMETRIC MRI ERA?
Dimitrios Moschonas*, Edward Bass, Pavlos Pavlakis, Murthy Kusuma, Stylianos Chintzoglou, Krishnaji Patil, Christopher Eden, Matthew Perry, Stephen Langley, Guildford, United Kingdom

PROSPECTIVE VALIDATION OF THE FOUR KALLIKREIN PANEL IN ACADEMIC CLINICAL PRACTICE

PROSPECTIVE VALIDATION OF THE FOUR KALLIKREIN PANEL IN ACADEMIC CLINICAL PRACTICE

COMBINATION OF PSA DENSITY, PROSTATE CANCER ANTIGEN 3 AND PI-RADS IN THE PREDICTION OF PROSTATE CANCER IN INITIAL BIOPSY
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP47-01</td>
<td>TRANSURETHRAL ENDOSCOPIC ULTRASOUND TO ASSESS TUMOR STAGE IN BLADDER CANCER</td>
</tr>
<tr>
<td>Ashima Singal*, Ryan Brancamp, Nabeel Hamoui, Shilajit Kundu, Chicago, IL</td>
<td></td>
</tr>
<tr>
<td>MP47-02</td>
<td>EN BLOC TRANSURETHRAL RESECTION WITH HYBRID KNIFE FOR TREATMENT PRIMARY NON-MUSCLE-INVASIVE BLADDER CANCER: A SINGLE-CENTER, CONTROLLED TRIAL BASED ON PATHOLOGICAL STAGING</td>
</tr>
<tr>
<td>Jia Hu*, Wuhan, China, People’s Republic of China</td>
<td></td>
</tr>
<tr>
<td>MP47-03</td>
<td>THE CKD-EPI EQUATION IS THE MOST ACCURATE MODEL TO DETECT IMPAIRED RENAL FUNCTION PRIOR AND AFTER RADICAL CYSTECTOMY</td>
</tr>
<tr>
<td>Matthias Meunier*, Mathieu Rouanne, Aurélie Mbeutcha, Yann Neuzillet, Henry Botto, Suresnes, France, Marie Courbebaïsse, Paris, France, Thierry Lebret, Suresnes, France</td>
<td></td>
</tr>
<tr>
<td>MP47-04</td>
<td>REFINING SELECTION CRITERIA FOR NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER: COMBINING CLINICAL RISK FEATURES AND INTRINSIC MOLECULAR SUBTYPES</td>
</tr>
<tr>
<td>Jonathan Duplisea*, Michael Metcalfe, Debasish Sundi, Jed Ferguson, Roger Li, Shanna Freieisch, Ashish Kat, Neema Navai, Jay Shah, Jolanta Bondurak, Bogdan Czerniak, Houston, TX, Woonyoung Choi, David McConkey, Bethesda, MD, Peter Black, Vancouver, Canada, Colin Dinney, Houston, TX</td>
<td></td>
</tr>
<tr>
<td>MP47-05</td>
<td>TIMELY CYSTECTOMY IS CRITICAL FOR VARIANT HISTOLOGY OF UROTHELIAL BLADDER CANCER</td>
</tr>
<tr>
<td>Michael Lin-Brande*, Shane Pearce, Akbar Ashrafi, Ankeet Shah, Madeleine Burg, Gus Miranda, Hooman Djadlat, Anne Schuckman, Siamak Daneshmand, Los Angeles, CA</td>
<td></td>
</tr>
<tr>
<td>MP47-06</td>
<td>IMPACT OF VARIANT HISTOLOGY ON RESPONSE TO NEOADJUVANT CHEMOTHERAPY FOR UROTHELIAL BLADDER CANCER</td>
</tr>
<tr>
<td>Michael Lin-Brande*, Daniel Zainfeld, Saum Ghodoussi, Jie Cai, Gus Miranda, Hooman Djadlat, Anne Schuckman, Sarmad Sadeghi, Tanya Dorff, David Quinn, Siamak Daneshmand, Los Angeles, CA</td>
<td></td>
</tr>
<tr>
<td>MP47-07</td>
<td>PREOPERATIVE CHRONIC KIDNEY DISEASE PREDICTS POOR ONCOLOGICAL OUTCOMES AFTER RADICAL CYSTECTOMY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER</td>
</tr>
<tr>
<td>Itsuto Hamano*, Shingo Hatakeyama, Teppei Matsumoto, Osamu Soma, Ayumu Kusaka, Shogo Hosogoe, Yuki Tobiwasa, Tohru Yoneyama, Hayato Yamamoto, Atsushi Imai, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Kio, Aomori, Japan, Hiroyuki Ito, Hachinohe, Aomori, Japan, Kazuaki Yoshikawa, Mutsu, Aomori, Japan, Toshiaki Kawaguchi, Aomori, Japan, Chikara Ohyama, Aomori, Japan</td>
<td></td>
</tr>
<tr>
<td>MP47-08</td>
<td>RISK-STRATIFIED SURVEILLANCE AND COST EFFECTIVENESS OF FOLLOW-UP AFTER RADICAL CYSTECTOMY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER</td>
</tr>
<tr>
<td>Ayumu Kusaka*, Shingo Hatakeyama, Hiroaki, Japan, Hiromichi Iwamura, Sendai, Japan, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Kio, Hiroaki, Japan, Hiroyuki Ito, Hachinohe, Japan, Kazuaki Yoshikawa, Mutsu, Japan, Toshiaki Kawaguchi, Aomori, Japan, Chikara Ohyama, Hiroaki, Japan</td>
<td></td>
</tr>
<tr>
<td>MP47-09</td>
<td>COST-EFFECTIVENESS ANALYSIS OF A BIOMARKER-BASED APPROACH TO SELECT PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER FOR NEOADJUVANT CHEMOTHERAPY</td>
</tr>
<tr>
<td>Solomon Woldu*, Dallas, TX, Omer Sanli, Istanbul, Turkey, Peter Black, Vancouver, Canada, Matthew Milowsky, Chapel Hill, NC, Yair Lotan, Dallas, TX</td>
<td></td>
</tr>
<tr>
<td>MP47-10</td>
<td>MAKING A CASE FOR ROUTINE IMPLEMENTATION OF THE COMPREHENSIVE COMPLICATION INDEX® INTO PERIOPERATIVE QUALITY ASSESSMENT AFTER RADICAL CYSTECTOMY</td>
</tr>
<tr>
<td>Malte W. Vetterlein*, Philipp Gild, Jakob Klemm, Marlon Bradtke, Armin Soave, Roland Dahlem, Margit Fisch, Michael Rink, Hamburg, Germany</td>
<td></td>
</tr>
</tbody>
</table>
MP47-11 SURGICAL APPROACH AS A DETERMINANT FACTOR OF CLINICAL OUTCOMES FOLLOWING RADICAL CYSTECTOMY: DOES ENHANCED RECOVERY AFTER SURGERY (ERAS) LEVEL THE PLAYING FIELD?
Jian Chen*, Hooman Djaladat, Anne Schuckman, Monish Aron, Mihir Desai, Inderbir Gill, Thomas Clifford, Gus Miranda, Jie Cai, Siamak Daneshmand, Los Angeles, CA

MP47-12 COMPARISON OF PERIOPERATIVE OUTCOMES, FUNCTIONAL OUTCOMES, AND COMPLICATIONS FOR ROBOT ASSISTED RADICAL CYSTECTOMY WITH ORTHOTOPIC NEOBLADDER IN ELDERLY VS. YOUNG PATIENTS
Avinash Chenam*, William Chu, Nora Ruel, Patrick Kilday, Juzar Jamnagerwalla, Clayton Lau, Ali Zhuymkhawala, Kevin Chan, Jonathan Yamzon, Bertram Yuh, Duarte, CA

MP47-13 ROBOT-ASSISTED RADICAL CYSTECTOMY IN OCTOGENARIANS AND THE EFFECT OF AN ENHANCED RECOVERY PATHWAY ON PERIOPERATIVE INDICES
Avinash Chenam*, Justin Emtage, Nora Ruel, Patrick Kilday, Juzar Jamnagerwalla, Clayton Lau, Jonathan Yamzon, Ali Zhuymkhawala, Bertram Yuh, Kevin Chan, Duarte, CA

MP47-15 MULTICENTRIC COMPARISON OF SURGICAL OUTCOMES OBTAINED AFTER OPEN RADICAL CYSTECTOMY AND ROBOT-ASSISTED LAPAROSCOPIC RADICAL CYSTECTOMY FOR MUSCLE-INVASIVE BLADDER CANCER

MP47-16 ONE YEAR FOLLOW UP OF THE EFFICACY OF PHYSICAL PREHABILITATION IN RADICAL CYSTECTOMY PATHWAYS - SECONDARY RESULTS FROM A RANDOMIZED CONTROLLED TRIAL
Bente Thoft Jensen*, Michael Borre, Mette Borre, Ingrid Soendergaard, Jørgen Bjerggaard Jensen, Aarhus, Denmark

MP47-17 PREHABILITATION FOR PATIENTS UNDERGOING CYSTECTOMY: PRELIMINARY ANALYSIS OF A SINGLE-CENTER, RANDOMIZED CONTROLLED TRIAL
Wassim Kassouf*, Enrico Minnella, Ramon Awasthi, Vanessa Ferreira, Armen Aprkian, Simon Tanguay, Franco Carli, Montreal, Canada

MP47-18 GYNECOLOGIC ORGAN INVOLVEMENT IN BLADDER CANCER: IS ANTERIOR EXENTERATION NECESSARY?
Michelle Whittum*, Ahmed Aly Hussein, Youssef Ahmed, Hijab Khan, Collin Krasowski, Neil Huben, Paul May, Qiang Li, Khurshid Guru, Buffalo, NY

MP47-19 EFFECT OF LONG ACTING ANTICHOLINERGIC ON NOCTURNAL INCONTINENCE AFTER RADICAL CYSTECTOMY AND ORTHOTOPIC NEOBLADDER. A RANDOMIZED PLACEBO-CONTROLLED CROSSOVER STUDY

MP47-20 THE IMPACT OF CIGARETTE SMOKING ON ADVERSE PATHOLOGICAL FEATURES AND SURVIVAL IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR UROTHELIAL CARCINOMA OF THE BLADDER - A PROSPECTIVE, EUROPEAN MULTICENTER STUDY OF THE EAU YOUNG ACADEMIC UROLOGISTS (YAU) UROTHELI
Philipp Gild, Malte W. Vetterlein*, Hamburg, Germany, Paolo Gontero, Torino, Italy, Florian Röghmann, Herne, Germany, Marcus Cumberbatch, Sheffield, United Kingdom, Jakub Dobruch, Warsaw, Poland, Laura Mertens, Amsterdam, Netherlands, Andrea Necchi, Milano, Italy, Thomas Seisen, Julian Anract, Paris, France, Armin Pycha, Bolzano, Italy, Karim Saba, Cedric Peyot, Zurich, Switzerland, Aidan P. Noon, Sheffield, United Kingdom, Bas W. van Rhijn, Amsterdam, Netherlands, Morgan Roupret, Paris, France, Roland Seiler, Berne, Switzerland, Shahrokh F. Shariat, Vienna, Austria, Evangelos Xylinas, Paris, France, Michael Rink, Hamburg, Germany

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP48-01</td>
<td>PSEUDOCAPSULE INFILTRATION, POSITIVE SURGICAL MARGINS AND LOCAL RECURRENCE AFTER ENUCLEATIVE ROBOT-ASSISTED PARTIAL NEPHRECTOMY (RAPN) FOR RENAL CELL CARCINOMA (RCC): RESULTS AT A MEDIAN FOLLOW-UP OF 56 MONTHS</td>
</tr>
<tr>
<td>Riccardo Campi*, Fabrizio Di Maida, Andrea Mari, Giulia Bencini, Ilaria Montagnani, Simone Morselli, Andrea Cocci, Alessandro Pili, Alberto Lapini, Marco Carini, Maria Rosaria Raspollini, Andrea Minervini, Florence, Italy</td>
<td></td>
</tr>
<tr>
<td>MP48-02</td>
<td>POSITIVE SURGICAL MARGINS PREDICT PROGRESSION-FREE SURVIVAL AFTER NEPHRON SPARING SURGERY FOR RENAL CELL CARCINOMA: RESULTS FROM A SINGLE CENTRE COHORT OF ALMOST 500 CASES WITH A MINIMUM FOLLOW-UP OF 5 YEARS</td>
</tr>
<tr>
<td>Riccardo Tellini, Alessandro Antonelli, Carlotta Palumbo*, Alessandro Vecchia, Maria Furlan, Regina Tardanico, Simona Fisogni, Claudio Simone, Brescia, Italy</td>
<td></td>
</tr>
<tr>
<td>MP48-03</td>
<td>THE LEARNING CURVE FOR ROBOT-ASSISTED PARTIAL NEPHRECTOMY: IMPACT OF SURGICAL EXPERIENCE ON PERIOPERATIVE OUTCOMES</td>
</tr>
<tr>
<td>Alessandro Larcher*, Melle, Belgium, Benoit Peyronnet, Rennes, France, Geert De Naeyer, Aalst, Belgium, Fabio Muttin, Milan, Italy, Zine-Edidine Khene, Rennes, France, Peter Schatteman, Frederiek D’Hondt, Cristina Ferriero, Aalst, Belgium, Umberto Capitanio, Francesco Montorsi, Milan, Italy, Karim Bensalah, Rennes, France, Alexandre Mottrie, Melle, Belgium</td>
<td></td>
</tr>
<tr>
<td>MP48-04</td>
<td>ROBOTIC-ASSISTANCE IS ASSOCIATED WITH IMPROVED PERIOPERATIVE OUTCOMES IN MINIMALLY-INVASIVE RADICAL NEPHRECTOMY</td>
</tr>
<tr>
<td>Joseph Rodriguez*, Zachary Smith, Vignesh Packiam, Ryan Wernitz, Joel Wackerbarth, Scott Eggenger, Arieh Shalhav, Chicago, IL</td>
<td></td>
</tr>
<tr>
<td>MP48-05</td>
<td>3-DIMENSIONAL, VIRTUAL REALITY PLANNING FOR ROBOTIC PARTIAL NEPHRECTOMY</td>
</tr>
<tr>
<td>Joseph Shirk*, Loma Kwan, Christopher Saigal, Los Angeles, CA</td>
<td></td>
</tr>
<tr>
<td>MP48-06</td>
<td>THE IMPACT OF SURGICAL STRATEGY IN ROBOT-ASSISTED PARTIAL NEPHRECTOMY: SHOULD WE TREAT ANTERIOR TUMOURS WITH TRANSPERITONEAL ACCESS AND POSTERIOR TUMOURS WITH RETROPERITONEAL ACCESS?</td>
</tr>
<tr>
<td>Alessandro Larcher*, Melle, Belgium, Geert De Naeyer, Aalst, Belgium, Lyu Xiangjun, Beijing, China, People’s Republic of, Zachary Hamilton, San Diego, CA, Francesco Cianfiore, Milan, Italy, Frederiek D’Hondt, Aalst, Belgium, Ahmet Bindayi, San Diego, CA, Xin Ma, Beijing, China, People’s Republic of, Umberto Capitanio, Milan, Italy, Peter Schatteman, Aalst, Belgium, Ithaar Denweesh, San Diego, CA, Xu Zhang, Beijing, China, People’s Republic of, Francesco Montorsi, Milan, Italy, Alexandre Mottrie, Melle, Belgium</td>
<td></td>
</tr>
<tr>
<td>MP48-07</td>
<td>PATTERNS AND PREDICTORS OF RESECTION TECHNIQUES DURING PARTIAL NEPHRECTOMY FOR T1 RENAL MASSES: RESULTS OF A MULTICENTRE PROSPECTIVE CohORT STUDY FROM THE SURFACE-INTERMEDIATE-BASE (SIB) MARGIN SCORE INTERNATIONAL CONSORTIUM (IDEAL PHASE 2B)</td>
</tr>
<tr>
<td>Alexander Kutikov*, Philadelphia, PA, Riccardo Campi, Florence, Italy, Brian Lane, Grand Rapids, MI, Ottavio De Cobelli, Milan, Italy, Francesco Sanguedolce, Barcelona, Spain, Christian Villeda Sandoval, Mexico City, Mexico, Georgios Hatzichristodoulou, Würzburg, Germany, Andrea Mari, Florence, Italy, Alessandro Antonelli, Brescia, Italy, Oscar Rodriguez Faba, Barcelona, Spain, Hans Langenhuijsen, Nijmegen, Netherlands, Tobias Klatte, Vienna, Austria, Marco Roscigno, Bergamo, Italy, Bulent Akdogan, Nihat Karakoyunlu, Ankara, Turkey, Martin Marszalek, Vienna, Austria, Umberto Capitanio, Milan, Italy, Alessandro Volpe, Novara, Italy, Sabine Brookman-May, Munich, Germany, Robert Uzzo, Philadelphia, PA, Marco Carini, Andrea Minervini, Florence, Italy</td>
<td></td>
</tr>
<tr>
<td>MP48-08</td>
<td>ONCOLOGIC OUTCOMES OF SIMPLE ENucleATION PARTIAL NEPHRECTOMY IN SPORADIC TYPE 2 PAPILLARY RENAL CELL CARCINOMA</td>
</tr>
<tr>
<td>Avinash Maganty*, Pittsburgh, PA, Andres Correa, Philadelphia, PA, Jathin Bandari, Ronald Hrebinko, Benjamin Davies, Jodi Maranchie, Stephen Jackman, Pittsburgh, PA</td>
<td></td>
</tr>
</tbody>
</table>
MP48-09 SAFE AND EFFECTIVE PARTIAL NEPHRECTOMY IS FEASIBLE IN APPROPRIATELY SELECTED PATIENTS WITH COMPLEX (RENAL NEPHROMETRY SCORE 10-12) RENAL TUMORS: A MULTI-INSTITUTIONAL ANALYSIS
Benjamin Ristau*, Farmington, CT, Ithaar Derweesh, La Jolla, CA, Zachary Hamilton, St. Louis, MO, Lyudmila DeMora, Philadelphia, PA, Charles Field, Aaron Block, Sean Berquist, La Jolla, CA, Richard Greenberg, Rosalia Viterbo, David Chen, Marc Smaldone, Alexander Kutikov, Philadelphia, PA, Brian Lane, Grand Rapids, MI, Robert Uzzo, Philadelphia, PA

MP48-14 RADICAL VERSUS PARTIAL INTEROBSERVER COMPARISON OF COMPREHENSIVE COMPARISON OF CSA, FUNCTIONAL PARENCHYMAL VOLUME-INSTITUTIONAL ANALYSIS
Benjamin Ristau*, Farmington, CT, Ithaar Derweesh, La Jolla, CA, Zachary Hamilton, St. Louis, MO, Lyudmila DeMora, Philadelphia, PA, Charles Field, Aaron Block, Sean Berquist, La Jolla, CA, Richard Greenberg, Rosalia Viterbo, David Chen, Marc Smaldone, Alexander Kutikov, Philadelphia, PA, Brian Lane, Grand Rapids, MI, Robert Uzzo, Philadelphia, PA

MP48-12 VARIATIONS IN RENAL CORTEX VOLUMES BEFORE AND AFTER PARTIAL NEPHRECTOMY: A PILOT STUDY ON 30 CASES
Riccardo Tellini, Alessandro Vecchia*, Filippo Ferrari, Carlotta Palumbo, Stefania Zamboni, Roberta Ambrosini, Claudio Simeone, Alessandro Antonelli, Brescia, Italy

MP48-11 FUNCTIONAL PARENCHYMAL VOLUME-BASED SPECTRUM SCORE IS ABLE TO QUANTIFY ISCHEMIC INJURY AFTER PARTIAL NEPHRECTOMY
Ziho Lee*, Robert Uzzo, Aeen Asghar, Phyillis Parkansky, Tianyu Li, Rosalia Viterbo, David Chen, Marc Smaldone, Alexander Kutikov, Philadelphia, PA

MP48-13 COMPREHENSIVE COMPARISON OF CSA, RENAL, PADUA, AND C-INDEX IN PREDICTING FUNCTIONAL CHANGE AFTER PARTIAL NEPHRECTOMY IN SMALL RENAL MASS: AN APPROACH USING COMPUTED TOMOGRAPHY-BASED RENAL VOLUMETRY
Chan Ho Lee, Ja Yoon Ku, Won Ik Seo, Jae Il Chung, Wansuk Kim*, Hong Koo Ha, Busan, Korea, Republic of

MP48-14 INTEROBSERVER COMPARISON OF PADUA AND RENAL SCORING SYSTEMS IN A CONTEMPORARY COHORT OF PATIENTS WITH RENAL MASS UNDERGOING PARTIAL NEPHRECTOMY
Lisa Dahlkamp*, Lorine Haueser, Guido Winniekendonk, Joachim Noldus, Christian von Bodman, Rein-Jueri Palisaar, Florian Roghmann, Herne, Germany

MP48-15 RADICAL VERSUS PARTIAL NEPHRECTOMY FOR BIOPSY PROVEN FUHRMAN GRADE 3/4 RENAL CELL CARCINOMA CONFER WORSE OUTCOMES COMPARED TO RADIAL NEPHRECTOMY? RESULTS FROM A CANADIAN MULTICENTER COHORT
Hanah Goldberg*, Thenapanan Chandrasekar, Zachary Klaassen, Toronto, Canada, Rodney Breau, Ranjeeta Malick, Ottawa, Canada, Ranjena Maloni, Neil Fleshner, Girish Kulkami, Robert Hamilton, Alexander Zlotta, Toronto, Canada, Ricardo Rendon, Halifax, Canada, Simon Tanguay, Montreal, Canada, Jun Kawakami, Calgary, Canada, Luke Lavallee, Ottawa, Canada, Frederick Pouliot, Quebec City, Canada, Michael Jewett, Antonio Finelli, Toronto, Canada

MP48-16 ON-CLAMP VERSUS OFF-CLAMP PARTIAL NEPHRECTOMY: PROPENSITY SCORE MATCHED COMPARISON OF LONG TERM FUNCTIONAL OUTCOMES
Giuseppe Simone, Rome, Italy, Umberto Capitanio, Alessandro Larcher, Milan, Italy, Gabriele Tuderti*, Mariaconsiglia Ferriero, Leonardo Misuraca, Manuela Costantini, Francesco Minisola, Salvatore Guaglionone, Rome, Italy, Fabio Mutti, Alessandro Nini, Francesco Trevisani, Francesco Montorsi, Roberto Bertini, Milan, Italy, Michele Gallucci, Rome, Italy

MP48-17 OUTCOMES OF PARTIAL VERSUS RADICAL NEPHRECTOMY IN OCTOGENARIAN PATIENTS: RESULTS FROM THE RESURGE PROJECT
Alessandro Antonelli, Carlotta Palumbo*, Maria Furlan, Brescia, Italy, Nicola Pavan, Trieste, Italy, Carmen Mir, Valencia, Spain, Albert Breda, Barcelona, Spain, Estefania Linares, Madrid, Spain, Toshio Takagi, Tokyo, Japan, Koon Rha, Seoul, Korea, Republic of, Francesco Porpiglia, Turin, Italy, Tobias Maurer, Munich, Germany, Bo Yang, Shanghai, China, People’s Republic of, Paolo Umari, Asl, Belgium, Jean-Alexandre Long, Grenoble, France, Cosimo De Nunzio, Rome, Italy, Andrew Tracey, Richmond, VA, Matteo Ferro, Milan, Italy, Salvatore Micali, Modena, Italy, Estevão Lima, Braga, Portugal, Alfredo Aguileria, Madrid, Spain, Kazunari Tanabe, Tokyo, Japan, Ali Rameen, Seoul, Korea, Republic of, Riccardo Bentolo, Turin, Italy, Thomas Amiel, Munich, Germany, Chao Zang, Shanghai, China, People’s Republic of, Paolo Umari, Asl, Belgium, Jean-Alexandre Long, Grenoble, France, Cosimo De Nunzio, Rome, Italy, Andrew Tracey, Richmond, VA, Matteo Ferro, Milan, Italy, Salvatore Micali, Modena, Italy, Estevão Lima, Braga, Portugal, Alfredo Aguileria, Madrid, Spain, Kazunari Tanabe, Tokyo, Japan, Ali Rameen, Seoul, Korea, Republic of, Riccardo Bentolo, Turin, Italy, Thomas Amiel, Munich, Germany, Chao Zang, Shanghai, China, People’s Republic of, Paolo Umari, Asl, Belgium, Jean-Alexandre Long, Grenoble, France, Cosimo De Nunzio, Rome, Italy, Andrew Tracey, Richmond, VA, Matteo Ferro, Milan, Italy, Salvatore Micali, Modena, Italy, Estevão Lima, Braga, Portugal

MP48-18 RADICAL NEPHRECTOMY FOR CT1 RENAL CELL CARCINOMA: A PROPENSITY-SCORE BASED ANALYSIS
Boris Gershman*, Providence, RI, R. Houston Thompson, Stephen Boorjian, Christine Lohse, Brian Costello, John Cheville, Bradley Leibovich, Rochester, MN
### Podium Session 30

**Saturday, May 19, 2018**

Podium Session 30

**TRAUMA/RECONSTRUCTION/DIVERSION: URETHRAL RECONSTRUCTION (INCLUDING STRICTURE, DIVERTICULUM) II**

**Moderators:** Kenneth Angermeier, Kurt McCammon and Ricarda Bauer

<table>
<thead>
<tr>
<th>Time</th>
<th>Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30</td>
<td>PD30-01</td>
<td>PRIMARY REALIGNMENT FOR BLUNT STRADDLE INJURY OF THE BULBAR URETHRA IS ASSOCIATED WITH PROLONGED TIME TO URETHROPLASTY AND INCREASED STRUTURE COMPLEXITY</td>
<td>Kenichiro Ojima*, Akio Horiguchi, Masayuki Shinchi, Ayako Masunaga, Saitama, Japan, Eiji Takahashi, Fumihiro Kimura, Saitama, Japan, Keichi Ito, Tomohiko Asano, Ryuichi Azuma, Saitama, Japan</td>
</tr>
<tr>
<td>3:40</td>
<td>PD30-02</td>
<td>LONG TERM OUTCOMES OF RE DO URETHROPLASTY: OUTCOME EVALUATION THROUGH FLEXIBLE CYSTOSCOPY</td>
<td>Francesco Esperto*, Nadir Osman, Sheffield, United Kingdom, Joon Jae Park, Singapore, Singapore, Marta Barretta, Richard Inman, Christopher Chapple, Sheffield, United Kingdom</td>
</tr>
<tr>
<td>3:50</td>
<td>PD30-03</td>
<td>CLINICAL SIGNIFICANCE OF CYSTOSCOPIC RECURRENCE AFTER ANTERIOR URETHROPLASTY: A MULTI-INSTITUTION ANALYSIS FROM TRAUMA AND UROLOGIC RECONSTRUCTIVE NETWORK OF SURGEONS (TURNS)</td>
<td>Nima Baradararan*, Kirkpatrick Fergus, Thomas Gaither, San Francisco, CA, Gregory Murphy, St. Louis, MO, Sean Elliott, Minneapolis, MN, Jeremy Myers, Salt Lake City, UT, Bryan Voelzke, Seattle, WA, Thomas Smith 3rd, Houston, TX, Bradley Erickson, Iowa City, IA, Nejd Alsikafi, Chicago, IL, Alex Vanni, Burlington, MA, Jill Buckley, San Diego, CA, Lee Zhao, New York, NY, Benjamin Breyer, San Francisco, CA</td>
</tr>
<tr>
<td>4:00</td>
<td>PD30-04</td>
<td>URETHROPLASTY IN PATIENTS WITH FAILED URETHRAL STENT: AN INTERNATIONAL EXPERIENCE</td>
<td>Javier C. Angulo*, Madrid, Spain, Ramón Virasoro, Jessica DeLong, Norfolk, VA, Sanjay Kulikarni, Joshi Pankaj, Pune, India, Francisco E. Martins, Lisbon, Portugal, Reynaldo Gómez, Santiago de Chile, Chile, Carlos Gudice, Buenos Aires, Argentina, Nicolaas Lumen, Ghent, Belgium, Ignacio Aranse, Cristina Esquinases, Madrid, Spain, Pedro Suárez, Leandro Capiel, Buenos Aires, Argentina, Oscar A. Suárez, Nuevo Leon, Mexico, Nicolás Menéndez, Javier Belinky, Buenos Aires, Argentina, Maha M. Husainat, Richard Santucci, Detroit, MI</td>
</tr>
</tbody>
</table>

*Presenting author
4:10 PD30-05 COMPARATIVE EFFECTIVENESS OF INITIAL, REPEAT, AND SECONDARY ANTERIOR ONE-STAGE BUCCAL MUCOSAL GRAFT URETHROPLASTY

4:20 PD30-06 ANTERIOR URETHROPLASTY USING A NEW TISSUE ENGINEERED ORAL MUCOSA GRAFT: SURGICAL TECHNIQUES AND OUTCOMES
Guido Barbagli, Arezzo, Italy, Ilgar Akbarov Akbarov, Vahudin Zugor, Cologne, Germany, Roberto Olianas, Maurizio Aragona, Lueneburg, Germany, Giuseppe Romano, Montevarchi, Italy, Ulf Balsmeyer, Dirk Fahlenkamp, Udo Rebmann, Diana Standhaft, Chemnitz, Germany, Massimo Lazzer*, Milan, Italy, Axel Heidenreich, Cologne, Germany

4:30 PD30-07 PREVALENCE OF POST-VOID DRIBBLING BEFORE AND AFTER ANTERIOR URETHROPLASTY
Katherine J. Cotter*, Kevin J. Flynn, Amy E. Hahn, Iowa City, IA, Bryan B. Voelzke, Seattle, WA, Jeremy B. Myers, Salt Lake City, UT, Thomas G. Smith 3rd, Houston, TX, Sean P. Elliott, Minneapolis, MN, Nejd F. Alsikafi, Maywood, IL, Benjamin N. Breyer, San Francisco, CA, Alex J. Vanni, Burlington, MA, Jill C. Buckley, San Diego, CA, Lee C. Zhao, New York, NY, Bradley A. Erickson, Iowa City, IA

4:40 PD30-08 EVALUATION OF PATIENT REPORTED OUTCOME METHODS (PROM) IN PATIENTS UNDERGOING DIFFERENT APPROACHES TO BULBAR URETHROPLASTY
Simon Bugeja*, Stelila Ivaz, Anastasia Frost, Mariya Dragova, Felix Campos Juanatey, Daniela E. Andrich, Anthony R. Mundy, London, United Kingdom

4:50 PD30-09 NON-TRANSECTING TECHNIQUES REDUCE SEXUAL DYSFUNCTION AFTER ANASTOMOTIC BULBAR URETHROPLASTY: RESULTS OF A MULTICENTER COMPARATIVE ANALYSIS
David W. Chapman*, Edmonton, Canada, Katherine Cotter, Iowa City, IA, Niels V. Johnsen, Seattle, WA, Sunil Patel, San Diego, CA, Adam Kinnaird, Edmonton, Canada, Bradley A. Erickson, Iowa City, IA, Bryan Voelzke, Seattle, WA, Jill Buckley, San Diego, CA, Keith Rourke, Edmonton, Canada

5:00 PD30-10 A PROSPECTIVE STUDY OF PATIENT-REPORTED PAIN AFTER BULBAR URETHROPLASTY
Patrick Evans*, Sorena Keihani, Salt Lake City, UT, Benjamin Breyer, San Francisco, CA, Bradley Erickson, Iowa City, IA, James Hotaling, Sara Lennherr, Jeremy Myers, Salt Lake City, UT

5:20 PD30-12 OUTCOMES OF RECTAL MUCOSA GRAFT FOR ANTERIOR URETHRAL RECONSTRUCTION

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
3:50 PD31-03 PELVIC MUSCLE FLOOR REHABILITATION AS A THERAPEUTIC OPTION IN LIFELONG PREMATURE EJACULATION: LONG-TERM OUTCOMES
Antonio Luigi Pastore*, Giovanni Palleschi, Andrea Fuschi, Yazan Al Salhi, Latina, Italy, Alessandro Zucchi, Perugia, Italy, Giorgio Bozzini, Castellanza (VA), Italy, Ester Illiano, Elisabetta Costantini, Perugia, Italy, Antonio Carbone, Latina, Italy

4:00 PD31-04 EFFICACY OF TAMSULOSIN FOR THE MANAGEMENT OF PAINFUL ORGASM AFTER RADICAL PROSTATECTOMY: A PROSPECTIVE, NON-PLACEBO CONTROLLED STUDY
Hyun Jun Park*, Nam Cheol Park, Jong Kil Nam, Tae Nam Kim, Sung Woo Park, Busan, Korea, Republic of

4:10 PD31-05 PROSTATE SPECIFIC ANTIGEN LEVELS OF YOUNG MEN PRESENTING FOR EVALUATION OF HYPOGONADISM

4:20 PD31-06 TESTOSTERONE RECOVERY IN PATIENTS TREATED WITH INTENSITY-MODULATED RADIATION THERAPY COMBINED WITH ANDROGEN DEPRIVATION THERAPY
Kazuo Nishimura*, Sohei Kuribayashi, Hirotaka Tsuji, Satoru Yumiba, Koji Hatano, Yasutomo Nakai, Masashi Nakayama, Ken-ichi Kakimoto, Koji Konishi, Teruki Teshima, Osaka, Japan

4:30 PD31-07 TESTOSTERONE USE DOES NOT RESULT IN WORSE CARDIOVASCULAR RISK: A LONGITUDINAL EVALUATION OF CARDIOVASCULAR RISK BIOMARKERS
John Sigalos*, Zachary Dao, Luis Cartagenova, Taylor Kohn, Alexander Pastuszak, Larry Lipshultz, Houston, TX

4:40 PD31-08 INFLUENCE OF GENETIC VARIATION IN THE ANDROGEN RECEPTOR ON THE RISK OF CARDIOVASCULAR DISEASE IN HYPOGONADAL MEN
Matthew Panizzon, La Jolla, CA, Tung-Chin Haieh, Kelly Bree*, San Diego, CA, Carol Franz, Richard Hauger, William Kremen, La Jolla, CA

4:50 PD31-09 PRE-BIOPSY HYPOGONADISM IN PROSTATE CANCER PATIENTS IS ASSOCIATED WITH METASTATIC PROSTATE CANCER IN THE VETERAN POPULATION
Alan Hsieh*, Lorenzo DiGiorgio, Sri Pentakota, Chrystal Chang, Hossein Sadeghi-Nejad, Newark, NJ

5:00 PD31-10 COMPARISON BETWEEN NANOTECHNOLOGY STRUCTURED WATER AND TADAFAIL FOR THE TREATMENT OF ERECTILE DYSFUNCTION

5:10 PD31-11 PRESERVATION OF BASELINE ERECTILE FUNCTION IN RADIOTHERAPY PATIENTS USING PDE5I
Eduardo P. Miranda*, Fortaleza, Brazil, Lawrence Jenkins, Columbus, OH, Christian Nelson, Michael Zeliefsky, John P. Mulhall, New York, NY

5:20 PD31-12 THE EFFECTS OF MULTIPLE ADIPOSE-DERIVED STEM CELL INTRACORPOREAL INJECTIONS ON ERECTILE DYSFUNCTION IN A RAT MODEL OF CAVERNOSAL NERVE INJURY

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 19, 2018
Podium Session 32
3:30 pm - 5:30 pm
URODYNAMICS/LOWER URINARY TRACT DYSFUNCTION/FEMALE PELVIC MEDICINE: FEMALE INCONTINENCE: THERAPY II
Room 2011 @ MCC West
Moderators: Anne Pelletier Cameron, Michael DiSanto and Flavio Trigo Rocha

ABSTRACT

TIME NUMBER TITLE
3:30 PD32-01 A RANDOMIZED TRIAL OF A GROUP-BASED THERAPEUTIC YOGA PROGRAM FOR AMBULATORY WOMEN WITH URINARY INCONTINENCE
Alison Huang*, Margaret Chesney, Michael Schembri, San Francisco, CA, Lestee Subak, Palo Alto, CA

3:40 PD32-02 OCCUPATIONAL GROUPS AND LOWER URINARY TRACT SYMPTOMS IN WOMEN

*Presenting author
3:50 PD32-03 PREVALENCE OF NOCTURIA IN US WOMEN: RESULTS FROM NHANES
Michael Daugherty*, Natasha Ginzburg, Timothy Byler, Syracuse, NY

4:00 PD32-04 ROBOT-ASSISTED ARTIFICIAL URINARY SPHINCTER IMPLANTATION IN FEMALE PATIENTS: LESSONS LEARNT AFTER A 58 CASES MULTICENTER EXPERIENCE

4:10 PD32-05 LONG-TERM OUTCOMES OF ARTIFICIAL URINARY SPHINCTER IN FEMALE PATIENTS WITH SPINA BIFIDA

4:20 PD32-06 PATIENTS HAVE POOR COMPLIANCE WITH REPEAT ONABOTULINUMTOXIN A INJECTIONS FOR OVERACTIVE BLADDER
Justina Tam, Anh Nguyen*, Chris Du, Qingjie Wang, Michael Hung, Steven Weissbart, Jason Kim, Stony Brook, NY

4:30 PD32-07 SIX MONTH RESULTS OF DENERVATION TO THE TRIGONE FOR THE TREATMENT OF OVERACTIVE BLADDER
Roger Dmochowski*, Nashville, TN, Stefan De Wachter, Antwerp, Belgium, Magali Robert, Calgery, Canada, Karel Everaert, Ghent, Belgium, Le Mai Tu, Sherbrooke, Canada

4:40 PD32-08 VITAMIN D SUPPLEMENTATION FOR URGENCY URINARY INCONTINENCE IN POST-MENOPAUSAL WOMEN: A PILOT RANDOMIZED CLINICAL TRIAL
Alayne Markland*, T. Mark Beasley, Kathryn Burgio, Birmingham, AL, Camille Vaughan, Vin Tangpricha, Atlanta, GA, Patricia Goode, Birmingham, AL

4:50 PD32-09 MID-TERM MACROPLASTIQUE OUTCOME IN WOMEN WITH STRESS URINARY INCONTINENCE SECONDARY TO INTRINSIC SPHINCTER DEFICIENCY
Philippe Zimmerm, Timothy Carroll*, Alana Christie, Melissa Foreman, Gaurav Khatri, Dallas, TX

5:00 PD32-10 OUTCOMES OF SACRAL NEUROMODULATION IN DETRUSOR HYPERACTIVITY WITH IMPAIRED CONTRACTILITY
Katherine Amin*, Dena Moskowitz, Alvaro Lucioni, Una J. Lee, Kathleen C. Kobashi, Seattle, WA

5:10 PD32-11 A NOVEL WEARABLE, INTRAVAGINAL DEVICE FOR CONTINUOUS NEUROMODULATORY TREATMENT OF OVERACTIVE BLADDER
Suzette E. Sutherland*, Seattle, WA, Steven Siegel, Woodbury, MN

5:20 PD32-12 FINANCIAL BURDEN OF RECURRENT URINARY TRACT INFECTIONS IN WOMEN: A TIME-DRIVEN ACTIVITY-BASED COST ANALYSIS
Shivani Gaitonde*, Rena Malik, Philippe Zimmerm, Dallas, TX

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
3:50  PD33-03  CELL MOBILIZATION AS A TREATMENT STRATEGY FOR CHRONIC URINARY INCONTINENCE
James Koudy Williams*, Doug Shankle, Frank Marini, Shannon Lankford, Gopal Badlani, Karl-Erik Andersson, Winston-Salem, NC

4:00  PD33-04  URETHRAL SPHINCTER REGENERATION BY THREE-DIMENSIONAL BIOFABRICATED AUTOLOGOUS ADIPOSE-DERIVED CELL STRUCTURE IN RABBITS
Sudha Silwal Gautam*, Tetsuya Imamura, Matsumoto, Japan, Mitsuru Shimamura, Tokyo, Japan, Tomonori Minagawa, Takashi Nagai, Manabu Ueno, Tetsuichi Saito, Masaki Nakazawa, Tenyuki Ogawa, Osamu Ishizuka, Matsumoto, Japan

4:10  PD33-05  INITIAL EXPERIENCE OF INJECTION OF DEHYDRATED HUMAN AMNION/CHORION ON OUTCOMES OF URETHROTOMY FOR RECURRENT URETHRAL STRICTURES
Joseph Pariser*, Maha Husainat, Omar Soto-Aviles, Richard Santucci, Detroit, MI

4:20  PD33-06  EFFECTS OF CONTROLLED OXYGEN RELEASE FROM HOLLOW MICROPARTICLES FOR PROLONGED STEM CELL SURVIVAL AND IMPROVED ERECTILE FUNCTION
Yong Hyun Park*, Ae Ryang Jung, Ka Eun Kim, Mee Young Kim, Hyong Woo Moon, Kyu Won Lee, Ji Youl Lee, Seoul, Korea, Republic of

4:30  PD33-07  SAFETY AND EFFECTIVENESS OF AUTOLOGOUS ADIPOSE TISSUE DERIVED STROMAL VASCULAR FRACTION INJECTION FOR TREATMENT OF ERECTILE DYSFUNCTION
Maya Epifanova, Michael Chaly, Ilya Eremin, Andrey Pulin, Irina Nadelyaeva, Badria Gvasaliya, Sergey Artemenko, Maksim Durashov*, Moscow, Russian Federation

4:40  PD33-08  SINGLE-CELL TRANSCRIPTOME ANALYSIS OF HUMAN SPERMATOGONIAL STEM CELLS
Hye-Won Song*, Tung-Chin Hsieh, La Jolla, CA, Sue Hammoud, Ann Arbor, MI, Miles Wilkinson, La Jolla, CA

4:50  PD33-09  MIR-135A IS ASSOCIATED WITH CRYPTOCHIDISM INFERTILITY THROUGH SUPPRESSION OF FOXO1 IN SPERMATOGONIAL STEM CELLS
Yoshinobu Mortoki*,Kentaro Mizuno, Hideyuki Kamisawa, Satoshi Kurokawa, Akihiro Nakane, Tetsuji Maruyama, Yutaro Hayashi, Takahiro Yasui, Nagoya, Japan

5:00  PD33-10  HUMAN INDUCED PLURIPOTENT STEM CELL-DERIVED TESTOSTERONE-PRODUCING LEYDIG CELLS AMELIORATE SERUM TESTOSTERONE LEVEL IN RATS
Takaki Ishida*, Mikito Tanaka, Kenta Sumii, Keisuke Okada, Koji Chiba, Kei Matsushita, Masato Fujisawa, Takashi Aoi, Hyougo Kobe, Japan

5:10  PD33-11  PROGRESSIVE MUSCLE CELL DELIVERY AS A SOLUTION FOR VOLUMETRIC MUSCLE DEFECT REPAIR
Ji Hyun Kim, In Kap Ko, John Jackson, Anthony Atala, James Yoo*, Winston Salem, NC

5:20  PD33-12  IN VIVO EVALUATION OF FUNCTIONALIZED MUSCLE SCAFFOLDS FOR RECONSTRUCTION
Lindsey Shapiro, Young Min Ju, John Jackson, James Yoo, Anthony Atala, Sang Jin Lee*, Winston Salem, NC

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 19, 2018
Podium Session 34
3:30 pm - 5:30 pm

PROSTATE CANCER: LOCALIZED: ABLATIVE THERAPY II
Room 3018 @ MCC West

Moderators: Martin Dineen, Marcelo Bendhack and Ben Challacombe

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30</td>
<td>PD34-01</td>
<td>USING ADT-FREE SURVIVAL TO EVALUATE THE UTILITY OF SALVAGE CRYOABLATION IN MEN WITH LOCALLY RECURRENT PROSTATE CANCER AFTER RADIATION</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:40</td>
<td>PD34-02</td>
<td>SALVAGE RADICAL PROSTATECTOMY VERSUS SALVAGE CRYOTHERAPY FOR LOCALIZED RADIORECURRENT PROSTATE CANCER: COMPARATIVE LONG-TERM OUTCOMES</td>
</tr>
</tbody>
</table>

*Presenting author
3:50 PD34-03 PRIMARY TREATMENT MODALITY FOR PROSTATE CANCER IS ASSOCIATED WITH RISK OF BIOCHEMICAL RECURRENCE FOLLOWING SALVAGE CRYOTHERAPY

4:00 PD34-04 BIOPSY OUTCOMES AND PATTERNS OF PROSTATE CANCER GRADE PROGRESSION IN THE PCM301 RANDOMIZED TRIAL OF VASCULAR TARGETED PHOTODYNAMIC THERAPY AND ACTIVE SURVEILLANCE: IMPLICATIONS FOR FOCAL THERAPY

4:10 PD34-05 THE COMPARISON OF PRIMARY FOCAL CRYOTHERAPY AND PRIMARY WHOLE GLAND CRYOTHERAPY FOR PROSTATE CANCER; EVALUATION OF MULTIPLE ONCOLOGICAL AND FUNCTIONAL OUTCOMES

4:20 PD34-06 COMPREHENSIVE EVALUATION OF complications of focal therapy: a standardized methodology
Arnas Bakavicius*, Rafael Sanchez-Salas, Paolo Dell'Oglio, Silvia Garcia-Barreras, Adalberto Castro-Alfaro, Francois Rozet, Alexandre Ingels, Eric Barret, Marc Galiano, Jordan Sapetti, Annick Mombet, Nathalie Cathala, Dominique Prapotnich, Xavier Cathelineau, Paris, France

4:30 PD34-07 PSA FAILS TO PREDICT TREATMENT FAILURE IN FOCAL HIGH-INTENSITY FOCUSED ULTRASOUND THERAPY IN PROSTATE CANCER
Philipp M. Huber*, Bern, Switzerland, Naveed Afzal, Dorset, United Kingdom, Manit Arya, London, United Kingdom, Silvan Boxler, Bern, Switzerland, Susan Charmian, London, United Kingdom, Andrew Cornaby, Dorset, United Kingdom, Tim Dudderidge, Southampton, United Kingdom, Mark Emberton, Stephanie Guillamier, London, United Kingdom, Richard J. Hindley, Basingstoke, United Kingdom, Lucas Leemann, Zurich, Switzerland, Henry Lewi, Chelmsford, United Kingdom, Neil McCallan, Caroline M. Moore, London, United Kingdom, Raj Nigam, Surrey, United Kingdom, Chris Ogden, London, United Kingdom, Raj Persad, Bristol, United Kingdom, Karimsha Shah, London, United Kingdom, George N. Thalhammer, Bern, Switzerland, Jaspal Virdi, Harlow, United Kingdom, Mathias Winkler, Hashim U. Ahmed, London, United Kingdom

4:40 PD34-08 DETERMINANTS OF ERECTILE DYSFUNCTION FOLLOWING FOCAL ABLATIVE THERAPY FOR LOCALISED PROSTATE CANCER

4:50 PD34-09 PRIMARY FOCAL CRYOABLATION FOR LOW-, INTERMEDIATE AND HIGH-RISK PROSTATE CANCER: OUTCOMES OF 180 PATIENTS IN MEDIAN OF 33 MONTHS FOLLOW UP

5:00 PD34-10 ATTRACTIVENESS AND ACCESSIBILITY OF FOCAL THERAPY FOR PROSTATE CANCER: RESULTS OF AN INTERNATIONAL WEB-BASED SURVEY
Giancarlo Marra*, Turin, Italy, Guillaume Ploussard, Toulouse, France, Piet Ost, Pieter J. L. De Visschere, Ghent, Belgium, Prasanna Sooriakumaran, London, United Kingdom, Alberto Briganti, Giorgio Gandaglia, Milano, Italy, Derya Tili, Hamburg, Germany, Christian I. Surcel, Bucharest, Romania, Igor Tsaur, Mainz, Germany, Roderick Van Den Bergh, Utrecht, Netherlands, Alexander Kretschmer, Munich, Germany, Sanchia Goonewardene, London, United Kingdom, Hendrik Borgmann, Mainz, Germany, Paolo Gontero, Turin, Italy, Hashim Ahmed, London, United Kingdom, Massimo Valerio, Lausanne, Switzerland

5:10 PD34-11 MISINFORMATION ON THE INTERNET REGARDING ABLATIVE THERAPIES FOR PROSTATE CANCER
Denise Asafu-Adjei*, Nina Mikkilineni, Elisabeth Sebesta, Elias S. Hyams, New York, NY

5:20 PD34-12 DEVELOPMENT OF A NATIONALLY-REPRESENTATIVE FOCAL THERAPY MEDICAL DEVICE REGISTRY
Ron Golan*, Adrien Bernstein, Art Sedrakyan, Timothy McClure, Jim Hu, New York, NY

168
## Video Session 6

**ADRENAL, TESTIS, UTUC ONCOLOGY & MORE**

The videos in this session as well as the video libraries from the 2011-2016 Annual Meetings may be viewed in the Surgical Video Library and purchased in the AUA Store during the Annual Meeting. Both are located in Hall A. AUA members receive free online access to the Surgical Video Library throughout the year through AUA University. Visit www.AUAnet.org/University to access.

**Room 3002 @ MCC West**

**Moderators:** Costas Lallas, David Canes and Bradley Schwartz

---

### ABSTRACT

<table>
<thead>
<tr>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>V06-01</td>
<td>RETROPERITONEAL LYMPH NODE DISSECTION: LEARNING MODULE FOR TRAINEES</td>
</tr>
</tbody>
</table>

Laura Douglass*, Evan Kovac, Bronx, NY, Patrick Meade, Chicago, IL, Andrew Stephenson, Steven Campbell, Cleveland, OH, Max Maizels, Chicago, IL

| V06-02 | ROBOTIC-ASSISTED INFERIOR VENA CAVA TUMOR THROMBECTOMY WITH INTRACAVAL BALLOON OCCLUSION: A STEP-BY-STEP TECHNIQUE |

Akbar Ashrafi*, Niroshan Rajarubendra, Hung Nguyen, Ricardo Brandina, Darryl Hwang, Vinay Duddalwar, Inderbir Gill, Los Angeles, CA

| V06-03 | ROBOTIC DISTAL URETERECTOMY AND BOARI FLAP URETERONEOCYSTOSTOMY AFTER AORTO-BIFEMORAL BYPASS |

Jaya Sai Chavali*, Daniel Sagalovich, Juan Garisto, Julien Dagenais, Robert Stein, Cleveland, OH

| V06-04 | ROBOT ASSISTED INFERIOR VENA CAVOSCOPY |

Haidar Abdul-Muhsin*, Anthony Chau, Richard Fowl, Erik Castle, Phoenix, AZ

| V06-05 | ROBOTIC RENAL ANEURYSM REPAIR: USC EXPERIENCE |


| V06-06 | ROBOT-ASSISTED RETROPERITONEAL LYMPH NODE DISSECTION FOR ADVANCED TESTICULAR CANCER |

Akbar Ashrafi*, Hatim Thaker, Inderbir Gill, Hooman Djaladat, Los Angeles, CA

| V06-07 | ROBOTIC NEPHROURETERECTOMY FOR COMPLEX RENAL ANATOMY |

Tom Feng*, James Porter, Seattle, WA

| V06-08 | INTRODUCTION OF SUPINE EXTRAPERITONEAL LAPAROSCOPIC NEPHROURETERECTOMY WITHOUT PATIENT REPOSITIONING |

Jun Miki*, Takafumi Yanagisawa, Seiro Tanaka, Yuzo Inaba, Kosuke Iwatan, Hajime Onuma, Kagenori Ito, Takahiro Kimura, Koichi Kishimoto, Shin Egawa, Chiba, Japan

| V06-09 | ROBOTIC-ASSISTED LAPAROSCOPIC RIGHT NEPHROURETERECTOMY: MAKING UROLOGY RETROPERITONEAL AGAIN |

Kian Asanad*, Los Angeles, CA, Amy Luckenaugh, Alon Weizer, Samuel Kaffengerber, Ann Arbor, MI

| V06-10 | ROBOT-ASSISTED ADRENALECTOMY FOR RECURRENT METASTATIC RENAL CELL CANCER IN NON-VIRGIN ABDOMENS: THE CITY OF HOPE EXPERIENCE |

Avinash Chenam*, Justin Emtage, William Chu, Clayton Lau, Jonathan Yamzon, Bertram Yuh, Paul Gellhaus, Duarte, CA

| V06-11 | ROBOTIC RADICAL ADRENALECTOMY FOR PHEOCHROMOCYTOMA ASSOCIATED WITH ADRENAL AND RENAL VEIN TUMOR THROMBECTOMY |

Chirag Doshi*, Parth Patel, Gopal Gupta, Chicago, IL

| V06-12 | INTERDISCIPLINARY APPROACH TO DERMOID CYST OF THE SPINE: HOW CAN UROLOGISTS HELP NEUROSURGEONS? |

Ryan Mauck, Lee Zhao, Nirmish Singla*, Charles Hatchette, Dallas, TX

---

*Presenting author

**APPROVED FOR AMA PRA CATEGORY 1 CREDIT™**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30</td>
<td><strong>HIGHLIGHTS: SOCIETY FOR PEDIATRIC UROLOGY</strong></td>
<td><strong>Presenter:</strong> Caleb Nelson</td>
</tr>
<tr>
<td>7:45</td>
<td><strong>JOURNAL OF UROLOGY HIGHLIGHTS: PEDIATRICS</strong></td>
<td><strong>Presenter:</strong> Julian Wan</td>
</tr>
<tr>
<td>7:55</td>
<td><strong>PANEL DISCUSSION: FERTILITY PRESERVATION IN THE PEDIATRIC CANCER PATIENT</strong></td>
<td><strong>Moderator:</strong> Stacy Tanaka, <strong>Panelists:</strong> Nicholas Cost, James Smith, Richard Yu</td>
</tr>
<tr>
<td>8:15</td>
<td><strong>STATE-OF-THE-ART LECTURE: PRENATAL URINARY TRACT DILATION: ROLE OF ANTIBIOTICS AND IMAGING</strong></td>
<td><strong>Presenter:</strong> C. Anthony Herndon</td>
</tr>
<tr>
<td>8:30</td>
<td><strong>POINT-COUNTER POINT DEBATE: COMPLEX SURGICAL CASES SHOULD BE CENTRALIZED</strong></td>
<td><strong>Moderator:</strong> David Joseph, <strong>Debater - Pro:</strong> Aseem Shukla, <strong>Debater - Con:</strong> Jacob Ben-Chaim</td>
</tr>
<tr>
<td>8:50</td>
<td><strong>STATE-OF-THE-ART LECTURE: CANCER SCREENING IN THE PEDIATRIC CANCER PATIENT</strong></td>
<td><strong>Presenter:</strong> Douglas Husmann</td>
</tr>
<tr>
<td>9:05</td>
<td><strong>JOHN DUCKETT MEMORIAL LECTURE: IMPROVING THE DIAGNOSIS OF GENITOURINARY DEFECTS</strong></td>
<td><strong>Presenter:</strong> Dolores Lamb</td>
</tr>
<tr>
<td>9:20</td>
<td><strong>PANEL DISCUSSION: UPDATE ON UROLOGIC EMERGENCIES</strong></td>
<td><strong>Moderator:</strong> Christopher Colwell, <strong>Panelists:</strong> William Brant, Gregory Broderick, Anthony Caldamone</td>
</tr>
<tr>
<td>9:50</td>
<td><strong>STATE-OF-THE-ART LECTURE: DISPARITIES IN UROLOGY: RENAL TRANSPLANT</strong></td>
<td><strong>Presenter:</strong> Charles Modlin</td>
</tr>
<tr>
<td>10:00</td>
<td><strong>AUA WHITE PAPERS: OPTIMIZING SURGICAL OUTCOMES: PREOPERATIVE</strong></td>
<td><strong>Presenter:</strong> John Stoffel</td>
</tr>
<tr>
<td>10:10</td>
<td><strong>AUA WHITE PAPERS: OPTIMIZING SURGICAL OUTCOMES: INTRAOPERATIVE</strong></td>
<td><strong>Presenter:</strong> Kristin Chrouser</td>
</tr>
<tr>
<td>10:20</td>
<td><strong>AUA WHITE PAPERS: OPTIMIZING SURGICAL OUTCOMES: POSTOPERATIVE</strong></td>
<td><strong>Presenter:</strong> Angela Smith</td>
</tr>
<tr>
<td>10:30</td>
<td><strong>STATE-OF-THE-ART LECTURE: MOLECULAR CHARACTERIZATION AND BIOMARKER DEVELOPMENT IN PROSTATE CANCER</strong></td>
<td><strong>Presenter:</strong> Felix Feng</td>
</tr>
<tr>
<td>10:45</td>
<td><strong>STATE-OF-THE-ART LECTURE: COLOR-CODED SURGERY: FLUORESCENCE IMAGE-DIRECTED RESECTION</strong></td>
<td><strong>Presenter:</strong> Robert Reiter</td>
</tr>
<tr>
<td>11:00</td>
<td><strong>PANEL DISCUSSION: MRI: BEYOND PROSTATE CANCER</strong></td>
<td><strong>Moderator:</strong> Krishnanath Gaitonde, <strong>Panelists:</strong> Tim Boone, Jeffrey Cadeddu, Claus Roehborn</td>
</tr>
</tbody>
</table>

**APPROVED FOR AMA PRA CATEGORY 1 CREDIT™**

---

*Presenting author*
SECOND OPINION CASES (ASK THE GUIDELINES!): ERECTILE DYSFUNCTION
Moderator: Lawrence Hakim
Panelists: Arthur Burnett, Christian Nelson, Alan Shindel

9:00 PANEL DISCUSSION: INNOVATIVE APPROACHES TO ERECTILE DYSFUNCTION
Moderator: Serge Carrier
Panelists: Trinity Bivalacqua, Tom Lue

9:15 SURGICAL TECHNIQUES: TIPS & TRICKS: REPLACEMENT AND REVISION OF THE ARTIFICIAL URINARY SPHINCTER
Moderator: Brian Flynn
Surgeon: Ryan Terlecki

9:30 LBA-07 HUMAN PLACENTAL STEM CELLS PROMOTE ERECTILE FUNCTION RECOVERY IN A RODENT NEUROVASCULAR ERECTILE DYSFUNCTION MODEL
Presenter: Ethan Matz

9:40 LBA-08 PRELIMINARY OUTCOMES OF A NOVEL PENILE TRACTION DEVICE (RESTOREX) IN MEN WITH PEYRONIE’S DISEASE: A RANDOMIZED, CONTROLLED TRIAL
Presenter: Matthew Ziegelmann

9:50 LBA-09: INTERIM ANALYSIS OF THE FIRST PROSPECTIVE RANDOMIZED CONTROLLED TRIAL USING A DEHYDRATED HUMAN AMNION/CHORION MEMBRANE WRAP AROUND THE PROSTATIC NEUROVASCULAR BUNDLE DURING RADICAL PROSTATECTOMY – EFFECT ON POTENCY OUTCOMES
Presenter: Hariharan Palayapalayam Ganapathi

10:00 SECOND OPINION CASES (ASK THE GUIDELINES!): TESTOSTERONE REPLACEMENT
Moderator: John Mulhall
Panelists: Robert Brannigan, Emily Kurtz, Landon Trost

10:30 STATE-OF-THE-ART LECTURE: DISPARITIES IN UROLOGY – PRIAPISM AND SICKLE CELL
Presenter: Arthur Burnett

10:40 SURVIVOR DEBATE: PEYRONIE’S DISEASE
Moderator: Randall Meacham
Debaters: Gerald Brock, Rafael Carrion, Martin Gelbard, Lawrence Hakim, Wayne Hellstrom, Laurence Levine, Run Wang, Steven Wilson, Landon Trost

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 20, 2018
Plenary: Next Frontier, Sunday Afternoon Session
1:00 pm - 5:00 pm

HALL E @ MCC North

1:00 STATE-OF-THE-ART LECTURE: BIOMINERALIZATION IN NATURE: WHO GETS THE PLAQUE?
Presenter: Sunita Ho

1:15 CRITICAL DISCUSSION: TISSUE ENGINEERING 2018
Moderator: Anthony Atala
Discussants: Christopher Chapple, Janos Peti Peterdi

1:45 PANEL DISCUSSION: CATHETER ASSOCIATED UTIS
Moderator: Brian Schwartz
Panelists: Timothy Averch, Tomas Griebling

Presenter: Brian Matlaga

2:30 STATE-OF-THE-ART LECTURE: PRECISION MEDICINE IN BENIGN UROLOGY: PHENOTYPES, CLUSTERS AND PERSONALIZED THERAPY
Presenter: J. Quentin Clemens

2:45 STATE-OF-THE-ART LECTURE: SMARTPHONE SEMEN ANALYSIS
Presenter: Hadi Shafiee

3:00 AQUA REGISTRY: INFORMATION, CERTIFICATION, REGULATION, INNOVATION
Moderator: Steven Schlossberg
Panelists: Matthew Cooperberg, David Penson, Michael Ritchey

3:30 THE AUA ADVOCACY SUMMIT
Presenter: Christopher Gonzalez

3:40 LATE BREAKING ABSTRACTS – BENIGN
Moderators: Gary Lemack, Hossein Sadeghi-Nejad
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 3:40  | LBA-10 WATER VAPOR THERMAL THERAPY WITH REZÜM SYSTEM: 3-YEAR RESULTS OF PROSPECTIVE CROSSOVER TRIAL REPLICATE DURABLE OUTCOMES OF PHASE III RANDOMIZED CONTROLLED STUDY FOR TREATMENT OF LOWER URINARY TRACT SYMPTOMS / BENIGN PROSTATIC HYPERPLASIA  
Presenter: Kevin McVary |
| 3:50  | LBA-11 MULTI-CENTER PROSPECTIVE STUDY OF THE PROSTATIC URETHRAL LIFT FOR OBSTRUCTIVE MEDIAN LOBE: THE MELDIFT STUDY, AN EXTENSION OF THE LIFT RANDOMIZED STUDY  
Presenter: Daniel Rukstalis |
| 4:00  | LBA-12 AQUABLATION PROCEDURAL OUTCOMES FOR BPH IN LARGE PROSTATES (80-150G): RESULTS FROM THE WATERII STUDY  
Presenter: Mihir Desai |
| 4:10  | LBA-13 EFFICACY AND SAFETY OF ADD-ON MIRABEGRON VS. PLACEBO TO TAMSULOSIN IN MEN WITH OVERACTIVE BLADDER SYMPTOMS (MATCH STUDY)  
Presenter: Hidehiro Kakizaki |
| 4:20  | LBA-14 A PROSPECTIVE STUDY TO EVALUATE EFFICACY WITH THE NURO™ PERCUTANEOUS TIBIAL NEUROMODULATION SYSTEM IN DRUG NAÏVE PATIENTS WITH OVERACTIVE BLADDER SYNDROME (OAB)  
Presenter: Kathleen Kobashi |
| 4:30  | LBA-15 EXTENDED FIRST UNINTERRUPTED SLEEP PERIOD IN ELDERLY PATIENTS FOLLOWING TREATMENT WITH AV002, AN EMULIFIED LOW DOSE VASOPRESSIN ANALOG FOR NOCTURIA  
Presenter: Benjamin Brucker |
| 4:40  | LBA-16 DONOR VISCERAL ADIPOSE TISSUE BETTER PREDICTOR OF LONG-TERM RENAL FUNCTION DECLINE THAN BODY MASS INDEX  
Presenter: Karen Stern |
| 4:50  | LBA-17 THE FECAL MICROBIOME OF URINARY STONE FORMERS  
Presenter: Anna Zampini |

**APPROVED FOR AMA PRA CATEGORY 1 CREDIT™**

---

**Sunday, May 20, 2018**

**Plenary: Prime Time, Sunday Afternoon Session**

1:00 pm - 5:00 pm

**Esplanade BR @ MCC South**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 1:00  | CROSSFIRE: CONTROVERSIES IN UROLOGY: KIDNEY CANCER  
Moderator: Ralph Clayman  
Debaters - Pro: Jaime Landman, R. Houston Thompson  
Debaters - Con: Ketan Badani, Craig Rogers |
| 1:30  | STATE-OF-THE-ART LECTURE: PROSTATE CANCER: WHAT PET TO GET?  
Presenter: Thomas Hope |
| 1:45  | SURGICAL TECHNIQUES: TIPS & TRICKS: DISSECTION OF THE RENAL MASS WITH HILAR FAT INVASION  
Presenter: Monish Aron |
| 2:00  | SURGICAL TECHNIQUES: TIPS & TRICKS: BLADDER CANCER  
Moderator: Kristen Scarpato  
Surgeons: Bernard Bochner, Joseph Liao, James McKiernan |
| 2:45  | CASTRATION-RESISTANT PROSTATE CANCER: AUA GUIDELINE AMENDMENT 2018  
Presenter: Michael Cookson |
| 3:00  | COMPLEX CASES: LOCALLY ADVANCED AND METASTATIC KIDNEY CANCER  
Moderator: Christopher Wood  
Panelists: E. Jason Abel, Jose Karam, Primo Lara |
| 3:30  | CROWDSOURCING: ROBOTICS  
Moderator: Thomas Lendvay  
Panelists: James Peabody, Michael Stifelman, Chandru Sundaram |
| 4:00  | SURGICAL TECHNIQUES: TIPS & TRICKS: PARTIAL CYSTECTOMY  
Moderator: Ilhaar Derweesh  
Panelist: Steven Boorjian, Douglas Scherr, Robert Stein |

**APPROVED FOR AMA PRA CATEGORY 1 CREDIT™**

*Presenting author*
Sunday, May 20, 2018 6:30 am - 10:00 am

SOCIETY OF WOMEN IN UROLOGY (SWIU)
Golden Gate B @ Marriott Marquis

6:30 BREAKFAST BUFFET

6:45 PRESIDENT'S WELCOME
Society President: Suzette Sutherland

6:50 AUA UPDATE
AUA President-Elect: Robert Flanigan

7:05 ACHIEVING SUCCESS BY CLOSING THE GAPS BETWEEN MALE AND FEMALE PHYSICIANS
Kathleen O’Loughlin

8:05 SWIU AWARDS PRESENTATIONS

8:30 SWIU ADVOCACY UPDATE
Lindsey Kerr

8:50 ANNUAL BUSINESS MEETING

9:15 NETWORKING

10:00 ADJOURN

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 20, 2018 7:00 am - 9:00 am
Moderated Poster Session 49

TRAUMA/RECONSTRUCTION/DIVERSION: URETER (INCLUDING PYELOPLASTY) AND BLADDER RECONSTRUCTION (INCLUDING FISTULA), AUGMENTATION, SUBSTITUTION, DIVERSION I
Room 3004 @ MCC West
Moderators: Hunter Wessells, Alex Vanni and Urs Studer

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP49-01</td>
<td>OUTCOMES OF INTRACORPOREAL URINARY DIVERSION AFTER ROBOT-ASSISTED RADICAL CYSTECTOMY: RESULTS FROM THE INTERNATIONAL ROBOTIC CYSTECTOMY CONSORTIUM</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP49-02</td>
<td>COMPARING EXTRA-CORPOREAL AND INTRA-CORPOREAL NEOBLADDERS AFTER ROBOT-ASSISTED RADICAL CYSTECTOMY: RESULTS FROM THE INTERNATIONAL ROBOTIC CYSTECTOMY CONSORTIUM</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP49-03</td>
<td>POPULATION BASED ASSESSMENT OF CONTINENT DIVERSION UTILIZATION AND PERIOPERATIVE MORBIDITY IN THE UNITED STATES</td>
</tr>
<tr>
<td></td>
<td>Michael Lin-Brande*, Shane Pearce, Eli Thompson, Madeleine Burg, Hooman Djaladat, Anne Schuckman, Siamak Daneshmand, Los Angeles, CA</td>
</tr>
</tbody>
</table>
MP49-04 CONTINENT CUTANEOUS URINARY DIVERSION IS A VIABLE OPTION FOR ELDERLY PATIENTS UNDERGOING RADICAL CYSTECTOMY
Abimbola Ayangbesan*, Benjamin Taylor, Bashir Al Hussein Al Awamlh, Patrick Lewicki, New York, NY, Daniel Nguyen, Bern, Switzerland, David Golombos, Lamont Barlow, Douglas Scherr, New York, NY

MP49-05 STOMA COMPLICATIONS AND QUALITY OF LIFE IN INDIANA POUCH URINARY DIVERSION
Kai Wen Cheng*, Ankeet Shah, Gus Miranda, Anne Schuckman, Hooman Djaladat, Los Angeles, CA

MP49-06 RETROSPECTIVE OUTCOMES OF RIGHT COLON CONTINENT URINARY DIVERSION IN A SINGLE CENTER, IMPROVING THE CHARACTERIZATION OF COMPLICATION AND REOPERATION RISK
Christopher Martin*, Nathan Alder, Salt Lake City, UT, Jason Chandrapal, Durham, SC, Jeremy Myers, Salt Lake City, UT

MP49-07 HEMI-KOCK CONTINENT STOMA WITH AUGMENTATION CYSTOPLASTY FOR NEUROGENIC LOWER URINARY TRACT DYSFUNCTION
Sender Herschom*, Toronto, Canada

MP49-08 IS THE HYBRID ILEO-URETERIC ANASTOMOSIS A BETTER ALTERNATIVE THAN THE BRICKER OR WALLACE ANASTOMOSIS FOR ILEAL CONDUIT URINARY DIVERSION?
Dixon T.S. Woon*, Chinniv Vidyasagar, Athina Pirpiris, Melbourne, Australia, Jaime O. Herrera-Cáceres, Thenappan Chandrasekar, Hanan Goldberg, Zachary Klaassen, Toronto, Canada, Matthew Harper, Melbourne, Australia

MP49-09 ROBOTIC URETERAL REIMPLANTATION FOR URETERO-ENTERIC ANASTOMOTIC STRICTURES
Nariman Ahmadi*, Los Angeles, CA, Michael Granieri, New York, NY, Giuseppe Simone, Michele Gallucci, Rome, Italy, Alvin Goh, Houston, TX, Mehrdad Alemozaffar, Atlanta, GA, Lee Zhao, New York, NY, Mihir Desai, Monish Aron, Los Angeles, CA

MP49-10 OPEN REVISION OF URETEROENTERIC ANASTOMOSIS FOR BENIGN STRICTURES AFTER URINARY DIVERSION, A 7 YEAR REVIEW
Eric Schommer*, Andrew Davidiuk, Amulya Mandavalli, Michael Heckman, Kaitlynn Custer, Paul Young, Jacksonville, FL

MP49-11 DOES RADIATION EXPOSURE PORTEND WORSE POSTOPERATIVE OUTCOMES AFTER CYSTECTOMY WITH URINARY DIVERSION FOR BENIGN INDICATIONS?
Paurush Babbar*, Andrew Sun, Ann Kim, Daniel Hettel, Shree Agrawal, Alice Crane, Daniel Sun, Ryan Berglund, Hadley Wood, Kenneth Angermeier, Cleveland, OH

MP49-12 OUTCOMES OF RECONSTRUCTIVE UROLOGICAL SURGERY IN RADIOTHERAPY PATIENTS
Bogdan Toia*, Jai Seth, Hazel Eccleston, Mahreen Pakzad, Rizwan Hamid, Tamsin Greenwell, Jeremy Ockrim, London, United Kingdom

MP49-13 THE INCIDENCE OF PYOCYSTIS AND SUBSEQUENT REQUIREMENT FOR REMNANT BLADDER CYSTECTOMY FOLLOWING ILEAL CONDUIT URINARY DIVERSION FOR BENIGN AETIOLOGY
George Manekaryous, Rachel Barratt*, Mahreen Pakzad, Rizwan Hamid, Jeremy Ockrim, Tamsin Greenwell, London, United Kingdom

MP49-14 COMPLICATIONS OF NON-CONTINUOUS URINARY DIVERSION IN ADULT SPINAL CORD
Cyrille Guillot-Tantay*, Emmanuel Chartier-Kastler, Marie-Aimée Perrouin-Verbe, Paris, France, Pierre Denys, Garches, France, Priscilla Léon, Véronique Phé, Paris, France

MP49-15 AVOIDING THE NEED FOR BOWEL ANASTOMOSIS DURING PELVIC EXENTERATION - URINARY SIGMOID CONDUIT - SHORT AND LONG TERM COMPLICATIONS
Catherine Nam*, Mehrdad Alemozaffar, Mohammed Said, Dattatraya Patil, Viraj Master, Atlanta, GA

MP49-16 NOVEL NON-EVERTED STOMA CREATION DURING ILEAL CONDUIT URINARY DIVERSION: SHORT-TERM OUTCOMES
Katherine Thiesen*, Avinash Maganty, Ronald Hrebinko, Pittsburgh, PA

MP49-17 ROBOTIC-ASSISTED LAPAROSCOPIC SURGERY FOR ICS/IUGA CATEGORY 4 COMPLICATIONS OF GENITOURINARY PROSTHESIS AND GRAFT: A SINGLE-CENTER EXPERIENCE
Jason Warncke*, Michael Avallone, Alan Quach, Brian Flynn, Aurora, CO

MP49-18 CLINICAL AND RADIOGRAPHIC OUTCOMES FOLLOWING SALVAGE TREATMENT FOR URETEROPELVIC JUNCTION OBSTRUCTION
Joseph Crivelli*, Brett Johnson, Jodi Antonelli, Jeffrey Gahan, Allen Morey, Margaret Pearle, Jeffrey Cadeddu, Dallas, TX

MP49-19 URETERAL METALLIC STENTS IN BENIGN URETERAL STRICTURES: A RETROSPECTIVE COMPARISON OF UVENTA AND MEMOKATH STENT
Jae Dong Chung*, Chang Il Choi, Young Hyo Choi, Seoul, Korea, Republic of, Kyung Jin Chung, Incheon, Korea, Republic of, Seol Ho Choo, Suwon, Korea, Republic of, Kwang Ho Ryu, Gwangmyeong, Korea, Republic of, Deok Hyun Han, Minki Baek, Seoul, Korea, Republic of
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| MP50-01          | UROLITHIASIS IN PREGNANCY: DOES AN ANTEPARTUM STONE ADMISSION INCREASE THE RISK OF PRETERM DELIVERY?  
  Max Drescher*, Robert Blackwell, Parth Patel, Spencer Hart, Alexander Kandabarow, Paul Kuo, Ahmer Farooq, Thomas Turk, Kristin Baldea, Maywood, IL |
| MP50-02          | MAXIMIZING COST EFFECTIVENESS OF UROLITHIASIS MANAGEMENT IN PREGNANCY  
  Emily Clennon*, Brian Duty, Aaron Caughey, Portland, OR |
| MP50-03          | EMERGENCY ROOM UTILIZATION AND ASSOCIATED COSTS FOR PEDIATRIC VS. ADULT NEPHROLITHIASIS  
| MP50-04          | DEVELOPMENT AND INTERNAL VALIDATION OF A NOMOGRAM FOR PREDICTING SPONTANEOUS PASSAGE OF URETERAL STONES OF <10 MM  
  Takashi Yoshida*, Makoto Taguchi, Takaaki Inoue, Tomoaki Matsuzaki, Hidefumi Kinoshita, Tadashi Matsuda, Osaka, Japan |
| MP50-05          | RACIAL DISPARITIES IN ANALGESIC USE AMONGST PATIENTS PRESENTING TO THE EMERGENCY DEPARTMENT FOR ACUTE RENAL COLIC IN THE UNITED STATES: A POPULATION-BASED ANALYSIS  
  Alexandra Berger*, Ye Wang, Boston, MA, Benjamin Chung, Palo Alto, CA, Steven Chang, George Halebian, Boston, MA |
| MP50-06          | UNDERINSURED AND BLACK PATIENTS EXPERIENCE DELAYS IN RECEIPT OF URINARY STONE SURGERY  
  William Brubaker*, Kai Dallas, Stanford, CA, Christopher Elliott, Santa Jose, CA, Alan Pao, Stanford, CA, John Leppert, Palo Alto, CA, Simon Conti, Stanford, CA |
| MP50-07          | POPULATION MANAGEMENT KIDNEY STONE CARE APPROACH REDUCES OFFICE VISIT, SURGICAL PROCEDURE AND EMERGENCY DEPARTMENT ENCOUNTERS IN PATIENTS AT HIGH RISK FOR KIDNEY STONE RECURRENCE  
  Reza Goharderakshan, M.D.*, Harbor City, CA, Casey Ng, M.D., Panorama City, CA, Mitra De cogain, M.D., San Diego, CA, Cynthia Castillo, RN, Harbor City, CA, Michelle West, Harbor City, CA, Ronald Loo, M.D., Downey, CA |
| MP50-08          | TRANSITION OF CARE PROTOCOL FROM EMERGENCY DEPARTMENT TO STONE CLINIC IMPROVES NON-OPERATIVE MANAGEMENT  
  Andrew Portis*, Jennifer Portis, Suzanne Neises, St. Paul, MN |
| MP50-09          | REGIONAL VARIATION IN UTILIZATION OF URETEROSCOPY OVER SHOCKWAVE LITHOTRIPSY IN CALIFORNIA  
  Scott Wiener*, Marshall Stoller, Anne Suskind, San Francisco, CA |
| MP50-10          | PSYCHIATRIC DIAGNOSES AND OTHER FACTORS ASSOCIATED WITH EMERGENCY DEPARTMENT RETURN WITHIN 30 DAYS OF URETEROSCOPY  
  Evan Carlos, Chloe Peters*, Brenton Winship, Daniel Wollin, Leah Gerber, Jingqiu Li, Zachary Dionise, Charles Scales, Glenn Preminger, Michael Lipkin, Durham, NC |
| MP50-11          | DUSTING VS. RETRIEVAL: A SYSTEMATIC REVIEW OF URETEROSCOPIC TECHNIQUES AND STONE-FREE RATES FOR HOLMIUM LASER LITHOTRIPSY  
| MP50-12          | RESULTS OF THE IMPERIAL COLLEGE INTEGRATED STENT REGISTRATION SYSTEM  
  Hamid Abboudi*, Mitra Smith, Maryam Ahmed, Milad Hanna, Tamer El-Husseiny, Ranan DasGupta, London, United Kingdom |
MP50-13 NOVEL USE OF THE EPIC ELECTRONIC MEDICAL RECORD PLATFORM TO IDENTIFY LOST URETERAL STENTS
Juan F. Javier-Desloges*, Katelyn K. Johnson, Campbell F. Bryson, Rachel Olszyk, Patrick A. Kenney, Piruz Motamedinia, New Haven, CT

MP50-14 MINING KIDNEY STONE COMPOSITION FROM MILLIONS OF CLINICAL NOTES WITHIN THE ELECTRONIC HEALTH RECORD
Ryan Hsi*, Daniel Lee, Cosmin Bejan, Nashville, TN

MP50-15 AUTOMATED DATA EXTRACTION FROM AN INTEGRATED ELECTRONIC HEALTH RECORDS DATA REGISTRY YIELDS HIGHER ACCURACY THAN MANUAL ENTRY: RESULTS FROM THE REGISTRY FOR STONES OF THE KIDNEY AND URETER (RESKU)
Samuel Zetumer*, David Tzou, Tessel Ahmad, Shalonda Reilford-Titus, Marshall Stoller, Thomas Chi, San Francisco, CA

MP50-16 FALLING SHORT ON INITIAL URINE VOLUMES: IS HYDRATION THE BIGGEST INITIAL FACTOR PRESENTING TO A CONTEMPORARY STONE CLINIC?
Kimberly Tay MS3*, Sean McAdams MD, Anojan Navaratnam MD, Mira Keddis MD, Mitchell Humphreys MD, Phoenix, AZ

MP50-17 METABOLIC EVALUATION GUIDELINES IN PATIENTS WITH NEPHROLITHIASIS: ARE THEY BEING FOLLOWED? RESULTS OF A NATIONAL MULTI-CENTRIC QUALITY ASSESSMENT STUDY
Sabrina Harmouch*, Hiba About-Haidar, Hassan El Hawary, Montreal, Canada, Thomas Grigic, Vancouver, Canada, Andrea Lantz, Halifax, Canada, Ben H. Chew, Vancouver, Canada, Jason Lee, Toronto, Canada, Sero Andonian, Naeem Bhojani, Montreal, Canada

MP50-18 RELATIVE VALIDITY OF A DIETARY SCREENING TOOL TO IDENTIFY RISK FACTORS FOR UROLITHIASIS
Kristina L. Penniston*, Mariana M. Coughlin, Emma J. Leister, R. Allan Jhagroo, Madison, WI

MP50-19 MODELING THE INCIDENCE OF SECONDARY MALIGNANCY AND SUBSEQUENT MORTALITY RELATED TO IONIZING RADIATION USE IN THE EVALUATION AND MANAGEMENT OF NEPHROLITHIASIS
Todd Yecies*, Michelle Semins, Pittsburgh, PA

MP50-20 NATIONAL IMAGING TRENDS FOR ACUTE KIDNEY STONE DISEASE: DO RENAL ULTRASOUNDS FOR NEPHROLITHIASIS IN THE EMERGENCY DEPARTMENT PAVE THE WAY TO COMPUTERIZED TOMOGRAPHY?

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 20, 2018
7:00 am - 9:00 am
Moderated Poster Session 51
GENERAL & EPIDEMIOLOGICAL TRENDS & SOCIOECONOMICS: PRACTICE PATTERNS, QUALITY OF LIFE & SHARED DECISION MAKING II
Room 3009 @ MCC West
Moderators: J. Quentin Clemens, Christopher Saigal and Rodney Breau

ABSTRACT NUMBER TITLE
MP51-01 INCREDENTAL ADHERENCE TO GUIDELINE-BASED CARE IS ASSOCIATED WITH IMPROVED SURVIVAL AMONG PATIENTS WHO UNDERGO BLADDER PRESERVATION THERAPY OR RADICAL CYSTECTOMY FOR MUSCLE-INVASIVE BLADDER CANCER

ABSTRACT NUMBER TITLE
MP51-02 SLING REOPERATION RATES IN THE AUA QUALITY (AQUA) REGISTRY
Jennifer Anger*, Los Angeles, CA, J. Quentin Clemens, Livonia, MI, Steven Schlossberg, Norfolk, VA, Raymond Fang, Washington, DC, J. Stuart Wolf, Austin, TX, Matthew Cooperberg, San Francisco, CA

MP51-03 THE INFLUENCE OF STEREOTACTIC BODY RADIATION TREATMENT ADOPTION ON PROSTATE CANCER TREATMENT PATTERNS
Bruce Jacobs*, Jonathan Yabes, Samia Lopa, Dwight Heron, Chung-Chou Chang, Pittsburgh, PA, Justin Bekelman, Philadelphia, PA, Joel Nelson, Jeremy Kahn, Pittsburgh, PA, Julie Bynum, Amber Barnato, Lebanon, NH

*Presenting author
MP51-04 DIFFERENTIAL IMPACT OF SCREENING GUIDELINES ON PROSTATE CANCER STAGE DISTRIBUTION BETWEEN WHITE AND BLACK MEN
Seong Ho Jeong*, Erik B. Lehman, Jay D. Raman, MD, FACS, Hershey, PA

MP51-05 THE IMPACT OF VIDEO VISITS ON MEASURES OF CLINICAL EFFICIENCY AND REIMBURSEMENT

MP51-06 TELECONSULTATION SUPPORT PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA BEING DISCHARGED FROM SPECIALIZED CARE: A RANDOMIZED NONINFERIORITY STUDY
Rodrigo Da Silva*, Dimitris Rados, Emanuel Dos Santos, Natan Katz, Erno Harzheim, Carisí Polanczyk, Brasil Neto, Porto Alegre, Brazil

MP51-07 CONTRACEPTION IN THE ERA OF THE AFFORDABLE CARE ACT
Anuj S. Desai*, Alicia Roston, James Wren, Mary Kate Keeter, Mehul S. Patel, Matthew T. Hudnall, Minh N. Pham, Lauren F. Cooley, Nelson E. Bennett, Robert E. Brannigan, Chicago, IL

MP51-08 PRELIMINARY EXPERIENCE WITH COMPREHENSIVE GENOMIC PROFILING OF GENITOURINARY TUMORS; A TOOL TO DIRECT CLINICAL DECISIONS?

MP51-09 EXAMINING POST-OPERATIVE OPID PRESCRIBING PATTERNS FOLLOWING UROLOGIC SURGERY USING AN ENTERPRISE-WIDE ELECTRONIC MEDICAL RECORD
Jeannie Su*, Juan Javier-DesLoges, Michael Leapman, New Haven, CT

MP51-10 PROSTATE CANCER NAVIGATION AND TIME TO TREATMENT
Emily C. Serrell*, Boston, MA, Moritz Hansen, Andrew Perry, Melanie Feinberg, Tracy Robbins, Scot Remick, Lisa Beaulé, Tom Kinkead, Paul K.J. Han, Jesse D. Sammon, Portland, ME

MP51-11 FULLFILLING THE WHO CIRCUMCISION MANDATE: PATIENT MOTIVATION FOR CIRCUMCISION
Ryan Flannigan*, Neal Patel, Omar Al-Hussein Alawamleh, Quentin Awori, Soo Kim, Mark Barone, Marc Goldstein, Philip Li, Richard Lee, New York, NY

MP51-12 NATIONAL CANCER SCREENING DISPARITIES AND TRENDS OF AFRICAN AMERICANS COMPARED TO CAUCASIAN AMERICANS FROM 2000-2015
Bradly Waterai, Badrinath Konety*, Minneapolis, MN

MP51-13 THE IMPACT OF COMORBIDITY AND AGE ON TIMING OF ANDROGEN DEPRIVATION THERAPY IN MEN WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTECTOMY
Ariel Morazadeh*, Los Angeles, CA, Lauren Howard, Durham, NC, William Aronson, Los Angeles, CA, Martha Terss, Augusta, GA, Matthew Cooperberg, San Francisco, CA, Christopher Amling, Portland, OR, Christopher Kane, San Diego, CA, Stephen Freedland, Timothy Daskivich, Los Angeles, CA

MP51-14 TRENDS AND PREDICTORS OF ACTIVE SURVEILLANCE USE IN THE UNITED STATES FOR PATIENTS WITH CLINICAL T1 RENAL MASSES
Hiren Patel*, Stony Brook, NY, Itazka Khan, David Paulucci, Alp Tun A Bekesc, Nikhil Waingankar, John Stakianos, Ketan Badani, New York, NY

MP51-15 DO ACCOUNTABLE CARE ORGANIZATIONS EXACERBATE RACE MEDIATED DIFFERENCES IN CANCER SCREENING?
Daniel Lee*, Sunita Thapa, Amy Graves, Melinda Buntin, Matthew Resnick, Nashville, TN

MP51-16 THREE-YEAR ACTIVE SURVEILLANCE MANAGEMENT TRENDS IN A LARGE COMMUNITY UROLOGY COHORT
Jeremy Shelton*, Los Angeles, CA, Thomas Paiavanas, Fairfax, VA, Heidi Reichert, Xiaohui Jiang, Ann Arbor, MI, Neal Shore, Myrtle Beach, SC

MP51-17 IMPACT OF SURGEON PRACTICE LOCATION AND EMPLOYMENT TYPE ON PROCEDURAL PRACTICE PATTERNS: POTENTIAL IMPLICATIONS OF A DECLINING NON-METROPOLITAN (NM) WORKFORCE
J Lee Graves*, Jason Lomboy, Case Wood, Hung-Jui Tan, Matthew Nielsen, Angela Smith, Chapel Hill, NC, Amanda North, New York, NY, Patrick McKenna, Madison, WI, Raj Pruthi, Chapel Hill, NC

MP51-18 PRACTICE PATTERNS OF PROSTATE BIOPSY ANTIBiotic PROPHYLAXIS IN OVER 4000 PATIENTS FROM THE PENNSYLVANIA UROLOGIC REGIONAL COLLABORATION (PURC)
Jay D. Raman*, Hershey, PA, Marc Smaldone, Thomas Guzzo, Philadelphia, PA, John Danella, Danville, PA, Edouard Trabulsi, Adam Reese, Jeffrey Tomaszewski, Serge Ginzburg, Robert Uzzo, Claudette Fonsell, Bret Marlowe, Philadelphia, PA, Thomas Lanchoney, Bryn Mawr, PA
MP51-19 IS THERE A GENDER OR RACIAL PROMOTION DISPARITY IN ACADEMIC UROLOGY?
Benjamin Breyer*, San Francisco, CA, Raymond Fang, Linthicum, MD, Jennifer Anger, Los Angeles, CA

MP51-20 DIFFERENCES IN PERCEPTION OF SEXUAL SIDE EFFECTS FROM TREATMENT OF PROSTATE CANCER BY SEXUAL ORIENTATION
Vincent Wong*, Channa Amarasekera, James Burns, Kyle Tsai, David Victorson, Shiliajit Kundy, Chicago, IL

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 20, 2018
Moderated Poster Session 52
PROSTATE CANCER: ADVANCED (INCLUDING DRUG THERAPY) III
Room 3020 @ MCC West
Moderators: Edward Schaeffer, Karim Touijer and Athanasios Papatsoris

ABSTRACT TITLE
MP52-01 COMBINATION OF INDOMETHACIN AND ENZALUTAMIDE TO TREAT CASTRATION-RESISTANT PROSTATE CANCER
Chengfei Liu*, Wei Lou, Chong-xian Pan, Primo Lara, Christopher Evans, Mamta Parikh, Ralph deVerre White, Marc Dall’Era, Allen Gao, Sacramento, CA

MP52-02 A NOVEL ORAL A AND B TUBULIN INHIBITOR, VERU-111, HAS POTENT ACTIVITY AGAINST PACLITAXEL SENSITIVE AND RESISTANT PROSTATE CANCER
Robert Getzenberg, Miami, FL, James Dalton*, Ann Arbor, MI, Duane Miller, Memphis, TN, Mitchell Steiner, Miami, FL

MP52-03 CORRELATION OF THE TYPE OF PELVIC NODE DISSECTION DURING RADICAL PROSTATECTOMY TO THE PATTERN OF NODAL RECURRENCE AT SALVAGE L YMPHADENECTOMY FOR PROSTATE CANCER
Arjun Sivaraman*, Nicole Berfante, Karim Touijer, Jonathan Coleman, Peter Scardino, Vincent Laudone, James Eastham, New York, NY

MP52-04 2-YEAR FOLLOW-UP OF RADIUM-223 RETREATMENT IN AN INTERNATIONAL, OPEN-LABEL, PHASE 1/2 STUDY IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER AND BONE METASTASES
Neil Mariados*, Syracuse, NY, Oliver Sartor, New Orleans, LA, Daniel Heinrich, Lørenskog, Norway, Maria José Méndez Vidal, Cordoba, Spain, Daniel Keizman, Kfar Saba, Israel, Camilla Thellenberg Karlsson, Umeå, Sweden, Avivit Peer, Haifa, Israel, Giuseppe Procopio, Milan, Italy, Stephen J. Frank, Jerusalem, Israel, Kálevi Pullkanen, Kuopio, Finland, Eli Rosenbaum, Petah Tikva, Israel, Stefano Severi, Meldola, Italy, Jose Manuel Trigo Perez, Málaga, Spain, Lucia Trandsafir, Volker Wagner, Basel, Switzerland, Rui Li, Whippany, NJ, Luke T. Nordquist, Omaha, NE

ABSTRACT TITLE
MP52-05 PROGNOSTIC NUTRITIONAL INDEX PREDICTS PRIMARY RESISTANCE TO TREATMENT AND PROGNOSIS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS REATED WITH ABIRATERONE
Liancheng Fan*, Baijun Dong, Jiahua Pan, Chenfei Chi, Yinjie Zhu, Lixin Zhou, Wei Xue, shanghai, China, People’s Republic of China

MP52-06 SERUM LIPID PROFILE CANNOT IMPROVE AFTER WITHDRAWAL OF ANDROGEN DEPRIVATION THERAPY IN PATIENTS WITH PROSTATE CANCER DESPITE THE RECOVERY OF SERUM TESTOSTERONE: IS THE CARDIOVASCULAR RISK STILL REMAINING?
Ryo Oka*, Sakura, Japan, Takanobu Utsumi, Chapel Hill, NC, Takumi Endo, Masashi Yano, Naoto Kamiya, Hiroyoshi Suzuki, Chiba, Japan

MP52-07 WHICH PATIENTS SHOULD BE STILL CONSIDERED FOR LATE SALVAGE RADIOTHERAPY FOR RISING OR PERSISTENTLY ELEVATED PSA AFTER RADICAL PROSTATECTOMY? RESULTS FROM A LARGE MULTI-INSTITUTIONAL STUDY
Nicola Fossati*, Milan, Italy, Jeffrey R. Karnes, Matteo Soligo, Stephen A. Boorjian, Rochester, MN, Alberto Bossi, Gabriele Coraggio, Villejuif, France, Nadia Di Muzio, Claudio Fiorino, Cesare Cozzarini, Barbara Noris Chiorda, Giorgio Gandaglia, Milan, Italy, Detlef Bartkowiak, Volker Budach, Ulm, Germany, Shahrokh F. Shariat, Gregor Goldner, Vienna, Austria, Antonino Battaglia, Steven Joniau, Karin Haustermans, Geert De Meerleer, Leuven, Belgium, Valérie Fonteyne, Piet Ost, Ghent, Belgium, Hein Van Poppel, Leuven, Belgium, Francesco Montorsi, Milan, Italy, Thomas Wieglo, Ulm, Germany, Alberto Briganti, Milan, Italy

*Presenting author
MP52-08 ONCOLOGICAL OUTCOMES, SURGICAL SAFETY AND COMPLICATIONS OF PATIENTS TREATED WITH SPOT SPECIFIC SALVAGE LYMPHNODE DISSECTION (SLND) FOR POSITRON-EMISSION TOMOGRAPHY (PET) POSITIVE PROSTATE CANCER (PCA) RELAPSE
Andreas Hiester*, Duesseldorf, Germany, Alessandro Nini, Milan, Italy, Gunter Niegisch, Robert Rabenalt, Peter Albers, Duesseldorf, Germany

MP52-09 MULTICENTRIC PROSPECTIVE LOCAL TREATMENT OF METASTATIC PROSTATE CANCER (LOMP) TRIAL: INTERIM ANALYSIS OF CLINICAL OUTCOMES AND PROGNOSTIC FACTORS
Sarah Buelens*, Filip Poelaert, Bert Dhondt, Elise De Bleser, Caroline Verbaeys, Ghent, Belgium, Bernard Rappe, Aalst, Belgium, Bart Kimpe, Ghent, Belgium, Ignace Billiet, Kortrijk, Belgium, Hendrik Plancke, Bonheiden, Belgium, Karen Franais, Antwerp, Belgium, Patrick Willemen, Hasselt, Belgium, Bart De Troyer, Sint-Niklaas, Belgium, Piet Oost, Karel Decaestecker, Nicolaas Lumen, Ghent, Belgium

MP52-10 OPTIMAL SEQUENCING STRATEGY USING DOCETAXEL AND ANDROGEN RECEPTOR AXIS-TARGETED AGENTS IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER: UTILIZATION OF NEUTROPHIL-TO-LYMPHOCYTE RATIO
Kyo Chul Koo, Jong Soo Lee, Jee Soo Park, Yoon Soo Ha, Hyun Kyu Ahn*, Kwang Suk Lee, Jee Soo Ha, Do Kyung Kim, Kyung Taek Oh, Koon Ho Rha, Sung Joon Hong, Byung Ha Chung, Seoul, Korea, Republic of

MP52-11 ASSOCIATION OF DOSE REDUCTION OF ABRIRATERONE ACETATE PLUS PREDNISONE OR ENZALUTAMIDE AND PSA PROGRESSION IN VETERANS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Stephen Freedland*, Los Angeles, CA, Yinong Young-Xu, White River Junction, VT, Sophia Li, Horsham, PA, Dominic Pilone, Montréal, Canada, Rachel Bhak, Sahil Narkhede, Boston, MA, Rhiannon Kamstra, Montréal, Canada, Ajay Behl, Horsham, PA, Patrick Lefebvre, Montréal, Canada, Alexander Fuld, Hanover, NH

MP52-12 COMPARISON OF ALTERNATIVE ANDROGEN RECEPTOR-AXIS-TARGETED AGENT (ARATA) VERSUS DOCETAXEL AS SECOND-LINE THERAPY FOR PATIENTS WITH METASTATIC CAstration-resistant prostate cancer PROGRESSING AFTER INITIAL ARATA IN REAL-WORLD CLINICAL PRACTICE IN JAPAN
Yuto Matsushita*, Keita Tamura, Takayuki Sugiyama, Hideaki Miyake, Hamamatsu, Japan

MP52-13 NEUROENDOCRINE DIFFERENTIATION OF PROSTATE CANCER AND THE OUTCOMES OF EVEROLIMUS AGAINST NEUROENDOCRINE PROSTATE CANCER (NEPC)
Shimomura Tatsuya*, Takashi Kurauchi, Sakanaaka Keigo, Takahiro Kimura, Shin Egawa, Tokyo, Japan

MP52-14 THE EFFECTIVENESS AND SAFETY OF CABAZITAXEL (CBZ) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) IN ROUTINE CLINICAL PRACTICE: RESULTS OF A PROSPECTIVE OBSERVATIONAL STUDY (CAPRISTANA)
Joan Carles*, Barcelona, Spain, Jana Katolicka, Brno, Czech Republic, Hana Korunkova, Pizen, Czech Republic, Antoaneta Tomova, Plodviv, Bulgaria, Marwan Ghosn, Fadi El Karak, Joseph Makdessi, Beirut, Lebanon, Irina Koroleva, Samara, Russian Federation, Ayse Ozatligan, Cambridge, MA, Simon Hilter, Chilly-Mazarin, France, Angelika Pichler, Leoben, Austria

MP52-15 ANDROGEN DEPRIVATION THERAPY AND SUBSEQUENT HEMATOLOGIC DISORDERS IN 17,168 PATIENTS WITH PROSTATE CANCER
Jui-Ming Liu*, Heng-Chang Chuang, Taoyuan, Taiwan, Chun-Te Wu, Keelung, Taiwan, Yu-Li Su, Kaohsiung, Taiwan, Ren-Jun Hsu, Taipei, Taiwan

MP52-16 ANDROGEN DEPRIVATION THERAPY INCREASED THE RISK OF PULMOMARY EMBOLISM IN PATIENT WITH PROSTATE CANCER - FROM 24,464 PATIENTS, TAIWAN NATIONAL HEALTH INSURANCE RESEARCH DATABASE
Jian-Hua Hong*, Yu-Chuan Lu, Chao-Yuan Huang, Yeong-Shiau Pu, Taipei, Taiwan

MP52-17 CARDIOVASCULAR EVENTS AND BIOMARKERS IN A RANDOMIZED TRIAL COMPARING LHRH AGONIST AND ANTAGONIST AMONG PATIENTS WITH ADVANCED PROSTATE CANCER
David Margel*, Petach Tikva, Israel, Avivit Pe'er, Haifa, Israel, Yaara Ber, Petach Tikva, Israel, Marina Shaparberg, Haifa, Israel, Sivan Sela, Rachel Ozalvo, Tzili Tabachnik, Petach Tikva, Israel, Wilhelmmina Duivenvoorden, Jehonathan Pnithus, Hamilton, Canada, Jack Baniel, Petach Tikva, Israel

MP52-18 PRETREATMENT TESTOSTERONE LEVEL IS THE PREDICTIVE FACTOR ASSOCIATED WITH METABOLIC SYNDROME IN PATIENTS OF PROSTATE CANCER AFTER ANDROGEN DEPRIVATION THERAPY
Sung Jin Kim*, Chang Hoo Park, Han Kwon Kim, Jong Yeon Park, Gangneung-si, Korea, Republic of
MP52-19 IMPACT OF ENZALUTAMIDE ON PAIN AND HEALTH-RELATED QUALITY OF LIFE IN MEN WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: PROSPER STUDY RESULTS
Fred Saad*, Montreal, Canada, David Penson, Nashville, TN, Gerhardt Attard, Surrey, United Kingdom, Maha Hussain, Chicago, IL, Cora Sternberg, Rome, Italy, Shevani Naidoo, Chertsey, United Kingdom, Katharina Modelka, Eren Demirhan, San Francisco, CA, Krishnan Ramaswamy, New York, NY, Konstantina Skalktsa, Barcelona, Spain, Bertrand Tombal, Brussels, Belgium

MP52-20 PATIENT REPORTED OUTCOMES (PROS) IN SPARTAN, A PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY OF APALUTAMIDE (APA) PLUS ANDROGEN DEPRIVATION THERAPY (ADT) VS PLACEBO PLUS ADT IN MEN WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC)
Eric J. Small*, San Francisco, CA, Fred Saad, Montreal, Canada, Boris A. Hadaschik, Essen, Germany, Julie N. Graff, Portland, OR, Paul N. Mainwaring, Brisbane, Australia, Kelly McQuarrie, Horsham, PA, Susan Li, Spring House, PA, Joe Lawson, Raritan, NJ, Angela Lopez-Gillitiz, Los Angeles, CA, Matthew R. Smith, Boston, MA

Sunday, May 20, 2018
Moderated Poster Session 53
PROSTATE CANCER: STAGING I
Room 3005 @ MCC West
Moderators: Samir Taneja, Kirsten Greene and Declan Murphy

ABSTRACT NUMBER TITLE
MP53-01 CONTEMPORARY NATIONAL TRENDS IN LOCALIZED PROSTATE CANCER RISK PROFILE AT DIAGNOSIS
Sean A. Fletcher*, Boston, MA, Nicolas von Landenberg, Herne, Germany, Alexander P. Cole, Sebastian Berg, Boston, MA, Philipp Gild, Hamburg, Germany, Joachim Noldus, Herne, Germany, Mani Menon, Detroit, MI, Quoc-Dien Trinh, Adam S. Kibel, Boston, MA

MP53-02 EVALUATION OF GALLIUM-68 PSMA PET/CT IMAGING IN INDIVIDUALS WITH BIOCHEMICAL RECURRENCE FOLLOWING RADICAL PROSTATECTOMY
Chris Rothe, Yuigi Yuminaga*, Jonathan Kam, Kieran Beattie, Mohan Ariayagam, Bertram Canagasingham, Richard Ferguson, Mohamed Khadra, Raymond Ko, Ken Le, Sunny Nalavenkata, Celi Varol, Matthew Winter, Kingswood, Australia

MP53-03 PERFORMANCE OF QUANTITATIVE GLEASON GRADING: A HEAD TO HEAD COMPARISON WITH CAPRA SCORE AND D’AMICO GROUPS
Raisa Pompe*, Kyoko Winter, Guido Sauter, Laurenz Brandl, Markus Graefen, Derya Tilki, Thorsten Schloem, Hamburg, Germany

MP53-04 EFFECT OF TUMOR VOLUME AND PRESENCE OF GLEASON PATTERN 3 IN PROSTATE CANCER PATIENTS WITH GLEASON SCORE 8 ON PROSTATE NEEDLE BIOPSY
Kevin Ginsburg*, Michael Silverman, Joan Livingstone, Daryn Smith, Lance Heilbrun, Michael Cher, Detroit, MI

MP53-05 PELVIC LYMPH NODE METASTASES IN PROSTATE CANCER: PREOPERATIVE DETECTION WITH DYNAMIC CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING COMPARED WITH POSTOPERATIVE PATHOLOGIC RESULT OF PELVIC LYMPH NODE DISSECTION
Jinho Hwang*, Jung Jun Kim, Young Joo Lee, Hakmin Lee, Jong Jin Oh, Sung Kyu Hong, Sang Eun Lee, Seok-soo Byun, Sangchul Lee, Seoul, Korea, Republic of

MP53-06 PREVALENCE AND PATHOLOGICAL CHARACTERISTICS OF ANTERIOR PROSTATE CANCER IN A COHORT OF RADICAL PROSTATECTOMY PATIENTS DIAGNOSED BY BIOPSIES AND MRI
Gautier Marcq*, Claire Pincon, Jórdem Rizk, Jean-Christophe Fantoni, Sébastien Aubert, Xavier Leroy, Arnaud Villers, Lille, France

MP53-07 PREDICTORS OF IPSILATERAL EXTRAPROSTATIC EXTENSION ON RADICAL PROSTATECTOMY USING 3-TELSA MULTIPARAMETRIC MRI AND CONTEMPORARY PATHOLOGIC FEATURES
Diane Lu*, Matthew Truong, Eric Weinberg, Gary Hollenberg, Edward Messing, Bokai Wang, Changyong Feng, Hiroshi Miyamoto, Jean Joseph, Rochester, NY

MP53-08 USE OF PROSTATE MAGNETIC RESONANCE IMAGING AMONG MEDICARE BENEFICIARIES WITH LOW-RISK PROSTATE CANCER IS ASSOCIATED WITH A HIGHER LIKELIHOOD OF DEFINITIVE TREATMENT
Michael Leapman*, Rong Wang, Henry Park, James Yu, Cary Gross, Xiaomei Ma, New Haven, CT

*Presenting author
MP53-09 NEW ALGORITHM APHIGT FOR PROSTATE CANCER STAGING
Boris Alekseev*, Tatiana Skachkova, Natalia Sergeeva, Sergey Pirogov, Valentin Gitis, Evgeny Yurkov, Andrei Kaprin, Moscow, Russian Federation

MP53-10 ASSOCIATION OF SYSTEMATIC BIOPSY VS. MAGNETIC RESONANCE IMAGING/ULTRASOUND FUSION TARGETED BIOPSY WITH PROSTATE CANCER UPSTAGING AT RADICAL PROSTATECTOMY
Kamyar Ghabili Amirkhiz*, Alfredo Suarez-Sarmiento, Kevin A. Nguyen, Walter Hsiang, Sarah Amalraj, Jamil S. Syed, Michael S. Leapman, Peter G. Schulam, Preston C. Sprenkle, New Haven, CT

MP53-11 THE DECIPHER PROSTATE CANCER CLASSIFIER CORRELATES WITH CAPRA-S IN A HIGH RISK GROUP OF AFRICAN AMERICAN AND CAUCASIAN PATIENTS

MP53-12 MODERN MULTI-PARAMETRIC PROSTATE MRI (MPMRI) INDEPENDENTLY PREDICTS PATHOLOGY T3 DISEASE AT THE TIME OF RADICAL PROSTATECTOMY

MP53-13 IS THE CANCER OF THE PROSTATE RISK ASSESSMENT SCORE A VALID TOOL TO PREDICT BIOCHEMICAL RECURRENCE, METASTASIS AND DEATH AFTER RADICAL PROSTATECTOMY IN LATIN AMERICAN PATIENTS?
Rubén Bengió*, Leandro Arribillaga, Hernán García Onto, Javier Epelde, Esteban Cordero, Verónica Bengió, Ruben. H. Bengió, Córdoba, Argentina

MP53-14 EVALUATION OF GALLIUM-68 PSMA PET/CT FOR POST-PROSTATECTOMY BIOCHEMICAL RECURRENCE IN COMPARISON TO CT ABDOMEN/PELVIS AND BONE SCAN
Yuji Yuminaga*, Chris Rothe, Jonathan Kam, Kieran Beattie, Mohan Arianyagam, Bertram Canagasigham, Richard Ferguson, Mohamed Khadr, Raymond Ko, Ken Le, Sunny Nalvenkata, Cell Varol, Matthew Winter, Kingswood, Australia

MP53-15 LOCAL STAGING WITH MULTI-PARAMETRIC MRI PRIOR TO RADICAL PROSTATECTOMY: DIAGNOSTIC ACCURACY AND EVALUATION OF A RADIOLOGIC LEARNING CURVE IN A MULTICENTER, REAL-LIFE CLINICAL SETTING
Bernard Jansen*, Frederik Oudshoorn, Aline Tijans, Amsterdam, Netherlands, Marit Yska, Rotterdam, Netherlands, Anne Lont, Amersfoort, Netherlands, Eelco Collette, Rotterdam, Netherlands, Jakko Nieuwenhuijzen, André Vis, Amsterdam, Netherlands

Armando Stabile*, Paolo Dell’Oglio, Francesco De Cobelli, Antonio Esposito, Giorgio Gandaglia, Nicola Fossati, Giorgio Brembilla, Giulia Cristel, Gianpiero Cardone, Federico Dehò, Andrea Losa, Nazareno Suardi, Tommaso Maga, Franco Gaboardi, Alessandro Del Maschio, Milan, Italy, Shahrokh F. Shariat, Vienna, Austria, Francesco Montorsi, Alberto Briganti, Milan, Italy

MP53-17 WHERE DO WE MISS EXTRACAPSULAR EXTENSION AT MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING OF THE PROSTATE?
Giorgio Gandaglia*, Simone Scuderi, Nicola Fossati, Giorgio Brembilla, Paolo Dell’Oglio, Milan, Italy, Firas Abdollah, Detroit, MI, Massimo Freschi, Luca Grillo, Roberta Lucianò, Marco Bandini, Alessandro Ninì, Milan, Italy, Rodolfo Montironi, Ancona, Italy, Vincenzo Mirone, Naples, Italy, Franco Gaboardi, Esposito Antonio, Francesco De Cobelli, Francesco Montorsi, Alberto Briganti, Milan, Italy

MP53-18 PROPOSAL OF A NOVEL RISK SCORE TO IDENTIFY BIOPSY NAÏVE MEN WITH ELEVATED PSA WHO SHOULD BE CONSIDERED FOR A MULTI-PARAMETRIC MRI
Gandaglia Giorgio*, Nicola Fossati, Antonio Esposito, Giorgio Brembilla, Giulia Cristel, Paolo Dell’Oglio, Alessandro Ninì, Manuela Tutolo, Andrea Gallina, Simone Scuderi, Milan, Italy, Vito Cucchiara, Naples, Italy, Rodolfo Montironi, Ancona, Italy, Francesco De Cobelli, Francesco Montorsi, Alberto Briganti, Milan, Italy
MP53-19 PROSTATE CANCER UPGRADING AND UPSTAGING IN A MULTICENTER PROSTATE CANCER REGISTRY
Maha Husainat*, Mohamed Abdelhady, Detroit, MI, Susan Linsell, Ji Qi, Ann Arbor, MI, Mazen Abdelhady, Detroit, MI, Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI

MP53-20 MULTI-INSTITUTIONAL EXTERNAL VALIDATION OF THE EAU GUIDELINES RECOMMENDATIONS FOR THE USE OF STAGING MPMRI PRIOR TO RADICAL PROSTATECTOMY IN MEN WITH INTERMEDIATE AND HIGH-RISK PROSTATE CANCER

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 20, 2018
7:00 am - 9:00 am
Moderated Poster Session 54
BLADDER CANCER: BASIC RESEARCH & PATHOPHYSIOLOGY I
Room 2005 @ MCC West
Moderators: Vinata Lokeshwar, Jay Shah and Leonardo Reis

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP54-01</td>
<td>TRANSCRIPTION FACTOR ACTIVATOR PROTEIN 2 FAMILY MEMBERS ARE MARKERS OF THE BASAL MOLECULAR SUBTYPE OF HUMAN BLADDER CANCER AND REPRRESSED BY LUMINAL TRANSCRIPTIONAL MASTER REGULATORS</td>
</tr>
<tr>
<td>Lauren Shuman*, Hironobu Yamashita, Zongyu Zheng, Truc Tran, Vasty Osei-Amponsa, Joshua Warrick, Matthew Kaag, Jay Raman, Hershey, PA, Trevor Williams, Aurora, CO, David DeGraff, Hershey, PA</td>
<td></td>
</tr>
<tr>
<td>MP54-02</td>
<td>DEVELOPMENT OF INTRAVESICAL HUMAN H9003/H9004 T CELL BASED CHEMO-IMMUNOTHERAPY AGAINST URINARY BLADDER CANCER CELLS IN AN ORTHOTOPIC XENOGRAFT MODEL</td>
</tr>
<tr>
<td>Teruki Shimizu*, Mako Tomogane, Masatsugu Miyashita, Osamu Ukiuma, Eishi Ashihara, Kyoto, Japan</td>
<td></td>
</tr>
<tr>
<td>MP54-03</td>
<td>LENTIVIRAL INTERFERON: A NOVEL METHOD FOR GENE THERAPY IN BLADDER CANCER</td>
</tr>
<tr>
<td>Jonathan Duplisea*, Sharada Mokkapati, Michael Metcalfe, Ken Dunner, Bogdan Czerniak, Houston, TX, Tiina Nieminen, Tommi Heikura, Seppo Yla-Herttuala, Kuopio, Finland, Nigel Parker, London, United Kingdom, David McConkey, Bethesda, MD, Colin Dinney, Houston, TX</td>
<td></td>
</tr>
<tr>
<td>MP54-04</td>
<td>NEXT GENERATION SEQUENCING OF UROTHELIAL BLADDER CANCER: MEMORIAL SLOAN KETTERING CANCER CENTER EXPERIENCE IN 454 PATIENTS</td>
</tr>
<tr>
<td>Sumit Isharwal*, Francois Audenet, Esther Drill, Irina Ostrovmarya, Eugenie Pietzak, Hikmat Al-Ahmadi, Eugene Cha, Timothy Donahue, Min Yuen Teo, Samuel Funt, Maria Arcila, Michael Berger, Jonathan Rosenberg, Dean Bajorin, Guido Dalbagni, Bernard Bochner, David Solt, Gopa Iyer, New York, NY</td>
<td></td>
</tr>
<tr>
<td>MP54-05</td>
<td>PLASTICITY IN THE BIOLOGICAL RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN MUSCLE-INVASIVE BLADDER CANCER</td>
</tr>
<tr>
<td>Roland Seiler*, Bern, Switzerland, Ewan A. Gibb, Natalie Q. Wang, Htoo Zarni Oo, Vancouver, Canada, Hung-Ming Lam, Seattle, WA, Mandepi Takhar, Nicholas Erho, Vancouver, Canada, Kim E. van Kessel, Rotterdam, Netherlands, Brian Winters, Seattle, WA, James Douglas, Hampshire, United Kingdom, Funda Yakar Lopez, Seattle, WA, Simon J. Crabb, Hampshire, United Kingdom, Bas W.G. van Rhijn, Elisabeth E. Franzen van de Putte, Amsterdam, Netherlands, Ellen C. Zwarthoff, Rotterdam, Netherlands, George N. Thalmann, Bern, Switzerland, Elia Davicioni, Vancouver, Canada, Joost L. Boormans, Rotterdam, Netherlands, Marc Dall’Era, Sacramento, CA, Michel S. van der Heijden, Amsterdam, Netherlands, Jonathan L. Wright, Seattle, WA, Peter C. Black, Vancouver, Canada</td>
<td></td>
</tr>
</tbody>
</table>

*Presenting author
MP54-06 THREE-DIMENSIONAL ORGANOID CULTURE REVEALS INVOLVEMENT OF WNT/β-CATENIN PATHWAY IN PROLIFERATION OF BLADDER CANCER CELLS
Takahiro Yoshida*, Nikolai Sopko, Max Kates, Xiaopu Liu, Gregory Joice, David McConkey, Trinity Bivalacqua, Baltimore, MD

MP54-07 HEPATOCYTE GROWTH FACTOR RECEPTOR-C/MET IS ASSOCIATED WITH MALIGNANT AGGRESSIVENESS VIA REGULATION OF CYCLOOXYGENASE-2, HEMEOXYGENASE-1, AND PROGRAMMED DEATH LIGAND 1 IN PATIENTS WITH BLADDER CANCER
Yuichiro Nakamura*, Yasuyoshi Miyata, Kyoei Araki, Takuji Yasuda, Tomohiro Matsuo, Kojiro Ohba, Bungo Furusato, Junya Fukuoka, Hideki Sakai, Nagasaki, Japan

MP54-08 PROSTAGLANDIN RECEPTORS INDUCE UROTHELIAL TUMOURIGENESIS AS WELL AS BLADDER CANCER PROGRESSION AND CISPLATIN RESISTANCE PRESUMABLY VIA MODULATING PTEN EXPRESSION
Eiji Kashiwagi*, Fukuoka, Japan, Satoshi Inoue, Taichi Mizushima, Jinbo Chen, Hiroki Ide, Takashi Kawahara, Leonardo Reis, Alexander Baras, George Netto, Hiroshi Miyamoto, Baltimore, MD

MP54-09 TM4SF1 IS A NOVEL BIOMARKER FOR HUMAN MUSCLE INVASIVE BLADDER CANCER (MIBC)
Rui Cao*, Gang Wang, Kaiyu Qian, Liang Chen, Yu Xiao, Xinghuan Wang, Wuhan, China, People’s Republic of

4-10 M2 MUSCARINIC RECEPTORS INHIBIT CELL PROLIFERATION AND MIGRATION IN UROTHELIAL BLADDER CANCER CELLS
Giovanni Palleschi*, Antonio Luigi Pastore, Vincenzo Petrozza, Antonella Calogero, Elena De Falco, Antonio Carbone, Latina, Italy

MP54-11 IDENTIFICATION AND REPLICATION OF THE INTERPLAY OF FOUR GENETIC HIGH-RISK VARIANTS FOR URINARY BLADDER CANCER
Silvia Selinski, Meinolf Blaszkewicz, Katja Ickstadt, Dortmund, Germany, Holger Gerullis, Oldenburg, Germany, Thomas Otto, Neuss, Germany, Emanuel Roth, Frank Volkert, Lutherstadt Wittenberg, Germany, Daniel Ovsianikov, Koblenz, Germany, Thomas Beckwitz*, Oliver Moormann, Dortmund, Germany, Gergely Banfi, Peter Nyirady, Budapest, Hungary, Sita Vermeulen, Nijmegen, Netherlands, Montserrat Garcia-Closas, Bethesda, MD, Jonine Figueroa, Edinburgh, United Kingdom, Alison Johnson, Burlington, VT, Margaret Karagas, Hanover, NH, Manolis Kogevinas, Barcelona, Spain, Nuria Malats, Madrid, Spain, Molly Schwenn, Augusta, ME, Debra Silverman, Stella Koutros, Nathaniel Rothman, Bethesda, MD, Lambertus Kiemeney, Nijmegen, Netherlands, Jan Hengstler, Klaus Golka, Dortmund, Germany

MP54-12 MOLECULAR CHARACTERIZATION OF N-METHYL-N-NITROSOUREA-INDUCED BLADDER UROTHELIAL TUMOR IN RATS
Takahiro Yoshida*, Alexander Baras, Max Kates, Nikolai Sopko, Xiaopu Liu, Gregory Joice, David McConkey, Trinity Bivalacqua, Baltimore, MD

MP54-13 BLUE LIGHT IN COMBINATION WITH HAEMINOLEVULINATE (CYSVIEW®) LEADS TO BLADDER CANCER CELL DEATH IN AN IN VITRO MODEL
Justin T. Matulay*, Alanna B. Williams, Mark V. Silva, James M. McKiernan, Michael M. Shen, New York, NY

MP54-14 CHARACTERIZATION OF HUMAN BLADDER CANCER PATIENT-DERIVED XENOGRAFT IN VIVO AND IN ORGANOIDS
Hung-Ming Lam*, Yuzhen Liu, Funda Vakar-Lopez, Lisha Brown, Bruce Montgomery, Eva Corey, Andrew Hsieh, Jonathan Wright, Seattle, WA

MP54-15 UROTHELIAL BLADDER CANCER CELLS AFFECT TUMOR-PROMOTING PROCESSES IN NORMAL BLADDER FIBROBLASTS AND SUPPORT TUMORIGENESIS BY SECRETION OF TUMOR-ASSOCIATED EXOSOMES
Sophie Baumgart, Joana Heinzelmann, Elmar Krause, Homburg, Germany, Marie Stample-Ostenfeld, Aarhus, Denmark, Michael Stöckle, Kerstin Junker*, Homburg, Germany

MP54-16 URINARY EXOSOMAL AND CELL-FREE DNA DETECTS SOMATIC MUTATION AND COPY NUMBER ALTERATION IN UROTHELIAL CARCINOMA OF BLADDER
Kwang Hyun Kim*, Bong Suk Sim, Dong Hyeon Lee, Seoul, Korea, Republic of
MP54-17 GLUCOCORTICOID RECEPTOR AND FOXO1 EXPRESSION IN BLADDER CANCER AS AN INDEPENDENT PROGNOSTICATOR
Hiroki Ide*, Baltimore, MD, Satoshi Inoue, Taichi Mizushima, Rochester, NY, George Netto, Birmingham, AL, Hiroshi Miyamoto, Rochester, NY

MP54-18 QUANTITATIVE AND QUALITATIVE MULTIMODAL OPTICAL ANALYSIS TO DISCRIMINATE UROTHELIAL CARCINOMA GRADES
Benjamin Pradere*, Tours, France, Fanny Poulon, Steeve Doizi, Olivier Cussenot, Eva Compérat, Darine Abi Haidar, Olivier Traxer, Paris, France

MP54-19 DNA METHYLATION INHIBITORS COULD RE-SENSITIZE DRUG-RESISTANCE BLADDER CANCER CELLS IN VITRO AND IN VIVO
Naotaka Nishiyama*, Nobuo Shinkai, Sapporo, Japan, Stephanie Yi, Christopher E. Duymich, Los Angeles, CA, Tetsuya Shindo, Sapporo, Japan, Peter A Jones, Grand Rapids, MI, Hiromu Suzuki, Naoya Masumori, Sapporo, Japan, Gangning Liang, Los Angeles, CA

MP54-20 RASAL2 INHIBITS TUMOR ANGIogenesis VIA P-AKT/ETS1 SIGNALING IN BLADDER CANCER
Kaijie Wu*, Ke Hui, Shiqi Wu, Yangyang Yue, Dalin He, Xi'an, China, People's Republic of

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 20, 2018 7:00 am - 9:00 am
Podium Session 35
STONE DISEASE: SURGICAL THERAPY I
Room 2024 @ MCC West
Moderators: Michael Lipkin, David Duchene and Ali Kural

ABSTRACT
TIME NUMBER TITLE
7:00 PD35-01 SUPER-MINI PERCUTANEOUS NEPHROLITHOTOMY (SMP) VERSUS RETROGRADE INTRARENAL SURGERY FOR THE TREATMENT OF 1-2 CM LOWER POLE RENAL CALCULI: A MULTICENTER RANDOMIZED CONTROLLED TRIAL
Guohua Zeng*, Tao Zhang, Junhong Fan, Guangzhou, China, People's Republic of, Wei Zhang, Nanjing, China, People's Republic of, Sixing Yang, Wuhan, China, People's Republic of, Kefeng Xiao, Shenzhen, China, People's Republic of, Xuedong Li, Harbin, China, People's Republic of, Hulin Li, Guangzhou, China, People's Republic of, Xiang He, Zhejiang, China, People's Republic of, Changbao Xu, Zhengzhou, China, People's Republic of, Kemal Sarica, Ankara, Turkey, Madhu Agrawal, New Delhi, India

7:10 PD35-02 RISK FACTORS FOR BLOOD TRANSFUSION FOLLOWING PERCUTANEOUS NEPHROLITHOTOMY IN THE UK
Adam B. Althaus*, Cambridge, United Kingdom, John Withington, London, United Kingdom, Will Finch, Norwich, United Kingdom, Daron Smith, London, United Kingdom, Ben Turney, Oxford, United Kingdom, Sarah Fowler, London, United Kingdom, Jim Armitage, Cambridge, United Kingdom, Stuart Irving, Norwich, United Kingdom, Neil Burgess, Norwich, United Kingdom, Oliver J. Wiseman, Cambridge, United Kingdom

7:20 PD35-03 QSOFa (QUick Sequential ORGAN FAILURE ASSESSMENT SCORE) and SOFA scores are valuable tools to predict Postoperative SEPSis resulting from ureteroscopic lithotripsy (URSL)
Chun-Yo Laih*, Po-Jen Hsiao, Yu-De Wang, Sheng wei Lee, Chi-Ping Huang, Wei-Chin Chen, Chi-Rei Yang, Hsi-Chin Wu, Chao-Hsiang Chang, Taichung, Taiwan, Chun-Ming Lai, Davis, CA

7:30 PD35-04 DANGEROus TEMPERATURES CAN BE GENERATED DURING URETEROSCOPIC HOLMIUM LASER LITHOTRIPSY, AN IN VITRO ASSESSMENT
Daniel Wollin, Evan Carlos*, Brenton Winship, Westin Tom, W. Neal Simmons, Glenn Preminger, Michael Lipkin, Durham, NC

7:40 PD35-05 THE USE OF OPIOIDS FOR STONES AND URETERAL STENTS: INSIGHTS FROM AN EDGE CONSORTIUM PATIENT SURVEY
Annah Vollstedt*, Lebanon, NH, Rajiv Raghavan, Hanover, NH, Manoj Monga, Anna Zampini, Cleveland, OH, Amy Krambeck, Indianapolis, IN, Ojas Shah, New York, NY, Roger Sur, San Diego, CA, Ben Chew, Vancouver, Canada, Brian Eisner, Boston, MA, Stephanie Thompson, New York, NY, Tammer Yarmyany, Boston, MA, Vernon Pais, Lebanon, NH

*Presenting author
7:50 PD35-06 RANDOMIZED CONTROLLED TRIAL COMPARING PRETREATMENT WITH TOLTERODINE VS PLACEBO FOR THE ALLEVIATION OF URETERAL STENT SYMPTOMS: INTERIM ANALYSIS
John Roger Bell*, Lexington, KY, Kristina L. Penniston, Sara L. Best, Shuang Li, Viacheslav Iremashvili, Stephen Y. Nakada, Madison, WI

8:00 PD35-07 CHRONIC INWDELLING URETERAL STENTS: DOES STENT LENGTH OR STIFFNESS AFFECT ENCRLUSTATION?

8:10 PD35-08 DOUBLE LOOP URETERAL STENTS ENCRLUSTATION ACCORDING TO INWDELLING TIME: RESULTS OF A EUROPEAN MULTICENTRIC STUDY
Francois Legrand*, Sauzeau Thibaud, Brussels, Belgium, Antonio Celia, Modena, Italy, Farid Djouhri, Lyon, France, Genarro Musi, Milan, Italy, Antoine Ruffion, Lyon, France, Thierry Roumeguere, Brussels, Belgium

8:20 PD35-09 ENDOSCOPIC CLEARANCE LITHOTRIPSY DEVICES: COMPARISON OF STONE ELIMINATION CAPACITY AND DRILLING SPEED
Markus Bader*, Thomas Pongratz, Maximilian Eisel, Ronald Sroka, Christian Stief, Frank Strittmatter, Munich, Germany

8:30 PD35-10 RENAL TRACT DILATION IS A SIGNIFICANT SOURCE OF RADIATION EXPOSURE DURING PERCUTANEOUS NEPHROLITHOTOMY: RESULTS FROM THE REGISTRY FOR STONES OF THE KIDNEY AND URETER (RESKU)

8:40 PD35-11 RISK AND PROTECTIVE FACTORS FOR RECURRENT URINARY TRACT INFECTION FOLLOWING PERCUTANEOUS NEPHROLITHOTOMY
Chin-Fong AU*, Chung-You Tsai, Shiu-Dong Chung, New Taipei City, Taiwan

8:50 PD35-12 RETROGRADE INTRARENAL SURGERY - SINGLE HAND (RIRS-SH) BY NEW AFFIX URETEROSCOPY FOR MEDIUM SIZE (1.5 TO 2 CM) RENAL STONE: PRELIMINARY RESULTS FROM A SINGLE CENTRE STAGE 2A STUDY
Alberto Saita*, Massimo Lazzeri, Nicolo Maria Buffi, Paolo Casale, Rodolfo Hurle, Roberto Peschechera, Giovanni Luhezzani, Alessio Benetti, Luisa Pasini, Silvia Zandiegiamo, Giuliana Lista, Pasquale Cardone, Giorgio Guazzoni, Milan, Italy

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 20, 2018 7:00 am - 9:00 am
Podium Session 36

URODYNAMICS/LOWER URINARY TRACT DYSFUNCTION/FEMALE PELVIC MEDICINE: NEUROGENIC VOIDING DYSFUNCTION II
Room 2022 @ MCC West
Moderators: E. Ann Gormley, Brian Flynn and Linda Ng

<table>
<thead>
<tr>
<th>ABSTRACT TIME</th>
<th>ABSTRACT NUMBER</th>
<th>ABSTRACT TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00</td>
<td>PD36-01</td>
<td>THE 5-HT7 RECEPTOR IS UP-REGULATED IN ONUF’S NUCLEUS</td>
</tr>
<tr>
<td></td>
<td>Jianshu Ni*, Baojun Gu, NaiLong Cao, Xiaohu Wang, Shanghai, China, People’s Republic of China</td>
<td></td>
</tr>
<tr>
<td>7:10</td>
<td>PD36-02</td>
<td>VOLITIONAL VOIDING OF THE BLADDER AFTER SPINAL CORD INJURY: VALIDATION OF BILATERAL LOWER EXTREMITY MOTOR FUNCTION AS A KEY PREDICTOR</td>
</tr>
<tr>
<td></td>
<td>Christopher Elliott*, San Jose, CA, Kai Dallas, Dimitar Zlatev, Craig Comiter, Stanford, CA, James Crew, Kazuko Shem, San Jose, CA</td>
<td></td>
</tr>
<tr>
<td>7:20</td>
<td>PD36-03</td>
<td>EARLY FESOTERODINE FUMARATE ADMINISTRATION PREVENTS THE ONSET OF NEUROGENIC DETRUSOR OVERACTIVITY AFTER SPINALIZATION IN RATS</td>
</tr>
<tr>
<td></td>
<td>Mikolaj Przydzacz, George Loutochn, Philippe Cammisotto, Montreal, Canada, Grub, Zimoch, Zurich, Switzerland, Naciba Benlimame, Lysanne Campeau, Jacques Corcos*, Montreal, Canada</td>
<td></td>
</tr>
<tr>
<td>7:30</td>
<td>PD36-04</td>
<td>VEGF-INDUCED BLADDER NERVE REMODELING AND VISCERAL HYPERALGESIA IN BLADDER PAIN</td>
</tr>
<tr>
<td></td>
<td>Alison Xiaoqiao Xie*, BaiLachandar, Nedumaran, Randall Meacham, Anna Malykhina, Aurora, CO</td>
<td></td>
</tr>
<tr>
<td>7:40</td>
<td>PD36-05</td>
<td>PELVIC FLOOR MUSCLE EXERCISE-BASED BEHAVIORAL THERAPY IMPROVES URINARY SYMPTOMS IN PARKINSON DISEASE</td>
</tr>
<tr>
<td></td>
<td>Camille Vaughan*, Atlanta, GA, Kathryn Burgio, Patricia Goode, Birmingham, AL, Jorge Juncos, Lisa Muirhead, Atlanta, GA, Gerald McGwin, Birmingham, AL, Theodore Johnson, Atlanta, GA</td>
<td></td>
</tr>
<tr>
<td>7:50</td>
<td>PD36-06</td>
<td>THE EFFICACY OF ONABOTULINUMTOXIN A IN PATIENTS WITH PARKINSON’S DISEASE AND NEUROGENIC DETRUSOR OVERACTIVITY</td>
</tr>
<tr>
<td></td>
<td>Ranjan Ariyanayagam, Lewis Chan*, Vincent Tse, Sydney, Australia</td>
<td></td>
</tr>
</tbody>
</table>
8:00 PD36-07 PREDICTION OF AUTONOMIC DYSREFLEXIA DURING URODYNAMICS
Matthias Walter*, Vancouver, Canada, Stephanie C. Knüpfert, Jacquelyn J. Cragg, Lorenz Leitner, Marc P. Schneider, Ulrich Mehnert, Zürich, Switzerland, Andrei V. Krassioukov, Vancouver, Canada, Martin Schubert, Armin Curt, Thomas M. Kessler, Zürich, Switzerland

8:10 PD36-08 LOW RELIABILITY OF URODYNAMIC DIAGNOSIS OF DETRUSOR SPHINCTER DYSSYNERGIA
Brandi Miller*, Chris Tallman, Michael Randazzo, Timothy Boone, Rose Khavari, Houston, TX

8:20 PD36-09 HIGH RATES OF ADMISSION AMONG ADULT NEUROGENIC BLADDER PATIENTS PRESENTING TO THE EMERGENCY ROOM
Oluwarotimi Nettey*, Alicia Roston, Emily Yura, Amanda Vo, Stephanie Kleib, Chicago, IL

8:30 PD36-10 LONG TERM FOLLOW-UP REVEALS A LOW PERSISTENCE RATE OF ABOBOTULINUM TOXIN A AND ONABOTULINUM TOXIN A INJECTIONS FOR NEUROGENIC DETRUSOR OVERACTIVITY
Maximilien Baron*, Rouen, France, Benoit Peyronnet, Rennes, France, Annabelle Auble, Gabriel Miget, Rouen, France, Juliette Hascoc, Andrea Manunta, Rennes, France, Jean-Nicolas Cornu, Rouen, France, Xavier Game, Toulouse, France

8:40 PD36-11 INCONTINENT ILEOVESICOSTOMY FOR NEUROGENIC BLADDER DYSFUNCTION: LONG TERM CLINICAL AND URODYNAMIC PATIENT OUTCOMES
Mihir Shah*, Ali Syed, Alana Murphy, Akhil Das, Patrick Shenot, Philadelphia, PA

8:50 PD36-12 PERMANENT CUTANEOUS VESICOSTOMY URINARY DIVERSION IN TRANSITIONAL UROLOGY PATIENTS
Andrew Margules*, Whitney Smith, Lawrence Lee, Alana Murphy, Akhil Das, Patrick Shenot, Philadelphia, PA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
PD37-05 HISTOLOGIC VALIDATION OF 11CARBON-ACETATE POSITRON EMISSION TOMOGRAPHY/COMPUTER TOMOGRAPHY IN DETECTING LYMPH NODE METASTASES IN PROSTATE CANCER
Nieroshan Rajarubendra*, Zarko Manojlovic, Chisato Ohe, Nariman Ahmadi, Giovanni Cacciarmani, Michael Qiu, Andre Abreu, Jie Ca, Gus Miranda, John Carpten, Manju Aron, Los Angeles, CA, Fabio Almeida, Phoenix, AZ, Indirerib S. Gill, Los Angeles, CA

PD37-06 PROSPECTIVE VALIDATION OF PRIMUS™, THE PROSTATE RISK IDENTIFICATION USING MICRO-ULTRASOUND PROTOCOL FOR REAL-TIME DETECTION OF PROSTATE CANCER USING HIGH-RESOLUTION MICRO-ULTRASOUND IMAGING
M. Eric Hyndman*, Calgary, Canada, Christian P. Pavlovich, Baltimore, MD, Gregg Eure, Virginia Beach, VA, Vincent Fradet, Quebec, Canada, Sangeet Ghai, Toronto, Canada

PD37-07 CONTRAST ENHANCED ULTRASOUND FOR DETECTION OF RENAL CELL CARCINOMA RECURRENT FOLLOWING ABLATION
Brian Calio*, John Eisenbrey, Jingzhi Li, Andrej Lyshchik, Maria Stanczak, Collette Shaw, Robert Adamo, Ji-Bin Liu, Flemming Forsberg, Costas Lallas, Edouard Trabulsi, Philadelphia, PA

PD37-08 IDENTIFICATION OF RANDALL’S PLAQUES COMPARED TO BELLINI DUCT PLUGGING ON COMPUTED TOMOGRAPHY USING THE VALIDATED PPLA RENAL PAPILLARY GRADING SYSTEM
Blake B. Anderson*, Joshua M. Heiman, Tim Large, James C. Williams, Jr., Amy E. Krambeck, James E. Lingeman, Indianapolis, IN

PD37-09 KIDNEY STONE CONTRAST WITH COLOR-DOPPLER TWINKLING ARTIFACT AS A FUNCTION OF MECHANICAL INDEX
Bryan Cunitz, Jessica Dai*, Matthew Sorenson, Robert Sweet, Barbrina Dunmire, Jeffrey Thiel, Matthew Bruce, Michael Bailey, Seattle, WA, Ziyue Liu, Indianapolis, IN, Jonathan Harper, Seattle, WA

PD37-10 RADIATION EXPOSURE FROM CT SCANS FOR UROLITHIASIS: RESULTS FROM THE REGISTRY FOR STONES OF THE KIDNEY AND URETER (RESKU)

PD37-11 EFFECTIVE ULTRA LOW DOSE CT PROTOCOL WITH LOWER RADIATION DOSE THAN ABDOMINAL X-RAY
Kymora Scotland*, Jean Buckley, James Nugent, Savvas Nicolaou, Charles Zwirewich, Patrick McLaughlin, Ben Chew, Vancouver, Canada

PD37-12 PERINEAL ULTRASOUND ASSESSMENT OF PELVIC FLOOR FUNCTION: A NOVEL METHOD OF FUNCTIONAL IMAGING OF THE PELVIC FLOOR PRIOR TO RADICAL PROSTATECTOMY
Danielle Van Diepen*, Lewis Chan, Ruban Thanigasalam, Andre Lalak, Scott Leslie, Paul Sved, Vincent Tse, Sydney, Australia

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00</td>
<td>PD38-01</td>
<td>WHICH PATIENTS WITH LOW-RISK PROSTATE CANCER ARE STILL RECEIVING RADICAL PROSTATECTOMY? IMPACT OF PATIENT SELECTION ON INVERSE STAGE MIGRATION AT TWO TERTIARY REFERRAL CENTERS Emanuele Zaffuto*, Nicola Fossati, Giorgio Gandaglia, Elio Mazzone, Francesco Cianflone, Paolo Dell’Oglio, Marco Bandini, Armando Stabile, Marco Bianchi, Federico Dehò, Andrea Gallina, Milan, Italy, Rocco Damiano, Catanzaro, Italy, Firas Abdollah, Detroit, MI, Pierre I. Karakiewicz, Montreal, Canada, Felix Preisser, Markus Graefen, Derya Tilki, Hamburg, Germany, Francesco Montorsi, Alberto Briganti, Milan, Italy</td>
</tr>
<tr>
<td>7:10</td>
<td>PD38-02</td>
<td>FOUR-POINT PERITONEAL FLAP FIXATION IN PREVENTING LYMPHOCELE FORMATION FOLLOWING RADICAL PROSTATECTOMY Jens Uwe Stolzenburg, Vinodh Kumar Adithyaa Arthanareeswaran*, Anja Dietel, Toni Franz, Leipzig, Germany, Evangelos Liatiskos, Iason Kyriazis, Patras, Greece, Roman Ganzer, Bad Tölz, Germany, Abinaya Ravichandran Chandra, Hoang Minh Do, Leipzig, Germany</td>
</tr>
<tr>
<td>7:20</td>
<td>PD38-03</td>
<td>AUTOMATED PERFORMANCE METRICS DURING ROBOTIC-ASSISTED RADICAL PROSTATECTOMY CAN DIFFERENTIATE CLINICAL OUTCOME Andrew Hung, Paul Oh*, Jian Chen, Nathan Cheng, Michael Lin-Brande, Micha Titus, Nero Rajarubendra, Inderbir Gill, Los Angeles, CA</td>
</tr>
<tr>
<td>7:30</td>
<td>PD38-04</td>
<td>PATIENTS ADHERING TO STANDARDIZED PROTOCOLS FOR FUNCTIONAL OUTCOME ASSESSMENT AFTER RADICAL PROSTATECTOMY SHOW HIGHER RATES OF RETURN TO PRE-OPERATIVE STATUS: IMPLICATIONS FOR POSSIBLE SELECTION BIASES Manuela Tutolo*, Marco Bianchi, Nicola Fossati, Giorgio Gandaglia, Andrea Salonia, Daniele Robesti, Francesco Barletta, Simone Scuderi, Davide Orengia, Francesco Cianflone, Alessandro Nini, Emanuele Zaffuto, Nazareno Suardi, Francesco Montorsi, Alberto Briganti, Milan, Italy</td>
</tr>
<tr>
<td>7:40</td>
<td>PD38-05</td>
<td>PROSPECTIVE EVALUATION OF EFFECT ON INTRAOCULAR PRESSURE AND VISUAL FUNCTION IN PATIENTS WITHOUT AND WITH OPHTHALMIC DISEASES AFTER ROBOTIC ASSISTED LAPAROSCOPIC PROSTATECTOMY Shigenori Kakutani*, Hiroshi Fukuhara, Fumiyuki Araki, Masaaki Asamoto, Nobuko Ito, Makoto Aihara, Haruki Kume, Tokyo, Japan</td>
</tr>
<tr>
<td>7:50</td>
<td>PD38-06</td>
<td>CONTEMPORARY TRENDS IN UTILIZATION OF RADICAL PROSTATECTOMY Tyler R. McClintock*, Ye Wang, Alexander P. Cole, Boston, MA, Benjamin I. Chung, Stanford, CA, Joachim Noldus, Herne, Germany, Mani Menon, Detroit, MI, Steven L. Chang, Adam S. Kibel, Quoc-Dien Trinh, Boston, MA</td>
</tr>
<tr>
<td>8:00</td>
<td>PD38-07</td>
<td>MULTIPLATFORM METABOLIC REVEALS PREDICTIVE PROSTATE CANCER RECURRENCE PHENOTYPES FOLLOWING RADICAL PROSTATECTOMY Callan Brownfield*, Chaevien Clendinen, Arthur Edison, Rebecca Arnold, Atlanta, GA, Facundo Fernandez, John Petros, Atlanta, GA</td>
</tr>
</tbody>
</table>
A NOVEL TECHNIQUE USING THE ARTICULATING FLEXDEX(TM) LAPAROSCOPIC INSTRUMENT FOR PARTIAL NEPHRECTOMY
Hari Vigneswaran*, Simone Crivellaro, Chicago, IL

RESIDENT TRAINING FOR ROBOTIC RENAL SURGERY WITH A PORCINE MODEL
Niraj Badhiwala*, Kefu Du, Steven Monda, Venkatesh Ramakrishna, Angelia DeClue, Robert Figsenhaus, St. Louis, MO

ROBOTIC-ASSISTED PARTIAL NEPHRECTOMY WITH INTRACORPOREAL HYPOTHERMIA AFTER PAZOPANIB TREATMENT IN A SOLITARY KIDNEY WITH SEGMENTAL VEIN THROMBOSIS
Juan Garisto*, Julien Dagenais, Daniel Sagalovich, Brian Rini, Jihad Kaouk, Cleveland, OH

ROBOTIC NEPHRON-SPARING SURGERY FOR MODERATE AND HIGH COMPLEXITY TUMORS IN SOLITARY KIDNEYS WITH RENAL ARTERY COLD PERFUSION TECHNIQUE
Du Songliang*, Huang Qinbo, Ma Xin, Zhang Xu, Beijing, China, People’s Republic of China

MINIMALLY INVASIVE NEPHRON-SPARING SURGICAL MANAGEMENT OF MULTIFOCAL RENAL MASSES IN THE HEREDITARY KIDNEY CANCER SYNDROME PATIENT
Michael Zell*, Karen Stern, Erik Castle, Phoenix, AZ

LAPAROSCOPIC RADICAL NEPHRECTOMY WITH INFERIOR VENA CAVA THROMBECTOMY
Patricio García-Marchiñena*, Miguel Basualdo, Diego Santillán, Guillermo Gueglio, Alberto Jurado, Caba, Argentina

TIPS AND TRICKS FOR ROBOT-ASSISTED RADICAL NEPHRECTOMY AND LEVEL III INFERIOR VENA CAVA TUMOR THROMBECTOMY

RESIDENT TRAINING FOR ROBOTIC RENAL SURGERY WITH A PORCINE MODEL
Niraj Badhiwala*, Kefu Du, Steven Monda, Venkatesh Ramakrishna, Angelia DeClue, Robert Figsenhaus, St. Louis, MO

ROBOTIC-ASSISTED PARTIAL NEPHRECTOMY WITH INTRACORPOREAL HYPOTHERMIA AFTER PAZOPANIB TREATMENT IN A SOLITARY KIDNEY WITH SEGMENTAL VEIN THROMBOSIS
Juan Garisto*, Julien Dagenais, Daniel Sagalovich, Brian Rini, Jihad Kaouk, Cleveland, OH

ROBOTIC NEPHRON-SPARING SURGERY FOR MODERATE AND HIGH COMPLEXITY TUMORS IN SOLITARY KIDNEYS WITH RENAL ARTERY COLD PERFUSION TECHNIQUE
Du Songliang*, Huang Qinbo, Ma Xin, Zhang Xu, Beijing, China, People’s Republic of China

MINIMALLY INVASIVE NEPHRON-SPARING SURGICAL MANAGEMENT OF MULTIFOCAL RENAL MASSES IN THE HEREDITARY KIDNEY CANCER SYNDROME PATIENT
Michael Zell*, Karen Stern, Erik Castle, Phoenix, AZ

LAPAROSCOPIC RADICAL NEPHRECTOMY WITH INFERIOR VENA CAVA THROMBECTOMY
Patricio García-Marchiñena*, Miguel Basualdo, Diego Santillán, Guillermo Gueglio, Alberto Jurado, Caba, Argentina
Sunday, May 20, 2018

Forums

CHALLENGES FOR UROLOGIC RESEARCH: MOVING BIOMARKERS INTO PRACTICE
Room 208 @ MCC South

7:30 WELCOME AND SYMPOSIUM INTRODUCTION
John Gore

7:35 SESSION I: BIOMARKER DEVELOPMENT
USE OF FIT-FOR-PURPOSE BIOMARKERS IN UROLOGICAL CLINICAL TRIALS
S. Percy Ivy

STRATEGIES TO MOVE BIOMARKERS FROM DISCOVERY TO CLINICS: EXAMPLES FOR PROSTATE CANCER BIOMARKERS
Ziding Feng

REGULATORY PROCESSES FOR BIOMARKERS
Maria Chan

THE PATH(S) OF NOVEL BIOMARKERS: FROM RESEARCH PROJECT TO INSURANCE COVERAGE
Stephen Lyle

NCI EDRN - HOW TO GET INVOLVED
Richard Mazurchuk

CHANGING PROVIDER BEHAVIORS
Steve Asch

9:35 BREAK

9:45 SESSION II: BIOMARKERS IN USE
MOLECULAR BIOMARKERS FOR PROSTATE CANCER DETECTION AND PROGNOSIS: DECISION AIDS OR DECISION MADE?
Daniel Lin

DEBATE: CAN BIOMARKERS DECREASE NEED FOR SURVEILLANCE CYSTOSCOPY?
Debaters: Tracy Downs, Yair Lotan

STATISTICAL CONSIDERATIONS FOR CLINICAL UTILITY OF A BLADDER CANCER BIOMARKER
Shahrokh Shariat

DEBATE: MRI AS BIOMARKER IN PROSTATE CARE
Debater - Pro: M. Minhaj Siddiqui
Debater - Con: Christopher Filson

11:25 CLOSING REMARKS
John Gore

11:30 ADJOURN

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
Sunday, May 20, 2018 9:30 am - 11:30 am

Moderated Poster Session 55
STONE DISEASE: SURGICAL THERAPY II
Room 3004 @ MCC West
Moderators: Jodi Antonelli, Ben Chew and Alex Meller

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>ABSTRACT TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP55-01</td>
<td>STENT CARDS - A SIMPLE SOLUTION FOR FORGOTTEN STENTS? Masood Moghul*, Stefanos Almpanis, London, United Kingdom</td>
</tr>
<tr>
<td>MP55-02</td>
<td>RANDOMIZED TRIAL COMPARING THE SAFETY AND CLARITY OF WATER VERSUS SALINE IRRIGANT IN URETEROSCOPY Farha Pirani*, Atlanta, GA, Salima Makhani, Macon, GA, Frances Kim, Aaron Lay, Cara Cimmino, Lindsey Hartsell, Ashley Spence, Viraj Master, Kenneth Ogan, Atlanta, GA</td>
</tr>
<tr>
<td>MP55-03</td>
<td>URETEROSCOPY SEEMS TO BE CLINICALLY AND FINANCIALLY MORE COST EFFECTIVE THAN SHOCK WAVE LITHOTRIPSY: SYSTEMATIC REVIEW AND META-ANALYSIS OVER LAST 2 DECADES Robert Geraghty, Patrick Jones*, Bhaskar Somani, Southampton, United Kingdom</td>
</tr>
<tr>
<td>MP55-04</td>
<td>GLOBAL MORTALITY OF KIDNEY STONE DISEASE FOLLOWING SURGICAL AND CONSERVATIVE MANAGEMENT IN THE LAST TWO DECADES Lily Whitehurst*, Portsmouth, United Kingdom, Patrick Jones, Bhaskar Somani, Southampton, United Kingdom</td>
</tr>
<tr>
<td>MP55-05</td>
<td>IMPACT OF DOUBLE-J STENT REMOVAL WITH A SINGLE USE CYSTOSCOPE DEDICATED TO THIS PROCEDURE: A COST ANALYSIS Steeve Doiz*, Maria Rodriguez-Monsalve, Vincent De Coninck, Etienne Keller, Emmanuelle Granier, Raphaelle Pesque, Olivier Traxer, Paris, France</td>
</tr>
<tr>
<td>MP55-06</td>
<td>A FLUOROSCOPY-FREE RETROGRADE INTRARENAL SURGERY FOR RENAL STONES Yi-Sheng Tai*, New Taipei City, Taiwan, Shi-Wei Huang, Yunlin, Taiwan, Yuan-Ju Lee, Taipei, Taiwan</td>
</tr>
<tr>
<td>MP55-07</td>
<td>COMPARISON OF THE EFFECT ON QUALITY OF LIFE BETWEEN STANDARD PCNL AND TUBELESS PCNL AT DISCHARGE USING THE WISCONSIN STONE QOL QUESTIONNAIRE Chao Wei*, Yucong Zhang, Gaurab Pokhrel, Jiahua Gan, Xaiming Liu, Zheqing Ye, Shaoqang Wang, Wuhan, China, People’s Republic of</td>
</tr>
<tr>
<td>MP55-08</td>
<td>HOLMIUM LASER LITHOTRIPSY FOR URETERAL AND RENAL STONES: IS DUSTING EQUIVALENT TO FRAGMENTING? Thomas Knoll*, Sindelfingen, Germany, Mira Sieg, Hamburg, Germany, Jan Jessen, Gunnar Wendt-Nordahl, Sindelfingen, Germany, Thorsten Bach, Hamburg, Germany</td>
</tr>
<tr>
<td>MP55-09</td>
<td>PERIOPERATIVE OUTCOMES OF FLEXIBLE URETERORENOSCOPY FOR UROLITHIASIS USING THE SHEATHLESS TECHNIQUE: A COMPARATIVE STUDY Benjamin Pradere*, Tours, France, Benoit Peyronnet, Zine Eddine Khene, Lucas Freton, Quentin Alimi, Romain Mathieu, Andrea Manunta, Karim Bensalah, Rennes, France</td>
</tr>
<tr>
<td>MP55-11</td>
<td>SUPINE PERCUTANEOUS NEPHROLITHOTRIPSY IN SEPTUAGENARIAN AND OCTOGENARIAN PATIENTS: OUTCOMES OF A CASE-CONTROL STUDY Fabio Torricelli*, Guilherme Ogawa, Fabio Vicentini, Giovanni Marchini, Alexandre Danilovic, Artur Brito, Miguel Srougi, William Nahas, Eduardo Mazzucchi, Sao Paulo, Brazil</td>
</tr>
</tbody>
</table>

*Presenting author
MP55-12 COMPARISON OF INTRARENAL PELVIC PRESSURE LEVELS DURING FLEXIBLE URETEROSCOPY, MINI-PERCUTANEOUS NEPHROLITHOTOMY AND STANDARD PERCUTANEOUS NEPHROLITHOTOMY IN A KIDNEY MODEL
Steeve Doizi*, Audrey Uzan, Etienne Keller, Vincent De Coninck, Maria Rodriguez-Monsalve, Olivier Traxer, Paris, France

MP55-13 SEEING IS BELIEVING- IS THE TYPE OF ANESTHESIA IN URETEROSCOPIC LITHOTRIPSY IMPORTANT?
Maniyur Raghavendran*, Kiran G. Kumar, Keyur Patel, Mysore, India

MP55-14 SOFA (SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE) SCORE IS A VALUABLE TOOL TO EVALUATE FOR PREOPERATIVE PERCUTANEOUS NEPHROSTOMY (PCN) INSERTION BEFORE URETEROSCOPIC LITHOTRIPSY (URSL) TO PREVENT POSTOPERATIVE SEPSIS
Chun-Yo Laih*, Po-Jen Hsiao, Yu-Deng Wang, Sheng wei Lee, Chi-Ping Huang, Wen-Chi Chen, Chi-Rei Yang, Hsi-Chin Wu, Chao-Hsiang Chang, Taichung, Taiwan, Chun-Ming Lai, Davis, CA

MP55-15 PROSPECTIVE COMPARATIVE STUDY OF THE EFFICACY AND SAFETY OF NEW-GENERATION VERSUS FIRST-GENERATION SYSTEM FOR SUPER-MINI-PERCUTANEOUS NEPHROLITHOTOMY (SMP): A REVOLUTIONARY APPROACH TO IMPROVE ENDOSCOPIC VISION AND STONE REMOVAL
Guohua Zeng*, Wei Zhu, Guangzhou, China, People’s Republic of

MP55-16 MINI-PCNL VERSUS STANDARD-PCNL FOR THE MANAGEMENT OF 20-40 MM SIZE KIDNEY STONES: THE INITIAL RESULT OF A MULTI-CENTER RANDOMIZED CONTROLLED TRIAL
Chao Cai, G, China, People’s Republic of, Guohua Zeng*, Guangzhou, China, People’s Republic of

MP55-17 NEW CONCEPTION FOR FLEXOR VUE DEFLECTING ENDOSCOPIC SYSTEM USE, IN ORDER TO IMPROVE STONE FREE RATE (SFR) AFTER RIRS: PRELIMINARY RESULTS FROM A SINGLE CENTRE STAGE 2A STUDY
Alberto Saita*, Paolo Casale, Massimo Lazzeri, NicolòMaria Buffi, Rodolfo Hurle, Roberto Peschechera, Giovanni Lughezzani, Alessio Benetti, Luisa Pasini, Silvia Zanediaglomo, Giuliana Lista, Pasquaile Cardone, Giorgio Guazzoni, Milan, Italy

MP55-18 PREDICTING URETEROSCOPI C LITHOTRIPSY OUTCOME BY THREE-DIMENTIONAL MEAN STONE DENSITY
Yuya Iwahashi*, Simpei Yamashita, Takashi Iguchi, Akinori Iba, Yasuo Kohjimoto, Isao Hara, Wakayama, Japan

MP55-19 DOES THE LASER PULSE SHAPE INFLUENCE THE TREATMENT OF STONES?
Frank Strittmatter*, Alexander Kretschmer, Christian Stief, Abdulmajeed Alghamdi, Munich, Germany

MP55-20 INDICATIONS FOR STENT OMISSION AFTER URETEROSCOPIC LITHOTRIPSY DEFINED
Paul Bower*, Jorge Pereira, Ohad Kott, Simone Thavaseelan, Gyan Pareek, Providence, RI

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 20, 2018
9:30 am - 11:30 am

Moderated Poster Session 56
PEDIATRICS: DYSFUNCTIONAL VOIDING & ENURESIS
Room 3006 @ MCC West
Moderators: Seth Alpert, Israel Franco and Mohamed Eissa

ABSTRACT NUMBER TITLE
MP56-01 CHANGES IN BRAIN ACTIVITY FOLLOWING TRANSCUTANEOUS POSTERIOR TibIAL NERVE STIMULATION FOR LOWER URINARY TRACT SYMPTOMS IN PEDIATRIC PATIENTS: A PET STUDY
Pankaj Gaur*, Sanjoy Sureka, Uday pratap Singh, Aneesh Srivastava, M.S. Ansari, Lucknow, India

ABSTRACT NUMBER TITLE
MP56-02 IMPROVED SLEEP QUALITY FOLLOWING ADENOTONSILLECTOMY IS ASSOCIATED WITH ENURESIS RESOLUTION IN CHILDREN WITH SLEEP-DISORDERED BREATHING
Larisa Kovačević*, Hong Lu, Yegappan Lakshmanan, Detroit, MI
MP56-03 CHARACTERIZATION OF VOIDING PHENOTYPE IN MALE MICE TREATED WITH DOXORUBICIN
Nao Iguchi*, Kevin Huang, Alonso Carrasco, Duncan Wilcox, Anna Malykhina, Nicholas Cost, Aurora, CO

MP56-04 DEFINING THE CORE MECHANISMS IN OVERACTIVE BLADDER BY APPLYING INTEGRATIVE TRANSCRIPTOMICS
Carlos Molina*, Scott Manson, Paul Austin, Houston, TX

MP56-05 VOIDING PATTERN OF NONTOILET-TRAINED FILIPINO CHILDREN WITH RECURRENT URINARY TRACT INFECTION AND WITHOUT URINARY TRACT INFECTION
Avelyn Lim*, David Bolong, Metro Manila, Philippines

MP56-06 NON-NEUROGENIC VOIDING DYSFUNCTION AND NEUROPSYCHIATRIC DISORDERS
Ryan Gillis*, Nicholas Rocco, Matthew Christman, San Diego, CA

MP56-07 EXPRESSION PROFILING OF EXPERIMENTAL NEUROGENIC BLADDER REVEALS DECREASED β3-ADRENERGIC RECEPTOR EXPRESSION THAT CAN BE REVERSED BY INOSINE TREATMENT
Bryan Sack*, Mary Piper, Justin Cotellese, Claire Doyle, Mehrnaz Gharaee-Kermani, Amy Avery, Fabilha Mahmood, Vivian Cristofaro, Maryrose Sullivan, Jill Macoska, Rosalyn Adam, Boston, MA

MP56-09 PICTORIAL URGENCY SCALE – A NEW TOOL FOR EVALUATING BLADDER PERCEPTION IN CHILDREN
Eric Kurzrock MD, Yvonne Chan MD*, Blythe Durbin-Johnson PhD, Lora DeCristoforo PhD, PsyD, Sacramento, CA

MP56-10 MULTIVARIATE ANALYSIS OF FACTORS AFFECTING THE COMPLIANCE OF ADOLESCENCE PATIENTS FOR CLEAN INTERMITTENT CATHETERIZATION: A HARD TOPIC IN TRANSITIONAL UROLOGY FOCUSING ON QUALITY OF LIFE

MP56-11 PEDIATRIC SACRAL NERVE STIMULATOR EXPLANATION DUE TO COMPLICATIONS OR CURE: A SURVIVAL ANALYSIS
Adam Rensing*, Konrad Szymanski, Sally Dunn, Shelly King, Mark Cain, Benjamin Whittam, Indianapolis, IN

MP56-12 PARASACRAL TRANSCUTANEOUS ELECTRICAL NEURAL STIMULATION VS. BEHAVIORAL THERAPY IN PRIMARY MONOSYMPTOMATIC ENURESIS: A PROSPECTIVE RANDOMIZED CLINICAL TRIAL
Liliana Oliveira*, Lidyann Paula, Hanny Franck, Ana Carolina Guedes, Kayleigh Guimarães, Jessika Stephani Cardoso, Andre Figueiredo, Juiz de Fora, Brazil, Ubirajara Barroso, Salvador, Brazil, Jose Bessa Jr, Feira de Santana, Brazil, Jose Murillo Bastos-Netto, Juiz de Fora, Brazil

MP56-13 A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL OF TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) FOR THE TREATMENT OF NOCTURNAL ENURESIS IN CHILDREN: PRELIMINARY RESULTS
Vinaya Vasudevan*, Adam Howe, Jessica Sultan, Jovita Kwan, Bradley A. Morganstern, Jordan Gitlin, Ronnie Fine, Lane S. Palmer, New Hyde Park, NY

MP56-14 PARASACRAL TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION FOR THE TREATMENT OF DYSFUNCTIONAL VOIDING IN CHILDREN
Natalia Mendonca, Maria Luiza Veiga, Ana Aparecida Braga, Ubirajara Barroso*, Salvador, Brazil

MP56-15 IMPACT OF THE ROUTE OF CLEAN INTERMITTENT CATHETERIZATION ON QUALITY OF LIFE IN CHILDREN WITH LOWER URINARY TRACT DYSFUNCTION
Valeria Alencar, Cristiano Gomes*, Eduardo P. Miranda, Maria Alice Leis dos Santos, Patricia Fera, Jose Bessa Jr, Miguel Srougi, Homero Burschini, Sao Paulo, Brazil

MP56-16 EFFICACY AND SAFETY OF TRANSDERMAL OXYBUTYNIN VERSUS ORAL OXYBUTYNIN IN THE MANAGEMENT OF PEDIATRIC NEUROGENIC BLADDER
Emily Rice*, Crawley, Australia, Laura Watkins, Gower Sivalingam, Subiaco, Australia, Maddison Burmaz, Crawley, Australia, Anna Thetford, Elizabeth Thomson, Jane Valentine, Anna Gubbay, Gavan Hotana, Katherine Langdon, Naem Samnakay, Andrew Barker, Japinder Khosa, Subiaco, Australia

MP56-17 SACRAL NERVE STIMULATOR SUCCESS AFTER FILUM SECTION FOR REFRACTORY VOIDING DYSFUNCTION
Adam Rensing*, Konrad Szymanski, Sally Dunn, Shelly King, Mark Cain, Benjamin Whittam, Indianapolis, IN

MP56-18 COMPARISON OF UROFLOWMETRY WITH AND WITHOUT URETHRAL CATHETERIZATION
MP56-20 IS IT IMPORTANT TO DO PELVIC FLOOR EMG TO DEVELOP “NORMAL” NOMOGRAMS
Israel Franco*, Therese Collett gardere, Kaitlyn K. Murphy., New Haven, CT

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 20, 2018
9:30 am - 11:30 am

Moderated Poster Session 57

PROSTATE CANCER: DETECTION & SCREENING V
Room 3009 @ MCC West

Moderators: Steven Joniau, Ashley Ross and Bernardo Rocco

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP57-01</td>
<td>THE EFFECT OF THE 2012 USPSTF ON PSA FOR PROSTATE CANCER SCREENING</td>
</tr>
<tr>
<td>MP57-02</td>
<td>THE ASSOCIATION BETWEEN PHYSICIAN TRUST AND PROSTATE SPECIFIC ANTIGEN SCREENING: IMPLICATIONS FOR SHARED DECISION MAKING</td>
</tr>
<tr>
<td>MP57-03</td>
<td>DECISION AIDS FOR PROSTATE CANCER SCREENING: A SYSTEMATIC REVIEW AND META-ANALYSIS</td>
</tr>
<tr>
<td>MP57-04</td>
<td>THE GERMAN RISK-ADAPTED PROSTATE CANCER SCREENING TRIAL (PROBASE) – FIRST RESULTS AFTER RECRUITMENT OF 30.000 MEN</td>
</tr>
<tr>
<td>MP57-05</td>
<td>PROSTATE CANCER SCREENING: RESULTS OF A UNIQUE COHORT AT 19 YEARS OF FOLLOW-UP</td>
</tr>
<tr>
<td>MP57-06</td>
<td>IS THE SUPPLY OF UROLOGISTS ASSOCIATED WITH SCREENING AND DETECTION OF PROSTATE CANCER IN OLDER MEN?</td>
</tr>
<tr>
<td>MP57-07</td>
<td>PROSTATE CANCER SCREENING AMONG ELDERLY MEN: SHOULD WE DIAGNOSE OR NOT?</td>
</tr>
<tr>
<td>MP57-08</td>
<td>NEGATIVE MRI: WHICH PATIENTS COULD SAFELY AVOID PROSTATE BIOPSY? RESULTS FROM MULTI-INSTITUTIONAL STUDY IN 401 PATIENTS</td>
</tr>
<tr>
<td>MP57-09</td>
<td>SURGICAL AND FUNCTIONAL OUTCOMES OF RADICAL RETROPUBIC PROSTATECTOMY AFTER BIOPSY RELATED ACUTE PROSTATITIS</td>
</tr>
</tbody>
</table>

Diana Cardona-Grau*, Kelly Nast, Rud Nast, George Chiang, Leslie Hsieh, San Diego, CA

Israel Franco*, Therese Collett gardere, Kaitlyn K. Murphy., New Haven, CT
MP57-10 PATHOLOGIC OUTCOMES OF PATIENTS WITH NEGATIVE MRI UNDERGOING PROSTATE BIOPSY AND RADICAL PROSTATECTOMY

MP57-11 IMPACT OF LESION VISIBILITY ON TRANSRECTAL ULTRASOUND ON THE PREDICTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER (GLEASON SCORE ≥ 3+4) WITH TRUS-MRI FUSION BIOPSY
Kirema Garcia-Reyes, Hao Nguyen, Ronald Zagoria, Katsuto Shinozaka, Peter Carroll, Spencer Behr, Antonio Westphalen*, San Francisco, CA

MP57-12 PREDICTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER IN PATIENTS WITH PREVIOUSLY NEGATIVE PROSTATE BIOPSY UNDERGOING MRI/ULTRASOUND-FUSION BIOPSY IN COMBINATION WITH SYSTEMATIC BIOPSY
Angelika Borkowetz*, Theresa Renner, Ivan Platzer, Marieta Toma, Michael Froehner, Stefan Zastrow, Manfred Wirth, Dresden, Germany

MP57-13 MULTIPARAMETRIC MRI INCREASES CLINICALLY SIGNIFICANT PROSTATE CANCER DETECTION RELATIVE TO STANDARD CLINICAL PREDICTORS: RESULTS OF A RISK ADAPTED ANALYSIS IN A NON-SCREENED POPULATION
Armando Stabile*, Paolo Dell’Oglio, Nicola Fossati, Giorgio Gandaglia, Elio Mazzone, Carlo Andrea Bravi, Francesca Cianfoni, Giulia Cristel, Anna Damascelli, Milan, Italy, Pierre I. Karakiewicz, Montreal, Canada, Shahrokhi F. Shariat, Vienna, Austria, Federico Dehò, Antonio Esposito, Francesco De Cobelli, Francesco Montorsi, Alberto Brigantti, Milan, Italy

MP57-14 PROSTATE BIOPSY CENTRALIZATION AT HIGH VOLUME, TERTIARY CARE CENTERS REPRESENTS THE MOST REFINED DIAGNOSTIC TOOL FOR PROSTATE CANCER PATIENTS: RESULTS FROM A PROSPECTIVE SERIES
Marco Bianchi*, Carlo Andrea Bravi, Nicola Fossati, Giorgio Gandaglia, Emanuele Zaffuto, Simone Scuderi, Elio Mazzone, Umberto Capitanio, Nazareno Suard, Milan, Italy, Pierre I. Karakiewicz, Montreal, Canada, Rodolfo Montironi, Ancona, Italy, Vincenzo Mirone, Naples, Italy, Massimo Freschi, Claudio Doglioni, Francesco Montorsi, Alberto Brigantti, Milan, Italy

MP57-15 ASSESSING PRIMARY CARE PATTERNS FOR PROSTATE SPECIFIC ANTIGEN SCREENING IN AN INNER CITY, INDIGENT POPULATION
Jyoti Chouhan*, John Sullivan, Melissa Lee, Anthony Sorrentino, Abdou Kabaritti, Andrew Winer, Brooklyn, NY

MP57-16 IMPACT OF PERCEIVED AMBIGUITY AND OTHER PSYCHOLOGICAL FACTORS ON PREVIOUS PROSTATE CANCER SCREENING BEHAVIOR AMONG 45-YEAR-OLD MEN: FINDINGS FROM THE PROBASE-STUDY
Kathleen Herkommer*, Jamila Strüh, Andreas Dinkel, Munich, Germany, Peters Albers, Christian Aros, Dusseldorf, Germany, Markus Hoehnlein, Heidelberg, Germany, Boris Hadisch, Essen, Germany, Markus Kucyk, Florian Imkamp, Hannover, Germany, Jürgen Gschwend, Munich, Germany

MP57-17 CAN PROSTATIC SPECIFIC ANTIGEN VELOCITY (PSAV) IMPROVE THE DIAGNOSTIC ACCURACY OF PROSTATE IMAGING REPORTING AND DATA SYSTEM (PI-RADS) SCORE FOR PREDICTING SIGNIFICANT PROSTATE CANCER
Amr Mahran, MD*, Johnny Su, Christina Buzzy, PhD, Julia Yang, MS, Vikas Gulani, MD, Lee Ponsky, MD, Cleveland, OH

MP57-18 THE PROMISE OF PRE-BIOPSY MRI IN A DISTRICT GENERAL HOSPITAL (DGH) SETTING
Kishan Tailor*, Barnaby Barrass, Asad Saleemi, Aza Mohammed, Sanjeev Taneja, Farooq Khan, Asher Alam, Luton, United Kingdom

MP57-19 MAGNETIC RESONANCE IMAGING-GUIDED IN-BORE PROSTATE BIOPSY: THE CORRELATION OF PROSTATE CANCER DETECTION AND NUMBER OF PREVIOUS BIOPSIES
Sebastian Blaut*, Stefan Rödel, Thomas Kittner, Frank Steinbach, Dresden, Germany

MP57-20 DELINEATION OF PROSTATE CANCER FROM BPH BY EXCESS PSA RELATIVE TO PREDICTED: A STUDY IN MEN UNDERGOING MRI-TARGETED BIOPSY
Nabeel Shakir, Niccolò Passoni*, Daniel Wong, Dallas, TX, Samuel Gold, Graham Hale, Kareem Rayn, Joseph Baiocco, Jonathan Bloom, Vladimir Valero, Maria Merino, Baris Turkbey, Peter Choyke, Bradford Wood, Peter Pinto, Bethesda, MD, Daniel Costa, Claus Roehrborn, Dallas, TX

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

*Presenting author
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP58-01</td>
<td>MOLECULAR SUBTYPES IN MUSCLE INVASIVE BLADDER CANCER: EVALUATION OF CLINICAL SIGNIFICANCE</td>
</tr>
<tr>
<td></td>
<td>Daniel Belew*, Daley Morera, Sarrah Lahorewala, Andre Jordan, Zachary Klaassen, Martha Terris, Augusta, GA, Mark Soloway, Miami, FL, Vinata Lokeshwar, Augusta, GA</td>
</tr>
<tr>
<td>MP58-02</td>
<td>ABERRANT N-GLYCOSYLATION PROFILE OF SERUM IMMUNOGLOBULINS IS A DIAGNOSTIC BIOMARKER OF UROTHELIAL CARCINOMAS</td>
</tr>
<tr>
<td></td>
<td>Toshikazu Tanaka*, Tohru Yoneyama, Daisuke Noro, Yuta Kojima, Kengo Imanishi, Hayato Yamamoto, Yuki Tobisawa, Kazuyuki Mori, Atsushi Imai, Shingo Hatakayama, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Koie, Hiroaki, Japan, Masakazu Tanaka, Shin-Ichiro Nishimura, Sapporo, Japan, Shizuka Kurauchi, Ippei Takahashi, Chikara Ohyama, Hiroaki, Japan</td>
</tr>
<tr>
<td>MP58-03</td>
<td>ANDROGEN RECEPTOR SIGNALING REDUCES RADIosenSITIVITY IN BLADDER CANCER</td>
</tr>
<tr>
<td></td>
<td>Hiroki Ide*, Baltimore, MD, Satoshi Inoue, Taichi Mizushima, Rochester, NY, Mototsugu Oya, Tokyo, Japan, Hiroshi Miyamoto, Rochester, NY</td>
</tr>
<tr>
<td>MP58-04</td>
<td>LONG NONCODING RNA LNMAT1 PROMOTES BLADDER CANCER LYMPHATIC METASTASIS VIA CCL2-DEPENDENT TUMOR-ASSOCIATED MACROPHAGE RECRUITMENT</td>
</tr>
<tr>
<td></td>
<td>Changhao Chen*, Yue Zhao, Wang He, Wen Dong, Jian Huang, Tianxin Lin, Guangzhou, China, People’s Republic of</td>
</tr>
<tr>
<td>MP58-05</td>
<td>THE LONG-TERM PROGNOSTIC VALUE OF SURVIVIN EXPRESSING CIRCULATING TUMOR CELLS IN PATIENTS WITH HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)</td>
</tr>
<tr>
<td></td>
<td>Gian Maria Busetto*, Francesco Del Giudice, Paola Gazzaniga, Ettore De Berardinis, Roma, Italy</td>
</tr>
<tr>
<td>MP58-06</td>
<td>AUTOMATED STAGING OF T1 BLADDER CANCER USING DIGITAL PATHOLOGIC H&amp;E IMAGES: A DEEP LEARNING APPROACH</td>
</tr>
<tr>
<td></td>
<td>Muhammad Khalid Khan Niazi, Thomas Tavolara, Vidya Arole, Anil Parwani, Cheryl Lee*, Columbus, OH, Metin Gurcan, Winston Salem, NC</td>
</tr>
<tr>
<td>MP58-07</td>
<td>MTOR PROTEIN EXPRESSION IN THE TUMOR AND ITS MICROENVIRONMENT CORRELATES WITH MORE AGGRESSIVE PATHOLOGY AT CYSTECTOMY</td>
</tr>
<tr>
<td></td>
<td>Brian Winters*, Funda Yakar-Lopez, Lisha Brown, Bruce Montgomery, Seattle, WA, Seiler Roland, Bern, Switzerland, Andrew Hsieh, Jonathan Wright, Hung-Ming Lam, Seattle, WA</td>
</tr>
<tr>
<td>MP58-08</td>
<td>CANCER-ASSOCIATED FIBROBLASTS SECRETED EXOSOMAL MIR-146A PROMOTES BLADDER CANCER CHEMORESISTANCE</td>
</tr>
<tr>
<td></td>
<td>Junlong Zhuang*, Lan Shen, Jun Yan, Hongqian Guo, Nanjing, China, People’s Republic of</td>
</tr>
<tr>
<td>MP58-09</td>
<td>COMPREHENSIVE ANALYSIS OF UPPER URINARY TRACT UROTHELIAL CARCINOMA</td>
</tr>
<tr>
<td></td>
<td>Yoichi Fujii*, Yusuke Sato, Tokyo, Japan, Hiromichi Suzuki, Tetsuichii Yoshizato, Kyoto, Japan, Yusuke Shiozawa, Tokyo, Japan, Kenichi Yoshida, Kyoto, Japan, Yuichi Shiraihii, Tohru Nakagawa, Hiroaki Nishimatsu, Tokyo, Japan, Masashi Sanada, Nagoya, Japan, Hideki Makishima, Kyoto, Japan, Satoru Miyano, Tokyo, Japan, Seishi Ogawa, Kyoto, Japan, Haruki Kume, Tokyo, Japan</td>
</tr>
<tr>
<td>MP58-10</td>
<td>IFIT5 PROMOTES EMT VIA DOWNREGULATION OF MATURE MIR-99A IN BLADDER CANCER</td>
</tr>
<tr>
<td></td>
<td>Jun Huang*, Xi’an, China, People’s Republic of, U-Ging Lo, Jer-Tsong Hsieh, Dallas, TX, Dain He, Kaijie Wu, Xi’an, China, People’s Republic of</td>
</tr>
<tr>
<td>MP58-11</td>
<td>THE DUAL-STRANDED MICRORNA-199 FAMILY MEMBERS HAVE TUMOR-SUPPRESSIVE FUNCTION VIA DIRECTLY TARGETING INTEGRIN AL3 (ITGA3) AS A POTENTIAL THERAPEUTIC TARGET IN BLADDER CANCER</td>
</tr>
<tr>
<td></td>
<td>Takashi Sakaguchi*, Hirofumi Yoshino, Satoshi Sugiwa, Masaya Yonemori, Kazutaka Miyamoto, Youichi Osako, Shuichi Tatarano, Takashi Yamane, Masayuki Nakagawa, Hideki Enokida, Kagoshima, Japan</td>
</tr>
<tr>
<td>MP58-12</td>
<td>A FOUR MIRNAS SIGNATURE AS A POTENTIAL BIOMARKER FOR PREDICTING SURVIVAL USING BIOINFORMATICS ANALYSIS IN BLADDER CANCER</td>
</tr>
<tr>
<td></td>
<td>He Xiao, Ping Chen, Deqiang Xu, Wuhan, China, People’s Republic of, Michael E. DiSanto, Camden, NJ, Xinhua Zhang, Xinhua Zhang*, Wuhan, China, People’s Republic of</td>
</tr>
</tbody>
</table>
MP58-13 THE ROLE OF G8 SCREENING TOOL IN ELDERLY POPULATION UNDERGOING RADICAL CYSTECTOMY: PRELIMINARY EVALUATION
Riccardo Boschian, Nicola Pavan*, Enrica Verzotti, Tommaso Silvestri, Fabio Traunero, Giovanni Ligouri, Carlo Trombetta, Trieste, Italy

MP58-14 USING T CELL RECEPTOR SEQUENCING TO CHARACTERIZE THE HOST IMMUNE RESPONSE IN UROTHELIAL CARCINOMA
Alexander Sankin*, Damini Chand, Mark Schoenberg, Xingxing Zang, Bronx, NY

MP58-15 M2 AND M3 MUSCARINIC RECEPTOR EXPRESSION IN BLADDER TUMOR
Mehmet Kazim Asutay*, Sanliurfa, Turkey, Banu Aydin, Hasan Toper, Deniz Filinte, Hülya Cabadak, Ilker Tinay, Istanbul, Turkey

MP58-16 UP-REGULATION OF PROGRAMMED DEATH-LIGAND 1 (PD-L1) EXPRESSION AS AN IMMUNE ESCAPE MECHANISM IN CISPLATIN-TREATED HUMAN BLADDER CANCER CELLS
Thomas I. Hwang*, Ji-Fan Lin, Yi-Chia Lin, Te-Fu Tsai, Hung-En Chen, Kuang-Yu Chou, Taipei, Taiwan

MP58-17 THE CONTRIBUTION OF HGF-MET-MMP1 SIGNALING IN BLADDER CANCER INVASION, AND MET INHIBITOR AS A POTENTIAL THERAPEUTIC OPTION FOR INVASIVE BLADDER CANCER
Tomoya Fukawa*, Kei Daizumoto, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama, Tokushima, Japan

MP58-18 REPRODUCIBILITY AND PROGNOSTIC VALUE OF THE 1973 AND 2004 WORLD HEALTH ORGANIZATION CLASSIFICATIONS FOR GRADE IN NON-MUSCLE-INVASIVE BLADDER CANCER: A MULTICENTER STUDY IN 328 BLADDER TUMOURS
Judith Bosschieter*, Anouk Hentschel, C. Dilara Savci-Heijink, J. Patrick van der Voorn, Rence L. Rozendaal, André N. Vis, Bas W.G. van Rhijn, Birgit I. Lissenberg-Witte, Elisabeth E. Fransen van de Putte, R. Jeroen A. van Moorselaar, Jakko A. Nieuwenhuijzen, Amsterdam, Netherlands

MP58-19 A GENOMIC CLASSIFIER FOR IDENTIFYING A NEUROENDOCRINE-LIKE BLADDER CANCER SUBTYPE
Yair Lotan*, Dallas, TX, Jonathan Wright, Seattle, WA, Marc A. Dall’Era, Davis, CA, Trinity Bivalacqua, Baltimore, MD, Roland Seiler, Bern, Switzerland, Yang Liu, Ewan Gibb, Qi Qi Wang, Nicholas Erho, Mohammed Alshalafla, Elai Davicioni, Vancouver, Canada, Jason A. Estathious, Boston, MA, James Douglas, Southampton, United Kingdom, Joost L. Boormans, Rotterdam, Netherlands, Michiel S. Van der Heijden, Amsterdam, Netherlands, Peter C. Black, Vancouver, Canada

MP58-20 SMYD3 AS A POOR PROGNOSTIC INDICATOR PROMOTES TUMORIGENIC PHENOTYPS AND PROGRESSION OF BLADDER CANCER VIA DIRECT ACTIVATION OF IGF-1R/AKT/MTOR SIGNALING PATHWAY
Cheng Liu*, Beijing, China, People’s Republic of, Li Liu, Yidong Fan, Jinan, China, People’s Republic of, Lulin Ma, Beijing, China, People’s Republic of

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
**ABSTRACT NUMBER** | **ABSTRACT TITLE**
---|---
**MP59-01** | IMPACT OF HOSPITAL VOLUME AND SURGEON VOLUME ON ROBOT-ASSISTED PARTIAL NEPHRECTOMY OUTCOMES: A MULTICENTER STUDY

**MP59-02** | CHARACTERISTICS AND PERIOPERATIVE OUTCOMES FOLLOWING SURGICAL TREATMENT FOR RENAL CELL CARCINOMA IN VERY ELDERLY PATIENTS (≥75 YEARS): DATA FROM THE LATIN AMERICAN RENAL CANCER GROUP (LARCG)
Adrian M. Garza-Gangemi*, Ricardo A. Castillejos-Molina, Ciudad de Mexico, Mexico, Mario Guillermo Gueglio Saccone, Alberto Jurado, Buenos Aires, Argentina, Luis Meza Montoya, Lima, Peru, Carlos Scorticati, Matias Lopez, Buenos Aires, Argentina, Walter H. da Costa, Sao Paulo, Brazil, Juan Yandian, Luis Ubillos, Montevideo, Uruguay, Sidney Olina, Marcos Tobias-Machado, Sao Paulo, Brazil, Oscar Rodriguez Faba, Barcelona, Spain, Carlos A. Ameri, Alejandro Nolazco, Pablo Martinez, Buenos Aires, Argentina, Gustavo Carvalhal, Carolina Cauduro, Pablo M. Barrios, Porto Alegre, Brazil, Ruben Bengio, Leandro Arribillaga, Cordoba, Argentina, Raúl Langenhin, Diego Muguruza, Paysandu, Uruguay, José G. Campos Salcedo, Edgar I. Bravo Castro, Mexico City, Mexico, Pablo Mingote, Nicolás Ginastar, Neuquén, Argentina, Roberto Puente, Ricardo Decia, Montevideo, Uruguay, Gustavo Cardoso Guimarães, Sao Paulo, Brazil, Joan Palau, Barcelona, Spain, Diego Abreu-Clavijo, Montevideo, Uruguay, Stenio de Cassio Zequi, Sao Paulo, Brazil, Francisco Rodríguez-Covarrubias, Mexico City, Mexico

**MP59-03** | A MULTICENTRE ANALYSIS OF THE ROLE OF THE G8 SCREENING TOOL IN THE ASSESSMENT OF PERIOPERATIVE AND FUNCTIONAL OUTCOME IN ELDERLY PATIENTS WITH KIDNEY TUMOURS
Tommaso Silvestri*, Nicola Pavan, Riccardo Boschian, Giacomio Di Cosmo, Trieste, Italy, Bernardino De Concilio, Antonio Celia, Bassano del Grappa, Italy, Giovanni Liguori, Carlo Trombetta, Trieste, Italy

**MP59-04** | IS THERE A ROLE FOR NEPHRON SPARING CYTOREDUCTIVE PARTIAL NEPHRECTOMY IN METASTATIC RENAL CELL CARCINOMA?
Lukas Hockman*, Logan McGuffey, Aaron Dwan, Naveen Pokaia, Columbia, MO

**MP59-05** | TRENDS IN RENAL SURGERY FROM THE NATIONAL INPATIENT SAMPLE: IMPLICATIONS FOR RESIDENT EDUCATION
Joseph Riney*, Amber Schilling, Hershey, PA, Christopher Hollenbeak, State College, PA, Susan Macdonald, Hershey, PA

**MP59-06** | POST-TREATMENT SURVEILLANCE PRACTICE PATTERNS FOR STAGE T1 RENAL CELL CARCINOMA

**MP59-07** | DEVELOPMENT AND INTERNAL VALIDATION OF A NOMOGRAM FOR THE DEVELOPMENT OF ACUTE KIDNEY INJURY AFTER ROBOT-ASSISTED PARTIAL NEPHRECTOMY

**MP59-08** | FOLLOW-UP OF MIT FAMILY TRANSLOCATION RCC IN YOUNG ADULTS
Shudong Zhang*, Lulin Ma, Shaochun Deng, Beijing, China, People's Republic of

**MP59-09** | UNPLANNED INTRAOPERATIVE CONVERSION TO OPEN DURING MINIMALLY INVASIVE KIDNEY SURGERY: THE IMPACT OF ROBOTICS
Abhinav Khanna*, Daniel Sun, Alvin Wee, Robert Abouassaly, Cleveland, OH
MP59-10 MINI-SUBCOSTAL INCISION FOR OPEN RADICAL NEPHRECTOMY IN THE MINIMALLY INVASIVE ERA
Kyle A. Blum*, New York City, NY, Maria F. Becerra, Miami, FL, Alejandro Sanchez, Maziar Ghanati, Renzo G. DiNatale, Mahyar Kashan, Shawn Mendonca, Brandon J. Manley, Nicole Benfante, A. Ari Hakimi, Paul Russo, New York City, NY

MP59-11 A COMPARISON OF ONCOLOGIC OUTCOME BETWEEN RADICAL AND PARTIAL NEPHRECTOMY FOR INCIDENTALLY UPSTAGED PT3A RENAL TUMORS

MP59-12 RETROSPECTIVE COMPARATIVE STUDY BETWEEN ROBOT-ASSISTED PARTIAL NEPHRECTOMY AND OPEN PARTIAL NEPHRECTOMY FOR THE TREATMENT OF HIGHLY COMPLEX RENAL TUMORS WITH RENAL NEPHROMETRY SCORE ≥8
Jung Jun Kim*, Sung Kyu Hong, Seok-Soo Byun, Seong Nam, Korea, Republic of

MP59-13 USING FUNNEL PLOTS, CALL RATE AND DIRECTED REPORT REVIEW FOR UNDERSTANDING DIAGNOSTIC BIAS IN 645 NEPHRECTOMIES WITH RENAL CELL CARCINOMA
Michael Bonert, Serge Kajaer Koujanian, Ihab El-Shinnawy, Samih Salama, Anil Kapoor*, Hamilton, Canada

MP59-14 CAN WE IMPROVE PROGNOSTIC DISCRIMINATION FOR PATIENTS WITH PT3A STAGE RENAL TUMORS?
Alexandre Cavalcante*, Mauricio Cordeiro, Fabio P. Gallucci, Henrique Nonemacher, Paulo Alfonso Carvalho, William Nahas, Sao Paulo, Brazil

MP59-15 HOW SURGICAL FACTORS INFLUENCE RENAL FUNCTIONAL PRESERVATION IN HEALTHY AND “AT-RISK” KIDNEYS AFTER PARTIAL NEPHRECTOMY
Julien Dagenais*, Juan Garisto, Jihad Kaouk, Cleveland, OH

MP59-16 ROBOTIC VERSUS LAPAROSCOPIC RADICAL NEPHRECTOMY: A MATCHED PAIRED MULTICENTER ANALYSIS (ROSULA GROUP)

MP59-17 FROZEN SECTIONS FOR MARGINS DURING PARTIAL NEPHRECTOMY DO NOT INFLUENCE RECURRENCE RATES
Julien Dagenais*, Juan Garisto, Jaya Chavali, Jihad Kaouk, Cleveland, OH

MP59-18 USE OF SURVEILLANCE VERSUS ACTIVE TREATMENT FOR RENAL MASSES ≤7 CM: RESULTS FROM THE MUSIC KIDNEY REGIONAL COLLABORATIVE
Brian Lane*, Grand Rapids, MI, Alon Weizer, Tae Kim, Ji Qi, Ann Arbor, MI, Sanjeev Kaul, Royal Oak, MI, Edward Schervish, Troy, MI, Benjamin Stockton, St. Joseph, MI, Craig Rogers, Detroit, MI, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI

MP59-19 RADICAL NEPHRECTOMY FOR RECURRENT RENAL CELL CARCINOMA: PATIENT SELECTION FOR LAPAROSCOPIC APPROACH

*Presenting author
MP59-20 COMPARATIVE ANALYSIS OF MINIMALLY INVASIVE RADICAL AND PARTIAL NEPHRECTOMY FOR CLINICAL T2 RENAL MASS: ANALYSIS OF THE ROBOTIC SURGERY FOR LARGE RENAL MASS (ROSULA) GROUP
Ahmet Bindayi*, Zachary Hamilton, Stephen Ryan, La Jolla, CA, Giuseppe Simone, Michele Gallici, Rome, Italy, Madhumitha Reddy, La Jolla, CA, Gabriele Tudenti, Rome, Italy, Kendrick Yim, La Jolla, CA, Manuela Costantini, Rome, Italy, Andrea Minervini, Andrea Mari, Marco Carini, Florence, Italy, Daniel Eun, Philadelphia, PA, Koon Rha, Seoul, Korea, Republic of, Bo Yang, Shanghai, China, People’s Republic of, Francesco Montorsi, Milan, Italy, Alexandre Mottrie, Aalst, Belgium, Alessandro Larcher, Umberto Capitanio, Milan, Italy, Aryeh Keehn, Philadelphia, PA, Francesco Porpiglia, Riccardo Bertolo, Turin, Italy, Robert Uzzo, Philadelphia, PA, Sisto Perdona, Giuseppe Quarto, Naples, Italy, James Porter, Michael Liao, Seattle, WA, Matteo Ferro, Ottavo De Cobelli, Milan, Italy, Geert De Naeyer, Aalst, Belgium, Kidon Chang, Seoul, Korea, Republic of, Alexander Kutikov, David Chen, Marc Smaldone, Philadelphia, PA, Luigi Schips, Francesco Berardinelli, Chieti, Italy, Wesley White, Knoxville, TN, Chao Zang, Shanghai, China, People’s Republic of, Ken Jacobsohn, Peter Langenstroer, Peter Dietrich, Milwaukee, WI, Prokar Dasgupta, Nicole de Luyk, Ben Challacombe, London, United Kingdom, Uzoma Anele, Lance Hampton, Richmond, VA, Clayton Lau, Patrick Kilday, Duarte, CA, Chandru Sundaram, Jay Sulek, Bloomington, IN, Riccardo Autorino, Richmond, VA, Ithaar Derweesh, La Jolla, CA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 20, 2018 9:30 am - 11:30 am
Moderated Poster Session 60
INFERTILITY: BASIC RESEARCH & PATHOPHYSIOLOGY
Room 2005 @ MCC West
Moderators: Dolores Lamb, Marc Goldstein and Sidney Glina

ABSTRACT NUMBER TITLE
MP60-01 HEDGEHOG SIGNALLING ENHANCES SUBCUTANEOUS LEYDIG STEM CELL AUTOGRAFT SURVIVAL AND TESTOSTERONE PRODUCTION
Himanshu Arora*, Marilia Sanches Santos Rizzo Zutti, Bruno Nahar, Joshua Hare, Ranjith Ramasamy, Miami, FL

MP60-02 MOLECULAR CHANGES INDUCED BY MIRABEGRON IN RAT SERTOLI CELL PRIMARY CULTURE
Mikito Tanaka*, Koji Chiba, Takaki Ishida, Kenta Sumii, Teruo Fukuda, Keisuke Okada, Kei Matsushita, Masato Fujisawa, Kobe, Japan

MP60-03 SERUM METABOLIC ANALYSIS IDENTIFIES UNIQUE SIGNATURES IN AZOOSPERMIC MEN
Zhe Zhang*, Hui Jiang, Beijing, China, People’s Republic of

MP60-04 VASAL PROTEIN PROFILE AND MICROSCOPIC SPERM PRESENCE AT TIME OF VASECTOMY REVERSAL

MP60-05 MELATONIN HORMONE LEVEL IN SERUM AND SEMINAL PLASMA OF PATIENTS WITH IDIOPATHIC OLIGOASTHENOTERATOZOOSPERMIA
Hassan Ibrahim*, Qena, Egypt, Moustafa El Taleb, Aswan, Egypt, Hanan Fayed, Nahed Fares, Qena, Egypt

MP60-06 UNCOVERING BIOLOGY OF KLINFELTER SYNDROME (47,XXY) INFERTILITY USING NOVEL 10X GENOMICS SINGLE CELL SEQUENCING
Ryan Flannigan*, Ana-Maria Sutii, Fabien Campagne, New York, NY, Jackson Hobgood, Johnson City, TN, Russell Hayden, Anna Mielnik, Alexander Bolyakov, Peter N. Schlegel, Darius Paduch, New York, NY

MP60-07 EVALUATING TRANSCRIPTIONAL REGULATION OF DILATED AND COLLAPSED TUBULES AMONG NON-OBSTRUCTIVE AZOOSPERMIC MEN USING 10X SINGLE CELL SEQUENCING PLATFORM
Ryan Flannigan*, Ana-Maria Sutii, Fabien Campagne, New York, NY, Jackson Hobgood, Johnson City, TN, Anna Mielnik, Russell Hayden, Alexander Bolyakov, Peter N. Schlegel, Darius Paduch, New York, NY

MP60-08 THE EFFECT OF OBSTRUCTED SEMINAL TRACT DURATION ON INTRATUBULAR CELL NUMBERS
Tomoki Takeda*, Yatomi City, Aichi, Japan, Shoichiro Iwatsuki, Satoshi Nozaki, Nagoya, Japan, Hiroki Kubota, Yatomi City, Aichi, Japan, Hiroyuki Kamiya, Shoichi Sasaki, Yukihiro Umemoto, Takahiro Yasui, Nagoya, Japan
MP60-09 DECREASED EXPRESSION OF P-TYPE ATPASES DURING PUBERTY IN RAT CRYPTOCHID TESTES AND ITS RELATION TO THERMAL ENVIRONMENTS
Shoichiro Iwatsuki*, Yukihiko Umemoto, Tomoki Takeda, Satoshi Nozaki, Takahiro Yasui, Nagoya, Japan

MP60-10 IN VITRO PROPAGATION OF XY AND XY SPERMATOGENIAL STEM CELLS FROM NON-MOSAIC HUMAN KLINFEELTER (XXY) SYNDROME TESTES

MP60-11 HUMAN TESTIS-SPECIFIC ACTIN CAPPING PROTEIN β3 AS A POSSIBLE BIOMARKER FOR MALE INFERTILITY
Shinichiro Fukuhara*, Tetsuji Soda, Yusuke Inagaki, Norichika Ueda, Hiroshi Kuchhi, Yasushi Miyagawa, Norio Nonomura, Suita, Japan

MP60-12 PROTECTIVE EFFECTS OF KOREAN RED GINSENG AGAINST SUB-ACUTE IMMObILIZATION STRESS-INDUCED TESTICULAR DAMAGE IN EXPERIMENTAL RATS
Kyung Hwa Choi*, Seongnam, Korea, Republic of, Sang-Ho Lee, Kyu-Min Cha, Chungju, Korea, Republic of, Soock-Yeon Hwang, Daejeon, Korea, Republic of, Un-Kyu Park, Min-Sik Jeong, Spandana Rajendra Kopalli, Chungju, Korea, Republic of, Jae Yup Hong, Seongnam, Korea, Republic of, Chang Kyun Han, Gyo In, Daejeon, Korea, Republic of, Seung Ryeol Lee, Young Kwon Hong, Dong Soo Park, Seok Heui Jang, Seongnam, Korea, Republic of, Si-Kwan Kim, Chungju, Korea, Republic of

MP60-13 WHEN TO PERFORM SEMEN CULTURE IN ASYMPTOMATIC INFERTILE MEN? HINTS FROM A CROSS SECTIONAL STUDY

MP60-14 DYSREGULATION OF RNA SEQUESTRATION BY YBX2 IS A NOVEL MECHANISM OF MATURATION ARREST AMONG MEN WITH NON-OBSTRUCTIVE AZOOSPERMIA
Ryan Flannigan*, Francesca Khan, Brian Robinson, Russell Hayden, Anna Mielnik, Alexander Bolyakov, Peter N. Schlegel, Darius Paduch, New York, NY

MP60-15 TRANSCRIPTOME ANALYSIS TO IDENTIFY HUMAN SPERMATOGENIAL CELLS FROM SERTOLI CELL-ONLY TESTES
Koji Shiraishi*, Hideyasu Matsuyama, Ube, Japan

MP60-16 HYPOGONADISM IS ASSOCIATED WITH LOWER SPERM MORPHOMETRY AND LOWER LIVE BIRTH RATES IN MEN WITH UNEXPLAINED INFERTILITY
JC Trussell*, Fayetteville, NY, Robert Coward, Chapel Hill, NC, Nanette Santoro, Denver, CO, Christy Stetter, Allen Kunselman, Hershey, PA, Michael Diamond, Augusta, GA, Karl Hansen, Oklahoma City, OK, Stephen Krawetz, Detroit, MI, Richard Legro, Hershey, PA, James Smith, San Francisco, CA, Anne Steiner, Chapel Hill, NC, Pasquale Patrizio, New Haven, CT, Robert Wild, Oklahoma City, OK, Esther Eisenberg, Rockville, MD, Heping Zhang, New Haven, CT, Mark Lindgren, Oklahoma City, OK

MP60-17 MALE REPRODUCTIVE HEALTH IS A KEY DETERMINANT OF UNHEALTHY AGING: RESULTS FROM A LONGITUDINAL COHORT STUDY

MP60-18 ANTI-MULLERIAN HORMONE-TO-TESTOSTERONE RATIO IS PREDICTIVE OF POSITIVE SPERM RETRIEVAL IN MEN WITH IDIOPATHIC NON-OBSTRUCTIVE AZOOSPERMIA
Massimo Alfano*, Eugenio Ventimiglia, Irene Locatelli, Paolo Capogrosso, Walter Cazzaniga, Filippo Pederzoli, Nicola Frego, Rayan Matloob, Milan, Italy, Antonino Saccà, Bergamo, Italy, Luca Boeri, Luca Pagliardini, Paola Viganò, Marina Pontillo, Manuela Nebuloni, Francesco Montorsi, Andrea Salonia, Milan, Italy

MP60-19 DIFFERENTIAL EXPRESSION OF LONG NON-CODING RNA’S AMONG MEN WITH SPERMATOGENIC ARREST
Russell Hayden*, Ryan Flannigan, Alexander Bolyakov, Anna Mielnik, Peter Schlegel, Darius Paduch, New York, NY

MP60-20 WITH-IN GROUP & BETWEEN GROUP DIFFERENCES OF SPERMATOGONIAL MARKERS AMONG MEN WITH NON-OBSTRUCTIVE AZOOSPERMIA
Ryan Flannigan*, Francesca Khan, Anna Mielnik, Brian Robinson, Russell Hayden, Alexander Bolyakov, Peter N. Schlegel, Darius Paduch, New York, NY

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

*Presenting author
ABSTRACT

TIME NUMBER TITLE
9:30 PD39-01 ARTIFICIAL URINARY SPHINCTER IN MALE PATIENTS WITH SPINA BIFIDA: COMPARISON OF PERIOPERATIVE AND FUNCTIONAL OUTCOMES BETWEEN BULBAR URETHRA AND BLADDER NECK CUFF PLACEMENT

9:40 PD39-02 EROSION RATES OF 3.5 CM ARTIFICIAL URINARY SPHINCTER CUFFS ARE SIMILAR TO LARGER CUFFS
Nabeel Shakir*, Maxim McKibben, Joceline Fuchs, Jeremy Scott, Allen Morey, Dallas, TX

9:50 PD39-03 OUTCOMES ASSOCIATED WITH DUAL ARTIFICIAL URINARY SPHINCTER AND INFLATABLE PENILE PROSTHESES: ANALYSIS OF A CONTEMPORARY, NEW YORK STATEWIDE COHORT
Ron Golan*, Joshua Halpern, Tianyi Sun, Denise Asafu-Adjei, Peter Stahl, New York, NY

10:00 PD39-04 COMBINED PLACEMENT OF ARTIFICIAL URINARY SPHINCTER AND INFLATABLE PENILE PROSTHESIS DOES NOT INCREASE RISK OF PERIOPERATIVE COMPLICATIONS OR IMPACT LONG-TERM DEVICE SURVIVAL
William Boysen*, Andrew Cohen, Kristine Kuchta, Jaclyn Milose, Chicago, IL

10:10 PD39-05 INCIDENCE AND MANAGEMENT OF PERSISTENT STRESS URINARY INCONTINENCE AFTER HOLMIUM LASER ENUCLEATION THE PROSTATE
Mihir Shah*, Ali Syed, Thomas Hardacker, Alana Murphy, Akhil Das, Philadelphia, PA

10:20 PD39-06 ARTIFICIAL URINARY SPHINCTER LONGEVITY FOLLOWING TRANSCURETHRAL RESECTION OF THE PROSTATE
Andrew Cohen*, William Boysen, Chicago, IL, Kristine Kuchta, Evanston, IL, Sarah Faris, Chicago, IL, Jaclyn Milose, Evanston, IL

10:30 PD39-07 ADJUSTABLE TRANSOBTURATOR MALE SYSTEM (ATOMS) FOR POST-PROSTATECTOMY INCONTINENCE: 2-YEAR RESULTS FROM A MULTICENTER IBERIAN STUDY
Francisco Cruz*, Oporto, Portugal, Javier C. Angulo, Cristina Esquinas, Ignacio Arance, Madrid, Spain, Margarida Manso, Oporto, Portugal, Andrés Rodríguez, Javier Pereira, Ferrol, Spain, Antonio Ojea, Manuel Carballo, Vigo, Spain, Miguel Rabassa, Antoine Teyrouz, Palma de Mallorca, Spain, Gregorio Escribano, Elena Rodríguez, Fernando Teba, Guillermo Celada, Madrid, Spain, Blanca Madurga, Jose L. Álvarez-Ossorio, Cádiz, Spain, João M. Padua, Francisco E. Martins, Lisbon, Portugal

10:40 PD39-08 THE EARLY CANADIAN EXPERIENCE WITH ATOMS FOR POST-PROSTATECTOMY INCONTINENCE: A MULTICENTER STUDY
Trevor Haines*, Edmonton, Canada, Genevieve Nadeau, Quebec City, Canada, Le-Mai Tu, Sherbrooke, Canada, Julie Morisset, Montreal, Canada, Chris Dorion, Stephen Steele, Kingston, Canada, Luc Vaillyquette, Montreal, Canada, Dean Eltermann, Toronto, Canada, Conrad Maciejewski, Ottawa, Canada, Keith Rourke, Edmonton, Canada

10:50 PD39-09 TREATMENT OF MALE STRESS URINARY INCONTINENCE WITH ADJUSTABLE SLINGS AND ARTIFICIAL URINARY SPHINCTER – FOCUS ON PATIENT SELECTION AND POSTOPERATIVE CONTINENCE STATUS
Markus Grabbert*, Cologne, Germany, Alexander Kretschmer, Munich, Germany, Tanja Huesch, Mainz, Germany, Ralf Anding, Bonn, Germany, Tobias Potteck, Berlin, Germany, Roberto Olianos, Lueneburg, Germany, Wilhelm Huebner, Korneuburg, Austria, Axel Heidenreich, Cologne, Germany, Fabian Queisser, Muenster, Germany, Carsten Maik Naumann, Kiel, Germany, Carola Wotzka, Stuttgart, Germany, Roland Homberg, Hamm, Germany, Jeso Pfitzenmaier, Bielefeld, Germany, Axel Haferkamp, Mainz, Germany, Ricardo Bauer, Munich, Germany
<table>
<thead>
<tr>
<th>Time</th>
<th>Number</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30</td>
<td>PD40-01</td>
<td>Effectiveness of Endoscopic Injection of 2% lignocaine in to the bladder wall to control obturator jerk during Trans Urethral Resection of Bladder Tumor (TURBT)</td>
</tr>
<tr>
<td>9:40</td>
<td>PD40-02</td>
<td>Understanding Litigation Trends for Robotic Urologic Surgeries</td>
</tr>
<tr>
<td>9:50</td>
<td>PD40-03</td>
<td>Utilization of MedMeasure, a Smartphone-Based App, as a Reliable Method for Fluoroscopic and Endoscopic Measurements</td>
</tr>
<tr>
<td>10:00</td>
<td>PD40-04</td>
<td>Semiautomatic Inflatable Electronic Penile Implant Prototype</td>
</tr>
<tr>
<td>10:10</td>
<td>PD40-05</td>
<td>Three-Dimensional Printing of Ring Retractor System for Urethroplasty</td>
</tr>
<tr>
<td>10:20</td>
<td>PD40-06</td>
<td>The Management and Efficacy of Surgical Outcomes Used for Erosive Mesh in the Urethra and Bladder</td>
</tr>
<tr>
<td>10:40</td>
<td>PD40-08</td>
<td>A Novel Urethral Catheter Design to Both Prevent and Minimize Morbidity with Intra-Urethral Catheter Injury (IUCI)</td>
</tr>
</tbody>
</table>

*Presenting author*
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>PD40-10</td>
<td>3D PRINTED VIRTUAL MODELS FOR PLANNING AND COUNSELING OF ROBOT-ASSISTED RADICAL PROSTATECTOMY AND PARTIAL NEPHRECTOMY</td>
<td>Francesco Porpiglia, Riccardo Bertolo*, Daniele Amparore, Enrico Checcucci, Matteo Manfredi, Cristian Fiori, Orbassano, Italy</td>
</tr>
<tr>
<td>9:30</td>
<td>PD41-01</td>
<td>NATIONAL PRACTICE PATTERNS AND OUTCOMES FOR ADJUVANT RADIOTHERAPY AFTER RADICAL CYSTECTOMY FOR UROTHELIAL BLADDER CANCER</td>
<td>Zhoobin Bateni*, Shane Pearce, Daniel Zainfeld, Leslie Ballas, Hooman Jaladat, Anne Schuckman, Siemak Daneshmand, Los Angeles, CA</td>
</tr>
<tr>
<td>9:40</td>
<td>PD41-02</td>
<td>OUTCOMES OF SALVAGE RADICAL CYSTECTOMY FOR RECURRENT UROTHELIAL CARCINOMA OF THE BLADDER FOLLOWING DEFINITIVE RADIOTHERAPY</td>
<td>Zhoobin Bateni*, Sorosh Bazargani, Daniel Zainfeld, Gus Miranda, Jie Cai, Leslie Ballas, Hooman Jaladat, Anne Schuckman, Siemak Daneshmand, Los Angeles, CA</td>
</tr>
<tr>
<td>9:50</td>
<td>PD41-03</td>
<td>VALIDATED HOSPITAL QUALITY METRICS FOR RADICAL CYSTECTOMY: DISEASE-SPECIFIC AND CORRELATED TO LONG-TERM OUTCOMES</td>
<td>Abhinav Khanna*, Cleveland, OH, Olli Saarela, Keith Lawson, Toronto, Canada, Andrew Stephenson, Georges-Pascal Haber, Byron Lee, Cleveland, OH, Antonio Finelli, Toronto, Canada, Robert Abouassaly, Cleveland, OH</td>
</tr>
<tr>
<td>10:00</td>
<td>PD41-04</td>
<td>ORAL NUTRITION INTERVENTION IN PATIENTS UNDERGOING RADICAL CYSTECTOMY: A PROSPECTIVE, RANDOMIZED CONTROLLED TRIAL</td>
<td>Chad Ritch*, Miami, FL, James Thu, St. Louis, MO, Veronica Ralls, Kareem Fakhoury, David Penson, Sam Chang, Joseph Smith Jr, Nashville, TN, Peter Clark, Charlotte, NC, Michael Cookson, Oklahoma City, OK, Heidi Silver, Nashville, TN</td>
</tr>
<tr>
<td>10:10</td>
<td>PD41-05</td>
<td>THE ROLE OF METASTATIC BURDEN IN CYTOREDUCITIVE/CONSOLIDATIVE RADICAL CYSTECTOMY</td>
<td>Roger Li*, Janet Kukreja, Firas Petros, Matthew Campbell, Justin Nguyen, Graciela Nogueras Gonzalez, Ashish Kamat, Louis Pisters, Colin Dinney, Neema Navai, Houston, TX</td>
</tr>
</tbody>
</table>
10:30 PD41-07 EXAMINING THE MD ANDERSON RISK CRITERIA FOR PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER: ARE LOW RISK PATIENTS HARMED WITH UPFRONT CYSTECTOMY?
Timothy Lyon*, Igor Frank, Paras Shah, Vidit Sharma, Matthew Tollefson, R. Houston Thompson, R. Jeffrey Karnes, Robert Tarrell, Prabir Thapa, John Cheville, Stephen Boorjian, Rochester, MN

10:40 PD41-08 DOES REGIONALIZATION OF RADICAL CYSTECTOMY IMPACT THE 30 AND 90-DAY MORTALITY IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER?
Juan Herrera*, Geraldine Klein, Wasim Chowdhury, Hanzhang Wang, Ahmed Mansour, Dharam Kaushik, Robert Svatek, San Antonio, TX

10:50 PD41-09 COMPARING INTRACORPOREAL URINARY DIVERSION AFTER ROBOT-ASSISTED RADICAL CYSTECTOMY: RESULTS FROM THE INTERNATIONAL ROBOTIC CYSTECTOMY CONSORTIUM; A MATCHED ANALYSIS

11:00 PD41-10 ROBOTIC RADICAL CYSTECTOMY IS ASSOCIATED WITH SHORTER LENGTH OF STAY AND LESS BLOOD LOSS THAN OPEN RADICAL CYSTECTOMY: RESULTS FROM A LARGE MULTICENTER RETROSPECTIVE COHORT

11:10 PD41-11 NATIONWIDE UTILIZATION OF CHEMOPROPHYLAXIS FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM FOLLOWING RADICAL CYSTECTOMY
Stephen Reese*, Matthew Mossanen, Dimitar Zlatev, Daniel Pucherel, Boston, MA, Benjamin I. Chung, Stanford, CA, Steven L. Chang, Boston, MA

11:20 PD41-12 THE BURDEN OF POST-OPERATIVE CLOSTRIDIUM DIFFICILE INFECTION IN RADICAL CYSTECTOMY CASES: A NATIONAL INPATIENT SAMPLE ANALYSIS
Niranjan Sathianathen*, Yunhua Fan, Stephanie Jarosek, Mary Kwaan, Badrinath Konety, Minneapolis, MN

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
HOW ACCURATELY DOES MAGNETIC RESONANCE IMAGING-ULTRASOUND FUSION BIOPSY PREDICT RADICAL PROSTATECTOMY PATHOLOGY?

OUTCOMES OF SALVAGE ROBOT-ASSISTED RADICAL PROSTATECTOMY POST PRIMARY RADIATION AND THERMAL ABLATION THERAPIES
Mario Mekhail*, Luis Medina, Giovanni Cacciari, Akbar Ashrafi, Matthew Winter, Peter Mekhail, Sameer Chopra, Andre Berger, Rene Sotelo, Hooman Djaladat, Mihir Desai, Inderbir Gill, Andre Abreu, Monish Aron, Los Angeles, CA

OUTCOMES OF SURGICAL MANAGEMENT OF LOCALIZED HIGH-RISK PROSTATE CANCER: RESULTS FROM THE PROSTATE CANCER CANADIAN COLLABORATION
Jesse Ory*, Halifax, Canada, Rodney Breau, Ottawa, Canada, Fred Saad, Wassim Kassouf, Montreal, Canada, Bobby Shayegan, Hamilton, Canada, Jonathan Duplisea, Houston, TX, Tarek Lawen, Halifax, Canada, Christopher Morash, Ottawa, Canada, Armen Aprikian, Montreal, Canada, Ricardo A Rendon, Halifax, Canada

SALVAGE RADICAL PROSTATECTOMY (SRP) FOR RADIORESISTANT PROSTATE CANCER (PCA): OUTCOME ANALYSIS OF 2 TERTIARY REFERRAL CENTRES
Axel Heidenreich*, Köln, Germany, Matteo Soligo, Rochester, MN, Tobias Kohl, Markus Grabbert, David Pflister, Köln, Germany, Alessandro Morlaco, Jeffrey R. Karnes, Rochester, MN

IMPACT OF LYMPH NODE METASTASES ON PROGNOSIS AFTER RADICAL PROSTATECTOMY FOR PATIENTS WITH OLIGOMETASTATIC PROSTATE CANCER
Jae Won Park*, Won Sik Jang, Dong Hoon Koh, Jong Soo Lee, Jee Soo Ha, Jee Soo Park, Seoul, Korea, Republic of, Won Tae Kim, Cheongju, Korea, Republic of, Young Sig Kim, In Rae Cho, Goyang, Korea, Republic of, Joong Shik Lee, Won Sik Ham, Young Deuk Choi, Seoul, Korea, Republic of

PREOPERATIVE PSMA-PET/CT IMPROVES THE OUTCOME OF ROBOTIC SALVAGE LYMPH NODE DISSECTION
Johannes Linxweiler*, Matthias Saar, Zaid Al-Kailani, Michael Stöckle, Stefan Siemer, Carsten Henning Ohlmann, Homburg Saar, Germany

EFFECTS OF OMEGA-3-RICH FISH OIL (MAG-EPA) ON PROSTATE CANCER: PRELIMINARY RESULTS OF A CLINICAL TRIAL
Lisanne Beaudoin*, Nikunj Gevariya, Karine Robitaille, Marie-Hélène Guertin, Jean-François Pelletier, Pierre Julien, Vincent Fradet, Québec, Canada

PROGNOSTIC VALUE OF CELL CYCLE PROGRESSION SCORE IN PROSTATE CANCER PATIENTS WITH LOCALLY ADVERSE PATHOLOGY AFTER RADICAL PROSTATECTOMY: IMPLICATIONS FOR TREATMENT GUIDANCE
Xun Shangguan*, Wei Xue, Baijun Dong, Jiahua Pan, Hongyang Qian, Fan Xu, Shanghai, China, People’s Republic of

RANDOMIZED COMPARISON OF TECHNIQUES FOR CONTROL OF THE DORSAL VENOUS COMPLEX DURING ROBOTIC RADICAL PROSTATECTOMY
Tom Feng*, Joy Lee, Gerald Heulitt, Michael Liao, Grace Li, James Porter, Seattle, WA

ONCOLOGICAL OUTCOMES OF UNFAVORABLE INTERMEDIATE-RISK IS COMPARABLE TO HIGH-RISK LOCALIZED PROSTATE CANCER IN PATIENTS TREATED WITH RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE DISSECTION
Youness Ahallal*, Davy Benarroche, Luis Felipe Snel Zanettini, Alexandre Colau, Clement Charbonnier, Jean-Francois Cote, Bertrand Guillonneau, Paris, France

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>V08-01</td>
<td>CHALLENGING SCENARIOS DURING BLADDER NECK DISSECTION IN ROBOT-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY</td>
</tr>
<tr>
<td></td>
<td>Fikret Onol*, Hariharan Palayapalayam, Ganapathi, Travis Rogers, Vipul Patel, Celebration, FL</td>
</tr>
<tr>
<td>V08-02</td>
<td>BLADDER NECK PRESERVATION DURING ROBOTIC PROSTATECTOMY: IF THE ONLY CONCERN IS ABOUT POSITIVE SURGICAL MARGINS, THERE IS NO PROBLEM!</td>
</tr>
<tr>
<td></td>
<td>Fabrizio Dal Moro*, Michele Zazzara, Marina Paola Gardiman, Massimo Rugge, Filiberto Zattoni, Padova, Italy</td>
</tr>
<tr>
<td>V08-03</td>
<td>FUNCTIONAL ANATOMY SPARING TECHNIQUE FOR PROSTATECTOMY</td>
</tr>
<tr>
<td></td>
<td>Andrew Radtke*, Joshua Piotrowski, Kevin Zeeck, Scott Johnson, Kenneth Jacobsohn, Milwaukee, WI</td>
</tr>
<tr>
<td>V08-04</td>
<td>ROBOT-ASSISTED RADICAL PROSTATECTOMY WITH 3D-BASED AUGMENTED REALITY</td>
</tr>
<tr>
<td></td>
<td>Francesco Porpiglia, Riccardo Bertolo*, Enrico Checucci, Daniele Amparore, Cristian Fiori, Orbassano, Italy</td>
</tr>
<tr>
<td>V08-05</td>
<td>HIGH ANTERIOR RELEASE OF NEUROVASCULAR BUNDLE BY HYDRODISSECTION DURING ROBOTIC ASSISTED RADICAL PROSTATECTOMY: TECHNIQUE AND SHORT-TERM OUTCOMES</td>
</tr>
<tr>
<td></td>
<td>Taoping Shi*, Xu Zhang, Xin Ma, Hongzhao Li, Baojun Wang, Yang Fan, Yu Gao, Beijing, China, People's Republic of</td>
</tr>
<tr>
<td>V08-06</td>
<td>HOW DOES THE BLADDER HEAL AFTER PERITONEAL ADVANCEMENT FLAPS? INSIGHTS FROM A REOPERATIVE CASE</td>
</tr>
<tr>
<td></td>
<td>Kevin Yang, Matthew Moynihan*, Christopher Lebeis, Alireza Moinzadeh, David Canes, Burlington, MA</td>
</tr>
<tr>
<td>V08-07</td>
<td>SALVAGE ROBOT-ASSISTED RETROPERITONEAL LYMPHADENECTOMY FOR PROSTATE CANCER NODAL RECURRENCE ONLY DETECTED BY 68GA-PSMA PET CT: TECHNICAL ASPECTS AND RESULTS</td>
</tr>
<tr>
<td></td>
<td>Luis Sávio*, Miami, FL, Francisco Hidelbrando A Mota Filho, Raphael Santos, Jose Arnaldo da Cruz, Carlo Passerotti, Sao Paulo, Brazil</td>
</tr>
<tr>
<td>V08-08</td>
<td>ROBOTIC PERINEAL RADICAL PROSTATECTOMY AND BILATERAL LYMPH NODE DISSECTION WITH PERINEAL APPROACH</td>
</tr>
<tr>
<td></td>
<td>Volkan Tugcu, Oktay Akca, Abdulmuttalip Simsek*, Ismail Yigitbasi, Selcuk Sahin, Mustafa Yenice, Ali Tasci, Istanbul, Turkey</td>
</tr>
<tr>
<td>V08-09</td>
<td>ROBOTIC TRANSVESICAL PARTIAL PROSTATECTOMY USING A PURPOSE-BUILT SINGLE PORT ROBOTIC SYSTEM</td>
</tr>
<tr>
<td></td>
<td>Jihad Kaouk, Daniel Sagalovich, Juan Garisto*, Cleveland, OH</td>
</tr>
<tr>
<td>V08-10</td>
<td>DESIGN AND VALIDATION OF A LOW-COST, HIGH-FIDELITY MODEL FOR RALP URETHROVESICAL ANASTOMOSIS</td>
</tr>
<tr>
<td></td>
<td>Brett Johnson*, Matthew Timberlake, Igor Sorokin, Jeffrey Cadeddu, Jeffrey Gahan, Dallas, TX</td>
</tr>
<tr>
<td>V08-11</td>
<td>ROBOT-ASSISTED PLACEMENT OF PELVIC TISSUE EXPANDER FOR RADIATION AFTER PROSTATECTOMY AND CYSTECTOMY FOR TREATMENT OF PROSTATE CANCER BIOCHEMICAL RECURRENCE</td>
</tr>
<tr>
<td></td>
<td>Scott Quarrier*, Guan Wu, Rochester, NY</td>
</tr>
<tr>
<td>V08-12</td>
<td>BLEEDING DISASTER MANAGEMENT DURING ROBOTIC RENAL SURGERY</td>
</tr>
<tr>
<td></td>
<td>Amit Patel*, Detroit, MI, Craig Rogers, Plymouth, MI</td>
</tr>
</tbody>
</table>
10:00 16TH IPF INTRODUCTIONS AND AUA PCA PROGRAMS
Program Co-Chair: John Davis
Program Co-Chair: Neal Shore

10:05 SESSION I: THE BEST OF SAN FRANCISCO!
CLINICAL RESEARCH HIGHLIGHTS THAT WILL IMPACT YOUR PRACTICE
Moderator: Badar Mian
Moderator: Neal Shore
Speakers: Peter Carroll, James Brooks, Sandy Srinivas, Charles Ryan, Mack Roach

11:20 SESSION II: PROSTATE CANCER IN THE OFFICE: DIAGNOSTIC UPDATES
Panelist: David Penson
Panelist: Scott Eggener
Panelist: Daniel Lin
Panelist: John Davis

PRO POSITION
Speaker: Matthew Cooperberg

CON POSITION
Speaker: Ben Davies

BIOMARKER DEBATE: PANEL CONSENSUS
Panelists: David Penson, Scott Eggener, Daniel Lin, John Davis

11:20 SESSION III: PROSTATE CANCER IN THE OFFICE: CO-MANAGEMENT UPDATES
Moderators: Satoru Takahashi, Mevlana Derya Balbay

TESTOSTERONE REPLACEMENT THERAPY ON ACTIVE SURVEILLANCE OR POST THERAPY
Speaker: Abraham Morgentaler

BPH INTERVENTIONS: WHAT TO DO ON ACTIVE SURVEILLANCE OR ELEVATED PSA
Speaker: Kevin McVary

SESSION IV: IMAGING UPDATES
Moderators: Derya Tilkı, Koji Okihara

PET IMAGING: HOW WE WILL TRANSLATE ABILITY INTO UTILITY
Speaker: Declan Murphy

MRI IMAGING: AUA STATEMENT ON ITS USE FOR DIAGNOSIS, STAGING, AND MANAGEMENT
Speaker: Peter Pinto

IMAGING CASE CHALLENGES
Moderators: Derya Tilkı, Koji Okihara

SESSION V: MULTIDISCIPLINARY PANEL ON FUTURE DIRECTIONS IN VERY HIGH RISK TO OLIGOMETASTATIC DISEASE
Moderator: Brian Chapin

PUSHING THE LIMITS OF SURGERY
Speaker: R. Jeffrey Karnes

PUSHING THE LIMITS OF XRT
Speaker: Pierre Blanchard

UK TRIALS
Speaker: Prasanna Sooriakumaran

BEST SYSTEMIC THERAPY
Speaker: Eric Small

CASE PRESENTATIONS
Speaker: Brian Chapin

3:15 SESSION V: MULTIDISCIPLINARY PANEL ON FUTURE DIRECTIONS IN VERY HIGH RISK TO OLIGOMETASTATIC DISEASE
Moderator: Brian Chapin

PUSHING THE LIMITS OF SURGERY
Speaker: R. Jeffrey Karnes

PUSHING THE LIMITS OF XRT
Speaker: Pierre Blanchard

UK TRIALS
Speaker: Prasanna Sooriakumaran

BEST SYSTEMIC THERAPY
Speaker: Eric Small

CASE PRESENTATIONS
Speaker: Brian Chapin

3:15 SESSION V: MULTIDISCIPLINARY PANEL ON FUTURE DIRECTIONS IN VERY HIGH RISK TO OLIGOMETASTATIC DISEASE
Moderator: Brian Chapin

PUSHING THE LIMITS OF SURGERY
Speaker: R. Jeffrey Karnes

PUSHING THE LIMITS OF XRT
Speaker: Pierre Blanchard

UK TRIALS
Speaker: Prasanna Sooriakumaran

BEST SYSTEMIC THERAPY
Speaker: Eric Small

CASE PRESENTATIONS
Speaker: Brian Chapin

ADJOURN
ROBOTIC RADICAL PROSTATECTOMY: TRANSVESICAL SINGLE PORT APPROACH
Jihad Kaouk

RARP IN METASTATIC AND LYMPH NODE RECURRENT DISEASE: WHAT ARE WE GETTING OURSELVES INTO AND WHAT ARE WE GAINING?
John Davis

ROBOTIC SURGERY IN PATIENTS WITH KIDNEY TRANSPLANT
Erik Castle

ROBOTIC SURGERY IN PATIENTS WITH RENAL ANOMALIES
James Porter

ROBOTIC DISTAL URETERAL SURGERY WITH TECHNICAL MODIFICATIONS FOR BOARI FLAP
Raju Thomas

2:10 SESSION II: ADVANCES AND CONTROVERSIES
Moderators: Monish Aron, Craig Rogers

MRI BASED IMAGING IS ESSENTIAL IN PLANNING FOR ROBOTIC PROSTATECTOMY
Ashutosh Tewari

IS ROBOTIC PARTIAL NEPHRECTOMY CHANGING THE FIELD FOR TUMOR BEYOND T1A?
Ketan Badani

IS IT IMPORTANT TO CHASE COMPLICATIONS FOLLOWING ROBOTIC RADICAL PROSTATECTOMY?
Francesco Montorsi

ROBOTIC TOTAL PROSTATECTOMY: A NEW TECHNIQUE FOR BPH
Ashok Hemal

2:58 SESSION III: INVITED LECTURE
Moderators: Thomas Ahlering, Jihad Kaouk

Inderbir Gill

3:13 IS BERNARD FISHER RIGHT?
Mani Menon

SESSION IV: THE PROGRESS AND FUTURE OF ROBOT-ASSISTED SURGERY IN THE FIELD OF UROLOGY: AN EDITOR’S PERSPECTIVE
Moderators: John Denstedt, Jens Rassweiler

MR. WICKHAM WAS RIGHT!
Ralph Clayman

NEW ROBOTS: WILL IT CHANGE THE FIELD?
Prokar Dasgupta

OPEN SURGERY IN ERA OF ROBOTIC-ASSISTED SURGERY
Andrew Stephenson

PROSTATE CANCER
Joseph Smith

BLADDER CANCER
James Catto

VIDEO BASED EDUCATION IN ROBOTIC SURGERY
Chandru Sundaram

SESSION V: BLADDER/URETER/RECONSTRUCTION
Moderators: Alvin Goh, Georges Pascal Haber

OUTCOMES TELL THE REAL STORY IN THE WORLD OF ROBOTIC RADICAL CYSTECTOMY
Khurshid Guru

SHOULD INTRACORPOREAL DIVERSION BE STANDARD OF CARE GIVEN ONCOLOGIC AND FUNCTIONAL OUTCOMES?
Peter Wiklund

ROBOTIC UPPER URETERAL SURGERY
Michael Stifelman

SIRS BUSINESS MEETING

ADJOURN

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 20, 2018 1:00 pm - 3:00 pm
SOCIETY FOR INFECTION AND INFLAMMATION IN UROLOGY (SIIU)
Room 214 @ MCC South

1:00 EVOLUTION OF ANTIMICROBAL COATINGS TO COMBAT BACTERIAL BIOFILMS ON INDWELLING URINARY DEVICES
Dirk Lange

2:00 RESIDENT AND FELLOW PODIUM PRESENTATIONS

SIIU BUSINESS MEETING

ADJOURN

211
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
<th>AUTHORS</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP61-01</td>
<td>EVALUATING THE FEASIBILITY OF A VOUCHER PROGRAM FOR KIDNEY DONATION</td>
<td>Avi Baskin*, San Francisco, CA, Patrick Shannon, Boise, ID, Rich Marta, Matt Ronin, Garet Hil, New York, NY, Jeffrey Veale, Los Angeles, CA</td>
</tr>
<tr>
<td>MP61-03</td>
<td>A BIOFUNCTIONAL VASCULAR SCAFFOLD FOR REPLACING SMALL-DIAMETER BLOOD VESSELS</td>
<td>Young Min Ju, Ickhee Kim, John Jackson, Anthony Atala, James Yoo, Sang Jin Lee*, Winston Salem, NC</td>
</tr>
<tr>
<td>MP61-04</td>
<td>ENHANCED ENDOTHELIAL CELL ATTACHMENT VIA ANTIBODY CONJUGATION: TOWARD KIDNEY IMPLANTATION USING AUTOLOGOUS CELL SOURCES</td>
<td>Jennifer Huling, Ethan Bassin, In Kap Ko, John Jackson*, James Yoo, Anthony Atala, Winston Salem, NC</td>
</tr>
<tr>
<td>MP61-05</td>
<td>UTILIZATION OF NOVEL TOOLS TO ASSESS RISK OF ESRD IN PATIENTS WHO UNDERWENT DONOR NEPHRECTOMY</td>
<td>Jason Scovell*, Andre F. Perez-Orozco, Zachary McDowell, Nannan Thirumavalavan, Samit Soni, Wesley A. Mayer, Richard E. Link, Houston, TX</td>
</tr>
<tr>
<td>MP61-06</td>
<td>CLCF1 IS UP-REGULATED IN RENAL ISCHEMIA/REPERFUSION INJURY AND SERVES AS A POTENTIAL BIOMARKER FOR DELAYED GRAFT FUNCTION IN KIDNEY TRANSPLANTATION</td>
<td>Wei Qiu*, Ye Tian, Beijing, China, People's Republic of</td>
</tr>
</tbody>
</table>
MP61-12 CLINICAL IMPACT OF GLOMERULAR BASEMENT MEMBRANE THICKNESS ON DONOR RENAL FUNCTION AFTER KIDNEY DONATION
Shingo Hatakeyama*, Tohru Yoneyama, Hirotake Kodama, Ayumu Kusaka, Shogo Hosogoe, Noriko Tokui, Hayato Yamamoto, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Koie, Chikara Ohyama, Hirosaki, Japan

MP61-13 OUTCOMES OF DUAL KIDNEY TRANSPLANTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS
Andrew Stokl*, Gaurav Vasisth, Anil Kapoor, Kevin Piercey, Forough Farrokyhar, Shahid Lambe, Hamilton, Canada

MP61-14 HIGH INCIDENCE OF BLADDER CARCINOMA IN RENAL-TRANSPLANTED PATIENTS WITH BLADDER AUGMENTATION: LONG-TERM CAREFUL ATTENTION IS DEMANDING
Kleiton Yamac¸ake, Hugo Barone*, Eder Ilario, Marcos Melo, Ricardo Haidar, Renato Falci Junior, Gustavo Ebaid, Hideki Kanashiro, William Nahas, Affonso Piovesan, Sao Paulo, Brazil

MP61-15 PSA SURVEILLANCE IN RENAL TRANSPLANT RECIPIENTS
Meghana Kulkarni*, Sharon Frame, Antonia Cronin, Ben Challacombe, Paul Cathcart, Jonathon Olsburgh, London, United Kingdom

MP61-16 CLINICOPATHOLOGICAL ANALYSIS OF PROSTATE CANCER IN PATIENTS WITH RENAL TRANSPLANT RECIPIENTS
Junpei Iizuka*, Tokyo, Japan, Yasunobu Hashimoto, Saitama, Japan, Tsunenori Kondo, Keisuke Hata, Toshih Takagi, Taichi Kanzawa, Kazuhiko Yoshida, Masayoshi Okumi, Hideki Ishida, Kazunari Tanabe, Tokyo, Japan

MP61-17 KIDNEYS RECEIVED FROM LIVING DONORS OVER 70 YEARS OF AGE: ARE THOSE FEASIBLE AS THE GRAFTS?
Mitsuru Saito*, Takamitsu Inoue, Shintaro Naita, Kazuyuki Numakura, Sohei Kanda, Syuji Chiba, Taketomi Nara, Shigeru Satoh, Tomonori Habuchi, Akita, Japan

MP61-18 IMPACT OF CIGARETTE SMOKING ON LIVING KIDNEY DONOR
Young Eun Yoon*, Seoul, Korea, Republic of, Hyung Ho Lee, Goyang, Korea, Republic of, Joon Chae Na, Sung Yul Park, Woong Kyu Han, Seoul, Korea, Republic of

MP61-19 PREOPERATIVE USE OF ANTIPLATELETS AND ANTICOAGULANTS IN DECEASED DONOR RENAL TRANSPLANTS DOES NOT RESULT IN INCREASED COMPLICATION RATES

MP61-20 CLINICAL IMPACT OF ABDOMINAL FAT DISTRIBUTION USING 3-D COMPUTED TOMOGRAPHY VOLUMETRY ON RENAL FUNCTION AFTER RENAL TRANSPLANTATION
Yosuke Mitsu*, Sadahira Takuya, Motoo Araki, Yuki Maruyama, Koichiro Wada, Ryuta Tanimoto, Yasuyuki Kobayashi, Masami Watanabe, Toyohiko Watanabe, Yasutomo Nasu, Okayama, Japan

MP62-01 THE WATER STUDY SEXUAL FUNCTION RESULTS – A PHASE III BLINDED RANDOMIZED PARALLEL GROUP TRIAL OF AQUBATION VS. TRANURETHRAL RESECTION OF THE PROSTATE WITH BLINDED OUTCOME ASSESSMENT FOR MODERATE-TO-SEVERE LUTS IN MEN WITH BENIGN PROSTATIC HYPERPLASIA
Neil Barber*, Surrey, United Kingdom

MP62-02 EJACULATORY PRESERVING MIDDLE LOBE ONLY - TRANURETHRAL RESECTION AND VAPORIZATION OF THE PROSTATE: 12 YEAR EXPERIENCE
Zeynep Gul*, Bilal Chughtai, Alexis Te, Steven Kaplan, New York, NY

MP62-03 EJACULATION-PRESERVING GREENLIGHT PHOTOVAPORIZATION: SHORT- AND LONG TERM RESULTS
Steve Doizi*, Bertrand Lukacs, Paris, France

MP62-04 COMPARISON OF CONVEXTIVE RADIOFREQUENCY THERMAL THERAPY OF PROSTATE (REZUM®) TO MTOPS STUDY COHORT SEXUAL FUNCTION RESPONSE AT 3 YEARS
Sevann Helo*, Nicholas Tadros, Springfield, IL, Nikhil Gupta, New Brunswick, NJ, Bradley Holland, Danuta Dynda, Kevin McVary, Springfield, IL

*Presenting author

SUNDAY

1:00 pm - 3:00 pm

Moderated Poster Session 62

BENIGN PROSTATIC HYPERPLASIA: SURGICAL THERAPY & NEW TECHNOLOGY I

ABSTRACT NUMBER TITLE
MP62-01 THE WATER STUDY SEXUAL FUNCTION RESULTS – A PHASE III BLINDED RANDOMIZED PARALLEL GROUP TRIAL OF AQUBATION VS. TRANURETHRAL RESECTION OF THE PROSTATE WITH BLINDED OUTCOME ASSESSMENT FOR MODERATE-TO-SEVERE LUTS IN MEN WITH BENIGN PROSTATIC HYPERPLASIA
Neil Barber*, Surrey, United Kingdom

MP62-02 EJACULATORY PRESERVING MIDDLE LOBE ONLY - TRANURETHRAL RESECTION AND VAPORIZATION OF THE PROSTATE: 12 YEAR EXPERIENCE
Zeynep Gul*, Bilal Chughtai, Alexis Te, Steven Kaplan, New York, NY

ABSTRACT NUMBER TITLE
MP62-03 EJACULATION-PRESERVING GREENLIGHT PHOTOVAPORIZATION: SHORT- AND LONG TERM RESULTS
Steve Doizi*, Bertrand Lukacs, Paris, France

MP62-04 COMPARISON OF CONVEXTIVE RADIOFREQUENCY THERMAL THERAPY OF PROSTATE (REZUM®) TO MTOPS STUDY COHORT SEXUAL FUNCTION RESPONSE AT 3 YEARS
Sevann Helo*, Nicholas Tadros, Springfield, IL, Nikhil Gupta, New Brunswick, NJ, Bradley Holland, Danuta Dynda, Kevin McVary, Springfield, IL

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 20, 2018

Moderated Poster Session 62

Benign Prostatic Hyperplasia: Surgical Therapy & New Technology I

Room 3006 @ MCC West

Moderators: Alexis Te, Ricardo Gonzalez and Karin Lehrich

213
MP62-05 OUTCOMES ASSESSMENT OF AQUABLATION IN PROSTATES 50 TO 80ML IN VOLUME - A SUBGROUP ANALYSIS FROM THE PHASE III BLINDED RANDOMIZED WATER STUDY COMPARING AQUABLATION VS. TRANSPERCUTANEOUS RESECTION OF THE PROSTATE FOR MODERATE-TO-SEVERE LUTS IN MEN WITH BPH
Claus Roehrborn*, Dallas, TX, Peter Gilling, Tauranga, New Zealand

MP62-06 MULTIPLE HEMOSTASIS TECHNIQUES USED FOLLOWING AQUABLATION ANALYZED FOR POST-PROCEDURE BLEEDING COMPLICATIONS
Mihir Desai*, Los Angeles, CA, on behalf of the Aquablation Investigators, Redwood Shores, CA

MP62-07 PREDICTORS OF RESPONSE TO THE PROSTATIC URETHRAL LIFT TREATMENT
Steven Kaplan*, New York, NY, Claus Roehrborn, Dallas, TX

MP62-08 EVALUATION OF PERIOPERATIVE OUTCOMES OF PATIENTS WITH PROSTATES SMALLER THAN 60CC TREATED FOR LOWER URINARY TRACT SYMPTOMS (LUTS) WITH HOLMIUM LASER ENUCLEATION OF THE PROSTATE (HOLEP) VERSUS TRANSPERCUTANEOUS RESECTION OF THE PROSTATE (TURP)
Thilo Westhofen*, Giuseppe Magistro, Maurice Kolb, Christian Gratzke, Christian C. Stief, Philipp Weinhold, Munich, Germany

MP62-09 PROSTATE ARTERY EMBOLISATION VERSUS TURP: A MULTICENTRIC PROSPECTIVE COMPARISON: THE UK-ROPE STUDY
Ranan Dasgupta*, London, United Kingdom, Mark Speakman, Taunton, United Kingdom, Alistair Ray, Cardiff, United Kingdom, John Powell, London, United Kingdom, Sachin Modi, Southampton, United Kingdom, Grace Carolan-Rees, Cardiff, United Kingdom, Nigel Hacking, Southampton, United Kingdom

MP62-10 MONOPOLAR VERSUS LASER (THUFLP, HOLEP) ENDOSCOPIC ENUCLEATION OF THE PROSTATE: A SINGLE-CENTER EXPERIENCE
Dmitry Enikeev*, Petr Glybochko, Yuriy Alyaev, Leonid Rapoport, Dmitry Tsarichenko, Mikhail Enikeev, Nikolay Sorokin, Roman Sukhanov, Alim Dymov, Mark Taratkin, Moscow, Russian Federation

MP62-11 HOLMIUM LASER ENUCLEATION VERSUS BIPOLAR RESECTION FOR LARGE PROSTATE
Ahmed Yehia, Enmar Habib, Mohammed ElSheemy*, Hussein Aly, Samir Morsy, A. Hossam, M. Abdelazeem, Cairo, Egypt

MP62-12 THE 3 YEARS’ TEST OF TIME IN LARGE PROSTATE SURGERY – BIPOLAR PLASMA VAPORIZATION, RESECTION AND ENUCLEATION VERSUS OPEN PROSTATECTOMY IN A PROSPECTIVE, RANDOMIZED-CONTROLLED CLINICAL SETTING
Bogdan Geavlete*, Cosmin Ene, Catalin Bulai, Georgiana Balan, Petrisor Geavlete, Bucharest, Romania

Vincent Misrai*, Marie Pasquie, Benoît Bordier, Julien Guillotreau, Toulouse, France, Benoît Peyronnet, Rennes, France, Kevin Zorn, Montréal, Canada

MP62-14 A RANDOMISED TRIAL COMPARING THULIUM VAPONEUCLEATION VERSUS HOLMIUM LASER ENUCLEATION OF THE PROSTATE: RESULTS AT 12-MONTHS
Christopher Netsch*, Benedikt Becker, Arcangelo Venneri Becoi, Hamburg, Germany, Thomas Herrmann, Hannover, Germany, Andreas Gross, Hamburg, Germany

MP62-15 SAFETY OF HOLMIUM LASER ENUCLEATION OF THE PROSTATE (HOLEP) IN PATIENTS WITH ANTITHROMBOTIC AGENTS
Camilla Grunewald, Alessandro Nini, Peter Albers, Achim Lusch*, Dusseldorf, Germany

MP62-16 CLINICAL APPLICATION OF DAY SURGERY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH THE MODIFIED HOLMIUM LASER ENUCLEATION OF PROSTATE WITH PRESERVATION OF PARTIAL URETHRAL MUCOSA: A SINGLE INSTITUTION EXPERIENCE
Wanhai Xu*, Keliang Wang, Harbin, China, People’s Republic of

MP62-17 EIGHTEEN YEARS OF HOLMIUM LASER ENUCLEATION OF THE PROSTATE: A SINGLE CENTER EXPERIENCE
Ahmed Ibrahim, Mohammad Alharbi*, Mostafa Elhilali, Serge Carrier, Montreal, Canada

MP62-18 PHOTOSELECTIVE VAPORIZATION OF THE PROSTATE WITH THE 180-W XPS- GREENLIGHT LASER: 5-YEAR EXPERIENCE OF SAFETY, EFFICIENCY AND FUNCTIONAL OUTCOMES
Khaled Ajib*, Felix Couture, Come Tholomier, Daniel Liberman, Pierre-Alain Hueber, Benjamin Pradere, Vincent Misrai, Dean Elterman, Kevin Zorn, Montreal, Canada

MP62-19 HOLMIUM LASER ENUCLEATION OF THE PROSTATE: PERIOPERATIVE OUTCOMES FOR SAME DAY PROCEDURES
Aye Lwin*, Kieran Hynes, Michael Phung, Elinora Price, Christian Twiss, Joel Funk, Tucson, AZ
**MP62-20 STENTING IN CASES OF URETERAL ORIFICE DAMAGE DURING LASER ENUCLEATION OF THE PROSTATE FOR BPH: IS IT WORTH IT?**

Dmitry Enikeev*, Petr Glybochko, Yuriy Alyaev, Leonid Rapoport, Mikhail Enikeev, Nikolay Sorokin, Roman Sukhanov, Alim Dymov, Mark Taratkin, Moscow, Russian Federation

---

**ABSTRACT NUMBER TITLE**

**MP63-01 FEASIBILITY OF NEXT GENERATION NON-LINEAR BEAMFORMING ULTRASOUND METHODS TO CHARACTERIZE AND SIZE KIDNEY STONES**

Ryan Hsi*, Siegfried Schlunk, Jaime Tierney, Rebecca Jones, Mark George, Pranav Karve, Ravindra Duddu, Brett Byram, Nashville, TN

**MP63-02 CHARACTERIZATION OF RENAL STONES USING SPECTRAL DETECTOR COMPUTED TOMOGRAPHY**

N. Große Hokamp, Leonidas Karapanos*, Johannes Salem, JA Holz, Cologne, Germany, A. Hesse, Bonn, Germany, M. Ritter, Mannheim, Germany, Axel Heidenreich, David Maintz, Stefan Haneder, Cologne, Germany

**MP63-03 DOES THE SURGEON’S HEIGHT AND DISTANCE FROM THE C-ARM AFFECT BRAIN AND EYE RADIATION EXPOSURE DURING FLUOROSCOPY?**

Joel Willard, Christopher Heinrich, Mohammad Hajitha*, Julie W. Cheng, Hillary Wagner, Jonathan Ewald, Darrell Petersen, P. Ben Nava, Bertha Escobar-Poni, D. Duane Baldwin, Loma Linda, CA

**MP63-04 DO LEAD GLASSES PROTECT THE EYES AND BRAIN FROM SCATTERED RADIATION DURING PERCUTANEOUS NEPHROLITHOTOMY?**

Christopher Heinrich, Joel Willard, Mohammad Hajitha, Julie Cheng, Hillary Wagner*, Jonathan Ewald, D. Duane Baldwin, Loma Linda, CA

**MP63-05 FLUOROSCOPY PULSE RATE AND RADIATION ABSORBED DOSE DEMONSTRATE A NEAR-PERFECT LINEAR CORRELATION**

Todd Yecies*, Michelle Semins, Michael Sheetz, Mark Durango, Rajeev Chaudhry, Pittsburgh, PA

---

**APPROVED FOR AMA PRA CATEGORY 1 CREDIT™**

Sunday, May 20, 2018

1:00 pm - 3:00 pm

**Moderated Poster Session 63**

**IMAGING/RADIOLOGY: URORADIOLOGY IV**

Room 3009 @ MCC West

**Moderators: Art Rastinehad, Erick Remer**

---

**ABSTRACT NUMBER TITLE**

**MP63-06 COMPARISON OF PATIENT RADIATION EXPOSURE DURING PERCUTANEOUS NEPHROLITHOTOMY USING 3 DIFFERENT TECHNIQUES: A CADAVER STUDY**


**MP63-07 COMPARATIVE RADIATION EXPOSURE AND COSTS ASSOCIATED WITH PERCUTANEOUS NEPHROSTOMY TUBE VS URETERIC STENT FOR EMERGENCY RENAL DECOMPRESSION**

Simeon Ngweso*, Jean O’Riordan, Trenton Barrett, Melvyn Kuan, Dickon Hayne, Perth, Australia

**MP63-08 NOVEL OBSERVATIONS OF FEMALE PELVIC ANATOMY IN CLASSIC BLADDER EXSTROPHY USING THREE-DIMENSIONAL MRI RECONSTRUCTION**

Karl Benz*, Emily Dunn, Meiyappan Solaiyappan, Matthew Kaspréski, Mahir Maruf, John Jayman, John Gearhart, Baltimore, MD

**MP63-09 A CLINICAL PROTOCOL FOR 3D IMAGE RECONSTRUCTION OF THE FEMALE PELVIS AND LEVATOR ANI DEFECTS SEEN WITH UPRIGHT POSTURE USING UPRIGHT OPEN MRI (MRO) IMAGING**

M Abdulaziz, Lynn Stothers*, Andrew Macnab, Vancouver, Canada

**MP63-10 DEVELOPMENT OF A CLINICAL DECISION-SUPPORT TOOL FOR CLASSIFICATION OF RENAL MASSES**

Gautam Kunapuli, Priya Ganapathy, Bino Vargheese, Darryl Hwang, Steven Cen, Bhushan Desai, Manju Aron, Inderbir Gill, Vinay Duddalwar*, Mihir Desai, Los Angeles, CA
MP63-11 OPTICAL BIOPSY USING CONFOCAL MICROSCOPY FOR DIFFERENTIATION OF RENAL CELL CARCINOMA VERSUS BENIGN TISSUE

MP63-12 DIFFERENTIATION OF RENAL CELL CARCINOMA SUBTYPES USING DUAL-ENERGY COMPUTED TOMOGRAPHY AND IODINE CONCENTRATION ANALYSIS - CORRELATION WITH MICROVASCULAR DENSITY IN TUMOR SPECIMENS
Julian Marcon*, Anno Graser, David Horst, Jozefina Casuscelli, Christian G. Stief, Maximilian F. Reiser, Alexander Buchner, Michael Staehler, Munich, Germany

MP63-13 “PIN THE TUMOR ON THE KIDNEY”: AN EVALUATION OF HOW SURGEONS TRANSLATE CT AND MRI DATA TO 3D MODELS
Nicole Wake*, Marc Bjurlin, James Wysock, Hersh Chandarana, William Huang, New York, NY

MP63-14 ANTICIPATED POST-OPERATIVE RADIOGRAPHIC CHANGES OF HEMOSTATIC AGENTS IN PARTIAL NEPHRECTOMY
Ahmad El-Arabi*, Ryan Tubre, Kansas City, KS, Travis Dum, St. Louis, MO, William Parker, Kansas City, KS, Zachary Hamilton, St. Louis, MO, Moben Mirza, David Duchene, Kansas City, KS

MP63-15 CAN RENAL TRACT ULTRASOUND REPLACE CT UROGRAPHY FOR THE EVALUATION OF MICROSCOPIC HEMATURIA? RESULTS OF A PROSPECTIVE OBSERVATIONAL STUDY
Wei Shen Tan*, Andrew Feber, Liqin Dong, Rachael Sarpong, Simon Rodney, Pramit Khetrapal, Patricia de Winter, Rumana Jalil, Norman Williams, Chris Brew-Graves, John Kelly, London, United Kingdom, DETECT I trial group, England, United Kingdom

MP63-16 PROSPECTIVE RANDOMIZED COMPARISON OF CONVENTIONAL AND TRIPLE BOLUS COMPUTED TOMOGRAPHY FOR HEMATURIA EVALUATION
Daniel Lama, Egor Parkhomenko*, Chandana Lall, Roshan Patel, Kamaljit Kaler, Ralph Clayman, Jaime Landman, Orange, CA

MP63-17 A NOVEL METHOD TO DETERMINE URETERAL LENGTH BY CT UROGRAPHY WITH IMPLICATIONS ON URETERAL STENT LENGTH CHOICE
Blake B. Anderson*, Tariq A. Hameed, Joshua M. Heiman, James C. Williams, Jr., Amy E. Krambeck, James E. Lingeman, Indianapolis, IN

MP63-18 PREOPERATIVE 3D TRANSLABIAL ULTRASOUND AIDS IN THE MANAGEMENT OF SYNTHETIC MID-URETHRAL SLING REMOVAL
Nabeel Shakir, Connie Wang*, Melissa Foreman, Melissa Foreman, Gaurav Khatri, Philippe Zimmern, Dallas, TX

MP63-19 INTRAOPERATIVE IDENTIFICATION OF NERVES WITH AN INTRAVENOUS NERVE-BINDING FLUOROPHORE: SUBJECTIVE AND OBJECTIVE ASSESSMENT OF FLUORESCENCE IN PORCINE MODELS

MP63-20 SUBCUTANEOUS FAT DISTRIBUTION IS A PROGNOSTIC BIOMARKER FOR MEN WITH CASTRATION-RESISTANT PROSTATE CANCER
Jong Soo Lee*, Jee Soo Park, Yoon Soo Ha, Kwang Suk Lee, Hyun Kyu Ahn, Jee Soo Ha, Do Kyung Kim, Dong Hoon Lee, Koon Ho Rha, Sung Joon Hong, Byung Ha Chung, Kyo Chul Koo, Seoul, Korea, Republic of

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| MP64-01 | EXPOSURE TO CHLORDECONE AND PROSTATE CANCER: INTERACTIONS WITH GENES CODING FOR ESTROGEN  
Laurent Bruere*, Elise Emeville, Ferdinand Severine, Marc Romana, Pascal Blanchet, Luc Multigner, Pointe-à-Pitre, Guadeloupe |
| MP64-02 | THERAPEUTIC TARGETING OF TRANSCRIPTIONAL REPRESSOR BCL-6 FOR CAstration-RESISTANT PROSTATE CANCER THROUGH REPRESSING ANDROGEN RECEPTOR VARIANTS  
Hiroshi Hongo*, Takeo Kosaka, Yota Yasumizu, Yasumasa Miyazaki, Eiji Kikuchi, Mototsugu Oya, Shinjuku-ku, Japan |
| MP64-03 | MIR-361-5P MODULATES METABOLISM AND AUTOPHAGY VIA THE SP1-MEDIATED REGULATION OF PKM2 IN PROSTATE CANCER  
Tao Tao*, Zhixin Ling, Jun Xiao, Hefei, China, People's Republic of |
| MP64-04 | SLC02B1 HIGH EXPRESSED TUMOR IN HIGH GLEASON SCORE PROSTATE CANCER PATIENTS RECURRE EARLIER AFTER RADICAL PROSTATECTOMY  
Tomoaki Terakawa*, Kobe, Japan, Eriko Katsuta, Khurshid Guru, Kauzuki Takabe, Buffalo, NY, Masato Fujisawa, Kobe, Japan |
| MP64-05 | THE APPLICATION OF MINIMAL SCORE OF APPARENT DIFFUSION COEFFICIENT (ADC) IN PROSTATE MRI TO PREDICT THE PROSTATE CANCER MICROENVIRONMENT  
Manabu Kato*, Tsu, Japan, Placencio Veronica, Los Angeles, CA, Kenichiro Ishii, Kohei Nishikawa, Kiminobu Anima, Yoshihumi Hirokawa, Masatoshi Watanabe, Yoshiki Sugimura, Tsu, Japan |
| MP64-06 | BIOINFORMATIC ANALYSIS IDENTIFIED CANDIDATE DRUGS FOR ANDROGEN SIGNALING THROUGH MODULATING ANDROGEN RECEPTOR AND ITS SPLICE VARIANTS  
Hiroshi Hongo*, Takeo Kosaka, Yota Yasumizu, Yasumasa Miyazaki, Eiji Kikuchi, Mototsugu Oya, Shinjuku-ku, Japan |
| MP64-07 | VASCULAR HURST INDEX IN NON-TUMORAL BIOPSY CORES AS POTENTIAL HISTOPATHOLOGICAL PARAMETER TO SELECT PATIENTS WITH HIDDEN PROSTATE CANCER  
Fabio Grizzi*, Rozzano (MI), Italy, Alberto Mandressi, Castellanza (VA), Italy, Piergiuseppe Colombo, Rozzano (MI), Italy, Sara Melegari, Matteo Justich, Giorgio Bozzini, Mauro Seveso, Oliviero De Francesco, Castellanza (VA), Italy, Nicola Buffi, Giovanni Lughezzani, Massimo Lazzeri, Rodolfo Hurle, Luisa Pasini, Alessio Benetti, Silvia Zandegiacomo, Roberto Peschechera, Paolo Casale, Giorgio F. Guazzoni, Rozzano (MI), Italy, Gianluigi Taverna, Castellanza (VA), Italy |
| MP64-08 | A NOVEL BIGUANIDE DERIVATIVE DRUG, IM176, INHIBITS PROSTATE CANCER  
Choung-Soo Kim, Wonseok Choi*, Yoonr Im, Bong-Min Kim, Seoul, Korea, Republic of |
| MP64-09 | IN SILICO SCREENING USING RNA-SEQ DATA SETS OF NEUROENDOCRINE PROSTATE CANCER HAS IDENTIFIED CANDIDATE DRUGS FOR REPROGRAMMING NEPC-SPECIFIC SIGNATURES  
Takeo Kosaka*, Hiroshi Hongo, Shuji Mikami, Kazuhiro Matsumoto, Eiji Kikuchi, Mototsugu Oya, Tokyo, Japan |
| MP64-10 | INFILTRATING CD4+ T CELLS ATTENUATED THE SENSITIVITY OF CHEMOTHERAPY IN PROSTATE CANCER VIA SECRETING CCL5  
Peng Xiang*, Shuai Hu, Song Jin, Yang Yang, Jing Dong Sheng, Jie Jin, Bei Jing, China, People's Republic of |
| MP64-11 | CHEMOPREVENTIVE AND CHEMOTHERAPEUTIC POTENTIALS OF LUTEOLIN VIA REGULATION OF OXIDATIVE STRESS IN CASTRATION-RESISTANT PROSTATE CANCER  
Taku Naiki*, Aya Naiki-Ito, Toshiki Etani, Keitaro Iida, Ryosuke Ando, Takashi Nagai, Nonyasu Kawai, Satoru Takahashi, Takahiro Yasui, Nagoya, Japan |

*Presenting author
MP64-12 AKR1C3, AS A NOVEL TARGET OF DAB2IP SIGNALING, MAINTAINS THE PROTEIN STABILITY OF ANDROGEN RECEPTOR SPlicing VARIANT IN PROSTATE CANCER
Bin Wang, Dalin He, Xi’an, China, People’s Republic of, Jer-Tsong Hsieh, Dallas, TX, Kaijie Wu*, Xi’an, China, People’s Republic of

MP64-13 COMBINED N-TERMINAL ANDROGEN RECEPTOR AND AUTOPHAGY INHIBITION INCREASES THE ANTI-TUMOR EFFECT IN ENZALUTAMIDE-SENSITIVE AND ENZALUTAMIDE-RESISTANT LNCAP CELLS
Benedikt Kranzburger*, Souzan Salemi, Tullio Sulser, Daniel Eberli, Zurich, Switzerland

MP64-14 TARGETING HEAT SHOCK FACTOR 1 SENSITIZES CASTRATION-RESISTANT PROSTATE CANCER CELLS TO HSP90 INHIBITION IN PART BY DESTABILIZING ANDROGEN RECEPTOR SPLICE VARIANTS
Toshiki Kijima*, Tokyo, Japan, Thomas Prince, Danville, PA, Katsuo Mor, Soichiro Yoshi, Minato Yokoyama, Junichiro Ishioka, Yoh Matsuoka, Kazutaka Saito, Kazunori Kihara, Tokyo, Japan, Len Neckers, Bethesda, MD, Yasuhisa Fujii, Tokyo, Japan

MP64-15 PRO-INFLAMMATORY CYTOKINE GENES ARE DRIVERS OF PROSTATE CANCER PROGRESSION AND CASTRATE RESISTANT PROSTATE CANCER
Isaac Powell*, Aliccia Bollig-Fischer, Elisabeth Heath, Detroit, MI

MP64-16 HYPOFRACTIONATED STEREOTACTIC RADIOTHERAPY INCREASES BOTH TUMOR-INFILTRATING LYMPHOCYTES AND SUPPRESSIVE IMMUNE CELLS IN PROSTATE CANCER
Lin Lin*, Nathan Kane, Naoko Kobayashi, Siliva Diaz-Perez, Rajan Kulikarni, Nicholas Nichols, Robert Reiter, Los Angeles, CA

MP64-17 EXTRACELLULAR COLLAGENIC TYPE AND STRUCTURAL ORGANIZATION CHANGES IN PROSTATE CANCER AND BENIGN PROSTATIC HYPERPLASIA
Fabio Grizzl*, Rozzano (MI), Italy, Alberto Mandressi, Castellanza (VA), Italy, Piergiuseppe Colombo, Rozzano (MI), Italy, Sara Melegari, Matteo Justich, Giorgio Bozzini, Mauro Seveso, Oliviero De Francesco, Castellanza (VA), Italy, Nicolò Buffi, Giovanni Lugezani, Massimo Lazzeri, Rodolfo Hurle, Luisa Pasini, Alessio Benetti, Silvia Zandegracomo, Roberto Pescheccher, Paolo Casale, Giorgio F. Guazzoni, Rozzano (MI), Italy, Gianluigi Taverna, Castellanza (VA), Italy

MP64-18 THE ANALYSIS OF EXPRESSION AND MOLECULAR MECHANISM FOR VASOHBIN-2 IN PROSTATE CANCER
Yasumasa Miyazaki*, Takeo Kosaka, Shuji Mikami, Hiroshi Hongo, Yota Yasumizu, Nobuyuki Tanaka, Eiji Kikuchi, Tokyo, Japan, Yasufumi Sato, Miyagi, Japan, Mototsugu Oya, Tokyo, Japan

MP64-19 GENE EXPRESSION SIGNATURE PREDICTS BIOCHEMICAL AND METASTATIC RECURRENCE IN MEN WITH CLINICALLY LOCALIZED PROSTATE CANCER TREATED WITH RADICAL PROSTATECTOMY
Albert Carrion*, Mercedes Ingelmo-Torres, Maurizio D’Anna, Claudia Mercader, Juan Jose Lozano, Maria Jose Ribal, Lourdes Mengual, Antonio Alcaraz, Barcelona, Spain

MP64-20 A NOVEL NITROXOLINE TREATMENT, TARGETING THE PI3K PATHWAY, IN COMBINATION WITH PD-1 BLOCKAGE, EXERTS A POTENT PROSTATE CANCER ANTI-TUMOR EFFECT
Naijin Xu*, Chaoming Li Masami Watanabe, Okayama, Japan, Abai Xu, Chunxiao Liu, Guangzhou, China, People’s Republic of Qi Li, Taizhou, China, People’s Republic of, Araki Motoo, Koichiro Wada, Yasutomo Nasu, Peng Huang, Okayama, Japan

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
ABSTRACT NUMBER TITLE
MP65-01 4N1K-PEPTIDE DERIVED FROM THROMBOSPONIDIN-2 IS ASSOCIATED WITH MALIGNANT AGGRESSIVENESS AND PROGNOSIS IN BLADDER CANCER Yasuyoshi Miyata, Tsutomu Yuno*, Kyohei Araki, Yuichiro Nakamura, Takui Yasuda, Yuji Sagara, Tomohiro Matsu, Kojiro Ohba, Hideki Sakai, Nagasaki, Japan

MP65-02 DIAGNOSTIC CLASSIFICATION OF CYSTOSCOPIC IMAGES USING DEEP CONVOLUTIONAL NEURAL NETWORK Okyaz Eminaga*, Cologne, Germany, Axel Semjonow, Muenster, Germany, Bernhard Breil, Krefeld, Germany

MP65-03 GENOMIC ANALYSIS ON SUBJECTS EXPOSED TO ARSENIC IDENTIFIES GENETIC RISK VARIANTS ASSOCIATED WITH BLADDER CANCER AND VARIANTS UNDER RECENT ADAPTIVE SELECTION Mario Fernandez*, Lucas Vicuña, Santiago, Chile, Patricio Valdebenito, Eduardo Chaparro, Antofagasta, Chile, Cecilia Vial, Annemarie Ziegler, Alberto Bustamante, Susana Eyheramendy, Santiago, Chile

MP65-04 LONG NON-CODING RNA GAS5 MODULATES GEMCITABINE EFFICACY IN BLADDER CANCER VIA REGULATION OF DEOXYCYTIDINE KINASE EXPRESSION Wei Chen*, Junlong Zhuang, Wenmin Cao, Wenli Diao, Hongqian Guo, Nanjing, China, People’s Republic of

MP65-05 NOTCH2 IN THE BLADDER PROMOTES TUMOR DEVELOPMENT AND LEADS TO MORE MALIGNANT PHENOTYPE Akihiro Goriki*, Hiroshima, Japan, Takeshi Sano, Alberto Contreras, Htoo Oo, Vancouver, Canada, Tetsutarou Hayashi, Akio Matsubara, Hiroshima, Japan, Peter Black, Vancouver, Canada

MP65-06 THE URINARY MICROBIOME DIFFERS BETWEEN BLADDER CANCER AND CONTROL CASES Hai Bi*, Jianui Li, Chuan Song, Ya Tian, Tingting Liu, Chen Chen, Lulin Ma, Yuanyuan Zhang, Beijing, China, People’s Republic of


ABSTRACT NUMBER TITLE
MP65-08 THE NEUTROPHIL-TO-LYMPHOCYTE RATIO AS A PROGNOSTIC FACTOR FOR PATIENTS WITH UROTHELIAL CARCINOMA OF THE BLADDER FOLLOWING RADICAL CYSTECTOMY Fabio Zattoni*, Gianluca Giannarini, Alessandro Crestani, Udine, Italy, Giacomo Novara, Padua, Italy, Vincenzo Ficarra, Messina, Italy


MP65-10 THE TUMOR SUPPRESSOR MICRORNAs 223 TARGETS WDR62 DIRECTLY IN BLADDER CANCER Satoshi Sugita*, Hirofumi Yoshino, Kazutaka Miyamoto, Masaya Yonemori, Takashi Sakaguchi, Ryojuke Matsushita, Shuichi Tafarano, Takashi Yamane, Hideki Enokida, Masayuki Nakagawa, Kagoshima, Japan


MP65-12 ORGANOID 3D CULTURE SYSTEM FOR BLADDER CANCER MODELING Victor Romanov, William Berg*, Terry Whyard, Wei Lee, Olga Povcher, Daniel Rittenberg, Wayne Waltzer, Stony Brook, NY

MP65-13 UROSEEK: A NOVEL NON-INVASIVE MOLECULAR METHOD FOR EARLY DETECTION OF BLADDER CANCER Simeon Springer, Baltimore, MD, Maria Del Carmen Rodriguez Pena*, Birmingham, AL, Aline Tregnago, Baltimore, MD, Diana Taheri, Tehran, Islamic Republic of Iran, Stephania Bezerra, Isabelia Cunha, Sao Paulo, Brazil, Kazutoshi Fujita, Osaka, Japan, Dilek Baydar, Hacettepe, Turkey, Trinity Bivalacqua, Nickolas Papadopoulos, Kenneth W. Kinzler, Bert Vogelstein, Baltimore, MD, George Netto, Birmingham, AL

*Presenting author
MP65-14 UROSEEK: A NOVEL NON-INVASIVE MOLECULAR ASSAY FOR SURVEILLANCE OF BLADDER CANCER
Simeon Springer, Baltimore, MD, Maria Del Carmen Rodriguez Pena*, Birmingham, AL, Aline Tregnago, Baltimore, MD, Diana Taheri, Tehran, Islamic Republic of Iran, Stephanie Bezerra, Isabela Cunha, São Paulo, Brazil, Kazutoshi Fujita, Osaka, Japan, Dilek Baydar, Hacettepe, Turkey, Trinity Bivalacqua, Nicholas Papadopoulos, Kenneth W. Kinzler, Bert Vogelstein, Baltimore, MD, George Netto, Birmingham, AL

MP65-15 HUMANIZED ANTI-CD47 ANTIBODY (HU-5F9-G4) FOR METASTATIC BLADDER CANCER IS SUPERIOR TO CONVENTIONAL CHEMOTHERAPY WITH CISPLATIN AND GEMCITABINE IN A MURINE BLADDER CANCER MODEL
Bernhard Kiss*, Anne Volkmer, Joseph Liao, Jens-Peter Volker, Irving Weissman, Stanford, CA

MP65-16 NOVEL BIOMARKER SIGNATURE FOR PREDICTING PATHOLOGIC RESPONSE OF UROTHELIAL CARCINOMA OF THE BLADDER TO CISPLATIN-BASED NEOADJUVANT CHEMOTHERAPY
Patrick Hensley*, Matthew Purdom, Natasha Kyprianou, Chi Wang, Andrew James, Lexington, KY

MP65-17 MICRORNA-411 DOWNREGULATION PROMOTES TUMORIGENESIS AND INHIBITS CHEMOTHERAPY SENSITIVITY BY UPREGULATING MLLT11 EXPRESSION IN HUMAN BLADDER CANCER
Xiaohui Hua*, tuxedo park, NY, Honglei Jin, Haishan Huang, Wenzhou, China, People’s Republic of, JingXia Li, Chuanshu Huang, Tuxedo Park, NY

MP65-18 BLADDER CANCER EXTRACELLULAR VESICLES FACILITATE METASTASIS
Yu-Ru Liu*, Yi-Fen Lee, Peng-Nien Yin, Edward Messing, Rochester, NY

MP65-19 A MURINE MODEL OF OX-40 AND PD-1 IMMUNOTHERAPY IN COMBINATION WITH VASCULAR TARGET PHOTODYNAMIC THERAPY (VTP) ON UROTHELIAL CANCER TREATMENT
Ricardo Alvim*, Souhil Lebdai, Alexander Somma, Karan Nagar, Christopher Hughes, Sebastien Monette, Petrina Georgala, Rui Gardner, Kwanghee Kim, Jonathan Coleman, New York, NY

MP65-20 BCG INTERNALIZATION RELEASES INCREASED LEVELS OF IMMUNE-ACTIVE EXTRACELLULAR VESICLES
Carlos Ortiz Bonilla*, Yi-Fen Lee, Edward Messing, Rochester, NY

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 20, 2018
1:00 pm - 3:00 pm

Moderated Poster Session 66
KIDNEY CANCER: ADVANCED (INCLUDING DRUG THERAPY) II
Room 2005 @ MCC West
Moderators: Megan Merrill, Robert Abouassaly and Marc-Olivier Timsit

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP66-01</td>
<td>BRAIN METASTASIS FROM RENAL CELL CARCINOMA: AN INSTITUTIONAL STUDY</td>
</tr>
<tr>
<td>Alfredo Suarez-Sarmiento*, Kevin Nguyen, Adam Nölte, Michelle Cheng, Brian Shuch, New Haven, CT</td>
<td></td>
</tr>
<tr>
<td>MP66-02</td>
<td>SURVIVAL ANALYSIS OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA UNDERGOING CYTOREDUCTIVE NEPHRECTOMY WITH OR WITHOUT A NEOADJUVANT TYROSINE KINASE INHIBITOR</td>
</tr>
<tr>
<td>Jing Zhi Lo*, Peter Sunaryo, David Paulucci, Ketan Badani, New York, NY</td>
<td></td>
</tr>
<tr>
<td>MP66-03</td>
<td>DISTRIBUTION OF M0 RENAL CELL CARCINOMA METASTASES STRATIFIED BY PATHOLOGIC NODAL STATUS</td>
</tr>
<tr>
<td>David Yang*, Theodora Potretzke, Christine Lohsa, John Cheville, Bernard King, Bradley Leibovich, R. Houston Thompson, Aaron Potretzke, Rochester, MN</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP66-04</td>
<td>COMPARISON OF ROBOTIC AND OPEN TECHNIQUES IN PATIENTS UNDERGOING RADICAL NEPHRECTOMY AND LEVEL II/III INFERIOR VENA CAVA THROMBECTOMY</td>
</tr>
<tr>
<td>MP66-05</td>
<td>CLINICOPATHOLOGICAL AND SURVIVAL ANALYSIS OF STAGE III/IV PAPILLARY AND CHROMOPHOBE RENAL CELL CARCINOMA: IMPLICATIONS FOR FUTURE CLINICAL TRIALS</td>
</tr>
<tr>
<td>Alain Kaldany*, David Paulucci, Harry Anastos, Alp Tuna Bekzac, John Sfakianos, Ketan Badani, New York, NY</td>
<td></td>
</tr>
</tbody>
</table>
MP66-06 PROGNOSTIC SIGNIFICANCE OF SARCOMATOID FEATURES IN METASTATIC RENAL CELL CARCINOMA TREATED WITH CYTOREDUCTIVE NEPHRECTOMY AND TARGETED THERAPY
Raju Chelluri*, Leilei Xia, Philadelphia, PA, Benjamin Taylor, New York, NY, Jay Raman, Hershey, PA, Thomas Guzzo, Philadelphia, PA

MP66-07 TRENDS AND MORBIDITY FOR MINIMALLY INVASIVE VERSUS OPEN CYTOREDUCTIVE NEPHRECTOMY IN THE MANAGEMENT OF METASTATIC RENAL CELL CARCINOMA
Dimitar Zlatev*, Manuel Ozambela, Ye Wang, Matthew Mossanen, Daniel Pucheril, Matthew D. Ingham, Philip V. Barbosa, Boston, MA, Benjamin I. Chung, Stanford, CA, Steven L. Chang, Boston, MA

MP66-08 THE EFFECT OF ONSET AGE AND INVOLVED ORGANS ON OVERALL SURVIVAL IN VON HIPPEL-LINDAU DISEASE
Zhou Bowen*, Geng Kan, Cai Lin, Wang Jiayi, Hong Baoan, Liu Shengjie, Ma Kaifang, Zhang Jiuwen, Peng Xiang, Beijing, China, People’s Republic of China

MP66-09 DECISION MAKING AND STRATEGIES IN INFERIOR VENA CAVA TRANSACTION DURING ROBOTIC VENOUS THROMBECTOMY: A FEASIBILITY STUDY BASED ON VENOGRAPHY
Songliang Du, Dan Shen, Qingbo Huang, Cheng Peng, Xu Zhang, Xin Ma*, Beijing, China, People’s Republic of China

MP66-10 CYTOREDUCTIVE NEPHRECTOMY AND VENOUS TUMOR THROMBECTOMY: THE ROLE OF QUANTIFIED METASTATIC DISEASE BURDEN IN A TARGETED THERAPY ERA
Deepak Pruthi*, Hanzhang Wang, Michael Liss, Wasim Chowdhury, Ronald Rodriguez, Dharam Kaushik, San Antonio, TX

MP66-11 RETROSPECTIVE ANALYSIS OF THE CONCORDANCE OF 20 IMMUNOHISTOCHEMICAL TISSUE MARKERS IN METASTATECTOMY LESIONS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
Sung Han Kim, Eun Young Park, Ho Kyung Seo*, Jae Young Joung, Kang Hyun Lee, Yoon Seok Suh, Jungnam Joo, Jinsoo Chung, Goyang, Korea, Republic of Korea

MP66-12 BIM EXPRESSION IN PERITUMORAL LYMPHOCYTES IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Bimal Bhindi*, John Cheville, Christine Lohse, Ross Mason, Susan Harrington, Haidong Dong, Stephen Boorjian, R. Houston Thompson, Bradley Leibovich, Rochester, MN

MP66-13 PROGNOSTIC IMPACT OF KINETICS OF C-REACTIVE PROTEIN BETWEEN BEFORE AND AFTER SURGERY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA UNDERGOING CYTOREDUCTIVE NEPHRECTOMY TREATED WITH TYROSINE KINASE INHIBITOR
Jun Teishima*, Shinuya Ohara, Keisuke Hieda, Shunsuke Shinmei, Shogo Inoue, Tetsutaro Hayashi, Hideki Mochizuki, Koji Mita, Akio Matsubara, Hiroshima, Japan

MP66-14 EFFECT OF EARLY-PERIOD RELATIVE DOSE INTENSITY IN FIRST-LINE SUNITINIB THERAPY WITH A 2-WEEKS-ON AND 1-WEEK-OFF REGIMEN FOR METASTATIC RENAL CELL CARCINOMA
Kana Iwamoto*, Hiroki Ishihara, Toshio Takagi, Tsunenori Kondo, Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Kenji Omae, Junpei Iizuka, Hirohito Kobayashi, Kazunari Tanabe, Tokyo, Japan

MP66-15 THE PROGNOSTIC VALUE OF NEUTROPHIL-LYMPHOCYTE RATIO FOR METASTATIC RENAL CELL CARCINOMA WITH VENOUS TUMOR THROMBUS PATIENTS UNDERGOING CYTOREDUCTIVE NEPHRECTOMY: A MULTI-INSTITUTION CONSORTIUM ANALYSIS
Charles Peyton*, Tampa, FL, Jason Abel, Madison, WI, Juan Chipollini, David Boulware, Mounis Ali, Tampa, FL, Jose Karam, Houston, TX, Vitaly Margulis, Dallas, TX, Viraj Master, Atlanta, GA, Surena Matin, Houston, TX, Jay Raman, Hershey, PA, Wade Sexton, Tampa, FL, Christopher Wood, Houston, TX, Kamran Zargar-Shoshtari, Auckland, New Zealand, Philippe Spiess, Tampa, FL

MP66-16 CLINICAL OUTCOMES OF Axitinib Versus Sunitinib as a First-Line Therapy for Metastatic Renal Cell Carcinoma in Japanese Patients
Yusuke Kiso*, Takamitsu Inoue, Taketoshi Nara, Sohei Kanda, Kazuyuki Numakura, Hiroshi Tsuruta, Mitsuru Saigo, Shigeru Satoh, Tomonori Habuchi, Akita, Japan

MP66-17 PATIENTS’ PERSPECTIVES ON ADJUVANT THERAPY IN RENAL CELL CARCINOMA
Dena Battle*, Alexandria, VA, Hans Hammers, Dallas, TX, Eric Jonasch, Houston, TX, Ithaar Derweesh, La Jolla, CA, Daniel George, Durham, NC, Börje Ljungberg, Umeå, Sweden, Axel Bex, Amsterdam, Netherlands, Michael Staehler, Munich, Germany

MP66-18 INTAKE OF ROYAL JELLY PREVENTS SUNITINIB-INDUCED APPETITE LOSS IN PATIENTS WITH RENAL CELL CARCINOMA: CORRELATION WITH SERUM LEVELS OF TRANSFORMING GROWTH FACTOR-β AND MACROPHAGE COLONY-STIMULATING FACTOR
Kojiro Ohba*, Yasuyoshi Miyata, Yuichiro Nakamura, Kyohei Araki, Takuji Yasuda, Yuji Sagara, Tomohiro Matsuo, Yasushi Mochizuki, Hideki Sakai, Nagasaki, Japan

*Presenting author
MP66-19 PREDICTIVE VALUE OF INFLAMMATION-BASED PROGNOSTIC SCORES IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH CYTOREDUCTIVE NEPHRECTOMY
Hironori Fukuda*, Toshio Takagi, Tsunenori Kondo, Kazuhiko Yoshida, Satoru Shimizu, Kazunari Tanabe, Tokyo, Japan

MP66-20 ZFAS1 PROMOTES RENAL CANCER SUNITINIB RESISTANCE AND PROGRESSION BY ACTING AS A COMPETING ENDOGENOUS RNA
Xiaoping Zhang, Haibing Xiao*, Yan Qu, Ke Chen, Wuhan, China, People’s Republic of

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 20, 2018 1:00 pm - 3:00 pm
Podium Session 43
TRAUMA/RECONSTRUCTION/DIVERSION: URETER (INCLUDING PYELOPLASTY) AND BLADDER RECONSTRUCTION (INCLUDING FISTULA), AUGMENTATION, SUBSTITUTION, DIVERSION II
Room 2024 @ MCC West
Moderators: Bryan Voelzke, John Lacy and Richard Hautmann

<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD43-01</td>
<td>1:00</td>
<td>PROSPECTIVE EVALUATION OF CONTINENCE FOLLOWING OPEN RADICAL CYSTECTOMY AND ORTHOTOPIC URINARY DIVERSION AND THE EFFECT OF PELVIC FLOOR PHYSICAL THERAPY Soroush Bazargani*, Zhoo bin Bateni, Eileen Johnson, Kevin Wayne, Jie Cai, Gus Miranda, Hooman Djaladat, Anne Schuckman, Siamak Daneshmand, Los Angeles, CA</td>
<td></td>
</tr>
<tr>
<td>PD43-02</td>
<td>1:10</td>
<td>EVALUATION OF URINARY CONTINENCE FOLLOWING NERVE SPARING OPEN RADICAL CYSTOPROSTATECTOMY AND ORTHOTOPIC URINARY DIVERSION Zhoo bin Bateni*, Ankeet Shah, Soroush Bazargani, Kevin Wayne, Gus Miranda, Jie Cai, Hooman Djaladat, Anne Schuckman, Siamak Daneshmand, Los Angeles, CA</td>
<td></td>
</tr>
<tr>
<td>PD43-03</td>
<td>1:20</td>
<td>FUNCTIONAL OUTCOMES AFTER RADICAL CYSTECTOMY WITH ILEAL NEobladder Nicolas von Landenberg*, Julian Hanske, Sebastian Berg, Jana Schmidt, Marko Brock, Rein-Jüri Palisaar, Christian von Bodman, Florian Roghmann, Joachim Noldus, Herne, Germany</td>
<td></td>
</tr>
<tr>
<td>PD43-04</td>
<td>1:30</td>
<td>A RETROSIGMOID ILEAL CONDUIT WITH NO TRANPOSITION OF THE LEFT URETER DECREASES THE RISK OF URETERAL STRURECTURE FOLLOWING RADICAL CYSTECTOMY: A COMPARATIVE STUDY Vincenzo Ficarra, Messina, Italy, Alessandro Crestani*, Udine, Italy, Marta Rossanese, Catania, Italy, Vito Palumbo, Messina, Italy, Mattia Calandrillo, Claudio Valotto, Gianluca Giannarini, Udine, Italy</td>
<td></td>
</tr>
<tr>
<td>PD43-05</td>
<td>1:40</td>
<td>CHANGE IN RENAL FUNCTIONS AND RISK OF CHRONIC KIDNEY DISEASE AFTER ROBOT-ASSISTED RADICAL CYSTECTOMY AND URINARY DIVERSION Tomoka Terakawa, Ahmed Aly Hussein*, Paul May, The Jing, Youssef Ahmed, Derek Wang, Hijab Khan, Adam Hasasneh, Adam Cole, Omer Rana, Kevin Stone, Alicia Skowronska, Sierra Broad, Gurkamal Chatta, Qiang Li, Khurshid Guru, Buffalo, NY</td>
<td></td>
</tr>
<tr>
<td>PD43-06</td>
<td>1:50</td>
<td>MANAGEMENT OF IATROGENIC URINARY FISTULAE WITH THE USE OF SUPRAPUBIC TRANSVESICAL LAPAROENDOSCOPIC SINGLE-SITE SURGERY (T-LESS): CLINICAL EXPERIENCE WITH SIXTEEN PATIENTS Marek Roslan, Olsztyn, Poland, Marcin Markuszewski, Gdansk, Poland, Piotr Jarzemski, Bydgoszcz, Poland, Krzysztof Szkarlat, Koocierzyna, Poland, Magdalena Mikulaska-Jovanovic, Gruziadz, Poland, Michal Borowik, Maciej Przudzik*, Olsztyn, Poland</td>
<td></td>
</tr>
<tr>
<td>PD43-07</td>
<td>2:00</td>
<td>MANAGEMENT OF URINARY/PERINEAL FISTULAE COMPLICATING THE MODERN TREATMENT OF RECTAL CANCER Simon Bugeja, Stella Ivaz*, Anastasias Frost, Mariya Dragova, Daniela E. Andrich, Anthony R. Mundy, London, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>PD43-08</td>
<td>2:10</td>
<td>COMPARISON OF OUTCOMES OF DOUBLE-BARRELLED WET COLOSTOMY VS ILEAL CONDUIT AND END COLOSTOMY FOR URINARY AND FAECAL DIVERSION FOLLOWING TOTAL PELVIC EXENTERATION - SINGLE CENTRE EXPERIENCE Lawrence H. C. Kim*, Bhagya Parkash, Alan C. Thompson, Pardeep Kumar, London, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>
2:20 PD43-09 ROBOTIC URETEROPLASTY WITH BUCCAL MUCOSA GRAFT FOR THE MANAGEMENT OF RECURRENT PROXIMAL AND MIDDLE URETERAL STRICTURES AFTER PREVIOUSLY FAILED URETERAL RECONSTRUCTION  
Ziho Lee*, Aryeh Keehn, Matthew Sterling, Martus Gn, David Strauss, Jeffrey Liu, Michael Metro, Daniel Eun, Philadelphia, PA

2:30 PD43-10 THE EFFECTS OF AUGMENTATION CYSTOPLASTY AND BOTULINUM TOXIN INJECTION ON PATIENT-REPORTED BLADDER FUNCTION AND SATISFACTION AMONG SPINAL CORD INJURY PATIENTS PERFORMING INTERRUPTED CATHETERIZATION  
Jeremy Myers*, Sara Lenherr, Salt Lake City, UT, John Stoffel, Ann Arbor, MI, Sean Elliott, Minneapolis, MN, Angela Presson, Chong Zhang, Salt Lake City, UT, Blayne Welk, London, Canada

2:40 PD43-11 THE LONG-TERM OUTCOMES OF AUGMENTATION CYSTOPLASTY AT 20-30 YEARS FOLLOW UP  
Anastasia Frost*, Simon Bugeja, Mariya Dragova, Daniela Andrich, Anthony Mundy, Reading, United Kingdom

2:50 PD43-12 KIDNEY TRANSPLANT RECIPIENTS WITH BLADDER AUGMENTATION AND WITHOUT URINARY RECONSTRUCTION: SIMILAR OUTCOMES?  
Kleiton Yamaçake, Alfonso Piovesan, Renato Falci, Gustavo Messi, Ioannis Antonopoulos, Marcos Mello*, Eder Nisi Ilario, Hideki Kanashiro, William Nahas, Sao Paulo, Brazil

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 20, 2018 1:00 pm - 3:00 pm  
Podium Session 44  
SEXUAL FUNCTION/DYSFUNCTION: PEYRONIE’S DISEASE I  
Room 2022 @ MCC West  
Moderators: Daniel Culkin, Landon Trost and Luiz Otavio Torres

<table>
<thead>
<tr>
<th>TIME</th>
<th>ABSTRACT</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| 1:00 | PD44-01 | THE DEVELOPMENT OF A VALIDATED PATIENT REPORTED OUTCOME MEASURE (PROM) FOR PENILE CURVATURE SURGERY  
“Richard Akiboye”, Angus Campbell, London, United Kingdom, Pareeta Patel, Surrey, United Kingdom, Nick Watkin, London, United Kingdom |
| 1:10 | PD44-02 | TREATMENT TRENDS AND COST ASSOCIATED WITH PEYRONIE’S DISEASE  
Saneal Rajanahally*, Sarah Holt, Omer Raheem, Kevin Ostrowski, Thomas Walsh, Seattle, WA |
| 1:20 | PD44-03 | ERECTILE DYSFUNCTION IS A RISK FACTOR FOR SUBSEQUENT PEYRONIE’S DISEASE  
Saneal Rajanahally*, Sarah Holt, Omer Raheem, Kevin Ostrowski, Thomas Walsh, Seattle, WA |
| 1:30 | PD44-04 | THE SPATIAL DISTRIBUTION OF INORGANIC NANOPARTICLES WITHIN CALCIFIED PEYRONIE’S PLAQUE  
Ling Chen, Matthew Hennefarth*, Misun Kang, Scott Wiener, Tom Lue, Marshall Stoller, Sunita Ho, San Francisco, CA |
| 1:40 | PD44-05 | CORPORAL RUPTURE AND COLLAGENASE CLOSTRIDIUM HISTOLYTICUM: A POPULATION BASED STUDY  
Andrew Sun*, Shufeng Li, Michael Eisenberg, Stanford, CA |

<table>
<thead>
<tr>
<th>TIME</th>
<th>ABSTRACT</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| 1:50 | PD44-06 | COMPARISON OF STANDARD COLLAGENASE CLOSTRIDIUM HISTOLYTICUM PROTOCOL AND MODIFIED INTERFERON ALPHA 2 BETA PROTOCOL FOR THE MANAGEMENT OF PEYRONIE’S DISEASE AT 2 LARGE HEALTHCARE ORGANIZATIONS  
Rachel Rubin, Washington, DC, Ashley Winter, Portland, OR, Eric Biewenga, Eugene Rhee, Kyoko Sakamoto, Irwin Goldstein*, San Diego, CA |
| 2:00 | PD44-07 | PEYRONIE’S DISEASE: THE IMPACT OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM ON DIAGNOSIS, TREATMENT, AND COST  
Andrew Sun*, Shufeng Li, Michael Eisenberg, Stanford, CA |
| 2:10 | PD44-08 | DOES REPEATING ANOTHER COURSE OF INTRALESIONAL COLLAGENASE CLOSTRIDIUM INJECTIONS IMPROVE PENILE CURVATURE IN MEN WITH PEYRONIE’S DISEASE?  
Ziho Lee*, Matthew Sterling, Mary Dunphy, Michael Metro, Philadelphia, PA |
| 2:20 | PD44-09 | COMPARATIVE ANALYSIS OF THE NATURAL HISTORY OF DE NOVO PEYRONIE’S DISEASE VERSUS POST-RADICAL PROSTATECTOMY PEYRONIE’S DISEASE  
John Sullivan*, Yanira Ortega, John Mulhall, New York, NY |

*Presenting author
2:30 PD44-10 INCREASED RISK OF CANCER IN MEN WITH PEYRONIE'S DISEASE
Alexander W. Pastuszak*, Taylor P. Kohn, Houston, TX, Michael L. Eisenberg, Stanford, CA, Dolores J. Lamb, Larry I. Lipshultz, Houston, TX

2:40 PD44-11 COMPARISON OF PATIENT'S SATISFACTION AND LONG TERM RESULTS OF TWO PLACEMENT TECHNIQUES: LESSONS LEARNED FROM 387 PATIENTS WITH PENILE CURVATURE
Selahittin Çayan*, Mersin, Turkey, Ramazan Aşçi, Samsun, Turkey, Ozan Efesoy, Mersin, Turkey, Fatih Kocamanoğlu, Samsun, Turkey, Erdem Akbay, Mersin, Turkey, Önder Yaman, Ankara, Turkey

2:50 PD44-12 IS MODELING ALONE ENOUGH FOR MANAGEMENT OF SIGNIFICANT CURVATURE DURING INFLATABLE PENILE PROSTHESIS (IPP) IMPLANTATION?
Matthew Brennan, Ryan Griggs*, Ryan Barlotta, Jacob Lucas, Jay Simhan, Philadelphia, PA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 20, 2018
Podium Session 45
STONE DISEASE: SURGICAL THERAPY III
Room 2011 @ MCC West
Moderators: Brian Eisner, Roger Sur and Mahesh Desai

<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD45-01</td>
<td>1:00</td>
<td>PD45-01</td>
<td>DOES VOLUMETRIC STONE MEASUREMENT AUGMENT OUR UNDERSTANDING?</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Parth Patel*, Maywood, IL, Abrar Mian, Chicago, IL, Alexander Kandabarow, Spencer Hart, Carrie Johans, Ryan Dornbier, Robert Blackwell, Ahmer Farooq, Kristin Baldea, Thomas Turk, Maywood, IL</td>
</tr>
<tr>
<td>PD45-02</td>
<td>1:10</td>
<td>PD45-02</td>
<td>NATURAL HISTORY OF RESIDUAL FRAGMENTS CONFIRMED BY COMPUTED TOMOGRAPHY AFTER URETEROSCOPY</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Igor Sorokin*, Noah Canvasser, Aaron Lay, Jodi Antonelli, Margaret Pearle, Dallas, TX</td>
</tr>
<tr>
<td>PD45-03</td>
<td>1:20</td>
<td>PD45-03</td>
<td>SURGICAL ALGORITHM FOR ENCRUSTED URETERAL STENT REMOVAL USING THE KIDNEY,URETER, AND BLADDER (KUB) GRADING SYSTEM</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Dustin Luse*, Justin Nguyen, Melina McCarty, Nadeem Dhanani, Steven Canfield, Houston, TX</td>
</tr>
<tr>
<td>PD45-04</td>
<td>1:30</td>
<td>PD45-04</td>
<td>URGENT SURGICAL INTERVENTION IN PATIENTS WITH RENAL COLIC PRESENTING TO THE EMERGENCY DEPARTMENT – DOES SIZE MATTER?</td>
</tr>
<tr>
<td>PD45-05</td>
<td>1:40</td>
<td>PD45-05</td>
<td>COMPARATIVE ANALYSIS OF PHYSICAL AND OPTICAL PROPERTIES OF SINGLE-USE VERSUS REUSABLE URETERORENOSCOPES FOR RETROGRADE INTRARENAL SURGERY (RIRS)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Susanne Deininger, Stephan Kruck, Luis Haberstorck, Jens Bedke, Tilman Todenhoefer, Eva Neumann*, Arnulf Stenzl, Steffen Rausch, Tuebingen, Germany</td>
</tr>
<tr>
<td>PD45-06</td>
<td>1:50</td>
<td>PD45-06</td>
<td>MECHANICAL, PHYSICAL AND PERFORMANCE CHARACTERISTICS OF HOLMIUM:YAG OPTICAL FIBERS FOR FLEXIBLE URETEROSCOPY</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Andrew Nguyen*, Rajat Jain, Emily Rose, Manoj Monga, Cleveland, OH, Bodo Knudsen, Columbus, OH</td>
</tr>
<tr>
<td>PD45-07</td>
<td>2:00</td>
<td>PD45-07</td>
<td>HYPOTHERMIA AFTER PERCUTANEOUS NEPHROLITHOTOMY: A RANDOMIZED SINGLE-BLIND CLINICAL TRIAL EVALUATING IMPACT OF IRRIGATION FLUID TEMPERATURE</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Mohamed Omar*, Shibin el Kom, Egypt, Manoj Monga, Mark Noble, Sri Sivalingam, Cleveland, OH</td>
</tr>
<tr>
<td>PD45-08</td>
<td>2:10</td>
<td>PD45-08</td>
<td>PREOPERATIVE FRAILTY ASSESSMENT HELPS PREDICT POST-OPERATIVE COMPLICATIONS IN PERCUTANEOUS RENAL SURGERY</td>
</tr>
<tr>
<td>PD45-09</td>
<td>2:20</td>
<td>PD45-09</td>
<td>A NOVEL CONCEPT FOR REPORTING OUTCOMES OF A SUCCESSFUL TREATMENT IN ENDUROLOGY FOR STONES: THE STONE- FECTA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Giovanni Cacciapuoti*, Luis Medina, Josesh Thum, Byron Lopez de Mesa, Angelica Hernandez, Inderbir Gill, Gerhard Fuchs, Los Angeles, CA</td>
</tr>
</tbody>
</table>
THE UTILITY OF EMERGENTLY PLACED INTERVENTIONAL RADIOLOGY NEPHROSTOMY TUBE TRACTS FOR SUBSEQUENT PERCUTANEOUS NEPHROLITHOTOMY


A NOMOGRAM FOR PREDICTING THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME AFTER FLEXIBLE URETEROSCOPE LITHOTRIPSY FOR UPPER URINARY TRACT CALCULI

Yuqing Liu*, Jian LU, Chunlei Xiao, Lulin Ma, Beijing, China, People’s Republic of China

BAP1 DE-UBIQUITINASE IS ALLOSTERICALLY REGULATED BY ASXL1/2: SOMATIC BAP1 MUTATION IN RCC AND OTHER TUMORS INACTIVE THIS REGULATION BY TARGETING MULTIPLE INDEPENDENT DOMAINS


CARCINOMAS OF THE RENAL MEDULLA: A COMPREHENSIVE GENOMIC PROFILING (CGP) STUDY


GENOMIC HALLMARKS OF RENAL MEDULLARY CARCINOMA

Jesse M. Fox, Denise Young, Yingjie Song, Rockville, MD, Heng Cheng Hu, Anthony Soltis, Matthew Wilkerson, Clifton L. Daigard, Inger L. Rosner, Bethesda, MD, Shiv Srivastava, Rockville, MD, Isabella A. Sesterhenn, Silver Spring, MD, Shyh-Han Tan*, Rockville, MD

ELOC-MUTATED RENAL CELL CARCINOMA: A DISTINCT CLINICAL ENTITY WITH UNCLEAR DISEASE COURSE

Renzo DiNatale*, Mahyar Kashan, Satish Tickoo, Yingbei Chen, Victor Reuter, Ari Hakimi, New York, NY

INTRA-TUMOR MOLECULAR HETEROGENEITY OF CLEAR CELL RENAL CELL CARCINOMA SEEMS TO CONTRIBUTE TO THE DIVERSITY OF RESPONSE TO TARGETED THERAPIES

Baoan Hong*, Yong Yang, Sheng Guo, Qixiang Li, Ning Zhang, Kan Gong, Beijing, China, People’s Republic of China

NOVEL INSIGHTS ON WILM’S TUMOR: USING HUMAN NEPHRON PROGENITORS

Astgik Petrosyan, Stefano Da Sacco, Roger E. De Filippo, Laura Perin*, Los Angeles, CA

CLEAR CELL PAPILLARY RENAL CELL CARCINOMA: GENOMIC CHARACTERIZATION OF A DISTINCT AND INDOLENT TUMOR

Kartik Viswanathan, Kyung Park, Francesca Khani, Juan Miguel Mosquera, Brian Robinson*, New York, NY

*Presenting author
2:20 PD46-09 COMPREHENSIVE GENETIC ANALYSIS OF TFE3-OVEREXPRESSED RENAL CELL CARCINOMA
Chang Wook Jeong*, Jae So Cho, Moses Lee, Murim Choi, Cheryn Song, Ja Hyeon Ku, Cheol Kwak, Hyeon Hoe Kim, Seoul, Korea, Republic of

2:30 PD46-10 CHARACTERIZATION OF CHIMERIC TFE3 TRANSCRIPTION FACTORS FOUND IN XP11.2 TRANSLOCATION RENAL CELL CARCINOMA
Takanobu Motoshima*, Yorifumi Satou, Paola Miyazato, Kumamoto, Japan, Hisashi Hasumi, Yokohama, Japan, Ying Huang, Bethesda, MD, Tsuyoshi Kadomatsu, Kumamoto, Japan, Masahiro Yao, Yokohama, Japan, Yoji Nagashima, Tokyo, Japan, Mitsuko Furuya, Yokohama, Japan, Yuchi Oike, Kumamoto, Japan, Laura S. Schmidt, Bethesda, MD, Tomomi Kamba, Kumamoto, Japan, W Marston Linehan, Bethesda, MD, Masaya Baba, Kumamoto, Japan

2:40 PD46-11 PHOSPHORYLATION AND UBQUITINATION REGULATE PROTEIN PHOSPHATASE-5 ACTIVITY AND ITS PROSURVIVAL ROLE IN KIDNEY CANCER
Natela Dushukyan, Michael Daneshvar*, Rebecca Sager, Mark Woodford, Alexander Baker-Williams, John Chisholm, Syracuse, NY, David Loiselle, Durham, NC, Andrew Truman, Charlotte, NC, Timothy Haystead, Durham, NC, Oleg Shapiro, Dimitra Bourboulia, Gennady Bratslavsky, Mehdi Mollapour, Syracuse, NY

2:50 PD46-12 SETD2-MEDIATED LOSS OF MIR-10B DETERMINES MAP4K4 ACTIVATION IN RENAL CELL CARCINOMA
Libin Yan*, Heng Li, Yuccong Zhang, Hua Xu, zhangqun Ye, Wuhan, China, People’s Republic of

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 20, 2018
1:00 pm - 3:00 pm
Podium Session 47
PROSTATE CANCER: STAGING II
Room 3018 @ MCC West
Moderators: Ryan Berglund, Paul Lange and Edmund Chiong

ABSTRACT | ABSTRACT
--- | ---
TIME | NUMBER | TITLE | TIME | NUMBER | TITLE
1:00 | PD47-01 | DETECTION OF CYTOKERATIN 19 EXPRESSION USING ONE-STEP NUCLEIC ACID AMPLIFICATION (OSNA): A NEW MOLECULAR METHOD FOR LYMPH NODE STAGING IN PROSTATE CANCER? Alexander Winter*, Svenja Engels, Philipp Goos, Marie Christin Süykers, Rolf Peter Henke, Holger Gerullis, Friedhelm Wawroschek, Oldenburg, Germany | 1:20 | PD47-03 | DEVELOPMENT AND SPLIT-SAMPLE VALIDATION OF THE FIRST NOMOGRAM TO IDENTIFY THE CANDIDATES FOR EXTENDED PELVIC LYMPH NODE DISSECTION AMONG MEN STAGED WITH MULTI-PARAMETRIC MRI FOR CLINICALLY LOCALIZED PROSTATE CANCER

1:10 | PD47-02 | 99MTC-NANOCOLLOID TARGETED PROSTATE INJECTION TO INDEX LESION FOR SENTINEL NODE IDENTIFICATION IN PROSTATE CANCER PATIENTS
Lluis Fumadó*, Jose Maria Abascal, Antoni Mestre, Marina Suárez, Sergi Vidal-Sicart, Núria Juanpere, Lluis Cecchini, Barcelona, Spain | 2:20 | PD47-05 | DETECTION OF CYTOKERATIN 19 EXPRESSION USING ONE-STEP NUCLEIC ACID AMPLIFICATION (OSNA): A NEW MOLECULAR METHOD FOR LYMPH NODE STAGING IN PROSTATE CANCER? Alexander Winter*, Svenja Engels, Philipp Goos, Marie Christin Süykers, Rolf Peter Henke, Holger Gerullis, Friedhelm Wawroschek, Oldenburg, Germany | 2:30 | PD47-06 | CHARACTERIZATION OF CHIMERIC TFE3 TRANSCRIPTION FACTORS FOUND IN XP11.2 TRANSLOCATION RENAL CELL CARCINOMA
Takanobu Motoshima*, Yorifumi Satou, Paola Miyazato, Kumamoto, Japan, Hisashi Hasumi, Yokohama, Japan, Ying Huang, Bethesda, MD, Tsuyoshi Kadomatsu, Kumamoto, Japan, Masahiro Yao, Yokohama, Japan, Yoji Nagashima, Tokyo, Japan, Mitsuko Furuya, Yokohama, Japan, Yuchi Oike, Kumamoto, Japan, Laura S. Schmidt, Bethesda, MD, Tomomi Kamba, Kumamoto, Japan, W Marston Linehan, Bethesda, MD, Masaya Baba, Kumamoto, Japan

2:40 | PD47-11 | PHOSPHORYLATION AND UBQUITINATION REGULATE PROTEIN PHOSPHATASE-5 ACTIVITY AND ITS PROSURVIVAL ROLE IN KIDNEY CANCER
Natela Dushukyan, Michael Daneshvar*, Rebecca Sager, Mark Woodford, Alexander Baker-Williams, John Chisholm, Syracuse, NY, David Loiselle, Durham, NC, Andrew Truman, Charlotte, NC, Timothy Haystead, Durham, NC, Oleg Shapiro, Dimitra Bourboulia, Gennady Bratslavsky, Mehdi Mollapour, Syracuse, NY

2:50 | PD47-12 | SETD2-MEDIATED LOSS OF MIR-10B DETERMINES MAP4K4 ACTIVATION IN RENAL CELL CARCINOMA
Libin Yan*, Heng Li, Yuccong Zhang, Hua Xu, zhangqun Ye, Wuhan, China, People’s Republic of

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
1:30 PD47-04 CORRELATION BETWEEN GENOMIC INDEX LESIONS, MULTI-PARAMETRIC MRI AND 68GA-PSMA-PET/CT IMAGING FEATURES IN PRIMARY PROSTATE CANCER
Claudia Kesch*, Jan P. Radtke, Heidelberg, Germany, Axel Wintsche, Leipzig, Germany, Manuel Wiesenfarth, Heidelberg, Germany, Mariska Luttje, Utrecht, Netherlands, Claudia Gasch, Svenja Dieffenbacher, Gencay Hatbaglu, Joanne Nyaranagi-Dix, Tobias Simplendörfer, Antonia Dimitrakopoulou-Strauß, Martin Freitag, Heidelberg, Germany, Anette Duensing, Pittsburgh, PA, Carsten Grüllich, Michael Götz, Dirk Jäger, Niels Grabe, Heidelberg, Germany, Michal R. Schweiger, Cologne, Germany, Frederik L. Giesel, Heidelberg, Germany, Wilfried Roth, Mainz, Germany, Sven Perner, Luebeck, Germany, Jörg Galle, Klaus Maier-Hein, Heidelberg, Germany, Boris A. Hadaschik, Essen, Germany, Heinz P. Schlemmer, Markus Hohenellner, David Bonekamp, Holger Siltmann, Stefan Duensing, Heidelberg, Germany

1:40 PD47-05 USING MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING AND TARGETED BIOPSY TO RULE OUT SEMINAL VESICLE INVASION IN PROSTATE CANCER
Samuel Gold*, Sherif Mehralivand, Jonathan Bloom, Bethesda, MD, Stephanie Harmon, Frederick, MD, Graham Hale, Kareem Rayn, Vik Sabarwal, Shawn Marhamati, Marcin Czarniecki, Clayton Smith, Vladimir Valera Romero, Maria Merino, Baris Turkbey, Peter Pinto, Bethesda, MD

1:50 PD47-06 PATHOLOGICAL UPGRADING FROM GLEASON 3+3 DISEASE AFTER RADICAL PROSTATECTOMY: THE IMPLICATIONS FOR CONFIRMATORY TESTING
Deborah Kaye*, Ji Qi, Ann Arbor, MI, Brian Lane, Grand Rapids, MI, Susan Linsell, Ann Arbor, MI, Richard Sarle, Dearborn, MI, James Montie, David Miller, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI

2:00 PD47-07 TARGETED CANCER CORE LENGTH AND RISK-STRATIFICATION OF PROSTATE CANCER
Demetrios Simopoulos*, Anthony Sisk, Alan Priester, Lorna Kwan, Robert Reiter, Leonard Marks, Los Angeles, CA

2:10 PD47-08 PREDICTORS OF ORGAN CONFINED DISEASE IN HIGH AND VERY HIGH RISK PROSTATE CANCER PATIENTS STAGED WITH MP- MRI: IMPLICATIONS FOR SELECTIVE APPLICATION OF MULTIMODAL THERAPY
Chad A. Reichard*, Justin R. Gregg, Tharakeswala Bathala, Mary F. Achim, Quynh-Nhu Nguyen, John W. Davis, Brian F. Chapin, Houston, TX

2:20 PD47-09 OPTIMIZING USE OF MRI-US FUSION TARGETED BIOPSY: UPDATED EXPERIENCE IN 1639 COMBINED SYSTEMATIC AND TARGETED PROSTATE BIOPSYs
Xiaosong Meng*, Andrew B. Rosenkrantz, Richard Huang, Fang-Ming Deng, James S. Wysock, William C. Huang, Herbert Lepor, Samir S. Taneja, New York, NY

2:30 PD47-10 MRI TUMOR CONTACT LENGTH AS A PREDICTOR OF EXTRACAPSULAR EXTENSION: OPTIMAL THRESHOLD FOR ANTERIOR AND POSTERIOR PROSTATE CANCER
Kazuhiro Matsumoto*, Kimiharu Takamatsu, Seiya Hattori, Toshikazu Takeda, Takeo Kosaka, Ryuchi Mizuno, Eiji Kikuchi, Hiroshi Asanuma, Mototsugu Oya, Tokyo, Japan

2:40 PD47-11 THE ROLE OF MRI-TARGETED BIOPSY IN PREDICTION OF ADVERSE PATHOLOGICAL AND ONCOLOGICAL OUTCOME AFTER RADICAL PROSTATECTOMY
Yoh Matsuoka*, Hiroshi Tanaka, Tomo Kimura, Yuma Waseda, Shou Uehara, Yasuke Yasuda, Toshiki Kijima, Soichiro Yoshida, Minato Yokoyama, Junichiro Ishioka, Kazutaka Saito, Kazunori Kihara, Yasuhsa Fuji, Tokyo, Japan

2:50 PD47-12 DIAGNOSTIC PERFORMANCE OF PROSPECTIVELY ASSIGNED LIKERT SCALE SCORES FOR DETERMINATION OF EXTRAPROSTATIC TUMOR EXTENSION WITH MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING OF THE PROSTATE
Daniel Costa*, Yuval Freifeld, Yin Xi, Franto Francis, Claus Roehrborn, Ivan Pedrosa, Dallas, TX

*Presenting author

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
## ABSTRACT NUMBER TITLE

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| V09-01 | BLADDER EXSTROPHY RADIAL ARTERY PHALLOPLASTY: EXSTROPHY RELATED ISSUES AND SAPHENOUS VEIN INTERPOSITION GRAFT  
Giovanni Chiriaco, Gideon Blecher*, Mark Johnson, Philippa Sangster, Nim Christopher, David Ralph, London, United Kingdom |
| V09-02 | ABDOMINOPLASTY WITHOUT OSTEOTOMIES USING GROIN FLAPS TO CLOSE THE ABDOMINAL WALL DEFECT IN THE MANAGEMENT OF EXSTROPHY-EPISPADIAS COMPLEX  
Amilcar Giron, Marcos Mello*, Ricardo Haider, Marcos Machado, Gabriel Anjos, Bruno Cezarino, Lorena Oliveira, Roberto Lopes, Francisco Dénes, Sao Paulo, Brazil |
| V09-03 | SAFE AND SOUND: PRINCIPLES FOR SUCCESSFUL COMPLETE PRIMARY REPAIR OF BLADDER EXSTROPHY (CPRE) IN THE BOY  
| V09-04 | THE MITCHELL COMPLETE PENILE DISASSEMBLY FOR EPISPADIAS REPAIR  
Joshua Chamberlin*, Ahmed Abdelhalim, Orange, CA, Zhan Tao Wang, London, Canada, Antoine Khoury, Orange, CA |
| V09-05 | SIX-WEEK-OLD INFANT ROBOTIC PYELOPLASTY: KEY POINTS FOR SAFETY AND PROFICIENCY  
Maria Veronica Rodriguez*, Nimrod Barashi, Joseph Rodriguez, Mohan S. Gundeti, Chicago, IL |
| V09-06 | ROBOTIC-ASSISTED BLADDER NECK RECONSTRUCTION WITH SLING IN CHILD WITH HISTORY OF BLADDER EXSTROPHY CLOSURE AND APPENDICOVESICOSTOMY  
Patricio Gargollo, Joseph Scales*, Rochester, MN |
| V09-07 | ROBOTIC CONTINENCE PROCEDURE IN A NEUROGENIC BLADDER PATIENT  
Maria Veronica Rodriguez*, Ashley Wilkens, Mohan S. Gundeti, Chicago, IL |
| V09-08 | ROBOTIC ASSISTED NEO-MALONE, BLADDER NECK RECONSTRUCTION WITH SLING AND MITROFANOFF IN A PATIENT WITH MYELOMENINGOECELE  
Daniel DaJusta*, Christina Ching, Molly Fuchs, Christopher Brown, Alejandro Sanchez, Marc Levitt, Richard Wood, Columbus, OH |
| V09-09 | ROBOT-ASSISTED LAPAROSCOPIC PYELOTOMY & ILEAL URETER SUBSTITUTION: VIDEO DEMONSTRATION  
Rachel Shannon, BS*, Deborah L. Jacobson, MD, Edward M. Gong, MD, Bruce W. Lindgren, MD, Chicago, IL |
| V09-10 | MULTI-QUADRANT HIDDEN INCISION ENDOSCOPIC SURGERY (HIDES) FOR PEDIATRIC URETERO-URETEROSTOMY AND DISTAL URETERECTOMY  
Hatim Thaker*, Paul Kokorowski, Los Angeles, CA |
| V09-11 | ROBOT-ASSISTED LAPAROSCOPIC ILEOVESICOSTOMY  
Aylin Bligutay*, Andrew Kirsch, Michael Garcia-Roig, Atlanta, GA |
| V09-12 | ROBOTIC ASSISTED LAPAROSCOPIC UROGENITAL SINUS MOBILIZATION AND BLADDER NECK SLING  
Saum Ghodoussi, Sameer Chopra, Hatim Thaker*, Juliet Han, Roger De Filippo, Evalynn Vasquez, Los Angeles, CA |

**APPROVED FOR AMA PRA CATEGORY 1 CREDIT™**
### BASIC SCIENCES SYMPOSIUM: SESSION I: UNDERSTANDING DISORDERS AND DIFFERENCES IN SEXUAL DEVELOPMENT

**Room 208 @ MCC South**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Chair(s)</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td>WELCOME AND SYMPOSIUM INTRODUCTION</td>
<td>Dolores Lamb, Aria Olumi, Peter Schlegel</td>
<td></td>
</tr>
<tr>
<td>1:10</td>
<td>SESSION 1: UNDERSTANDING DISORDERS AND DIFFERENCES IN SEXUAL DEVELOPMENT</td>
<td>Thomas Kolon</td>
<td>Martin Cohn, Eric Vilain, Laurence Baskin, Steven Zderic, Heino Meyer-Bahlburg, Linda Baker, Dolores Lamb, Aria Olumi, Peter Schlegel, Emily Finlayson, Pradeep Tyagi</td>
</tr>
<tr>
<td>4:10</td>
<td>GENETIC CONTROL OF EXTERNAL MALE GENITALIA DEVELOPMENT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:25</td>
<td>ENDOCRINE DISRUPTORS AND THEIR ROLE IN HYPOSPADIAS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:00</td>
<td>NEURAL AND ENDOCRINE PATHWAYS IN CRYPTORCHIDISM SUSCEPTIBILITY</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Sunday, May 20, 2018 1:00 pm - 5:00 pm**

### GERIATRIC UROLOGICAL SOCIETY (GUS)

**Room 22 @ MCC North**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Chair(s)</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td>WELCOME AND INTRODUCTION</td>
<td>Tomas Griebling</td>
<td></td>
</tr>
<tr>
<td>1:05</td>
<td>STATE-OF-THE-ART LECTURE: THE PREVENTION OF LOWER URINARY TRACT SYMPTOMS</td>
<td>Anne Suskind</td>
<td>Tamara Bavendam, Emily Finlayson, Pradeep Tyagi, Maryrose Sullivan, Victoria Tang</td>
</tr>
<tr>
<td></td>
<td>(PLUS) RESEARCH CONSORTUM – MOVING TOWARDS HEALTH AND PREVENTION</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:25</td>
<td>CLINICAL SCIENCE PANEL DISCUSSION</td>
<td>Anne Suskind</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CANCER SCREENING AND PROGNOSIS IN OLDER ADULTS</td>
<td>Louise Walter</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AMERICAN COLLEGE OF SURGEONS (ACS) COALITION FOR QUALITY IN GERIATIC SURGERY</td>
<td>Emily Finlayson</td>
<td></td>
</tr>
<tr>
<td></td>
<td>UCSF SURGERY WELLNESS PROGRAM: A PRE-OPERATIVE CARE PROGRAM FOR OLDER ADULTS</td>
<td>Victoria Tang</td>
<td></td>
</tr>
<tr>
<td>2:15</td>
<td>TRANSLATIONAL SCIENCE PANEL DISCUSSION</td>
<td>Lori Birder</td>
<td></td>
</tr>
<tr>
<td></td>
<td>THE IMPACT OF AGING ON OXIDATIVE STRESS AND CELLULAR SENESCENCE IN THE URINARY BLADDER</td>
<td>Lori Birder</td>
<td></td>
</tr>
<tr>
<td>3:05</td>
<td>UNDERSTANDING THE SIGNIFICANCE OF EPIGENETIC CHANGES IN THE AGING BLADDER</td>
<td>Pradeep Tyagi</td>
<td></td>
</tr>
<tr>
<td>3:10</td>
<td>INTERNATIONAL RESEARCH ROUNDTABLE</td>
<td>Ananias Diokno, Tomas Griebling</td>
<td></td>
</tr>
<tr>
<td>3:15</td>
<td>BREAK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:20</td>
<td>NOVEL KLOTHO KNOCKOUT ANIMAL MODEL FOR AGING BLADDER RESEARCH</td>
<td>Laura Lamb</td>
<td></td>
</tr>
<tr>
<td>4:10</td>
<td>ENHANCED BLADDER SENSITIVITY IN MICE WITH ESTROGEN DEFICIENCY INDUCED BY OVARIECTOMY</td>
<td>El-ichiroy Takaoka, Naoki Yoshimura</td>
<td></td>
</tr>
<tr>
<td>4:25</td>
<td>NEUROTRANSMISSION DEFECTS IN AGING BLADDERS ASSOCIATED WITH PARKINSON'S DISEASE</td>
<td>Maryrose Sullivan</td>
<td></td>
</tr>
<tr>
<td>5:00</td>
<td>UNDERSTANDING THE SIGNIFICANCE OF EPIGENETIC CHANGES IN THE AGING BLADDER</td>
<td>Pradeep Tyagi</td>
<td></td>
</tr>
</tbody>
</table>

*Presenting author*
METABOLIC SYNDROME AND LOWER URINARY TRACT SYMPTOMS
Anthony Ng

PREVALENCE OF NOCTURIA IN THE GERIATRIC POPULATIONS
Michael Daugherty

THE FEASIBILITY OF CLEAN INTERMITTENT CATHETERIZATION (CIC) IN THE GERIATRIC AGE RANGE IN TURKEY
Ibrahim Cevik

URINARY TRACT INFECTIONS IN GERIATRIC AMBULATORY PATIENTS WITH INDIRECTING CATHETERS
Laura Nguyen

EFFICACY OF PERCUTANEOUS TibIAL NERVE STIMULATION AMONG OLDER ADULTS: AN INSTITUTIONAL ANALYSIS
Stephanie Gleicher

OFFICE BASED NEWER TREATMENT OPTIONS FOR LOWER URINARY TRACT SYMPTOMS DUE TO BPH IN ELDERLY PATIENTS
Puneet Sindhwani

EXPERIENCE OF SURGICAL TREATMENT FOR BENIGN PROSTATIC OBSTRUCTION IN PATIENTS OLDER THAN 80 YEARS
Oscar Storme

EPIDEMIOLOGY AND DEMOGRAPHICS OF THE UNDERACTIVE BLADDER: A CROSS-SECTIONAL SURVEY
Michael Chancellor

ADJOURN

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 20, 2018 1:00 pm - 5:00 pm
KOREAN WORLD UROLOGIC CONGRESS (KWUC)
Room 2001 @ MCC West

Program Chair: Gyung Tak Sung

1:00 LUNCH AND NETWORKING

1:20 WELCOME ADDRESS BY KUA PRESIDENT-ELECT
Society President-Elect: Kyu-Sung Lee

1:30 SESSION I: PROSTATE CANCER UPDATE IN DIAGNOSIS
Moderators: Moon Chung, Christopher Kane

ISUP GROUP 4: A HOMOGENOUS GROUP OF PROSTATE CANCERS?
Seock Hwan Choi

ROLE OF CTCS AND EXOSOMES IN THE DIAGNOSIS OF PROSTATE CANCER
Martin Sarda

USEFULNESS OF WHOLE-BODY MRI IN THE DIAGNOSIS OF METASTATIC PROSTATE CANCER
Karim Touijer

PANEL DISCUSSION
Case Presenter: Soodong Kim
Panelists: Seock Hwan Choi, Benjamin Chung, Sung Kyu Hong, Martin Sarda, Karim Touijer

2:30 SESSION II: MANAGEMENT OF FUNCTIONAL PROBLEM AFTER RADICAL PROSTATECTOMY
Moderators: Jeong-Gu Lee, Isaac Kim, John Stoffel

UPDATE OF AUS FOR THE MANAGEMENT OF POST-PROSTATECTOMY INCONTINENCE
Kyu-Sung Lee

IS MALE SLING BETTER TREATMENT OPTION THAN AUS?
Angelo Gousse

SEXUAL REHABILITATION AFTER RADICAL PROSTATECTOMY
Mohit Khera

PANEL DISCUSSION
Case Presenter: Joon Chul Kim
Panelists: Myung-Soo Choo, Angelo Gousse, Mohit Khera, Philip Kim, Kyu-Sung Lee

SESSION III: IMMUNE CHECKPOINT INHIBITORS IN UROLOGIC CANCER
Moderators: Choung-Soo Kim, Ashish Kamat, Gyung Tak Sung

IMMUNE CHECKPOINT INHIBITORS FOR UROTHELIAL CANCER
Ho Kyung Seo

IMMUNE CHECKPOINT INHIBITORS FOR ADVANCED OR METASTATIC RENAL CELL CARCINOMA
Karim Chamie

IMMUNE CHECKPOINT INHIBITORS FOR PROSTATE CANCER
Ravi Madan

PANEL DISCUSSION
Case Presenter: Seong Il Seo
Panelists: Karim Chamie, Jun Hong, Ravi Madan, Ho Kyung Seo

SESSION IV: KUA/SKAU FELLOW/RESIDENT PRESENTATIONS
Moderators: Chester Koh, Cheol Kwak

CHANGE IN PROSTATE SPECIFIC ANTIGEN CONCENTRATION IN MEN WITH PROSTATE SPECIFIC ANTIGEN LESS THAN 2.5 NG/ML TAKING LOW DOSE FINASTERIDE OR DUTASTERIDE FOR MALE ANDROGENETIC ALOPECIA
Hyeong Dong Yuk
**R. FRANK JONES UROLOGICAL SOCIETY (RFJUS)**  
1:00 pm - 5:00 am

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 1:00  | **WELCOME AND PRESIDENT'S UPDATE**  
Society President: Jacqueline Hamilton |
| 1:05  | **WELCOME FROM THE AUA** |
| 1:10  | **Q & A**  
Robert Waterhouse |
| 1:15  | **AUA PUBLIC POLICY COUNCIL LIAISON UPDATE**  
Robert Waterhouse |
| 1:25  | **INTRODUCTION AND PRETEST** |
| 1:35  | **MINORITY ORGAN DONATION: THE POWER OF AN EDUCATED COMMUNITY**  
Clive Callendar |
| 1:40  | **Q & A/AUDIENCE RESPONSE TECHNOLOGY**  
Kevin Abbott |
| 2:05  | **Q & A/AUDIENCE RESPONSE TECHNOLOGY**  
Kevin Abbott |
| 2:10  | **ASSESSING TRANSPLANT ATTITUDES: UNDERSTANDING MINORITY MEN'S PERSPECTIVES ON THE MULTIFARIOUS BARRIERS TO ORGAN DONATION**  
Charles Modlin, Yaw Nyame |
| 2:40  | **Q & A/AUDIENCE RESPONSE TECHNOLOGY** |

---

**SOCIETY FOR THE STUDY OF MALE REPRODUCTION (SSMR)**  
Yerba Buena Salon 9 @ Marriott Marquis  
Sunday, May 20, 2018  
1:00 pm - 5:15 pm

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 1:00  | **INTRODUCTION**  
James Hotaling |
| 1:10  | **SESSION I: SEMEN ANALYSIS: STATE OF THE ART?**  
**STRENGTHS AND LIMITATIONS OF THE SEMEN ANALYSIS**  
Samuel Ohlander  
**PRO: MORPHOLOGY CAN PROGNOSTICATE FERTILITY**  
Richard Scott  
**CON: MORPHOLOGY CAN PROGNOSTICATE FERTILITY**  
Alexander Pastuszak  
**REBUTTAL**  
Alexander Pastuszak, Richard Scott  
**DISCUSSION**  
Samuel Ohlander, Alexander Pastuszak, Richard Scott |
| 1:45  | **REFINING THE PHENOTYPE OF MALE INFERTILITY: IMPROVING SEMEN ANALYSIS CLINICAL TRIALS**  
Enrique Schisterman  
**MALE FACTOR INFERTILITY AND THE FUTURE OF IVF**  
Richard Scott  
**PICKING THE BEST SPERM FOR IVF/ICSI**  
Keith Jarvi  
**THE GENETIC REVOLUTION & MALE INFERTILITY**  
Douglas Carrell  
**BREAK** |
| 3:30  | **SESSION II: SPERMATOGONIAL STEM CELLS: THE KEY TO PERSONALIZED CARE OF INFERTILE MALES?**  
**PRESENTING AUTHOR** |

---

*Presenting author*
THE HUMAN TESTIS CELL ATLAS: INSIGHTS INTO SPERMATOGONIAL STEM CELL (SCC) DEVELOPMENT AND GAMETOGENESIS FROM SINGLE-CELL PROFILING OF RNA TRANSCRIPTOMES
Brad Cairns

WHAT WOULD PERSONALIZED MEDICINE FOR THE INFERTILE MALE LOOK LIKE?
James Smith

PANEL DISCUSSION: SHOULD WE FREEZE AZOOSPERMIC TESTICULAR TISSUE FROM PRE-PUBERTAL BOYS UNDERGOING CHEMO?
Panelists: Brad Cairns, Tim Jenkins, Larry Lipshultz, Kirk Lo, Richard Scott, James Smith

THE DIAGNOSTIC POTENTIAL AND CLINICAL UTILITY OF SPERM EPIGENETIC ANALYSES
Tim Jenkins

PANEL DISCUSSION: HOW MIGHT SSC/TESTIS PROFILING BE UTILIZED BY FERTILITY CLINICIANS?
Panelists: Brad Cairns, Tim Jenkins, Larry Lipshultz, Kirk Lo, Richard Scott, James Smith

PANEL DISCUSSION: THE FUTURE - SSC PROFILING AND CULTURING?
Panelists: Tim Jenkins, Brad Cairns, Larry Lipshultz, Kirk Lo, Richard Scott, James Smith

BUSINESS MEETING

ADJOURN

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
LEARNING FROM YOUR MISTAKES: HOW TO GET IT RIGHT!
Tom McNicholas

OVERVIEW OF NOVEL SURGICAL TREATMENTS OF BPH
Peter Gilling

4:55 BJUI PEER REVIEW PRIZE FOR BEST REVIEWER FROM THE AMERICAS
Prokar Dasgupta

Sunday, May 20, 2018
2:00 pm - 5:00 pm
JAPANESE UROLOGICAL ASSOCIATION (JUA)
Golden Gate A @ Marriott Marquis

Program Chair: Yoshihiko Tomita

2:00 OPENING REMARKS
AUA President-Elect: Robert Flanigan

2:05 THEME 1: PROSTATE CANCER
Moderators: Michael Cookson, Akio Matsubara

NOVEL STRATEGIES FOR TARGETING CRPC RESISTANT TO AR-DIRECTED THERAPIES
Daisuke Obinata
IDENTIFYING AND TREATING THERAPEUTIC RESISTANCE IN CRPC: TRANSLATIONAL APPROACHES
Christopher Evans

PANEL DISCUSSION ON CLINICAL CASES: WHAT IS YOUR CHOICE OF TREATMENT?
Panelists: Naoko Aichi, Michael Cookson, Christopher Evans, Toru Suzuki

3:00 THEME 2: KIDNEY CANCER
Moderators: Masatoshi Eto, Robert Flanigan

ADVANCES IN IMAGING FOR RECURRENT TUMORS
Mihir Desai
CURRENT STATUS AND FUTURE PERSPECTIVE OF PARTIAL NEPHRECTOMY FOR KIDNEY CANCER
Kenji Zennami

2:30 PANEL DISCUSSION ON CLINICAL CASES: HOW DO YOU TREAT THIS PATIENT? DIFFERENCES IN APPROACHES?
Panelists: Robert Flanigan, John Leppert, Makito Miyake, Yusuke Sato

THEME 3: BPH
Moderators: J. Kellogg Parsons, Satoru Takahashi

COMBINATION PHARMACOTHERAPY IN BPH MANAGEMENT
Masafumi Kita

CONTEMPORARY APPROACHES TO SURGICAL MANAGEMENT OF BPH
Dicken Ko

PANEL DISCUSSION ON CLINICAL CASES: HOW TO APPROACH THIS SITUATION?
Panelists: Yukiko Kanno, Dicken Ko, J. Kellogg Parsons, Takahisa Suzuki

3:55 CLOSING REMARKS
Society President: Masato Fujisawa

ADJOURN
APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 20, 2018
2:00 pm - 6:00 pm
SOCIEDAD ARGENTINA DE UROLOGÍA (SAU)
Golden Gate C @ Marriott Marquis

Directors: Miguel Costa, Claudio Rosenfeld
Secretaries: Claudio Graziano, Ricardo Nardone

2:00 APERTURA (PROGRAM OPENING)

2:10 ANÁLISIS CRÍTICO DE LA CIRUGÍA MÍNIMAMENTE INVASIVA EN LATINOAMÉRICA (CRITICAL ANALYSIS OF MINIMALLY INVASIVE SURGERY IN LATIN-AMERICA)
Moderator: Alejandro Nolazco
Speaker: Fernando Secin

2:30 TRATAMIENTO QUIRÚRGICO DE LA ESTENOSIS URETRO VESICAL RECIDIVANTE POST PROSTECTOMÍA RADICAL (OPEN RECONSTRUCTION OF RECURRENT VESICoureTHRAL ANASTOMOTIC STRicture AFTER RADICAL PROSTATECTOMY)
Moderator: Javier Belinky
Speaker: Carlos Giudice

2:50 HPV EN EL HOMBRE: ENFOQUE ACTUAL (MALE HPV: CURRENT APPROACH)
Moderator: Norberto Lafos
Speaker: Adrián Momesso

*Presenting author
3:10 OPTIMIZACIÓN DEL TRATAMIENTO DEL CRPC
(OPTIMIZING TREATMENT FOR CRPC)
Moderator: Miguel Costa
Speaker: José Manuel Cozar

3:50 LITOTRICIA EXTRACORPÓREA 2018:
EVIDENCIA DE SU VIGENCIA Y EFECTIVIDAD
(EXTRACORPOREAL LITHOTRIPSY IN 2018:
EVIDENCE OF IT'S VALIDITY AND
EFFECTIVENESS)
Moderator: Roberto Hernández
Speaker: Pablo Contreras

4:10 BREAK

4:40 PROSTATECTOMÍA RADICAL EN CÁNCER DE
PRÓSTATA METASTÁSICO: ¿SOLO
SOBREVIDA O MÁS ALLÁ? (RADICAL
PROSTATECTOMY FOR MESTASTASIC
PROSTATE CANCER: JUST SURVIVAL OR
THERE'S MORE?)
Moderator: Ricardo Nardone
Speaker: Claudio Graziano

5:00 EN LAS ERA DE LA URETEROSCOPIA
FLEXIBLE, ¿HAY LUGAR PARA LA LITOTRICA
EXTRACORPÓREA? (IN THE ERA OF
FLEXIBLE URETEROSCOPY, IS THERE STILL
A PLACE FOR SHOCK-WAVE LITHOTRIPSY?)
Moderator: Horacio Sanguinetti
Speaker: Norberto Bernardo

Sunday, May 20, 2018 3:30 pm - 5:30 pm
ASSOCIATION FRANÇAISE D'UROLOGIE (AFU)
Union Square 22 @ Hilton SF Union Sq

3:30 WELCOME BY THE AFU DELEGATE TO THE
INTERNATIONAL AUA COMMITTEE
Jean-Nicolas Cornu

3:35 NEW INSIGHTS IN HIGH-GRADE, NON-
MUSCLE INVASIVE BLADDER CANCER
Brant Inman, Morgan Roupret

5:30 ADJOURN

Sunday, May 20, 2018
Moderated Poster Session 67
SEXUAL FUNCTION/DYSFUNCTION: PEYRONIE'S DISEASE I
Room 3004 @ MCC West
Moderators: Gregory Broderick, Nelson Bennett and Muammer Kendirci

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| MP67-01         | PENILE ULTRASOUND: A COST-EFFECTIVE TEST FOR PRE-TREATMENT EVALUATION OF PEYRONIE’S DISEASE
Kevin Wymer*, Matthew Ziegelmann, Landon Trost, Rochester, MN |

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| MP67-02         | DOES PRE-OPERATIVE PENILE ULTRASOUND HELP WITH SURGICAL PLANNING IN PATIENTS WITH PEYRONIE’S DISEASE AND ERECTILE DYSFUNCTION?
Dorota Hawksworth*, Emad Rajih, Osama Ali, Arthur Burnett, Baltimore, MD |

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| MP67-03         | PILOT STUDY OF 3D PHOTOGRAPHY FOR ASSESSMENT OF PENILE DEFORMITY IN MEN WITH PEYRONIE’S DISEASE
Denise Asafu-Adjei*, Ezra Margolin, Gen Li, Doron Stemper, Peter J. Stahl, New York, NY |
**MP67-04** IMPACT OF CAMERA DEVIATION ON CURVATURE ASSESSMENTS USING GONIOMETER AND 2D PHOTOGRAPHIES  
Bruno Nascimento*, Ivan Cerqueira, Eduardo P. Miranda, Jose Bessa Jr., Renato Fidelis, Giuliano Guglielmetti, Carlos Batagelo, Gabriel C. Silva, William Nahas, Miguel Srougi, Giorgio Chiesa, Jose Cury, Sao Paulo, Brazil

**MP67-05** PRELIMINARY OUTCOMES OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM (CCH) USING A MODIFIED TECHNIQUE “PERCUTANEOUS NEEDLING TUNNELING (PNT)” IN THE TREATMENT OF PEYRONIE’S DISEASE (PD): PROSPECTIVE RANDOMIZED STUDY  
Esau Fernández-Pascual, Jorge Turo, Claudio Martinez-Ballesteros, Maria Rodríguez-Monsalve, Diego Marcos, Joaquín Carballido, Juan Ignacio Martínez-Salamanca*, Majadahonda, Madrid, Spain

**MP67-06** MULTI-INSTITUTIONAL PROSPECTIVE ANALYSIS OF INTRALESIONAL INJECTION OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM, TUNICAL PLICATION AND PARTIAL PLAQUE EXCISION AND GRAFTING FOR THE MANAGEMENT OF PEYRONIE’S DISEASE  

**MP67-07** PLAQUE CALCIFICATION: AN IMPORTANT PREDICTOR OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM TREATMENT SUCCESS FOR MEN WITH PEYRONIE’S DISEASE  
Kevin Wymer*, Matthew Ziegelmann, Landon Trost, Rochester, MN

**MP67-08** COLLAGENASE CLOSTRIDIUM HISTOLYTICUM FOR THE TREATMENT OF VENTRAL PENILE CURVATURE – INTERIM ANALYSIS OF OBJECTIVE OUTCOMES  
Matthew Ziegelmann*, Kevin Wymer, Raevti Bole, Joshua Savage, Manaf Alom, Tobias Kohler, Landon Trost, Rochester, MN

**MP67-09** THE IMPACT OF INTRALESIONAL XIAFLEX ON PSYCHOSOCIAL OUTCOMES IN MEN WITH PEYRONIE’S DISEASE (PD)  
Bruno Nascimento*, Helen L. Bernie, Hisanori Taniguchi, Eduardo Miranda, Jean-Etienne Terrier, Patrick Teloken, John P. Mulhall, New York, NY

**MP67-10** CLINICAL EFFICACY OF INTRALESIONAL THERAPY FOR PEYRONIE’S DISEASE IN RANDOMIZED CLINICAL TRIALS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS  
Giorgio Ivan Russo*, Catania, Italy, Giovanni Cacciamani, Verona, Italy, Andrea Cocci, Firenze, Italy, Giuseppe Morgia, Catania, Italy, Vincenzo Mirone, Napoli, Italy, Thomas Kessler, Zurich, Switzerland, Ege Can Serefoglu, Istanbul, Italy, Maarten Albersen, Leuven, Belgium, Paolo Verze, Napoli, Italy

**MP67-11** PATIENT REPORTED OUTCOMES ON SEXUAL FUNCTION AFTER SURGICAL TREATMENT OF PEYRONIES DISEASE  
Daan Mohede*, Alida Weidenaar, Mels Van Driel, Harry van de Wiel, Iggle De Jong, Groningen, Netherlands

**MP67-12** PEYRONIE’S DISEASE IS ASSOCIATED WITH INCREASED IMMUNE REACTIVITY: ANALYSIS OF UNITED STATES CLAIMS DATA  
Taylor P. Kohn*, Houston, TX, Daniel Pichardo, Linthicum, MD, Katherine M. Rodriguez, Houston, TX, William Meeks, Linthicum, MD, Larry I. Lipschultz, Alexander W. Pastuszak, Houston, TX

**MP67-13** INCIDENCE OF PEYRONIE’S DISEASE AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY IN MEN WITH POST-OPERATIVE SUPRAPUBIC CATHETERS AND NO URETHRAL FOLEY CATHETERS  
Alex Borchert*, Mustafa Deebajah, Mahdi Bazzi, Mireya Diaz-Insua, Jordan Chick, Mahendra Bandari, James Peabody, Mani Menon, Shaheen Alamee, Ali Dabaja, Detroit, MI

**MP67-14** ANTI-FIBROTIC EFFECTS OF VERTEPORFIN ON MYOFIBROBLASTS IN PEYRONIE DISEASE  
Daan Mohede*, Ruud Bank, Mels Van Driel, Iggle De Jong, Groningen, Netherlands

**MP67-15** ANTI-FIBROTIC EFFECT OF MYCOPHENOLATE MOFETIL IN RATS WITH PEYRONIE’S DISEASE  
Fernando Facio, Jr.*, Luis Spessoto, Thiago Antoniassi, Sebastião Taboga, Sao Jose do Rio Preto, Brazil

**MP67-16** PILOT STUDY TO ASSESS FEASIBILITY, SAFETY AND EFFICACY OF PENILE SPLINT DEVICE IN THE IMMEDIATE POSTOPERATIVE MANAGEMENT OF GRAFTING TECHNIQUE IN PEYRONIE’S DISEASE (PD) SURGERY: PROSPECTIVE RANDOMIZED STUDY  
Esau Fernández-Pascual, Jorge Turo, Maria Rodríguez-Monsalve, Aura Daniella Souto, Claudio Martinez- Ballesteros, Joaquín Carballido, Juan Ignacio Martínez-Salamanca*, Majadahonda, Madrid, Spain

*Presenting author
MP67-17 PLICATION FOR SEVERE PEYRONIE’S DEFORMITIES HAS SIMILAR OUTCOMES TO MILD CASES
    Rohit Reddy*, Maxim McKibben, Nabeel Shakir, Joceline Fuchs, Jeremy Scott, Allen Morey, Dallas, TX

MP67-18 SURGICAL TREATMENT OF PEYRONIE’S DISEASE IN THE OLDER MAN: CHARACTERISTICS AND OUTCOMES
    George Abdelsayed*, Shaan Setia, Laurence Levine, Chicago, IL

MP67-19 THE COMPARISON OF AN ACELLULAR MATRIX GRAFT (XENOGUARD®) WITH AN AUTOLOGOUS VENOUS GRAFT IN THE SURGICAL TREATMENT OF PEYRONIE’S DISEASE: PRELIMINARY RESULTS
    Onder Kayigil*, Muhammet Ozcan, Ozer Cakici, Ankara, Turkey

MP67-20 MULTICENTER PROSPECTIVE STUDY OF PATIENTS WITH PEYRONIE’S DISEASE (PD) WHO UNDERWENT INCISION OR PARTIAL-PLAQUE EXCISION WITH COLLAGEN-FIBRINOBLEN-THROMBIN FLEECE GRAFTING
    Esau Fernández-Pascual, Majadahonda, Madrid, Spain, Josep Torremadé, Barcelona, Spain, François Peinado, Madrid, Spain, Joaquim Sarquella, Barcelona, Spain, Javier Romero, Madrid, Spain, Rodrigo García-Baquero, Cádiz, Spain, Jorge Turo, Majadahonda, Madrid, Spain, Agustin Fraile, Madrid, Spain, Mariano Roselló, Palma de Mallorca, Spain, Félix Campos, Santander, Spain, Alejandra Egui, Fuenlabrada, Madrid, Spain, Ignacio Moncada, Madrid, Spain, Joaquín Carballido, Claudia Martínez-Ballesteros, Juan Ignacio Martínez-Salamanca*, Majadahonda, Madrid, Spain

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 20, 2018

Moderated Poster Session 68
STONE DISEASE: SURGICAL THERAPY IV
Room 3006 @ MCC West
Moderators: Amy Krambeck, Gyan Pareek and Eduardo Mazzucchi

ABSTRACT NUMBER TITLE
MP68-01 USE OF DUSTING TECHNIQUE: RISK OF REPEAT INTERVENTION AFTER URETEROSCOPY FOR RENAL AND URETERAL STONES
    Viacheslav Iremashvili*, Shuang Li, Sean P. Hedican, Sara L. Best, Stephen Y. Nakada, Madison, WI

MP68-02 PREDICTORS OF PERSISTENT OPIATE USE AFTER URETEROSCOPY
    Caroline L. Kang*, Xiang Shu, S. Duke Herrell, Nicole Miller, Ryan Hsi, Nashville, TN

MP68-03 COMPARISON OF EIGHT DIGITAL (REUSABLE AND DISPOSABLE) FLEXIBLE URETEROSCOPES DEFLECTION PROPERTIES: IN-VITRO STUDY IN 10 DIFFERENT SCOPE SETTINGS
    Laurian Dragos*, Sandra M. Martis, Timisoara, Romania, Bhaskar K. Somani, Southampton, United Kingdom, Maria Rodriguez-Monsalve Herrera, Etienne X. Keller, Vincent M.J. De Coninck, Catalin Iacoboaie, Stevee Doizi, Paris, France, Ewa Brez- Niewada, Warsaw, Poland, Livius C. Daminescu, Razvan T. Bardan, Timisoara, Romania, Emre T. Sener, Istanbul, Turkey, Salvatore Buttice, Agrigento, Italy, Silvia Proietti, Milan, Italy, Olivier Traxer, Paris, France

MP68-04 COMPARISON OF TWO DIGITAL, SINGLE USE FLEXIBLE URETERORENOSCOPES (BOSTON SCIENTIFIC LITHOVUE AND PUSEN PU3022)- A PROSPECTIVE STUDY
    Jonathan Kam*, Yuigi Yuminaga, Kieran Beatle, Sunny Nalavenkata, Mohan Aranayagam, Bertram Canagasingham, Richard Ferguson, Cell Varol, Mohamed Khadra, Matthew Winter, Raymond Ko, Kingswood, Australia

MP68-05 TAKING ADVANTAGE OF SINGLE-USE FLEXIBLE URETEROSCOPES: TECHNIQUES OF FORCED TIP DEFLECTION AND FORCED TORQUE
    Etienne Xavier Keller*, Vincent De Coninck, Maria Rodriguez-Monsalve, Paris, France, Laurian Dragos, Timisoara, Romania, Steeve Doizi, Olivier Traxer, Paris, France

MP68-06 ARE POST-OPERATIVE URETERIC CATHETERS A SAFE ALTERNATIVE TO SHORT-DWELL URETERIC STENTS?
    Martina Smekal*, Vimooshan Arumuham, Michael Mikhail, Ali Tasleem, Simon Choong, Daron Smith, Sian Allen, London, United Kingdom

MP68-07 ACUTE KIDNEY INJURY BIOMARKERS IN PATIENTS WITH PROXIMAL URETERIC STONES: COMPARATIVE STUDY OF DIFFERENT TREATMENT METHODS
    Igor Aboyan, Kirill Shiranov*, Sergey Pakus, Rostov-on-Don, Russian Federation

236
MP68-08 EARLY URETEROSCOPIC TREATMENT IS AS SAFE AS DEFERRED TREATMENT IN PATIENTS WITH UROSEPSIS ASSOCIATED WITH URETERAL CALCULI. A PROSPECTIVE, RANDOMIZED CLINICAL TRIAL
Gaston Astroza*, Miguel Sarras, Alejandro Majerson, Jose Salvado, Javier Dominguez, Santiago, Chile

MP68-09 SPONTANEOUS URETERAL STONE PASSAGE IN THE PRESENCE OF A URETERAL STENT

MP68-10 ESTABLISHMENT OF TREATMENT STRATEGIES FOR IMPACTED CALCULI BY ANALYZING THE URETEROSCOPIC FINDINGS
Shuzo Hamamoto*, Rei Unno, Kazumi Taguchi, Ryosuke Ando, Nagoya, Japan, Shinauke Okada, Chiba, Japan, Takaaki Inoue, Osaka, Japan, Atsushi Okada, Keiichi Tozawa, Nagoya, Japan, Hiroyasu Miura, Hachinohe, Japan, Tadashi Matsuda, Osaka, Japan, Takahiro Yasui, Nagoya, Japan

MP68-11 POSITIVE URINE CULTURE COMBINED WITH POSITIVE STONE CULTURE WAS IMPORTANT MARKER TO PREDICT POSTOPERATIVE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME AFTER PERCUTANEOUS NPHROLITHOTOMY IN PATIENTS WITH COMPLEX KIDNEY STONES
Wenqi Wu*, Dong Chen, Guangzhou, China, People’s Republic of, Yuyan Zhang, Guangzhou, China, People’s Republic of, Jian Huang, Xiongfang Liang, Tao Zeng, Guchua Zeng, Guangzhou, China, People’s Republic of

MP68-12 RESIDENT EXPERIENCE IN PERCUTANEOUS NPHROLITHOTOMY ACCESS: A NATIONWIDE SURVEY
Joshua Ebel*, Amy Lehman, Bodo Knudsen, Columbus, OH

MP68-13 THE NEXT GENERATION: IN VITRO COMPARISON OF A NOVEL SINGLE-PROBE DUAL-ENERGY LITHOTRIPTER TO CURRENT DEVICES
Daniel Wollin, Evan Carlos, Brenton Winship*, Michael Gustafson, Westin Tom, Daniela Radvak, Ruiyang Jiang, Charles Scales, Michael Ferrandino, W. Neal Simmons, Glenn Preminger, Michael Lipkin, Durham, NC

MP68-14 ARE TWO VIEWS BETTER THAN ONE? MULTI-SCOPE PERCUTANEOUS NPHROLITHOTOMY HAS HIGH STONE CLEARANCE RATES ON POSTOPERATIVE CT
Mark V. Silva*, Baltimore, MD, Alexander C. Small, New York, NY, Joel E. Abbott, Julio G. Davalos, Baltimore, MD

MP68-15 THE EVOLUTION OF PERCUTANEOUS NPHROLITHOTOMY: ANALYSIS OF A SINGLE INSTITUTION EXPERIENCE OVER 25 YEARS
Jennifer Bjazevic*, Linda Nott, John Denstedt, Hassan Razvi, London, Canada

MP68-16 PERCUTANEOUS NPHROLITHOTOMY: DOES A HANDS-ON COURSE MAKE A DIFFERENCE?
Roshan Patel*, Arman Wali, Zhamshid Okhunov, Kamaljit Kaler, Kathryn Osann, Jaime Landman, Ralph Clayman, Orange, CA

MP68-17 A RANDOMISED CONTROLLED STUDY COMPARING STANDARD TUBELESS PCNL & TUBELESS MINI-PCNL FOR RENAL STONES LESS THAN 2CM
Aditya Yelikar*, Pratik Shah, Pankaj Dholaria, Amish Mehta, Jitendra Amlani, Vivek Joshi, Rajkot, India

MP68-18 IS THE STONE-FREE STATUS THE DESIRED OUTCOME FOR PATIENTS UNDERGOING PERCUTANEOUS NPHROLITHOTOMY?
Jorge Moreno Palacios*, Virgilio Augusto López Sámano, Rodrigo Leon Mar, Oswaldo José Áviles Ibarra, León Octavio Torres Mercado, Efrain Maldonado Alcaraz, Mexico City, Mexico

Mokhtar Bibi*, Ahmed Sallami, Chaker Kais, Yassine Ouanes, Sami Ben Rhouma, Yassine Nouira, Tunis, Tunisia

MP68-20 QUALITY AND READABILITY OF ONLINE INFORMATION ABOUT URETERAL STENTS
Sarah Mozafarpour*, Boston, MA, Briony Norris, James Bonin, New York, NY, Brian Eisner, Boston, MA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

*Presenting author
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP69-01</td>
<td>COST ANALYSIS OF THE MANAGEMENT OF PEDIATRIC FEBRILE UTI: TRADITIONAL, AAP, AND POPULATION HEALTH ALGORITHMS</td>
<td>MP69-07</td>
<td>INCIDENCE OF URINARY TRACT INFECTIONS IN NEWBORNS WITH SPINA BIFIDA: IS ANTIBIOTIC PROPHYLAXIS NECESSARY?</td>
</tr>
<tr>
<td>Jathin Bandari*, Pittsburgh, PA, Gayanna Raju, Madera, CA, Steven Docimo, Philadelphia, PA</td>
<td>M. Chad Wallis*, Salt Lake City, UT, Pangaja Paramsothy, Judy Thibadeau, Atlanta, GA, Jonathan Routh, Durham, NC, David Joseph, Birmingham, AL, Earl Cheng, Chicago, IL, Duong Tu, Houston, TX, Chris Austin, Portland, OR, Chester Koh, Paul Austin, Houston, TX, Stacy Tanaka, Nashville, TN, William Walker, Seattle, WA, Kathy Smith, Los Angeles, CA, Michelle Baum, Boston, MA, John Wiener, Durham, NC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MP69-02</td>
<td>OPEN VERSUS ROBOTIC URETERONEOCYSTOSTOMY FOR PEDIATRIC VESICOURETERAL REFLUX: A SYSTEMATIC REVIEW</td>
<td>MP69-08</td>
<td>TOP-DOWN VERSUS BOTTOM-UP APPROACH IN CHILDREN PRESENTING WITH FEBRILE URINARY TRACT INFECTION- ANALYSIS USING RANDOMIZED INTERVENTION FOR CHILDREN WITH VESICOURETERAL REFLUX (RIVUR) AND CAREFUL URINARY TRACT INFECTION EVALUATION (CUTIE) DATABASES</td>
</tr>
<tr>
<td>MP69-03</td>
<td>SURGICAL OUTCOMES AFTER PEDIATRIC URETERAL REIMPLANT FOR HIGH-GRADE VESICOURETERAL REFLUX: AS SUCCESSFUL AS WE THINK?</td>
<td>MP69-09</td>
<td>ARE DUPLEX REIMPLANTS WORTH LESS THAN SINGLE SYSTEM REIMPLANTS: AN ANALYSIS OF 30 DAY OUTCOMES</td>
</tr>
<tr>
<td>Mary Wang, Yi Li*, Rachel Selekmian, Thomas Gaither, Laurence Baskin, San Francisco, CA</td>
<td>Kristina Suson*, Janae Preece, Yegappan Lakshmanan, Detroit, MI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MP69-04</td>
<td>NATIONAL IMAGING AND ANTIBIOTIC PRACTICE PATTERNS IN CHILDREN PRESENTING WITH URINARY TRACT INFECTION: LITTLE IMPACT OF AAP GUIDELINES?</td>
<td>MP69-10</td>
<td>THE EFFECT OF PRIOR ENDOSCOPIC CORRECTION OF VESICOURETERAL REFLUX ON OPEN URETERAL REIMPLANTATION: SURGICAL OUTCOMES AND COSTS</td>
</tr>
<tr>
<td>MP69-05</td>
<td>PREDICTORS OF FAILURE IN 90 COMPLEX URETERS USING ROBOT-ASSISTED LAPAROSCOPIC SURGERY</td>
<td>MP69-11</td>
<td>PREDICTORS OF BACTERIURIA AND ANTIBIOTIC RESISTANCE IN ASYMPTOMATIC CHILDREN USING CIC FOR BLADDER MANAGEMENT</td>
</tr>
<tr>
<td>Maria Veronica Rodriguez*, Aaron Wallace, Nimrod Barashi, William Boysen, Mohan S. Gundeti, Chicago, IL</td>
<td>Renea Sturm*, Emilie Johnson, Christopher Halline, Theresa Meyer, Devon Snow-Lisy, Iliana Rosoklija, Lauren Balmert, Earl Cheng, Elizabeth Yerkes, Chicago, IL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MP69-06</td>
<td>VESICOURETERAL REFLUX IN CHILDREN WITH CEREBRAL PALSY: INCIDENCE AND ASSOCIATION WITH DETRUSOR SPHINCTER DYSSYNERGY</td>
<td>MP69-12</td>
<td>DOES BREASTFEEDING REDUCE THE RISK OF UTI IN INFANTS WITH PRENATAL HYDRONEPHROSIS?</td>
</tr>
</tbody>
</table>
MP69-13 DOES PREOPERATIVE URINE CULTURE SCREENING REDUCE THE INCIDENCE OF POSTOPERATIVE INFECTIONS?
Jennifer Ahn*, Margareth Shnorhavorian, Parul Merguerian, Seattle, WA

MP69-14 DEEPER DIVE INTO NEW RENAL SCARRING IN THE RANDOMIZED INTERVENTION FOR CHILDREN WITH VESICOURETERAL REFLUX (RIVUR) TRIAL
Hsinhsiao Wang*, Michael Kurtz, Caleb Nelson, Boston, MA

MP69-15 RELATIVE IMPORTANCE OF EFFECTIVENESS AND COST IN PARENTAL PREFERENCES FOR VESICOURETERAL REFLUX TREATMENT
Zachary Dionise*, Durham, NC, Michael Garcia-Roig, Andrew Kirsch, Atlanta, GA, Jonathan Routh, Durham, NC

MP69-16 CHARACTERISTICS AND MORBIDITY OF BACTEREMIA OF UROLOGIC ORIGIN IN THE PEDIATRIC PATIENT
Jesse Jacobs*, Kevin Ginsburg, Kahlil Saad, George Steinhardt, Detroit, MI

MP69-17 SURGICAL MANAGEMENT OF UPPER POLE NONFUNCTIONING RENAL MOIETIES – THE TIMELESS DEBATE
Kunj R. Sheth*, Jeffrey T. White, Abhishek Seth, Houston, TX

MP69-18 PREGNANCY WITH REDUCED RENAL MASS AND NEPHRON COUNT CAUSES METABOLIC AND RENAL STRUCTURAL CHANGES
Xiaoyuan Han*, Neeraja Kambham, Phil Tsao, Linda Shortliffe, Palo Alto, CA

MP69-19 INDICATIONS AND OUTCOMES OF THE CUFF-NIPPLE URETERONEOCYSTOMY
Samuel Aly MD*, Livingston, NJ, Moneer Hanna MD, FRCS, New York, NY

MP69-20 USE OF BEST PRACTICE ALERTS TO IMPROVE ADHERENCE TO AMERICAN UROLOGIC ASSOCIATION VESICOURETERAL REFLUX GUIDELINES
Sarah Ha*, Longmont, CO, Carter Sevick, Vijaya Vemulakonda, Aurora, CO

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 20, 2018
3:30 pm - 5:30 pm

Moderated Poster Session 70
PROSTATE CANCER: BASIC RESEARCH & PATHOPHYSIOLOGY III
Room 3020 @ MCC West
Moderators: K.C. Balaji, Ralph Buttyan and Allen Gao

ABSTRACT NUMBER TITLE
MP70-01 STATE-OF-THE-ART AUTOMATED EXTRACTION OF DETAILED PATHOLOGICAL DATA FROM NARRATIVELY WRITTEN ELECTRONIC HEALTH RECORDS
Sami-Ramzi Leyh-Bannurah*, Hamburg, Germany, Tian Zhe, Pierre Karakiewicz, Montreal, Canada, Ulrich Wolfgang, Muenster, Germany, Dirk Pehrke, Margit Fisch, Hartwig Huland, Markus Graefen, Lars Budäus, Hamburg, Germany

MP70-02 AN OVERVIEW OF PUBLICLY AVAILABLE PATIENT-CENTERED PROSTATE CANCER DATASETS
Tim Hulsen*, Eindhoven, Netherlands, Chris Bangma, Rotterdam, Netherlands

MP70-03 PUDENDAL NERVE SOMATOSENSORY EVOKED POTENTIALS IN PATIENTS WITH POSTPROSTATECTOMY INCONTINENCE AND ERECTILE DYSFUNCTION
Se Yun Kwon*, Jin-Mo Park, Ki Ho Kim, Young Jin Seo, Kyung Seop Lee, Gyeongju, Korea, Republic of

MP70-04 HIGH ACCURACY AND EFFECTIVENESS WITH DEEP NEURAL NETWORKS AND ARTIFICIAL INTELLIGENCE IN PATHOLOGICAL DIAGNOSIS OF PROSTATE CANCER: INITIAL RESULTS
Chengwei Zhang*, Qing Zhang, XiuBin Gao, Peng Liu, Hongqian Guo, Nanjing, China, People’s Republic of

MP70-05 PELVIC DENERVATION INDUCES PROSTATE METAPLASIA BUT DOES NOT AFFECT ADRENERGIC NOR PROLACTIN RECEPTORS OF POSGANGLIONIC PELVIC NEURONS OF RATS
Alejandro Mateos*, Fausto Rojas, Gonzalez E. Aranda, Deissy Herrera, Maria C. Aguierre, Veracruz, Mexico, Yolanda Cruz Gomez, Tlaxcala, Mexico, Maria E. Hernandez, Veracruz, Mexico

MP70-06 MICRO- AND MACRO-FLUIDIC MODELS OF PROSTATE CANCER METASTASIS
Takahiro Osawa*, Sapporo, Japan, Stephen Robinson, Brendan Leung, Jinlu Dai, Shunichi Takayama, Evan T. Keller, Ann Arbor, MI

*Presenting author
MP70-07 IDENTIFYING OF PROSTATE CANCER CELL-SPECIFIC INTERNALIZING APTAMERS AND ENGINEERING OF APTAMER-TARGETED NANOPARTICLES FOR PROSTATE CANCER THERAPY
Changwei Ji*, Hongqian Guo, Nanjing, China, People's Republic of

MP70-08 ESTABLISHING AND CHARACTERIZATION OF AN INNOVATIVE IN-VIVO MODEL OF METASTASIZING PROSTATE CANCER USING ORTHOTOPIC XENOGRAFTS
Matthias Saar, Christina Körbel, Andreas Müller, Markus Hammer, Michael Stöckle, Kerstin Junker, Michael D. Menger, Johannes Linxweiler*, Homburg Saar, Germany

MP70-09 IDENTIFICATION OF NINE NEW SUSCEPTIBILITY LOCI FOR PROSTATE CANCER IN THE JAPANESE POPULATION
Ryo Takata*, Morioka, Japan, Shusuke Akamatsu, Tokyo, Japan, Naoki Terada, Kyoto, Japan, Yoichiro Kato, Mitsugu Kanehira, Jun Sugimura, So Omori, Takaya Abe, Morioka, Japan, Johji Inazawa, Tokyo, Japan, Osamu Ogawa, Kyoto, Japan, Wataru Obara, Morioka, Japan

MP70-10 ASSOCIATION OF SINGLE NUCLEOTIDE POLYMORPHISMS WITH ERG FUSION STATUS IN PROSTATE CANCER
Indu Kohaar*, Yongmei Chen, Lakshmi Ravindranath, Denise Young, Amina Ali, Rockville, MD, Qiyuan Li, Xiamen, Fujian, China, People’s Republic of, Albert Dobi, David McLeod, Inger Rosner, Rockville, MD, Isabell Sesterhenn, Silver Spring, MD, Jennifer Cullen, Rockville, MD, Matthew Freedman, Boston, MA, Shiv Srivastava, Gyorgy Petrovics, Rockville, MD

MP70-11 REVERSE OF DOCEATEXEL RESISTANCE IN PROSTATE CANCER VIA NOTCH SIGNALING INHIBITION
Qiu Shi*, Xiang Tu, Qiang Wei, Lu Yang, Chengdu, China, People’s Republic of

MP70-12 ROLES OF TOPOISOMERASE INHIBITORS AND CISPLATIN FOR CRPC IN THE POST-CABAZITAXEL SETTING
Takeo Kosaka*, Hiroshi Hongo, Yota Yasumizu, Yasumasa Miyazaki, Eiji Kikuchi, Mototsugu Oya, Shinjuku-ku, Japan

MP70-13 DEPLETION OF PMEPA1 GENE CONFRS INCREASED CELL PROLIFERATION IN MOUSE PROSTATE EPITHELIUM
Hua Li*, Shashwat Sharad, Talai Barbiev, Wei Huang, Yingjie Song, Denise Young, Rockville, MD, Isabell Sesterhenn, Silver Spring, MD, Inger Rosner, Bethesda, MD, Albert Dobi, Shiv Srivastava, Taduru Sreenath, Rockville, MD

MP70-14 REGULATION OF PROSTATE CANCER METABOLISM AND INVASIVENESS BY THE LIVER X RECEPTOR
Allison May*, Suemia Abuirqeba, Zachary Hamilton, Colin Flavens, Sameer Siddiqui, St. Louis, MO

MP70-15 TRANSCRIPTIONAL ACTIVATION OF B-CATENIN BY MIR-138 PROMOTES UP-REGULATION OF ALPHA-METHYLCO A ACETATE RACEMASE IN PROSTATE CANCER CELLS
Kati Erdmann*, Knut Kaulke, Susanne Fuessel, Manfred P. Wirth, Dresden, Germany

MP70-16 SEMA3C DRIVES CANCER GROWTH AND TREATMENT RESISTANCE VIA COGNATE LIGAND-INDEPENDENT ACTIVATION
Ario Takeuchi*, Masaki Shiot, Junichi Inokuchi, Katsumori Tatsugami, Masatoshi Eto, Fukuoka, Japan

MP70-17 DECIPHERING THE EFFECTS OF OMEGA-3 FATTY ACID SUPPLEMENTS ON PROSTATE CANCER
Gabriel Lachance*, Nikunj Geveriya, Karine Robitaille, Alain Bergeron, Valérie Picard, Mickael Leclerc, Charles Joly, Yves Fradet, Arnaud Drot, André Marette, Vincent Fradet, Québec, Canada

MP70-18 THE ROLE OF POLYUNSATURATED FATTY ACID METABOLISM ON PROSTATE CANCER AGGRESSIVENESS: AN ANALYSIS OF THE NORTH CAROLINA-Louisiana PROSTATE CANCER PROJECT (PCAP)

MP70-19 SIGNIFICANTLY HIGH LEVELS OF ACTIVATED CYTOTOXIC T-LYMPHOCYTES ARE FOUND IN BOTH BENIGN AND MALIGNANT PROSTATE TISSUES
Dixon T.S. Woon*, Melbourne, Australia, Genevieve Whitty, Heidelberg, Australia, Weranja K.B. Ranaasinghe, Melbourne, Australia, Manvendra Saxena, Heidelberg, Australia, Damien Bolton, Melbourne, Australia, Ian Davis, Heidelberg, Australia

MP70-20 B CELL CONCENTRATION IN HIGH RISK PROSTATE CANCER SPECIMENS AFTER NEOADJUVANT RITUXIMAB
Stephen Ryan*, Christina Jamieson, Ahmed Shabaik, Emily Pittman, Jing Zhang, Michelle Muldong, Shabnam Shalapour, Michael Karin, Karen Messer, Stephen Howell, Christopher Kane, San Diego, CA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP71-01</td>
<td>VARIATION IN TREATMENT OF MUSCLE INVASIVE BLADDER CANCER ASSOCIATED WITH AGE, COMORBIDITY, AND LIFE EXPECTANCY</td>
</tr>
<tr>
<td></td>
<td>Devin Patel*, Michael Luu, Zachary Zumsteg, Maurice Garcia, Timothy Daskivich, Los Angeles, CA</td>
</tr>
<tr>
<td>MP71-02</td>
<td>REFRAMING READMISSION REDUCTION INCENTIVES AFTER RADICAL CYSTECTOMY</td>
</tr>
<tr>
<td></td>
<td>Michael Sessine*, Tudor Borza, Alon Weizer, Peter Kirk, Xiang Liu, Benjamin Li, Brent Hollenbeck, Yongmei Qin, Ann Arbor, MI, Bruce Jacobs, Ken Urish, Pittsburgh, PA, Jonathan Helm, Tempe, AZ, Mariel Lavieri, Ted Skolarus, Ann Arbor, MI</td>
</tr>
<tr>
<td>MP71-03</td>
<td>VARIATION IN UNPLANNED THIRTY-DAY READMISSIONS ACROSS UNITED STATES COC-ACCREDITED FACILITIES AFTER RADICAL CYSTECTOMY FOR CARCINOMA OF THE BLADDER</td>
</tr>
<tr>
<td>MP71-04</td>
<td>ASSESSING LABORATORY PARAMETERS AND READMISSIONS AFTER RADICAL CYSTECTOMY</td>
</tr>
<tr>
<td></td>
<td>Peter Kirk*, Xiang Liu, Tudor Borza, Benjamin Li, Michael Sessine, Kevin Zhu, Yongmei Qin, Ann Arbor, MI, Bruce Jacobs, Ken Urish, Pittsburgh, PA, Jonathan Helm, Tempe, AZ, Scott Gilbert, Tampa, FL, Alon Weizer, Jeffrey Montgomery, Brent Hollenbeck, Mariel Lavieri, Ted Skolarus, Ann Arbor, MI</td>
</tr>
<tr>
<td>MP71-05</td>
<td>THE IMPACT OF THE AFFORDABLE CARE ACT AND MEDICAID EXPANSION ON INSURANCE STATUS AND CANCER STAGING FOR BLADDER CANCER PATIENTS</td>
</tr>
<tr>
<td></td>
<td>Kyle Plante*, Natasha Ginzburg, Joseph Jacob, Oleg Shapiro, Gennady Bratslavsky, Elizabeth Ferry, Syracuse, NY</td>
</tr>
<tr>
<td>MP71-06</td>
<td>RISK OF BONE FRACTURES FOLLOWING URINARY INTESTINAL DIVERSION: A POPULATION-BASED STUDY</td>
</tr>
<tr>
<td></td>
<td>Patrick O. Richard*, Sherbrooke, Canada, Shaheena Bashir, Toronto, Canada, Amit Gupta, Los Angeles, CA, Neil Fleshner, Alexandre Ziotta, Toronto, Canada, Roselyne Choinière, Sherbrooke, Canada, Aza Mohammed, Luton, United Kingdom, Girish Kulkarni, Toronto, Canada</td>
</tr>
<tr>
<td>MP71-07</td>
<td>METFORMIN USE IN DIABETIC MEDICARE BENEFICIARIES IS ASSOCIATED WITH IMPROVED SURVIVAL FOLLOWING RADICAL CYSTECTOMY</td>
</tr>
<tr>
<td></td>
<td>Brian Winters*, Sarah Holt, Jonathan Wright, Wayne Brisbane, Jorge Ramos, John Gore, Evan Yu, George Schade, Seattle, WA</td>
</tr>
<tr>
<td>MP71-08</td>
<td>FINASTERIDE DOES NOT PREVENT BLADDER CANCER: A SECONDARY ANALYSIS OF THE MEDICAL THERAPY FOR PROSTATIC SYMPTOMS STUDY</td>
</tr>
<tr>
<td></td>
<td>Niranjan Sathianathan*, Yunhua Fan, Stephanie Jarosek, Minneapolis, MN, Nathan Lawrence, Heidelberg, Australia, Badrinath Konety, Minneapolis, MN</td>
</tr>
<tr>
<td>MP71-09</td>
<td>FDG-POSITRON EMISSION TOMOGRAPHY FOR ASSESSING THE RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN BLADDER CANCER PATIENTS</td>
</tr>
<tr>
<td></td>
<td>Ayman Soubra*, Mehmet Genceturk, Jerry Froehlich, Priya Balaji, Shilpa Gupta, Gautam Jha, Badrinath Konety, Minneapolis, MN</td>
</tr>
<tr>
<td>MP71-10</td>
<td>SCREENING LOGS FROM A PILOT RANDOMIZED CONTROLLED TRIAL OF RADICAL CYSTECTOMY VERSUS CHEMORADIATION THERAPY FOR MUSCLE INVASIVE BLADDER CANCER</td>
</tr>
<tr>
<td></td>
<td>Dharam Kaushik*, Ahmed M. Mansour, Michael A. Liss, Richapriya Jha, Robert S. Svatek, San Antonio, TX</td>
</tr>
<tr>
<td>MP71-11</td>
<td>NEOADJUVANT CHEMOTHERAPY UTILIZATION IN SOUTH FLORIDA: A SINGLE-INSTITUTION REPORT OF BARRIERS TO RECEIPT OF NEOADJUVANT CHEMOTHERAPY</td>
</tr>
<tr>
<td></td>
<td>Maurilio Garcia-Gil*, Miami Beach, FL, Corey Weinstein, Eric Marten, Nikita Bodoukhin, Jonathan Dahan, Miami, FL, Akshay Bhandari, Alan M. Nieder, Miami Beach, FL</td>
</tr>
<tr>
<td>MP71-12</td>
<td>REPORTED RATES OF CLOSTRIDIUM DIFFICILE FOLLOWING RADICAL CYSTECTOMY IN NATIONAL DATASETS COMPARED TO INDIVIDUAL INSTITUTIONS</td>
</tr>
<tr>
<td></td>
<td>Reece Miller*, Jonathan Heinlen, Oklahoma City, OK</td>
</tr>
</tbody>
</table>
MP71-13 INITIAL TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) IN A LARGE INTEGRATED DELIVERY SYSTEM
Stephen Williams*, Riverside, CA, Tiffany Luong, David Yi, Ayae Yamamoto, Pasadena, CA, Aniket Kawatkar, Santa Fe Springs, CA, Philip Kim, San Diego, CA, Ronald Loo, Downey, CA, Margo Sidell, Kim Danforth, Pasadena, CA

MP71-14 FREQUENCY OF LOW GRADE T1 BLADDER CANCER HAS DECREASED BUT CONTINUES TO VARY BY INSTITUTION
Brian Jordan*, Adam Weiner, Joshua Meeks, Chicago, IL

MP71-15 EARLY OPIOID USE IN EARLY RECOVERY AFTER SURGERY (ERAS) PATHWAY IN RADICAL CYSTECTOMY CORRELATES WITH INCREASED LENGTH OF STAY AND COST
Carissa Chu*, Lee-Lynn Chen, Kirsten Greene, Maxwell Meng, Ann Lazar, Sima Porten, San Francisco, CA

MP71-16 THE IMPACT OF TREATMENT AT MINORITY-SERVING HOSPITALS ON OUTCOMES FOR BLADDER CANCER
Sean A. Fletcher*, Boston, MA, Philipp Gild, Hamburg, Germany, Alexander P. Cole, Boston, MA, Malte W. Vetterlein, Hamburg, Germany, Daniel Pucheril, Guru P. Sonpavde, Mark A. Preston, Adam S. Kibel, Boston, MA, Felix K.H. Chun, Frankfurt, Germany, Firas Abdollah, Detroit, MI, Mani Menon, Detroit, MI, Stuart R. Lipsitz, Quoc-Dien Trinh, Boston, MA

MP71-17 BIPOLAR TRANSURETHRAL RESECTION OF BLADDER TUMOR PROVIDES BETTER TISSUE FOR HISTOPATHOLOGY BUT HAS NO SUPERIOR EFFICACY AND SAFETY: A RANDOMIZED CONTROLLED TRIAL
Pragatheeswarane Murugavaithianathan, Shrawan Singh, Sudheer K. Devana, Ravimohan Mavuduru*, Santosh Kumar, Nandita Kakkar, Arup Kumar Mandal, Chandigarh, India

MP71-18 THE USE OF FITNESS TRACKER IN MONITORING FUNCTIONAL ACTIVITY OF PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR BLADDER CANCER: A FEASIBILITY REPORT AND ANALYSIS AS PART OF THE MULTI-CENTRE RANDOMISED IROC TRIAL
Pramit Khetrapal*, Norman Williams, Melanie Tan, Andrew Feber, Gareth Ambler, Rachael Sarpong, Shamim Khan, London, United Kingdom, Simon Dixon, Louise Goodwin, Sheffield, United Kingdom, John McGrath, Exeter, United Kingdom, Edward Rowe, Anthony Koupparis, Bristol, United Kingdom, Chris Brew-Graves, London, United Kingdom, James Catto, Sheffield, United Kingdom, John Kelly, London, United Kingdom

MP71-19 THE MICROHEMATURIA NOMOGRAM: A SIMPLIFIED BLADDER CANCER RISK ASSESSMENT TOOL
Richard Matulewicz*, Joshua Meeks, Chicago, IL

MP71-20 COMPARATIVE EFFECTIVENESS OF NEOADJUVANT AND ADJUVANT CHEMOTHERAPY IN THE MEDICARE BLADDER CANCER POPULATION
Mina Fam*, Jonathan Yabes, Pittsburgh, PA, Nathan Hale, Charleston, WV, Robert Turner, Jathin Bandari, Liam Macleod, Lee Hugar, Jeffrey Gingrich, Pittsburgh, PA, Tudor Borza, Ted Skolarus, Ann Arbor, MI, Benjamin Davies, Bruce Jacobs, Pittsburgh, PA

Sunday, May 20, 2018
Moderated Poster Session 72
KIDNEY CANCER: BASIC RESEARCH & PATHOPHYSIOLOGY II
Room 2005 @ MCC West
Moderators: Rajvir Dahiya, Ithaar Derweesh and Sandy Srinivas

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP72-01</td>
<td>MP72-02</td>
<td>SPHINGOSINE KINASE 1 OVEREXPRESSION CONTRIBUTES TO STEM-LIKE PHENOTYPE AND SUNITINIB RESISTANCE IN CLEAR CELL RENAL CELL CARCINOMA</td>
<td>METABOLISM RE-PROGRAMMING AS A THERAPEUTIC TARGET FOR DRUG RESISTANT RENAL CELL CARCINOMA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Yunze Xu*, Yiran Huang, Shanghai, China, People's Republic of</td>
<td>Hirofumi Yoshino*, Kazutaka Miyamoto, Masaya Yonemori, Satoru Sugita, Takashi Sakaguchi, Hideki Enokida, Masayuki Nakagawa, Kagoshima, Japan</td>
</tr>
</tbody>
</table>

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
MP72-03 SORAFENIB-TRIGGERED STRESS GRANULES PROMOTE RESISTANCE IN RENAL CANCER CELLS BY RECRUITING ANTI-APOPTOTIC CYCOOXYGENASE 2
Wei Chen*, Xiaozhi Zhao, Wenmin Cao, Wenli Diao, Hongqiang Guo, Nanjing, China, People’s Republic of

MP72-04 BROMODOMAIN PROTEIN BRD4 AS A POTENTIAL THERAPEUTIC TARGET IN SUNITINIB-RESISTANT RENAL CELL CARCINOMA
Takashi Sakaguchi*, Hirofumi Yoshino, Satoshi Sugita, Masayuki Nakagawa, Hideki Enokida, Kagoshima, Japan

MP72-05 IL-6-TRIGGERED POSITIVE FEEDBACK LOOP FOR NFκB SIGNALING INDUCES TKI RESISTANCE THROUGH METABOLIC ALTERATIONS ON RENAL CELL CARCINOMA CELLS
Kei Ishibashi*, Akihumi Onagi, Ryo Tanji, Runiko Takanami, Kanako Matsuoaka, Tomoyuki Koguchi, Seiji Hoshi, Junya Hata, Yuichi Sato, Hidenori Akaihata, Masao Kataoka, Soichiro Ogawa, Nobihuro Haga, Ken Aikawa, Yoshiyuki Kojima, Fukushima, Japan

MP72-06 CORRELATION OF THE INSULIN RECEPTOR EXPRESSION AND THE RESISTANCE TO VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS IN ADVANCED CLEAR CELL RENAL CELL CARCINOMA
Masayuki Takahashi*, Kei Daizumoto, Yayoi Fukuwara, Keisuke Ozaki, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Morii, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori, Hiroomi Kanayama, Tokushima, Japan

MP72-07 THE ROLE OF INTEGRINS AND EXOSOMES IN SUNITINIB RESISTANCE IN CCRCC CELL LINES
Jared Schober*, Marc Calabrese, Dan Kaufman, Kevin Yang, Burlington, MA, Juliana Kostas, Williamstown, MA, Travis Sullivan, Kimberly Rieger-Christ, Burlington, MA

MP72-08 ALTERNOL SENSITIZES RENAL CARCINOMA CELLS TO TRAIL-INDUCED APOPTOSIS
Yu Ren*, Shuaishuai Huang, Xue Wang, Xuping Yao, Ningbo, China, People’s Republic of, Guobin Wang, Ningbo, China, People’s Republic of

MP72-09 RITONAVIR AND IXAZOMIB INHIBIT RENAL CANCER GROWTH IN VITRO AND IN VIVO BY INDUCING ENDOPLASMIC RETICULUM STRESS SYNERGISTICALLY
Takashi Asano*, Akinori Sato, Kazuki Okubo, Makoto Isono, Tomohiko Asano, Tokorozawa, Japan

MP72-10 PHARMACOGENETIC-BASED AUC MODEL CAN PREDICT EFFICACY AND ADVERSE EVENTS OF AXITINIB IN INDIVIDUAL PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
Yoshiaki Yamamoto*, Ryouchi Tsunedomi, Yusuke Fujita, Ube, Japan, Toru Otori, Higashiosaka, Japan, Yoshihisa Kawai, Ryo Inoue, Hiroshi Hirata, Hiroaki Matsumoto, Tomoyuki Shimabukuro, Ube, Japan, Rajvir Dahiya, San Francisco, CA, Hideyasu Matsuyama, Ube, Japan

MP72-11 TARGETING SUNITINIB RESISTANT CELLS BY TUMOR SUPPRESSIVE MIRNA-99A-3P THROUGH RIBONUCLEOTIDE REDUCTASE REGULATION IN CLEAR CELL RENAL CELL CARCINOMA
Youichi Osako*, Hirofumi Yoshino, Takashi Sakaguchi, Satoshi Sugita, Shuichi Tatara, Takashi Yamane, Hideki Enokida, Masayuki Nakagawa, Kagoshima, Japan

MP72-12 CO-TREATMENT WITH L-METHADONE INCREASES THE EFFICACY OF ANTITUMOR AGENTS IN RENAL CELL CARCINOMA CELLS IN VITRO
Birgit Stadlbauer, Heike Pohl, Christian Stief, Alexander Buchner*, Munich, Germany

MP72-13 EFFECT OF A KETOGENIC DIET ON THE CLEAR CELL RENAL CELL CARCINOMA CELL GROWTH
Maxime Benoît*, Edouard Fortier, Magalie Barth, Vincent Procaccio, Jennifer Bourreault, Daniel Henrion, Pierre Bigot, Angers, France

MP72-14 IDENTIFYING THE SPATIO-FUNCTIONAL ORIGINS OF DRUG RESISTANCE WITH RAPID TUMOR XENOGRAFTS
Nicholas Power*, London, Canada, Matthew Lowerison, Yaroslav Fedyslyn, Rochester, MN, Karla Williams, Vancouver, Canada, Ann Chambers, James Lacefield, LONDON, Canada, Paul Boutros, Toronto, Canada, Hon Leong, Rochester, MN

MP72-15 CHARACTERIZATION OF ONCOLYTIC MEASLES VIRUS IN PATIENT-DERIVED RENAL CELL CARCINOMA XENOGRAFTS GROWN ON CHICKEN CHORIOALLANTOIC MEMBRANES AS A MODEL FOR EARLY METASTATIC DISEASE
Tanner Miest*, Ianko Iankov, Yaroslav Fedyshyn, Matthew Karnes, Stephen Boorjian, Stephen Thompson, Matthew Tollefson, Igor Frank, Evantheia Galanis, Hon Leong, Bradley Leibovich, Rochester, MN

MP72-16 CREATION OF A RENAL MEDULLARY CARCINOMA MOUSE MODEL: FEASIBILITY AND PRELIMINARY RESULTS AFTER TREATMENT WITH ANTI-NEOPLASTIC AGENTS
Barrett McCormick*, Matthew Meissner, Lei Wang, Tapaty Maity, Nizar Tannir, Christopher Wood, Jose Karam, Houston, TX

*Presenting author
MP72-17 THE ASSOCIATION BETWEEN SARCOPENIA AND MOLECULAR SUBTYPES OF CLEAR CELL RENAL CELL CARCINOMA

MP72-18 ASSOCIATION OF COMPUTED TOMOGRAPHY-BASED RADIOMIC FEATURES WITH EPIGENETIC VARIATION OF CLEAR CELL RENAL CELL CARCINOMA USING DNA METHYLATION
Vinay Duddalwar*, Gangning Liang, Kim Siegmund, Steven Cen, Bino Varghese, Darryl Hwang, Bhushan Desai, Mihir Desai, Manju Aron, Inderbir Gill, Los Angeles, CA

MP72-19 Plasma Glycosaminoglycan Scores in Renal Cell Carcinoma
Kyle A. Blum*, New York City, NY, Francesco Gatto, Goteberg, Sweden, Mazyar Ghanati, Alejandro Sanchez, New York City, NY, Francesco Maccari, Fabio Galeotti, Modena, Italy, James Hsieh, St. Louis, MO, Nicola Volpi, Modena, Italy, A. Ari Hakimi, New York City, NY, Jens Nielsen, Goteberg, Sweden

MP72-20 Somatic Mutations in Mitochondrial DNA Predict Postoperative Recurrence in Renal Cell Carcinoma

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 20, 2018
Podium Session 48
TRAUMA/RECONSTRUCTION/DIVERSION: TRANSITIONAL UROLOGY & GU CONGENITALISM
Room 2024 @ MCC West
Moderators: Hadley Wood, Jay Simhan and Dan Wood

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30</td>
<td>PD48-01</td>
<td>Urinary and Fecal Incontinence During Sexual Activity Is Common and Bothersome Among Adults With Spina Bifida</td>
</tr>
<tr>
<td>3:40</td>
<td>PD48-02</td>
<td>Caring for Adults with Congenital Genitourinary Anomalies: Adult Urology Department Leaders’ Perspectives on Programmatic Change</td>
</tr>
<tr>
<td>3:50</td>
<td>PD48-03</td>
<td>Analysis of Factors Associated with Patient or Caregiver Regret Following Surgery for Fecal Incontinence</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:00</td>
<td>PD48-04</td>
<td>Non-Clinical Barriers to Care in Complex Benign Urologic Reconstruction at a Quaternary Care Center</td>
</tr>
<tr>
<td>4:10</td>
<td>PD48-05</td>
<td>Discrepancy and Economic Impact in Urologic Care in Adult Spina Bifida Patients</td>
</tr>
<tr>
<td>4:20</td>
<td>PD48-06</td>
<td>A First Look at Inpatient Treatment for Prostate Cancer in Men with Spina Bifida</td>
</tr>
<tr>
<td>4:30</td>
<td>PD48-07</td>
<td>Bladder Changes After Catheterizable Channel Creation in Adults with Cerebral Palsy Who Are in Chronic Urinary Retention Pre-operatively</td>
</tr>
</tbody>
</table>

244
<table>
<thead>
<tr>
<th>Time</th>
<th>Number</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30</td>
<td>PD49-01</td>
<td>EFFICIENT PROMOTION OF AUTOPHAGY AND ANGIGENESIS USING MESENCHYMAL STEM CELLS THERAPY ENHANCED BY THE LOW-ENERGY SHOCKWAVES IN THE TREATMENT OF ERECTILE DYSFUNCTION</td>
</tr>
<tr>
<td>3:40</td>
<td>PD49-02</td>
<td>A NOVEL LASER SPECKLE CONTRAST IMAGING (LSCI) TECHNIQUE TO DETERMINE AGE-RELATED CHANGES IN PENILE MICROVASCULAR PERFUSION</td>
</tr>
<tr>
<td>3:50</td>
<td>PD49-03</td>
<td>EFFECT OF INTRACavernous ADMINISTRATION OF EMBRYONIC STEM CELL-DERIVED EXOSOME ON ERECTILE FUNCTION IN THE STREPTozOTOCIN-INDUCED DIABETIC MOUSE</td>
</tr>
<tr>
<td>4:00</td>
<td>PD49-04</td>
<td>ADIPOSE-DERIVED STEM CELL-DERIVED EXOSOMES AMELIORATE ERECTILE DYSFUNCTION IN A RAT MODEL OF TYPE 2 DIABETES</td>
</tr>
<tr>
<td>4:10</td>
<td>PD49-05</td>
<td>SYNERGISTIC EFFECT OF VARDENAFIL AND TAMOXIFEN IN A RAT MODEL OF Peyronie's DISEASE</td>
</tr>
<tr>
<td>4:20</td>
<td>PD49-06</td>
<td>IMPAIRED PREFRONTAL-AMYGDALA PATHWAY, SELF-REPORTED EMOTION AND ERECTION IN PSYCHOGENIC ERECTILE DYSFUNCTION PATIENTS WITH NORMAL NOCTURNAL ERECTION</td>
</tr>
<tr>
<td>4:30</td>
<td>PD49-07</td>
<td>PERSISTENT ERECTILE DYSFUNCTION AFTER DISCONTINUATION OF 5-ALPHA REDUCTASE INHIBITOR THERAPY IN RATS DEPENDING ON THE DURATION OF TREATMENT</td>
</tr>
</tbody>
</table>
4:40 PD49-08 INVESTIGATING CORPORAL GENE EXPRESSION PATTERNS IN ISCHEMIC PRIAPISM USING A BERK MOUSE MODEL
Amarnath Mukherjee*, Augene Park, Moses Tar, Henny Billet, Kelvin Davies, Bronx, NY

4:50 PD49-09 STROMAL DERIVED FACTOR-1 TREATMENT ACTIVATES STEM CELLS AND INCREASES NEURONAL TISSUE EXPRESSION OF NEUROTROPHINS
Nikolai Sopko*, Baltimore, MD, Hotaka Matsui, Tokyo, Japan, Gregory Joice, Michael Bell, Takahiro Yoshida, Xiaopu Liu, Max Kates, Trinity Bivalacqua, Baltimore, MD

5:00 PD49-10 TIME DEPENDENT IMPAIRED REGENERATIVE CAPACITY AND INCREASED NITRERIC APOPTOSIS IN PELVIC NEURONS POST- RADIATION THERAPY
Michael Odom, Shelby Powers, Elena Pak, Megan Moomaw, Greenville, NC, Kathleen Ashcroft, Bridget Koontz, Durham, NC, Johanna Hannan*, Greenville, NC

5:10 PD49-11 METABOLIC DYSFUNCTION AND HYPOGONADISM IN A COHORT OF YOUNG, HEALTHY MEN
Mark Lindgren*, Oklahoma City, OK, Christy Stetter, Allen Kunselman, Hershey, PA, Robert Coward, Chapel Hill, NC, Michael Diamond, Augusta, GA, Karl Hansen, Oklahoma City, OK, Stephen Krawetz, Detroit, Mi, Richard Legro, Hershey, PA, James Smith, San Francisco, CA, Anne Steiner, Chapel Hill, NC, Pasquale Patrizio, New Haven, CT, Bob Wild, Oklahoma City, OK, Esther Eisenberg, Bethesda, MD, Heping Zhang, New Haven, CT, Nanette Santoro, Denver, CO, J. C. Trussell, Syracuse, NY

Sunday, May 20, 2018 3:30 pm - 5:30 pm
Podium Session 50
URODYNAMICS/LOWER URINARY TRACT DYSFUNCTION/FEMALE PELVIC MEDICINE: NON-NEUROGENIC VOIDING DYSFUNCTION I
Room 2011 @ MCC West
Moderators: Eric Rovner, Alan Wein and Marcio Averbeck

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| 3:30 | PD50-01 | LUMBOSACRAL 1.5 TESLA MRI COMPATIBILITY WITH SACRAL NEUROMODULATION: AN IN-VIVO PROSPECTIVE STUDY
Juan M. Guzman-Negron*, Cleveland, OH, Javier Pizarro-Berdichevsky, Santiago, Chile, Bradley Gill, Howard B. Goldman, Cleveland, OH |

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| 4:00 | PD50-04 | SYMPTOM-BASED CLUSTERING OF FEMALE LUTS PARTICIPANTS IN THE SYMPTOMS OF LOWER URINARY TRACT DYSFUNCTION RESEARCH NETWORK (LURN) STUDY
Vicente P. Andreev PhD DSc*, Gang Liu PhD, Ann Arbor, MI, Claire C. Yang MD, Seattle, WA, Abigail R. Smith PhD, Margaret E. Heilmuth MA, Jonathan B. Wiseman MS, Robert M. Merion MD FACS, Ann Arbor, MI, Kevin P. Weinert PhD, Durham, NC, H. Henry Lai MD, St. Louis, MO, David Cella PhD, Chicago, IL, Brian T. Heffand MD PhD, Glenview, IL, James W. Griffith PhD, Chicago, IL, John O.L. DeLancey MD, Ann Arbor, MI, Matthew O. Fraser PhD, Durham, NC, Ziya Kirkali MD, and the LURN Study Group, Bethesda, MD |

4:40 PD50-02 ASSOCIATION BETWEEN OVERACTIVE BLADDER SEVERITY AND BOLD FMRI BRAIN ACTIVITY
Steven Weissbart, Stony Brook, NY, Rupal Bhavsar, Alan Wein, Lily Arya, Ariana Smith*, Philadelphia, PA

4:50 PD50-03 DURABLE EFFICACY AND SAFETY OF LONG-TERM ONCE-DAILY VIBEGRON, A NOVEL ORAL β-3 ADRENERGIC RECEPTOR AGONIST: A 52-WEEK PHASE 2 STUDY IN PATIENTS WITH OVERACTIVE BLADDER SYNDROME
Roger Dmochowski*, Nashville, TN, David Mitcheson, Boston, MA, Tara Frankl, Kenilworth, NJ, Nate Bennett, Paul N. Mudd Jr, Durham, NC

5:00 PD50-05 DO LUTS CORRELATE WITH UTERINE FIBROID SIZE AND LOCATION?
Robyn K. Shaffer*, Amy D. Dobberfuhl, Angela Fast, Kim N. Vu, David Hovsepian, Deirdre Lum, Peijman Ghanouni, Bertha Chen, Stanford, CA
A NOVEL MATHEMATICAL FORMULA FOR CALCULATING FLOW RESISTIVE FORCES INDEX, A NEW ESTIMATOR OF BLADDER OUTLET RESISTANCE ENHANCING THE DIAGNOSTIC PERFORMANCE (DISCRIMINATIVE ABILITY) OF UROFLOMETERS TESTING
Evangelos Spyropoulos*, Athens, Greece

NON-INFERIORITY OF A NOVEL CAPACITANCE FLUID HEIGHT DESIGN COMPARED TO ROTATING DISC AND WEIGHT TRANSDUCER DESIGNS FOR HOME UROFLOMETERS APPLICATIONS
Darshan Patel*, Kent Ogden, William Anderl, Suzette Mastrangelo, Alvin Le, James Hotaling, Stephen Summers, Salt Lake City, UT

INSOMNIA INDUCES LOWER URINARY TRACT SYMPTOMS: THE NATURAL HISTORY AND RISK FACTORS FOR LUTS FROM THE NAGAHAMA LONGITUDINAL STUDY
Hiromitsu Negoro*, Arinobu Fukunaga, Satoshi Funada, Takashi Kobayashi, Toshinari Yamazaki, Takahiro Inoue, Kyoto, Japan, Koji Yoshimura, Shizuoka, Japan, Takahisa Kawaguchi, Fumihiko Masuda, Osamu Ogawa, Kyoto, Japan

CHARACTERIZATION OF BLADDER DYSFUNCTION INDUCED BY OVARIECTOMY IN MICE
Ei-ichiro Takaoka*, Takahisa Suzuki, Shinsuke Mizoguchi, Jianshu Ni, Pittsburgh, PA, Jun Miyazaki, Chiba, Japan, Hiroyuki Nishiyama, Tsukuba, Japan, Naoki Yoshimura, Pittsburgh, PA

MANAGEMENT OF GENETICALLY DEFINED RENAL TUMORS UTILIZING SIZE-BASED RISK STRATIFICATION: LONG-TERM RESULTS
Mark Ball*, Julie An, James Peteron, Maria Merino, Ramaprasad Srinivasan, Adam Metwalli, W. Marston Linehan, Bethesda, MD

CONDITIONAL SURVIVAL AND LANDMARK ANALYSIS FOR PATIENTS WITH SMALL RENAL MASSES UNDERGOING ACTIVE SURVEILLANCE AT A TERTIARY CARE CENTER
Firas Petros*, Aradhana Venkatesan, Diana Kaya, Chaan Ng, Bryan Fellman, Jose Karam, Christopher Wood, Sarena Matin, Houston, TX

LONG-TERM ACTIVE SURVEILLANCE OF COMPLEX CYSTIC RENAL MASSES & THE HETEROGENEITY OF BOSNIAK 3 LESIONS
Deepak Pruthi*, Qianqian Liu, San Antonio, TX, Iain Kirkpatrick, Winnipeg, Canada, Jonathan Gelfond, San Antonio, TX, Darrel Drachenberg, Winnipeg, Canada

ACTIVE SURVEILLANCE FOR LOCALIZED RENAL MASSES: GROWTH RATES AND OUTCOMES IN PATIENTS WITH MASSES & [GE]4 CM
Andrew McIntosh*, Tianyu Lee, Richard Greenberg, David YT Chen, Rosalia Viterbo, Marc Smaldone, Alexander Kutikov, Robert Uzzo, Philadelphia, PA

URINARY MONOCYTE CHEMOTACTANT PROTEIN-1 (MCP-1) EXPRESSION, QUALITY OF LIFE AND SEVERITY OF SYMPTOMS IN PATIENT WITH OVERACTIVE BLADDER (OAB) IN RESPONSE TO SUCCESSFUL TREATMENT
Bilal Farhan*, Gamal Ghoniem, Frank Zaldivar, Orange, CA

THE ROLE OF CORTICOTROPIN-RELEASING FACTOR RECEPTORS SUBTYPES ON THE CLINICAL SYMPTOMS AND TREATMENT OUTCOME OF PATIENTS WITH INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME
Jia-Fong Jhang*, Han-Chen Ho, Yuan-Hong Jiang, Yung-Hsiang Hsu, Hann-Chong Kuo, Hualien, Taiwan

DO HEALTH DISPARITIES EXIST IN THE INSURED REFRACTORY OAB PATIENT POPULATION?
Raveen Syan*, Chiyuan A Zhang, Kai Dallas, Ekene Enemchukwu, Palo Alto, CA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
4:10 PD51-05 RATE OF ACTIVE SURVEILLANCE AS A MANAGEMENT STRATEGY FOR T1A RENAL MASSES: RESULTS FROM THE NATIONAL CANCER DATABASE
David Jiang*, Ann Martinez Acevedo, Ryan Kopp, Michael Conlin, Mark Garzotto, Christopher Amling, Jen-Jane Liu, Portland, OR

4:20 PD51-06 DETERMINANTS OF ACTIVE SURVEILLANCE IN PATIENTS WITH SMALL RENAL MASSES
Kevin Nguyen, Adam Nolte, Oriyomi Alimi, Walter Hsiang, Jamil Syed, Alfredo Suarez-Sarmiento, Amanda Lu, Kamyar Ghabili, Brian Shuch, Michael Leapman*, New Haven, CT

4:30 PD51-07 OUTCOMES OF SYNCHRONOUS AND METACHRONOUS BILATERAL SMALL RENAL MASSES (<4CM): A POPULATION BASED COHORT STUDY
Nissar Sheikh, Mohammad Khan, Stephen Lang, Sanjay Pillai, Ghulam Nabi*, Dundee, United Kingdom

4:40 PD51-08 ACTIVE SURVEILLANCE OF SPORADIC RENAL MASSES: EXPERIENCE FROM A SINGLE TERTIARY CENTRE
Joana B. Neves*, James Parker, Chandran Tanabalan, Lee Grant, Navin Ramachandran, Prasad Patki, Faiz Muntaz, Michael Alitchson, Ravi Barod, Maxine GB Tran, London, United Kingdom

4:50 PD51-09 SHARED DECISION MAKING FOR TREATMENT OF SMALL RENAL MASSES; A SURVEY OF PATIENT’S OPINIONS BEFORE AND AFTER INITIAL COUNSELING
Anthony Bui*, Daniel D. Shapiro, Sara L. Best, Shane A. Wells, Lori Mankowski Gettle, Timothy J. Ziemlewicz, Meghan G. Lubner, J. Louis Hinshaw, Fred T. Lee, David F. Jarrard, Kyle A. Richards, Tracy M. Downs, Stephen Y. Nakada, E. Jason Abel, Madison, WI

5:00 PD51-10 CHARACTERIZING THE INCIDENCE, PREDICTORS, AND SURVIVAL OF DISAPPEARING RENAL TUMORS FROM THE DISSRM REGISTRY
Anvar Srivastava*, Hiten Patel, Mohit Gupta, Gregory Joice, Zeyad Schwen, Ridwan Alam, Michael Gorin, Michael Johnson, Mohammad Allaf, Phillip Pierorazio, Baltimore, MD

5:10 PD51-11 INSTITUTION OF A SMALL RENAL MASS QUALITY IMPROVEMENT INITIATIVE IN A STATEWIDE COLLABORATIVE
Craig Rogers*, Tae Kim, Ann Arbor, MI, Sabrina Noyes, Grand Rapids, MI, Sanjeev Kaul, Royal Oak, MI, Ji Qi, Khurshid Ghani, James Montie, David Miller, Alon Weizer, Ann Arbor, MI, Brian Lane, Grand Rapids, MI, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI

5:20 PD51-12 COMPARISON OF MID-TERM ONCOLOGICAL OUTCOMES OF ACTIVE SURVEILLANCE AND PERCUTANEOUS CRYOABLATION OF SMALL RENAL MASSES
Paolo Umari*, Novara, Italy, Michele Rizzo, Trieste, Italy, Michele Billia, Novara, Italy, Nicola Pavan, Gaetano Chiapparrone, Giovanni Luguri, Fulvio Stacul, Trieste, Italy, Monica Zaccheria, Paolo De Angelis, Alessandro Volpe, Novara, Italy, Carlo Tombetta, Trieste, Italy

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
3:50 PD52-03 THE ASSOCIATION OF EDUCATION LEVEL WITH THE UTILIZATION OF SHARED DECISION MAKING IN PROSTATE CANCER SCREENING
Jorge Pereira*, Boris Gershman, Joseph Renzulli, Providence, RI

4:00 PD52-04 IMPACT OF A DECISION AID AND PREFERENCE ASSESSMENT ON UROLITHIASIS PATIENT DECISION MAKING
John Cabri*, Matthew Pollard MD, Adam Peña, Casey Pagan, Sylvia Lambrechts MPH, Hui Liu MS, Lorna Kwan MPH, Matthew Dunn MD, Nishant Patel MD, Christopher Saigal MD, Los Angeles, CA

4:10 PD52-05 DECISIONAL QUALITY AFTER USE OF A DECISION AID IN SMALL RENAL MASS TREATMENT
Joseph Shirk*, Adam Pena, Casey Pagan, Sylvia Lambrechts, Lorna Kwan, Hui Liu, Christopher Saigal, Los Angeles, CA

4:20 PD52-06 DISPARITIES IN UTILIZATION OF INFLATABLE PENILE PROSTHESIS FOR TREATMENT OF POST-PROSTATECTOMY ERECTILE DYSFUNCTION
William Boysen*, Andrew Cohen, Kristine Kuchta, Jaclyn Milose, Chicago, IL

4:30 PD52-07 BUILDING ACCESS TO UROLOGY SPECIALIST CARE THROUGH E-CONSULTATION IN MEDICALLY UNDERSERVED PATIENTS IN AREAS OF TENSION AND CONFLICT
Sataa Sallami*, Sana Abou El Makarim, Nabeul, Tunisia, Anwar Chalbak, Abdelwahab Abou Soua, Ali Massoud Jornaz, Nalut, Libyan Arab Jamahiriya

4:40 PD52-08 RISING PREVALENCE OF NODE-POSTIVE PROSTATE CANCER AMONG MEN TREATED WITH RADICAL PROSTATECTOMY
Melissa Taylor*, Mark Henry, Frances Kim, Viraj Master, Mehrdad Almeozaffar, John Pattaras, Christopher Filson, Atlanta, GA

4:50 PD52-09 TENDENCIES OF CENTRALIZATION FOR RADICAL RETROPERITONEAL LYMPH NODE DISSECTION FOR TESTICULAR CANCER: RESULTS OF TOTAL-POPULATION-DATA ANALYSIS IN GERMANY FROM 2006 TO 2014
Christer Groeben*, Rainer Koch, Martin Baunacke, Manfred P. Wirth, Johannes Huber, Dresden, Germany

5:00 PD52-10 EFFECT OF 2012 USPSTF RECOMMENDATIONS ON PROSTATE BIOPSY CHARACTERISTICS AND PROSTATE CANCER PRESENTATION AT A TERTIARY-CARE MEDICAL CENTER
Brian M. Blair*, Haley Robyak, Joseph Y. Clark, Matthew G. Kaag, Erik B. Lehman, Jay D. Raman, Hershey, PA

5:10 PD52-11 PSA SCREENING OF BLACK VETERANS BEFORE, DURING, AND AFTER IMPLEMENTATION OF THE 2012 US PREVENTATIVE SERVICES TASK FORCE RECOMMENDATIONS
Temitope Rude, Dawn Walter, Stacy Loeb, Huilin Li, Shannon Cipruit, New York, NY, Steven Zeliadt, Seattle, WA, Angela Fagerlin, Salt Lake City, UT, Herbert Lepor, Scott Sherman, Joseph Ravenell, Danil Makarov*, New York, NY

5:20 PD52-12 IMMEDIATE AND TEMPORAL CHANGES IN UROLOGIC SURGERY IN KENTUCKY AFTER THE AFFORDABLE CARE ACT
Jamal Nabhani*, James Weinberger, David Johnson, Mark Litwin, Los Angeles, CA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
Monday, May 21, 2018 7:30 am - 11:30 am

Plenary: Next Frontier, Monday Morning Session

Hall E @ MCC North

7:30 HIGHLIGHTS OF UROLOGIC ONCOLOGY RESEARCH
Presenter: Aria Olumi

7:45 DEEP LEARNING IN UROLOGIC DIAGNOSTICS: PROSTATE HISTOLOGY
Presenter: Larry Goldenberg

7:53 DEEP LEARNING IN UROLOGIC DIAGNOSTICS: IMAGING
Presenter: Peter Pinto

8:00 LATE BREAKING ABSTRACTS: ONCOLOGY
Moderators: Christopher Amling, Christopher Kane

8:00 LBA-18: IMPACT OF TRANSIENT ANDROGEN DEPRIVATION THERAPY (ADT) WITH LEUPRORELIN LP 11.25 MG ON THE HISTOLOGICAL PROGRESSION OF INDOLENT PROSTATE CANCER (PC)–RESULTS OF A PHASE III TRIAL VERSUS ACTIVE SURVEILLANCE (AS)IMPACT OF TRANSIENT ANDROGEN DEPRIVATION THERAPY (ADT) WITH LEUPRORELIN LP 11.25 MG ON THE HISTOLOGICAL PROGRESSION OF INDOLENT PROSTATE CANCER (PC)–RESULTS OF A PHASE III TRIAL VERSUS ACTIVE SURVEILLANCE (AS)
Presenter: Olivier Cussenot

8:10 LBA-19: THE MEN’S EATING AND LIVING (MEAL) STUDY (CALGB 70807 [ALLIANCE]): A RANDOMIZED CLINICAL TRIAL OF A DIET INTERVENTION IN MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER
Presenter: J. K. Parsons

8:20 LBA-20: MRI-GUIDED TRANSURETHRAL ULTRASOUND ABLATION (TULSA) IN PATIENTS WITH LOCALIZED PROSTATE CANCER: PRELIMINARY RESULTS OF TACT PIVOTAL STUDY
Presenter: Laurence Klutcz

8:30 LBA-21: PHASE 2 CLINICAL TRIAL IN PROSTATE CANCER EVALUATING 68GA-PSMA-11 DETECTION ON BOTH PREOPERATIVE PET-CT AND IMMEDIATE POSTOPERATIVE SPECIMEN SCANNING
Presenter: Clinton Bahler

8:40 LBA-22: SALVAGE HIGH-INTENSITY FOCUSED ULTRASOUND FOR LOCALLY RECURRENT PROSTATE CANCER AFTER LOW-DOSE-RATE BRACHYTHERAPY: ONCOLOGIC AND FUNCTIONAL OUTCOMES.
Presenter: Thomas Hostiou

8:50 LBA-23 FOUR-YEAR FOLLOW-UP OF A PHASE-3 PROSPECTIVE RANDOMIZED TRIAL OF VASCULAR-TARGETED PHOTOThERAPY VERSUS ACTIVE SURVEILLANCE FOR LOW-RISK PROSTATE CANCER
Presenter: Inderbir Gill

9:00 PANEL DISCUSSION: PROSTATE CANCER SCREENING, DIAGNOSIS AND TREATMENT IN THE GAY, BISEXUAL AND TRANSgendERN POPULATION
Panelists: Aria Olumi, B.R. Simon Rosser

9:30 POINT-COUNTERPOINT DEBATE: INFERIOR VENa CAVA LEVEL 2 TUMOR THROMBECTOMY: WHICH IS BEST: OPEN OR ROBOTIC?
Moderator: Mark Soloway
Debaters: Inderbir Gill, Bradley Leibovich

9:45 STATE-OF-THE-ART LECTURE: PREDICTING CHEMO SENSITIVITY IN UROTHELIAL MALIGNANCY: NANOtech AND PRECISION MEDICINE
Presenter: Chong-Xian Pan

10:00 STATE-OF-THE-ART LECTURE: MOLECULAR IMAGING IN GU MALIGNANCIES
Presenter: Andrei Iagaru

Presenter: Curtis Pettaway

10:30 LATE BREAKING ABSTRACTS: ONCOLOGY
Moderator: Michael Cookson, James McKiernan

10:30 LBA-24: CG0070, AN ONCOLYTIC ADENOvirus, FOR BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC): 12 MONTH INTERIM RESULTS FROM A MULTICENTER PHASE II TRIAL
Presenter: Vignesh Packiam

10:40 LBA-25: NON-SURGICAL MANAGEMENT OF LOW GRADE UPPER TRACT UROTHELIAL CANCER: AN INTERIM ANALYSIS OF THE INTERNATIONAL MULTICENTER OLYMPUS TRIAL (NCT02793128)
Presenter: Seth Lerner

*Presenting author
10:50 LBA-26: PHASE II TRIAL OF NEOADJUVANT CHEMOTHERAPY FOLLOWED BY EXTIRPATIVE SURGERY FOR
PATIENTS WITH HIGH GRADE UPPER TRACT UROTHELIAL CARCINOMA (HG UTUC): RESULTS FROM ECOG-
ACRIN 8141
Presenter: Vitaly Margulis

11:00 LBA-27: PHASE 3 STUDY OF VICINIUM IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER:
INITIAL RESULTS
Presenter: Rian Dickstein

11:10 LBA-28: SAFETY LEAD-IN OF A PHASE II TRIAL OF NEO-ADJUVANT SABR FOR IVC TUMOR THROMBUS IN
RCC
Presenter: Yuval Freifeld

11:20 LBA-29: COMPLEMENT ACTIVATION ORCHESTRATED BY CANCER CELLS SND C1Q-PRODUCING TUMOR
ASSOCIATED MACROPHAGES HAS A DELETERIOUS IMPACT ON PATIENT’S PROGNOSIS IN CLEAR CELL
RENAL CELL CANCER
Presenter: Rafael Sanchez-Salas

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Monday, May 21, 2018 Plenary: Prime Time, Monday Morning Session 7:30 am - 11:30 am
Esplanade BR @ MCC South

7:30 HIGHLIGHTS: SOCIETY OF GENITOURINARY RECONSTRUCTIVE SURGEONS (GURS) PROGRAM
Presenter: Thomas Smith

7:45 SURGICAL TECHNIQUES: TIPS & TRICKS: FEMALE URETHRAL STRICTURE DISEASE
Moderator: E. Ann Gormley
Surgeons: Rajveer Purohit, Anne Cameron, Bahaa Malaeb

8:30 CROSSFIRE: CONTROVERSIES IN UROLOGY: RECONSTRUCTION
Moderator: Sean Elliott
Debaters - Pro: Jill Buckley, Keith Rourke
Debaters - Con: Benjamin Breyer, Bradley Erickson

9:00 COMPLEX CASES: BLADDER AND GENITAL TRAUMA
Presenter: Richard Santucci
Panelists: Daniel Dugi, Steven Hudak, Bryan Voelzke

9:30 SURGICAL TECHNIQUES: TIPS & TRICKS: PENILE AND URETHRAL CANCER
Moderator: Hunter Wessells
Surgeons: Anne Schuckman, David Ralph, Maarten Albersen

10:15 COMPLEX CASES: URINARY DIVERSION FOR COMPLICATIONS OF RADIOTHERAPY
Presenter: Allen Morey
Panelists: Jeremy Myers, John Stoffel, Andrew Peterson

10:45 SURGICAL TECHNIQUES: TIPS & TRICKS: ROBOTIC RECONSTRUCTION OF THE URETER
Moderator: Jihad Kaouk
Surgeons: Daniel Eun, Patricio Gargollo, Andre Berger

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Monday, May 21, 2018 Plenary: Prime Time I, Monday Afternoon Session 1:00 pm - 5:30 pm
Esplanade BR @ MCC South

1:00 CROSSFIRE: CONTROVERSIES IN UROLOGY: PROSTATE: PSA OF 4-10 GETS AN MRI NOT A BIOPSY
Moderator: Christopher Evans
Debaters - Pro: Mark Emberton, Samir Taneja
Debaters - Con: Daniel Lin, Mark Frydenberg

1:30 PANEL DISCUSSION: WHERE IS THE VALUE IN CAP ACTIVE SURVEILLANCE MONITORING? COST AND
QUALITY
Moderator: David Penson
Panelists: Marc Dall’Era, Matthew Cooperberg, Peter Pinto, Karim Touijer

2:00 SURGICAL TECHNIQUES: TIPS & TRICKS: NEPHROURETERECTOMY
Moderator: Inderbir Gill
Surgeons: Ashok Hemal, Surena Matin, Arieh Shalhav

3:00 SURGICAL TECHNIQUES: TIPS & TRICKS: NEOBLADDER
Surgeons: Richard Hautmann, Siamak Daneshmand, George Thalmann

252
Monday, May 21, 2018  Plenary: Prime Time II, Monday Afternoon Session  1:00 pm - 5:40 pm

**HALL E @ MCC North**

1:00  HIGHLIGHTS: SOCIETY OF URODYNAMICS, FEMALE PELVIC MEDICINE & UROGENITAL RECONSTRUCTION (SUFU) PROGRAM

Presenter:  Lara MacLachlan

1:10  COMPLEX CASES: UROLOGIC MANAGEMENT OF RECURRENT URINARY TRACT INFECTIONS

Presenter:  Jennifer Anger
Panelists:  Duane Hickling, Leslie Rickey

1:30  CROSSFIRE: CONTROVERSIES IN UROLOGY: FAILED MID-URETHRAL SLING DESERVES ANOTHER TRY

Moderator:  Gary Lemack
Debater - Pro:  Michael Albo
Debater - Con:  Craig Comiter

2:00  COMPLEX CASES: CHRONIC PELVIC PAIN SYNDROME

Presenter:  J. Curtis Nickel
Panelists:  H. Henry Lai, Christopher Payne, Larissa Rodriguez, Robert Moldwin

2:30  SURGICAL TECHNIQUES: TIPS & TRICKS: SACRAL NEUROMODULATION

Moderator:  Victor Nitti
Surgeons:  Melissa Kaufman, Steven Siegel, Sandip Vasavada

3:00  COMPLEX CASES: TREATMENT OF FEMALE SUI IN OBESITY

Presenter:  Eric Rovner
Panelists:  Nirit Rosenblum, Alexander Gomelsky

3:15  STATE-OF-THE-ART LECTURE: UROLOGIC DERMATOLOGY

Presenter:  Joanna Badger

3:30  THE FUTURE OF E-LEARNING AT THE AUA

Presenter:  Victor Nitti

3:45  HIGHLIGHTS: BENIGN UROLOGIC RESEARCH

Co-Presenters:  Dolores Lamb, Peter Schlegel
4:00 TAKE HOME MESSAGES: BASIC SCIENCE (BENIGN)
Presenter: Tanecia Mitchell

4:10 TAKE HOME MESSAGES: TRAUMA/RECONSTRUCTION
Presenter: Courtnety Hollowell

4:20 TAKE HOME MESSAGES: ENDUROLOGY/STONES
Presenter: Zeph Okeke

4:30 TAKE HOME MESSAGES: INFECTION/INFLAMMATION
Presenter: O. Lenaine Westney

4:40 TAKE HOME MESSAGES: INFERTILITY/ANDROLOGY
Presenter: TBA

4:50 TAKE HOME MESSAGES: SEXUAL DYSFUNCTION
Presenter: Nelson Bennett

5:00 TAKE HOME MESSAGES: PEDIATRICS
Presenter: Emilie Johnson

5:10 TAKE HOME MESSAGES: TRANSPLANTATION
Presenter: Yaw Nyame

5:20 TAKE HOME MESSAGES: FEMALE/INCONTINENCE
Presenter: Tracey Wilson

5:30 TAKE HOME MESSAGES: BPH/LUTS
Presenter: Harris Foster

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Monday, May 21, 2018
Moderated Poster Session 73
BENIGN PROSTATIC HYPERPLASIA: SURGICAL THERAPY & NEW TECHNOLOGY II
Room 3004 @ MCC West
Moderators: Kevin Zorn, John Wei and Peter Gilling

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP73-01</td>
<td>PREDICTIVE FACTORS OF URINARY INCONTINENCE AFTER GREENLIGHT® LASER ENUCLEATION OF THE PROSTATE (GREENLEP)</td>
</tr>
<tr>
<td></td>
<td>benoit peyronnet*, Rennes, France, fernando gomez-sancha, madrid, Spain, shahin tabatabaei, boston, MA, enrique rijo, barcelona, Spain, fernando kai li, boston, France, bo woo, boston, MA, thomas herrmann, hannover, Germany, vincent misrai, toulouse, France</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP73-02</td>
<td>COMPARISON OF OUTCOMES OBTAINED AFTER LIVE OPERATIVE SURGICAL CASES VERSUS REGULAR SURGERY. A SINGLE- CENTRE EXPERIENCE WITH GREEN LASER ENUCLEATION OF THE PROSTATE</td>
</tr>
<tr>
<td></td>
<td>Vincent Misrai*, Marie Pasquie, Benoit Bordier, Julien Guillotreau, Toulouse, France, Benoit Peyronnet, Rennes, France, Fernando Gomez-Sancha, Madrid, Spain, Henry Woo, Sydney, Australia, Thomas Hermann, Hannover, Germany</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP73-03</td>
<td>THE LEARNING CURVE FOR GREEN LASER ENUCLEATION OF THE PROSTATE (GREENLEP): A MULTI-INSTITUTIONAL STUDY OF 584 CASES</td>
</tr>
<tr>
<td></td>
<td>enrique rijo, barcelona, Spain, fernando gomez-sancha, madrid, Spain, shahin tabatabaei, boston, MA, fernando kai li, boston, France, bo woo, boston, MA, thomas herrmann, hannover, Germany, giovanni ferrari, modena, Italy, benoit peyronnet, Rennes, France, vincent misrai*, toulouse, France</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP73-04</td>
<td>THE EFFECT OF OBESITY ON OUTCOMES OF LASER PHOTOVAPORIZATION OF THE PROSTATE</td>
</tr>
<tr>
<td></td>
<td>Ramy Gouell*, Bashir Al Hussein Al Awamlh, Dominique Thomas, New York, NY, Kevin Zorn, Montreal, Canada, Alexis Te, Bilal Chughtai, New York, NY</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP73-05</td>
<td>KARL STORZ® DRILLCUT™ VERSUS LUMENIS® VERSACUT™ PROSTATE TISSUE MORCELLATORS AFTER HOLMIUM LASER ENUCLEATION: A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL</td>
</tr>
<tr>
<td></td>
<td>Ahmed Ibrahim*, Mostafa Elhilali, Sero Andonian, Serge Carrier, Montreal, Canada</td>
</tr>
</tbody>
</table>
MP73-06 A PROSPECTIVE EVALUATION ON THE CATHETER SCIENCE M3 “MINI CATHETER” FOR PATIENTS WITH PROSTATIC OBSTRUCTION

Gaines Hammond*, Lakeland, FL

MP73-07 HOLMIUM LASER ENucleATION OF THE PROSTATE AS A PALLIATIVE MANAGEMENT FOR REFRACTORY BLADDER OUTLET OBSTRUCTION IN PATIENTS WITH ADVANCED PROSTATE CANCER

Hyeon Woo Kim*, Dong Gil Shin, Tae Nam Kim, Busan, Korea, Republic of, Moon Kee Chung, Yangsan, Korea, Republic of, Chul Soo Yoon, B, Korea, Republic of, Seong Choi, Busan, Korea, Republic of, Tae Hee Oh, Changwon, Korea, Republic of, Wan Lee, Jeong Zoo Lee, Busan, Korea, Republic of

MP73-08 FEASIBILITY OF HOLMIUM LASER ENucleATION OF THE PROSTATE AS A SAME DAY SURGERY

William Critchlow*, Mitchell Humphreys, Scott Cheney, Phoenix, AZ

MP73-09 COMPARATIVE EFFECTIVENESS OF BENIGN PROSTATE ENLARGEMENT INTERVENTIONS AT FACILITATING UROLOGIC MEDICATION DISCONTINUATION

Bradley Gill*, Navin Sabharwal, James Ulchaker, Khaled Fareed, Daniel Shoskes, Cleveland, OH

MP73-10 CARE PATHWAY IMPLEMENTATION INFLUENCES CONVERSION TO SURGICAL THERAPY IN BPH PATIENTS

Andrew Trainer*, Euclid deSouza, John Horgan, Bruce Lundak, Stefanie Bolte, C. Brent Wakefield, Andrew Arther, Omaha, NE

MP73-11 RISK FACTORS PREDICTING FEVER AFTER TRANS-URETHRAL PROSTATECTOMY

Kamil Malshy*, Omer Sade, Tarek Aro, Alexander Kravtsov, Alexander Kastin, David Kakiashvili, Gilad E. Amiel, Michael Mullerad, Haifa, Israel

MP73-12 POST HOSPITAL SYNDROME IS A RISK FACTOR FOR READMISSION AFTER ELECTIVE BLADDER OUTLET OBSTRUCTION SURGERY

Ryan Domblar*, Eric Kirshenbaum, Anai Kothari, Kristin Baldea, Gopal Gupta, Grace Delos Santos, Maywood, IL

MP73-13 DO FRAILER MEN BENEFIT FROM TURP?: A PROSPECTIVE AUDIT OF URO-FRAILTY MDT ASSESSMENT

Daniel Good, Helen Jones, Becky Drybrugh, Panos Tsavallas, Irwin Foo, Elizabeth MacDonald, Prasad Bollina*, Edinburgh, United Kingdom

MP73-14 TRANSURETHRAL RESECTION URINARY RETENTION PREDICTOR (TURP) SCORE: A NOVEL PERIOPERATIVE PREDICTOR OF POST-OPERATIVE URINARY RETENTION

David F. Friedlander*, Sebastian Berg, Boston, MA, Albert Ha, New York, NY, Alexander P. Cole, Junaid Nabi, Boston, MA, Joachim Noldus, Herne, Germany, Quoc-Dien Trinh, Boston, MA

MP73-15 HESITANCY SYMPTOM: THE FORGOTTEN SYMPTOM IN INTERNATIONAL PROSTATE SYMPTOM SCORE (IPSS) QUESTIONNAIRE

Woon Tsang*, Jonathan Kwong, Lata Raman, David Consiglieri, Edmund Chiong, Singapore, Singapore

MP73-16 DOES URODYNAMICS PREDICT VOIDING AFTER BPH SURGERY IN PATIENTS WITH DETRUSOR UNDERACTIVITY?

Dominique Thomas*, New York, NY, Kevin C. Zorn, Montreal, Canada, Stephanie Chen, Alexis Te, Bilal Chughtai, New York, NY

MP73-17 DOES THE DEGREE OF BLADDER OUTLET OBSTRUCTION (BOO) CORRELATE WITH THE POSTOPERATIVE RESULTS OF PATIENTS UNDERGOING SURGICAL TREATMENT FOR BENIGN PROSTATIC ENLARGEMENT (BPE)?

Alejandra Bravo-Balado, Mauricio Plata*, Juan Guillermo Catalaño, Carlos Gustavo Trujillo, Juan Ignacio Caicedo, Bogotá, D.C., Colombia

MP73-18 THE MANAGEMENT OF MALE HIGH PRESSURE VOIDING BEFORE AND AFTER DOUBLE THERAPY

Serge Marinkovic*, Belleville, IL

MP73-19 DIAGNOSIS AND TREATMENT OF CATHETER-DEPENDENT MEN AFTER TRANSURETHRAL RESECTION OF THE PROSTATE AND LASER FAILURES


MP73-20 THE INDUSTRIAL ERA OF BPH MANAGEMENT: PUBLICATION TRENDS OF SURGICAL AND MEDICAL THERAPIES OVER THE PAST 2 DECADES

Patrick Jones, Amelia Pietropaolo*, Robert Geraghty, Southampton, United Kingdom, Bhavan Prasad Rai, Middlesborough, United Kingdom, Domenico Veneziano, Reggio Calabria, Italy, Lajunian Dragos, Timisoara, Romania, Bhaskar Somani, Southampton, United Kingdom

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
SEXUAL FUNCTION/DYSFUNCTION: EVALUATION II
Room 3006 @ MCC West
Moderators: David Ralph, Christian Nelson and Gerald Brock

**MP74-01** SEXUAL LIFE SATISFACTION RELATED TO ERECTILE FUNCTION ACROSS DIFFERENT AGES

**MP74-02** DOES AGE MATTER? ASSOCIATIONS WITH INTERCOURSE FREQUENCY AMONG A MEN'S HEALTH CLINIC COHORT
Mary E. Westerman*, Francisco Maldonado, Matthew J. Ziegelmann, Brian D. Montgomery, Jack Andrews, Vidit Sharma, Tobias Kohler, Landon Trost, Rochester, MN

**MP74-03** MALE INFERTILITY IS ASSOCIATED WITH SEXUAL DYSFUNCTION, DEPRESSION AND LOW SELF-ESTEEM: PROSPECTIVE, CASE-CONTROL, CLINICAL STUDY
Murad Başar*, Hakan Sirin, Istanbul, Turkey, Altug Semiz, Istanbul, Turkey, Mirac Turan, Istanbul, Turkey, DERYA BALBAY, MUAMMER KENDIRCI, ISTANBUL, Turkey

**MP74-04** SEXUAL DYSFUNCTION AND LOWER URINARY TRACT SYMPTOMS IN STREET KETAMINE ABUSERS
chao-tse hung*, shang-jen chang, stephen shei-dei yang, Yi-Ju chen, new taipei, Taiwan

**MP74-05** SERUM PSA AS A PREDICTOR OF SYMPTOMATIC HYPOGONADISM PARTICULARLY IN RELATION TO PSYCHOLOGICAL SYMPTOMS
Kazuhito Matsushita*, Akira Tsujimura, Shigeo Horie, Tokyo, Japan

**MP74-06** DIFFERENCES IN SEXUAL FUNCTION IN PATIENTS WITH UROLOGIC CHRONIC PELVIC PAIN SYNDROMES (UCPPS) AND INDIVIDUALS WITH OTHER CHRONIC PAIN CONDITIONS AND HEALTHY CONTROLS IN THE MAPP RESEARCH NETWORK

**MP74-07** THE PENILE SENSITIVITY RATIO: OPTIMIZATION OF A BIOTHESIOMETRY PARAMETER TO ASSESS CHANGES IN PENILE SENSITIVITY
Peter Tsambarlis*, Adam Wiggins, M. Ryan Farrell, Laurence Levine, Chicago, IL

**MP74-08** PSYCHOLOGICAL AND PHYSICAL IMPACT OF STUTTERING PRIAPISM ON MEN WITH SICKLE CELL DISEASE
April Szafran*, Baltimore, MD, Belinda Morrison, Mona, Jamaica, Arthur Burnett, Baltimore, MD

**MP74-09** THERMAL IMAGING AS A NON-INVASIVE METHOD FOR ASSESSING ERECTILE FUNCTION
Alexandria Hertz*, Evalyn George, Amanda Reed-Maldonado, Timothy Brand, Shashikumar Salgar, Tacoma, WA

**MP74-10** NOCTURNAL PENILE ERECTIONS EVALUATION USING A NEW GENERATION OF RIGISCAN: SMALL SOMETIMES IS BETTER
Andrea Cocci*, Florence, Italy, Michele Rizzo, Trieste, Italy, Gianmartin Cito, Florence, Italy, Giovanni Cacciamani, Verona, Italy, Giorgio Ivan Russo, Catania, Italy, Marco Capece, Naples, Italy, Marco Falcone, Massimiliano Timpano, Turin, Italy, Giacomo Tanganelli, Pisa, Italy

**MP74-11** RISK FACTORS FOR ERECTILE DYSFUNCTION AMONG YOUNG MEN – FINDINGS OF A REAL-LIFE CROSS-SECTIONAL STUDY

**MP74-12** LOWER URINARY TRACT SYMPTOMS AMONG PATIENTS PRESENTING FOR PREMATURE EJACULATION

**MP74-13** SEX, PAIN, RELATIONSHIP BREAKDOWN AND VASECTOMY - LARGE COHORT STUDY
S. Mishriki*, Aberdeen, United Kingdom
MP74-14 NOMOGRAM USING METABOLIC SYNDROME COMPONENTS TO PREDICT TESTOSTERONE DEFICIENCY SYNDROME IN MEN
Monique Novaes*, Eduardo P. Miranda, Caroline S. Silva, Ricardo Tiraboschi, Mateus Alvaia, Victor Paschoalin, Lucas Borba, José Murillo Bastos-Netto, Cristiano Gomes, Jose Bessa Jr., Feira de Santana, Brazil

MP74-15 IMPACT OF PDE5 INHIBITOR (PDE5I) USE ON BIOCHEMICAL RECURRENCE RATES IN PROSTATE CANCERS PATIENTS FOLLOWING RADIOTHERAPY (RT)
Eduardo P. Miranda*, Fortaleza, Brazil, Lawrence Jenkins, Columbus, OH, Michael Zelefsky, Elizabeth Schofield, Christian Nelson, John P. Mulhall, New York, NY

MP74-16 MEASURING SEXUAL FUNCTION AFTER TREATMENT FOR PROSTATE CANCER IN MEN WHO HAVE SEX WITH MEN: A HIDDEN DOMAIN EMERGES
Channa Amarasekera*, Vincent Wong, James Burns, Kyle Tsai, David Victorson, Shilajit Kundu, Chicago, IL

MP74-17 TRAJECTORIES OF ERECTILE DYSFUNCTION SUBPHENOTYPES IN MEN WITH LONGSTANDING TYPE I DIABETES

MP74-18 ERECTILE DYSFUNCTION AMONG MALE ADULT ENTERTAINERS: A SURVEY
Justin Dubin*, Aubrey Greer, Miami, FL, Ian O’Brien, Eric Leue, Canoga Park, CA, Ranjith Ramasamy, Miami, FL

MP74-19 EFFECTS OF HYPOTHYROIDISM ON LOWER URINARY TRACT SYMPTOMS, TESTOSTERONE AND SEXUAL FUNCTION IN MEN
Seong Uk Jeh*, Jungmo Do, Sin Woo Lee, See Min Choi, Jeong Seok Hwa, Jinju, Korea, Republic of, Deok Ha Seo, Chunwoo Lee, Sung Chul Kam, Ky Hyun Chung, Changwon, Korea, Republic of, Jae Seog Hyun, Jinju, Korea, Republic of

MP74-20 THE RELATIONSHIP BETWEEN PSA AND TOTAL TESTOSTERONE LEVELS IN MEN WITH INTERMEDIATE AND HIGH GRADE PROSTATE CANCER
Helen L. Bernie*, Bruno Nascimento, Nicole E. Benfante, Amy Tin, Sigrid Carlsson, John P. Mulhall, New York, NY

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Monday, May 21, 2018
7:00 am - 9:00 am
Moderated Poster Session 75
URODYNAMICS/LOWER URINARY TRACT DYSFUNCTION/FEMALE PELVIC MEDICINE: FEMALE INCONTINENCE: THERAPY III
Room 3009 @ MCC West
Moderators: Lynn Stothers, Donna Deng and Mauricio Plata

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP75-01</td>
<td>REOPERATION RATES FOR STRESS URINARY INCONTINENCE AND PELVIC ORGAN PROLAPSE IN WOMEN UNDERGOING A MID-URETHRAL SLING</td>
</tr>
<tr>
<td>Alex Cantrell*, Stacey Wallach, Jennifer Rothschild, Sacramento, CA, Blythe Durbin-Johnson, Davis, CA, Eric Kurzrock, Sacramento, CA</td>
<td></td>
</tr>
<tr>
<td>MP75-02</td>
<td>SYNTHETIC MID-URETHRAL SLING COMPLICATIONS: DO PATIENTS BENEFIT FROM SLING REVISION?</td>
</tr>
<tr>
<td>Elizabeth Dray*, Anne Pelletier Cameron, Erin Crosby, Ashley Grable, J. Quentin Clemens, John Stoffel, Priyanka Gupta, Paholo Barboglio-Rom, Ann Arbor, MI</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP75-03</td>
<td>CONTEMPORARY REVIEW OF COMPLICATIONS ASSOCIATED WITH AUTOLOGOUS RECTUS FASCIA PUBOVAGINAL SLINGS</td>
</tr>
<tr>
<td>MP75-04</td>
<td>THE EFFECT OF SURGEON VOLUME ON PERIOPERATIVE OUTCOMES FOR MID-URETHRAL SLING SURGERY</td>
</tr>
<tr>
<td>Jacqueline Speed*, Ye Wang, Steven Chang, Eloi Dielubanza, Boston, MA</td>
<td></td>
</tr>
<tr>
<td>MP75-05</td>
<td>UNPLANNED HOSPITAL VISITS IN THE FIRST 30 DAYS FOLLOWING MIDURETHRAL SLING: A NATIONWIDE POPULATION-BASED STUDY</td>
</tr>
<tr>
<td>Yu-Hua Fan*, Hsiao-Jen Chung, Eric Huang, Chih-chieh Lin, Alex Lin, Taipei, Taiwan</td>
<td></td>
</tr>
</tbody>
</table>

*Presenting author
MP75-06 POST-HOSPITAL SYNDROME IS A TRANSIENT PREDICTOR OF 30-DAY HOSPITAL READMISSION FOLLOWING TRANSVAGINAL MIDURETHRAL SLING PLACEMENT
Marc Nelson, Spencer Hart*, Eric Kirshenbaum, Yufan Chen, Michelle Van Kuiken, Elizabeth Mueller, Maywood, IL

MP75-07 LONG-TERM EFFICACY AND SAFETY OF SINGLE-INCISION MINI-SLINGS EXCLUDING TVT-SECUR VERSUS STANDARD MIDURETHRAL SLINGS IN SURGICAL MANAGEMENT OF FEMALE STRESS URINARY INCONTINENCE: AN UPDATED SYSTEMIC REVIEW AND META-ANALYSIS
Sung Hyun Paick*, Young-Jin Park Park, Seoul, Korea, Republic of, Aram Kim, Seoul, Korea, Republic of, Woo Suk Choi, Hyo Young Keun Park, Seoul, Korea, Republic of, Hyeong On Kim, Seoul, Korea, Republic of

MP75-08 DIAGNOSTIC PERFORMANCE OF TRANSLABIAL ULTRASOUND IN SYNTHETIC MIDURETHRAL SLING LOCALIZATION AND ORGAN PERFORATION IN WOMEN WITH STRESS URINARY INCONTINENCE
Victoria Scott*, Los Angeles, CA, Karoly Viragh, New York, NY, Seth Cohen, Duarte, CA, Steve Raman, Shlomo Raz, Los Angeles, CA

MP75-09 TRANSPERINEAL ULTRASOUND AND THE TRANSOBOTURATOR TAPE SLING FAILURE
Elisabetta Costantini*, Terni, Perugia, Italy, Alessandro Zucchi, Perugia, Terni, Italy, Franca Natale, Rome, Italy, Ester Illiano, Terni, Perugia, Italy

MP75-10 COMPARISON OF ADJUSTABLE CONTINENCE THERAPY PERIURETHRAL BALLOONS AND ARTIFICIAL URINARY SPHINCTER IN FEMALE PATIENTS WITH STRESS URINARY INCONTINENCE DUE TO INTRINSIC SPHINCTER DEFICIENCY
Lucas Freton*, Lauranne Tondut, Isabelle Enderle, Juliette Hascoet, Nelly Senal, Thibault Honore, Jacques Kerdraon, Andrea Manunta, Benoit Peyronnet, Rennes, France

MP75-11 FUNCTIONAL OUTCOMES OF ADJUSTABLE CONTINENCE THERAPY BALLOONS IN WOMEN: A MULTICENTRIC RETROSPECTIVE STUDY
Claire Sanson*, Toulouse, France, Pauline Guiffart, Lille, France, Benoit Peyronnet, Rennes, France, Xavier Gamé, Toulouse, France, Xavier Biardeau, Lille, France

MP75-12 BLADDER NECK ARTIFICIAL URINARY SPHINCTER (BN AUS) FOR RECURRENT OR COMPLEX PRIMARY URODYNAMICALLY PROVEN STRESS AND MIXED URINARY INCONTINENCE – OUTCOMES FROM A TERTIARY REFERRAL CENTRE
Dunia Benamer, Eabhann O’Connor*, Jeremy Ockrim, Tamsin Greenwell, Daniela Andrich, Anthony Mundy, London, United Kingdom

MP75-13 CONCOMITANT TRANSURETHRAL AND TRANSVAGINAL-PERIURETHRAL INJECTION OF AUTOLOGOUS ADIPOSE DERIVED STEM CELLS FOR TREATMENT OF FEMALE STRESS URINARY INCONTINENCE: A PHASE ONE CLINICAL TRIAL
Gholamreza Pourmand*, Babak Arjmand, Majid Safavi, Reza Heidari, Hamidreza Aghayan, Soroush T. Bazargani, Sanaz Dehghani, Parisa Goodarzi, Fereishteh Mohammadi-Jahani, Fariba Heidari, Moloud Payab, Tehran, Islamic Republic of Iran

MP75-14 TWO YEARS FOLLOW UP OF TRANSURETHRAL INJECTION OF POLYACRYLAMIDE HYDROGEL (BULKAMID®) FOR URINARY INCONTINENCE (UI)
Abdel Hamid Hamed*, Holly Bekarma, Suzanne McPhee, Brain Little, Biju Nair, Ayr, United Kingdom

MP75-15 MIRABEGRON ESCALATION TO 50 MG FURTHER IMPROVE URGENCY AND URGENCY URINARY INCONTINENCE AFTER INITIAL 25 MG MIRABEGRON FOR FOUR WEEKS IN ASIAN OVERACTIVE BLADDER PATIENTS
Chiang Meng-Che*, Chun-Hou Liao, New Taipei, Taiwan, Hann-Chong Kuo, Hualien, Taiwan

MP75-16 ONABOTULINUMTOXINA INJECTION TO THE EXTERNAL URETHRAL SPHINCTER FOR VOIDING DYSFUNCTION IN FEMALES: A TERTIARY CENTRE EXPERIENCE
Mariele Trimboli*, Seth Jai, Sarah Itam, Eabhann O’Connor, Rizwan Hamid, Jeremy Ockrim, Tamsin Greenwell, Mahreen Pakzad, London, United Kingdom

MP75-17 DO PATIENTS DISCONTINUE OVERACTIVE BLADDER MEDICATIONS AFTER SACRAL NEUROMODULATION?
Katherine Amin*, Dena Moskowitz, Kathleen C. Kobashi, Una J. Lee, Alvaro Lucioni, Seattle, WA
**MP75-18 SAFETY & EFFICACY OF THE ECOIN™ IMPLANTABLE TIBIAL NERVE STIMULATION DEVICE FOR OVERACTIVE BLADDER SYNDROME**

Scott MacDiarmid*, Greensboro, NC, Vincent Lucente, Allentown, PA, Bilal Kaaki, Waterloo, IA, Sharon English, Christchurch, New Zealand, Patrick Meffan, Nelson, New Zealand, Peter Gilling, Tauranga, New Zealand, Matthew Clark, Newport Beach, CA, Subhro Sen, Silicon Valley, CA, Peter Sand, Evanston, IL

**MP75-19 DOES PELVIC SURGERY IMPACT THE EFFICACY OF PELVIC FLOOR PHYSICAL THERAPY FOR PELVIC PAIN?**

Esther Han*, Laura Nguyen, Yi Ling Dai, Jamie Bartley, Jason Gilleran, Lisa Odabachian, Kim Killinger, Kenneth Peters, Judith Boura, Larry Sirls, Royal Oak, MI

---

**MP76-01 VARIATION IN PHYSICIAN-SPECIFIC EPISODE PAYMENTS FOR MAJOR UROLOGIC CANCER SURGERY: IMPLICATIONS FOR MIPS**

Deborah Kaye*, Zaojun Ye, Lindsey Herrel, Jonathan Li, James Dupree, Chad Ellimoottil, David Miller, Ann Arbor, MI

**MP76-02 OVERUSE OF CYSTOSCOPIC SURVEILLANCE AMONG PATIENTS WITH LOW-RISK NON-MUSCLE-INVASIVE BLADDER CANCER – A NATIONAL STUDY OF PATIENT, PROVIDER, AND FACILITY FACTORS**

David Han*, Amanda Swanton, Lebanon, NH, Kristine Lynch, Ji Won Chang, Salt Lake City, UT, Brenda Sirovich, Douglas Robertson, John Seigne, Philip Goodney, Florian Schroeck, Lebanon, NH

**MP76-03 MARKED VARIATION IN PROSTATE CANCER CARE AMONG ACCOUNTABLE CARE ORGANIZATIONS**

Parth Modi*, Samuel Kaufman, Tudor Borza, Lindsey Herrel, John M. Hollingsworth, Ted Skolarus, David Miller, Vahakn Shahinian, Brent Olsenbeck, Ann Arbor, MI

**MP76-04 ACCOUNTABLE CARE ORGANIZATIONS AND THE COST AND QUALITY OF UROLOGICAL CANCER CARE AT THE END OF LIFE**

Lindsey Herrel*, Deborah Kaye, Alice Min, Chad Ellimoottil, James M. Dupree, David Miller, Ann Arbor, MI

---

**MP76-05 COSTS OF UROLOGIC CANCER CARE ACROSS THE DISEASE CONTINUUM**

Deborah Kaye*, Hye Sung Min, Lindsey Herrel, James Dupree, Chad Ellimoottil, David Miller, Ann Arbor, MI

**MP76-06 THE EFFECT OF AFFORDABLE CARE ACT-RELATED MEDICAID EXPANSION ON UTILIZATION OF UROLOGIC SURGICAL SERVICES**

Tyler R. McClintock*, Alexander P. Cole, Ye Wang, Daniel Pucheril, Sebastian Berg, Steven L. Chang, Adam S. Kibel, Quoc-Dien Trinh, Boston, MA

**MP76-07 UTILIZATION OF AN INTERNET OF THINGS INDOOR GPS SYSTEM AND TIME-DRIVEN ACTIVITY-BASED COSTING TO ENHANCE HEALTH CARE DELIVERY IN A UROLOGIC ONCOLOGY CLINIC: A PROOF-OF-PRINCIPLE**

Aaron Laviana*, Nashville, TN, Valeria Tringali, Milan, Italy, David Penson, Matthew Reznick, Nashville, TN

**MP76-08 THE IMPACT OF PRE-OPERATIVE PROSTATE IMAGING AND RESIDENT PARTICIPATION ON THE FINANCIAL MARGIN OF AN EPISODE-BASED PAYMENT MODEL FOR ROBOTIC PROSTATECTOMY**

David Johnson*, Los Angeles, CA, Aaron Laviana, Nashville, TN, Jamal Nabhani, Reshma Gupta, Eric Kwok, Christine Ahn, Gerald Kominski, Karim Chamie, Mark Litwin, Christopher Saigal, Los Angeles, CA

---

*Presenting author
MP76-09 IDENTIFYING AND CODIFYING COMPLICATIONS AFTER RADICAL CYSTECTOMY: COMPARISON OF ADMINISTRATIVE DIAGNOSTIC AND PROCEDURE CODES AND CLINICAL CHART REVIEW
Charles Peyton*, Richard Reich, Brandon Alford, Dominic Tang, Mounsif Azizi, Wade Saxton, Michael Poch, Scott Gilbert, Tampa, FL

MP76-10 TRENDS IN AMBULATORY UROLOGICAL SURGERY: AN ANALYSIS OF FIVE STATES IN THE HEALTHCARE COST AND UTILIZATION PROJECT
Hiten Patel*, Brian Matlaga, Baltimore, MD, Justin Ziemba, Philadelphia, PA

MP76-11 PULMONARY EMBOLI IN THE SETTING OF TESTOSTERONE THERAPY. A NESTED CASE CONTROL STUDY AMONG 40,081 TESTOSTERONE USERS
Ryan Flannigan*, New York, NY, Jennifer Locke, Hamid Tavakoli, Vancouver, Canada, Christopher Wallis, Toronto, Canada, Mahyar Elliman, Ted Hoyda, Larry Goldenberg, Vancouver, Canada

MP76-12 DETERMINING PARENTAL PREFERENCES FOR TREATMENT OF VESICOURETERAL REFLUX: PROFILE CASE BEST-WORST SCALING
Zachary Dionise*, Durham, NC, Michael Garcia-Roig, Andrew Kirsch, Atlanta, GA, Jonathan Routh, Durham, NC

MP76-13 PROSTATE BIOPSY COSTS FOR PRIVATELY-INSURED MEN: IMPACT OF MAGNETIC RESONANCE IMAGE-GUIDANCE AND USE OF ANESTHESIA SERVICES
Andrew Leung*, Wen Liu, Dattatraya Patil, Mark Henry, David Howard, Heqiong Wang, Renee Moore, Martin Sanda, Christopher Filson, Atlanta, GA

MP76-14 IMPACT OF PRACTICE SETTING AND USE OF PATHOLOGY SERVICES ON VASECTOMY PAYMENTS, 2009–2015
Vitaly Zholudev*, Dattatraya Patil, Christopher Filson, Akanksha Mehta, Atlanta, GA

MP76-15 PATIENT FOCUSED EDUCATION VIA SMARTPHONE: IS IT EFFECTIVE IN DECREASING SAME DAY SURGERY CANCELLATION RATE?
Esther Kim*, Karina Canadas, Christine Geistkemper, Kathleen Chen, Rahul Bajjal, Abishek Seth, Houston, TX

MP76-16 ELECTRONIC MEDICAL RECORD ALERT SIGNIFICANTLY REDUCED BLOOD TRANSFUSIONS: THE ST. JOHN PROVIDENCE HOSPITAL EXPERIENCE
Elizabeth Boes, Donna Robertson, Timothy Mervak, Ernesto Drelichman, David Wenzler*, Novi, MI

MP76-17 DRIVERS OF COST FOR AN EPISODE OF CARE IN RADICAL CYSTECTOMY
Janet Baack Kukreja*, Neema Navai, Marissa Mery, James Incalcaterra, Ashish Kamat, Colin Dinney, Houston, TX, Thomas Feeley, Cambridge, MA, Jay Shah, Palo Alto, CA

MP76-18 NATURAL LANGUAGE PROCESSING ALLOWS FOR ACCURATE AND AUTOMATED EXTRACTION OF DATA FROM PROSTATE BIOPSY PATHOLOGY REPORTS
Gregory Joice*, Brant Chee, Natasha Gupta, Michael Johnson, Baltimore, MD

MP76-19 EXTREME PRICE VARIATION IN GENERIC BENIGN PROSTATIC HYPERPLASIA AND OVERACTIVE BLADDER DRUGS
Katherine Theisen*, Seo Young Park, Kwonho Jeong, Jathin Bandari, Pittsburgh, PA, Anobel Odisho, San Francisco, CA, Bruce Jacobs, Benjamin Davies, Pittsburgh, PA

MP76-20 PATTERNS AND COSTS OF HEALTH CARE UTILIZATION PRIOR, DURING AND FOLLOWING EXPOSURE TO CRANBERRY IN THE PREVENTION OF FEMALE URINARY TRACT INFECTION: RESULTS FROM A RANDOMIZED CONTROLLED CLINICAL TRIAL (RCT) INVOLVING WOMEN WITH RECURRENT UTI
Lynn Stothers*, Marc Levine, Jonathan Berkowitz, Paula Brown, Vancouver, Canada

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
ABSTRACT NUMBER | TITLE
---|---
MP77-01 | WHICH PATIENTS WITH PIRADS 3 LESION AT MULTIPARAMETRIC MRI CAN AVOID PROSTATE BIOPSY?
Paolo Dell’Oglio*, Armando Stabile, Elio Mazzone, Milan, Italy, Matteo Soligo, Rochester, MN, Lisa Brunetti, Anna Damascelli, Milan, Italy, R. Jeffrey Kames, Rochester, MN, Pierre I. Karakiewicz, Montreal, Canada, Umberto Capitanio, Francesco Cianflone, Nicola Fossati, Giorgio Gandaglia, Emanuele Zaffuto, Milan, Italy, Rocco Damiano, Catanzaro, Italy, Antonio Esposito, Francesco De Cobelli, Francesco Montorsi, Alberto Briganti, Milan, Italy

MP77-02 | A NEW VERSUS AN OLD NOTION: IS THERE ANY CORRELATION BETWEEN MULTI-PARAMETRIC MRI (MPMRI) PIRADS (PROSTATE IMAGING-REPORTING AND DATA SYSTEM) SCORE AND PSA (PROSTATE SPECIFIC ANTIGEN) KINETICS?
Zhina Sadeghi*, Rayan Abboud, Bissan Abboud, Amr Mahar, Christina Buzzy, Julia Yang, Vikas Gulani, Lee Ponsky, Cleveland, OH

MP77-03 | ASSESSING THE IMPACT OF RADIOLoGIST EXPERTISE ON THE MISDIAGNOSIS OF CLINICALLY SIGNIFICANT PROSTATE CANCER AMONG MEN RECEIVING MULTI-PARAMETRIC MRI

MP77-04 | THE ROLE OF THE OPERATOR IN THE CANCER DETECTION WITH MRI/TRUS FUSION TRANSRECTAL PROSTATE BIOPSY
Francesco Porpiglia, Marco Cosso, Stefano De Luca, Matteo Manfredi, Fabrizio Mele, Riccardo Bertolo*, Daniele Amrapare, Enrico Checcucci, Diletta Garrou, Agostino De Pascale, Orbassano, Italy, Filippo Russo, Candido, Italy, Cristiano Fiori, Orbassano, Italy

MP77-05 | UROLOGIST LEARNING CURVE HAS AN IMPACT ON INCREASING PROBABILITY OF CLINICALLY SIGNIFICANT CANCER DETECTION RATE AT MPMRI-TRUS FUSION TARGET BIOPSY: A PROSPECTIVE STUDY IN A SINGLE HIGH VOLUME INSTITUTION
Giuliana Lista*, Giovanni Lughezzani, Massimo Lazzeri, Davide Maffei, Pasquale Cardone, Piergiuseppe Colombo, Niccolò Buffi, Rodolfo Hurle, Alberto Saita, Paolo Casale, Giorgio Guazzoni, Rozzano (MI), Italy

MP77-06 | FOLLOW-UP OF MEN WITH MRI SUSPICION SCORE 4 OR 5 REGIONS OF INTEREST ON PROSTATE MRI AND NON-MALIGNANT PATHOLOGIC FINDINGS ON INITIAL TARGETED PROSTATE BIOPSY
Xiaosong Meng*, Brian Chao, Fei Chen, Richard Huang, Fang-Ming Deng, Samir S. Taneja, New York, NY

MP77-07 | HOW MANY CORES ARE NEEDED TO DETECT CLINICALLY SIGNIFICANT PROSTATE CANCER ON TARGETED MRI-ULTRASOUND FUSION BIOPSY?
Amanda Lu*, Kamyar Ghabili Amirkhiz, Kevin Nguyen, Michael Leapman, Preston Sprenkle, New Haven, CT

MP77-08 | COGNITIVE TARGETING VS. SOFTWARE FUSION FOR MRI-TARGETED BIOPSY: EXPERIENCE BEFORE AND AFTER IMPLEMENTATION OF FUSION
Steven Monda*, Joel Vetter, Gerald Andriole, Kathryn Fowler, Anup Shetty, Eric Kim, St. Louis, MO

MP77-09 | EARLY AND LATE IMAGES OF 18F-CHOLINE (FCH) PET/CT FOR THE DETECTION OF PROSTATIC FOSSAE RECURRENCES IN PROSTATE CANCER WITH A BIOCHEMICAL FAILURE (PSA < 2 NG/ML)
Fabio Zattoni*, Udine, Italy, Francesco Cattaneo, Padua, Italy, Filiberto Zattoni, Italy, Italy, Laura Evangelista, Padua, Italy

MP77-10 | 68GALLIUM-PROSTATE-SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY/COMPUTER TOMOGRAPHY (68GA PSMA PET) HAS THE POTENTIAL TO REPLACE BIOPSY IN METASTATIC PROSTATE CANCER
gagan prakash*, kunal shah, archi agrawal, venkatesh rangarajan, ganesh bakshi, mahendra pal, vedang murthy, rahul krishna, santosh menon, swapnil rane, kumar prabhash, amit joshi, vanita noronha, Mumbai, India
MP77-11 IMPACT OF POSITRON EMISSION TOMOGRAPHY WITH 18F-FLUCICLOVINE ON MANAGEMENT OF PATIENTS WITH SUSPECTED RECURRENCE OF PROSTATE CANCER: RESULTS FROM THE LOCATE TRIAL
Gerald Andriole*, Saint Louis, MO

MP77-12 68GA-PSMA PET/CT VERSUS MPMRI FOR LOCOREGIONAL PROSTATE CANCER STAGING: CORRELATION WITH FINAL HISTOPATHOLOGY
Israel Berger, Chandra Annabattula, Jeffrey Lewis, Deepa Shetty, Jonathan Kam, Fiona Maclean, Mohan Arianayagam, Bertram Canagasingham, Richard Ferguson, Mohamed Khadra, Raymond Ko, Matthew Winter*, Han Loh, Celi Varol, Sydney, Australia

MP77-13 UTILITY OF POSITRON EMISSION TOMOGRAPHY IN BIOCHEMICALLY RECURRENT PROSTATE CANCER: A COMPARISON OF CARBON-11 ACETATE & 68GA-PROSTATE SPECIFIC MEMBRANE ANTIGEN RADIOTRACERS
Luke Shumaker*, Clinton Bahler, Thomas Gardner, Michael Koch, James Fletcher, Indianapolis, IN

MP77-14 CONTEMPORARY NATIONAL TRENDS IN PROSTATE MRI AMONG PATIENTS UNDERGOING A PROSTATE BIOPSY: RESULTS FROM A PRIVATELY INSURED PATIENT POPULATION

MP77-15 A MULTI-CENTRE RANDOMISED CONTROLLED TRIAL ASSESSING WHETHER MRI-TARGETED BIOPSY IS NON-INFERIOR TO STANDARD TRANSRECTAL ULTRASOUND GUIDED BIOPSY FOR THE DIAGNOSIS OF CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITHOUT PRIOR BIOPSY - THE PRECISION STUDY
Veeru Kasivisvanathan*, London, United Kingdom, Antti Rannikko, Helsinki, Finland, Marcelo Borghi, Buenos Aires, Argentina, Valeria Panebianco, Roma, Italy, Lance Mynderse, Rochester, MN, Markku Vaara, Oulu, Finland, Alberto Briganti, Milan, Italy, Lars Budäus, Hamburg, Germany, Giles Hellawell, London, United Kingdom, Richard Hindley, Basingstoke, United Kingdom, Monique Roobol, Rotterdam, Netherlands, Scott Eggener, Chicago, IL, Maneesh Ghei, London, United Kingdom, Arnauld Villers, Lille, France, Franch Bladou, Montreal, Canada, Geert Villeirs, Ghent, Belgium, Jaspal Virdi, Harlow, United Kingdom, Silvan Boxler, Bern, Switzerland, Grégoire Robert, Bordeaux, France, Paras Singh, London, United Kingdom, Wulphert Venderink, Rotterdam, Netherlands, Boris Hadaschik, Heidelberg, Germany, Alain Ruffion, Lyon, France, Jim Hu, Daniel Margolis, New York, NY, Sébastien Crouzet, Lyon, France, Laurence Klotz, Toronto, Canada, Samir Taneja, New York, NY, Peter Pinto, Bethesda, MD, Inderbir Gill, Los Angeles, CA, Clare Allen, Francesco Giganti, Alex Freeman, Steve Morris, Shonit Punwani, Norman Williams, Chris Brew-Graves, Yemisi Takwoingi, Mark Emberton, Caroline Moore, London, United Kingdom

MP77-16 INCIDENCE OF FALSE NEGATIVE PROSTATE CANCER SCREENING IN PATIENT TAKING 5-ALPHA REDUCTASE INHIBITORS
Ethan Fram*, Pedro Maria, Bronx, NY

MP77-17 NEIGHBORHOOD ASSOCIATED EXPOSURES AND SOCIOECONOMIC FACTORS ARE ASSOCIATED WITH PROSTATE BIOPSY OUTCOMES
Oluwarotimi Netty*, Chicago, IL, Lakisha David, Urbana, IL, Austin Walker, Chicago, IL, So Young Park, Urbana, IL, Borko Jovanovic, Chicago, IL, Kelsey Rydland, Evanston, IL, Rick Kittles, Duarte, CA, Christy Lleras, Urbana, IL, Adam Murphy, Chicago, IL

MP77-18 IMPACT OF SEXUAL ORIENTATION ON CONTEMPORARY RATES OF PROSTATE CANCER SCREENING
Daniel Pucheril*, Sebastian Berg, Alexander P. Cole, Sean A. Fletcher, Dimitar Zlatev, Steven L. Chang, Boston, MA, Jesse Sammon, Portland, ME, Mani Menon, Detroit, MI, Adam S. Kibel, Quoc-Dien Trinh, Boston, MA
**MP77-19** CLINICAL TOOL PREDICTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN  
Nancy N. Wang*, Richard E. Fan, Stanford, CA, Preston C. Sprenkle, New Haven, CT, Geoffrey A. Sonn, Stanford, CA

**MP77-20** PREDICTION OF SIGNIFICANT PROSTATE CANCER IN BIOPSY-NAÏVE MEN: EXTERNAL VALIDATION OF A NOVEL RISK MODEL COMBINING MRI AND CLINICAL PARAMETERS  
Jan Philipp Radtke*, Heidelberg, Germany, Francesco Giganti, London, United Kingdom, Manuel Wiesenfarth, Heidelberg, Germany, Jose Marencio, Clement Orczyk, Veeru Kasivisanathan, London, United Kingdom, Armando Stabile, Milan, Italy, Claudia Keach, Vancouver, Canada, Joanne Nyarangi-Dix, Viktoria Schütz, Albrecht Stenzinger, Wilfried Roth, Dogu Teber, David Bonekamp, Heinz-Peter Schlemmer, Markus Hohenfellner, Heidelberg, Germany, Mark Emberton, London, United Kingdom, Boris Hadaschik, Essen, Germany, Caroline Moore, London, United Kingdom

---

**Moderated Poster Session 78**

**BLADDER CANCER: INVASIVE VI**  
Room 2005 @ MCC West  
Moderators: Arthur Sagalowsky, Byron Lee and Ricardo Sanchez-Ortiz

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| MP78-01         | PATHOLOGICAL DOWNSTAGING AT RADICAL CYSTECTOMY FOR MUSCLE-INVASIVE BLADDER CANCER: SURVIVAL OUTCOMES IN THE SETTING OF NEOADJUVANT CHEMOTHERAPY VERSUS TRANSURETHRAL RESECTION ONLY  
Kris Miguel Cajipe*, Hanzhang Wang, Wasim Chowdhury, Robert Svatok, Dharam Kaushik, Ahmed Mansour, San Antonio, TX |
| MP78-02         | TRENDS IN NEOADJUVANT CHEMOTHERAPY USE AND ONCOLOGICAL OUTCOMES FOR MUSCLE-INVASIVE BLADDER CANCER IN JAPAN: A MULTICENTER STUDY  
Go Anan*, Shingo Hatakeyama, Naoki Fujita, Hirosaki, Japan, Hiromichi Iwamura, Sendai, Japan, Toshikazu Tanaka, Hayato Yamamoto, Yuki Tobisawa, Tohru Yoneyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Koie, Hirosaki, Japan, Hirohiko Ito, Hachinohe, Japan, Kazuaki Yoshikawa, Mutsu, Japan, Toshiaki Kawaguchi, Aomori, Japan, Makoto Sato, Sendai, Japan, Chikara Ohyama, Hirosaki, Japan |
| MP78-03         | IMMUNOHISTOCHEMICAL CLASSIFICATION USING UROTHELIAL DIFFERENTIATION MARKERS CAN STRATIFY PROGNOSIS IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER  
Tetsutaro Hayashi*, Kazuhiro Sentani, Keisuke Goto, Hiroshima, Japan, Htoo Zami Oo, Vancouver, Canada, Hamidezua Abdi, Ottawa, Canada, Kazuaki Mutaguchi, Nakatsu, Japan, Shunsuke Shinmei, Shogo Inoue, Jun Teishima, Wataru Yasui, Hiroshima, Japan, Peter C. Black, Vancouver, Canada, Akio Matsubara, Hiroshima, Japan |
| MP78-04         | PRETREATMENT GRANULOCYTIC MYELOID-DERIVED SUPPRESSOR CELLS CORRELATE PATIENT OUTCOMES UNDERGOING NEO-ADJUVANT CHEMOTHERAPY FOR BLADDER CANCER  
Guoliang Yang*, Shanghai, China, People’s Republic of China |
| MP78-05         | INVASION-ASSOCIATED MiRNAS AS POSSIBLE DIAGNOSTIC BIOMARKERS OF MUSCLE INVASIVE BLADDER CANCER IN TUMOR TISSUES AND URINARY EXOSOMES  
Sophie Baumgart, Pascal Meschkat, Philipp Edelmann, Homburg, Germany, Arndt Hartmann, Erlangen, Germany, Rainer Bohle, Alexey Pryalukhin, Joana Heinzlmann, Michael Stöckle, Kerstin Junker*, Homburg, Germany |

*Presenting author
MP78-06 THE EFFECT OF CIRCULATING TUMOR CELLS AND COPY NUMBER VARIATIONS OF CIRCULATING TUMOR DNA ON SURVIVAL IN BLADDER CANCER PATIENTS TREATED WITH RADICAL CYSTECTOMY
Armin Soave, Michael Rink*, Heidi Schwarzenbach, Malte Vetterlein, Jessica Rührup, Oliver Engel, Roland Dahlem, Margit Fisch, Klaus Pantel, Sabine Riehledorf, Hamburg, Germany

MP78-07 CLINICAL CHARACTERISTICS ASSOCIATED WITH EARLY PROGRESSION OR LONG-TERM RESPONSE FROM THE PHASE II IMVIGOR210 STUDY: ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

MP78-08 PROGNOSTIC UTILITY OF PD-L1 IN SQUAMOUS CELL CARCINOMA OF THE BLADDER
Michael Owyong*, Orange, CA, Yair Lotan, Payal Kapur, Vandana Panwar, Dallas, TX, Thomas K. Lee, Xiaolin Zi, Jeremy W. Martin, Orange, CA, Ahmed Mosbah, Hassan Abol-Enein, Mohamed Ghoneim, Mansoura, Egypt, Ramy F. Youssef, Orange, CA

MP78-09 PREDICTIVE AND PROGNOSTIC ROLE OF PD-L1 IN UROTHELIAL CARCINOMA PATIENTS WITH ANTI-PD-1/PD-L1 THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS
Kun Tang, Kehua Jiang*, Hui Zhou, Haoran Liu, Zhangqun Ye, Hua Xu, Wuhan, China, People's Republic of

MP78-10 INACCURACY OF CLINICAL STAGING AFTER NEOADJUVANT CHEMOTHERAPY FOR MUSCLE INVASIVE BLADDER CANCER
Alexa Meyer*, Aaron Brant, Paige Nichols, Max Kates, Baltimore, MD, Adam Reese, Philadelphia, PA, Noah Hahn, Baltimore, MD, Mark Schoenberg, Bronx, NY, Trinity Bivalacqua, Baltimore, MD

MP78-11 ONCOLOGICAL OUTCOMES WITH NEOADJUVANT CHEMOTHERAPY AND CYSTECTOMY FOR MALE PATIENTS WITH CT4A UROTHELIAL BLADDER CANCER
Jian Chen*, Gus Miranda, Jie Cai, Siamak Daneshmand, Hooman Djalalat, Los Angeles, CA

MP78-12 DOES NEOADJUVANT CHEMOTHERAPY WITH GEMCITABINE AND CISPLATIN IN BLADDER CANCER INCREASE THE COMPLICATIONS AT RADICAL CYSTECTOMY IN HIGH AGE PATIENTS?
Keishi Fukumoto*, Eiji Kikuchi, Tokyo, Japan, Suguru Shirotake, Saitama, Japan, Kyohi Hakozaki, Tokyo, Japan, Yasumasu Miyazaki, Kanagawa, Japan, Takahiro Maeda, Tokyo, Japan, Gou Kaneko, Kanagawa, Japan, Shunsuke Yoshimine, Saitama, Japan, Nobuhiro Tanaka, Tokyo, Japan, Kunimitsu Kanai, Masafumi Oyama, Saitama, Japan, Yosuke Nakajima, Kanagawa, Japan, Tetsuo Momma, Saitama, Japan, Mototsugu Oya, Tokyo, Japan

MP78-13 OUTCOME OF MAINTENANCE SYSTEMIC CHEMOTHERAPY WITH DRUG-FREE INTERVAL FOR METASTATIC UROTHELIAL CARCINOMA
Takashige Abe*, Junji Ishizaki, Keita Minami, Toru Harabayashi, Aitaru Sawada, Tango Mochizuki, Satoshi Chiba, Hiroki Chiba, Tomoshige Akino, Masashi Murakumo, Naoto Miyajima, Kunihiko Tsuchiya, Hiroshi Kikuchi, Haruka Miyata, Ryuji Matsumoto, Takahiro Osawa, Satoru Maruyama, Sachio Murai, Nobuo Shinohara, Sapporo, Japan

MP78-14 POTENTIAL PREDICTORS FOR THE UNDER-REPORTING BETWEEN PATIENT-REPORTED AND DOCTOR-REPORTED OUTCOMES IN ADVANCED UROTHELIAL CARCINOMA
Itsuto Hamano*, Shingo Hatakeyama, Tepppei Matsumoto, Osamu Soma, Ayumu Kusaka, Shogo Hosogoe, Yuki Tobisawa, Tohru Yoneyama, Hayato Yamamoto, Atsushi Imai, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Kole, Chikara Ohyama, Aomori, Japan

MP78-15 CAN UROLOGISTS INTRODUCE THE CONCEPT OF “OLIGOMETASTASIS” FOR METASTATIC BLADDER CANCER AFTER RADICAL CYSTECTOMY?
Koichiro Ogihara*, Eiji Kikuchi, Tokyo, Japan, Keitaro Watanabe, Tochigi, Japan, Ryohi Kufukihara, Yoshinori Yanai, Kimiharu Takamatsu, Saitama, Japan, Kazuhiro Matsumoto, Tokyo, Japan, Satoshi Hara, Kanagawa, Japan, Masafumi Oyama, Tetsuo Monma, Takeshi Masuda, Saitama, Japan, Shintaro Hasegawa, Tochigi, Japan, Mototsugu Oya, Tokyo, Japan

MP78-16 PROGNOSTIC SIGNIFICANCE OF LYMPH NODE YIELD AT RADICAL CYSTECTOMY AFTER NEOADJUVANT CHEMOTHERAPY FOR MUSCLE-INVASIVE BLADDER CANCER
Raju Chelluri*, Lilei Xia, Philadelphia, PA, Benjamin Taylor, New York, NY, Thomas Guzzo, Philadelphia, PA
MP78-17 LONG-TERM ONCOLOGICAL OUTCOMES AFTER TRIMODALITY THERAPY AND RADICAL CYSTECTOMY WITH OR WITHOUT NEOADJUVANT CHEMOTHERAPY FOR MUSCLE-INVASIVE BLADDER CANCER
Omar Fahmy*, Mohd Khairul-Asri, Serdang, Malaysia, Tina Schubert, Wuerzburg, Germany, Arnulf Stenzl, Fahmy Hassan, Markus Renninger, Tuebingen, Germany, Hubert Kübler, Georgios Gakis, Wuerzburg, Germany

MP78-18 BLADDER PRESERVATION THERAPY FOR THE TREATMENT OF MUSCLE INVASIVE BLADDER CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS
Teruo Inamoto*, Naokazu Ibuki, Kazumasa Komura, Koichiro Minami, Tomoaki Takai, Taizo Uchimoto, Kenkichi Saito, Naoki Tanda, Takuya Tsujino, Tomohisa Matsuanga, Yuki Yoshikawa, Hajime Hirano, Hayahito Nom, Hiroshi Juri, Kiyohiro Yamamoto, Kazuhiro Yamamoto, Yoshifumi Narumi, Haruhito Azuma, Takatsuki, Japan

MP78-19 CIGARETTE SMOKING IS ADVERSELY ASSOCIATED WITH PATHOLOGICAL RESPONSE TO PLATINUM-BASED NEOADJUVANT CHEMOTHERAPY IN PATIENTS UNDERGOING TREATMENT FOR URINARY BLADDER CANCER - A PROSPECTIVE EUROPEAN MULTICENTER STUDY OF THE EAU YOUNG ACADEMIC UROLOGISTS (YA)
Philipp Gild, Malte W. Vetterlein, Hamburg, Germany, Paolo Gontero, Torino, Italy, Florian Roghmann, Herne, Germany, Marcus Cumberbatch, Sheffield, United Kingdom, Jakub Dobruch, Warsaw, Poland, Laura Mertens, Amsterdam, Netherlands, Andrea Necchi, Milano, Italy, Thomas Seisen, Julian Anract, Paris, France, Armin Pycha, Bolzano, Italy, Karim Saba, Cedric Poyet, Zurich, Switzerland, Aidan P. Noon, Sheffield, United Kingdom, Bas C. van Rhijn, Amsterdam, Netherlands, Morgan Roupret, Paris, France, Roland Seiler, Berne, Switzerland, Shahrokh F. Shariat, Vienna, Austria, Evangelos Xylinas, Paris, France, Michael Rink*, Hamburg, Germany

MP78-20 THE MODIFIED GLASGOW PROGNOSTIC SCORE IS A POWERFUL PROGNOSTIC FACTOR IN METASTATIC UROTHELIAL CARCINOMA PATIENTS RECEIVING SECOND-LINE CHEMOTHERAPY
Ryujir Matsumoto*, Takashige Abe, Junji Ishizaki, Keita Minami, Toru Harabayashi, Ataru Sazawa, Tango Mochizuki, Tomoshige Akino, Masashi Murakumo, Naoto Miyajima, Kunihiko Tsuchiya, Hiroshi Kikuchi, Haruka Miyata, Takahiro Osawa, Satoru Manuyama, Sachio Murai, Nobuo Shinohara, Sapporo, Japan

APPORROFED FOR AMA PRA CATEGORY 1 CREDIT™

Monday, May 21, 2018
Podium Session 53
7:00 am - 9:00 am

STONE DISEASE: SURGICAL THERAPY V
Room 2024 @ MCC West
Moderators: Jorge Gutierrez-Aceves, Kelly Healy and Thomas Knoll

<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>TIME NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD53-01</td>
<td>7:00</td>
<td>REDUCING OPERATIVE COMPLICATIONS FROM KIDNEY STONES (ROCKS): UNDERSTANDING EMERGENCY DEPARTMENT VISITS AFTER URETEROSCOPY IN A STATEWIDE COLLABORATIVE</td>
</tr>
<tr>
<td>PD53-02</td>
<td>7:10</td>
<td>COST-EFFECTIVENESS OF DUSTING VS. BASKETING INTRARENAL STONES: A STUDY FROM THE EDGE CONSORTIUM</td>
</tr>
</tbody>
</table>

*Presenting author

265
7:20  PD53-03  COST ANALYSIS OF UTILIZATION OF DISPOSABLE FLEXIBLE URETEROSCOPES IN HIGH RISK FOR BREAKAGE CASES
Wilson Molina, Jason Warncke*, Rodrigo Donaldisio da Silva, Diedra Gustafson, Leticia Nogueira, Fernando Kim, Denver, CO

7:30  PD53-04  DOUBLE-BLIND PROSPECTIVE RANDOMIZED CLINICAL TRIAL COMPARING REGULAR AND MOSES MODES OF HOLMIUM LASER LITHOTRIPSY: PRELIMINARY RESULTS
Ahmed Ibrahim*, Nader Fahmy, Serge Carrier, Mostafa Elhilali, Sero Andonian, Montreal, Canada

7:40  PD53-05  THE MOSES HOLMIUM SYSTEM – TIME IS MONEY
Karen Stern*, Manoj Monga, Cleveland, OH

7:50  PD53-06  OPTIMAL COMBINATION OF FLEXIBLE URETERO-RENOscopes (FUR) AND URETERAL ACCESS SHEATH (UAS) SIZE FOR SAFEST INTRA-RENAL PRESSURE (IRP) AT DIFFERENT INFLOW RATES DURING RETROGRADE INTRA-RENAL SURGERY (RIRS)
Remzi Saglam, Ahmet Sinan Kabakci, Zafer Tokatli, ANKARA, Turkey, Kemal Sarica, Orhan Tannirverdi, Abdullah Armağan, Abdulkadir Tepeler, Ramazan Altintaş, Istanbul, Turkey, Jan Klein, Ulm, Germany, Anup Patel*, London, United Kingdom

8:00  PD53-07  THE FEASIBILITY OF DISCHARGING PATIENTS WITHOUT OPIOIDS AFTER URETEROSCOPY
David Sobel*, Theodore Cisu, Andrew Pham, Gillian Stearns, Kevan Sternberg, Burlington, VT


8:20  PD53-09  REDUCING FLUOROSCOPY TIME IN PERCUTANEOUS NEPHROLITHOTOMY
Michael Sourial*, Andrew Todd, Bodo Knudsen, Columbus, OH

8:30  PD53-10  USE OF THE QSOFA SCORE FOR PREDICTION OF ICU ADMISSION DUE TO SEPSIS AFTER PERCUTANEOUS NEPHROLITHOTOMY: A STUDY FROM THE EDGE CONSORTIUM
Alan Yaghoubian*, Timothy Batter, Sarah Mozafarpour, Boston, MA, Ben Chew, Vancouver, Canada, Manoj Monga, Cleveland, OH, Amy Krambeck, Indianapolis, IN, Roger Sur, San Diego, CA, Bodo Knudsen, Columbus, OH, Dianne Sacco, Boston, MA, Karen Stern, Cleveland, OH, Smita De, Nicole Miller, Nashville, TN, Tarek Kroudian, Michael Sourial, Jusin Rose, Columbus, OH, Tim Large, Indianapolis, IN, Kymora Scotland, Colin Lundeen, Dirk Lange, Vancouver, Canada, Seth Bechis, San Diego, CA, Brian Eisner, Boston, MA

8:40  PD53-11  CAN INCREASED DOSE OF SOLIFENACIN BE AN ANSWER FOR STENT RELATED SYMPTOMS?
Maniyur Raghavendran*, Kiran G. Kumar, Keyur Patel, Shashank Saraf, Mysore, India

8:50  PD53-12  CYSTINURIC STONE CONVERSION AND ASSOCIATIONS WITH MEDICAL AND SURGICAL INTERVENTIONS
Lael Reinstatler*, Lebanon, NH, Karen Stern, Cleveland, OH, Hunt Batter, Boston, MA, Marcelino Rivera, Indianapolis, IN, Kymora Scotland, Gholamreza Safaee Ardekani, Ben Chew, British Columbia, Canada, Brian Eisner, Boston, MA, Amy Krambeck, Indianapolis, IN, Manoj Monga, Cleveland, OH, Vernon Pais, Lebanon, NH

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
Podium Session 54

SEXUAL FUNCTION/DYSFUNCTION: FEMALE

Room 2022 @ MCC West

Moderators: Irwin Goldstein, Tami Rowen

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00</td>
<td>PD54-01</td>
<td>SAFETY OF FLIBANSERIN IN WOMEN WITH HYPOACTIVE SEXUAL DESIRE DISORDER TAKING ANTI DEPRESSANT MEDICATIONS</td>
</tr>
<tr>
<td>7:10</td>
<td>PD54-02</td>
<td>LOW RATES OF INSOMNIA ASSOCIATED WITH FLIBANSERIN IN PREMENOPAUSAL WOMEN WITH HYPOACTIVE SEXUAL DESIRE DISORDER</td>
</tr>
<tr>
<td>7:20</td>
<td>PD54-03</td>
<td>ONABOTULINUMTOXINA DETRUSOR INJECTION IMPROVES FEMALE SEXUAL FUNCTION IN WOMEN WITH IDIOPATHIC WET OVERACTIVE BLADDER SYNDROME</td>
</tr>
<tr>
<td>7:30</td>
<td>PD54-04</td>
<td>USE OF OSPEMIFENE IS ASSOCIATED WITH IMPROVEMENTS TO THE VULVA, VESTIBULE, AND VAGINA IN WOMEN WITH GENITOURINARY SYNDROME OF MENOPAUSE (GSM): A PROSPECTIVE VULVOSCOPIC ANALYSIS</td>
</tr>
<tr>
<td>7:40</td>
<td>PD54-05</td>
<td>IMPACT OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM TREATMENT OF MEN WITH PEYRONIE'S DISEASE ON IMPROVEMENT OF FEMALE PARTNER SEXUAL FUNCTION</td>
</tr>
<tr>
<td>7:50</td>
<td>PD54-06</td>
<td>CADAVERIC EVIDENCE THAT MIDURETHRAL SLING PLACEMENT INTERRUPTS PERIURETHRAL NEUROVASCULAR AND GLANDULAR STRUCTURES: POTENTIAL ROLE IN FEMALE SEXUAL DYSFUNCTION</td>
</tr>
<tr>
<td>8:00</td>
<td>PD54-07</td>
<td>VULVAR LICHEN SCLEROSUS IN MULTIDISCIPLINARY CLINICS: TREATMENT COMPLIANCE AND SEXUAL FUNCTION</td>
</tr>
<tr>
<td>8:10</td>
<td>PD54-08</td>
<td>VALIDATION OF THE VSQ TO ASSESS SEXUAL FUNCTION IN WOMEN WITH VULVAR LICHEN SCLEROSUS AND LICHEN PLANUS</td>
</tr>
<tr>
<td>8:20</td>
<td>PD54-09</td>
<td>PELVIC DISCOMFORT AND FEMALE SEXUAL DYSFUNCTION IN ADULT BICYCLISTS</td>
</tr>
<tr>
<td>8:30</td>
<td>PD54-10</td>
<td>SEXUAL DYSFUNCTION IN BREAST CANCER SURVIVORS</td>
</tr>
<tr>
<td>8:40</td>
<td>PD54-11</td>
<td>OFFICE-BASED NEURO-GENITAL TESTING TO ASSESS SOMATIC/AUTONOMIC NERVE INTEGRITY IN WOMEN WITH SUSPECTED NEUROGENIC SEXUAL DYSFUNCTION FROM CAUDA EQUINA-BASED SACRAL AND LUMBAR PATHOLOGIES</td>
</tr>
</tbody>
</table>

*Presenting author
CURING PATIENTS WITH NEUROGENIC SEXUAL DYSFUNCTION THROUGH A NOVEL COLLABORATIVE PROTOCOL INCORPORATING MINIMALLY-INVASIVE SPINAL SURGERY: LARGEST KNOWN RETROSPECTIVE SERIES
Eric Biewenga*, Sue Goldstein, Vera Trofimenko, San Diego, CA, Barry Komisaruk, Newark, NJ, Jennifer Hanley, Choll Kim, Irwin Goldstein, San Diego, CA

Podium Session 55
BLADDER & URETHRA: ANATOMY, PHYSIOLOGY & PHARMACOLOGY II
Room 2011 @ MCC West
Moderators: Nisrine Nakib, Michael Ruggieri and Lori Birder

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00</td>
<td>PD55-01</td>
<td>THE UROTHELIAL NEUROTROPHIN AND THEIR RECEPTORS EXPRESSION IN PATIENTS OF INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME WITH DIFFERENT CLINICAL PHENOTYPES AND SYMPTOM SEVERITY Jia-Fong Jhang*, Han-Chen Ho, Yuan-Hong Jiang, Yung-Hsiang Hsu, Hann-Chomg Kuo, Hualien, Taiwan</td>
</tr>
<tr>
<td>7:10</td>
<td>PD55-02</td>
<td>ALTERED TOLL-LIKE RECEPTOR 4 ACTIVATION PLAYS A CRITICAL ROLE IN CYSTITIS PAIN: A MAPP RESEARCH NETWORK ANIMAL MODEL STUDY Xiangrong Cui, Xuan Jing, Susan Lutgendorf, Catherine Bradley, Bradley Erickson, Vincent Magnotta, Iowa City, IA, Andrew Schrepf, Ann Arbor, MI, Karl Kreder, Michael O'Donnell, Yi Luo*, Iowa City, IA</td>
</tr>
<tr>
<td>7:20</td>
<td>PD55-03</td>
<td>PARA ACTIVATION AS A PERSISTENT MODEL OF BLADDER PAIN: ROLE OF MIF AND HMGB1 Fei Ma*, David Hunt, Lexington, KY, Lin Leng, Richard Bucala, New Haven, CT, Katherine Meyer-Siegler, St. Petersburg, FL, Pedro Vera, Lexington, KY</td>
</tr>
<tr>
<td>7:30</td>
<td>PD55-04</td>
<td>TIBIAL AND PUDENDAL NEUROMODULATION OF SPINAL NEURON ACTIVITY INDUCED BY BLADDER DISTENTION Todd Yecies*, Shun Li, Yan Zhang, Daniel Cai, Bing Wang, James Roppolo, William De Groat, Changfeng Tai, Pittsburgh, PA</td>
</tr>
<tr>
<td>7:40</td>
<td>PD55-05</td>
<td>THERAPEUTIC EFFECTS OF P38 MAP KINASE INHIBITOR ON BLADDER DYSFUNCTION IN MICE WITH SPINAL CORD INJURY (SCI) Nobutaka Shimizu*, Osaka-Sayama, Japan, Takahisa Suzuki, El-Ichiro Takaoka, Joombeom Kwon, Naoki Wada, Takahiro Shimizu, Pittsburgh, PA, Akihide Hirayama, Ikoma, Japan, Hirotugu Uemura, Osaka-Sayama, Japan, Anthony J. Kanai, William C. de Groat, Naoki Yoshimura, Pittsburgh, PA</td>
</tr>
<tr>
<td>7:50</td>
<td>PD55-06</td>
<td>MYOGENIC MECHANISMS OF DETERUSOR OVERACTIVITY IN SPINAL CORD INJURY Haeyeong Lee*, Byoung Koh, Robert Corrigan, Lauren Okane, Kenton Sanders, Sang Don Koh, Reno, NV</td>
</tr>
<tr>
<td>8:00</td>
<td>PD55-07</td>
<td>MAPPING AND NEUROMODULATION OF LOWER URINARY TRACT FUNCTION USING SPINAL CORD STIMULATION AFTER PELVIC NERVE CRUSH INJURY IN FEMALE RATS Huiyi Harriet Chang*, Irvine, CA, Jih-Chao Yeh, Los Angeles, CA, Ronald M. Ichiyama, Leeds, United Kingdom, Larissa Rodriguez, Leif Havton, Los Angeles, CA</td>
</tr>
<tr>
<td>8:10</td>
<td>PD55-08</td>
<td>CHARACTERIZATION OF RELAXIN RECEPTOR EXPRESSION IN HUMAN BLADDER SMOOTH MUSCLE CELLS AND EVALUATION OF ITS EFFECT ON TISSUE REMODELING AND FIBROSIS Edward Diaz*, Mason Briggs, Yan Wen, Amy Dobberfuhr, Bertha Chen, PALO ALTO, CA</td>
</tr>
<tr>
<td>8:20</td>
<td>PD55-09</td>
<td>A NOVEL IN VITRO MODEL OF HUMAN UROTHELium WITH BARRIER FUNCTION DIFFERENTIATED FROM URINE-DERIVED STEM CELLS Qian Wan, Guihua Liu, Anthony Atala, Yuanyuan Zhang*, Winston-Salem, NC</td>
</tr>
<tr>
<td>8:30</td>
<td>PD55-10</td>
<td>MACROSCOPIC WHOLE-MOUNTS CHARACTERIZING SEXUAL DIFFERENTIATION OF THE HUMAN Fetal UROGENITAL TRACT Joel Shen*, Dylan S. Isaacson, Mei Cao, Adriane W. Sinclair, Gerald R. Cunha, Laurence S. Baskin, San Francisco, CA</td>
</tr>
<tr>
<td>8:40</td>
<td>PD55-11</td>
<td>IDENTIFYING THE FUNCTIONAL SUBTYPES OF NADPH OXIDASES (NOX) FROM THE UROTHELium: IMPLICATION FOR ROS- CONTROLLING TARGETS Max Roberts, Josephine Amosah, Guildford, United Kingdom, Guiqing Sui, London, United Kingdom, Rui Wu, Coventry, United Kingdom, Simon Archer, Guildford, United Kingdom, Michael Ruggieri, Philadelphia, PA, Changhao Wu*, Guildford, United Kingdom</td>
</tr>
</tbody>
</table>
**Podium Session 56**

**PROSTATE CANCER: MARKERS II**

Room 3024 @ MCC West

**Moderators:** Christopher Evans, Peter Albertsen and Todd Morgan

<table>
<thead>
<tr>
<th>Time</th>
<th>Number</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00</td>
<td>PD56-01</td>
<td>COMPARATIVE GENOMIC ANALYSIS OF 1,043 AFRICAN AMERICAN AND NON-AFRICAN AMERICAN PROSTATE CANCERS: A REPORT FROM THE DECIPHER GRID COLLABORATIVE</td>
</tr>
<tr>
<td>7:10</td>
<td>PD56-02</td>
<td>A NOVEL RISK SCORE (P-SCORE) BASED ON A 3-GENE SIGNATURE FOR ESTIMATING RISK OF PROSTATE CANCER SPECIFIC MORTALITY</td>
</tr>
<tr>
<td>7:20</td>
<td>PD56-03</td>
<td>DETECTION OF PRIVATE CLONAL MUTATIONS IN LOCALISED PROSTATE CANCER FROM RARE MOLECULES OF CIRCULATING TUMOUR DNA</td>
</tr>
<tr>
<td>7:30</td>
<td>PD56-04</td>
<td>VALIDATION OF THE DECIPHER BIOPSY TEST TO PREDICT ADVERSE PATHOLOGY IN MEN DIAGNOSED WITH LOW AND FAVORABLE INTERMEDIATE RISK PROSTATE CANCER</td>
</tr>
<tr>
<td>7:40</td>
<td>PD56-05</td>
<td>A GERM-LINE GENETIC TEST FOR PROSTATE CANCER RISK (PGS-33) TOGETHER WITH A FAMILY HISTORY ARE ASSOCIATED WITH LETHAL PROSTATE CANCER</td>
</tr>
<tr>
<td>7:50</td>
<td>PD56-06</td>
<td>ARE GLEASON SCORE AND METASTATIC DISEASE STATUS IMPORTANT FOR MEN WITH PROSTATE CANCER UNDERGOING MULTIGENE PANEL TESTING?</td>
</tr>
<tr>
<td>8:00</td>
<td>PD56-07</td>
<td>COMPARISON WITH DIAGNOSTIC PERFORMANCE BETWEEN ABERRANT GLYCOSYLATED S2,3PSA TEST AND CONVENTIONAL PSA TESTS</td>
</tr>
</tbody>
</table>

*Presenting author*
8:10 PD56-08 MOLECULAR CLASSIFIER TESTING FOR NEWLY DIAGNOSED LOCALIZED PROSTATE CANCER IN THE STATE OF MICHIGAN
Jonathan Hu*, Rochester, MI, Daniel Spratt, Ann Arbor, MI, Jeffrey Tosoi, Baltimore, MD, Ji Qi, Deborah Kaye, Anna Johnson, Susan Linsell, James Montie, Khurshid Ghan, David Miller, Ann Arbor, MI, Kirk Wojno, Royal Oak, MI, Frank Burks, Rochester, MI, Todd Morgan, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI

8:20 PD56-09 CAN FREE PSA BE USED AS A BIOMARKER IN BIOCHEMICAL RECURRENCE AFTER SURGERY TO PREDICT CASTRATE RESISTANT PROSTATE CANCER?

8:30 PD56-10 ELEVATED KI-67 (MIB-1) EXPRESSION AS AN INDEPENDENT PREDICTOR FOR UNFAVORABLE PATHOLOGIC OUTCOMES AND BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY IN PATIENTS WITH LOCALIZED PROSTATE CANCER
Tae Jin Kim*, Jong Jin Oh, Sangchul Lee, Sung Kyu Hong, Sang Eun Lee, Seok-Soo Byun, Hakmin Lee, Seongnam-si, Korea, Republic of

8:40 PD56-11 ANALYSIS OF METHYLATED DNA MARKERS FOR PREDICTION OF CANCER PROGRESSION AFTER RADICAL PROSTATECTOMY
Matthew Gettman*, Ilya Sobol, Brian Dukek, William Taylor, Douglas Mahoney, Tracy Yab, Calise Berger, John Cheville, Jeffrey Karnes, David Ahlquist, Rochester, MN

8:50 PD56-12 COMPARISON OF A LOW-COST IMMUNOHISTOCHEMISTRY MARKER PANEL WITH A CELL-CYCLE PROGRESSION ASSAY FOR THE PREDICTION OF OUTCOME AFTER RADICAL PROSTATECTOMY
Michael Leapman*, NEW Haven, CT, Hao Nguyen, Janet Cowan, Lingru Xue, Bradley Stohr, Jeffry Simko, Matthew Cooperberg, Peter Carroll, San Francisco, CA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Monday, May 21, 2018 7:00 am - 9:00 am
Podium Session 57
KIDNEY CANCER: ADVANCED (INCLUDING DRUG THERAPY) III
Room 3018 @ MCC West
Moderators: Robert Uzzo, Christopher Wood and Norio Nonomura

ABSTRACT ABSTRACT
TIME NUMBER TITLE TIME NUMBER TITLE
7:00 PD57-01 WHOLE-TRANSCRIPTOME SEQUENCING IDENTIFIED GENE EXPRESSION SIGNATURES ASSOCIATED WITH AGGRESSIVE CLEAR CELL RENAL CELL CARCINOMA
Ken Batai*, Elliot Imler, Michael Phung, Robert Bell, Aye Lwin, Elinora Price, Tijana Milinic, Erika Bracamonte, Bruce Seligmann, Benjamin Lee, Tucson, AZ

7:10 PD57-02 CREATION OF A TISSUE EXPRESSION BIOMARKER-AUGMENTED PROGNOSTIC MODEL FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA

7:20 PD57-03 INFLUENCE OF POLYMORPHISM IN VASCULAR ENDOTHELIAL-RELATED GENES ON CLINICAL RESPONSE TO AXITINIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
Kazuyuki Numakura*, Ryoma Igarashi, Taketoshi Nara, Sohei Kanda, Hiroshi Tsuruta, Mitsuru Saito, Shintaro Naita, Takamitsu Inoue, Shigeru Satoh, Takenori Nioka, Masatomo Miura, Tomonori Habuchi, Akita, Japan

7:30 PD57-04 EXPLORATION OF SERUM BIOMARKERS TO PREDICT AXITINIB EFFICACY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
Naoko Honma*, Akita, Japan, Norihiko Tsuchiya, Yamagata, Japan, Takeyi Tsutsumi Inoue, Taketoshi Nara, Sohei Kanda, Kazuyuki Numakura, Hiroshi Tsuruta, Mitsuru Saito, Shintaro Naita, Shigeru Satoh, Tomonori Habuchi, Akita, Japan
7:40 PD57-05 SIMULTANEOUS CARDIAC AND RENAL SURGERY FOR RENAL AND RETROPERITONEAL TUMOURS INVADING THE RIGHT ATRIUM & PERIDIAPHRAGMATIC INFERIOR VENA CAVA: ONCOLOGICAL OUTCOME & LONG-TERM SURVIVAL
Hannah Warren*, Archana Fernando, Conal Austin, Kay Thomas, Simon Chowdhury, Tim O'Brien, London, United Kingdom

7:50 PD57-06 ALTERED IMMUNE CELL REPERTOIRE AND ACTIVITY AFTER CHECKPOINT BLOCKADE IMMUNOTHERAPY WITH NIVOLUMAB IN RENAL CELL CARCINOMA
Annabel Spek*, Munich, Germany, Chiara Massa, Daniel Bethmann, Juergen Bukur, Anja Mueller, Claudia Wickenhauser, Halle/Saale, Germany, Bernard Fox, Portland, OR, Barbara Seliger, Halle/Saale, Germany, Michael Staecker, Munich, Germany

8:00 PD57-07 RAPID PATIENT DERIVED XENOGRAFTS THAT CONSIDER TUMOR HETEROGENEITY FOR PREDICTION OF CANCER IMMUNOTHERAPY RESPONSES IN METASTATIC RENAL CELL CARCINOMA
Matthew Lowerison*, Mario Cepeda, Cindy Liu, Yaroslav Fedyslyn, Vidhu Joshi, Paras Shah, John Cheville, Bradley Leibovich, Stephen Boorjian, Haidong Dong, Hon Leong, Rochester, MN

8:10 PD57-08 TUMORAL CD8+ T CELLS CORRELATE WITH FAVORABLE OUTCOME IN METASTATIC RENAL CELL CARCINOMA TREATED WITH TYROSINE KINASE INHIBITORS
Jiajun Wang*, Li Liu, Wei Xi, Jiejie Xu, Jianming Guo, Shanghai, China, People’s Republic of

8:20 PD57-09 SYSTEMATIC REVIEW AND META-ANALYSIS OF ADJUVANT THERAPY AFTER NEPHRECTOMY FOR HIGH-RISK, NON-METASTATIC RENAL CELL CARCINOMA
Marco Bandini, Umberto Capitanio, Milan, Italy, Ariane Smith*, Sebastiano Nazari, Michele Marchioni, Montreal, Canada, Felix Preisser, Hamburg, Germany, Elio Mazzone, Milan, Italy, Helen Bondarekko, Montreal, Canada, Carlo Bravi, Milan, Italy, Zhe Tian, Montreal, Canada, Francesco Montorsi, Milan, Italy, Shahrokh Shariat, Vienna, Austria, Anil Kapoor, Hamilton, Canada, Alberto Briganti, Milan, Italy, Pierre Karakiewicz, Montreal, Canada

8:30 PD57-10 PD-L1 EXPRESSION IS ASSOCIATED WITH TUMOR PROGRESSION AND POOR PROGNOSIS IN XP11.2 TRANSLOCATION RENAL CELL CARCINOMA
Yuan-Yuan Qu*, Kun Chang, Wen-Jun Xiao, Hai-Liang Zhang, Ding-Wei Ye, Shanghai, China, People’s Republic of

8:40 PD57-11 IMPACT OF CYTOREDUCTIVE NEPHRECTOMY IN RENAL CELL CARCINOMA WITH METASTASIS TO THE BRAIN
Zain Hyder*, Michael Callegari, Daniel Parker, Michael Cookson, Brian Cross, Sanjay Patel, Oklahoma City, OK

8:50 PD57-12 THE PROGNOSTIC VALUE OF PROGRAMMED DEATH-LIGAND 1 IN A CHINESE COHORT WITH CLEAR CELL RENAL CELL CARCINOMA
Yuan-Yuan Qu*, Wen-Jun Xiao, Hai-Liang Zhang, Ding-Wei Ye, Shanghai, China, People’s Republic of

Monday, May 21, 2018 Video Session 10
7:00 am - 9:00 am

FEMALE PELVIC MEDICINE

The videos in this session as well as the video libraries from the 2011-2016 Annual Meetings may be viewed in the Surgical Video Library and purchased in the AUA Store during the Annual Meeting. Both are located in Hall A. AUA members receive free online access to the Surgical Video Library throughout the year through AUA University. Visit www.AUAnet.org/University to access.

Room 3002 @ MCC West

Moderators: Jennifer Anger, Maude Carmel and Oscar Martinez

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>V10-01</td>
<td>NOVEL VAGINOPLASTY TECHNIQUE: INVERSION OF PENILE SKIN AND USE OF SACROTAL GRAFT WITHOUT SACROSPINAL FIXATION</td>
</tr>
<tr>
<td>V10-02</td>
<td>ROBOT-ASSISTED VESICOVAGINAL FISTULA REPAIR WITH RECTUS ABDOMINALS FLAP: DESCRIPTION OF THE TECHNIQUE</td>
</tr>
<tr>
<td>V10-03</td>
<td>GENDER-AFFIRMING VAGINECTOMY AND COLPOCLEISIS</td>
</tr>
</tbody>
</table>

*Presenting author
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenters</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>V10-04</td>
<td>THE NOVEL HYBRID TECHNIQUE OF PELVIC ORGAN PROLAPSE TREATMENT</td>
<td>Dmitry Shkarupa*, Nikita Kubin, Ekaterina Shapovalova, Olga Staroseltseva,</td>
<td>Saint-Petersburg,</td>
</tr>
<tr>
<td></td>
<td>BASED ON APICAL SLING: 2 YEARS' FOLLOW-UP</td>
<td>Anastasia Zaytseva, Saint-Petersburg, Russian Federation</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>V10-05</td>
<td>TOTAL AUTOLOGOUS FASCIA LATA ROBOTIC SACROCOLPOPEXY: A NEW TECHNIQUE</td>
<td>Christian Twiss*, Frank Lin, Joel Funk, Tucson, AZ</td>
<td></td>
</tr>
<tr>
<td>V10-06</td>
<td>ROBOTIC-ASSISTED LAPAROSCOPIC SURGERY FOR BLADDER PERFORATION</td>
<td>Alan Quach*, Michael Avallone, Jason Warncke, Brian Flynn, Aurora, CO</td>
<td></td>
</tr>
<tr>
<td></td>
<td>DUE TO POLYPROPYLENE SACROCOLPOPEXY MESH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>V10-07</td>
<td>LAPAROSCOPIC APPROACH FOR VESICOUTERINE FISTULA: STEPPED TECHNIQUE</td>
<td>Patricio Garcia Marchihena*, Agustin Romeo, Matias Gonzalez, Juan Tejerizo,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gabriel Favre, Buenos Aires, Argentina</td>
<td></td>
</tr>
<tr>
<td>V10-08</td>
<td>ADJUSTABLE RETRO PUBLIC SLING FOR SURGICAL TREATMENT OF STRESS URBAN</td>
<td>Dmitry Shkarupa*, Nikita Kubin, Olga Staroseltseva, Ekaterina Shapovalova,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>URINARY INCONTINENCE IN COMPLICATED CASES</td>
<td>Anastasia Zaytseva, Saint-Petersburg, Russian Federation</td>
<td></td>
</tr>
<tr>
<td>V10-09</td>
<td>A NON-TRADITIONAL ROUTE TO THE VAGINAL HYSTERECTOMY: THE DOßERLEIN-KRÖNIG HYSTERECTOMY</td>
<td>Diane Thomas, MD*, Erin Dougher, DO, Barry Hallner, MD, New Orleans, LA</td>
<td></td>
</tr>
<tr>
<td>V10-10</td>
<td>A LIVE PORCINE MODEL FOR ROBOTIC SACROCOLPOPEXY TRAINING</td>
<td>Khushabu Kasabwala*, Ramy Goueli, Patrick Culligan, New York, NY</td>
<td></td>
</tr>
<tr>
<td>V10-11</td>
<td>SACRAL NEUROMODULATION LEAD REMOVAL; A NOVEL TECHNIQUE</td>
<td>Erin Dougher*, Ryan Krin, J. Christian Winters, New Orleans, LA</td>
<td></td>
</tr>
<tr>
<td>V10-12</td>
<td>VIDEO DEMONSTRATION OF LAPAROSCOPIC SUTURE HYSTERECTOMY FOR UTERINE PROLAPSE USING A BI-DIRECTIONAL BARBED SUTURE</td>
<td>Sandra Elmer*, Marcus Carey, Parkville, Australia</td>
<td></td>
</tr>
</tbody>
</table>

**Monday, May 21, 2018**

**7:30 am - 11:30 am**

**Forums**

**BASIC SCIENCES SYMPOSIUM: SESSION II: UNDERSTANDING MALE INFERTILITY**

Room 208 @ MCC South

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30</td>
<td>WELCOME AND SYMPOSIUM INTRODUCTION</td>
<td>Dolores Lamb, Aria Olumi, Peter Schlegel</td>
<td></td>
</tr>
<tr>
<td>7:40</td>
<td>SESSION II: UNDERSTANDING MALE INFERTILITY</td>
<td>Cigdem Tanrikut</td>
<td>Paula Cohen</td>
</tr>
<tr>
<td></td>
<td>PERSONALIZED MEDICINE: PROGRESS, CHALLENGES, AND PROMISE</td>
<td>Jennifer Posey</td>
<td>MALE INFERTILITY AND CONTRACEPTION</td>
</tr>
<tr>
<td>10:40</td>
<td>ETHICAL CHALLENGES OF HUMAN GERMLINE GENOME EDITING</td>
<td>François Baylis</td>
<td>Martin Matzuk</td>
</tr>
<tr>
<td></td>
<td>DNA FRAGMENTATION AND OXIDATIVE STRESS</td>
<td>John Aitken</td>
<td>TUMOR SUPPRESSORS IN THE PATERNAL AGE EFFECT</td>
</tr>
<tr>
<td>10:55</td>
<td>GENETIC DEFECTS IN NON-OBSTRUCTIVE AZOOSPERMIA</td>
<td>John Schimenti</td>
<td>Christi Walter</td>
</tr>
<tr>
<td>11:30</td>
<td>MEIOSIS DEFECTS IN MALE INFERTILITY</td>
<td></td>
<td>FINAL THOUGHTS &amp; ACKNOWLEDGEMENTS</td>
</tr>
<tr>
<td></td>
<td>MEIOSIS DEFECTS IN MALE INFERTILITY</td>
<td></td>
<td>Dolores Lamb, Aria Olumi, Peter Schlegel</td>
</tr>
<tr>
<td></td>
<td>MEIOSIS DEFECTS IN MALE INFERTILITY</td>
<td></td>
<td>POSTER SESSION</td>
</tr>
<tr>
<td></td>
<td>MALE INFERTILITY AND CONTRACEPTION</td>
<td></td>
<td>ADJOURN</td>
</tr>
<tr>
<td></td>
<td>TUMOR SUPPRESSORS IN THE PATERNAL AGE EFFECT</td>
<td></td>
<td>APPROVED FOR AMA PRA CATEGORY 1 CREDIT™</td>
</tr>
</tbody>
</table>

272
### AMERICAN SOCIETY FOR MEN’S HEALTH (ASMH)

**Room 3001 @ MCC West**

**Program Chairs:** Steven Kaplan, Bruce Kava

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 7:30   | **WELCOME**                                                                             
|        | Society President: Allen Seftel                                                         |
| 7:35   | **SESSION I: EMERGING THERAPIES FOR BPH**                                                   
|        | Moderator: Steven Kaplan                                                                |
|        | **AQUABLATION: WILL IT BE DURABLE OR A WASH OUT?**                                       
|        | Steven Kaplan                                                                           |
|        | **LONG-TERM DATA ON UROLIFT AND REZUM: DIFFERENCES?**                                     
|        | Claus Roehrborn                                                                         |
|        | **PROSTATIC ARTERIAL EMBOLIZATION? UROLOGIST FRIEND OR FOE?**                             
|        | Bruce Kava                                                                              |
|        | **ARE LASERS STILL VIABLE?**                                                             
|        | Alexis Te                                                                               |
| 8:50   | **DISCUSSION**                                                                          |
| 9:45   | **SESSION II: LGBTQ: IMPACT ON HEALTH CARE**                                             
|        | Moderator: Martin Miner                                                                  |
|        | **LGBTQ EPIDEMIOLOGIC FINDINGS AND HOW THESE MAY IMPACT A MEN’S HEALTH CENTER**           
|        | Maurice Garcia                                                                          |
|        | **HEALTH CARE NEEDS OF GAY, BISEXUAL AND QUEER MEN PRESENTING FOR MEN’S HEALTH: THE “GAP” IN CLINICAL CARE AND RESEARCH TODAY, AND WHAT HEALTHCARE PROVIDERS SHOULD KNOW** 
|        | Alan Shindel                                                                            |
|        | **CARE OF THE TRANSGENDER PATIENT: A UNIQUE INTERSECTION OF TRADITIONAL MEN’S HEALTH, LGBQ PATIENT CARE, AND WOMEN’S SEXUAL MEDICINE WHICH CAN ADVANCE THE FIELD OF UROLOGY** 
|        | Maurice Garcia                                                                          |
| 10:50  | **DISCUSSION**                                                                          |
| 10:00  | **BREAK**                                                                               |
| 10:00  | **SESSION III: IS OBESITY KILLING US? WHAT CAN WE DO?**                                  
|        | Moderator: Jason Jameson                                                                 |
|        | **THE NAKED FACTS AND FIGURES**                                                          
|        | Kevin McVary                                                                            |
|        | **CAN A LOW-INFLAMMATION DIET ALTER PROSTATE HEALTH?**                                   
|        | Mark Moyad                                                                              |
|        | **ED, DIABETES, AND CV RISK: UPDATE ON TREATMENT, RISK REDUCTION**                       
|        | Stephen Kopeck                                                                          |
|        | **CAN BPH AND PROSTATE CANCER BE PREVENTED?**                                           
|        | Ian Thompson                                                                            |
| 11:00  | **DISCUSSION**                                                                          |
| 11:00  | **SESSION IV: POTPOURRI OF MEN’S HEALTH ISSUES**                                        
|        | Moderator: Culley Carson                                                                 |
|        | **HPV INFECTION IN MEN: PREVALENCE AND VACCINATION COVERAGE**                           
|        | Philippe Spiess                                                                         |
|        | **WHY ARE MIDDLE-AGED CAUCASIAN MEN DYING EARLIER?**                                     
|        | Joel Heidelbaugh                                                                        |
|        | **THE AFFORDABLE CARE ACT: HOW IT HAS IMPACTED MEN’S HEALTH**                           
|        | Matthew Resnick                                                                         |
|        | **OPIOID ABUSE AND UROLOGY**                                                            
|        | Michael Leapman                                                                         |
| 11:00  | **ADJOURN**                                                                             |
|       | **APPROVED FOR AMA PRA CATEGORY 1 CREDIT™**                                              |

### UROLOGIC SOCIETY FOR TRANSPLANTATION & RENAL SURGERY (USTRS)

**Room 2001 @ MCC West**

**Presenting author**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 7:30   | **WELCOME REMARKS**                                                                            
|        | Society President: Anil Kapoor                                                               |
| 7:30   | **UPDATE ON SURGICAL TECHNIQUES IN TRANSPLANTATION AND RENAL SURGERY**                       
|        | Moderator: Evan Vapnek                                                                       |
|        | **MINIMALLY INVASIVE LAPAROSCOPIC DONOR NEPHRECTOMY TECHNIQUES, INCLUDING INSUFFLATION MANAGEMENT SYSTEMS** 
|        | James Porter                                                                               |
| 8:30   | **HEMOSTATIC TECHNIQUES IN ROBOTIC AND LAPAROSCOPIC RENAL SURGERY**                         
|        | Anil Kapoor                                                                                |
|        | **NEW INNOVATIONS IN TRANSPLANT SURGERY, INCLUDING WOUND CARE AND RENAL FUNCTIONAL IMPROVEMENTS** 
|        | Alp Sener                                                                                  |
|        | **IVC TUMOR THROMBUS HOUR**                                                                    
<p>|        | Moderator: Neal Rowe                                                                        |
|        | Speakers: Gaetano Ciancio, Darrel Drachenberg, Craig Rogers, Christopher Wood                |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speakers/Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30</td>
<td>FERTILITY AND HORMONE CHANGES IN THE MALE KIDNEY TRANSPLANT RECIPIENT</td>
<td>John Barry, Larry Lipshultz</td>
</tr>
<tr>
<td>10:30</td>
<td>NOVICK AWARD RESIDENT AND FELLOW ABSTRACT PRESENTATIONS</td>
<td>Moderator: Alp Sener, Speakers: Samir Bidnur, Katherine Cockerill, Lukas Hockman, Samarprit Rai, Kristin Schafer, John Stites</td>
</tr>
<tr>
<td>11:30</td>
<td>BUSINESS MEETING</td>
<td>APPROVED FOR AMA PRA CATEGORY 1 CREDIT™</td>
</tr>
</tbody>
</table>

### Monday, May 21, 2018

**AMERICAN BOARD OF UROLOGY TOWN HALL**

Room 214 @ MCC South

**Moderated Poster Session 79**

**URODYNAMICS/LOWER URINARY TRACT DYSFUNCTION/FEMALE PELVIC MEDICINE: NON-NEUROGENIC VOIDING DYSFUNCTION II**

Room 3004 @ MCC West

**Moderators:** Gary Lemack, Sara Lenherr and Vincent Tse

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
<th>Authors/Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP79-02</td>
<td>ARE COMPLETE THREE-DAY VOIDING DIARIES FEASIBLE? RESULTS FROM THE SYMPTOMS OF LOWER URINARY TRACT DYSFUNCTION RESEARCH NETWORK (LURN) OBSERVATIONAL COHORT</td>
<td>Anne P. Cameron MD*, Jonathan B. Wiseman MS, Ann Arbor, MI, Cindy L. Amundsen MD, Durham, NC, H. Henry Lai MD, St. Louis, MO, Megan S. Bradley MD, Durham, NC, Catherine S. Bradley MD, MCSE, Iowa City, IA, Ziya Kirkali MD, Bethesda, MD, John O.L. DeLancey MD, Victor P. Andreev PhD DSc, J. Quentin Clemens MD FACS MSci and the LURN Study Group, Ann Arbor, MI</td>
</tr>
<tr>
<td>MP79-03</td>
<td>RESULTS OF TRANSURETHRAL RESECTION OF THE PROSTATE IN MALES WITH DETRUSOR UNDERACTIVITY</td>
<td>Emanuele Rubilotta*, Matteo Balzarro, Nicolò Trabacchin, Antonio D'Amico, Irene Tamanini, Marco Sebben, Marco Pirozzi, Maria Angela Cerruto, Walter Artibani, Verona, Italy</td>
</tr>
<tr>
<td>MP79-04</td>
<td>A COMPARISON OF SCHAEFER, INTERNATIONAL CONTINENCE SOCIETY AND BLADDER CONTRACTILITY INDEX NOMOGRAMS IN THE DIAGNOSIS OF OBSTRUCTION AND DETRUSOR UNDERACTIVITY IN MEN WITH LOWER URINARY TRACT SYMPTOMS</td>
<td>Emanuele Rubilotta*, Matteo Balzarro, Silvia Bassi, Alberto Diminutto, Maria Angela Cerruto, Walter Artibani, Verona, Italy</td>
</tr>
<tr>
<td>MP79-05</td>
<td>ELEVATED POST-VOID RESIDUAL VOLUMES ARE NOT ASSOCIATED WITH SELF-REPORTED URINARY TRACT INFECTIONS: A REPORT FROM THE SYMPTOMS OF LOWER URINARY TRACT DYSFUNCTION RESEARCH NETWORK (LURN) OBSERVATIONAL COHORT STUDY</td>
<td>Andrew C. Peterson MD*, Durham, NC, Abigail R. Smith PhD, Ann Arbor, MI, Matthew O. Fraser PhD, Durham, NC, Claire C. Yang MD, Seattle, WA, John O.L. DeLancey MD, Brenda W. Gillespie PhD, Ann Arbor, MI, John L. Gore MD MS, Seattle, WA, Pooja Talaty MS MHA, Glenview, IL, Victor P. Andreev PhD DSc, Anca Stefan PhD, Ann Arbor, MI, Karl J. Kreder MD MBA, Iowa City, IA, Margaret G. Mueller MD, Chicago, IL, H. Henry Lai MD, St. Louis, MO, Bradley A. Erickson MD MS FACS, Iowa City, IA, Ziya Kirkali MD and the LURN Study Group, Bethesda, MD</td>
</tr>
</tbody>
</table>
MP79-06 SYMPTOM-BASED CLUSTERING OF MALE PARTICIPANTS IN THE SYMPTOMS OF LOWER URINARY TRACT DYSFUNCTION RESEARCH NETWORK (LURN) OBSERVATIONAL COHORT STUDY
Gang Liu PhD*, Victor P. Andreev PhD DSc, Margaret E. Helmuth MA, Ann Arbor, MI, Claire C. Yang MD, Seattle, WA, Abigail R. Smith PhD, Jonathan B. Wiseman MS, Robert M. Merion MD FACS, Ann Arbor, MI, H. Henry Lai MD, St. Louis, MO, Bradley A. Erickson MD MS FACS, Iowa City, IA, David Cella PhD, James W. Griffith PhD, Chicago, IL, John L. Gore MD MS, Seattle, WA, John O.L. DeLancey MD FACS, Ann Arbor, MI, Ziya Kirkali MD and the LURN Study Group, Bethesda, MD

MP79-07 NO INCREASED RISK OF CLEAN INTERMITTENT CATHETERIZATION WITH ONABOTULINUMTOXINA RETREATMENT: POOLED ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Gary Lemack*, Dallas, TX, Eric Rovner, Charleston, SC, Kurt McCammon, Norfolk, VA, Francisco Cruz, Porto, Portugal, Rizwan Hamid, London, United Kingdom, Sidney Radomski, Toronto, Canada, Amelia Orejudos, Tamer Aboushwareb, Irvine, CA, Jennifer Sobol, West Bloomfield, MI

MP79-08 SAFETY AND EFFICACY OF ONABOTULINUMTOXINA INJECTIONS IN OCTO AND NONAGENARIANS
Patricia M. Zahner MD*, Laura L. Giusto MD, Jessica C. Lloyd MD, Juan M. Guzman-Negron MD, Shree Agrawal BS, Courtenay K. Moore MD, Raymond R. Rackley MD, Sandip P. Vasavada MD, Howard B. Goldman MD, Cleveland, OH

MP79-09 SAFETY AND EFFICACY OF ONABOTULINUMTOXINA INJECTIONS IN THE SETTING OF SUPRAPUBIC CATHETERS
Laura L. Giusto MD, Patricia M. Zahner MD, Jessica C. Lloyd MD*, Juan M. Guzman-Negron MD, Shree Agrawal BS, Courtenay K. Moore MD, Raymond R. Rackley MD, Sandip P. Vasavada MD, Howard B. Goldman MD, Cleveland, OH

MP79-10 EFFECTS OF TRAINING AND MECHANICAL FORCE OF ULTRASOUND ON BLADDER FILLING: REPEATABILITY OF ORAL HYDRATION STUDIES IN HEALTHY ADULTS
Derek Sheen*, Anna S. Nagle, Hiren Kolli, Naomi N. Vinod, Hameeda Naimi, Naomi Vinod, Uzoma Anele, Richmond, VA, Stefan De Wachter, Wilrijk, Belgium, John E. Speich, Adam P. Klausner, Richmond, VA

MP79-11 REAL-TIME BLADDER SENSATION IN NORMAL VOLUNTEERS: INFLUENCE OF VISUAL AND AUDITORY CUES OF BLADDER VOLUME
Hiren Kolli*, Anna Nagle, Derek Sheen, Hameeda Naimi, Naomi Vinod, Uzoma Anele, Richmond, VA, Stefan De Wachter, Wilrijk, Belgium, John Speich, Adam Klausner, Richmond, VA

MP79-12 NOVEL PROLONGED ACTION FORMULATION ACETAMINOPHEN-IBUPROFEN COMBINATION THERAPY FOR TREATMENT OF NOCTURIA - A MULTI-CENTER, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, 4-ARM PHASE 2 TRIAL

MP79-13 NOCTURNAL ANTIDIURESIS AFTER ADMINISTRATION OF IMIDAFENACIN IS INDUCED BY CONCENTRATION OF URINE OSMOLALITY
Mamoru Hashimoto*, Nobutaka Shimizu, Tomoki Takahashi, Koichi Sugimoto, Takafumi Minami, Hirotsugu Uemura, Osakaya, Japan, Akihide Hirayama, Ikoma, Japan

MP79-14 NOCTURNAL POLYURIA AND NOCTURNAL BLOOD PRESSURE PATTERNS IN MALE PATIENTS WITH LOWER URINARY TRACT SYMPTOMS
Misato Takayama*, So Omori, Daiki Ikarashi, Tomohiko Matsuura, Yoichiro Kato, Mitsugu Kanehira, Ryo Takata, Jun Sugimura, Takaya Abe, Wataru Obara, Morioka City, Iwate, Japan

MP79-15 RISK FACTORS FOR NOCTURNAL POLYURIA
Hajjot Singh*, Jeffrey Weiss, Brooklyn, NY, Jerry Blaivas, Linda Dayan, Manhattan, NY, Noam Fine, Brooklyn, NY

MP79-16 RELATIONSHIP BETWEEN EXCESS VISCERAL FAT VOLUME AND OVERACTIVE BLADDER
Tomohiro Matsuo*, Kyoei Araki, Yuichiro Nakamura, Yuji Sagara, Kojiro Ohba, Yasuyoshi Miyata, Hideki Sakai, Nagasaki, Japan

MP79-17 LEVEL OF DIFFICULTY AND TRAUMA ASSOCIATED WITH REMOVAL OF THE TINED LEAD FOR SACRAL NEUROMODULATION
Steven Siegel*, Woodbury, MN, Jeffrey Mangel, Cleveland, OH, Jason Bennett, Grand Rapids, MI, Craig Comiter, Stanford, CA, Samuel Zylstra, Walthinsville, MA, Erin Bird, Temple, TX, Tomas L. Griebling, Kansas City, KS, Daniel Cullin, Oklahoma City, OK, Suzette E. Sutherland, Seattle, WA, Fangyu Kan, Kellie Berg, Minneapolis, MN

*Presenting author
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP80-01</td>
<td>TRANSPERINEAL PROCEDURES (BIOPSY AND CRYOABLATION) UNDER LOCAL ANESTHESIA: OUR EXPERIENCE AFTER 1,015 PROCEDURES</td>
<td>MP80-06</td>
<td>THE EFFECT OF CHRONIC NARCOTIC USE ON RECOVERY FOLLOWING RADICAL CYSTECTOMY WITH ENHANCED RECOVERY PROTOCOL</td>
</tr>
<tr>
<td>MP80-02</td>
<td>LEVERAGING STRUCTURED DATA IN AN ENTERPRISE-WIDE ELECTRONIC HEALTH RECORD TO IDENTIFY RISK FACTORS FOR POSTOPERATIVE URINARY RETENTION</td>
<td>MP80-07</td>
<td>TRANSRECTAL ULTRASOUND GUIDED PROSTATE BIOPSY PERFORMED BY SUPERVISED JUNIOR AND SENIOR RESIDENTS IS SAFE AND DOES NOT RESULT IN INFERIOR OUTCOMES</td>
</tr>
<tr>
<td>MP80-03</td>
<td>CAUSES OF 30-DAYS REOPERATION AND READMISSIONS POST ENDUROLOGIC SURGERY: A NATIONAL DATABASE ANALYSES</td>
<td>MP80-08</td>
<td>ASSOCIATIONS BETWEEN PREOPERATIVE PREPAREDNESS FOR RADICAL PROSTECTOMY AND PATIENT-REPORTED PAIN OUTCOMES</td>
</tr>
<tr>
<td></td>
<td>Saad Hatahet*, Kareem Saleh, Aaron Turnquist, Mohamed Hendawi, Ahmad Shabsigh, Columbus, OH</td>
<td></td>
<td>Anna M. Zampini, Bradley C. Gill, Aghinav Khanna, Daniel R. Hettel, Anna ER Faris*, Hadley M. Wood, Edmund S. Sabanegh, Cleveland, OH</td>
</tr>
<tr>
<td>MP80-04</td>
<td>WIDE VARIATION IN POSTOPERATIVE UROLOGIC SURGERY OPIOID PRESCRIBING IN TERTIARY CARE CENTERS</td>
<td>MP80-09</td>
<td>APPROPRIATE HEMATURIA WORK-UPS – IS THIS A PROBLEM WITH REFERRALS, UROLOGIC EVALUATION, OR BOTH?</td>
</tr>
<tr>
<td></td>
<td>Matthew Ziegelmans*, Jason Joseph, Derek Lomas, Elizabeth Habermann, Amy Glasgow, Halena Gazelka, Rochester, MN, Mark Tyson, Scottsdale, AZ, Matthew Gettman, Rochester, MN</td>
<td></td>
<td>Luisa De Souza*, Deep Patel, Jay D. Raman, Hershey, PA</td>
</tr>
<tr>
<td>MP80-05</td>
<td>OUTCOMES FROM A TEXT MESSAGING STUDY PERFORMED TO BETTER PREDICT POST-URETEROSCOPY OPIOID USE</td>
<td>MP80-10</td>
<td>ANALYSIS OF UROLOGIC CONSULTS AT A TERTIARY CARE CENTER HELPS TO OPTIMIZE QUALITY OF PATIENT CARE AND EDUCATIONAL OBJECTIVES</td>
</tr>
<tr>
<td></td>
<td>Kevin Flynn*, Paul Guidos, Shelby Francis, Jacob Simmering, Philip Polgreen, Chad Tracy, Bradley Erickson, Iowa City, IA</td>
<td></td>
<td>Jennifer Kuo*, Akira Yamamoto, Rishi Modh, James Mason, Gainesville, FL</td>
</tr>
<tr>
<td>MP80-11</td>
<td>POST-OPERATIVE OPIOID PREscribing IN UROLOGY: ARE WE CONTRIBUTING TO THE NATIONAL CRISIS?</td>
<td></td>
<td>Kathryn Hacker*, Jae Jung, J. Lee Graves, Hannah Cook, Peggy McNaul, Brooke Chidgey, Jami Mann, Angela Smith, Matthew Nielsen, Chapel Hill, NC</td>
</tr>
</tbody>
</table>
MP80-12 Performance and Cost of the Renal Cancer Specialist Multidisciplinary Team Meeting: Results from 1500 Discussions
Joana B. Neves*, Scott Shepherd, David Cullen, Thomas Powles, Michael Aitchison, Maxine GB Tran, London, United Kingdom

MP80-13 The Use of Videoconferencing for Monitoring Inpatient Post-Operative Urologic Patients

MP80-14 Readmission to Index Hospital: Improving Post-Operative Care in Radical Cystectomy Patients
Chirag Doshi*, Eric Kirshenbaum, Alex Gorbonos, Marcus Quek, Gopal Gupta, Maywood, IL

Alexander D. Tapper*, Derek Leale, Gregory Megahan, Kimberly Nacker, Jason Hafron, Royal Oak, MI

MP80-16 Favorable Outcomes of the Institution of a Massive Transfusion Protocol in Patients Undergoing Major Urologic Oncology Surgery with High Anticipated Blood Loss

MP80-17 Modeling the Risk of Radiation from CT Urography in the Evaluation of Asymptomatic Microscopic Hematuria
Todd Yecies, Jathin Bandari*, Benjamin Davies, Bruce Jacobs, Pittsburgh, PA

MP80-18 Oral Opioids Should Not Routinely Be Prescribed at Time of Office Vasectomy
Patrick Murray, Portland, ME, Adam Ludvigson*, Portland, ME, Cristina Cosner, Parker, CO, Josh Linscott, Boston, MA, Brian Jumper, Portland, ME

MP80-19 What Happens in Patients with Interstitial Cystitis/Bladder Pain Syndrome Who Had Been Lost to Follow-Up?
Jia-Fong Jhang*, Han-Chen Ho, Yuan-Hong Jiang, Yung-Hsiang Hsu, Hann-Chong Kuo, Hualien, Taiwan

MP80-20 Use of Non-Testosterone Based Hormone Therapies Among Privately Insured U.S. Men, 2009-2015
Mark Henry*, Dattatraya Patil, Decatur, GA, Ajay Nangia, Kansas City, KS, Akanksha Mehta, Decatur, GA

Approved for AMA PRA Category 1 Credit™

Monday, May 21, 2018
9:30 am - 11:30 am
Moderated Poster Session 81

STEM CELL RESEARCH: STEM CELL RESEARCH II
Room 3009 @ MCC West
Moderators: Anthony Atala, Adonis Hijaz and Margot Damaser

ABSTRACT NUMBER TITLE
MP81-01 EFFECT OF INTEGRIN SIGNALING BLOCKADE ON SELF-RENEWAL AND DIFFERENTIATION OF HUMAN NEPHROGENIC PROGENITORS IN VITRO
Astgik Petrosyan, Sinem Kargin, Matthew Thornton, Brendan Grubbs, Roger De Filippo, Laura Perin, Stefano Da Sacco*, Los Angeles, CA

MP81-02 CONTROLLED DELIVERY OF STEM CELL-DERIVED TROPHIC FACTORS TO TREAT KIDNEY INJURY
Doosang Kim, Hyunguen Yim, Hyun Chul Chung, Brian Shing, Kyung Hyun Moon, Sunil George, John Jackson*, In Kap Ko, James Yoo, Anthony Atala, Winston Salem, NC

MP81-03 COMPARATIVE STUDY OF NORMOXIC CULTURED AND HYPOXIC PRECONDITIONED HUMAN BONE MARROW-DERIVED MESENCHYMAL STROMAL CELL THERAPY IN A RAT MODEL OF RENAL ISCHEMIA-REPERFUSION INJURY
Jae Hyeon Han*, Dalsan You, Myoung Jin Jang, Jin Young Park, Kyung Kim, Joo Min Aum, Seoul, Korea, Republic of, Ha Chul Shin, Seongnam, Korea, Republic of, Nayoung Suh, Asan, Korea, Republic of, Yong Man Kim, Seongnam, Korea, Republic of, Choung-Soo Kim, Seoul, Korea, Republic of

*Presenting author
MP81-04 3D RENAL TUBULAR ORGANOIDs GENERATED FROM URINE-DERIVED STEM CELLS
Fangpong Shu, Hailin Guo, Xiong Geng, Anthony Atala, Yuanyuan Zhang*, Winston-Salem, NC

MP81-05 MIR34A/GOLPH3 AXIS ABROGATES UROTHELIAL BLADDER CANCER CHEMORESISTANCE VIA REDUCED CANCER STEMNESS
Qing Zhang*, Junlong Zhuang, Yongming Deng, Lin Yang, Hongqian Guo, Nanjing, China, People’s Republic of

MP81-06 THE THERAPEUTIC EFFECT OF HUMAN EMBRYONIC STEM CELL-DERIVED MULTIPOTENT MESENCHYMAL STEM CELLS ON KETAMINE-INDUCED CYSTITIS IN RATS
Jung hyun Shin*, Seoul, Korea, Republic of, Sang Wook Lee, Chunchoon, Korea, Republic of, Chae-Min Ryu, Aram Kim, Hwan Yeul Yu, Dong-Myung Shin, Myung-Soo Choo, Seoul, Korea, Republic of

MP81-07 REGENERATION AFTER PARTIAL CYSTECTOMY IS ASSOCIATED WITH PARTICULAR BDNF DOSEAGES AND ISOFORMS
Karen Aitken*, Martin Sidler, Aliza Siebenaller, Prateek Aggarwal, Thanukha Thanabalasingham, Chris Sotiropoulos, Paul Delgado-Olguin, Darius Bagli, Toronto, Canada

MP81-08 THE COMPARISON OF THERAPEUTIC EFFICACY OF CHA1 MSC AND ADMSC AND EVALUATE THE THERAPEUTIC MECHANISM IN A CHRONIC INTERSTITIAL CYSTITIS RAT MODEL
Young Eun Lee, Seung Ryel Lee, Young Kwon Hong, Dong Soo Park, Jae Yup Hong, Seongnam, Korea, Republic of, Seok Heun Jang, Seong nam, Korea, Republic of, Kyung Hwa Choi*, Seongnam, Korea, Republic of

MP81-09 RECELLULARIZED ACCELLULAR MATRIX VS NON-RECELLULARIZED ACCELLULAR MATRIX IN A RAT MODEL FOR IN VIVO NEO-BLADDER REGENERATION
Maria Jose Morera Esteve*, Mara Mellado-Lopez, Jeronimo Forteza, Victoria Moreno-Manzano, Cesar David Vera-Donoso, Valencia, Spain

MP81-10 MOLECULAR CHARACTERIZATION OF THE MURINE URINARY BLADDER USING SINGLE CELL RNA SEQUENCING
Bernhard Kiss*, Aaron Kershner, Wan-Jin Lu, Philip Beachy, Stanford, CA

MP81-11 BRAIN-DERIVED NEUROTROPHIC FACTOR IS ONE IMPORTANT PROTEIN FOUND IN STEM CELL SECRETIONS THAT PROMOTES RECOVERY FROM STRESS URINARY INCONTINENCE
Xiaoyi Yuan*, Wuhan, China, People’s Republic of, Dan Il Lin, Brett Hanzlicek, Mei Kuang, Cleveland, OH, Hao Yan, Beijing Shi, China, People’s Republic of, Brian Balog, Margot Damaser, Cleveland, OH

MP81-12 GENERATION OF TISSUE-SPECIFIC EXTRACELLULAR MATRIX PROTEINS TO ENHANCE SKELETAL MYOCYTE EXPANSION AND DIFFERENTIATION OF MUSCLE PROGENITOR CELLS
Deying Zhang, Yong Zhang, Yuanyuan Zhang*, Hualin Yi, Zhan Wang, James Yoo, Yu Zhou, Anthony Atala, Winston-Salem, NC

MP81-13 DESIGN OF A TRIAL FOR HYPOSPADIAS FAILURE TREATMENT, A REGENERATIVE MEDICINE APPROACH
Grazia delley*, Virginia Scęberras, Modena, Italy, Massimo Lazzeri, Rozzano, Milano, Italy, Carlo Trombetta, Michele Rizzo, Trieste, Italy, Gianpaolo Bianchi, Modena, Italy, Guido Barbagli, Arezzo, Italy

MP81-14 EXOSOMES SECRETED BY PLACENTAL STEM CELLS SELECTIVELY INHIBIT GROWTH OF PROSTATE CANCER CELLS

MP81-15 PROSTATE SMALL CELL CARCINOMA EXPRESS STEM CELL FACTORS THAT CAN TRANSFORM NORMAL AND CANCER CELLS INTO STEM-LIKE
Adelle Kanan, Alvin Liu*, Seattle, WA

MP81-16 MOLECULAR CHARACTERIZATION OF CANCER STEM CELLS FROM PROSTATE CANCER XENOGRAFTS
Sofia Karkampouna*, Maria De Menna, Markus Germann, Joel Grosjean, Bern, Switzerland, Peter Clark Gray, La Jolla, CA, George N. Thalmann, Marianna Kruithof-de Julio, Bern, Switzerland

MP81-17 TARGETING MITOCHONDRIAL OXIDATIVE PHOSPHORYLATION INDUCES APOPTOSIS VIA ER STRESS SELECTIVELY TO CD44V9 POSITIVE CELLS WITH CANCER STEM CELL-LIKE PROPERTIES: IMPORTANCE OF PLASTICITY
Takashi Matsumoto*, Takeshi Uchiumi, Masaki Shiota, Kenjiro Imada, Takanori Kiyoshima, Junichi Inokuchi, Katsunori Tatsugami, Masatoshi Eto, Fukuoka, Japan

MP81-18 INTRACAVERNOUS INJECTION OF BONE MARROW MESENCHYMAL STEM CELLS MODIFIED WITH PDE5-RNAI IMPROVES ERECTILE DYSFUNCTION IN AGED RATS
Hengjun Xiao*, Weixin Yan, Yubin Cui, Jun Chen, Liao Yuan Li, Guangzhou, China, People’s Republic of

MP81-19 EFFECTS OF MESENCHYMAL STEM CELLS ON ERECTILE FUNCTION IN A PELVIC NEUROVASCULAR TRAUMA MODEL
Alexandria Hertz*, Evalyn George, Amanda Reed-Maldonado, Timothy Brand, Shashikumar Salgar, Tacoma, WA
Monday, May 21, 2018

Moderated Poster Session 82
PROSTATE CANCER: DETECTION & SCREENING VII
Room 3020 @ MCC West
Moderators: Kevin Loughlin, Eric Klein and Armando Juliao

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP82-01</td>
<td>THE INFLUENCE OF DECISION AIDS ON PROSTATE CANCER SCREENING PREFERENCES</td>
<td>MP82-06</td>
<td>INVERSE STAGE MIGRATION PATTERNS IN NORTH AMERICAN PATIENTS UNDERGOING LOCAL PROSTATE CANCER TREATMENT: A CONTEMPORARY POPULATION-BASED UPDATE IN LIGHT OF THE 2012 USPSTF RECOMMENDATIONS</td>
</tr>
<tr>
<td></td>
<td>Adam Weiner*, Kyle Tsai, Mary Kate Keeter, David Victorson, Edward Schaeffer, Shilajit Kundu, Chicago, IL</td>
<td></td>
<td>Sami-Ramzi Leyh-Bannurah*, Pierre Karakiewicz, Montreal, Canada, Raisa Pompe, Felix Preissner, Hamburg, Germany, Emmanuelle Zaffuto, Paolo Dell’Oglio, Alberto Briganti, Milan, Italy, Omar Nafez, Stade, Germany, Margit Fisch, Thomas Steuber, Markus Graefen, Lars Budäus, Hamburg, Germany</td>
</tr>
<tr>
<td>MP82-02</td>
<td>SHARED DECISION MAKING FOR PROSTATE CANCER SCREENING: REALITY OR FARCE?</td>
<td>MP82-07</td>
<td>ADVERSE IMPACT OF THE PLCO TRIAL AND USPSTF RECOMMENDATION ON RATES OF DISTANT PROSTATE CANCER: DATA FROM A STATEWIDE CANCER REGISTRY</td>
</tr>
<tr>
<td></td>
<td>Daniel Pucheril*, Sean A. Fletcher, Sebastian Berg, Alexander P. Cole, Dimitar Zlatev, Steven L. Chang, Boston, MA, Jesse Sammon, Portland, ME, Mani Menon, Detroit, MI, Adam S. Kibel, Quoc-Dien Trinh, Boston, MA</td>
<td></td>
<td>Seong Ho Jeong*, Erik B. Lehman, Jay D. Raman, MD, FACS, Hershey, PA</td>
</tr>
<tr>
<td>MP82-03</td>
<td>IMPACT OF LATE MEDICAID EXPANSION ON PROSTATE CANCER SCREENING</td>
<td>MP82-08</td>
<td>UNINTENDED CONSEQUENCES OF DECREASED PSA-BASED PROSTATE CANCER SCREENING</td>
</tr>
<tr>
<td>MP82-04</td>
<td>DO ACCOUNTABLE CARE ORGANIZATIONS IMPACT PROSTATE CANCER SCREENING?</td>
<td>MP82-09</td>
<td>THE CHUN NOMOGRAM SIGNIFICANTLY OUTPERFORMS THE PCPT, ERSPC, KAWAKAMI AND KARAKIEWICZ NOMOGRAMS IN THE PREDICTION OF PROSTATE CANCER: A SINGLE CENTER COHORT-STUDY</td>
</tr>
<tr>
<td></td>
<td>Anna Krasnova*, Maxine Sun, Alexander P. Cole, Joel Weissman, Alexander A. Fletcher, Stuart R. Lipsitz, Adam S. Kibel, Quoc-Dien Trinh, Boston, MA</td>
<td></td>
<td>Cosimo De Nunzio*, Riccardo Lombardo, Fabiana Cancrini, Giorgia Tema, Filippo Zammitti, Hassan Akhatalbeh, Rome, Italy, Giorgio Gandaglia, Alberto Briganti, Milan, Italy, Andrea Tubaro, Rome, Italy</td>
</tr>
<tr>
<td>MP82-05</td>
<td>PROSTATE CANCER CHARACTERISTICS IN THE U.S. PREVENTIVE SERVICES TASK FORCE GRADE D ERA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Matthew Clements*, Basil Abdalla, Raymond Costabile, Stephen Culp, Tracey Krupski, Charlottesville, VA</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Presenting author
MP82-10 DEVELOPMENT AND EXTERNAL VALIDATION OF MRI-BASED NOMOGRAM TO PREDICT THE PROBABILITY OF PROSTATE CANCER DIAGNOSIS WITH MRI-US FUSION BIOPSY

MP82-11 COMPARATIVE OUTCOMES AFTER 4 DIFFERENT PROSTATE BIOPSY TECHNIQUES: A FOCUS ON STANDARDIZED COMPLICATION REPORTING
Cihan Demirel*, Muammer Altok, John Ward, Stephen McRae, Mary Achim, John Davis, Houston, TX

MP82-12 COMBINATION OF A CEPHALOSPORIN/FLUOROQUINOLONE ANTIBIOTIC REGIMEN AND ISOPROPYL ALCOHOL NEEDLE WASHING IS SIGNIFICANTLY ASSOCIATED WITH REDUCED RISK OF SEPSIS AFTER PROSTATE BIOPSY
Matthew Simmons*, Andrew Neeb, Marta Johnson-Mitchell, Bend, OR

MP82-13 THE ROLE OF LIQUID BIOPSY TO GET URINARY STEROIDAL PROFILE: A CHEAP INNOVATIVE TOOL IN THE DIFFERENTIAL DIAGNOSIS BETWEEN BENIGN PROSTATIC HYPERPLASIA AND PROSTATE CANCER
Francesco Porpiglia, Riccardo Bertolo*, Matteo Manfredi, Fabrizio Mele, Diletta Garrou, Daniele Amparore, Enrico Checcucci, Alleva Giorgio, Marco Vincenti, Eleonora Amante, Cristian Fiori, Stefano De Luca, Orbassano, Italy

MP82-14 SINGLE NUCLEOTIDE POLYMORPHISMS AND RISK OF PROSTATE CANCER: DEVELOPMENT AND VALIDATION OF A NOVEL GENETIC RISK SCORE FOR INDIVIDUALIZED SCREENING AND DIAGNOSTIC PROGRAMMES
Vito Cuccia*, Vincenzo Mirone, Naples, Italy, Dejan Lazarevic, Davide Cittaro, Giovanni Tonon, Matteo Zoccoli, Marco Emilio Bianchi, Giorgio Gandaglia, Nicola Fossati, Milan, Italy, Shahrokh F. Shariat, Vienna, Austria, Francesco Montorsi, Alberto Briganti, Milan, Italy

MP82-15 HYPOGONADISM IS ASSOCIATED WITH A REDUCED RISK OF HIGH GRADE PROSTATE CANCER
Cosimo De Nunzio*, Francesco Esperto, Riccardo Lombardo, Mariangela Bellangino, Antonio Nacchia, Angela Sica, Fabiana Cancrini, Andrea Tubaro, Rome, Italy

MP82-16 INTESTINAL MICROBIOME ANALYSIS IDENTIFIES BACTERIA AND BIOSYNTHESIS PATHWAYS ASSOCIATED WITH PROSTATE CANCER
Michael Liss*, Dimpy Shah, Robin Leach, Elizabeth Rourke, Joseph Basler, San Antonio, TX, James White, Baltimore, MD

MP82-17 RIGID VS. ELASTIC MRI/TRUS FUSION TARGETED PROSTATE BIOPSY – WHAT’S BETTER?
Julian Hanske*, Yannic Risse, Florian Rogmann, Rein-Jueri Palisaar, Christian von Bodman, Joachim Noldus, Marko Brock, Herne, Germany

MP82-18 ASSESSING THE DIAGNOSTIC ACCURACY OF MICRO-ULTRASOUND FOR THE DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER: RESULTS FROM A SINGLE-INSTITUTIONAL PRELIMINARY EXPERIENCE
Giovanni Lughezzani*, Davide Maffei, Massimo Lazzeri, Pasquale Cardone, Giuliana Lista, Piergiuseppe Colombo, Paolo Casale, Alberto Saita, Nicola’ Buffi, Rodolfo Hurle, Giorgio Guazzoni, Rozzano, Italy

MP82-19 ZONAL DISTRIBUTION OF PROSTATE CANCER FOCI IN PATIENTS UNDERGOING INITIAL AND MULTIPLE BIOPSY SERIES: MRI FUSION TARGETED RESULTS FROM 1,365 PATIENTS
Sami-Ramzi Leyh-Bannurah*, Mykyta Kachanov, Beyersdorff Dirk, Gerhard Adam, Felix Preisser, Margit Fisch, Georg Salomon, Markus Graefen, Lars Budäus, Hamburg, Germany

MP82-20 IMPROVING THE DETECTION OF HIGH-GRADE PROSTATE CANCER WITH MULTIPARAMETRIC MRI AND THE KALLIKREIN PANEL
Adam Gadzinski*, Hao Nguyen, Niloufar Ameli, Khaled Refaai, Katsuto Shinohara, Huiqing Wang, Benjamin Cedars, Zachary Kornberg, Peter Carroll, San Francisco, CA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>ABSTRACT TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP83-01</td>
<td>ELECTROMOTIVE DRUG ADMINISTRATION (EMDA) OF MITOMYCIN C AS FIRST LINE SALVAGE THERAPY IN HIGH RISK “BCG-FAILURE” NON MUSCLE INVASIVE BLADDER CANCER: 3 YEARS FOLLOWUP OUTCOMES</td>
</tr>
<tr>
<td>Luca Di Gianfrancesco*, Marco Racioppi, Mauro Ragonese, Giuseppe Palermo, Niccolò Lenci, Emilio Sacco, PierFrancesco Bassi, Rome, Italy</td>
<td></td>
</tr>
<tr>
<td>MP83-02</td>
<td>LYMPH NODE DISSECTION AND SURVIVAL IN PATIENTS WITH CLINICAL T1 HIGH-GRADE BLADDER CANCER UNDERGOING RADICAL CYSTECTOMY</td>
</tr>
<tr>
<td>Leilei Xia*, Raju Chelluri, Philadelphia, PA, Benjamin Taylor, New York, NY, Thomas Guzzo, Philadelphia, PA</td>
<td></td>
</tr>
<tr>
<td>MP83-03</td>
<td>DETECTION OF UROTHELIAL CARCINOMA USING SELECTED URINE-DNA METHYLATION BIOMARKERS IN PATIENTS WITH GROSS HEMATURIA: A PROSPECTIVE, SINGLE-CENTER STUDY</td>
</tr>
<tr>
<td>Runqi Guo*, Gengyan Xiong, Xuesong Li, Liqun Zhou, Beijing, China, People's Republic of</td>
<td></td>
</tr>
<tr>
<td>MP83-04</td>
<td>THE CHALLENGE OF HIGH RISK NON MUSCLE INVASIVE BLADDER CANCER TREATMENT IN ELDERLY PATIENTS</td>
</tr>
<tr>
<td>Marco Racioppi, Luca Di Gianfrancesco*, Mauro Ragonese, Giuseppe Palermo, Niccolò Lenci, Emilio Sacco, PierFrancesco Bassi, Rome, Italy</td>
<td></td>
</tr>
<tr>
<td>MP83-05</td>
<td>ONCOLOGICAL OUTCOME IN A RETROSPECTIVE COHORT OF T1G3 PRIMARY PATIENTS. DOES THE LOCATION OF CIS REALLY MATTER?</td>
</tr>
<tr>
<td>Francesca Pisano*, Oscar Rodriguez Faba, Ferran Albaga, Lucia Mosquera Seoane, Jose Maria Gaya, Ruben Parada, Helena Vila Reles, Joan Palou, Barcelona, Spain</td>
<td></td>
</tr>
<tr>
<td>MP83-06</td>
<td>THULIUM FIBER LASER EN BLOC RESECTION OF BLADDER CANCER</td>
</tr>
<tr>
<td>Alim Dymov*, Leonid Rapoport, Andrey Vinarov, Dmitry Enikeev, Nikolay Sorokin, Roman Sukhanov, Dmitry Kislyakov, Alexandra Proskura, Akhmed Damiev, Gregory Gololobov, Moscow, Russian Federation</td>
<td></td>
</tr>
<tr>
<td>MP83-07</td>
<td>RADICAL CYSTECTOMY FOR CLINICAL T1 BLADDER CANCER: DOES TIMING MATTER?</td>
</tr>
<tr>
<td>Akbar Ashrafi*, Matthew Winter, Giovanni Cacciamani, Shane Pearce, Gus Miranda, Jie Cai, Andre de Castro Abreu, Hooman Djaladat, Siamak Daneshmand, Mithir Desai, Inderbir Gill, Monish Aron, Los Angeles, CA</td>
<td></td>
</tr>
<tr>
<td>MP83-08</td>
<td>EN-BLOC EXCISION OF UROTHELIAL BLADDER CANCERS BY HOLMIUM LASER: A FEASIBILITY STUDY</td>
</tr>
<tr>
<td>Pankaj Maheshwari*, Saurabh Patil, Mumbai, India</td>
<td></td>
</tr>
<tr>
<td>MP83-09</td>
<td>CHEMOHYPERTHERMIA WITH MITOMYCIN C AND COMBAT SYSTEM A NEW ALTERNATIVE TO BCG IN HIGH RISK NON MUSCLE INVASIVE BLADDER CANCER?</td>
</tr>
<tr>
<td>Ana Plata Bello*, La Laguna, Spain, Felipe Villacampa, Javier Diaz Goizueta, Emilio Rios, Madrid, Spain, Peter Rimmer, Eastbourne, United Kingdom, Jose Castillo, Vinaroz, Spain, Jose Luis Pontones, Valencia, Spain, Cezar Nzezh, Gladbeck, Germany, Antonin Brisida, Prague, Czech Republic, Juan Leon, Lugo, Spain, Francesco Chiancone, Naples, Italy, Kees Hendricksen, Amsterdam, Netherlands, Thomas-Alexander Vogeli, Aachen, Germany, Daniel Wilby, Portsmouth, United Kingdom, Daniel Gonzalez-Padilla, Madrid, Spain, Carlos Garcia Alvarez, La Laguna, Spain, Luis Llanos, Madrid, Spain, Alejandro Sousa, Lugo, Spain, Eric Frank, Aachen, Germany, D.J. Castillo, Vinaroz, Spain, Paolo Fedeleini, Naples, Italy</td>
<td></td>
</tr>
<tr>
<td>MP83-10</td>
<td>CLINICAL EFFICACY OF SUB-STAGING AND EN-BLOC TUR SPECIMEN FOR PT1 BLADDER CANCER</td>
</tr>
<tr>
<td>Takafumi Yanagisawa*, Shinagawa Ward, Japan, Jun Miki, Takashi Yorozu, Akhiro Matsukawa, Yuzu Inaba, Kosuke Iwataki, Kagenori Ito, Hajime Onuma, Keiji Yasue, Seiro Tanaka, Takahiro Kimura, Hitoyuki Takahashi, Koichi Kishimoto, Shin Egawa, Tokyo, Japan</td>
<td></td>
</tr>
<tr>
<td>MP83-11</td>
<td>SINGLE OR TWO-TIME INTRAVESICAL INSTILLATION OF PIRARUBICIN AFTER TRANSURETHRAL RESECTION OF A SOLITARY NON-MUSCLE INVASIVE BLADDER CANCER: A PROSPECTIVE RANDOMIZED CONTROL STUDY</td>
</tr>
<tr>
<td>Ryuta Tanimoto*, Okayama, Japan, Saika Takashi, Toon, Japan, Shin Ebara, Hiroshima, Japan, Yasuyuki Kobayashi, Okayama, Japan, Ryoji Nasu, Kochi, Japan, Yamada Daisuke, Kanonji, Japan, Hitoshi Takamoto, Kurashiki, Japan, Yoshiyuki Miyaji, Iwakuni, Japan, Yasutomo Nasu, Tomoyasu Tatsushima, Hiromi Kumon, Okayama, Japan</td>
<td></td>
</tr>
</tbody>
</table>
MP84-03 INTERPOSITION OF NOVEL NERVE-REGENERATION CONDUIT AFTER WIDE EXCISION OF THE NEUROVASCULAR BUNDLE DURING RADICAL PROSTATECTOMY DID NOT IMPROVE POSTOPERATIVE ERECTILE FUNCTION
Nobuyuki Hinata*, Junya Furukawa, Ken-ichi Harada, Yuzo Nakano, Masato Fujisawa, Kobe, Japan

MP84-04 PRACTICE PATTERNS AND ATTITUDES AMONG UROLOGISTS IN THE MANAGEMENT OF ACUTE ISCHEMIC PRIAPISM
Jessica Dai*, Omer Raheem, Thomas Walsh, Seattle, WA

MP84-05 NOVEL NOMOGRAM PREDICTING THE PROBABILITY OF PENILE CURVATURE IMPROVEMENT IN PATIENTS COLLAGENASE CLOSTRIDIUM HISTOLYTICUM (CCH-XIAPEX®) USING A NEW SHORTENED PROTOCOL
Andrea Cocci*, Florence, Italy, Giorgio Ivan Russo, Catania, Italy, Gianmartin Cito, Florence, Italy, Marco Capece, naples, Italy, Marco Falcone, Massimiliano Timpano, turin, Italy, Giovanni Cacciamani, Gaia Polloni, Verona, Italy, Giulia Bencini, Andrea Minervini, Sergio Semi, Mauro Gacci, Marco Carini, Florence, Italy, Bruno Giammusso, Catania, Italy, Paolo Verze, Davide Arcaniolo, Vincenzo Mirone, naples, Italy, Riccardo Campi, Francesco Sessa, Della Camera pierandrea, Isabella Greco, Florence, Italy, Gianluca Giubilei, Empoli, Italy, Franco Blefari, Prato, Italy, Paolo Michele Giorgi, Michele Rizzo, Trieste, Italy, Nicola Mondaini, Florence, Italy

MP84-06 PROSPECTIVE TRIAL COMPARING PENO-SCROTAL VERSUS MINIMALLY INVASIVE INFRAPUBIC APPROACH FOR INFLATABLE PENILE PROSTHESIS PLACEMENT: A SINGLE-CENTRE MATCHED PAIRED ANALYSIS
Pietro Grande*, Gabriele Antonini, Cristiano Cristini, Ettore De Berardinis, Giuseppe Gentile, Giovanni Di Lascio, Andrea Lemma, Giovanni Battista Di Pierro, Rome, Italy

MP84-07 TRANSURETHRAL SEMINAL VESICULO-SCOPY WITH A URETEROSCOPE FOR THE TREATMENT OF SEMINAL VESICLE STONES
Song Tao*, Zhang Peng, Wang Chunyang, Sun Shengkun, Zhang Xu, Beijing, China, People’s Republic of

MP84-08 NEW INSIGHT INTO THE ASSOCIATION OF BICYCLE RELATED GENITAL NUMBNESS AND SEXUAL FUNCTION: RESULTS FROM A LARGE, MULTINATIONAL, CROSS-SECTIONAL STUDY
Nima Baradaran*, Mohannd Awad, Thomas Gaither, Kirkpatrick Fergus, Aron Liaw, Tom Sanford, San Francisco, CA, Michael Eisenberg, Stanford, CA, Benjamin Breyer, San Francisco, CA

MP84-09 LOW COMPLIANCE TO POST-VASECTOMY SEMEN ANALYSIS GUIDELINES IN VETERANS
Richmond Owusu*, Eric Ballon-Landa, Tung-Chin Hsieh, San Diego, CA

MP84-10 ORGASMIC AND ERECTILE DYSFUNCTION IN MEN WITH LONGSTANDING TYPE 1 DIABETES

MP84-11 THE ROLE OF PENILE REHABILITATION AFTER NERVE-SPARING RADICAL PROSTATECTOMY
Sergey Kotov*, Aleksandr Osadchinskii, Moscow, Russian Federation

MP84-12 OUTCOMES AND FACTORS ASSOCIATED WITH RECEIPT OF OPEN VS MINIMALLY INVASIVE RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) FOR TESTIS CANCER: ANALYZING THE NATIONAL CANCER DATABASE (NCDB) FROM 2010-2014

MP84-13 PROGRAMMED DEATH LIGAND-1 (PD-L1) EXPRESSION STATUS IN PENILE SQUAMOUS CELL CARCINOMA TUMOR CELLS AND TUMOR INFILTRATING IMMUNE CELLS
Jennifer Rider*, Alyssa Harlow, Boston, MA, Francesca Giunchi, Bologna, Italy, Jessica Carlsson, Peter Kirrander, Orebro, Sweden, Michelangelo Fiorentino, Bologna, Italy, Ove Andren, Sabina Davidsson, Orebro, Sweden

MP84-14 THE IMPACT OF MICRO-METASTATIC PELVIC LYMPH NODE INVOLVEMENT ON 3 YEAR SURVIVAL IN SQUAMOUS CELL CARCINOMA OF THE PENIS
Benjamin Ayres*, Rami Issa, Alison Tree, Brendan Tinwell, Cathy Corbishley, Nick Watkin, London, United Kingdom

*Presenting author
MP84-15 PREDICTIVE FACTORS OF PATIENTS’ AND PARTNERS’ SEXUAL FUNCTION IMPROVEMENT AFTER CLOSTRIDIUM COLLAGENASE INJECTION FOR PEYRONIE’S DISEASE. ANALYSIS FROM THE LARGEST ITALIAN MULTICENTRE SINGLE-ARM STUDY
Andrea Cocci*, Florence, Italy, Giorgio Ivan Russo, Catania, Italy, Gianmartin Cito, Florence, Italy, Marco Capace, naples, Italy, Marco Falcone, Massimiliano Timpano, turin, Italy, Giovanni Cacciarmi, Verona, Italy, Gaia Polloni, Como, Italy, Giulia Bencini, Andrea Minervini, Sergio Serri, Mauro Gacci, Marco Carini, Florence, Italy, Bruno Giammusso, Catania, Italy, Paolo Verze, Davide Arcaniolo, Vincenzo Mirone, naples, Italy, Isabella Greco, Florence, Italy, Gianluca Giubilei, Empoli, Italy, Franco Blefari, Prato, Italy, Paolo Michele Giorgi, Michele Rizzo, Trieste, Italy, Nicola Mondaini, Florence, Italy

MP84-16 FACTORS ASSOCIATED WITH EARLY MORTALITY AND SURVIVAL OUTCOMES AMONG PATIENTS WITH TESTICULAR NEOPLASMS: A POPULATION-LEVEL ANALYSIS

MP84-17 NOCTURIA IS ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN CAUCASIAN-EUROPEAN MEN SEEKING MEDICAL HELP FOR SEXUAL DYSFUNCTION WITHOUT KNOWN PSYCHIATRIC DISORDERS
Filippo Pederzoli*, Luca Boeri, Paolo Capogrosso, Eugenio Ventimiglia, Walter Cazzani, Nicola Frego, Francesca Chierigo, Edoardo Pozzi, Federico Delhò, Milan, Italy, Emanuele Montanari, Milano, Italy, Franco Gaboardi, Milan, Italy, Vincenzo Mirone, Naples, Italy, Francesco Montorsi, Andrea Salonia, Milan, Italy

MP84-18 PROGNOSTIC IMPACT OF BLEOMYCIN PULMONARY TOXICITY ON THE OUTCOME OF PATIENTS WITH TESTICULAR CANCER
Yuki Maruyama*, Takuya Sadahira, Yosuke Mitsui, Atsushi Takamoto, Koichiro Wada, Ryuta Tanimoto, Yasuyuki Kobayashi, Motoo Araki, Masami Watanabe, Toyohiko Watanabe, Yasutomo Nasu, Okayama, Japan

MP84-19 THE ROLE OF ROBOTIC ASSISTED ABDOMINAL DENERVATION FOR THE TREATMENT OF CHRONIC GROIN PAIN
Mohamed Etafy*, Jamin Brahmbhatt, Sijo Parekattil, Clermont, FL

MP84-20 RECOGNITION AND MANAGEMENT OF THE 3 HISTOLOGICAL SUBTYPES OF GENITO-URINARY EXTRAMAMMARY PAGETS DISEASE
Sylvia Yan*, Aditya Marjunath, Elsie Mensah, Brendan Tinwell, Catherine Corbishley, Benjamin Ayres, Nicholas Watkin, London, United Kingdom

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Monday, May 21, 2018
Podium Session 58
9:30 am - 11:30 am
SURGICAL TECHNOLOGY & SIMULATION: TRAINING & SKILLS ASSESSMENT II
Room 2024 @ MCC West
Moderators: Chandru Sundaram, Jaime Landman and Edward Matsumoto

ABSTRACT TIME NUMBER TITLE
9:30 PD58-01 UTILIZATION OF MACHINE LEARNING AND AUTOMATED PERFORMANCE METRICS TO EVALUATE ROBOT-ASSISTED RADICAL PROSTATECTOMY PERFORMANCE AND PREDICT PATIENT OUTCOMES
Andrew Hung*, Jian Chen, Zhengping Che, Tanachat Nilanon, Los Angeles, CA, Anthony Jarc, Liheng Guo, Norcross, GA, Paul Oh, Inderbir Gill, Yan Liu, Los Angeles, CA

ABSTRACT TIME NUMBER TITLE
9:40 PD58-02 VALIDATION OF REAL-TIME, INTRAOPERATIVE, SURGICAL COMPETENCE (RISC) ASSESSMENTS LINKED TO CLINICALLY RELEVANT PATIENT OUTCOMES: A MODEL OF COMPETENCY ASSESSMENT IN UROLOGY
Ethan Grober*, Mitchell Goldenberg, Michael Elfassy, Armando Lorenzo, Matthew Roberts, Trustin Domes, Mohamed Mahdi, Michael AS Jewett, Toronto, Canada

9:50 PD58-03 LEARNING CURVE WITH THE NO-FLIP SHANGRING CIRCUMCISION IN KENYA
Omar Al Hussein Alawamth*, Ryan Flannigan, Quentin Awori, Soo Jeong Kim, Mark Barone, Marc Goldstein, Philip S. Li, Richard K. Lee, New York, NY
9:50 PD59-03 EFFICACY AND SAFETY OF TEVERelix LA, A GNRH ANTAGONIST, IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA (BPH) (CLINICAL TRIAL EP-24332T-A012)
Steven Kaplan*, New York, NY, Carol MacLean, Finn Larsen, London, United Kingdom

10:00 PD59-04 A DOUBLE BLINDED, RANDOMIZED CONTROLLED TRIAL COMPARING TAMSLUSIN AND PLACEBO VERSUS TAMSLUSIN AND TADALAFIL IN MALE LOWER URINARY TRACT SYMPTOMS
Santhosh Nagasebramanian*, Nirmal Thampi John, Belavendra Antonisamy, Chandrasingh J, Santosh Kumar, Antony Devasia, Nitin Sudhakar Keke, Vellore, India

10:10 PD59-05 ANTICHOLINERGICS COMBINED WITH ALPHA-BLOCKERS FOR TREATMENT OF LOWER URINARY TRACT SYMPTOMS IN MEN WITH BENIGN PROSTATIC HYPERPLASIA: A COCHRANE SYSTEMATIC REVIEW AND META-ANALYSIS
Ran Pang*, Xinyao Zhou, Xuelai Yin, Hai Bo, Bin Wang, Beijing, China, People’s Republic of

10:20 PD59-06 TAILORING MEDICATION FOR LOWER URINARY TRACT SYMPTOMS IN MEN BASED ON INTERNATIONAL PROSTATE SYMPTOM SCORE VOIDING TO STORAGE RATIO
Cheng-Ling Lee*, Hueih-Ling Ong, Yu-Khun Lee, Hahn-Chong Kuo, Hualien, Taiwan

10:30 PD59-07 RISK FACTORS OF PHARMACOTHERAPY FOR STORAGE SYMPTOMS AFTER TRUSSURETHRAL RESECTION OF THE PROSTATE IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
Cheng-Han Tsai*, Yu-Hua Fan, Alex T. L. Lin, Taipei, Taiwan

10:40 PD59-08 METFORMIN USE IS ASSOCIATED WITH IMPROVED INTERNATIONAL PROSTATE SYMPTOM SCORES IN MEN WITH METABOLIC SYNDROME

10:50 PD59-09 PHOSPHODIESTERASE INHIBITORS COULD REVERSE THE PROLIFERATION OF BPH EPITHELIAL CELLS INDUCED BY CD8+ T CELLS IN LOW ANDROGEN CONDITION
Song Jin*, Yang Yang, Shuai Hu, Jindong Sheng, Peng Xiang, Jing Peng, Jie Jin, Beijing, China, People’s Republic of

11:00 PD59-10 WHAT ARE THE PREDICTING FACTORS FOR THE THERAPEUTIC EFFECTS OF TADALAFIL IN MALE PATIENTS WITH LOWER URINARY TRACT SYMPTOMS?
Yoshihisa Matsukawa*, Shun Takai, Shohei Ishida, Yashuhito Funahashi, Takashi Fujita, Tokunori Yamamoto, Momokazu Gotoh, Nagoya, Japan

11:10 PD59-11 DAILY TADALAFIL 5 MG TO TREAT MEN WITH LUTS DUE TO BPE AND ED, ALONE OR IN COMBINATION WITH TAMSLUSIN 0.4 MG: AN OBSERVATIONAL MULTICENTER TRIAL
Mauro Gacci, Florence, Italy, Cosimo De Nunzio, Rome, Italy, Riccardo Schiavina, Bologna, Italy, Pietro Spatafora, Jacopo Frizzi, Arcangelo Sebastianelli*, Matteo Salvi, Omar Saleh, Florence, Italy, Fabrizio Presicce, Rome, Italy, Marco Borghesi, Bologna, Italy, Linda Vignozzi, Mario Maggi, Florence, Italy, Andrea Tubaro, Rome, Italy, Eugenio Brunocilla, Bologna, Italy, Sergio Serni, Florence, Italy

11:20 PD59-12 TRENDS IN THE PHARMACOLOGICAL AND SURGICAL MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA: AUSTRALIAN POPULATION BASED DATA
Michael Williams*, Sachinka Ranasinghe, Marlon Perera, Brisbane, Australia

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
Presenting author

9:40 PD60-02 DISCOVERY AND VALIDATION OF A NOVEL FLUID BIOMARKER FOR THE DIAGNOSIS AND RISK STRATIFICATION OF PROSTATE CANCER

Lina Carmona Echeverria*, London, United Kingdom, Thomas Johnston, Cambridge, UK, United Kingdom, Avi Rosenfeld, Jerusalem, Israel, Matthew Eldridge, Sarah Vowler, Anne George, Marie Corcoran, Johanna Burge, Sara Stearn, Charles Massie, Cambridge, UK, United Kingdom, David Neal, Oxford, United Kingdom, Susan Heavey, Hayley Pye, Hashim U. Ahmed, Mark Emberton, Hayley Whitaker, London, United Kingdom

9:50 PD60-03 THE PROGNOSTIC SIGNIFICANCE OF PERSISTENTLY ELEVATED PSA AFTER RADICAL PROSTATECTOMY IS HIGHLY ASSOCIATED WITH PATHOLOGICAL STAGE: IMPLICATIONS FOR TIMELY USE OF SALVAGE TREATMENTS


10:00 PD60-04 DEFINING A FAVORABLE INTERMEDIATE-RISK GROUP: UTILITY OF MAGNETIC RESONANCE IMAGING AND GENETIC TESTS

Ugo Giovanni Falagario*, Alp Tunç Bekşac, Shivaram Cumarasamy, Paige Xu, Alberto Martini, Akriti Gupta, Kanika Mahajan, Isuru Jayaratna, Ashutosh Tewari, New York, NY

10:10 PD60-05 PROSPECTIVE VALIDATION OF THE ISOPSA® ASSAY FOR DETECTION OF HIGH GRADE PROSTATE CANCER

Eric Klein*, Amnon Chait, Cleveland, OH, Jason Haftron, Kenneth Kernen, Troy, MI, Kannan Manickam, Baltimore, MD, Andrew Stephenson, Cleveland, OH, Matthew Wagner, Clackamas, OR, Hui Zhu, Cleveland, OH, Martin Dineen, Daytona Beach, FL, Yair Lotan, Dallas, TX, Alan Partin, Baltimore, MD, Jack Daniel, Petah Tikva, Israel, Aimee Kestranek, Boris Zaslavsky, Mark Stovsky, Cleveland, OH

10:20 PD60-06 VALIDATION OF A GENOMIC RISK CLASSIFIER TO PREDICT METASTASIS AND PROSTATE CANCER-SPECIFIC MORTALITY IN MEN WITH POSITIVE LYMPH NODES

Bruce Ttrack*, Baltimore, MD, R. Jeffrey Karnes, Rochester, MN, Frank Claessens, Leuven, Belgium, John Davis, Houston, TX, Zaid Haddad, Kasra Youssefi, Elai Davicioni, Vancouver, Canada, Ashley Ross, Dallas, TX

10:30 PD60-07 DECIPHER TEST IMPACTS ADJUVANT AND SALVAGE TREATMENTS RECEIVED FOLLOWING RADICAL PROSTATECTOMY


10:40 PD60-08 PROTEOMIC-BASED BIOMARKERS FOR RISK OF PROGRESSION IN EARLY PROSTATE CANCER

Justin Gregg*, Johannes Fahrmann, Christine Peterson, Jody Vykoukal, Jennifer Dennison, Samir Hanash, John Davis, Jeri Kim, Timothy Thompson, Houston, TX

10:50 PD60-09 DISCOVERY AND VALIDATION OF NOVEL LONG NONCODING RNAs THAT DIFFERENTIATE AGGRESSIVE AND INDOLENT PROSTATE CANCER

Anthony J. Cesnik, Andrew V. Truong, Tyler Etheridge*, Bing Yang, Michele Spiniello, Maisie I. Steinbrink, Michael R. Shortreed, Brian L. Frey, Glenn O. Allen, David F. Jarrard, Lloyd M. Smith, Madison, WI
## Podium Session 61

### KIDNEY CANCER: LOCALIZED:ABLATIVE THERAPY

**Room 3024 @ MCC West**

**Moderators:** Louis Kavoussi, Jeffrey Cadeddu and Antonio Finelli

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
<th>ABSTRACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30</td>
<td>PD61-01</td>
<td>CLINICAL OBSERVATION ON ROBOT-ASSISTED LAPAROSCOPIC RADIOFREQUENCY ABLATION FOR COMPLEX INTRARENAL TUMORS</td>
<td></td>
</tr>
<tr>
<td>9:40</td>
<td>PD61-02</td>
<td>FEASIBILITY AND ONCOLOGIC OUTCOMES OF MICROWAVE ABLATION WITH RENAL TUMORS: A RETROSPECTIVE STUDY OF INTERMEDIATE-TERM FOLLOW-UP RESULTS</td>
<td></td>
</tr>
<tr>
<td>9:50</td>
<td>PD61-03</td>
<td>ROBOT-ASSISTED ULTRASOUND-GUIDED RADIOFREQUENCY ABLATION FOR RENAL CALYX CARCINOMA IN SOLITARY KIDNEY COMBINED WITH CONTINUOUS IRRIGATION OF RENAL PELVIS</td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>PD61-04</td>
<td>AN PILOT STUDY ON ROBOTIC-ASSISTED LAPAROSCOPIC RADIOFREQUENCY ABLATION FOR RENAL TUMOR</td>
<td></td>
</tr>
<tr>
<td>10:10</td>
<td>PD61-05</td>
<td>PERCUTANEOUS CRYOABLATION OF RENAL TUMORS IN SOLITARY KIDNEY: RESULTS FROM AN ITALIAN MULTICENTRIC STUDY</td>
<td></td>
</tr>
<tr>
<td>10:20</td>
<td>PD61-06</td>
<td>OUT COME OF PARTIAL NEPHRECTOMY IN T2 RCC</td>
<td></td>
</tr>
</tbody>
</table>
10:30 PD61-07 COMPARATIVE ANALYSIS OF PERIOPERATIVE OUTCOMES FOR PATIENTS WITH 4-7CM RCC TREATED WITH EITHER MICROWAVE ABLATION, PARTIAL NEPHRECTOMY OR RADICAL NEPHRECTOMY


11:00 PD61-10 SAFETY AND EFFICACY OF PERCUTANEOUS US AND CT GUIDED MICROWAVE ABLATION OF T1A AND T1B RENAL TUMORS

Sepideh Shakeri*, Sohrab Afshari Mirak, Allan Pantuck, Anthony Sisk, Preeti Ahuja, David S Lu, Steven Raman, Los Angeles, CA

11:10 PD61-11 PERCUTANEOUS ABLATION OF LOCALIZED RENAL TUMORS: FEASIBILITY STUDY, EVOLUTION AND OPERATIVE COMPLICATIONS

Marco Arap*, Carlos Henrique Segall Jr, Livia Neto, Mark Neumaier, Marcos Menezes, Sao Paulo, Brazil

10:40 PD61-08 PARTIAL NEPHRECTOMY VERSUS PERCUTANEOUS CRYOABLATION FOR CLINICAL T1B RENAL TUMOR

Takafumi Yanagisawa*, Shinagawa Ward, Japan, Jun Miki, Yuzo Inaba, Kosuke Iwatanri, Kagenori Ito, Hajime Onuma, Keiichiro Mori, Seiro Tanaka, Hiroshi Sasaki, Takahiro Kimura, Kanichiro Shimizu, Koichi Kishimoto, Shin Egawa, Tokyo, Japan

10:50 PD61-09 PREOPERATIVE LIPIODOL MARKING IMPROVED SAFETY AND SUCCESS RATE ON CT-GUIDED CRYOABLATION FOR SMALL RENAL MASSESS

Fumiya Hongo*, Yasuihro Yamada, Kenji Hiraoka, Munehiro Ohashi, Atsuko Fujihara, Koji Okihara, Kanji Miura, Kei Yamada, Osamu Ukimura, Kyoto, Japan

11:20 PD61-12 CONTRAST ENHANCED ULTRASONOGRAPHY GUIDED PERCUTANEOUS CRYOABLATION FOR CYSTIC RENAL TUMORS

Rong Yang*, Huibo Lian, Wei Wang, Hongqian Guo, Nanjing, China, People’s Republic of

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Monday, May 21, 2018 9:30 am - 11:30 am

Podium Session 62

INFECTIONS/INFLAMMATION/CYSTIC DISEASE OF THE GENITOURINARY TRACT: PROSTATE & GENITALIA II

Room 3018 @ MCC West

Moderators: Jordan Dimitrakoff, Michael Whalen and Dirk Lange

<table>
<thead>
<tr>
<th>TIME</th>
<th>ABSTRACT NUMBER</th>
<th>ABSTRACT TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30</td>
<td>PD62-01</td>
<td>DAILY LOW DOSE TADALAFIL IN TREATMENT OF CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME: RANDOMIZED CONTROLLED STUDY OF EFFICACY AND SAFETY</td>
</tr>
<tr>
<td>9:40</td>
<td>PD62-02</td>
<td>INTRA-PROSTATIC INJECTION THERAPY FOR CHRONIC PROSTATITIS: A PILOT STUDY</td>
</tr>
<tr>
<td>9:50</td>
<td>PD62-03</td>
<td>CASE SERIES OF LOW INTENSITY SHOCK WAVE THERAPY FOR MEN WITH CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TIME</th>
<th>ABSTRACT NUMBER</th>
<th>ABSTRACT TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00</td>
<td>PD62-04</td>
<td>THERAPEUTIC EFFECT OF INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR IN THE PROSTATITIS</td>
</tr>
<tr>
<td>10:10</td>
<td>PD62-05</td>
<td>BRIDGING THE GAP BETWEEN LOW TESTOSTERONE AND PROSTATE INFLAMMATION IN HYPOGONADAL MEN</td>
</tr>
<tr>
<td>10:20</td>
<td>PD62-06</td>
<td>VALIDATION OF THE CHRONIC ORCHIALGIA SYMPTOM INDEX FOR SYMPTOM SEVERITY AND RESPONSIVENESS TO THERAPY</td>
</tr>
</tbody>
</table>

*Presenting author

289
10:30 PD62-07 VALIDATION OF TARGETED MICROSURGICAL SPERMATIC CORD DENERVATION: COMPARISON OF OUTCOMES TO TRADITIONAL COMPLETE MICROSURGICAL SPERMATIC CORD DENERVATION
Parviz Kavoussi*, Austin, TX

10:40 PD62-08 TRIGGER POINT DRY NEEDLING AS A TREATMENT FOR ORCHIALGIA
Matthew A. Nielsen*, Charles Gresham, Erin Glace, Courtney Anderson, Jessica Delong, Ramon Virasoro, Jeremy Tonkin, Kurt McCammon, Virginia Beach, VA

10:50 PD62-09 PHYSICAL THERAPY FOR ORCHIALGIA EFFECTIVE IN PREVIOUSLY TREATED PATIENTS
Matthew A. Nielsen*, Charles Gresham, Erin Glace, Courtney Anderson, Jessica Delong, Ramon Virasoro, Jeremy Tonkin, Kurt McCammon, Virginia Beach, VA

11:00 PD62-10 PRE-OPERATIVE RISK FACTORS FOR WOUND COMPLICATIONS FOLLOWING CIRCUMCISION IN THE VETERAN POPULATION
Alan Hsieh, Newark, NJ, Samuel Aly MD*, Hossein Sadeghi-Nejad MD, FACS, East Orange, NJ, Robert Bonitz MD, Newark, NJ

11:10 PD62-11 PUBOPROSTATIC FISTULAE FOLLOWING PHOTOSELECTIVE VAPORIZATION OF THE PROSTATE
Nicholas Hauser*, Kenneth Angermeier, Amr Fergany, Hadley Wood, Cleveland, OH

11:20 PD62-12 CONCURRENT UROLOGIC SURGERIES INCREASE THE RISK OF INFECTION: A NATIONAL DATABASE STUDY
Valary Raup*, Ramy Abou Gayda, H. Abraham Chiang, Julie Szymaniak, Steven L. Chang, Benjamin I. Chung, Martin Kathrins, Boston, MA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Video Session 11
ED, INFERTILITY & MALE INCONTINENCE
The videos in this session as well as the video libraries from the 2011-2016 Annual Meetings may be viewed in the Surgical Video Library and purchased in the AUA Store during the Annual Meeting. Both are located in Hall A. AUA members receive free online access to the Surgical Video Library throughout the year through AUA University. Visit www.AUAnet.org/University to access.

Room 3002 @ MCC West
Moderators: Bobby Najari, David Shin and Sukhbinder Minhas

ABSTRACT NUMBER TITLE
V11-01 SUTURE-FREE SEALING OF TUNICAL DEFECT WITH COLLAGEN FLEECE AFTER PARTIAL PLAQUE EXCISION IN PEYRONIE'S DISEASE: LONG-TERM OUTCOMES OF THE SEALING TECHNIQUE
Georgios Hatzichristodoulou*, Scarlet Fiechnier, Würzburg, Germany, Jürgen Gschwend, Munich, Germany, Hubert Kübler, Würzburg, Germany, Sven Lahme, Pforzheim, Germany

V11-02 A RANDOMIZED CLINICAL TRIAL ON SAFETY AND EFFICACY OF LOW INTENSITY SHOCKWAVES FOR THE TREATMENT OF ERECTILE DYSFUNCTION – COMPARISON OF TWO TREATMENT SCHEDULES
Manuel L. Molina*, Luis Sávio, Miami, FL, Raúl Clavijo, Sacramento, CA, John Lee, Nachiketh Soodana Prakash, Ranjith Ramasamy, Miami, FL

V11-03 CORRECTING PEYRONIE'S CURVATURE WITH PLAQUE INCISION AND GRAFTING USING TEMPORALIS FASCIA
Jeffrey Loh-Doyle, Natalie Hartman*, Los Angeles, CA, Mukul Patil, Washington, PA, Martin Gelbard, Burbank, CA, Stuart Boyd, Los Angeles, CA

V11-04 INFLATABLE PENILE PROSTHESIS IMPLANTATION POST PHALLOPLASTY
Ervin Kocjancic*, Jorge Jaunarena, Laurel Sofer, Luca Morgantini, Loren Schechter, Chicago, IL

V11-05 PROMISING NEW TREATMENT PARADIGM FOR REFRACTORY ISCHEMIC PRIAPISM AFTER FAILED DISTAL SHUNT: PENOSCROTAL DECOMPRESSION
Joceline Fuchs*, Nabeel Shakir, Maxim McKibben, Shawn Mathur, Dallas, TX, Sloan Teeple, Amarillo, TX, Jeremy Scott, Allen Morey, Dallas, TX
### V11-06 SUBCUFF CAPSULOTOMY AND PRESSURE REGULATING BALLOON INTERROGATION: DISPELLING URETHRAL ATROPHY DURING ARTIFICIAL URINARY SPHINCTER REVISION FOR RECURRENT INCONTINENCE
Amy Pearlman*, Ryan Terlecki, Winston Salem, NC

### V11-07 ROBOT-ASSISTED AMS 800®-SPHINCTER IMPLANTATION AROUND THE MEMBRANOUS URETHRA IN SPINA BIFIDA – A NEW CUFF POSITION
Nadim Abo Youssef*, Winterthur, Switzerland, Jürgen Pannek, Nottwil, Switzerland, Kevin Horton, Marco Randazzo, Hubert John, Winterthur, Switzerland

### V11-08 NEW TRANSCRROTAL APPROACH FOR ROBOTIC MICROSURGICAL DENERVATION OF THE SPERMATIC CORD WITH ROBOTIC MICROSURGICAL VARICOCELECTOMY
Mohamed Etalfy*, Clermont, FL, Ahmet Gudeloglu, Ankara, Turkey, Jamin Brahmbhatt, Sijo Parekatattil, Clermont, FL

### V11-09 USING MICROSCOPE FOR ONCO-TESTICULAR SPERM EXTRACTION FOR BILATERAL TESTIS TUMORS
Robert J. Carrasquillo*, Luis F. Savio, Vivek Venkatramani, Dipen J. Parekh, Ranjith Ramasamy, Miami, FL

### V11-10 SURGICAL TECHNIQUES OF TRANSURETHRAL SEMINAL VESICULOSCOPY FOR INTRACTABLE HEMOSPERMIA
Ju-Chuan Hu*, Chuan-Shu Chen, Taichung, Taiwan

### V11-11 HYDROCELECTOMY USING A MINIMALLY-INVASIVE, OFFICE-BASED APPROACH
Matthew Ziegelmann*, Manaf Alom, Kevin Wymer, Tobias Kohler, Landon Trost, Rochester, MN

### V11-12 PENILE SCLEROSING GRANULOMA – SURGICAL EXCISION
Gideon Blecher*, Nathan Asher, Gulio Garaffa, David Ralph, London, United Kingdom

---

**APPROVED FOR AMA PRA CATEGORY 1 CREDIT™**

---

**Monday, May 21, 2018**

### Forums

**YOUNG UROLOGISTS**

Room 215 @ MCC South

---

**Monday, May 21, 2018**

### Moderated Poster Session 85

**SEXUAL FUNCTION/DYSFUNCTION: MEDICAL, HORMONAL & NON-SURGICAL THERAPY II**

Room 3004 @ MCC West

**Moderators:** Ronald Lewis, Tobias Kohler and Mohamad Habous

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP85-01</td>
<td>RISK OF MELANOMA WITH PHOSPHODIESTERASE TYPE 5 INHIBITOR USE AMONGST PATIENTS WITH ERECTILE DYSFUNCTION, PULMONARY HYPERTENSION AND LOWER URINARY TRACT SYMPTOMS</td>
</tr>
<tr>
<td>MP85-02</td>
<td>IMPACT OF GROWTH HORMONE SECRETAGOGUES ON ANTHROPOMORPHIC PARAMETERS IN MEN USING BODY COMPOSITION ANALYSIS</td>
</tr>
<tr>
<td>MP85-04</td>
<td>DOES IMIPRAMINE AND PSEUDOEPHEDRINE MEDICAL TREATMENT HAVE CLINICAL IMPLICATION IN TREATMENT OF RETROGRADE EJACULATION CAUSED BY DIABETES MELLITUS?</td>
</tr>
</tbody>
</table>

---

*Presenting author
MP85-05 | SEXUAL DYSFUNCTION AFTER 5-ALPHA REDUCTASE INHIBITOR USE: INSIGHTS FROM THE REDUCE STUDY GROUP DATABASE
Kelly T. Harris*, Amin S. Herati, Baltimore, MD, Gerald L. Andriole, St. Louis, MO, Ramiro Castro- Santamaria, King of Prussia, PA, Stephen J. Freedland, Los Angeles, CA, Daniel M. Moreira, Chicago, IL

MP85-06 | TOREMIFENE CITRATE IMPROVES HIGH-DENSITY LIPOPROTEIN LEVELS IN MEN ON TESTOSTERONE REPLACEMENT THERAPY

MP85-07 | TESTOSTERONE PROFILES AFTER RADIATION THERAPY FOR PROSTATE CANCER
Hisanori Taniguchi*, John Mulhall, New York, NY

MP85-08 | PENILE REHABILITATION FOR POST-PROSTATECTOMY ERECTILE DYSFUNCTION: A COCHRANE SYSTEMATIC REVIEW AND META-ANALYSIS
Yiannis Philippou*, Oxford, United Kingdom, Jee Hung Jung, Minneapolis, MN, Martin Stegall, Pontypridd, United Kingdom, Caitlin Bakker, Philipp Dahm, Minneapolis, MN

MP85-09 | DIRECTED EDUCATION AND MANAGEMENT BY A SEXUAL MEDICINE SPECIALIST INCREASES SEXUAL FUNCTION SATISFACTION FOLLOWING COLORECTAL SURGERY
Kazuhito Matsushita*, Tokyo, Japan, Doron Stemper, New York, NY, Shigeo Horie, Tokyo, Japan

MP85-10 | PROSTATE CANCER REHABILITATION: OUTCOMES OF A SEXUAL HEALTH CLINIC
Andrew Matthew*, Leah Jamnicky, Kristen Currie, Anika Gentile, John Trachtenberg, Shabbir Aliabadi, Antonio Finelli, Neil Fleschner, Gideon Yang, Lisa Osqui, Toronto, Canada, Joyce Davidson, Vancouver, Canada, Dean Elferman, Toronto, Canada

MP85-11 | PENILE REHABILITATION AND LONG TERM FOLLOW-UP – HOW IMPORTANT IS THE PRESERVATION OF NOCTURNAL PENUMESCENCE WITH DAILY LOW-DOSE SILDENAFIL 6 WEEKS AFTER NERVE-SPARING RADICAL PROSTATECTOMY FOR THE ERECTILE FUNCTION AFTER 2 YEARS?
Andreas Bannowsky*, Caroline Wedel, Kasiet Aidarbekova, Florian Armbrecht, Rendsburg, Germany, Stefan U¨ckert, Hannover, Germany

MP85-12 | PREDICTIVE FACTORS FOR MAINTENANCE OF EFFICACY AFTER CESSION OF TESTOSTERONE TREATMENT
Jeong Kyun Yeo*, Min Gu Park, DaejYeon Cho, Seoul, Korea, Republic of

MP85-13 | ERECTILE FUNCTION IN 478 HYPOGONADAL MEN WITH MODERATE TO SEVERE ED WITH AND WITHOUT TESTOSTERONE THERAPY FOR UP TO 10 YEARS
Ahmad Haider*, Karim Sultan Haider, Bremerhaven, Germany, Gheorghe Doros, Abdulmaged Traish, Boston, MA

MP85-14 | VARIANCE IN PEAK AND TROUGH TESTOSTERONE LEVELS IN MEN USING INTRAMUSCULAR TESTOSTERONE
Bruno Nascimento*, Helen L. Bemie, Elizabeth Schofield, John P. Mulhall, New York, NY

MP85-15 | TESTOSTERONE TREATMENT IN MEN WITH CLASSICAL VS FUNCTIONAL HYPOGONADISM: RESULTS FROM A 9-YEAR-REGISTRY
Michael Zitzmann*, Eberhard Nieschlag, Muenster, Germany, Abdul Traish, Boston, MA, Sabine Kliesch, Muenster, Germany

MP85-16 | EXTRACORPOREAL SHOCK-WAVE THERAPY (ESWT) IN TREATMENT OF ED: RESULTS OF SHAM-CONTROLLED STUDY
Leonid Spivak*, Andrei Vinarov, Darina Platonova, Yuri Demidko, Moscow, Russian Federation

MP85-17 | THE EFFECT OF INSULIN-LIKE GROWTH FACTOR-1 (IGF-1) DELIVERED VIA POLYMERIC PLGA MICROSPHERES ON ERECTILE FUNCTION AFTER BILATERAL CAVERNOUS NERVE INJURY IN THE RAT

MP85-18 | IVABRADINE (FIRST HCN CHANNEL BLOCKER) ATTENUATES HUMAN CORPUS Cavernosum Contraction IN VITRO VIA INTERFERENCE WITH THE CALCIUM AND POTASSIUM TRANSFER: A POTENTIAL NEW THERAPEUTIC OPTION FOR ERECTILE DYSFUNCTION
Serap Gur, Ankara, Turkey, Laith Alzweri*, Asim Abdel-Mageed, Suresh Sikka, Philip Kadowitz, Wayne Hellstrom, New Orleans, LA

MP85-19 | EUGONADAL TESTOSTERONE LEVELS POSITIVELY REGULATES ERECTILE FUNCTION IN ISOLATED HUMAN CORPUS CAVERNOSUM

MP85-20 | RELATIONSHIP BETWEEN ENDOGENOUS TESTOSTERONE AND LIPID PARAMETERS: INSIGHT FROM REDUCE STUDY GROUP DATABASE
Kelly T. Harris*, Amin S. Herati, Baltimore, MD, Gerald L. Andriole, St. Louis, MO, Ramiro Castro- Santamaria, King of Prussia, PA, Stephen J. Freedland, Los Angeles, CA, Daniel M. Moreira, Chicago, IL

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>Abstract Number</th>
<th>Title</th>
<th>Authors</th>
<th>City</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP86-01</td>
<td>Variability of Retail Pricing of Generic Urologic Medications in a Major US Metropolitan Area</td>
<td>Perry Xu*, Justin Barnes, Emily Choe, Johar Syed, Sameer Siddiqui</td>
<td>Saint Louis, MO</td>
</tr>
<tr>
<td>MP86-02</td>
<td>A Model of a Capitated System for Treatment of Benign Prostatic Hyperplasia</td>
<td>Laurel Sofer*, Chicago, IL, Paolo Serafini, Udine, Italy, Simone Crivellaro</td>
<td>Chicago, IL</td>
</tr>
<tr>
<td>MP86-04</td>
<td>Initial Experience of a Urology Practice Participating in an Episode-Based Payment Model for Cancer Care, The Oncology Care Model (OCM)</td>
<td>Jeremy Shelton*, Encino, CA, Richard David, Shirley Lee, Melanie Reed, Kambiz Dardashti, Timothy Lesser, Los Angeles, CA, Mayank Patel, Encino, CA, Alec Borsook, Bryan Renslo, Anthony Lam, Alec Koo, Los Angeles, CA</td>
<td></td>
</tr>
<tr>
<td>MP86-05</td>
<td>Implementation of Medical Scribes in an Academic Urology Practice: An Analysis of Productivity, Revenue, and Satisfaction</td>
<td>Benjamin McCormick*, Allison Deal, Kristy Borawski, Mathew Raynor, Davis Viprakasit, Eric Wallen, Michael Woods, Raj Pruthi, Chapel Hill, NC</td>
<td></td>
</tr>
<tr>
<td>MP86-06</td>
<td>Office Based Pediatric Urology Procedures: Reduced Costs and Improved Utilization of Resources</td>
<td>Christopher Brown*, Seth Alpert, Daniel DuJusta, Daryl McLeod, Christina Ching, Molly Fuchs, Venkata Jayanthi, Columbus, OH</td>
<td></td>
</tr>
<tr>
<td>MP86-07</td>
<td>Contributions of Readmissions to 90-Day Episode Costs Following Major Urologic Oncology Surgeries: Which Surgeries Should Be Targeted for Improvement?</td>
<td>Meera Chappidi*, San Francisco, CA, Max Kates, Trinity Bivalacqua, Baltimore, MD</td>
<td></td>
</tr>
<tr>
<td>MP86-08</td>
<td>Thematic Content Analysis of Online Physician Reviews in Urology</td>
<td>Ariel Moradzadeh*, Pooja Parameshwar, Justin Houman, Timothy Daskivich, Jennifer Anger, Los Angeles, CA</td>
<td></td>
</tr>
<tr>
<td>MP86-09</td>
<td>Increased Resource Utilization in Men with Metastatic Prostate Does Not Result in Improved Survival or Quality of Life</td>
<td>Ron Golan*, Adrien Bernstein, Xiangmei Gu, Brian Dinerman, Art Sedrakyan, Jim Hu, New York, NY</td>
<td></td>
</tr>
<tr>
<td>MP86-10</td>
<td>An Analysis of Urologic Patients Transferred to a Tertiary Care Center Over a 2 Year Period Highlights Lack of Access to Care and Cost</td>
<td>Marilyn Hopkins*, Patrick Michael, Andrew James, Andrew Harris, Lexington, KY</td>
<td></td>
</tr>
<tr>
<td>MP86-12</td>
<td>Routine Referral for Preoperative Medical Evaluation May Be Safely Omitted Among Patients Undergoing Radical Prostatectomy</td>
<td>Nima Almassi*, Michelle Ponziano, Howard Goldman, Venkatesh Krishnamurthi, Cleveland, OH</td>
<td></td>
</tr>
<tr>
<td>ABSTRACT NUMBER</td>
<td>TITLE</td>
<td>ABSTRACT NUMBER</td>
<td>TITLE</td>
</tr>
<tr>
<td>-----------------</td>
<td>-------</td>
<td>-----------------</td>
<td>-------</td>
</tr>
<tr>
<td>MP86-14</td>
<td>PATIENT VALUATION OF CASTRATION-RESISTANT PROSTATE CANCER HEALTH STATES</td>
<td>MP86-17</td>
<td>SCREENING POSTOPERATIVE HEMOGLOBIN AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY: FREQUENTLY UTILIZED, BUT NECESSARY?</td>
</tr>
<tr>
<td>MP86-15</td>
<td>HACKENSACK MULTI-DISCIPLINARY ROBOTIC-ASSISTED LAPAROSCOPIC PARTIAL NEPHRECTOMY (RPN) PATHWAY: IMPROVING QUALITY METRICS</td>
<td>MP86-18</td>
<td>RESOURCE USAGE FOR UROLOGIST-PERFORMED INPATIENT URETHRAL CATHETERIZATION IN A TERTIARY CARE TEACHING HOSPITAL: A QUALITY IMPROVEMENT STUDY</td>
</tr>
<tr>
<td>MP86-16</td>
<td>SPILLOVER EFFECTS OF THE HOSPITAL READMISSION REDUCTION PROGRAM ON RADICAL CYSTECTOMY READMISSIONS</td>
<td>MP86-19</td>
<td>VENOUS THROMBOEMBOLISM PROPHYLAXIS FOLLOWING RADICAL PROSTATECTOMY – MONEY WELL SPENT?</td>
</tr>
<tr>
<td>Matthew Lee*, Brent Hollenbeck, Mary Oerline, Ted Skolarus, Ann Arbor, MI, Bruce Jacobs, Pittsburgh, PA, Rita Jen, Amy Luckenaugh, Vahahn Shahinian, Tudor Borza, Ann Arbor, MI</td>
<td>Bridget Heijkoop*, Natalie Parker, Dan Spernat, Adelaide, Australia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MP86-17</td>
<td>SCREENING POSTOPERATIVE HEMOGLOBIN AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY: FREQUENTLY UTILIZED, BUT NECESSARY?</td>
<td>MP86-20</td>
<td>PRIMARY TESTICULAR LYMPHOMA: ONCOLOGIC OUTCOMES AND TREATMENT PATTERNS</td>
</tr>
<tr>
<td>MP86-18</td>
<td>RESOURCE USAGE FOR UROLOGIST-PERFORMED INPATIENT URETHRAL CATHETERIZATION IN A TERTIARY CARE TEACHING HOSPITAL: A QUALITY IMPROVEMENT STUDY</td>
<td></td>
<td>Fernando Caumont*, John Burns, Seattle, WA, Mazen Alsinawi, Pittsburgh, PA, John Paul Flores, Sydney Akapame, Christopher Porter, Seattle, WA</td>
</tr>
<tr>
<td>MP86-19</td>
<td>VENOUS THROMBOEMBOLISM PROPHYLAXIS FOLLOWING RADICAL PROSTATECTOMY – MONEY WELL SPENT?</td>
<td></td>
<td>APPROVED FOR AMA PRA CATEGORY 1 CREDIT™</td>
</tr>
<tr>
<td>MP86-20</td>
<td>PRIMARY TESTICULAR LYMPHOMA: ONCOLOGIC OUTCOMES AND TREATMENT PATTERNS</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
MP87-05 SUPERIOR EFFICACY OF DEGARELIX AS NEOADJUVANT HORMONE THERAPY IN CONTROL OF ACUTE GENITOURINARY TOXICITY ASSOCIATED WITH RADIATION THERAPY FOR PROSTATE CANCER COMPARED TO LHRH AGONIST; A PROPENSITY-SCORE MATCHING ANALYSIS
Junpei Iizuka*, Tokyo, Japan, Yasunobu Hashimoto, Saitama, Japan, Taunenori Kondo, Keisuke Hata, Toshiro Takagi, Taichi Kanzawa, Kazuhiko Yoshida, Kazunari Tanabe, Tokyo, Japan

MP87-06 SARCOPENIA RATHER THAN OBESITY MAY BE ASSOCIATED WITH SURVIVAL AMONG PATIENTS WITH METASTATIC OR CASTRATE RESISTANT PROSTATE CANCER

MP87-07 STATIN USE IS ASSOCIATED WITH IMPROVED PROSTATE CANCER-SPECIFIC OUTCOMES IN WHITE BUT NOT BLACK MEN INITIATING ANDROGEN DEPRIVATION THERAPY
Emma Allott*, Chapel Hill, NC, Lauren Howard, Durham, NC, William Aronson, Los Angeles, CA, Martha Terris, Augusta, GA, Christopher Kane, San Diego, CA, Christopher Amling, Portland, OR, Matthew Cooperberg, San Francisco, CA, Stephen Freedland, Los Angeles, CA

MP87-08 SYNTHESIS AND EVALUATION OF STRUCTURE-ACTIVITY RELATIONSHIP OF DERIVATIVES OF A SELECTIVE INHIBITOR FOR ERG POSITIVE PROSTATE CANCER CELLS

MP87-09 TESTOSTERONE REDUCTION >480 NG/DL PREDICTS FAVORABLE PROGNOSIS OF ADVANCED PROSTATE CANCER TREATED WITH ANDROGEN-DEPRIVATION THERAPY
Satoshi Yamamoto, Shinichi Sakamoto*, Takaaki Tamura, Chiba, Japan, Akinori Takei, Asahi, Japan, Yusuke Imamura, Koji Kawamura, Takashi Imano, Akira Komiya, Tomohiko Ichikawa, Chiba, Japan, Koichiro Akakura, Shinjuku, Japan

MP87-10 NEW DESIGNER DRUGS FOR CASTRATE RESISTANT PROSTATE CANCER
Carrie Sun*, Subhasish Tapadar, David Gaul, Rebecca Arnold, Adegboyega Oyelere, John Petros, Atlanta, GA

MP87-11 INTERIM ANALYSIS OF AN OPEN LABEL PHASE II STUDY OF ENZALUTAMIDE AND RADIUM RA 233 DICHLORIDE IN SYMPTOMATIC, METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS
Neal Shore*, Myrtle Beach, SC, Paul Schellhammer, Virginia Beach, VA, Ronald Tutrone, Towson, MD, Neil Mariados, Syracuse, NY, Stacey Harrelson, Myrtle Beach, SC

MP87-12 THE IMPACT OF METFORMIN USE ON ONCOLOGIC OUTCOMES IN PROSTATE CANCER PATIENTS RECEIVING DOCETAXEL CHEMOTHERAPY
Andrew Truong*, Gray Roberge, Jinn-ing Liou, E. Jason Abel, Tracy Downs, David Jarrard, Kyle Richards, Madison, WI

MP87-13 ANDROGEN DEPRIVATION THERAPY CAUSES VITAMIN K DEFICIENCY AND DECREASED BONE MINERAL DENSITY IN CASTRATION-SENSITIVE PROSTATE CANCER: A PROSPECTIVE STUDY
Takahiro Kimura*, Yusuke Koike, Koichi Aikawa, Shoji Kimura, Keilichiro Mori, Hiroshi Sasaki, Kenta Miki, Ken Watanabe, Mitsuru Saito, Shin Egawa, Tokyo, Japan

MP87-14 RELATIONSHIP BETWEEN COGNITIVE IMPAIRMENT AND BRAIN MORPHOLOGICAL-FUNCTIONAL FEATURES IN PROSTATE CANCER PATIENTS TREATED WITH ADT
Ana Plata Bello*, Yaiza Pérez Martín, Tomas Concepcion Masip, Jose Maria Pérez González, Jose Luis González Mora, Julio Plata Bello, La Laguna, Spain

MP87-15 USE OF STATINS IN COMBINATION WITH ANDROGEN DEPRIVATION THERAPY IN PATIENTS WITH ADVANCED PROSTATE CANCER: IMPACT ON ONCOLOGICAL OUTCOMES
Natasha Posielski*, India Anderson-Carter, Jinn-ing Liou, E. Jason Abel, Tracy Downs, David Jarrard, Kyle Richards, Madison, WI

MP87-16 EFFECT OF RACE ON THE RISK OF METASTASIS AND MORTALITY IN PATIENTS EXPERIENCING EARLY BIOCHEMICAL RECURRENCE FOLLOWING ROBOTIC RADICAL PROSTATECTOMY
Akshay Sood*, Firas Abdollah, Jacob keeley, Ali Dabaja, James Peabody, Mani Menon, Shaheen Alanee, Detroit, MI

*Presenting author
MP87-17 FACTORS ASSOCIATED WITH TESTOSTERONE RECOVERY AFTER ANDROGEN DEPRIVATION THERAPY IN PATIENTS WITH PROSTATE CANCER
Wook Nam, Se Young Choi, Jeman Ryu, Yoon Soo Kyung, Kyung Hyun Moon, Sungchan Park, Han Kyu Chae, Wonchul Lee, Jaehoon Lee*, Wonseok Choi, Dalsan You, In Gab Jeong, Jun Hyuk Hong, Hanjong Ahn, Choung-Soo Kim, Seoul, Korea, Republic of

MP87-18 EARLY EXPERIENCE OF A RANDOMIZED CONTROLLED TRIAL OF RADICAL PROSTATECTOMY FOR OLIGO-METASTATIC PROSTATE CANCER: CHALLENGES TO PATIENT RECRUITMENT AND EFFECTIVE SOLUTIONS
Prasanna Sooriakumaran*, Surrey, United Kingdom, Prabhakar Rajan, Ashwin Sridhar, Pramit Khetrapal, London, United Kingdom, Christopher Eden, Surrey, United Kingdom, Freddie Hamdy, Oxford, United Kingdom, John Kelly, Senthil Nathan, London, United Kingdom, Caroline Wilson, Bristol, United Kingdom

MP87-19 MULTIMODAL SYSTEMIC THERAPY WITH DEFINITIVE PROSTATECTOMY IN DE NOVO METASTATIC PROSTATE CANCER
Ramkishen Narayanan*, Jennifer Linehan, Santa Monica, CA, Nicholas Vogelzang, Las Vegas, NV, Chikako Matsuba, Przemyslaw Twardowski, Timothy Wilson, Santa Monica, CA

MP87-20 NEW CONCEPT FOR TREATING URINARY INCONTINENCE AFTER RADICAL PROSTATECTOMY WITH RADIOFREQUENCY: RESULTS OF A PHASE ONE STUDY
Danielle Sodre*, Cristina Brasil, Alcina Teles, Cintia Pinheiro, Luiz Eduardo Café, Patrícia Lordelo*, Salvador, Brazil

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Monday, May 21, 2018

Modulated Poster Session 88
KIDNEY CANCER: BASIC RESEARCH & PATHOPHYSIOLOGY III
Room 3005 @ MCC West
Moderators: W. Marston Linehan, Guan Wu and Kerstin Junker

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MP88-01</strong></td>
<td>METABOLOMICS SIGNATURES IN URINE FROM RENAL CELL CARCINOMA PATIENTS</td>
</tr>
<tr>
<td>Annelise Bonvillain*, David Gaul, Chaevien Clendinen, Rebecca Facundo Fernandez, Viraj Master, Kenneth Ogan, David Roberts, Sharon Bergquist, John Petros, Atlanta, GA</td>
<td></td>
</tr>
</tbody>
</table>

| **MP88-02** | A PILOT INVESTIGATION OF THE URINARY METABOLIC VARIATIONS AND BIOMARKER DISCOVERY IN RENAL CELL CARCINOMA |
| Mingxin Zhang*, Hanzhong Li, Wei Sun, Yushi Zhang, Beijing, China, People’s Republic of |

| **MP88-03** | USE OF URINARY METABOLOMICS TO IDENTIFY HIGH-RISK CLEAR CELL RENAL CELL CARCINOMA |
| Mohit Gupta*, Hiten Patel, Alice Semerjian, Michael Gorin, Michael Johnson, Mohamad Allaf, Phillip Pierorazio, Baltimore, MD |

| **MP88-04** | THE CLINICAL UTILITY OF ABSOLUTE COPY NUMBER AND FRAGMENT SIZE OF PLASMA CIRCULATING CELL-FREE DNA AS NOVEL BIOMARKERS IN RENAL CELL CARCINOMA PATIENTS |
| Yoshiyuki Yamamoto*, Motohide Uemura, Kosuke Nakano, Yujiro Hayashi, Cong Wang, Yu Ishizuya, Kyosuke Matsuzaki, Takuji Hayashi, Toshiro Kinouchi, Kentaro Jingushi, Taigo Kato, Atsunari Kawashima, Takeshi Ujike, Akira Nagahara, Kazutoshi Fujita, Ryoichi Imamura, Norio Nonomura, Suita City, Japan |

| **MP88-05** | CLINICAL SIGNIFICANCE OF PHENOTYPING AND KARYOTYPING OF DETECTING CIRCULATING TUMOR CELLS IN RENAL CELL CARCINOMA USING SUBTRACTION ENRICHMENT AND IMMUNOSTAINING-FLOURESCENCE IN SITU HYBRIDIZATION (SET-IFISH) |
| Mingxin Zhang*, Hanzhong Li, Yushi Zhang, Beijing, China, People’s Republic of |
MP88-06 EXPLORATION OF BIOMARKERS ASSOCIATED WITH PROGNOSIS IN PATIENTS WITH CLEAR CELL RENAL CELL CARCINOMA UNDERGOING SURGICAL RESECTION BY DESORPTION ELECTROSPRAY IONIZATION IMAGING MASS SPECTROMETRY
Keita Tamura*, Makoto Horikawa, Takayuki Sugiyama, Hideaki Miyake, Mitsutoshi Setou, Hamamatsu, Japan

MP88-07 THE ISYNA1 EXPRESSION IN PRIMARY RENAL CANCER AS A POTENTIAL PROGNOSTIC BIOMARKER FOR THE POST-OPERATIVE METASTASIS
Tomoyuki Koguchi*, Kei Ishibashi, Akifumi Onagi, Ryoo Tanji, Runiko Takinami, Seiji Hoshi, Junya Hata, Yuichi Sato, Hidenori Akaflata, Masao Kataoka, Soichiro Ogawa, Nobuhiro Haga, Ken Akaiwa, Yoshiyuki Kojima, Fukushima, Japan

MP88-08 TR4 NUCLEAR RECEPTOR PROMOTES CLEAR CELL RENAL CELL CARCINOMA (CCRCC) VASCULOGENIC MIMICRY (VM) FORMATION AND METASTASIS VIA ALTERING THE MIR490-3P/VIMENTIN SIGNALS
Jian Bai, Jinbo Chen*, Xiaofu Qiu, Shuyuan Yeh, Linyi Hu, Rochester, NY, Jun Zeng, Yangke Cai, Guangzhou, China, People’s Republic of, Chawnshang Chang, Rochester, NY

MP88-09 MIR-144-3P PROMOTES CELL PROLIFERATION, METASTASIS, SUNITINIB RESISTANCE IN CLEAR CELL RENAL CELL CARCINOMA BY DOWNREGULATING ARID1A
xiaping zhang*, wen xiao, wu han, china, People’s Republic of

MP88-10 ESTROGEN RECEPTOR β PROMOTES RENAL CELL CARCINOMA PROGRESSION VIA REGULATING LNCRNA HOTAIR- MIR-138/200C/204/217 ASSOCIATED CERNA NETWORK
Jie Ding*, Jinbo Chen, Chixun Ren Yeh, Sun Yin, Changyi Lin, Joshua Chou, Zhenyu Ou, Chawnshang Chang, Edward M. Messing, Rochester, NY, Un Qi, Shanghai, China, People’s Republic of, Shuyuan Yeh, Rochester, NY

MP88-11 CROSSTALK BETWEEN MIR-124 AND MEG3 REGULATES CELL PROLIFERATION AND METASTASIS OF RENAL CELL CARCINOMA
Kun Tang*, Hui Zhou, Haoran Liu, Tao Ye, Hua Xu, Zhangqun Ye, Wuhan, China, People’s Republic of

MP88-12 CIRCULAR RNA PROFILE IDENTIFIES CRIC-FOXM1 AS A METASTATIC FACTOR AND PROGNOSTIC MARKER IN CLEAR CELL RENAL CELL CARCINOMA
Yunze Xu*, Yiran Huang, Shanghai, China, People’s Republic of

MP88-13 TUMOR SUPPRESSOR TSC1 IS A NEW HSP90 COCHAPERONE THAT FACILITATES FOLDING OF KINASE AND NON-KINASE CLIENTS
Mark Woodford, Rebecca Sager, Adam Blanden, Stewart Loh, Syracuse, NY, David Gutmann, St. Louis, MO, Oleg Shapiro, Dimitra Bourboula, Syracuse, NY, Michael Wong, St. Louis, MO, Gennady Bratalsky, Mehdi Mollaou*, Syracuse, NY

MP88-14 CANCER STEM CELL FEATURE CAN INDUCE RESISTANCE TO MTOR INHIBITORS VIA THE NOTCH PATHWAY IN RENAL CELL CARCINOMAS
Kazuyuki Numakura*, Akita, Japan, Jesse Novac, Jean-Christophe Pignon, Toni Choueiri, Sabina Signoretti, Boston, MA

MP88-15 HIGH ACTIVATION BUT NOT OVEREXPRESSION OF CAMP RESPONSIVE ELEMENT BINDING PROTEIN 1 (CREB1) IS AN FEATURE OF POOR PROGNOSIS IN ADVANCED CLEAR CELL RENAL CELL CARCINOMA
Liqun Zhou*, Xuesong Li, Yifan Li, Beijing, China, People’s Republic of

MP88-16 THE DOWNREGULATION AND TUMOR SUPPRESSIVE FUNCTION OF RASAL2 IN RENAL CELL CARCINOMA
Ke Hui*, Kaijie Wu, Xi’an, China, People’s Republic of, Jer-Tsong Hsieh, Dallas, TX, Dallin He, Xi’an, China, People’s Republic of

MP88-17 DOWNREGULATION OF ENSG00000241684 IS ASSOCIATED WITH POOR PROGNOSIS IN ADVANCED CLEAR CELL RENAL CELL CARCINOMA
Hengchuan Su*, ShangHai, China, People’s Republic of

MP88-18 ERK5 IS A PROMISING THERAPEUTIC TARGET FOR CLEAR CELL RENAL CELL CARCINOMA
Hidenori Kanno*, Sei Naito, Osamu Ichiyanghi, Takahumi Narisawa, Hiromi Ito, Yamagata City, Japan, Akira Nagaoka, Yonezawa City, Japan, Suguru Ito, Shinta Suenaga, Hiroki Fukuhara, Yuta Kurota, Mayu Yagi, Atsumi Yamagishi, Toshihiko Sakurai, Hayato Nishida, Hisashi Kawazoe, Akihiko Abe, Takuya Yamanobe, Tomoyuki Kato, Norihiko Tsuchiya, Yamagata City, Japan

MP88-19 THE IMPORTANT ROLE OF GLYCINE N-METHYLTRANSFERASE IN THE PROLIFERATION OF RENAL AND UROTHELIAL CARCINOMA
Ario Takeuchi*, Masaki Shiota, Junichi Inokuchi, Katsunori Tatsugami, Masatoshi Eto, Fukuoka, Japan

MP88-20 DNAJB8 EXPRESSION IS ASSOCIATED WITH RECURRENCE OF RENAL CELL CARCINOMA
Satoshi Nishizawa*, Yuya Iwahashi, Haruka Miyai, Yuko Ueda, Takahito Wakamiya, Takashi Iguchi, Shinpei Yamashita, Akinori Iba, Yasuo Kohjimoto, Isao Hara, Wakayama, Japan

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP89-01</td>
<td>PRONE SPLIT-LEG VERSUS SUPINE PERCUTANEOUS NEPHROLITHOTOMY: OUTCOMES STRATIFIED BY GUY'S STONE SCORE Carlos Alfredo Batagello*, Cleveland, OH, Hugo Barone, Sao Paulo, Brazil, Emily Rose, Luay Alshara, Li Jianbo, Cleveland, OH, Eduardo Mazzucchi, Sao Paulo, Brazil, Manoj Monga, Cleveland, OH</td>
</tr>
<tr>
<td>MP89-02</td>
<td>AMBULATORY PERCUTANEOUS NEPHROLITHOTOMY PERFORMED IN A FREE-STANDING SURGERY CENTER: OUTCOMES OF THE FIRST 219 CASES Joel E. Abbott*, Mark V. Silva, Julio G. Davalos, Baltimore, MD</td>
</tr>
<tr>
<td>MP89-03</td>
<td>OUTPATIENT PCNL OUTCOMES: THE UC SAN DIEGO EXPERIENCE Daniel Han*, Seth Bechis, San Diego, CA, Joel Abbott, Hanover, MD, Roger Sur, San Diego, CA</td>
</tr>
<tr>
<td>MP89-04</td>
<td>BODY MASS INDEX (BMI) STRATIFIED OUTCOMES OF PERCUTANEOUS NEPHROLITHOTOMY Tim Larg*, Joshua M. Heiman, Blake B. Anderson, James E. Lingeman, Amy E. Krambeck, Indianapolis, IN</td>
</tr>
<tr>
<td>MP89-06</td>
<td>TREATMENT OF NON-OBSTRUCTIVE UROLITHIASIS IS EFFECTIVE IN TREATMENT OF RECURRENT URINARY TRACT INFECTIONS Deepak K. Agarwal*, Rochester, MN, Amy E. Krambeck, Indianapolis, IN, Francisco Maldonado, Mary E. Westerman, Rochester, MN, John J. Knoedler, Hershey, PA, Marcelino E. Rivera, Rochester, MN</td>
</tr>
<tr>
<td>MP89-07</td>
<td>PERCUTANEOUS NEPHROSTOMY VERSUS RETROGRADE URETERAL STENTING IN PATIENTS WITH OBSTRUCTIVE PYELONEPHRITIS AND SEPSIS: IMPLEMENTATION OF A HOSPITAL-WIDE PROTOCOL Elisabeth M. Sebesta*, Stephanie Thompson, David Mobley, Ojas Shah, New York, NY</td>
</tr>
<tr>
<td>MP89-08</td>
<td>STONE CULTURE IS NOT BETTER THAN BLADDER URINE CULTURE AS SIRS PREDICTOR AFTER PERCUTANEOUS NEPHROLITHOTOMY Alfio Corsaro*, Mehmet Özsoy, Julian Veser, Christian Seitz, Vienna, Austria</td>
</tr>
<tr>
<td>MP89-09</td>
<td>IS PREOPERATIVE PYURIA ASSOCIATED WITH POSTOPERATIVE FEBRILE COMPLICATION AFTER URETEROSCOPIC STONE REMOVAL FOR URETER OR RENAL STONES? Jae Min Chung*, Seungsoo Lee, Dong Hoon Lee, Moon Kee Chung, Jung Woo Lee, Sung-Woo Park, Ji-Yeon Han, Sang Don Lee, Yangsan, Korea, Republic of</td>
</tr>
<tr>
<td>MP89-10</td>
<td>OUTCOMES OF ELECTIVE URETEROSCOPY FOLLOWING RECENT UROSEPSIS AND EMERGENCY DRAINAGE RELATED TO STONE DISEASE: PROSPECTIVE RESULTS OVER 5-YEARS FROM A UNIVERSITY HOSPITAL Amelia Pietropaolo*, Patrick Jones, Robert Geraghty, Rachel Oliver, Bhaskar K. Somani, Southampton, United Kingdom</td>
</tr>
<tr>
<td>MP89-11</td>
<td>DO PATIENTS UNDERGOING PRIMARY URETEROSCOPY FOR URETERAL STONES HAVE A LOWER POST-OPERATIVE SEPSIS RATE COMPARED TO THOSE PREVIOUSLY STENTED? Nina Mikkilinen*, Benjamin Muller, Gen Li, Gina Badalato, Sven Wenske, David Weiner, Ojas Shah, NY, NY</td>
</tr>
<tr>
<td>MP89-12</td>
<td>THE EFFECT OF PRE-STENTING ON COMPLICATIONS AFTER URETEROSCOPY IN PATIENTS ON ANTICOAGULATION OR ANTIPLATELET THERAPY Seth Bechis*, Thomas DiPina, San Diego, CA, Luay Alshara, Carlos Batagello, Cleveland, OH, Joshua Heiman, Timothy Large, Indianapolis, IN, Sri Sivalingam, Cleveland, OH, Roger Sur, San Diego, CA, Amy Krambeck, Indianapolis, IN</td>
</tr>
<tr>
<td>MP89-13</td>
<td>IS IT SAFE TO USE A URETERAL ACCESS SHEATH IN AN UNSTENTED URETER? Asaf Shvero, Dorit Zilberman, Jacob Ramon, Harry Winkler, Nir Kleinmann*, Ramat Gan, Israel</td>
</tr>
<tr>
<td>MP89-14</td>
<td>THE TWO-POINT FLUOROSCOPY TECHNIQUE FOR URETEROSCOPY Jonathan Wagmater*, Valhalla, NY, Ariel Schulman, Durham, NC, Roger Yau, Majid Eshghi, Valhalla, NY</td>
</tr>
</tbody>
</table>
MP89-15 EVALUATION OF THE NEW MOSES TECHNOLOGY OF HOLMIUM LASER LITHOTRIPSY: A PROSPECTIVE MULTI-INSTITUTIONAL PILOT STUDY
Ahmed Ibrahim, Montreal, Canada, Andrew Symes, Brighton, United Kingdom, Khurshid Ghani, Ann Arbor, MI, Serge Carrier, Sero Andonian*, Montreal, Canada

MP89-16 WHAT IS THE BEST WAY TO POPCORN? ROLE OF FLOW RATE, FIBER SIZE, FIBER TO STONE DISTANCE, AND CALYCEAL SIZE ON SUB-MILLIMETER FRAGMENTATION

MP89-17 BAD OUT OF THE BOX: A REPORT ON PRE-OPERATIVE FAILURE RATES OF REUSABLE FLEXIBLE URETEROSCOPES AT A SINGLE INSTITUTION
Brian Calio*, Scott Hubosky, Philadelphia, PA, Kelly A. Healy, New York, NY, Demetrius Bagley, Philadelphia, PA

MP89-18 FAST TRACK STENT STUDY - IMPACT OF URETER STENTING AFTER URETERORENOROSCOPIC STONE EXTRACTION ON QUALITY OF LIFE - A PROSPECTIVE- RANDOMIZED EVALUATION
Peter Bach, Alina Reicherz*, Verena Maas, Patrizia Wenzel, Nicolas von Landenberg, Lisa Dahlkamp, Jueri Palisaar, Joachim Noldus, Christian von Bodman, Herne, Germany

MP89-19 WISCONSIN STONE QUALITY OF LIFE QUESTIONNAIRE: IS STONE REMOVAL SURGERY ASSOCIATED WITH BETTER QUALITY OF LIFE?
Igor Sorokin*, Dallas, TX, Benjamin Chew, Vancouver, Canada, Timothy Averch, Pittsburgh, PA, Vincent Bird, Gainesville, FL, Necole Streeper, Hershey, PA, Stephen Nakada, Kristina Penniston, Madison, WI, Jodi Antonelli, Dallas, TX

MP89-20 POST-OPERATIVE EMERGENCY ROOM VISITS AFTER URINARY STONE SURGERY: VARIATION BASED ON SURGICAL MODALITY
Akhinir Khanna*, Manoj Monga, Tianming Gao, Andrew Nguyen, Paurush Babbar, Jesse Schold, Robert Abouassaly, Cleveland, OH

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
Monday, May 21, 2018 1:00 pm - 3:00 pm
Podium Session 63
TRAUMA/RECONSTRUCTION/DIVERSION: URETHRAL RECONSTRUCTION (INCLUDING STRICTURE, DIVERTICULUM) III
Room 2024 @ MCC West
Moderators: Sean Elliott, Laura Leddy and Fabian Daza-Almendræs

<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD63-01</td>
<td>1:00</td>
<td></td>
<td>STENOSIS LENGTH IS INDEPENDENTLY ASSOCIATED WITH POSTERIOR URETHROTOMY FAILURE: STRENGTHENING THE CASE FOR ACCURATE PREOPERATIVE STAGING OF POSTERIOR URETHRAL STENOSES</td>
</tr>
<tr>
<td>PD63-00</td>
<td>1:10</td>
<td></td>
<td>COMPARATIVE STUDY BETWEEN THE USE OF INTERNAL URETHROTOMY WITH COLD KNIFE AND LASER IN THE MANAGEMENT OF ANASTOMOTIC STENOSIS AFTER RADICAL PROSTATECTOMY</td>
</tr>
</tbody>
</table>

*Presenting author
<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30</td>
<td>PD63-04</td>
<td>TRANSPERINEAL PRE-RECTAL APPROACH TO OPEN REPAIR OF VESICOURETHRAL</td>
<td>2:20</td>
<td>PD63-09</td>
<td>IDENTIFICATION OF MICROBIAL COLONIZATION PATTERNS IN EXPLANTED</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ANASTOMOTIC STENOSIS: OUR INITIAL EXPERIENCE AND RESULTS</td>
<td></td>
<td></td>
<td>ARTIFICIAL URINARY SPHINCTERS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Alexei Zhivot*, Moscow, Russian Federation,</td>
<td></td>
<td></td>
<td>Derek Jensen*, Jason Farrow, Dana</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Alexei Plekhanov, St. Petersburg, Russian Federation,</td>
<td></td>
<td></td>
<td>Hawkinsion, Joshua Broghammer, Kansas</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Alexander Koshmelev, Igor Revu, Oleg Loran, Dmitry Pushkar, Moscow,</td>
<td></td>
<td></td>
<td>City, KS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Russian Federation</td>
<td></td>
<td></td>
<td>Kyle Rose*, Kassem Faraj, Alexandra</td>
</tr>
<tr>
<td></td>
<td>1:40</td>
<td>PD63-05 BULBAR URETHRAL STRICTURES AFTER THE TREATMENT OF PROSTATE</td>
<td>2:30</td>
<td>PD63-10</td>
<td>CONTINENCE AND PAIN OUTCOMES IN EIGHTY-ONE CONSECUTIVE URETHROLYSIS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CANcer</td>
<td></td>
<td></td>
<td>PATIENTS: A SINGLE CENTER EXPERIENCE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Simon Bugeja, Stella Ivaz, Anastasia Frost*, Mariya Dragova,</td>
<td></td>
<td></td>
<td>Kyle Rose*, Kassem Faraj, Alexandra, Aqsa Khan, Christopher Wolter,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Daniela E. Andrich, Anthony R. Mundy, London, United Kingdom</td>
<td></td>
<td></td>
<td>Phoenix, AZ</td>
</tr>
<tr>
<td></td>
<td>1:50</td>
<td>PD63-06 INCIDENCE OF AND FACTORS AFFECTING POSTOPERATIVE INFECTION</td>
<td>2:40</td>
<td>PD63-11</td>
<td>CHANGING TRENDS IN RECONSTRUCTION OF COMPLEX URETHRAL STRICTURES:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IN URETHROPLASTY: A MULTI-CENTER STUDY</td>
<td></td>
<td></td>
<td>FROM SKIN FLAP TO PERINEAL URETHROSTOMY</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Saatchi Patell*, La Jolla, CA, Alex Vanni, Karem Alazem,</td>
<td></td>
<td></td>
<td>Joceline Fuchs*, Nabeel Shakir, Maxim</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Burlington, MA, Lee Zhao, New York City, NY, Jeremy Myers, Salt Lake</td>
<td></td>
<td></td>
<td>McKibben, Jeremy Scott, Boyd Viers, Travis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>City, UT, Benjamin Brenyer, Nima Baradaran, San Francisco, CA,</td>
<td></td>
<td></td>
<td>Pagliara, Allen Morey, Dallas, TX</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sean Elliott, Minneapolis, MN, Jill Buckley, La Jolla, CA</td>
<td></td>
<td></td>
<td>Maxim McKibben*, Alexander Rozanski</td>
</tr>
<tr>
<td></td>
<td>2:00</td>
<td>PD63-07 ANTIMICROBIAL PROPHYLAXIS MAY BE UNNECESSARY AFTER</td>
<td>2:50</td>
<td>PD63-12</td>
<td>VERSATILE ALGORITHMIC MIDLINE APPROACH TO PERINEAL URETHROSTOMY</td>
</tr>
<tr>
<td></td>
<td></td>
<td>URETHROPLASTY</td>
<td></td>
<td></td>
<td>Maxim McKibben*, Alexander Rozanski, Joceline Fuchs, Jeremy Scott,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Adarsh Manjunath*, Chicago, IL, Chris Gonzalez, Cleveland, OH,</td>
<td></td>
<td></td>
<td>Allen Morey, Dallas, TX</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Matthias Hofer, Chicago, IL</td>
<td></td>
<td></td>
<td>Maxim McKibben*, Alexander Rozanski, Joceline Fuchs, Jeremy Scott,</td>
</tr>
<tr>
<td></td>
<td>2:10</td>
<td>PD63-08 EXAMINING DIFFERENCES IN PATIENT-CENTERED OUTCOMES BY</td>
<td></td>
<td></td>
<td>Allen Morey, Dallas, TX</td>
</tr>
<tr>
<td></td>
<td></td>
<td>URINARY DIVERSION PROCEDURE IN PATIENTS WITH BLADDER CANCER: RESULTS</td>
<td></td>
<td></td>
<td>Maxim McKibben*, Alexander Rozanski</td>
</tr>
<tr>
<td></td>
<td></td>
<td>OF A NATION-WIDE SURVEY</td>
<td></td>
<td></td>
<td>Joceline Fuchs, Jeremy Scott, Allen Morey, Dallas, TX</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nihal Mohamed*, Tung Ming Leung, Rozza Mehrazin, John Sfakianos,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Emma Benn, New York, NY, Cheryl Lee, Ohio, OH, Diane Quale,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Washington DC, DC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2:20</td>
<td>PD63-09 IDENTIFICATION OF MICROBIAL COLONIZATION PATTERNS IN</td>
<td>2:30</td>
<td>PD63-10</td>
<td>CONTINENCE AND PAIN OUTCOMES IN EIGHTY-ONE CONSECUTIVE URETHROLYSIS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EXPLANTED ARTIFICIAL URINARY SPHINCTERS</td>
<td></td>
<td></td>
<td>PATIENTS: A SINGLE CENTER EXPERIENCE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Derek Jensen*, Jason Farrow, Dana</td>
<td></td>
<td></td>
<td>Kyle Rose*, Kassem Faraj, Alexandra, Aqsa Khan, Christopher Wolter,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hawkinsion, Joshua Broghammer, Kansas</td>
<td></td>
<td></td>
<td>Phoenix, AZ</td>
</tr>
<tr>
<td>1:00</td>
<td>PD64-01</td>
<td>THE WATER STUDY Clinical Results – A PHASE III BLINDED RANDOMIZED</td>
<td>1:20</td>
<td>PD64-03</td>
<td>THE IMPACT OF SURGICAL DURATION ON TRANURETHRAL RESECTION OF THE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Trial of Aquablation vs. TURP with Blinded Outcome Assessment for</td>
<td></td>
<td></td>
<td>PROSTATE ON COMPLICATIONS: AN ANALYSIS OF NSQIP DATA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Moderate-to-Severe LUTs in Men with BPH</td>
<td></td>
<td></td>
<td>Christopher B. Riedinger*, Richard J. Fantus, Ryan P. Wentz, Joseph F.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Peter Gilling*, Tauranga, New Zealand, Claus Roehrborn, Dallas, TX</td>
<td></td>
<td></td>
<td>Rodriguez, Norm D. Smith, Chicago, IL</td>
</tr>
<tr>
<td>1:10</td>
<td>PD64-02</td>
<td>REAL LIFE EXPERIENCE WITH THE REZUM SYSTEM FOR BENIGN PROSTATIC</td>
<td>1:20</td>
<td>PD64-03</td>
<td>THE IMPACT OF SURGICAL DURATION ON TRANURETHRAL RESECTION OF THE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HYPERPLASIA</td>
<td></td>
<td></td>
<td>PROSTATE ON COMPLICATIONS: AN ANALYSIS OF NSQIP DATA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Daniel Mollengarden*, Kenneth Goldberg, Daniel Wong, Claus Goerg</td>
<td></td>
<td></td>
<td>Christopher B. Riedinger*, Richard J. Fantus, Ryan P. Wentz, Joseph F.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Roehrborn, Dallas, TX</td>
<td></td>
<td></td>
<td>Rodriguez, Norm D. Smith, Chicago, IL</td>
</tr>
</tbody>
</table>

### Podium Session 64

**BENIGN PROSTATIC HYPERPLASIA: SURGICAL THERAPY & NEW TECHNOLOGY III**

Room 2022 @ MCC West

**Moderators:** David Chan, Steven Kaplan and Joyce Baard

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00 pm</td>
<td></td>
<td>THE WATER STUDY Clinical Results – A PHASE III BLINDED RANDOMIZED</td>
</tr>
<tr>
<td>1:00</td>
<td>PD64-01</td>
<td>Trial of Aquablation vs. TURP with Blinded Outcome Assessment for</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Moderate-to-Severe LUTs in Men with BPH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Peter Gilling*, Tauranga, New Zealand, Claus Roehrborn, Dallas, TX</td>
</tr>
<tr>
<td>1:10</td>
<td>PD64-02</td>
<td>REAL LIFE EXPERIENCE WITH THE REZUM SYSTEM FOR BENIGN PROSTATIC</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HYPERPLASIA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Daniel Mollengarden*, Kenneth Goldberg, Daniel Wong, Claus Goerg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Roehrborn, Dallas, TX</td>
</tr>
</tbody>
</table>
1:30 PD64-04 DEVICE MALFUNCTIONS AND COMPLICATIONS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA (BPH) SURGERY: REVIEW OF THE MANUFACTURER AND USER FACILITY DEVICE EXPERIENCE (MAUDE) DATABASE


1:40 PD64-05 A PROSPECTIVE ANALYSIS CONCERNING THE MICROBIAL RESISTANCE RATES IN PATIENTS UNDERGOING TURP

Evert Baten*, Hasselt, Belgium, Frank Vanden Aa, Christophe Orye, Leuven, Belgium, Reinoud Cartuyvels, Koenraad van Renterghem, Hasselt, Belgium

1:50 PD64-06 ANALYZING THE COST-EFFECTIVENESS OF SIX THERAPIES FOR TREATING LOWER URINARY TRACT SYMPTOMS DUE TO BENIGN PROSTATIC HYPERPLASIA

James Ulchaker*, Cleveland, OH, Melissa Martinson, Minneapolis, MN

2:00 PD64-07 DETERMINING THE MOST COST-EFFECTIVE LASER PROCEDURE FOR BENIGN PROSTATIC HYPERPLASIA

Laurel Sofer*, Simone Crivellaro, Chicago, IL, Paolo Serafini, Udine, Italy

2:10 PD64-08 COCHRANE SYSTEMATIC REVIEWS OF PROSTATIC URETHRAL LIFT AND PROSTATIC ARTERIAL EMBOLIZATION

Jae Hung Jung*, Wonju, Korea, Republic of, Balaji Reddy, Boston, MA, Karen Ann McCutcheon, Belfast, United Kingdom, Michael Borofsky, Vikram Narayan, Shamar Young, Jafar Goltzarian, Minneapolis, MN, Myung Ha Kim, Wonju, Korea, Republic of, Tae Young Shin, Chuncheon, Korea, Republic of, Philipp Dahm, Minneapolis, MN

2:20 PD64-09 A LONG TERM COMPARISON OF PERSISTENCE OF DRUG THERAPY IN 1,970 PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA

Keishi Kajikawa*, Kent Kanao, Miho Sugie, Aichi, Japan, Shingo Morinaga, Hiroki Muramatsu, Ikuo Kobayashi, Genya Nishikawa, Yoshiharu Kato, Masahito Watanabe, Kogenta Nakamura, Makoto Sumitomo, Nagakute-city Aichi-ken, Japan

2:30 PD64-10 LONG-TERM OUTCOMES OF LASER PROSTATECTOMY FOR STORAGE SYMPTOMS: COMPARISON OF SERIAL 5-YEAR FOLLOW-UP DATA BETWEEN 120W HPS PHOTO-SELECTIVE VAPORIZATION OF THE PROSTATE AND HOLMIUM LASER ENUCLEATION OF THE PROSTATE


2:40 PD64-11 THULIUM:YAG LASER VAPORIZATION VERSUS BIPOLAR TRANSMURAL RESECTION OF THE PROSTATE FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA: COMPARATIVE STUDY

Mohamed Rokba, Mohamed Selim, Mohamed Abdalh*, Alaa Elmahdy, Mohamed Omr, Shebin elkom, Egypt

2:50 PD64-12 ANTERIOR DEPTH OF PROSTATE: MORPHOLOGICAL FACTOR ASSOCIATED WITH DE NOVO URINARY INCONTINENCE FOLLOWING HOLMIUM LASER ENUCLEATION OF THE PROSTATE

Jun Seok Kim*, Dong Hoon Yoo, Wonsik Jeong, Byung Seok Oh, Dong Hoon Lim, Eun Mi Yang, Gwangju, Korea, Republic of, Seung Wook Lee, Seoul, Korea, Republic of, Joon Hwa Nah, Gwangju, Korea, Republic of

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
ABSTRACT | TIME | NUMBER | TITLE
--- | --- | --- | ---
1:10 | PD65-02 | IDENTIFICATION OF COORDINATED TRANSCRIPTION FACTOR GROUPS ASSOCIATED WITH ANDROGEN DEPRIVATION THERAPY RESPONSE AND METASTATIC PROGRESSION IN PROSTATE CANCER
Callan Brownfield*, Nitya Sharma, Kathry Pellegrini, Atlanta, GA, Veronique Ouellet, Montreal, Canada, Michael Feeman, Los Angeles, CA, Adeboyce Osunkoya, Atlanta, GA, Fred Saad, Montreal, Canada, Carlos Moreno, John Petros, Atlanta, GA | 1:10 | PD65-02 | PROSTATE CANCER: BASIC RESEARCH & PATHOPHYSIOLOGY IV
1:20 | PD65-03 | IDENTIFICATION OF PROGNOSTIC GENES THAT DETERMINE MRI VISIBILITY
Ping Li PhD, Sungyong You PhD, Hanson H. Zhao MD*, Christopher Nguyen PhD, Yanping Wang MD, Jayoung Kim PhD, Deepika Sirohi MD, Asha Ziembiec MD, Daniel Luthringer MD, Los Angeles, CA, Shih-Chieh Lin PhD, Houston, TX, Timothy Deskivich MD, Jonathan Wu MD, Michael R. Freeman PhD, Rola Saouaf MD, Debiao Li PhD, Hyung L. Kim MD, Los Angeles, CA | 1:20 | PD65-03 | PROSTATE CANCER: BASIC RESEARCH & PATHOPHYSIOLOGY IV
1:30 | PD65-04 | MR/US FUSION GUIDED ULTRA-FOCAL GOLD NANOPARTICLE DIRECTED LASER ABLATION OF PROSTATE TUMORS: RESULTS IN THE FIRST 11 PATIENTS (PHASE I/II TRIAL)
Harry Anastos*, Jared Winoker, Pratik Shukla, Shivaram Cumarasamy, John Sfakianos, Michael Carrick, Bodhi Rastinehad, Cynthia Krauer, Bachir Taouli, Sara Lewis, New York, NY, Jon Schwartz, Houston, TX, Ardeshir Rastinehad, New York, NY | 1:30 | PD65-04 | PROSTATE CANCER: BASIC RESEARCH & PATHOPHYSIOLOGY IV
1:40 | PD65-05 | USING METABOLIC PATHWAYS TO IMPROVE DIAGNOSIS AND RISK-STRATIFICATION OF PROSTATE CANCER
Aymen Alqazzaz*, Dexue Fu, Arman Karimi, Gustavo Ferreira, Mary Mckenna, Mohummad Siddiqui, Baltimore, MD | 1:40 | PD65-05 | PROSTATE CANCER: BASIC RESEARCH & PATHOPHYSIOLOGY IV
1:50 | PD65-06 | CHARACTERISTICS OF BONE PAIN AND NEURAL MECHANISMS IN AN IMMUNOCOMPETENT PROSTATE CANCER BONE METASTASES-ASSOCIATED PAIN MODEL
Zhiquiang Liu, Stephen Murphy, Christel Hall, Praveen Thumbikat*, Chicago, IL | 1:50 | PD65-06 | PROSTATE CANCER: BASIC RESEARCH & PATHOPHYSIOLOGY IV
2:00 | PD65-07 | THE IMPACT OF ANDROGEN DEPRIVATION THERAPY ON T CELL CHARACTERISTICS IN PROSTATE CANCER PATIENTS
Dixon T.S. Woon*, Melbourne, Australia, Genevieve Whitty, Heidelberg, Australia, Tatenda Nzenza, Melbourne, Australia, Manvendra Saxena, Heidelberg, Australia, Damien Bolton, Melbourne, Australia, Ian Davis, Heidelberg, Australia | 2:00 | PD65-07 | PROSTATE CANCER: BASIC RESEARCH & PATHOPHYSIOLOGY IV
2:10 | PD65-08 | SEMENOGELIN I AS AN ANDROGEN RECEPTOR CO-ACTIVATOR: A SYNTHETIC LXXLL PEPTIDE ANTAGONIST INHIBITS THE GROWTH OF PROSTATE CANCER CELLS
2:20 | PD65-09 | KINASE INHIBITORS INCREASE MCL1 DEGRADATION INDEPENDENT OF GSK3β AND SYNERGIZE WITH NAVITOCLOX TO DRIVE PROSTATE CANCER APOPTOSIS
2:30 | PD65-10 | PRLZ INCREASES PROSTATE CANCER DOCE TAXEL RESISTANCE BY INHIBITING LKB1/AMPK-MEDIATED AUTOPHAGY
Jin Zeng*, Wei Liu, Yizeng Fan, Dalin He, Lei Xi, An, China, People’s Republic of | 2:30 | PD65-10 | PROSTATE CANCER: BASIC RESEARCH & PATHOPHYSIOLOGY IV
2:40 | PD65-11 | MOLECULAR RATIONALE FOR TARGETING DNA-PKC TO ENHANCE UTILITY OF RADIATION THERAPY IN PROSTATE CANCER
Timothy Clinton*, Yi Yin, Ganesh Raj, Dallas, TX | 2:40 | PD65-11 | PROSTATE CANCER: BASIC RESEARCH & PATHOPHYSIOLOGY IV
2:50 | PD65-12 | PATIENT-DERIVED CANCER-ASSOCIATED FIBROBLASTS PROMOTE ORTHOTOPIC TUMOR GROWTH AND METASTATIC SPREAD IN A PROSTATE CANCER XENOGRAFT MODEL
Johannes Linxweiler*, Markus Hammer, Christina Körbel, Andreas Müller, Michael Stöckle, Michael D. Menger, Kerstin Junker, Matthias Saar, Homburg Saar, Germany | 2:50 | PD65-12 | PROSTATE CANCER: BASIC RESEARCH & PATHOPHYSIOLOGY IV

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
<th>ABSTRACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td>PD66-01</td>
<td>IMMEDIATE POST TURB INTRAVESICAL GEMCITABINE: A COST COMPARISON BASED ON SWOG S0337</td>
<td>Jacob Gantz*, Rochester, NY, Ekaterina Noyes, Buffalo, NY, Catherine Tangen, Seattle, WA, Seth Lerner, Ian Thompson, San Antonio, TX, Ralph Madeb, Brooklyn, NY, Edward Messing, Rochester, NY</td>
</tr>
<tr>
<td>1:10</td>
<td>PD66-02</td>
<td>THE CLINICAL IMPACT OF INURATION RESULTING FROM PURIFIED PROTEIN DEPRIVATION SKIN TEST IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER TREATED WITH BACILLUS-CALMETTE GUÉRIN</td>
<td>Naoya Niwa*, Eiji Kikuchi, Kazuhiro Matsumoto, Takeo Kosaka, Ryuichi Mizuno, Mototsugu Oya, Tokyo, Japan</td>
</tr>
<tr>
<td>1:20</td>
<td>PD66-03</td>
<td>SEQUENTIAL ADMINISTRATION OF BCG AND ELECTROMOTIVE DRUG ADMINISTRATION (EMDA) OF MITOMYCIN C (MMC) IN NON-MUSCLE INVASIVE BLADDER CANCER HAVING PREVIOUSLY RECEIVED INTRAVESICAL THERAPY</td>
<td>Tristan Juvet*, Christopher Wallis, Lior Krimus, Annette Erlich, Girish Kulkarni, Alexandre Zlotta, Toronto, Canada</td>
</tr>
<tr>
<td>1:30</td>
<td>PD66-04</td>
<td>RESULTS OF CALIBER: A PHASE II RANDOMISED FEASIBILITY TRIAL OF CHEMOABLATION VERSUS SURGICAL MANAGEMENT IN LOW RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)</td>
<td>Hugh Mostafid*, Guildford, United Kingdom, Joanne Cresswell, Middlesbrough, United Kingdom, Leyshon Griffiths, Leicester, United Kingdom, John Kelly, London, United Kingdom, Allen Knight, Hampshire, United Kingdom, James Catto, Sheffield, United Kingdom, Kim Davenport, Cheltenham, United Kingdom, Andrew Feber, London, United Kingdom, Margaret Knowles, Leeds, United Kingdom, John McGrath, Exeter, United Kingdom, Peter Cooke, Wolverhampton, United Kingdom, Shikohe Masood, Gillingham, United Kingdom, Aicha Goubar, Steven Penegar, Nuria Porta, Laura Wiley, Rebecca Lewis, Emma Hall, London, United Kingdom</td>
</tr>
<tr>
<td>1:40</td>
<td>PD66-05</td>
<td>INTRAOPERATIVE FROZEN SECTION EVALUATION OF THE TUMOR AND ITS BASE IN PATIENTS WITH T1 UROTHELIAL BLADDER CANCER UNDERWENT TRANSURETHRAL RESECTION</td>
<td>Yijun Shen*, Dingwei Ye, Shanghai, China, People’s Republic of</td>
</tr>
<tr>
<td>2:00</td>
<td>PD66-07</td>
<td>AN IMMEDIATE INTRAVESICAL INSTILLATION OF MITOMYCIN C IN PATIENTS WITH NON-MUSCLE-INVASIVE BLADDER CANCER: DO ALL PATIENTS BENEFIT?</td>
<td>Judith Bosschieter*, Jakko Nieuwenhuijzen, André N. Vis, Tessa van Ginkel, Birgit I. Lissenberg-Witte, Goedele M.A. Beckers, R. Jeroen A. van Moorselaar, Amsterdam, Netherlands</td>
</tr>
<tr>
<td>2:10</td>
<td>PD66-08</td>
<td>BCG UNRESPONSIVE DEFINITION SUPERSESDES DISTINCTION BETWEEN REFRACTORY AND RELAPSING DISEASE</td>
<td>Roger Li*, William Tabayoyong, Charles Guo, Graciela Nogueras Gonzalez, Neema Navai, H. Barton Grossman, Colin Dinney, Ashish Kamat, Houston, TX</td>
</tr>
<tr>
<td>2:20</td>
<td>PD66-09</td>
<td>ACCURATE PREDICTION OF PROGRESSION TO MUSCLE INVASIVE DISEASE IN PATIENTS WITH T1G3 BLADDER CANCER: A CLINICAL DECISION-MAKING TOOL</td>
<td>David D’Andrea*, Mohammad Abufrarj, Martin Susani, Robin Ristl, Beat Foerster, Shoji Kimura, Andrea Mari, Vienna, Austria, Alberto Briganti, Milan, Italy, Pierre Karakiewicz, Montreal, Canada, Kilian Gust, Vienna, Austria, Morgan Roupret, Paris, France, Shahrokh Shariat, Vienna, Austria</td>
</tr>
<tr>
<td>2:30</td>
<td>PD66-10</td>
<td>IDENTIFYING POLYMORPHISMS THAT MODULATE RESPONSE TO BACILLUS CALMETTE-GUERIN THERAPY IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CARCINOMA</td>
<td>Ziting Wang*, Jen-Hwei Sng, Yew Koon Lim, Esuvaranathan Kesavan, Ratha Mahendran, Lata Raman Nee Mani, Yong Huak Chan, Singapore, Singapore, Jeremy Yuen Chun Yeo, Chi Fai Ng, Shu Yin Eddie Chan, Hong Kong, Hong Kong, Edmund Chiong, Singapore, Singapore</td>
</tr>
</tbody>
</table>
HYPERTHERMIC INTRAVESICAL CHEMOTHERAPY FOR BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER
Joep de Jong*, Rotterdam, Netherlands, Kees Hendrickxen, Amsterdam, Netherlands, Marloes Rosier, Joost Boormans, Rotterdam, Netherlands, Hugh Mostafid, Guildford, United Kingdom

PATIENT CENTERED OUTCOMES OF INTRAVESICAL BACILLUS CALMETTE-GUERIN (BCG) PLUS INTERFERON
Ryan Steinberg*, Lewis Thomas, Sarah Mott, Michael O'Donnell, Iowa City, IA

2:50 PD66-12

IMAGING BASED TECHNIQUES & URORADIOLOGY
The videos in this session as well as the video libraries from the 2011-2016 Annual Meetings may be viewed in the Surgical Video Library and purchased in the AUA Store during the Annual Meeting. Both are located in Hall A. AUA members receive free online access to the Surgical Video Library throughout the year through AUA University. Visit www.AUAnet.org/University to access.

Video Session 12

Monday, May 21, 2018 1:00 pm - 3:00 pm

Room 3002 @ MCC West
Moderators: Isaac Kim, Khurshid Ghani and Norberto Bernardo

Computational Fluid Dynamics Simulations of Male Voiding: A Novel Method Using Real-Time Magnetic Resonance Image
Shigehiro Soh*, Toshiyuki Iwahata, Yukihito Shimomura, Keisuke Suzuki, Hisamitsu Ide, Hiroshi Okada, Koshigaya, Japan

Analysis of Surgeon Biometrics During Open and Robotic Radical Cystectomy with Electromyography and Motion Capture Analysis
Adam Baumgarten*, Jeff Robison, John Mayer, Dustin Hardwick, Trushar Patel, Tampa, FL

Three Dimensional Printing and Augmented Reality: Enhanced Precision for Robotic Assisted Partial Nephrectomy
Nicole Wake*, Marc Bjurlin, Pooya Rostami, Hersh Chandarana, William Huang, New York, NY

Telecytoscopy: Use of Remote Video Technology for Bedside Flexible Cystoscopy
Alexander D. Tapper*, Laura N. Nguyen, Jay B. Hollander, Frank N. Burks, Royal Oak, MI

Intraoperative Nerve Visualization with Ge3126

Indocyanine Green for Ureteral Identification During Non-Urologic Robotic Surgery: Mayo Clinic Pilot Experience
David Yang*, Adam Miller, Ross Avant, Matthew Tollesfon, Boyd Viers, Rochester, MN

Implementation of Multiparametric Magnetic Resonance Imaging Into Robotic-Assisted Radical Prostatectomy Using Virtual Reality

Initial Experience with Virtual Reality Enhanced Partial Nephrectomy
Egor Parkhomenko*, Roshan Patel, Shoaib Saflullah, Ryan James, Kamaljot Kaler, Edward Uchio, Ralph Clayman, Jaime Landman, Orange, CA

Dynamic Magnetic Resonance Angiography in Men with Idiopathic Erectile Dysfunction
Rand Wilcox Vanden Berg*, Russell Hayden, Ryan Flannigan, Daniel Margolis, Darius Paduch, New York, NY

Evaluating the Diagnostic Role of In-Bore Magnetic Resonance Imaging Guided Prostate Biopsy
Tiffany Cherry, Diarmidt Moran*, Paul Simkin, Richard Dowling, Stefan Heinze, Homayoun Zargar, Melbourne, Australia
2:30 SESSION 3: URETEROSCOPY
Judge: Demetrius Bagley
INTRODUCTION
Demetrius Bagley
2:35 DUSTING NO SHEATH SINGLE-USE DIGITAL FLEXIBLE URETEROSCOPE
Brian Matlaga
2:40 DUSTING SHEATH DIGITAL
Khurshid Ghani
2:45 BASKETING NO SHEATH FIBEROPTIC
Timothy Averch
2:50 BASKETING SHEATH DIGITAL
Matthew Sorensen
2:55 DISCUSSION

3:00 COFFEE BREAK

3:15 SESSION 4: PREVENTING CAOX
Judge: John Lieske
INTRODUCTION
John Lieske
3:20 DIET IS ALL YOU NEED
Kristina Penniston
3:30 EMPIRIC THIAZIDES AND CITRATE
Glenn Preminger
3:40 24 HR URINE GUIDED THERAPY
Jodi Antonelli
3:50 DISCUSSION

3:55 SESSION 5: THE FUTURE IS BRIGHT
Judge: Dean Assimos
MICROBIOME
Aaron Miller
BIG DATA
Charles Scales
MACROPHAGES
Paul Dominguez-Gutierrez
PUSHING THE ENVELOPE
Michael Bailey
DISCUSSION

4:05 LEVERAGE THE BEVERAGE
John Asplin

4:15 BIODEGRADABLE AND NEW MATERIALS IN URETERAL STENTS
Ben Chew

4:25 GOTTA WEAR SHADES
Dean Assimos

4:30 DISCUSSION

4:45 LEVERAGE THE BEVERAGE
John Asplin

4:55 BIODEGRADABLE AND NEW MATERIALS IN URETERAL STENTS
Ben Chew

5:05 GOTTA WEAR SHADES
Dean Assimos

5:15 ADJOURN

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Monday, May 21, 2018

PAN AFRICAN UROLOGICAL ASSOCIATION/CARIBBEAN UROLOGICAL SURGEONS ASSOCIATION (PAUSA/ CURA)
Room 214 @ MCC South

Program Chair: E. Oluwabunmi Olapade-Olaopa

1:15 WELCOME REMARKS
1:30 SESSION I: INVITED LECTURES
Chair: Lester Goetz
MINIMALLY INVASIVE MANAGEMENT OF FEMALE SUI
Suzette Sutherland
BLADDER AND URETERAL CHANGES LEADING TO HYDROURETERONEPHROSIS IN ADULTS
Gopal Badlani
2:00 SESSION II: ON THE SCIENTIFIC FRONTIER
Chair: Serigne Gueye
BASIC SCIENCE EVIDENCE OF EFFECT OF DIET ON THE BLADDER
E. Oluwabunmi Olapade-Olaopa
USE OF GENOMIC MARKERS IN THE MANAGEMENT OF LOCALIZED PROSTATE CANCER
Walter Rayford
UPDATE ON MANAGEMENT OF PROSTATE CANCER IN AFRICA
Mohamed Jalloh
THE SABRESOURCE: A NOVEL APPARATUS TO ASSIST PCNL PUNCTURE
Justin Howlett
OUTCOME OF ANTERIOR URETHRAL STRICTURE REPAIR IN YAOUNDE
Mbassi Achille Aurele
TRAUMA AND URETHRA STRICTURE
Medina Ndoye
CHANGING TRENDS IN THE MANAGEMENT OF PROSTATE CANCER IN TRINIDAD AND TOBAGO
Trudy Kawal
DISCUSSION

3:30 SESSION III: PANEL DISCUSSION: BLADDER CANCER IN AFRICA AND THE CARIBBEAN
Moderators: Alex Danso, Mohamed Jalloh
CURRENT EPIDEMIOLOGY OF BLADDER CANCER IN NIGERIA
E. Oluwabunmi Olapade-Olaopa
SQUAMOUS CELL CANCER OF THE BLADDER IN AFRICA: A DIFFERENT AND DISTINCT DISEASE
Kasonde Bowa
### Forums

**HISTORY OF UROLOGY**  
*Room 3018 @ MCC West*

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
<th>ABSTRACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30</td>
<td>FR-01</td>
<td>THE MEMOIR MAKES THE MAN: A CRITICAL HISTORIOGRAPHY OF HUGH HAMPTON YOUNG</td>
<td>Barbara Chubak*, New York, NY</td>
</tr>
<tr>
<td>1:37</td>
<td>FR-02</td>
<td>EPONYMOUS UROLOGIC GIANTS</td>
<td>Michael Moran*, Whiteville, NC</td>
</tr>
<tr>
<td>1:44</td>
<td>FR-03</td>
<td>SIMON-EMMANUEL DUPLAY: THE DAWN OF HYPOSPADIOLOGY</td>
<td>Marc Cendon*, Michael Kurtz, Erin McNamara, David Diamond, Boston, MA</td>
</tr>
<tr>
<td>2:05</td>
<td>FR-06</td>
<td>GODS ASSOCIATED TO MALE FERTILITY AND VIRILITY</td>
<td>Filipe Tenorio Lira Neto*, Jarys Borges Cabral Junior, Ricardo Jose Lisboa Lyra, Recife, Brazil</td>
</tr>
<tr>
<td>2:12</td>
<td>FR-07</td>
<td>UROLOGY AND SEXOLOGY IN GERMANY, 1900-1933</td>
<td>Matthias Krischel*, Thorsten Halling, Nils Hansson, Heiner Fangerau, Friedrich Moll, Düsseldorf, Germany</td>
</tr>
<tr>
<td>2:19</td>
<td>FR-08</td>
<td>ANCIENT UROGENITAL DISEASES IN THE LIGHT OF UROGENITAL VOTIVES</td>
<td>Ekrem Guner*, Sabnem Izmir Guner, Volkan Tugcu, Istanbul, Turkey</td>
</tr>
<tr>
<td>2:33</td>
<td>FR-10</td>
<td>BIFOCALS AND BLADDER OUTLET OBSTRUCTION: BENJAMIN FRANKLIN AND HIS FASCINATING UROLOGIC MORBIDITIES AND CONTRIBUTIONS TO OUR FIELD</td>
<td>Allison Glass*, Marc Dall’Era, Sacramento, CA</td>
</tr>
<tr>
<td>2:40</td>
<td>FR-11</td>
<td>A HURRICANE REOPENS AN OLD WOUND</td>
<td>Lawrence Wyner*, Huntington, WV</td>
</tr>
<tr>
<td>3:41</td>
<td>FR-14</td>
<td>SOLID, ENHANCING, AND LARGE: BOSNIAK’S CONTRIBUTION TO UROLOGY</td>
<td>Milan Shah*, Natan Davoudzadeh, Caner Dinlenc, New York, NY</td>
</tr>
<tr>
<td>4:02</td>
<td>FR-17</td>
<td>MEMORIAL OF EDWARD MARTIN, GENITOURINARY SURGEON, PIONEER OF CLINICAL ANDROLOGY, EDUCATOR AND PHILANTHROPIST</td>
<td>William Berg*, David Schulsinger, Yefim Sheynkin, Stony Brook, NY</td>
</tr>
</tbody>
</table>

*Presenting author
FR-18 4:09 HOW DO ASTRONAUTS URINATE? THE HISTORY OF INNOVATIONS ENABLING VOIDING IN THE VOID
Kimberly A. Maciolek*, Sara L. Best, Madison, WI

FR-19 4:16 STONE GIANTS AND ROCKET MEN & WOMEN
Sutchin R. Patel*, Stephen Y. Nakada, Madison, WI

FR-20 4:23 UROLOGY DURING THE FIRST WORLD WAR: TOPICS OF RESEARCH IN GERMANY AND ABROAD
Friedrich Moll*, Cologne, Germany, Thorsten Halling, Nils Hansson, Heiner Fangerau, Matthias Krischel, Dusseldorf, Germany

FR-21 4:30 THE CREATION OF A UROLOGY TRAINING PROGRAM: ROBERT PRENTISS AND THE SAN DIEGO COUNTY HOSPITAL
Unwanaobong Nseyo*, San Diego, CA

FR-22 4:37 FROM “END OF UROLOGY” TO ENDOUROLOGY: UROLOGIC LEGACY OF THE MINNEAPOLIS VA
Giulia Lane*, Maria Ulloko, Vikram Narayan, Cesar Ercole, Minneapolis, MN

FR-19 4:44 THE HISTORY BEHIND THE MACMILLAN CANCER SUPPORT GROUP
Shikohe Masood*, Gillingham, United Kingdom, Mohammed Quraishi, Birmingham, United Kingdom

FR-23 4:51 DR. MAURICE GONDER: FAMILY MAN, KOREAN WAR VETERAN AND UROLOGY PIONEER
Daniel Rittenberg*, Charles A. Loeb, Tal Cohen, Howard L. Adler, Stony Brook NY

5:00 ADJOURN
APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Monday, May 21, 2018 2:00 pm - 4:00 pm

PHILIPPINE UROLOGICAL ASSOCIATION (PUA)
Yerna Buena Salon 10 @ Marriott Marquis

2:00 INVOCATION & PHILIPPINE NATIONAL ANTHEM
3:00 FUTURE DEVELOPMENT OF PRACTICE IN UROLOGY
Raoul Concepcion

2:15 WELCOME REMARKS & INTRODUCTION TO SPEAKERS
2:30 ADVANCEMENT IN THE PRACTICE OF UROLOGY IN THE PAST 60 YEARS: PHILIPPINE SETTING
Dennis Lusaya

2:45 PRACTICE OF UROLOGY THROUGH THE YEARS IN THE WESTERN SETTING
Ananias Diokno

3:30 CLOSING REMARKS
Chair: Samuel Vincent Yrastorza

4:00 ADJOURN
APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Monday, May 21, 2018 2:30 pm - 5:30 pm

SOCIETA ITALIANA DI UROLOGIA (SIU)
Golden Gate A @ Marriott Marquis

2:30 WELCOME AND INTRODUCTION
Walter Artibani
AUA Secretary: Manoj Monga

2:35 SESSION I: INNOVATIVE CONTRIBUTIONS IN UROLOGY
Moderators: Giuseppe Carriero, Vincenzo Miron
RETZIUS SPARING PROSTATECTOMY: BOCCIARDI’S TECHNIQUE
Mani Menon
POSTERIOR RECONSTRUCTION: THE ROCCO STITCH
Vip Patel
RENAL TUMOR ENUCLEATION: THE FLORENTINE INNOVATION
Jihad Kaouk

3:35 SESSION II: PROSTATE CANCER HOT TOPICS
Moderators: Francesco Montorsi, Giuseppe Morgia
VIP RESERVOIR: THE NEOBLAGDER FROM PADUA
Inderbir Gill
PROSTATE BIOPSY: OPTIMIZING PATIENT SELECTION AND METHODS
Stacy Loeb
PRECISION SURGERY IN PROSTATE CANCER
Prokar Dasgupta
FOCAL THERAPY
Mark Emberton

3:00 SEXUAL REHABILITATION/THE SAN RAFFAELE PROTOCOL
John Mulhall
NEW HORMONAL AGENTS: THE UROLOGICAL PERSPECTIVE
A. Oliver Sartor

4:35 SESSION III: HOT TOPICS
Moderators: Luca Carmignani, Bernardo Rocco

PREDICTIVE TOOLS AND 3D PRINTING IN RENAL CANCER
Georges Pascal Haber

LASER THERAPY FOR BPO
John Wei

NEW TECHNOLOGY IN ENDOUROLOGY: WHAT’S NEW?
Michael Borofsky

5:05 SESSION IV: FACE TO FACE
Walter Artibani

SAFETY AND OUTCOMES OF ROBOTIC CYSTECTOMY
Moderator: Mark Soloway
Debaters: Trinity Bivalacqua, Peter Wiklund

5:30 AWARD: BEST ITALIAN ABSTRACT PRESENTED AT THE AUA MEETING 2018
Giuseppe Vespasiani

5:35 ADJOURN
<table>
<thead>
<tr>
<th>Booth(s)</th>
<th>Company Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>6359, Hall D</td>
<td>Confederación Americana de Urología</td>
</tr>
<tr>
<td>6281, Hall D</td>
<td>Indiana University Kelley School of Business</td>
</tr>
<tr>
<td>6573, Hall D</td>
<td>of Medicine Physician MBA</td>
</tr>
<tr>
<td>6542, Hall D</td>
<td>INEX Surgical Inc.</td>
</tr>
<tr>
<td>6521, Hall D</td>
<td>Infinity Massage Chairs</td>
</tr>
<tr>
<td>6519, Hall D</td>
<td>Inform Diagnostics</td>
</tr>
<tr>
<td>6485, Hall D</td>
<td>Innovex Medical Co., LTD</td>
</tr>
<tr>
<td>6514, Hall D</td>
<td>INTERNATIONAL CONTINENTINE SOCIETY</td>
</tr>
<tr>
<td>6468, Hall D</td>
<td>IntrinsIQ Specialty Solutions</td>
</tr>
<tr>
<td>6466, Hall D</td>
<td>Intuitive Surgical</td>
</tr>
<tr>
<td>6574, Hall D</td>
<td>IsoRay Medical</td>
</tr>
<tr>
<td>6476, Hall D</td>
<td>IVUmed</td>
</tr>
<tr>
<td>6429, Hall D</td>
<td>Jackson &amp; Coker</td>
</tr>
<tr>
<td>6460, Hall D</td>
<td>Jansen Laser Biotech, Inc.</td>
</tr>
<tr>
<td>6482, Hall D</td>
<td>Japanese Urological Association</td>
</tr>
<tr>
<td>6542, Hall D</td>
<td>Jeunesse Innovations</td>
</tr>
<tr>
<td>6357, Hall D</td>
<td>Jiangsu BONSS Medical Technology Co., Ltd.</td>
</tr>
<tr>
<td>6386, Hall D</td>
<td>Kaiser Permanente</td>
</tr>
<tr>
<td>6209, Hall D</td>
<td>KAXINN bladder scanner</td>
</tr>
<tr>
<td>6423, Hall D</td>
<td>KARL STORZ Endoscopica - Latino America</td>
</tr>
<tr>
<td>6209, Hall D</td>
<td>KARL STORZ Endoscopy - America, Inc.</td>
</tr>
<tr>
<td>6227, Hall D</td>
<td>Kettering Health Network</td>
</tr>
<tr>
<td>6762, Hall D</td>
<td>Koelis</td>
</tr>
<tr>
<td>6542, Hall D</td>
<td>LABORIE</td>
</tr>
<tr>
<td>6226, Hall D</td>
<td>Lazarus 3D</td>
</tr>
<tr>
<td>6482, Hall D</td>
<td>Lehigh Valley Health Network</td>
</tr>
<tr>
<td>6656, Hall D</td>
<td>LEONI Fiber Optics, Inc.</td>
</tr>
<tr>
<td>6669, Hall D</td>
<td>Liebel-Flarsheim, a Guerbet company</td>
</tr>
<tr>
<td>6209, Hall D</td>
<td>Life Sense Group</td>
</tr>
<tr>
<td>6180, Hall D</td>
<td>Lilly USA</td>
</tr>
<tr>
<td>6566, Hall D</td>
<td>USA, LDSA</td>
</tr>
<tr>
<td>6215, Hall D</td>
<td>Locumtenens.com</td>
</tr>
<tr>
<td>6534, Hall D</td>
<td>LP Surgical Fibers</td>
</tr>
<tr>
<td>6543, Hall D</td>
<td>(formerly Laser Peripherals)</td>
</tr>
<tr>
<td>6257, Hall D</td>
<td>Lumenis, Inc.</td>
</tr>
<tr>
<td>6209, Hall D</td>
<td>Lutonics Inc.</td>
</tr>
<tr>
<td>6227, Hall D</td>
<td>Marina Medical Instruments</td>
</tr>
<tr>
<td>6208, Hall D</td>
<td>Marley Drug</td>
</tr>
<tr>
<td>6567, Hall D</td>
<td>Massachusetts General Hospital</td>
</tr>
<tr>
<td>6209, Hall D</td>
<td>MaxiFlex, LLC</td>
</tr>
<tr>
<td>6209, Hall D</td>
<td>MAVIG GmbH</td>
</tr>
<tr>
<td>6209, Hall D</td>
<td>McArdle's Inc.</td>
</tr>
<tr>
<td>6209, Hall D</td>
<td>Medica Co., LTD</td>
</tr>
<tr>
<td>6209, Hall D</td>
<td>Medical Device Depot LLC</td>
</tr>
<tr>
<td>6209, Hall D</td>
<td>Medixflx</td>
</tr>
<tr>
<td>6209, Hall D</td>
<td>Medipace Ltd.</td>
</tr>
<tr>
<td>6209, Hall D</td>
<td>Meditec Ltd.</td>
</tr>
<tr>
<td>6209, Hall D</td>
<td>Medtronic</td>
</tr>
<tr>
<td>6209, Hall D</td>
<td>MERCCK &amp; CO.</td>
</tr>
<tr>
<td>6209, Hall D</td>
<td>Medtronic Nanosystems, Inc.</td>
</tr>
<tr>
<td>6209, Hall D</td>
<td>MEM Software Inc.</td>
</tr>
<tr>
<td>6209, Hall D</td>
<td>Medical Device Systems, Inc.</td>
</tr>
<tr>
<td>6209, Hall D</td>
<td>MicroGen DX</td>
</tr>
<tr>
<td>6209, Hall D</td>
<td>Micromedical Technologies</td>
</tr>
<tr>
<td>6209, Hall D</td>
<td>Microsurgery Instruments, Inc.</td>
</tr>
<tr>
<td>6209, Hall D</td>
<td>MIM Software Inc.</td>
</tr>
<tr>
<td>6209, Hall D</td>
<td>Mimic Technologies, Inc.</td>
</tr>
<tr>
<td>6209, Hall D</td>
<td>Mission Pharmacal Company</td>
</tr>
<tr>
<td>6209, Hall D</td>
<td>Mist Pharmaceuticals</td>
</tr>
<tr>
<td>6209, Hall D</td>
<td>Modernizing Medicine</td>
</tr>
<tr>
<td>6209, Hall D</td>
<td>Monarch Biobrains GmbH</td>
</tr>
<tr>
<td>6209, Hall D</td>
<td>Myriad Genetic</td>
</tr>
<tr>
<td>6209, Hall D</td>
<td>Laboratories, Inc.</td>
</tr>
<tr>
<td>6209, Hall D</td>
<td>NAMOCIRBONIX INC.</td>
</tr>
<tr>
<td>6209, Hall D</td>
<td>National Death Index</td>
</tr>
<tr>
<td>6209, Hall D</td>
<td>Neoscope</td>
</tr>
<tr>
<td>6209, Hall D</td>
<td>Ne未婚</td>
</tr>
</tbody>
</table>
Kocamanog˘lu, Fatih ............................. PD44-11
Kobayashi, Yasuyuki ........... MP61-20, MP83-11,
Knie, Christopher ................................ MP42-15
Knauer, Cynthia ... PD15-03, PD65-04, MP14-12,
Knietz, Laurence ...... MP77-15, p11, p97, p95,
Koh, Raymond ...... MP40-09, MP53-02, MP53-14,
Ko, In Kap ................... PD33-11, PD64-01, MP81-02
Ko, Raymond ...... MP40-09, MP53-02, MP53-14,
Ko, Yoon-Cha ................................ PD45-17
Kobashi, Kentaro .......... PD03-02, PD14-08, MP03-17
Kobashi, Hiroyuki .......... PD32-10, PM75-17, p119
Kobayashi, Daichi ................................ PD46-01
Kobayashi, Hiroshi .......... PD42-03, PD66-14
Kobayashi, Hiroki .......... PD34-02, PD34-13
Kobayashi, Takahiro .......... PD05-03, MP03-15
Kobayashi, Yashuuki ................... MP61-20, MP83-11,
Koch, Michael ............. PD15-08, MP11-19, MP77-13
Kochen, Rainer ................... PD52-09, PD12-04
Kocher, Neil .... PD08-03, PD28-03, PD52-09,
Kocik, Jurek ................... PD02-08, MP25-18
Kocijancic, Ervin ................... V10-01, V11-04
Kockelberger, Roger ............... MP18-03
Kodama, Hirotsaka .......... MP03-06, PD28-03,
Kodama, Ronald .... PD20-08, PD21-20, MP22-09
Kodaitte, Thomas Alex .......... MP08-19
Kogane, Masaaki ........... MP18-11, PD04-12
Kogevinas, Manolis .................. MP54-11
Koguchi, Tomoyuki ........ MP38-16, MP61-08,
Koh, Byoung ..................... PD42-08, MP56-02
Koh, Chelsea .................. PD69-07, p230
Koh, Dong Hoon .... PD16-07, PD42-07, MP16-09
Koh, Sang Don ...................... PD56-06
Kohar, Indhu ................... PD57-06, PD67-05
Kohan, Alfred .................... MP27-12
Kojimoto, Yasuo ................ PD08-12, PD29-05,
Koh, Tobias ...................... PD42-04, PD18-05
Köhler, Tobias ................ PD18-02, PD18-05, MP34-12,
Kolm, Thomas .............. MP47-02, MP67-04, MP74-02
Kolm, Michael .............. MP05-05, MP05-06,
Kolm, Maxim .................. PD56-03, PD56-09
Kolm, Jonas .................... PD14-12, PD16-16
Kolm, Rachel ..................... MP18-15, MP24-10
Kolok, Thomas .................. PD60-16, PD70-10
Komiya, Akira ...... PD03-03, MP22-11, MP24-08,
Kontturi, Erkki ................ PD11-01, PD17-08,
Kontturi, Karina ........ MP05-13, MP14-12,
Kopanski, Stanislaw ............. MP62-01, MP62-02
Kopp-Schneider, Annette ........ PD20-07
Kopp, Ryan ........ PD16-10, PD51-05, MP16-07,
Kopp-Schnieder, Annetette .... PD20-07
Korac, Gradimir ................ PD25-12
Körbel, Christina .......... PD65-12, MP70-08
Korcula, Martina ........ MP01-13, MP01-14
Korjus, Jürgen .......... PD01-03, PD01-06, MP03-17
Koretz, Rus ....................... MP15-06, PD28-03
Kore, Vinayak .................. V02-09
Korolev, Roman ........ MP19-10, MP36-17
Kornberg, Zachary .......... PD20-06, MP12-12,
Korolev, Dmitry .................. MP62-20
Korolova, Irena .......... PD14-11, PD56-14
Kouroukova, Hans .......... PD14-11, MP62-14
Kour-Sengul, Tulay .......... PD15-06, PD15-09
Kosaka, Noriko ............... MP30-06, MP50-06,
Kosaka, Takao ........ PD47-10, PD66-02, MP30-05,
Kosarek, Christopher ........ PD11-01, PD11-07
Koschel, Samanthta .......... PD17-08
Koshelev, Alexander ........ MP63-04
Kosinski, Karllin ........ MP30-09, MP12-13
Kost, Harald ....................... MP31-16
Koutsis, Georgios ........ MP05-13, MP12-19
Kovacs, Lajos ............................ MP84-12
Kovacevic, Ljubisa ........ MP39-06, MP39-07
Kowalczuk, Keith ................ MP35-11, MP63-11
Kowalewski, Timothy .................. p20
Kola, Raymond ..................... PD08-03
Ko, Kyo Chul ........ PD13-10, PD29-02, MP52-10,
Ko, Kevin ......................... PD17-04, PD28-03
Ko, Raymond ........................ PD20-01, PD28-04
Ko, Young-Hwii ................ MP01-08, MP11-07
Ko, Rha ......................... PD01-17, PD01-19
Kolb, Maurice ..................... MP62-08
Kolagunda, Abhishek ........ PD40-09, V12-07
Kolbas, Maurice .................. PD62-08
Kolle, Per ........................................ PD65-07
Kolli, Hiren ............. MP14-08, MP79-10, MP79-11
Kolb, Steffen ....................... MP07-02, MP15-03
Kolb, Mathias ..................... PD61-08, PD61-10
Kolberg, Peter ...................... MP07-02, MP15-03
Kolberg, Martin ..................... PD08-03, PD08-04,
Kolesnik, Tyler ................. PD43-05, PD43-12
Kolos, Mark ....................... PD67-02, PD67-05
Kolos, Michael ....................... PD67-02, PD67-05
Koll, Thomas .................. MP58-04, p96, 256, p305
Komba, Kaito .................... PD38-01, PD38-02
Kolle, Christian .................. MP11-12, MP11-17
Kolm, Jonathan Claudius .......... MP11-04, MP11-08,
Kolb, Christian ................. PD40-09, MP39-04
Kolb, Hans-Peter .................. MP11-14, MP11-17
Ko, Kevin ............. PD17-04, PD28-03, MP14-03,
Ko, Kyu-Cha .................. PD13-10, PM52-10,
Ko, Kyo Chul .......... PD13-10, PD29-02, MP52-10,
Ko, Kevin ....................... PD17-04, PD28-03
Ko, Kyu-Cha .................. PD13-10, PM52-10,
Ko, Kevin ....................... PD17-04, PD28-03
Ko, Kyu-Cha .................. PD13-10, PM52-10,
Ko, Kevin ....................... PD17-04, PD28-03
Ko, Kyu-Cha .................. PD13-10, PM52-10,
Ko, Kevin ....................... PD17-04, PD28-03
Ko, Kyu-Cha .................. PD13-10, PM52-10,
Ko, Kevin ....................... PD17-04, PD28-03
<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zheng, Yingye</td>
<td>PD20-01</td>
</tr>
<tr>
<td>Zheng, Zongyu</td>
<td>MP54-01</td>
</tr>
<tr>
<td>Zhivov, Alexei</td>
<td>PD63-04</td>
</tr>
<tr>
<td>Zholudev, Vitaly</td>
<td>MP76-14</td>
</tr>
<tr>
<td>Zhong, Xiaogang</td>
<td>MP35-11</td>
</tr>
<tr>
<td>Zhou, Hui</td>
<td>MP78-09, MP98-11</td>
</tr>
<tr>
<td>Zhou, Jing-Cheng</td>
<td>MP36-14</td>
</tr>
<tr>
<td>Zhou, Qian</td>
<td>MP92-06</td>
</tr>
<tr>
<td>Zhou, Qi</td>
<td>MP57-03</td>
</tr>
<tr>
<td>Zhou, Rui</td>
<td>V05-09</td>
</tr>
<tr>
<td>Zhou, Tie</td>
<td>P07-01</td>
</tr>
<tr>
<td>Zhou, Xinyao</td>
<td>P09-05</td>
</tr>
<tr>
<td>Zhou, Yibin</td>
<td>MP45-15</td>
</tr>
<tr>
<td>Zhou, Yu</td>
<td>MP81-12</td>
</tr>
<tr>
<td>Zhu, Guan Qun</td>
<td>PD49-01</td>
</tr>
<tr>
<td>Zhu, Guangjing</td>
<td>MP12-17, MP35-02</td>
</tr>
<tr>
<td>Zhu, Hui</td>
<td>MP60-05</td>
</tr>
<tr>
<td>Zhu, Jie</td>
<td>MP83-18</td>
</tr>
<tr>
<td>Zhu, Kevin</td>
<td>MP71-04</td>
</tr>
<tr>
<td>Zhu, Giongian</td>
<td>MP21-16</td>
</tr>
<tr>
<td>Zhu, Wei</td>
<td>MP55-15</td>
</tr>
<tr>
<td>Zhu, Yao</td>
<td>MP03-09, MP06-01, MP28-01</td>
</tr>
<tr>
<td>Zhu, Yinjie</td>
<td>MP52-06</td>
</tr>
<tr>
<td>Zhuang, Guangjie</td>
<td>MP06-16</td>
</tr>
<tr>
<td>Zhuang, Junlong</td>
<td>PD61-03, MP58-08, MP65-04, MP81-05</td>
</tr>
<tr>
<td>Zhu, Xiuli</td>
<td>PD26-06, PD28-07, MP67-01, MP67-07, MP67-08, MP74-02, MP80-04, V11-11, p172</td>
</tr>
<tr>
<td>Ziegler, Annemarie</td>
<td>MP65-03</td>
</tr>
<tr>
<td>Ziel-van der Made, Angélique</td>
<td>PD66-06</td>
</tr>
<tr>
<td>Zemba, Justin</td>
<td>PD28-02, MP76-10</td>
</tr>
<tr>
<td>Ziemieci, Asha</td>
<td>PD65-03</td>
</tr>
<tr>
<td>Ziemlewicz, Timothy</td>
<td>PD61-09, PD61-07, MP28-05</td>
</tr>
<tr>
<td>Zietman, Anthony</td>
<td>MP17-14</td>
</tr>
<tr>
<td>Zigeuner, Richard</td>
<td>MP48-19</td>
</tr>
<tr>
<td>Zilberman, Dort</td>
<td>MP89-13</td>
</tr>
<tr>
<td>Zilinskas, Brooke</td>
<td>p118</td>
</tr>
<tr>
<td>Zilloux, Jacqueline</td>
<td>MP07-04</td>
</tr>
<tr>
<td>Zimmer, Philippe</td>
<td>PD32-09, PD32-12, MP09-12, MP27-04, MP33-04, MP33-20, MP63-18</td>
</tr>
<tr>
<td>Zimoch, Jakub</td>
<td>PD36-03</td>
</tr>
<tr>
<td>Zini, Armand</td>
<td>PD01-02, MP19-09</td>
</tr>
<tr>
<td>Zilberstein, Lose</td>
<td></td>
</tr>
<tr>
<td>Ziegler, Annemarie</td>
<td>MP65-03</td>
</tr>
<tr>
<td>Ziel-van der Made, Angélique</td>
<td>PD66-06</td>
</tr>
<tr>
<td>Zemba, Justin</td>
<td>PD28-02, MP76-10</td>
</tr>
<tr>
<td>Ziemieci, Asha</td>
<td>PD65-03</td>
</tr>
<tr>
<td>Ziemlewicz, Timothy</td>
<td>PD61-09, PD61-07, MP28-05</td>
</tr>
<tr>
<td>Zietman, Anthony</td>
<td>MP17-14</td>
</tr>
<tr>
<td>Zigeuner, Richard</td>
<td>MP48-19</td>
</tr>
<tr>
<td>Zilberman, Dort</td>
<td>MP89-13</td>
</tr>
<tr>
<td>Zilinskas, Brooke</td>
<td>p118</td>
</tr>
<tr>
<td>Zilloux, Jacqueline</td>
<td>MP07-04</td>
</tr>
<tr>
<td>Zimmer, Philippe</td>
<td>PD32-09, PD32-12, MP09-12, MP27-04, MP33-04, MP33-20, MP63-18</td>
</tr>
<tr>
<td>Zimoch, Jakub</td>
<td>PD36-03</td>
</tr>
<tr>
<td>Zini, Armand</td>
<td>PD01-02, MP19-09</td>
</tr>
<tr>
<td>Ziogas, Argyrios</td>
<td>MP27-08</td>
</tr>
<tr>
<td>Zisman, Anna</td>
<td>MP13-20</td>
</tr>
<tr>
<td>Zitzmann, Michael</td>
<td>MP85-15</td>
</tr>
<tr>
<td>Zlatev, Dimitar</td>
<td>PD36-02, PD41-11, MP17-14, MP66-07, MP77-18, MP82-02, MP82-03</td>
</tr>
<tr>
<td>Zlotta, Alexandre</td>
<td>PD66-03, MP66-18, MP48-15, MP65-11, MP71-06, p13, p198</td>
</tr>
<tr>
<td>Zoccoli, Matteo</td>
<td>MP29-17, MP82-14</td>
</tr>
<tr>
<td>Zohar, Yithshak</td>
<td>PD21-06</td>
</tr>
<tr>
<td>Zondervan, Patricia</td>
<td>MP28-13</td>
</tr>
<tr>
<td>Zorn, Kevin</td>
<td>MP05-10, MP05-11, MP62-13, MP62-18, MP73-04, MP73-16, p254</td>
</tr>
<tr>
<td>Zu, Suo</td>
<td>MP09-03, MP09-09</td>
</tr>
<tr>
<td>Zubert, Tricia</td>
<td>p192</td>
</tr>
<tr>
<td>Zucchi, Alessandro</td>
<td>PD06-06, PD31-03, MP33-11, MP75-09</td>
</tr>
<tr>
<td>Zuckerman, Jack</td>
<td>PD21-11</td>
</tr>
<tr>
<td>Zugor, Vahudin</td>
<td>PD30-06</td>
</tr>
<tr>
<td>Zucan, Chiara</td>
<td>MP03-19</td>
</tr>
<tr>
<td>Zumsteig, Zachary</td>
<td>MP71-01</td>
</tr>
<tr>
<td>Zwaans, Bernadette</td>
<td>MP10-08, MP39-11</td>
</tr>
<tr>
<td>Zwartshoff, Ellen</td>
<td>PD66-06, MP54-05</td>
</tr>
<tr>
<td>Zwiederman, Koos</td>
<td>PD10-10</td>
</tr>
<tr>
<td>Zwirwich, Charles</td>
<td>PD37-11</td>
</tr>
<tr>
<td>Zylstra, Samuel</td>
<td>MP79-17</td>
</tr>
</tbody>
</table>
AUA-2019
MAY 3–6 chicago
SAVE THE DATE!
www.AUA2019.org
Give More Patients the OPDIVO® Opportunity.

OPDIVO (nivolumab)™
INJECTION FOR INTRAVENOUS USE 10 mg/mL

While attending this meeting, please visit us at Booth 6544